<SEC-DOCUMENT>0001493152-23-010384.txt : 20230331
<SEC-HEADER>0001493152-23-010384.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331170108
ACCESSION NUMBER:		0001493152-23-010384
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MyMD Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001321834
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36268
		FILM NUMBER:		23788939

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 623
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		856-848-8698

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 623
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Akers Biosciences, Inc.
		DATE OF NAME CHANGE:	20170413

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Akers Biosciences Inc
		DATE OF NAME CHANGE:	20050325
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:MYMD="http://mymd.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_MYMD_mymd.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001321834 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_063_Days_5_utr%2D%2DD -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001321834</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0189" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0190" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0194" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0195" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:AccretionOfDebtDiscount" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:StockOptionModificationExpenses" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:GainOnDebtForgiveness" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0333" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0344" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ModificationTermsOfPreMergerStockOptions" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ModificationTermsOfPreMergerStockOptions" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ModificationTermsOfPreMergerStockOptions" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ModificationTermsOfPreMergerStockOptions" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStock" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:AccruedInterestdividends" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:GainOnForgivenessOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:StockOptionModificationExpenses" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:OtherAssetInvestment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31_custom_HydeParkFacilityMember" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-12-31_custom_HydeParkFacilityMember" id="xdx2ixbrl0742" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" id="xdx2ixbrl0769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1002" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1004" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1006" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1008" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1010" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1012" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1014" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1016" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1018" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember" id="xdx2ixbrl1054" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P7Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember" id="xdx2ixbrl1072" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1146" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1148" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1154" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1156" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1158" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1160" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl1248" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl1250" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl1252" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl1254" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl1266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl1274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-07-07_us-gaap_WarrantMember" id="xdx2ixbrl1294" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" id="xdx2ixbrl1312" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" id="xdx2ixbrl1314" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" id="xdx2ixbrl1320" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" id="xdx2ixbrl1322" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" id="xdx2ixbrl1324" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" id="xdx2ixbrl1326" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1354" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1356" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1358" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1360" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1362" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1364" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1366" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1368" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" id="xdx2ixbrl1384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="AsOf2021-12-31" id="xdx2ixbrl1452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mymd-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockNoParValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonStockNoParValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockNoParValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CommonStockNoParValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockNoParValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16_custom_MyMDPharmaceuticalsFloridaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MYMD:MyMDPharmaceuticalsFloridaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-122021-04-16_custom_SuperaPharmaceuticalsIncMember_custom_AssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:SuperaPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:AssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-12</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-02_srt_MinimumMember_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-02_srt_MaximumMember_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-02_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-02_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-202018-10-26_custom_SuperaAviationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SuperaAviationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-20</xbrli:startDate>
        <xbrli:endDate>2018-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-26_custom_SuperaAviationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SuperaAviationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-052020-11-09_srt_MinimumMember_custom_TwoThousandTwentyBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-05</xbrli:startDate>
        <xbrli:endDate>2020-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-052020-11-09_srt_MaximumMember_custom_TwoThousandTwentyBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-05</xbrli:startDate>
        <xbrli:endDate>2020-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-09_custom_TwoThousandTwentyBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-052020-11-09_custom_TwoThousandTwentyBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-05</xbrli:startDate>
        <xbrli:endDate>2020-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-15</xbrli:startDate>
        <xbrli:endDate>2021-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-15</xbrli:startDate>
        <xbrli:endDate>2021-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-17_custom_TwoThousandTwentyOneBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-15</xbrli:startDate>
        <xbrli:endDate>2021-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-02_custom_PlattStreetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-02_custom_PlattStreetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MYMD:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MYMD:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PlattStreetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PlattStreetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SuperaAviationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SuperaAviationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandTwentyBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_HydeParkFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_UnvestedRestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_UnvestedRestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:PreFundedWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:PreFundedWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesCPreferredConvertibleWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesCPreferredConvertibleWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesCPreferredConvertibleWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesCPreferredConvertibleWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesDPreferredConvertibleStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesDPreferredConvertibleStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesDPreferredConvertibleStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesDPreferredConvertibleStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-23_custom_CystronBiotechLLCMember_custom_MembershipInterestPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:CystronBiotechLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MembershipInterestPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ContributionAgreementMember_custom_PremasBiotechPVTLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:ContributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MYMD:PremasBiotechPVTLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-122021-04-16_custom_MergerAgreementMember_custom_PreMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:PreMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-12</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-122021-04-16_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-12</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16_custom_PrefundedWarrantsMember_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16_custom_AkersBiosciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-12</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-12</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-16_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-162021-04-16_custom_AkersBiosciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-16</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MilestonePeriodOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MilestonePeriodFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember_custom_EventOfDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">MYMD:EventOfDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">MYMD:MyMDPharmaceuticalsFloridaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">MYMD:MyMDPharmaceuticalsFloridaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-01-23_custom_TwoThousandThirteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-01-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AmendedPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:AmendedPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AmendedPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:AmendedPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-21_custom_TwoThousandAndSixteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-07_custom_TwoThousandAndSeventeenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-07_custom_TwoThousandAndEighteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-15_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember98108171">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-27</xbrli:startDate>
        <xbrli:endDate>2022-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-28_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-272022-01-28_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-27</xbrli:startDate>
        <xbrli:endDate>2022-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-19</xbrli:startDate>
        <xbrli:endDate>2022-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-21_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-192022-06-21_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-19</xbrli:startDate>
        <xbrli:endDate>2022-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember98108296">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-292022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-29</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MYMD:MyMDFloridaStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MYMD:MyMDFloridaStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MYMD:MyMDFloridaStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-10</xbrli:startDate>
        <xbrli:endDate>2020-09-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-15</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-272022-01-28_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JanuaryTwentyEightTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-27</xbrli:startDate>
        <xbrli:endDate>2022-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JanuaryTwentyEightTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-062022-07-07_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JulySevenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-06</xbrli:startDate>
        <xbrli:endDate>2022-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JulySevenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-222020-03-24_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-22</xbrli:startDate>
        <xbrli:endDate>2020-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-15_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-16_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-102021-02-11_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-10</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-11_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-172021-05-18_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-17</xbrli:startDate>
        <xbrli:endDate>2021-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-172021-05-18_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-17</xbrli:startDate>
        <xbrli:endDate>2021-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-042021-08-05_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-04</xbrli:startDate>
        <xbrli:endDate>2021-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-082021-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-08</xbrli:startDate>
        <xbrli:endDate>2021-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-152022-02-16_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-15</xbrli:startDate>
        <xbrli:endDate>2022-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-152022-02-16_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-15</xbrli:startDate>
        <xbrli:endDate>2022-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-162022-08-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-16</xbrli:startDate>
        <xbrli:endDate>2022-08-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-062022-07-07_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-06</xbrli:startDate>
        <xbrli:endDate>2022-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-07_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-062022-07-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-06</xbrli:startDate>
        <xbrli:endDate>2022-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-07_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-07_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-17_srt_MaximumMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-17_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:SeriesCConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:SeriesCConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:SeriesCConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-292018-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-29</xbrli:startDate>
        <xbrli:endDate>2018-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-222020-11-23_custom_TaglichBrothersIncMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MYMD:TaglichBrothersIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-22</xbrli:startDate>
        <xbrli:endDate>2020-11-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TaglichBrothersIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MYMD:TaglichBrothersIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-28_custom_MrWilliamsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:MrWilliamsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012018-10-31_custom_SuperaAviationILLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SuperaAviationILLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-28_custom_SuperaAviationILLCMember_custom_NegotiatedSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:NegotiatedSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-012018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-272021-04-28_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-27</xbrli:startDate>
        <xbrli:endDate>2021-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FourZeroOneKPlanMatchesFiftyPercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">MYMD:FourZeroOneKPlanMatchesFiftyPercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FourZeroOneKPlanMaximumFivePercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">MYMD:FourZeroOneKPlanMaximumFivePercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:PaycheckProtectionProgramLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-15</xbrli:startDate>
        <xbrli:endDate>2020-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-01_custom_PaycheckProtectionProgramLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:PaycheckProtectionProgramLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-21</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-21</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001321834</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-21</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Days">
      <xbrli:measure>utr:D</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20220101__20221231_zVSf1WsoxUT5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--DocumentAnnualReport_c20220101__20221231_z5VQE4E0kzye"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20220101__20221231_zZGP9ao9F4l9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_901_edei--CurrentFiscalYearEndDate_c20220101__20221231_zTICZQXzN7ic"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_907_edei--DocumentFiscalYearFocus_c20220101__20221231_z3Kz81A5cFfl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--DocumentTransitionReport_c20220101__20221231_zQe7zdktmXlc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ____________ to</b> ____________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span id="xdx_909_edei--EntityFileNumber_c20220101__20221231_zbCmytR1UrTe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-36268</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_901_edei--EntityRegistrantName_c20220101__20221231_z9Fcs2zlLold" style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">MyMD
Pharmaceuticals, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220101__20221231_z6j7R1M7qi5d"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New Jersey</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220101__20221231_zNQViRcZzQnk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">22-2983783</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction of</b><br />
    <b>incorporation or organization)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    Number)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_906_edei--EntityAddressAddressLine1_c20220101__20221231_zndMAjMMU3P2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">855
                                            N. Wolfe Street</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
                                            <span id="xdx_90D_edei--EntityAddressAddressLine2_c20220101__20221231_zO14WF0YCrl9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite
                                            601</ix:nonNumeric></span></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--EntityAddressCityOrTown_c20220101__20221231_zbqZzDd3ST6c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Baltimore</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_900_edei--EntityAddressStateOrProvince_c20220101__20221231_zDkXZyjxxdz1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric></span></span></b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span id="xdx_907_edei--EntityAddressPostalZipCode_c20220101__20221231_zELTARYtKnjb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">21205</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_905_edei--CityAreaCode_c20220101__20221231_zqZ5zLft7Pth"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(856)</ix:nonNumeric></span></b></span><b>
<span id="xdx_90A_edei--LocalPhoneNumber_c20220101__20221231_zxYDwoeiIIel" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">848-8698</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Each Exchange on Which Registered:</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_edei--Security12bTitle_c20220101__20221231_zikDefBDNxL4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Shares
    of Common Stock, no par value</ix:nonNumeric></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_edei--TradingSymbol_c20220101__20221231_ztH67ae1JvSj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">MYMD</ix:nonNumeric></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_90A_edei--SecurityExchangeName_c20220101__20221231_z4xaqed6hfac"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span></b></span><b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Market LLC</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act: None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zpX8O5cXBQkl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_908_edei--EntityVoluntaryFilers_c20220101__20221231_zZnPC16C8IT6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_901_edei--EntityCurrentReportingStatus_c20220101__20221231_zpxiv7EVRZif"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). <span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20220101__20221231_zksr72CRyDS9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer, &#8220;smaller
reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--EntityFilerCategory_c20220101__20221231_z1Yu6IwFvFpe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--EntitySmallBusiness_c20220101__20221231_zwoi87k9XuHg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20220101__20221231_zbb5SKuSk946" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90B_edei--IcfrAuditorAttestationFlag_c20220101__20221231_z4Py2PgeO2n9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; <span id="xdx_901_edei--EntityShellCompany_c20220101__20221231_zKUVSaKNGjBg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2022, based on
a closing price of $2.17 was $<span id="xdx_900_edei--EntityPublicFloat_iI_c20220630_zaZfwyxduxV"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,298,348</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 29, 2023, the registrant had <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20230329_z9IRTKw56CNl"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-29" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,470,009</ix:nonFraction></span> shares of its Common Stock, no par value per share, outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report is the Annual Report on Form 10-K for the year ended December 31, 2022 of MyMD Pharmaceuticals, Inc., which was formerly known
as Akers Biosciences, Inc. prior to the consummation on April 16, 2021 of the merger described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the previously announced Agreement and Plan of Merger and Reorganization, dated November 11, 2020 (the &#8220;Original
Merger Agreement&#8221;), as amended by Amendment No. 1 thereto, dated March 16, 2021 (the Original Merger Agreement, as amended by Amendment
No. 1, the &#8220;Merger Agreement&#8221;), by and among MyMD Pharmaceuticals, Inc., a New Jersey corporation previously known as Akers
Biosciences, Inc. (the &#8220;Company&#8221;), XYZ Merger Sub Inc., a Florida corporation and a wholly owned subsidiary of the Company
(&#8220;Merger Sub&#8221;), and MyMD Pharmaceuticals (Florida), Inc., a Florida corporation previously known as MyMD Pharmaceuticals,
Inc. (&#8220;MyMD Florida&#8221;), Merger Sub was merged with and into MyMD Florida, with MyMD Florida continuing after the merger as
the surviving entity and a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). At the effective time of the Merger, without
any action on the part of any stockholder, each issued and outstanding share of pre-Merger MyMD Florida&#8217;s Common Stock, par value
$0.001 per share (the &#8220;MyMD Florida Common Stock&#8221;), including shares underlying pre-Merger MyMD Florida&#8217;s outstanding
equity awards, was converted into the right to receive (x) 0.7718 shares (the &#8220;Exchange Ratio&#8221;) of the Company&#8217;s Common
Stock, no par value per share (the &#8220;Company Common Stock&#8221; or &#8220;Common Stock&#8221;), (y) an amount in cash, on a pro
rata basis, equal to the aggregate cash proceeds received by the Company from the exercise of any options to purchase shares of MyMD
Florida Common Stock outstanding at the effective time of the Merger assumed by the Company upon closing of the Merger prior to the second-year
anniversary of the closing of the Merger (the &#8220;Option Exercise Period&#8221;), such payment (the &#8220;Additional Consideration&#8221;),
and (z) potential milestone payments in shares of Company Common Stock up to the aggregate number of shares issued by the Company to
pre-merger MyMD Florida stockholders at the closing of the Merger payable upon the achievement of certain market capitalization milestone
events during the 36-month period immediately following the closing of the Merger. Upon completion of the Merger and the transactions
contemplated in the Merger Agreement, (i) the former MyMD Florida equity holders owned approximately 77.05% of the outstanding equity
of the Company on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company
Common stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of MyMD Florida Common Stock
assumed by the company at closing and after adjustments based on the Company&#8217;s net cash at closing; and (ii) former Akers Biosciences,
Inc. stockholders owned approximately 22.95% of the outstanding equity of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of 4:05 pm Eastern Time on April 16, 2021, immediately
following the effective time of the Merger, the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company Common
Stock (the &#8220;Reverse Stock Split&#8221;). All share numbers and exercise prices included herein have been adjusted to give retroactive
effect to the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger is being treated as a reverse recapitalization effected by a share exchange for financial accounting and reporting purposes. MyMD
Florida is being treated as the accounting acquirer, as its stockholders control the Company after the Merger, even though Akers Biosciences,
Inc. was the legal acquirer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 1 of the Consolidated Financial Statements for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">TABLE
OF CONTENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART
    I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk
    Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved
    Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Mine
    Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">PART
    II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Reserved</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Other
    Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">PART
    III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Executive
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#item12_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_01">Certain
    Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_02">Principal
    Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_03">PART
    IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_04">Exhibit
    and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_05">Form
    10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report and the documents we have filed with the Securities and Exchange Commission (which we refer to herein as the &#8220;SEC&#8221;)
that are incorporated by reference herein contain &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms
such as &#8220;anticipates,&#8221; &#8220;assumes,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221;
&#8220;expects,&#8221; &#8220;forecasts,&#8221; &#8220;future,&#8221; &#8220;guides,&#8221; &#8220;intends,&#8221; &#8220;is confident
that,&#8221;, &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;projects,&#8221; &#8220;targets,&#8221; and &#8220;would&#8221;
or the negative of such terms or other variations on such terms or comparable terminology. These statements relate to future events or
our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our
actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of forward-looking statements in this Annual Report and our other SEC filings include, but are not limited to, our expectations regarding
our business strategy, business prospects, operating results, operating expenses, working capital, liquidity and capital expenditure
requirements. These statements are based on our management&#8217;s expectations, beliefs and assumptions concerning future events affecting
us, which in turn are based on currently available information and are subject to significant risks and uncertainties that could cause
actual outcomes and results to differ materially. Important factors that could cause actual results to differ materially from those indicated
by such forward-looking statements include, without limitation, the risks and uncertainties set forth under &#8220;Risk Factors&#8221;
in Item 1A of this Annual Report on Form 10-K, which discussions are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks and uncertainties include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuation
    and volatility in market price of our Common Stock due to market and industry factors, as well as general economic, political and
    market conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of dilution on our shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to realize the intended benefits of the Merger (as defined below) and the Contribution Transaction (as defined below);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of our ability to realize the anticipated tax impact of the Merger;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delisting
    of our Common Stock from the Nasdaq Capital Market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    availability and ability to continue to obtain sufficient funding to conduct planned research and development efforts and realize
    potential profits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and commercialize our product candidates, including MYMD-1, Supera-CBD and other future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the complexity of the regulatory landscape on our ability to seek and obtain regulatory approval for our product candidates,
    both within and outside of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    required investment of substantial time, resources and effort for successful clinical development and marketization of our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    we may face with maintaining regulatory approval, if achieved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential impact of changes in the legal and regulatory landscape, both within and outside of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 pandemic on the administration, funding and policies of regulatory authorities, both within and outside of
    the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties to conduct pre-clinical and clinical trials and manufacture its product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 pandemic on our results of operations, business plan and the global economy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    we may face with respect to our product candidates achieving market acceptance by providers, patients, patient advocacy groups, third
    party payors and the general medical community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of pricing, insurance coverage and reimbursement status of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emerging
    competition and rapidly advancing technology in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, maintain and protect our trade secrets or other proprietary rights, operate without infringing upon the proprietary
    rights of others and prevent others from infringing on its proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain adequate cyber security and information systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to achieve the expected benefits and costs of the transactions related to the acquisition of Supera Pharmaceuticals, Inc.
    (&#8220;Supera&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively execute and deliver our plans related to commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emerging
    competition and rapidly advancing technology in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain adequate financing in the future on reasonable terms, as and when needed;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    we may face in identifying, acquiring and operating new business opportunities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain and attract senior management and other key employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to quickly and effectively respond to new technological developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome of litigation or other proceedings to which are subject as described in the &#8220;Legal Proceedings&#8221; section of this
    Annual Report on Form 10-K, or to we may become subject to in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    levels of competition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in political, economic or regulatory conditions generally and in the markets in which we operate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market acceptance of our products and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    compliance with all laws, rules, and regulations applicable to our business and drug product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected
    gains, revenue growth or expense savings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks, including those described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict
all of those risks, nor can we assess the impact of all of those risks on our business or the extent to which any factor may cause actual
results to differ materially from those contained in any forward-looking statement. The forward-looking statements in this Annual Report
on Form 10-K and our other filings with the SEC are based on assumptions management believes are reasonable. However, due to the uncertainties
associated with forward-looking statements, you should not place undue reliance on any forward-looking statements. Further, forward-looking
statements speak only as of the date they are made, and unless required by law, we expressly disclaim any obligation or undertaking to
publicly update any of them in light of new information, future events, or otherwise. All subsequent written and oral forward-looking
statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements
contained throughout this Annual Report and the documents we have filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item
1. Business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>On
April 16, 2021, pursuant to the previously announced Agreement and Plan of Merger and Reorganization, dated November 11, 2020 (the &#8220;Original
Merger Agreement&#8221;), as amended by Amendment No. 1 thereto, dated March 16, 2021 (the Original Merger Agreement, as amended by Amendment
No. 1, the &#8220;Merger Agreement&#8221;), by and among MyMD Pharmaceuticals, Inc., a New Jersey corporation previously known as Akers
Biosciences, Inc. (the &#8220;Company&#8221;), XYZ Merger Sub Inc., a Florida corporation and a wholly owned subsidiary of the Company
(&#8220;Merger Sub&#8221;), and MyMD Pharmaceuticals (Florida), Inc., a Florida corporation previously known as MyMD Pharmaceuticals,
Inc. (&#8220;MyMD Florida&#8221;), Merger Sub was merged with and into MyMD Florida, with MyMD Florida continuing after the merger as
the surviving entity and a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). In this Annual Report on Form 10-K, unless
the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company&#8221; and &#8220;MyMD&#8221;
refer to MyMD Pharmaceuticals, Inc. and its subsidiaries. References to &#8220;Akers&#8221; refer to Akers Biosciences, Inc. prior to
the Merger. For more information on the merger or the sale of assets, see &#8220;MyMD Background and Corporate History &#8211; Merger.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
is a clinical stage pharmaceutical company committed to extending healthy lifespan. MyMD is focused on developing and commercializing
two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
    is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including (but not limited
    to) multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related
    illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as
    TNF-&#945;, interleukin 6 (&#8220;IL-6&#8221;) and interleukin 17 (&#8220;IL-17&#8221;)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera-CBD
    is a synthetic analog of CBD being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety/depression,
    through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (&#8220;MAO&#8221;) type B. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights to Supera-CBD<sup>TM</sup> were previously owned by Supera and were acquired by MyMD Florida immediately prior to the closing
of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MyMD
Background and Corporate History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
was organized under the laws of the State of Florida in November 2014 for the purpose of developing and commercializing certain technology
and patent rights relating to MYMD-1 that were developed and/or held by the company&#8217;s founder, Jonnie R. Williams, Sr. The company&#8217;s
sole initial stockholder was The Starwood Trust, a trust for which Mr. Williams is settlor/grantor. During the period from November 2014
through November 2016, MyMD was primarily focused on drug discovery and establishing its patent position through SRQ Patent Holdings,
an entity affiliated with Mr. Williams. In November 2016, SRQ Patent Holdings assigned to MyMD all of the patent rights and other intellectual
property relating to MYMD-1 pursuant to an agreement under which MyMD granted to SRQ Patent Holdings a royalty based on product sales
and other revenue arising from the assigned intellectual property (as further described below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period 2016 through October of 2020, MyMD&#8217;s principal business activities consisted of the execution and completion of <i>in
vitro</i> assays, <i>in vivo</i> pre-clinical animal studies, and genotoxicity and toxicology studies relating to MYMD-1 (as further
described below). On June 25, 2019, MyMD commenced a Phase 1 trial in healthy volunteers for pharmacokinetics and tolerability studies,
and in December of 2019 MyMD filed an IND for MYMD-1 for treatment of Hashimoto thyroiditis. The Phase 1 trial was completed on January
30, 2020, after which MyMD commenced preparation of a Phase 2 clinical trial for MYMD-1 focused on the treatment of depression and inflammation
in COVID-19 positive patients. The company has also commenced a Phase 2 clinical trial for patients with sarcopenia, with dosing begin
in the first quarter of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, MyMD had 500,000,000 shares of authorized Common Stock, of which approximately 39,470,009 shares were outstanding
and 14,202,928 shares were reserved for issuance of Common Stock upon the exercise of outstanding stock options, Common Stock warrants,
restricted stock units and convertible preferred stock and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Merger</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the Merger Agreement, by and among the Company, Merger Sub and MyMD Florida, Merger Sub was merged with
and into MyMD Florida, with MyMD Florida continuing after the merger as the surviving entity and a wholly owned subsidiary of the
Company. At the effective time of the Merger, without any action on the part of any stockholder, each issued and outstanding share
of pre-Merger MyMD Florida&#8217;s Common Stock, par value $0.001 per share (the &#8220;MyMD Florida Common Stock&#8221;), including shares underlying pre-Merger MyMD Florida&#8217;s outstanding equity awards, was converted
into the right to receive (x) 0.7718 shares (the &#8220;Exchange Ratio&#8221;) of the Company&#8217;s Common Stock, no par value per
share (the &#8220;Company Common Stock&#8221; or &#8220;Common Stock&#8221;), (y) an amount in cash, on a pro rata basis, equal to the aggregate cash proceeds
received by the Company from the exercise of any options to purchase shares of MyMD Florida Common Stock outstanding at the
effective time of the Merger assumed by the Company upon closing of the Merger prior to the second-year anniversary of the closing
of the Merger (the &#8220;Option Exercise Period&#8221;), such payment (the &#8220;Additional Consideration&#8221;), and (z)
potential milestone payments in shares of Company Common Stock up to the aggregate number of shares issued by the Company to
pre-merger MyMD Florida stockholders at the closing of the Merger payable upon the achievement of certain market capitalization
milestone events during the 36-month period immediately following the closing of the Merger. Immediately following the effective
time of the Merger, the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company Common Stock (the
&#8220;Reverse Stock Split&#8221;). Upon completion of the Merger and the transactions contemplated in the Merger Agreement, (i) the
former MyMD Florida equity holders owned approximately 77.05% of the outstanding equity of the Company on a fully diluted basis,
assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common stock and including 4,188,315
shares of Company Common Stock underlying options to purchase shares of MyMD Florida Common Stock assumed by the company at closing
and after adjustments based on the Company&#8217;s net cash at closing; and (ii) former Akers Biosciences, Inc. stockholders owned
approximately 22.95% of the outstanding equity of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger was treated as a reverse recapitalization effected by a share exchange for financial accounting and reporting purposes. MyMD Florida
was being treated as the accounting acquirer, as its stockholders control the Company after the Merger, even though Akers Biosciences,
Inc. was the legal acquirer. As a result, the assets and liabilities and the historical operations that are reflected in our consolidated
financial statements are those of MyMD Florida as if MyMD Florida had always been the reporting company. All references to MyMD Florida
shares of common stock, warrants and options have been presented on a post-merger, post-reverse split basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supera
Asset Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, in connection with entering into the Merger Agreement, MyMD Florida entered into the Supera Asset Purchase Agreement
pursuant to which MyMD Florida agreed to acquire from Supera substantially all of the assets (including all rights to Supera-CBD) and
certain obligations of Supera in consideration of the issuance to Supera of an aggregate of 13,096,640 shares of MyMD Florida Common
Stock. Supera is owned principally by The Starwood Trust and is controlled by Mr. Williams. Supera is a Florida corporation that was
incorporated in September 2018 by Mr. Williams and The Starwood Trust in order to develop and commercialize Supera-CBD. In December 2018,
Mr. Williams assigned his rights and intellectual property relating to Supera-CBD to Supera. As partial consideration for such assignment,
Supera has granted to SRQ Patent Holdings II, LLC a royalty with respect to product sales and other consideration arising from the assigned
intellectual property (as further described below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquisition
and Disposition of Cystron</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired 100% of the membership interests of Cystron pursuant to a Membership Interest Purchase Agreement, dated March 23, 2020
(as amended by Amendment No. 1 on May 14, 2020, the &#8220;MIPA&#8221;) from certain selling parties (the &#8220;Cystron Sellers&#8221;).
The acquisition of Cystron was accounted for as a purchase of an asset. Cystron is a party to a License and Development Agreement (as
amended and restated on March 19, 2020, in connection with our entry into the MIPA, the &#8220;License Agreement&#8221;) with Premas
Biotech PVT Ltd. (&#8220;Premas&#8221;) whereby Premas granted Cystron, amongst other things, an exclusive license with respect to Premas&#8217;
vaccine platform for the development of a vaccine against COVID-19 and other coronavirus infections. Cystron was incorporated on March
10, 2020. Since its formation and through the date of its acquisition by the Company, Cystron did not have any employees and its sole
asset consisted of the exclusive license from Premas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company and the Cystron Sellers, which are also shareholders of Oravax, entered into a Termination and Release Agreement
terminating the MIPA effective upon consummation of the Contribution Agreement. In addition, the Cystron Sellers agreed to waive any
change of control payment triggered under the MIPA as a result of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the Contribution and Assignment Agreement, dated March 18, 2021 (the &#8220;Contribution Agreement&#8221;)
by and among the Company, Cystron, Oravax Medical, Inc. (&#8220;Oravax&#8221;) and, for the limited purpose set forth therein, Premas,
the parties consummated the transactions contemplated therein. Pursuant to the Contribution Agreement, among other things, the Company
caused Cystron to contribute substantially all of the assets associated with its business of developing and manufacturing Cystron&#8217;s
COVID-19 vaccine candidate to Oravax (the &#8220;Contribution Transaction&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oravax
is pursuing the development of the COVID-19 vaccine candidate. MyMD has evaluated several options with respect to its interest
in Oravax, including a potential distribution of Oravax shares to the MyMD shareholders. This would make Oravax a publicly held company.
MyMD&#8217;s interest in Oravax consists of 13% of Oravax&#8217;s outstanding shares of capital stock and the rights to a 2.5% royalty
on all future net sales. In addition, MyMD currently has the right to designate a member of the board of directors of Oravax, pursuant
to which Mr. Joshua Silverman, our Chairman of the Board, has been designated to serve as a director of Oravax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Status of MyMD Florida</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 8, 2022, the MyMD
Florida subsidiary was dissolved and merged into the New Jersey corporation MyMD Pharmaceuticals, Inc. pursuant to an Agreement and Plan
of Merger dated April 8, 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
is developing two platform drugs targeting numerous disease indications. Below is MyMD&#8217;s development pipeline:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" style="height: 518px; width: 636px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD&#8217;s
strategy is to focus on extending healthy life span through the development and commercialization of novel drug platforms based on well-defined
therapeutic targets. Below are MyMD&#8217;s key clinical strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    Phase 2 clinical trial in sarcopenia (i.e., age-related muscle loss) in the second quarter of 2023;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    MYMD-1 into Phase 2 clinical trials for treatment of diabetes, rheumatoid arthritis, and inflammatory bowel disease;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execute
    on IND-enabling studies of Supera-CBD to enable submission of an IND for a Phase 1 clinical trial in healthy volunteers followed
    by Phase 2 clinical trials in epilepsy, addiction and anxiety disorders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    and validate additional novel targets and utilize translational platforms to develop a pipeline of product candidates for aging and
    other autoimmune disease;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintain
    broad commercial rights to MyMD&#8217;s product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
    to strengthen and expand MyMD&#8217;s intellectual property portfolio.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MYMD-1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
is a clinical stage drug that targets the immune system by inhibiting the release of pro-inflammatory cytokines, such as TNF-&#945;.
Cytokines are a broad category of molecules involved in immune system coordination. Immunometabolic regulation is the system of regulating
the immune system and its pro-inflammatory cytokines in order to prevent and treat autoimmune diseases and age-related illnesses. By
affecting the initial triggers that drive autoimmunity, MYMD-1 targets the underlying cause of these diseases rather than just their
symptoms. Based on MYMD-1&#8217;s Phase 1 clinical trial, completed in January 2020, MyMD has commenced a Phase 2 clinical trial for
sarcopenia (age-related muscle loss) and is planning multiple Phase 2 clinical trials in autoimmune disease, including (1) multiple sclerosis,
diabetes, inflammatory bowel disease and rheumatoid arthritis; (2) inflammation related depression and anxiety; and (3) COVID-19 associated
depression. MyMD has an active IND with the Endocrinology Division at the FDA for other autoimmune diseases. Studies have been completed
on the mechanisms of action and efficacy of MYMD-1 in several pre-clinical models of autoimmune diseases (i.e., experimental autoimmune
encephalomyelitis (&#8220;EAE&#8221;) that models multiple sclerosis and autoimmune thyroiditis), and these studies have been published
in peer reviewed journals. MyMD plans to pursue these indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1<i>:
An Immunometabolic Regulator</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflammation,
activated through the release of TNF-&#945; and other cytokines, is the body&#8217;s normal physiological defense against infections
and pathogens, and under normal circumstances such inflammation quickly resolves once the intruder is neutralized. However, elevated
levels of pro-inflammatory cytokines, including TNF-&#945;, can lead to prolonged, chronic inflammation, which is closely linked to
autoimmune diseases (such as multiple sclerosis, diabetes, rheumatoid arthritis) and aging (i.e., inflamm-aging) as well as cardiovascular
disease and cancers, all of which may result in reduced health span (the period of life spent in good health).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goal of immunometabolic regulatory drugs such as MYMD-1 is to target immune cells that overproduce pro-inflammatory cytokines, such as
TNF-&#945;, without preventing normal immune cell function. TNF-&#945; is a cytokine that is released by immune cells that plays a
key role in acute and chronic inflammation, autoimmune diseases and aging. Examples of currently approved immunometabolic regulating
drugs include Dimethyl Fumarate (&#8220;DMF&#8221;) (approved for the treatment of multiple sclerosis) and Rapamycin (used in kidney
transplants and being studied in aging).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
is a novel immunometabolic regulator that has demonstrated <i>in vitro</i> and <i>in vivo</i> ability to regulate the release of multiple
cytokines from immune cells, including TNF-&#945;. MYMD-1 is being developed to treat chronic inflammatory diseases, such as multiple
sclerosis, diabetes, inflammatory bowel disease, rheumatoid arthritis, and aging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
<i>Regulates Multiple Cytokines</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
conducted an in vitro study to demonstrate that MYMD-1 regulates a broad range of cytokines, including TNF-&#945;, interferon gamma
(INF&#947;) and interleukins, including interleukin 2 (&#8220;IL-2&#8221;) and IL-17A. By blocking these cytokines that have been shown
to play key roles in the development and maintenance of autoimmune diseases, MYMD-1 treats the causes&#8212;and not just the symptoms&#8212;of
this class of illnesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" style="height: 672px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
1. </i>MYMD-1 <i>modulates the release of a broad spectrum of cytokines.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
additional <i>in vitro </i>study demonstrates that MYMD-1 has broad cytokine inhibiting activity including inhibition of TNF-&#945;,
IL-16 and IL-17. The study also suggested MYMD-1 has limited toxicity, even at high doses, and none up to 2,000 micromoles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="height: 230px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an <i>in vivo</i> study (NOD.H2 mouse model), MYMD-1 decreased serum levels of TNF-&#945; and INF&#947;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><img src="form10-k_004.jpg" alt="" style="height: 606px; width: 624px" /></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
2. MYMD-1 decreases the serum levels TNF-&#945; and IFN-g in NOD.H-2h4 mice. NOD.H-2h4 mice were treated with either regular water or
iodinated water (500 mg/l of sodium iodide), and each group was treated or not treated with MYMD-1 (185 mg/l). Cytokines were measured
at baseline and after 6 and 12 weeks of treatment using a multiplex magnetic bead array. (A and B) MYMD-1 significantly decreased serum
TNF-&#945; levels in the regular water group and tended to decrease it in the iodinated water group. (C and D) MYMD-1 showed a modest
effect on serum IFN-g in the iodinated water group. Results are from three independent experiments. Statistical comparisons were made
by longitudinal data analysis with generalized estimating equations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MYMD-1
Targets Autoimmune Diseases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
is designed to regulate the immunometabolic system and intended for development as a potential treatment for certain autoimmune
diseases, including (but not limited to) multiple sclerosis, diabetes, rheumatoid arthritis, and/or inflammatory bowel disease. MYMD-1
is also being developed to treat age-related illnesses such as frailty and sarcopenia. Autoimmune diseases are a broad category of
diseases that result from an overactive immune response, where immunometabolic system dysregulation is believed to play an important
role. A healthy immune system defends the body against disease and infection. If the immune system malfunctions, it can mistakenly
attack healthy cells, tissues, and organs. In response to an often-unknown trigger, the immune system starts producing antibodies
that attack the body&#8217;s own cells instead of fighting infections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNF-&#945;,
produced primarily by specific white blood cells, belongs to a category of proteins called cytokines that act as chemical messengers
throughout the body to regulate many aspects of the immune system. Other key cytokines include IL-6, IL-17A, interleukin 10 (&#8220;IL-10&#8221;)
and Interferon gamma (&#8220;INF&#947;&#8221;). Cytokines are essential to mounting an inflammatory response. However, chronic or excessive
production of cytokines has been implicated in a number of acute and chronic inflammatory diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of drugs target the immunometabolic system to treat autoimmune diseases, including DMF (approved for the treatment of multiple
sclerosis) and Rapamycin (being studied in aging, rheumatoid arthritis, and other autoimmune diseases). Additional therapies for autoimmune
diseases include anti-inflammatory drugs and immunosuppressive agents including drugs that non-selectively inhibit or block TNF-&#945;
(generally referred to as &#8220;TNF-&#945; blocking drugs&#8221;). Currently available TNF-&#945; blocking drugs must be injected
or infused to work. In some instances, the efficacy of a given dosage of TNF-&#945; blockers declines with repeated administration,
and side effects can also be a concern. These non-selective TNF-&#945; blockers can cause serious bacterial, fungal, and viral infections.
MYMD-1 is a selective, oral TNF-&#945; inhibitor that might provide a safer alternative to existing products on the market. The global
market for TNF-&#945; blockers was estimated at $41.6 billion in 2020 and is projected to reach $45.5 billion by 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
<i>in vitro </i>study involving human blood cells analyzed the cytokine inhibitory effects of MYMD-1 together with leading approved TNF-&#945;
blockers (monoclonal antibodies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><img src="form10-k_005.jpg" alt="" style="height: 416px; width: 403px" /></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
3. Comparison of inhibitory effect of MYMD-1 with other TNF-&#945; blockers. MYMD-1 exhibits a dose-dependent reduction in release of
several cytokine more effectively than Humira, Enbrel and Remicade.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe MYMD-1 is distinguishable from currently marketed TNF-&#945; blockers because it selectively blocks TNF-&#945; production
related to adaptive immunity (involved in autoimmunity) but spares the role of this cytokine in innate immunity (which plays a
primary protective role in fighting off invading organisms). Because of the crucial role that TNF-&#945; plays in front line
protection by the innate immune system (e.g., from bacterial, fungal, and viral infections), the indiscriminate blockade of
TNF-&#945; by TNF-&#945; blocking agents can cause serious and even fatal infections, which is one of the primary limiting factors
in the use of this class of drugs. Based on our belief regarding the selectivity of MYMD-1 in blocking TNF-&#945;, therefore, we
intend to explore the extent to which MYMD-1 may be a safer alternative to treat infectious, inflammatory, and autoimmune
conditions, as well as its potential to ameliorate immune mediated depression in such illnesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Clinical
Study of MYMD-1 in Multiple Sclerosis Study (EAE Mouse Model)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
sclerosis is an autoimmune disease in which T cells lead an attack on oligodendrocytes and neurons. Multiple sclerosis is the leading
neurological cause of disability in adults aged 30&#8211;50, and approximately one million people in the United States are affected with
this debilitating disease. T cells are one of the major components of the adaptive immune system. Their roles include directly killing
infected host cells, activating other immune cells, producing cytokines and regulating the immune response. When na&#239;ve, undifferentiated
T cells become activated, they differentiate and acquire effector functions that can be delineated by the cytokines they secrete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
<i>in vivo</i> studies of the therapeutic efficacy of MYMD-1 in the animal model for multiple sclerosis, known as EAE, indicate that
MYMD-1 modulates autoreactive T cell activation in a dose-dependent manner, suppresses T cell activation and ameliorates the course of
EAE. Further EAE mouse studies suggest that MYMD-1 suppresses the influx of CD4+ T cells into the brain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="" style="height: 400px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
4. Effects of MYMD-1 on the influx of T cells into the CNS early in EAE. To assess the effects of MYMD-1 on the infiltration of T cells
into the CNS, mice were immunized and treated with either vehicle control or 25 mg/mouse/day MYMD-1. Ten to 14 days later, mice were
perfused and brains collected for analysis. Infiltration was determined by flow cytometry. Analysis of Th1 and Th17 subsets are shown;
data compiled from 2 to 3 experiments, n &gt; 3/group per experiment). Student&#8217;s t-test was conducted for statistics.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MYMD-1
In Vivo Study of Autoimmune Thyroiditis (NODH.2 Mouse Model)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thyroiditis
or Hashimoto thyroiditis is an autoimmune disease characterized by lymphocytic infiltration of the thyroid gland. It has been shown that
tobacco smoking has a protective effect against Hashimoto thyroiditis as tobacco smokers have a lower prevalence of thyroid autoantibodies
than non-smokers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
conducted an <i>in vivo</i> study of autoimmune thyroiditis in a spontaneous thyroiditis (NODH.2) mouse model. We believe the
results of this study show MYMD-1&#8217;s ability to suppress TNF-&#945; production by CD-4+ T cells in a dose dependent manner. Additionally, the
study reported that MYMD-1 statistically decreases the incidence and severity (p &lt;0.001) of thyroiditis in this mouse model.
Pre-clinical studies have demonstrated that MYMD-1 ameliorated autoimmune thyroiditis in the thyroiditis mouse model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_007.jpg" alt="" style="height: 351px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Figure
5. MYMD-1 decreases the incidence and severity of autoimmune thyroiditis in NOD.H-2h4 mice, as assessed by H&amp;E histopathology. At
8 weeks old, 58 NOD.H-2h4 mice were divided into regular water and iodinated water groups. In the regular water group, 10 mice (7 M,
3 F) drank water that contained MYMD-1 (185 mg/l), and 16 mice (10 M, 6 F) drank water without it. In the iodinated water group, the
water was supplemented with 500 mg/l of sodium iodide and contained (16 mice: 10 M, 6 F) or did not contain (16 mice: 10 M, 6 F) MYMD-1
(185 mg/l). After 12 weeks of treatment, thyroids were removed and divided in half. (A and B) Thyroiditis severity and incidence assessed
by histopathology in the regular water group. (C) A representative thyroid from a mouse in the regular water group, showing a severity
score of 2. (D) A representative thyroid from a mouse in the regular water group treated with MYMD-1, showing thyroid follicle preservation
and an overall normal glandular size (severity score of 0). (E and F) Thyroiditis incidence and severity scores assessed by histopathology
in the iodinated water group. (G) A representative thyroid from a mouse in the iodine group, showing marked lymphocytic infiltration,
follicular enlargement, and architectural disruption (severity score of 4). (H) A representative thyroid from a mouse in the iodine plus
MYMD-1 group (severity score of 2). Results represent the summary of 10 independent experiments, each analyzing 4 to 6 mice, for a total
of 58 mice.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MYMD-1
Targets Inflamm-Aging and Related Disorders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aging
is associated with a loss of tight regulation of the immune system. This leads to increased inflammatory activity in the body,
including increased circulating levels of TNF-&#945;. Chronic inflammation is a hallmark of aging, referred to as inflamm-aging.
Inflamm-aging and chronic inflammation are closely linked to a number of disorders such as obesity, insulin resistance/type 2
diabetes, cardiovascular diseases, and cancers. TNF-&#945; is a multifunctional pro-inflammatory
cytokine which may play a part in the pathogenesis of certain age-related disorders such as atherosclerosis. A multi-year
pre-clinical, proof of concept <i>in vivo </i>study in aging and longevity confirmed our belief regarding MYMD-1&#8217;s potential
therapeutic effect on inflamm-aging and other age-related disorders, which we intend to explore further in clinical trials, pending our submission,
and the corresponding acceptance, of the requisite regulatory and other relevant submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bascom
Palmer Eye Institute Collaboration&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2022, we announced a new collaboration with Bascom Palmer Eye Institute of Miami, Florida (&#8220;Bascom Palmer&#8221;) to collaborate
on a pre-clinical study using MYMD-1 as a potential treatment for traumatic optic neuropathy (TON). To date, our collaboration with Bascom
Palmer has included pre-clinical and clinical investigations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Clinical&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July&#160;2022 we entered into a Material
Transfer Agreement with Bascom Palmer. Our collaboration was announced in a press release and in an article in <i>Ophthalmology Times</i>.
Bascom Palmer confirmed in August&#160;2022 that it had received a quantity of our MYMD-1 product candidate and MYMD provided a material
safety datasheet and certification of analysis. In August 2022, Bascom Palmer researchers conducted a preliminary introductory study
of TON in mice. Investigators ran a crush injury of the mice&#8217;s optic nerves with and without MYMD-1. The study drug was given
once per day via oral gavage at a dosage of 30&#160;mg/kg&#160;of body weight. The mice were treated for five days, untreated for two
days, and then sacrificed, and their TNF-&#945; levels were measured. Data from this study is pending. We intend to plan additional
pre-clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the pre-clinical study described above, we are collaborating with Bascom Palmer to plan future a clinical study. In
August 2022, Bascom Palmer researchers executed a confidentiality and non-disclosure agreement and Bascom Palmer produced a draft
protocol synopsis entitled, Assessment of the Anti-Inflammatory Effects of MYMD-1 in Non-Infectious Anterior Uveitis: A Randomized
Controlled, Double Blind Clinical Study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>MYMD-1
Commercialization Targets </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt">MYMD-1 is being developed to address serious and debilitating autoimmune and inflammatory diseases, including sarcopenia,
frailty resulting from aging process, and rheumatoid arthritis (RA). According to the U.S. Census Bureau,&#160;in 2020, there were approximately
54 million U.S. residents over 65 years of age, representing 16% of the U.S. population. This figure is expected to increase to nearly
22% by the year 2040.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>&#160;The Arthritis Foundation
estimates that approximately 1.5 million people in the U.S. have RA.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><sup>2</sup></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supera-CBD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera-CBD
is a synthetic small molecule that is an analog of naturally grown CBD derived from the Cannabis sativa plant. Supera-CBD is being
developed to treat conditions with which CBD is often anecdotally associated but for which no natural or synthetic CBD-containing
drugs have been approved by the FDA, such as pain, anxiety/depression and seizures from epilepsy. While naturally grown CBD is a
constituent of Cannabis sativa, Supera-CBD is a synthetic analog of CBD, thus eliminating potential complications associated with
the psychoactive effects of Tetrahydrocannabinol (&#8220;THC&#8221;), which is also a constituent of the Cannabis sativa plant.
Studies have suggested that CBD may have broad therapeutic properties, including the treatment of neuropsychiatric
disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><sup>1</sup></span>
U.S. Department of Health and Human Services. 2020 Profile of Older Americans. May 2021 Page 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2
</sup>The Arthritis Foundation. Rheumatoid Arthritis: Causes, Symptoms, Treatments and More.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Pharmacology and Therapeutic Profile</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD
inhibits a number of important receptors, including the CB2 receptor and opioid receptors, and can also inhibit MAO enzymes. In the immune
system, one of the important functions of the CB2 receptor is in the regulation of cytokine release from immune cells. Antagonists targeting
the CB2 receptor have been proposed for the treatment or management of a range of painful conditions as well as for treating several
neurological diseases. The Company conducted an <i>in vitro</i> binding assay study to analyze the CB2 inhibition of Supera-CBD together
with that of CBD derived from naturally grown plants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" style="height: 459px; width: 360px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioid
receptors are widely expressed in the brain, spinal cord, peripheral nerves and digestive tract. MyMD conducted an <i>in vitro </i>binding
analysis of Supera-CBD with the three types of opioid receptors. The profile suggests that Supera-CBD could possibly play a role in
treating opioid addiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_009.jpg" alt="" style="height: 459px; width: 423px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAOs
are enzymes involved in the catabolism, or digestion, of certain neurotransmitters. MyMD conducted an <i>in vitro</i> MAO inhibition
study. In this study, Supera-CBD and commercial CBD were analyzed against positive and negative controls. In this study, Supera-CBD far
exceeded CBD in dose-dependent inhibition of MAOs, particularly MAO-B. Drugs that inhibit MAOs have been commercially used for decades
to treat depression, and more recent studies have suggested MAO-B inhibiting drugs might have a role to play in treating cognitive decline
in aging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_010.jpg" alt="" style="height: 357px; width: 347px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supera-CBD
Early-Stage Plans for Development and Potential Commercialization Targets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera-CBD
is in early-stage development for pain, anxiety, and sleep disorders. There are currently a number of over-the-counter CBD products marketed
with unapproved therapeutic claims relating to these conditions, among other conditions. While there are a substantial number of such
products on the market that have not been subject to regulatory enforcement action, the FDA has consistently reiterated, in guidance
and warning letters against a number of the companies marketing such CBD products for such uses, that CBD products may not be lawfully
marketed for therapeutic uses in the United States without first-obtaining FDA approval via the NDA process. CBD product sales in the
US&#160;reportedly reached $5.3 billion in 2021, 15% growth over 2020 sales, and are projected to reach $16 billion by 2026.<sup>3</sup>
MyMD believes that if Supera-CBD is approved by the FDA, it may have competitive advantages over currently marketed CBD products that
have not been approved by FDA as drug products, as approved drugs must undergo rigorous premarket study and generate results sufficient
to support a finding that they are safe and effective for their intended use(s) and remain subject to ongoing FDA postmarket regulation,
which provides additional assurances relating to quality, consistency and safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there is one FDA-approved drug with plant-derived CBD as an active ingredient. FDA subsequently approved three other cannabinoid-containing
drugs, two of which utilize synthetic cannabinoids analogous or similar to THC as the active ingredient and the other, a combination
of synthetic CBD and THC. Epidiolex is being commercialized by GW Pharmaceuticals, plc (&#8220;GWPH&#8221;) to treat seizures associated
with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age and older. The reported revenues from Epidiolex in fiscal
year 2019 were approximately $296 million. MYMD believes that, by utilizing synthetic, rather than naturally derived, CBD in Supera-CBD
may mitigate a number of obstacles generally associated with growing and processing an active drug ingredient produced from naturally
grown plant extracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On March&#160;2, 2023, we announced that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific
review and determined that it would not Supera-CBD a controlled substance or listed chemical under the Controlled Substances Act (CSA)
and its governing regulations. We believe that this decision will expedite future research involving Supera-CBD by relieving us or our
research partners from having to comply with regulations relating to controlled substances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
does not currently have sales and marketing infrastructure to support the launch of its products. MyMD intends to build such
capabilities in North America prior to launch the commercial MYMD-1, if successfully developed and granted the requisite FDA
approval. Outside of North America, MyMD may rely on licensing, co-sale and co-promotion agreements with strategic partners for
commercialization of its products. If MyMD builds a commercial infrastructure to support marketing in North America, such commercial
infrastructure could be expected to include a targeted sales force supported by sales management, internal sales support, an
internal marketing group and distribution support. To develop the appropriate commercial infrastructure internally, MyMD would have
to invest financial and management resources, some of which would have to be deployed prior to any confirmation that MYMD-1 or
Supera-CBD will be approved, which cannot be guaranteed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and biopharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and vigorous
defense of intellectual property. Any product candidates that MyMD successfully develops and commercializes will have to compete with
existing and future new therapies. While MyMD believes that its drug candidates, development experience and scientific knowledge may
provide it with certain competitive advantages, MyMD faces potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
therapies for autoimmune diseases include anti-inflammatory drugs and immunosuppressive agents, including drugs that seek to
selectively inhibit or block TNF-&#945; (generally referred to as &#8220;TNF-&#945; blocking drugs&#8221;). TNF-&#945; blocking
drugs are large molecules that are generally injected or infused. In some instances, the period of efficacy of a given dosage of
TNF-&#945; blockers can decline with repeated administration and side effects can be a concern.&#160;Leading TNF-&#945; blocking
drugs include Etanercept (Enbrel), Infliximab (Remicade), and Adalimumab (Humira). The total TNF-&#945; market collectively
represented approximately $41 billion in global sales in 2022.<sup>4</sup> All of these existing TNF-&#945; blocking drugs require
injection, whereas MYMD-1 is being developed to be orally bioavailable. Our management believes patients and providers would view
the fact that MYMD-1 can be administered orally as a significant advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
currently marketed TNF-&#945; blockers, MYMD-1 is designed to selectively block TNF-&#945; production related to adaptive immunity
(involved in autoimmunity) but to spare the role of this cytokine in innate immunity (which plays the primary initial role in fighting
off invading organisms). Because of the crucial role that TNF-&#945; plays in front line protection by the innate immune system from
bacterial, fungal, and viral infections, the indiscriminate blockade of TNF-&#945; by TNF-&#945; blocking agents can cause serious
and even fatal infections, which is the primary limiting factor in the use of this class of drugs. MyMD thus believes that, if MYMD-1
is approved for marketing, the potential selectivity of MYMD-1 in blocking TNF-&#945; might make it a preferrable alternative to some
existing treatments for infectious, inflammatory, and autoimmune conditions, as well as simultaneously resulting in amelioration of immune
mediated depression in such illnesses if it is also approved for such indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3
</sup>Benzinga: US Hemp CBD Market To Hit $5.3B In Sales In 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>4
</sup>https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD&#8217;s
policy is to develop and maintain MyMD&#8217;s proprietary position by, among other methods, filing or in-licensing U.S. and foreign
patents and applications related to MyMD&#8217;s drug candidates and methods of treatment that are material to the development and implementation
of MyMD&#8217;s business. MyMD also relies on trademarks, know-how, confidentiality agreements and invention assignment agreements to
develop and maintain MyMD&#8217;s proprietary position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD&#8217;s
patent portfolio includes protection for MYMD&#8217;s lead product candidates, MYMD-1 and Supera-CBD. Currently, there are multiple patent
families relating to (i) age reversal and treatments of age-related disorders including sarcopenia; (ii) reduction of TNF-&#945; levels
and treatments of autoimmune disorders; (iii) addiction treatments; (iv) methods of increasing hair growth and (v) plant nutrition. As
of the date of this document, MyMD has 16 issued U.S. patents, four pending U.S. patent applications, 50 issued foreign patents, and
15 foreign patent applications pending in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea,
which, if issued, are expected to expire between 2036 and 2039.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which MyMD files, the patent term is 20 years from the date of filing of the first non-provisional application in which priority is
claimed. In the U.S. patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays
by the USPTO in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the U.S.,
the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the
Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the
patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension
under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval
and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single
patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and
certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD&#8217;s
commercial success depends in part on its ability to obtain and maintain proprietary protection for MyMD&#8217;s product candidates,
as well as novel discoveries, core technologies, and know-how, as well as its ability to operate without infringing on the proprietary
rights of others and to prevent others from infringing its proprietary rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assignment
and Royalty Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
is a party to two Amended and Restated Confirmatory Patent Assignment and Royalty Agreements, both dated November 11, 2020, with SRQ
Patent Holdings and SRQ Patent Holdings II, under which MyMD (or its successor) will be obligated to pay to SRQ Patent Holdings or SRQ
Patent Holdings II (or its designees) certain royalties on product sales or other revenue received on products that incorporate or are
covered by the intellectual property that was assigned to MyMD. The royalty is equal to 8% of the net sales price on product sales and,
without duplication, 8% of milestone revenue or sublicense compensation. SRQ Patent Holdings and SRQ Patent Holdings II are affiliates
of Mr. Williams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in the U.S. at the federal, state, and local level and in other countries regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising,
distribution, post-approval monitoring and reporting, marketing and export and import of drugs and biological products. Generally,
before a new drug can be marketed, considerable data demonstrating its quality, safety, and efficacy in connection with the target
indication(s) for use must be obtained, organized into a format specific for each regulatory authority, submitted for review and
approved by the regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 16pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., pharmaceutical products are subject to extensive regulation under the FD&amp;C Act and the FDA&#8217;s implementing regulations
and other federal and state statutes and regulations governing, among other things, the research, development, testing, manufacture,
storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and
import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety
enforcement actions and/or administrative or judicial sanctions, including, but not limited to clinical holds, FDA refusal to approve
NDA submissions and/or revocation or limitation of existing NDAs for approved products, warning or untitled letters, product recalls,
product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
product development for a new drug product or certain changes to an approved product in the U.S. typically requires pre-clinical
laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing on human
subjects may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for
each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements are inherently uncertain,
expensive, and it typically takes many years to generate sufficient data to apply for approval, even when such approval is not
ultimately granted, and the actual time required may vary substantially based upon the type, complexity and novelty of the product
or disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements,
including good laboratory practices. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other
information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term
pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day
waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither
commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve
the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator.
Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCP, an international standard
meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; and
(iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria
to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as
part of the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes
that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical
trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an IRB
and ethics committee for approval. The IRB will also monitor the clinical trial until completed. An IRB may also require the clinical
trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose
other conditions. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical
trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward
at designated checkpoints based on access to certain data from the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase
1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics,
pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually
involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance
and optimum dosage, and to identify common adverse effects and safety risks. If a drug demonstrates evidence of effectiveness and an
acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy
and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate
the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases the
FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial
may be sufficient in rare instances, including (1) where the trial is a large multicenter trial demonstrating internal consistency and
a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease
with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2)
when in conjunction with other confirmatory evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer of an investigational drug in a Phase 2 or 3 clinical trial for a serious or life-threatening disease is required to make
available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before
marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical and other testing and a
compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application
user fee, currently exceeding $3.1 million for fiscal year 2022 (for applications containing clinical data), which increased from $2.9
million for fiscal year 2021. Fee waivers or reductions are available in certain circumstances, including a waiver of the application
fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan
drugs, unless the product also includes a non-orphan indication. The applicant under an approved NDA is also subject to annual program
fees, currently exceeding $369,413 for fiscal year 2022 for each prescription product. The FDA adjusts the user fees on an annual basis,
and the fees typically increase annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews each submitted NDA before it determines whether to file it and may request additional information. The FDA must make a decision
on whether to file an NDA within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission
is filed, the FDA begins an in-depth review of the NDA. The FDA has agreed to certain performance goals in the review of NDAs. Most applications
for standard review drug products are reviewed within ten to twelve months&#894; most applications for priority review drugs are reviewed
in six to eight months. Priority review can be applied to drugs that the FDA determines may offer significant improvement in safety or
effectiveness compared to marketed products or where no adequate therapy exists. The review process for both standard and priority review
may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify
information already provided in the submission. The FDA does not always meet its goal dates for standard and priority NDAs, and the review
process can be extended by FDA requests for additional information or clarification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to
an outside advisory committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation and a recommendation
as to whether the application should be approved and under what conditions, if any. The FDA is not bound by the recommendation of an
advisory committee, but it generally follows such recommendations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether
they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications.
The FDA also typically inspects clinical trial sites to ensure compliance with GCP requirements and the integrity of the data supporting
safety and efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter (&#8220;CRL&#8221;).
A CRL generally outlines the deficiencies in the submission, which may be minor and more technical, or major and more substantive and,
in the latter case may require substantial additional testing or data to be eligible for substantive review by FDA upon resubmission,
such as additional clinical data, additional pivotal clinical trial(s), and/or other significant and time-consuming requirements related
to clinical trials, pre-clinical studies or manufacturing. If a CRL is issued, the applicant may resubmit the NDA addressing all of the
deficiencies identified in the letter, withdraw the application, engage in formal dispute resolution or request an opportunity for a
hearing. The FDA has committed to reviewing resubmissions in two to six months depending on the type of information included. Even if
such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the deficiencies identified in the CRL are addressed to FDA&#8217;s satisfaction in a resubmission of the NDA (and FDA does not identify
any other issues that need to be corrected prior to approval or that, otherwise, cause the agency to determine that approval is not appropriate
at the given time), the FDA will issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific
prescribing information for specific indications. In addition, under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;),
as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness
of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant
deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers
from the pediatric data requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition of NDA approval, the FDA may also require a REMS, to help ensure that the benefits of the drug outweigh the potential risks
to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use
(&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing
only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect
the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance
to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards
is not maintained or problems are identified following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes
or facilities, require submission and FDA approval of an NDA supplement or, in some case, a new NDA, before the change can be implemented.
An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses
the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
as a result of the COVID-19 pandemic, the extent and length of which is uncertain, MyMD will be required to develop and implement additional
clinical study policies and procedures designed to help protect study participants from the SARS-CoV-2 virus, which may include using
telemedicine visits and remote monitoring of patients and clinical sites. MyMD will also need to ensure data from its clinical studies
that may be disrupted as a result of the pandemic is collected pursuant to the study protocol and is consistent with GCPs, with any material
protocol deviation reviewed and approved by the site IRB. Patients who may miss scheduled appointments, any interruption in study drug
supply, or other consequence that may result in incomplete data being generated during a study as a result of the pandemic must be adequately
documented and justified. For example, on March 18, 2020, the FDA issued guidance on conducting clinical trials during the pandemic,
which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include
in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of
the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruption by unique subject identifier
and by investigational site, and a description of how the individual&#8217;s participation was altered; and analyses and corresponding
discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product
and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported
for the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of Clinical Trial Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial information
to the U.S. public by publishing such information on clinicaltrials.gov. Information related to the product, patient population, phase
of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration.
Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials
can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly
available information to gain knowledge regarding the progress of development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition. These programs are fast track designation, breakthrough therapy designation, and
priority review designation. MyMD has not applied for expedited approval under any of these pathways to-date but intends to explore the
extent to which any of its current or future product candidates may be eligible for one or more such pathways. There is no guarantee
that FDA will grant any of MyMD&#8217;s products candidates the expedited designation(s) for which it is submitted, if any, or that MyMD
will secure any of the applicable benefits associated with any of any expedited designations that may be granted to its current or future
product candidates, if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fast-Track
Designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
track designation may be granted for a product that is intended to treat a serious or life-threatening disease or condition for which
pre-clinical or clinical data demonstrate the potential to address unmet medical needs for the condition. The sponsor of an investigational
drug product may request that the FDA designate the drug candidate for a specific indication as a fast-track drug concurrent with, or
after, the submission of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast-track designation
within 60 days of receipt of the sponsor&#8217;s request. For fast-track products, sponsors may have greater interactions with the FDA
and the FDA may initiate review of sections of a fast-track product&#8217;s NDA before the application is complete. This rolling review
is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast-track product
may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information
and the sponsor must pay applicable user fees. At the time of NDA filing, the FDA will determine whether to grant priority review designation.
Additionally, fast track designation may be withdrawn if the FDA believes that the designation is no longer supported by data emerging
in the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Breakthrough
Therapy Designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory scheme
allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough
therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA
may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review
process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an
efficient manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Priority
Review Designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant
improvement in safety or effectiveness. The FDA determines, on a case- by-case basis, whether the proposed drug represents a significant
improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness
in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of
patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation.
A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the
FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accelerated
Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
approval may be granted for a product that is intended to treat a serious or life-threatening condition and that generally provides a
meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on
the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or
mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or
lack of alternative treatments. The accelerated approval pathway is most often used in settings in which the course of a disease is long,
and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate
or intermediate clinical endpoint occurs rapidly. The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct
additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials
must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled
prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies,
would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved
under accelerated regulations are subject to prior review by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
as a result of the COVID-19 pandemic, the extent and length of which is uncertain, MyMD will be required to develop and implement additional
clinical study policies and procedures designed to help protect study participants from the SARS-CoV-2 virus, which may include using
telemedicine visits and remote monitoring of patients and clinical sites. MyMD will also need to ensure data from its clinical studies
that may be disrupted as a result of the pandemic is collected pursuant to the study protocol and is consistent with GCPs, with any material
protocol deviation reviewed and approved by the site IRB. Patients who may miss scheduled appointments, any interruption in study drug
supply, or other consequence that may result in incomplete data being generated during a study as a result of the pandemic must be adequately
documented and justified. For example, on March 18, 2020, the FDA issued guidance on conducting clinical trials during the pandemic,
which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include
in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of
the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruption by unique subject identifier
and by investigational site, and a description of how the individual&#8217;s participation was altered; and analyses and corresponding
discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product
and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported
for the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-marketing
Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA. Drug manufacturers&#8217;
and/or sponsors&#8217; post-marketing FDA obligations, include, among other things, monitoring and record-keeping activities, reporting
of adverse experiences, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved
uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities,
and a number of other specific requirements for prescription-drug advertising. Although physicians may prescribe legally available products
for off-label uses, manufacturers may not market or promote their approved drug products for off-label uses. Product approvals may be
withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. Newly discovered or developed
safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications,
and may also require the implementation of other risk management measures, including a REMS, or the conduct of post-marketing studies
to assess a newly discovered safety issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
regulations require that drug products be manufactured in registered drug-manufacturing facilities and in accordance with cGMP regulations.
MYMD currently relies on third parties to produce clinical quantities of its drug candidates under development in accordance with applicable
GCPs and GLPs, and expects to continue to rely, on third parties to produce clinical and commercial quantities of MYMD&#8217;s products
that are approved for marketing in the United States, if any, in accordance with cGMP regulations. These manufacturers must comply with
cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation
and the obligation to investigate and correct any deviations from cGMP. Accordingly, manufacturers must continue to expend time, money
and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including
failure to conform to cGMP regulations, could result in a wide range of enforcement actions against the manufacturer, including, but
not limited to, recalls, warning letters, &#8220;dear doctor&#8221; letters, civil lawsuits, fines, and criminal prosecution. And the
discovery of previously unknown safety or efficacy problems with a product after approval may result in restrictions on, revocation of,
or the addition of conditions to the product&#8217;s approval, among other potential adverse actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the requirements applicable to approved drug products, sponsors may also be subject to enforcement action in connection with
any promotion of any investigational new drug. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator,
may not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under
investigation or otherwise promote or market the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Regulatory Matters</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in
the U.S. in addition to the FDA, including the CMS, other divisions of the HHS, the DOJ, the Drug Enforcement Administration, the Consumer
Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection
Agency and state and local governments and governmental agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Healthcare Laws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which
MyMD may obtain marketing approval. MyMD&#8217;s current and future arrangements with third-party payors, healthcare providers and physicians
may expose MyMD to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which MyMD markets, sells and distributes any drugs for which MYMD obtains marketing approval.
In the U.S., these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient
data privacy and security laws and regulations, including but not limited to those described below. MYMD&#8217;s business operations,
including its research, marketing, and activities relating to the reporting of wholesale or estimated retail prices for MyMD&#8217;s
products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party
reimbursement for MyMD&#8217;s products, and the sale and marketing of MyMD&#8217;s product and any future product candidates, are subject
to scrutiny under these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    AKS, makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly
    and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, that
    is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for
    which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable
    by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs.
    In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil and criminal false claims laws, including the FCA, which can be enforced through civil whistleblower or qui tam actions,
    which impose penalties against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or
    causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record
    material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government.
    The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example,
    providing inaccurate billing or coding information to customers or promoting a product off-label. Claims that include items or services
    resulting from a violation of the AKS are false or fraudulent claims for purposes of the FCA.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without
    limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare
    or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular
    supplier of items or services reimbursable by a federal or state governmental program.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud
    any healthcare benefit program, including private payors, or falsifying, concealing or covering up a material fact or making any
    materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to
    the AKS, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific
    intent to violate it in order to have committed a violation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by HITECH, and their respective implementing regulations, imposes, among other things, specified requirements on covered
    entities and their business associates relating to the privacy and security of individually identifiable health information including
    mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers
    of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave
    state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA
    laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    PPSA, enacted as part of the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics,
    and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, for
    certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists,
    podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their
    immediate family members. Effective January 1, 2022, these reporting obligations extend to include transfers of value made during
    the previous year to certain non-physician providers such as physician assistants and nurse practitioners.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader in
    scope and apply regardless of payor. These laws are enforced by various state agencies and through private actions. Some state laws
    require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant
    federal government compliance guidance, require drug manufacturers to report information related to payments and other transfers
    of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures.
    In addition, certain state and local laws require the registration of pharmaceutical sales representatives.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
and foreign laws also govern the privacy and security of health information in some circumstances. These data privacy and security laws
may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. Furthermore,
most states in the United States have enacted laws regulating the confidentiality and security of medical information and increased public
focus on privacy may result in amendments or changes to these laws in ways that may have an impact on MyMD&#8217;s business activities
related to the collection and use of health-related information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increased attention on privacy in the United States may also impact MyMD&#8217;s business activities for the processing of personal information
not otherwise governed by HIPAA. The EU General Data Protection Regulation (&#8220;GDPR&#8221;) imposes significant privacy and cybersecurity
requirements related to the handling of all types of personal information, with heightened requirements on sensitive personal information,
such as health information. The GDPR imposes significant limitations on the use of this personal information and grants individuals in
the EU certain rights associated with the collection and use of personal information. In the U.S., California recently enacted the CCPA,
which creates new individual privacy rights for California consumers (generally defined as any resident of California, including employees
and other business relations) and places increased privacy and security obligations on entities handling personal information of consumers
or households. The CCPA also greatly extends the obligations of entities that process personal information to include information not
traditionally viewed as personal information and regulated by laws, such as Internet Protocol (IP) addresses, unique identifiers for
individuals, and information in online cookies and other online technologies. A majority of other states have already proposed laws similar
to the CCPA, each differing in scope of the personal information covered and the rights of individuals. Furthermore, the CCPA has already
been replaced with the passage of California&#8217;s Proposition 24 (the California Privacy Rights Act, &#8220;CPRA&#8221;), which adds
additional rights and obligations. While the CCPA and CPRA currently provide relatively broad exclusions for protected health information
regulated by HIPAA and clinical trials and a limited exception for consumer and business to business information, some of the proposed
laws in other states may not contain the same exceptions. Furthermore, there have been a number of competing proposals for federal laws,
some of which propose to not preempt other state laws. The uncertainty surrounding proposed new and changes to existing privacy laws
may lead to operational challenges for MYMD to comply with multiple, potentially conflicting, privacy and cybersecurity laws related
to the collection and use of personal information in each jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
state and federal laws and regulations also require entities to implement &#8220;reasonable&#8221; or &#8220;adequate&#8221; security
measures to protect personal information, but generally do not provide any specific sets of security measures that would be considered
compliant to avoid liability. Instead, different regulators have adopted inconsistent and evolving standards based on the regulator&#8217;s
view of what is appropriate given the nature and scope of the personal information and the processing performed, resulting in unclear
obligations. This may result in potential liability if a regulator finds that MYMD&#8217;s security practices do not meet or exceed the
types of security measures that the regulator believes to be adequate or reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially considering the lack of applicable precedent and regulations. Federal and state enforcement bodies have continued to increase
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to investigations, prosecutions,
convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that MyMD&#8217;s
business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If MyMD&#8217;s operations are found to be in violation of any of these laws or any other related governmental
regulations that may apply to it, MyMD may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment,
disgorgement, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional
oversight and reporting obligations if MyMD becomes subject to a corporate integrity agreement or similar settlement to resolve allegations
of non-compliance with these laws and the curtailment or restructuring of MyMD&#8217;s operations. If any of the physicians or other
healthcare providers or entities with whom MyMD expects to do business is found to be not in compliance with applicable laws, they may
be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well
as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s
attention from its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
and Future Healthcare Reform Legislation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2010, President Obama signed the &#8220;Patient Protection and Affordable Care Act&#8221; (P.L. 111-148) (the &#8220;ACA&#8221;)
and on March 30, 2010, he signed the &#8220;Health Care and Education Reconciliation Act&#8221; (P.L. 111-152), collectively commonly
referred to as the &#8220;Healthcare Reform Law.&#8221; The Healthcare Reform Law included a number of new rules regarding health insurance,
the provision of healthcare, conditions to reimbursement for healthcare services provided to Medicare and Medicaid patients, and other
healthcare policy reforms. Through the law-making process, substantial changes have been and continue to be made to the current system
for paying for healthcare in the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage
and to contain or reduce healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and drugs,
and imposing additional taxes, fees, and rebate obligations on pharmaceutical and medical device companies). This legislation was one
of the most comprehensive and significant reforms ever experienced by the U.S. in the healthcare industry and has significantly changed
the way healthcare is financed by both governmental and private insurers. This legislation has impacted the scope of healthcare insurance
and incentives for consumers and insurance companies, among others. Additionally, the Healthcare Reform Law&#8217;s provisions were designed
to encourage providers to find cost savings in their clinical operations. Pharmaceuticals represent a significant portion of the cost
of providing care. This environment has caused changes in the purchasing habits of consumers and providers and resulted in specific attention
to the pricing negotiation, product selection and utilization review surrounding pharmaceuticals. This attention may result in our product
candidates, to the extent approved for commercialization in the future, being chosen less frequently or the pricing being substantially
lowered. At this stage, it is difficult to estimate the full extent of the direct or indirect impact of the Healthcare Reform Law on
us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
structural changes could entail further modifications to the existing system of private payors and government programs (such as Medicare,
Medicaid, and the State Children&#8217;s Health Insurance Program), creation of government-sponsored healthcare insurance sources, or
some combination of both, as well as other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement
for prescribed drugs and pharmaceuticals, including any products hat we may commercialize or promote in the future. If reimbursement
for the products we currently commercialize or promote, any product we may commercialize or promote, or approved therapeutic candidates
is substantially reduced or otherwise adversely affected in the future, or rebate obligations associated with them are substantially
increased, it could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extending
medical benefits to those who currently lack coverage will likely result in substantial costs to the U.S. federal government, which may
force significant additional changes to the healthcare system in the U.S. Much of the funding for expanded healthcare coverage may be
sought through cost savings. While some of these savings may come from realizing greater efficiencies in delivering care, improving the
effectiveness of preventive care and enhancing the overall quality of care, much of the cost savings may come from reducing the cost
of care and increased enforcement activities. Cost of care could be reduced further by decreasing the level of reimbursement for medical
services or products or by restricting coverage (and, thereby, utilization) of medical services or products. In either case, a reduction
in the utilization of, or reimbursement for any product we may commercialize or promote in the future, could have a material adverse
effect on our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
states and private entities initially mounted legal challenges to the Healthcare Reform Law, in particular, the ACA, and they continue
to litigate various aspects of the legislation. On July 26, 2012, the U.S. Supreme Court generally upheld the provisions of the ACA at
issue as constitutional. However, the U.S. Supreme Court held that the legislation improperly required the states to expand their Medicaid
programs to cover more individuals. As a result, states have a choice as to whether they will expand the number of individuals covered
by their respective state Medicaid programs. Some states have not expanded their Medicaid programs and have chosen to develop other cost-saving
and coverage measures to provide care to currently uninsured individuals. Many of these efforts to date have included the institution
of Medicaid-managed care programs. The manner in which these cost-saving and coverage measures are implemented could have a material
adverse effect on our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the healthcare regulatory environment has seen significant changes in recent years and is still in flux. Legislative initiatives to modify,
limit, replace, or repeal the ACA and judicial challenges have continued. We cannot predict the impact on our business of future legislative
and legal challenges to the ACA or other aspects of the Healthcare Reform Law or other changes to the current laws and regulations. The
financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the policies
reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation. From time
to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions
governing coverage, reimbursement, and marketing of pharmaceutical products. In addition, third-party payor coverage and reimbursement
policies are often revised or interpreted in ways that may significantly affect our business and our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
his time in office, former President Trump supported the repeal of all or portions of the ACA. President Trump also issued an executive
order in which he stated that it is his administration&#8217;s policy to seek the prompt repeal of the ACA and in which he directed executive
departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to
the maximum extent permitted by law. Congress has enacted legislation that repeals certain portions of the ACA, including but not limited
to the Tax Cuts and Jobs Act, passed in December 2017, which included a provision that eliminates the penalty under the ACA&#8217;s individual
mandate, effective January 1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things,
repealed the Independent Payment Advisory Board (which was established by the ACA and was intended to reduce the rate of growth in Medicare
spending).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in December 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the ACA is, therefore,
invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded the case back to the
lower court to reassess whether and how such holding affects the validity of the rest of the ACA. The Fifth Circuit&#8217;s decision
on the individual mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court held that the plaintiffs (comprised
of the state of Texas, as well as numerous other states and certain individuals) did not have standing to challenge the constitutionality
of the ACA&#8217;s individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s decision and instructed the district court
to dismiss the case. As a result, the ACA will remain in-effect in its current form for the foreseeable future; however, we cannot predict
what additional challenges may arise in the future, the outcome thereof, or the impact any such actions may have on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden administration also introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on
January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health
insurance coverage through the ACA marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive
order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On the legislative front, the
American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid drug
rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, beginning January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021,
HHS released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and
sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take
to advance these principles. And, in November 2021, President Biden announced the &#8220;Prescription Drug Pricing Plan&#8221; as part
of the Build Back Better Act (H.R. 5376) passed by the House of Representatives on November 19, 2021, which aims to lower prescription
drug pricing by, among other things, allowing Medicare to negotiate prices for certain high-cost prescription drugs covered under Medicare
Part D and Part B after the drugs have been on the market for a certain number of years and imposing tax penalties on drug manufacturers
that refuse to negotiate pricing with Medicare or increase drug prices &#8220;faster than inflation.&#8221; If enacted, this bill could
have a substantial impact on our business. In the coming years, additional legislative and regulatory changes could be made to governmental
health programs that could significantly impact pharmaceutical companies and the success of our product candidates. At the state level,
legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is uncertainty as to what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the
United States or the effect of any future legislation or regulation. Furthermore, we cannot predict what actions the Biden administration
will implement in connection with the Health Reform Law. However, it is possible that such initiatives could have an adverse effect on
our ability to obtain approval and/or successfully commercialize products in the United States in the future. For example, any changes
that reduce, or impede the ability to obtain, reimbursement for our product candidates approved for commercialization in the United States,
if any, or any other drug products we may commercialize in the future or that reduce medical procedure volumes could adversely affect
our operations and/or future business plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Packaging
and Distribution in the United States</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
MyMD&#8217;s product candidates that are approved for commercialization in the United States, if any, are made available to authorized
users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements may apply. In relevant
part, products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing,
sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending
on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties,
injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production,
denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts.
Any action against MyMD for violation of these laws, even if MyMD is successful in defending against it, could cause MyMD to incur significant
legal expenses and divert MyMD&#8217;s management&#8217;s attention from the operation of its business. Prohibitions or restrictions
on sales or withdrawal of future products marketed by MyMD could materially affect its business in an adverse way.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in regulations, statutes or the interpretation of existing regulations could impact MyMD&#8217;s business in the future by requiring,
for example: (i) changes to MyMD&#8217;s manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall
or discontinuation of MyMD&#8217;s products; or (iv) additional record-keeping requirements. If any such changes were to be imposed,
they could adversely affect the operation of MyMD&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reimbursement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of any of MyMD&#8217;s product candidates that are approved for marketing in the United States or any other products MyMD may commercialize
in the future, as applicable, will depend, in part, on the extent to which MyMD&#8217;s products, if approved, will be covered by third-party
payors, such as government health programs, commercial insurers and managed healthcare organizations, as well as the level of reimbursement
such that those third-party payors provide for MyMD&#8217;s products. Patients and providers are unlikely to use MyMD&#8217;s products
unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of MyMD&#8217;s products in which
MyMD&#8217;s products are used. In the U.S., no uniform policy of coverage and reimbursement for drugs or biological products exists,
and one payor&#8217;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will
make a similar determination. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for
any of MyMD&#8217;s products candidates, if approved, will be made on a payor-by-payor basis. As a result, the coverage determination
process may be a time-consuming and costly process that will require MyMD to provide scientific and clinical support for the use of MyMD&#8217;s
products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with
the Secretary of the HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished
to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217;
rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs and adding a new rebate calculation
for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded
products, creating a new method by which rebates owed by pharmaceutical manufacturers are calculated for drugs that are inhaled, infused,
instilled, implanted or injected, as well as potentially impacting their rebate liability by modifying the statutory definition of average
manufacturer&#8217;s price (&#8220;AMP&#8221;). The ACA also expanded the universe of Medicaid utilization subject to drug rebates by
requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially
eligible for Medicaid drug benefits. Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus
Budget Reconciliation Act of 1990.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare Prescription Drug Improvement and Modernization Act of 2003 (&#8220;MMA&#8221;) established the Medicare Part D program to provide
a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug
plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage
is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription
drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies
which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic
category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part
D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs
of prescription drugs may increase demand for products for which MyMD receives marketing approval. However, any negotiated prices for
MyMD&#8217;s products covered by a Part D prescription drug plan likely will be lower than the prices MyMD might otherwise obtain. Moreover,
while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction
in payments from non-governmental payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government
agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B
discount on a given product is calculated based on the AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the
ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the
exception of children&#8217;s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan
drugs. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula
and AMP definition described above could cause the required 340B discount to increase. The 340B program imposes ceilings on prices that
drug manufacturers can charge for medications sold to certain health care facilities. It is unclear how this decision could affect covered
hospitals who might purchase MyMD&#8217;s products in the future and affect the rates MyMD may charge such facilities for its approved
products. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities
or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, the marketability of any products for which MyMD receives regulatory approval for commercial sale may suffer if the government
and other third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures
in the U.S. has increased and MyMD expects it will continue to increase the pressure on pharmaceutical pricing. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more
products for which MyMD receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in
the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions
in Medicare and other healthcare funding and otherwise affect the prices MyMD may obtain for any of its product candidates for which
MyMD may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its Member States
to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage
between low-priced and high-priced Member States, can further reduce prices. A Member State may approve a specific price for the medicinal
product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. In some countries, MyMD may be required to conduct a clinical study or other studies that compare the cost-effectiveness
of any of MyMD&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any of MyMD&#8217;s products. Historically, products launched in the EU do not follow
price structures of the U.S. and, generally, prices tend to be significantly lower. Publication of discounts by third-party payors or
authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, MyMD had nine full-time employees and no part-time employees. MyMD has not experienced any work stoppages. None
of MyMD&#8217;s employees are represented by a labor union or covered by collective bargaining agreements, and MyMD considers its relationship
with its employees to be good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management
Plans for 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, the company published data from the Phase 1 dosing study for MYMD-1 as a treatment for aging. There was a statistically
significant decrease in TNF-&#945; levels (p-value &lt;0.05) found in one MYMD-1 treated cohort, but no change in the levels in subjects
given placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on closing out our pivotal Phase 2 aging and sarcopenia study. Final efficacy data from the Phase 2 study is expected in
the second quarter of 2023. We anticipate that we will review the safety and efficacy of this study and present the mandatory end of
Phase 2 data to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company intends to submit an IND to the FDA in the second quarter 2023 for the indication of Rheumatoid Arthritis. This will be followed
by a Phase 2 clinical trial with patients with Rheumatoid Arthritis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020 we completed several
in vitro studies from human primary cell-based BioMap systems at Eurofins contrasting MYMD-1 with Humira, Enbrel and Remicade.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MYMD-1
Product Candidate</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently completing enrollment in the fourth and final cohort of patients in the Phase 2 Aging and Sarcopenia Study (&#8220;A Double-Blind,
Placebo-controlled, Randomized Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD-1 in The Treatment of Participants
Aged 65 Years or Older with Chronic Inflammation Associated with Sarcopenia/Frailty&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed a Phase 1 Dosing Study (&#8220;A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to
Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose of MYMD-1 Capsules in Healthy Male and Female Adult Subjects&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investigational New Drug (IND) application for Aging and Sarcopenia was accepted by FDA.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IND was submitted to support a Phase 2 study focused on Aging and Sarcopenia in adults 65 years and older. The FDA reviewed the
    IND with its corresponding protocol and allowed the company to proceed to a Phase 2 clinical trial on November 1, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    obtained IRB approval on November 16, 2021 which permitted us to start enrollment and dosing qualified participants. To date, the trial has dosed 80% of its goal sample size of 40 subjects. The primary objects of the study are to
a) Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD-1<sup>&#174;</sup> versus placebo and b) To
evaluate the PK of oral doses of MYMD-1<sup>&#174;</sup> capsules.</span> </td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    will be accomplished by analyzing the effect on serum levels of sTNFR1, IL-6, and TNF-&#945; over 28 days of treatment as well as
    plasma concentrations and urine and parameters of MYMD-1<sup>&#174;,</sup> respectively. To qualify for the clinical trial, subjects&#8217;
    biomarkers during the screening period must be within the following Criteria: IL-6 &#8805; 2.5pg/mL; and/or sTNFR-1 &#8805; 1500pg/mL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    date, we have randomized and dosed 30/40 subjects across Cohorts 1 (n=10; 600mg), 2 (n=10; 750mg), 3 (n=10; 900mg) and 4 (n=pending;
    1050mg).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>IND
for Autoimmune Diseases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Animal
Studies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-month
    Dog Study &#8211; completed on December 20, 2021: A 39-Week Toxicity and Toxicokinetic Study of MYMD-1 by Oral Gavage in Beagle Dogs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-month
    Rat Study &#8211; completed on December 17, 2021: A 26-Week Toxicity and Toxicokinetic Study of MYMD-1 by Oral Gavage in Rats.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5-Day
                                            Mouse Study &#8211; Completed May 2020 with results pending: A Preliminary Introductory Traumatic
                                            Optic Neuropathy (TON) in a Mouse study</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
    produced guidance on dosing levels and overall safety in the human studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Publications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
scientific journal article on MYMD-1 was published in The Journals of Gerontology in August 2022. This manuscript supports our continued
efforts to conduct a second Phase 2 Trial for Rheumatoid Arthritis in 2023 and additional autoimmune diseases that we may pursue.&#160;
Additionally, &#8220;MyMD-1 Improves Health Span and Prolongs Life Span in Old Mice: A Noninferiority Study to Rapamycin&#8221; by Johns
Hopkins Medical School. This journal article details a 12-month mouse trial studying aging and longevity with MYMD-1. We also completed
several in vitro studies from human primary cell-based BioMap systems at Eurofins contrasting MYMD-1 versus Rapamycin further supporting
our transition to Rheumatoid Arthritis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, MyMD published &#8220;A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study
to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects&#8221; Authors:
Jenna Brager, Chris Chapman, Leonard Dunn, and Adam Kaplin in Drug Research. This became available in print in February 28, 2023. This
journal article details the results from the Phase 1 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br />&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Later, an abstract was accepted for presentation at the British Society of Immunology, Liverpool, UK in December 2022. &#8220;Pharmacology
and clinical profile of MYMD-1<sup>&#174;</sup> (isomyosamine), an oral, selective, next-generation, TNF- &#945; inhibitor that crosses
the blood brain barrier&#8221; authored by Jenna Brager, Ronald Christopher, Adam Kaplin, and Chris Chapman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
in to the 2023, an abstract was accepted for presentation at the Society of Toxicology to be presented in March 2023, entitled, &#8220;A
Naturally Occurring Novel Therapeutic and Oral Selective Inhibitor of TNFa, MYMD-1 (Isomyosamine), Significantly Reduced the Inflammation
and Disease Severity in Murine Model of Collagen Antibody-Induced Arthritis&#8221; authored by Chris Chapman and Sonia Edaye.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All publications and abstracts support
the continued development of MYMD-1<sup>&#174; </sup>across various indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>IND
for Hashimoto&#8217;s Thyroiditis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 18, 2022, we submitted an Annual Update to the FDA for the previously opened Hashimoto&#8217;s Thyroiditis IND.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    April 2021, the FDA gave clearance for a Phase 1 dosing study in normal healthy volunteers; Institutional Review Board (IRB) approval
    was obtained on April 4, 2021. The clinical trial was conducted by The Clinical Research of West Florida Phase 1 unit with a closeout
    visit taking place on November 22, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analyses
    of laboratory parameters, vital sign, ECG, and physical findings did not reveal any clinically relevant effect of MYMD-1. In one
    dose group, there was a decrease in TNF-&#945; levels found in MYMD-1 treated subjects, but no change in the levels in subjects
    given placebo. In one dose group, there was a decrease in TNF-&#945; levels found in MYMD-1 treated subjects, but no change in the
    levels in subjects given placebo.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    data from the Phase 1 clinical trial was submitted to the FDA on September 14, 2021 as part of the Annual IND update for Hashimoto&#8217;s
    Thyroiditis IND. The FDA responded by providing guidance on moving forward with Phase 2 clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    data was also included in a new commercial IND to the FDA on September 22, 2021.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company completed CYP in vitro studies which concluded that clinical drug-drug interactions are not expected with MYMD-1. CYP induction
is the most commonly studied form of induction in drug metabolism and is required by regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had MYMD-1 synthesized in August 2021 to [14C] MYMD-1 radiolabeled product for Mass Balance, Pharmacokinetic, and Metabolism. Analysis
of the rat study results demonstrated that MYMD-1 was metabolized extensively throughout the tissues, crosses the blood brain barrier,
was cleared in the urine and feces, and there were no nitrosated metabolite biological samples detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
a Metabolite Identification and Quantitation of MYMD-1 in Rat, Dog, and Human Plasma Samples: Metabolites in Safety Testing (MIST) was
completed in October 2022. MYMD-1 was extensively metabolized, and was detected at low levels (&lt;5%) in human plasma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, the company published data from the Phase 1 dosing study for MYMD-1 as a treatment for aging. There was a statistically
significant decrease in TNF-&#945; levels (p-value &lt;0.05) found in one MYMD-1 treated subjects cohort, but no change in the levels
in subjects given placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to manage our pivotal Phase 2 aging and sarcopenia study. Final efficacy data from the Phase 2 study is expected in the second quarter
2023. We anticipate that we will review the safety and efficacy of this study and present the mandatory end of Phase 2 data to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company intends to submit an IND to the FDA in the second quarter 2023 for the indication Rheumatoid Arthritis. MyMD Pharmaceuticals,
Inc. completed several in vitro studies from human primary cell-based BioMap systems at Eurofins contrasting MYMD-1 to Humira, Enbrel
and Remicade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2021, Eurofins showed Commonality in a Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used
for Arthritis, Colitis and Dermatitis. On October 26, 2021, our President and Chief Medical Officer, Chris Chapman, M.D., was named Honoree
of the year by the Arthritis Foundation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2021, our lead product candidate MYMD-1 was shown to suppress cytokines, which are the major cause of death in COVID-19 patients,
in a human cell study. The company plans to consult with the FDA on this indication for post COVID-19 immune mediated depression in the
second quarter 2024. During this time, MyMD Pharmaceuticals, Inc. also expects to seek additional FDA guidance on depression in MS patients
under an Orphan Drug Designation (ODD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an active IND to start a Phase 2 study for the indication Hashimoto&#8217;s Thyroiditis, and plan to present the FDA with a protocol
for this pilot Phase 2 study in the fourth quarter 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to begin long-term reproductive toxicity studies in the fourth quarter 2022. These will include study of Fertility and Early Embryonic
Development to Implantation in Mice, and study for Effects on Embryo Fetal Development in Mice and Rabbits with a toxicokinetic evaluation.
These studies will continue to support long-term dosing in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
manufacturing, we will continue to provide GMP MYMD-1 capsules for Phase 2 clinical trials. We plan to continue analytical analysis to
provide GMP product other that capsules for long-term human trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received domestic patent protection for MYMD-1, including its use in methods of extending lifespan and treating arthritis, autoimmune
diseases, and inflammatory and age-related disorders including sarcopenia. We will continue to prosecute patents to protect intellectual
property for MYMD-1 in the United States and abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Supera-CBD
Product Candidate</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from Eurofins studies involving human primary cell-based BioMap system demonstrated that Supera-CBD delivers an extremely potent therapeutic
benefit of 8,000 times that of plant-derived CBD at activating CB2 receptors, permitting its delivery at a very low non-toxic dose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 10, 2021 the company was awarded U.S. Patent 11,085,047 B2, titled &#8220;Synthetic Cannabinoid Compounds for Treatment of Substance
Addiction and Other Disorders,&#8221; covering the Super-CBD product candidate and its pharmaceutical formulations. During 2021 and 2022
corresponding foreign patents were awarded in Australia, Canada, Europe, Israel, and South Korea, and patents are pending in China and
Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johns
Hopkins Medicine researchers presented Supera-CBD data at the 3<sup>rd</sup> annual Neuroimmunology Drug Development Summit on April
26, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company presented data referencing Super-CBD at the 4<sup>th</sup> Annual International Cannabinoid Summit on September 9, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March&#160;2,
2023, we announced that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific review and determined that it would
not Supera-CBD a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations. We
believe that this decision will expedite future research involving Supera-CBD by relieving us or our research partners from having to
comply with regulations relating to controlled substances.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to continue our preclinical program starting genotoxicity studies in Europe. Those studies include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolic
    profiling and Ames test (initiation December 21, 2021; completion January 20, 2022) and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Micronucleus test (initiation December 21, 2021; completion February 20,
2022).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
study of Behavioral Biology at Johns Hopkins University Supera-CBD vs. CBD Acute Pain and Inflammation begins has been funded for
2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Institutes of Health is planning to work on a grant for Supera-CBD in Epilepsy for the third quarter 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
manufacturing, we expect to continue providing GMP Supera-CBD materials for the preclinical toxicity programs. We plan to continue analytical
analysis to provide GMP materials for long term toxicity and Human trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
example of continued efforts include the JHM Research is conducting a study with MYMD-1 and L/R-Supera-CBD for Depression and
Anxiety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forced
    Swim Test</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tail
    suspension</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elevated
    Plus Maze and Fear Conditioning</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
    response study. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera-CBD
    open field and Y maze study. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
    LPS induced depression.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is <span style="text-decoration: underline">www.mymd.com</span>. We do not intend our website address to be an active link or to otherwise incorporate by reference
the contents of the website into this Annual Report on Form 10-K. The SEC maintains an Internet website (<span style="text-decoration: underline">www.sec.gov</span>) that contains
reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
1A. Risk Factors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our Common Stock involves a high degree of risk. Before deciding whether to invest in our securities, you should consider
carefully the risks described below, together with other information in this Annual Report on Form 10-K and the other information and
documents we file with the SEC. Our business, financial condition and operating results can be affected by a number of factors, whether
currently known or unknown, including but not limited to those described below, any one or more of which could, directly, or indirectly,
cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition
and operating results. Any of these factors in whole or in part, could materially and adversely affect our business, financial condition,
operating results and stock price.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other
statements in this Form 10-K. The following information should be read in conjunction with our consolidated financial statements and
related notes thereto and with Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221;
included elsewhere in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factor Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of the principal factors that make an investment in our Common Stock speculative or risky. This summary does not address
all of the risks that we face. Additional discussion of risks summarized in this risk factor summary, and other risks that we face, can
be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this
Annual Report on Form 10-K and our other filings with the SEC before making investment decisions regarding our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to the Company Following the Merger</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they experienced in connection with
    the Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our Common Stock may be subject to significant fluctuations and volatility, and the stockholders of the Company may
    be unable to resell their shares at a profit and may incur losses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may issue additional equity securities in the future, which may result in dilution to existing investors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    concentration of the capital stock ownership with insiders of the Company following the Merger will likely limit the ability of our
    stockholders to influence corporate matters.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    sale or availability for sale of a substantial number of shares of our Common Stock after expiration of the lock-up period could
    adversely affect the market price of such shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    active trading market for our Common Stock may not be sustained.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    intended benefits of the Contribution Transaction may not be realized.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security
    or those of third-party providers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to our Product Development and Regulatory Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to develop, obtain regulatory approval for and commercialize MYMD-1, Supera-CBD, or other future product candidates,
    or if we experience significant delays in doing so, our business will be materially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Success
    in pre-clinical studies and earlier clinical trials for our product candidates may not be indicative of the results that may be obtained
    in later clinical trials, including our Phase 2 clinical trial for MYMD-1, which may delay or prevent obtaining regulatory approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we complete the necessary pre-clinical studies and clinical trials, we cannot predict
                                            when, or if, we will</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    COVID-19 pandemic, or similar public health crises, could have a material adverse impact the execution of our planned clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and
    could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply
    with regulatory requirements or if it experiences unanticipated problems with our product candidates, when and if any of them are
    approved.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    development program for Supera-CBD, a synthetic analog of CBD, is uncertain and may not yield commercial results and is subject to
    significant regulatory risks.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to Commercialization and Manufacturing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    commercial success of our product candidates, including MYMD-1 and Supera-CBD, will depend upon their degree of market acceptance
    by providers, patients, patient advocacy groups, third-party payors, and the general medical community.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    pricing, insurance coverage, and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate
    coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease
    our ability to generate product revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    third parties on which we depend to conduct our planned pre-clinical studies or clinical trials, do not perform as contractually
    required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with
    adverse effects on our business, financial condition, results of operations and prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition in an environment of rapid pharmacological change and it is possible that our competitors may achieve
    regulatory approval before us or develop therapies that are more advanced or effective than ours, which may harm our business, financial
    condition and our ability to successfully market or commercialize MYMD-1, Supera-CBD and our other product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party
    manufacturers encounter such difficulties, our ability to provide supply of MYMD-1, Supera-CBD or our other product candidates for
    clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our product candidates for patients,
    if approved, could be delayed or stopped.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enacted
    and future legislation may increase the difficulty and cost for us to commercialize and obtain marketing approval of our product
    candidates and may affect the prices we may set.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA&#8217;s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels,
    ability to hire and retain key personnel, statutory, regulatory and policy changes and global health concerns.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    operations and relationships with future customers, providers and third-party payors will be subject to applicable anti-kickback,
    fraud and abuse and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil
    penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to Our Intellectual Property</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success depends in part on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect
    our proprietary rights and technology, and we may not be able to ensure their adequate protection.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    potential strategy of obtaining rights to key technologies through in-licenses may not be successful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in patent law in the U.S. and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability
    to protect our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Risks Related to Our Series&#160;F Convertible
Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Series F Convertible
    Preferred Stock (the &#8220;Series&#160;F Preferred Stock&#8221;) provides for the payment of dividends in cash or in shares of our
    Common Stock. If we pay such dividends in shares of Common Stock, it may result in dilution to existing investors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not receive approval
    from our stockholders, we will be unable to pay dividends due to the holders of our Series F Preferred Stock in shares of Common
    Stock and we will be required to pay such dividends in cash, which may force us to divert cash from other uses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certificate of designation
    for the Series F Preferred Stock and the warrants issued concurrently contain anti-dilution provisions that may result in the reduction
    of the conversion price of the Series F Preferred Stock or the exercise price of such warrants in the future. These features may
    result in an indeterminate number of shares of Common Stock being issued upon conversion of the Series F Preferred Stock or exercise
    of the warrants.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, we face other business,
financial, operational and legal risks and uncertainties set forth under &#8220;Risk Factors&#8221; in Item 1A of this Annual Report on
Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Company Following the Merger</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they experienced in connection with
the Merger.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to realize the full strategic and financial benefits currently anticipated from the Merger, our stockholders will have
experienced substantial dilution of their ownership interests in their respective pre-Merger companies without receiving any
commensurate benefit, or only while receiving part of the commensurate benefit to the extent the combined organization is able to
realize only part of the strategic and financial benefits anticipated at the time of the Merger. Furthermore, if we fail to realize
the intended benefits of the Merger, the market price of our Common Stock could decline to the extent that the market price reflects
those benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our Common Stock after the Merger has been and may continue to be subject to significant fluctuations and volatility, and the stockholders of
the Company may be unable to resell their shares at a profit and may incur losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to April 2021, there was no public market for the combined Company&#8217;s Common Stock. The market price of our Common Stock
following the Merger has begun and could continue to be subject to significant fluctuation following the Merger. The pre-Merger
business of the Company differs from its post-Merger business in important respects and, accordingly, the results of operations of
the combined Company and the market price of the combined Company&#8217;s Common Stock following the Merger may be affected by
factors different from those affecting the results of operations of the Company prior to the Merger. Market prices for securities of
life sciences and biopharmaceutical companies in particular have historically been volatile and have shown extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and
industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may
seriously affect the market price of our Common Stock, regardless of the actual operating performance of the combined company. Some
of the factors that may cause the market price of our Common Stock to fluctuate include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors
    reacting negatively to the effect on our business and prospects from the Merger;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    announcement of new products, new developments, services or technological innovations by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in our business, operations or
    prospects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or
    other events by the us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the life sciences and biopharmaceutical industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of other life sciences and biopharmaceutical companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our Common Stock by stockholders, including executives and directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our Common Stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the market prices and trading volumes of the life sciences and biopharmaceutical stocks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to finance our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to secure resources and the necessary personnel to pursue our plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet external expectations or management guidance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales or distributions of large blocks of Common Stock
    by stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendations and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigation related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigations
    by regulators into our operations or those of our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which may be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the overall market and the market prices of particular companies&#8217; securities, securities
class action litigation has often been instituted against these companies. Litigation of this type, if instituted against us, could result
in substantial costs and a diversion of management&#8217;s attention and resources of the Company. Any adverse determination in any such
litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the COVID-19 pandemic, inflation, war and other macroeconomic and geopolitical factors have resulted in significant financial market volatility and uncertainty in recent years. A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital,
on our business, results of operations and financial condition, and on the market price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of operating losses, and we may not achieve or sustain profitability. We anticipates that we will continue to incur losses
for the foreseeable future. If we fails to obtain additional funding to conduct our planned research and development efforts, we could
be forced to delay, reduce or eliminate our product development programs or commercial development efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage pharmaceutical company with a limited operating history. Pharmaceutical product development is a highly speculative
undertaking and involves a substantial degree of risk. Our operations to date have been limited primarily to business planning, raising
capital and conducting research and development activities for our product candidates. We have never generated any revenue from product
sales. We have not obtained regulatory approvals for any of our product candidates and we have funded our operations to date through
proceeds from private placements of Common Stock and a line of credit from an affiliate of MyMD&#8217;s founder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
have incurred net losses in each year since our inception. We incurred net losses of $15,197,336 and $29,889,045 for the years ended
December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $93,758,904. Substantially all our
operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative
costs associated with our operations. We expect to continue to incur significant expenses and operating losses over the next several
years and for the foreseeable future as we intend to continue to conduct research and development, clinical testing, regulatory compliance
activities, manufacturing activities, and, if any of our product candidates is approved, sales and marketing activities that, together
with anticipated general and administrative expenses, will likely result in the company incurring significant losses for the foreseeable
future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&#8217;
equity and working capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD&#8217;s
predecessor, MyMD Florida, was formed in late 2014. Our operations to date have been limited primarily to business planning, raising
capital and conducting research and development activities for our product candidates. We have not yet demonstrated the ability to complete
clinical trials of our product candidates, obtain marketing approvals, manufacture a commercial scale product or conduct sales and marketing
activities necessary for successful commercialization. Consequently, predictions about our future success or viability are speculative
and no assurances can be given about our future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>After
the Merger was consummated, the business operations, strategies and focus of the Company fundamentally changed, and these changes may
not result in an improvement in the value of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, our primary products are MyMD Florida&#8217;s therapeutic platforms: MYMD-1, a clinical-stage immunometabolic regulator and
Supera-CBD, a pre-clinical stage patented synthetic CBD analog. We expect to incur losses as we develop our product candidates, and our
product candidates, may never get approved by the FDA or, even if approved for marketing, may not be profitable. The failure to successfully
develop product candidates will significantly diminish the anticipated benefits of the Merger and have a material adverse effect on our
business. There is no assurance that our business operations, strategies or focus will be successful, which could depress the value of
our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
concentration of the capital stock ownership with insiders of the Company after the Merger will likely limit the ability of our stockholders
to influence corporate matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Supera Purchase and the Merger, the executive officers, directors, five percent or greater stockholders, and the respective affiliated
entities of the Company, in the aggregate, beneficially owned more than 10% of the Company&#8217;s outstanding Common Stock. As a result,
these stockholders, acting together, had, and continue to have, control over matters that require approval by our stockholders, including
the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders
oppose them. This concentration of ownership might also have the effect of delaying or preventing a corporate transaction that other
stockholders may view as beneficial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
stockholders could attempt to influence changes within the Company, which could adversely affect our operations, financial condition
and the value of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders may from time to time seek to acquire a controlling stake in the Company, engage in proxy solicitations, advance stockholder
proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly traded companies are sometimes
led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special
dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders
can be costly and time-consuming and could disrupt our operations and divert the attention of our Board of Directors and senior management.
These actions could adversely affect our operations, financial condition, and the value of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
sale or availability for sale of a substantial number of shares of our Common Stock after expiration of the lock-up period could adversely
affect the market price of such shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our Common Stock in the public market after expiration of the lock-up period and other legal
restrictions on resale, or the perception that these sales could occur, could adversely affect the market price of such shares and
could materially impair our ability to raise capital through equity offerings in the future. Upon completion of the Merger and the
transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common
Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Shares that were issued to pre-Merger MyMD
Florida stockholders as merger consideration could be resold in the public market immediately without restriction, unless such
stockholder was subject to a lock-up or other restriction on resale. All of the previous executive officers, directors and principal
stockholders of pre-Merger MyMD Florida, and all of our directors who continued to serve on the Board of Directors of the combined
Company after the Merger, were subject to lock-up agreements pursuant to which such stockholders agreed, except in limited
circumstances, not to transfer, grant an option with respect to, sell, exchange, pledge or otherwise dispose of, or encumber, any
shares of Company capital stock for 180 days following the effective time of the Merger; such lock-up agreements have now expired,
so the shares of our Common Stock (excluding securities underlying options and warrants) held by our directors, executive officers
and principal stockholders may now be sold, subject to volume limitations under Rule 144 under the Securities Act and various
vesting agreements. We are unable to predict what effect, if any, market sales of securities held by our significant stockholders,
directors or officers or the availability of these securities for future sale will have on the market price of our Common Stock in
the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also assumed approximately 4,188,315 shares of Common Stock subject to outstanding options to purchase pre-Merger MyMD Florida Common Stock. We registered all of the shares of Common Stock issuable upon exercise of outstanding options to purchase MyMD Florida Common Stock, and therefore upon the exercise of any options or other equity incentives we may grant in the future, for public resale under
the Securities Act. Accordingly, these shares will be able to be freely sold in the public market upon issuance as permitted by any applicable
vesting requirements, subject to the lock-up agreements described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions under New Jersey corporate law may make it difficult for our stockholders to replace or remove our Board of Directors and
could deter or delay third parties from acquiring us, which may be beneficial to our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the anti-takeover provisions of New Jersey law, including Section 14A-10A of the New Jersey Shareholders Protection Act.
These statutes prohibit an &#8220;interested stockholder&#8221; of the Company from effecting a business combination with us for a period
of five years unless our Board of Directors approved the combination or transaction or series of related transactions that caused such
person to become an interested stockholder prior to the stockholder becoming an interested stockholder or after the stockholder becomes
an interested stockholder if the subsequent business combination is approved by (i) our Board of Directors (or a committee thereof consisting
solely of persons independent from the interested stockholder), and (ii) the affirmative vote of a majority of the voting stock not beneficially
owned by such interested stockholder. In addition, but not in limitation of the five-year restriction, we may not engage at any time
in a business combination with any interested stockholder the Company unless the combination is approved by our Board of Directors (or
a committee thereof consisting solely of persons independent from such interested stockholder) prior to the consummation of the business
combination, and the combination receives the approval of a majority of the voting stock of the Company not beneficially owned by the
interested stockholder if the transaction or series of related transactions which caused the interested stockholder to become an interested
stockholder was approved by the Board of Directors prior to the stockholder becoming an interested stockholder. These provisions could
discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 14A-10A
of the New Jersey Shareholders Protection Act, &#8220;interested stockholder&#8221; means, generally, any beneficial owner of 10% or
more of the voting power of the outstanding voting stock of the corporation and any affiliate or associate of the corporation who within
the prior five year period has at any time owned 10% or more of the voting power of the then outstanding stock of the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect that we will need to raise additional funding before we can expect to become profitable from any potential future sales of our
product candidates. This additional financing may not be available on acceptable terms or at all. Failure to obtain this necessary capital
when needed may force us to delay, limit or terminate our product development efforts or other operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will require substantial future capital in order to complete planned and future pre-clinical and clinical development for MYMD-1 and
Supera-CBD and potentially commercialize these product candidates. We expect increased spending levels in connection with our clinical
trials of our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur
significant expenses related to commercial launch, product sales, medical affairs, regulatory, marketing, manufacturing and distribution.
Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations before any commercial revenue may occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional capital raised through the sale of equity or equity-backed securities may dilute our stockholders&#8217; ownership percentages
and could also result in a decrease in the market value of our equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences,
superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders
of any of our securities then outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting
fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash
expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
capital might not be available when we need it and our actual cash requirements might be greater than anticipated. If we require additional
capital at a time when investment in its industry or in the marketplace in general is limited, we might not be able to raise funding
on favorable terms, if at all. If we are not able to obtain financing when needed or on terms favorable to us, we may need to delay,
reduce or eliminate certain research and development programs or other operations, sell some or all of our assets or merge with another
entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
must attract and retain highly skilled employees to succeed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face
significant competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly
at the management level, it could adversely affect our ability to execute our business plan, harm our results of operations and increase
our capabilities to successfully commercialize MYMD-1, Supera-CBD and our other product candidates. The competition for qualified personnel
in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary
for the development of our business or to recruit suitable replacement personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for
career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we
are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product
candidates and our business will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate in a highly competitive industry.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face, and will continue to face, intense competition from large pharmaceutical companies, specialty pharmaceutical and biotechnology
companies as well as academic and research institutions pursuing research and development of technologies, drugs or other therapies that
would compete with our products or product candidates. The pharmaceutical market is highly competitive, subject to rapid technological
change and significantly affected by existing rival drugs and medical procedures, new product introductions and the market activities
of other participants. Our competitors may develop products more rapidly or more effectively than us. If our competitors are more successful
in commercializing their products than us, their success could adversely affect our competitive position and harm our business prospects
and may also lead to the diversion of funding away from us and toward other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may be materially adversely affected by the COVID-19 pandemic.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The global health crisis caused
by the COVID-19 pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite vaccination
efforts, remains uncertain and cannot be predicted with confidence. The ultimate impact of COVID-19, including its variants, cannot be
predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the effectiveness of COVID-19
vaccines against future COVID-19 variants and the response by governmental bodies and regulators to any resurgences. Given the ongoing
and dynamic nature of the circumstances, it is difficult to predict the impact of the COVID-19 pandemic on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to public health directives and orders, we have implemented and continue to maintain work-from-home policies for many of our
employees. The effects of the orders and related adjustments in our business have delayed and may continue to delay our timelines, including those with respect to patient enrollment in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Moreover, the COVID-19 pandemic has had and may continue to have indeterminable
adverse effects on general commercial activity and the world economy, and our business and results of operations have been and may continue
to be adversely affected to the extent that COVID-19 or any other epidemic harms the global economy generally.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations will involve the use of hazardous materials,
including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting
with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury
from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable
for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil
or criminal fines and penalties for failure to comply with such laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations.
These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these
laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security or
those of third-party providers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we and our third-party providers rely
on electronic communications and information system to conduct our operations. We and our third-party providers have been, and may continue
to be, targeted by parties using fraudulent e-mails and other communications in attempts to misappropriate bank accounting information,
passwords, or other personal information or to introduce viruses or other malware to our information systems. Between August and October
2021, we experienced a cybersecurity incident. A third-party forensic technology company&#8217;s investigation confirmed that we were
a victim of wire fraud due to a compromised electronic mail account. As of the date of this filing, we have identified losses totaling
$1,260,864 related to this incident, net of amounts recovered. Following the incident, we have taken measures to enhance our electronic
mail security and have modified our internal procedures to ensure the authenticity of payment instructions and we continue to evaluate
additional measures for improving cybersecurity. Despite these prophylactic measures, the risk of such cyber-attacks against us or our
third-party providers and business partners remains a serious issue. Cybersecurity incidents are pervasive, and the risks of cybercrime
are complex and continue to evolve. Although we are making significant efforts to maintain the security and integrity of our information
systems and are exploring various measures to manage the risk of a security breach or disruption, there can be no assurance that our security
efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we collect and store sensitive data, including intellectual property, research data, our proprietary business information and
that of our suppliers, technical information about our products, clinical trial plans and employee records. Similarly, our third-party
providers possess certain of our sensitive data and confidential information. The secure maintenance of this information is critical
to our operations and business strategy. Despite the implementation of security measures, our internal computer systems, and those of
third parties on which we rely, are vulnerable to damage from computer viruses, malware, ransomware, cyber fraud, natural disasters,
terrorism, war, telecommunication and electrical failures, cyberattacks or cyberintrusions over the Internet, attachments to emails,
persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption,
particularly through cyberattacks or cyberintrusions, including by computer hackers, foreign governments, and cyber terrorists, has generally
increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Any such
breach could compromise our networks and the information stored there could be accessed, publicly disclosed, encrypted, lost or stolen.
Any such access, inappropriate disclosure of confidential or proprietary information or other loss of information, including our data
being breached at third-party providers, could result in legal claims or proceedings, liability or financial loss under laws that protect
the privacy of personal information, disruption of our operations or our product development programs and damage to our reputation, which
could adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Product Development and Regulatory Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>With
regard to our Supera-CBD product candidate, we must conduct pre-clinical testing and prepare and submit an IND to the FDA. With regard
to both our MYMD-1 and Supera-CBD product candidates, we must conduct all phases of clinical studies (which may include post-market or
&#8220;Phase 4&#8221; studies), which will likely take several years and substantial expenses to complete, before we can submit an application
for marketing approval to the FDA. There is no guarantee that we will complete such clinical development in a timely manner or at all
or that we will obtain regulatory approval for either product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    &#8211; IND review is conducted and feedback is delivered within 30 days of receipt of the initial application. At the time, changes
    to the study protocol may be requested in order to proceed with the proposed Phase 2 clinical trial.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutional
    Review Board (IRB) &#8211; If the FDA requests changes to the protocol included in the initial application, an amendment must be
    submitted to the IRB for an additional review. This review may include changes to the protocol, informed consent form, surveys, and
    other assessments planned over the course of the clinical trial. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
    &#8211; Clinical sites must follow specific COVID-19 guidelines. Clinical trial activity must adhere to those guidelines which may
    change over the course of the study. For example, the protocol may need to be revised to accommodate for in-home visits (if necessary)
    to maximize patient and research staff safety. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Site
    Initiation Visit (SIV) &#8211; Site initiation visits are scheduled around principal investigator (PI) availability. Due to changing
    clinic schedules, SIVs may need to be rescheduled to accommodate various PI demands.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Central
    Lab &#8211; Central labs are responsible for creating all the kits (supplies) required for patient visits. Kits are created to execute
    all aspects of screening through study completion. Kits are developed based on specifications from core labs and third-party vendors
    (as applicable). All shipping and storing requirements need to be clearly articulated and lab manuals provided to make the kits.
    The central lab is also responsible for building a database to store all the lab results.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic
    Database &#8211; The overall database used for the study must be built around the schedule of assessments planned for each patient
    over the course of the clinical trial. This includes every assessment and data element collected. The complexity of the Phase 2
    trial also requires development and testing of drug randomization across treatment groups to ensure blinding is maintained. Thorough
    user-acceptability testing (UAT) is required and is time-intensive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CoreRx
    &#8211; To maintain adequate blinding across treatment groups, new labels were created and applied to the active drug and placebo
    bottles. Logistics and manufacturing need to work together to ensure capsules were not only filled appropriately, but also labelled
    correctly to ensure the electronic database and randomization schemes maintain alignment over the course of the study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
drug development is a lengthy, expensive, and inherently uncertain process, and we may experience delays in completing, or ultimately
be unable to complete, the development and commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA must approve any new drug products before they can be marketed in the United States, and such approval is contingent upon the collection
of sufficient safety- and efficacy-data from preclinical and clinical studies. We must complete preclinical development and conduct extensive
clinical trials to demonstrate the safety and efficacy of our product candidates for their respective targeted indications. With regard
to Supera-CBD, we are still in the pre-clinical stage, and we are in relatively early clinical stages with regard to certain indications
for which MyMD-1 is being developed and in pre-clinical stages for others. Clinical trials are expensive, difficult to design and implement,
and can take many years to complete, and their outcomes are inherently uncertain. Failure can occur at any time during the clinical trial
process. Nonclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies have believed
their product candidates performed satisfactorily in nonclinical studies and clinical trials and, nonetheless, were denied marketing
approval for such candidates due to insufficient safety or efficacy data and/or other clinical-study deficiencies. It is impossible to
predict whether we will be able to prove that either or both of our product candidates are safe and effective for any of the indications
for which they are, respectively, being developed and, accordingly, when they will be approved for commercialization in the United States
for any given indication, if ever.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completing the requisite preclinical testing, IND submission, internal review board (&#8220;IRB&#8221;) review, and any other applicable
early-development obligations, sponsors must conduct extensive clinical trials to demonstrate the safety and efficacy of the product
candidates. We have completed such early-stage preclinical testing and IND-submission for some, but not all, indications for which MyMD-1
is being developed and are currently working towards completion of such pre-IND activities for Supera-CBD. Even if the results of our
clinical trials are favorable, we expect our product candidates to remain in clinical development for several years before they may be
considered for regulatory approval, and clinical development of either or both candidates for one or more targeted indications may take
significantly longer to complete and may never be successful. Failures in connection with one or more clinical trials can occur at any
stage of testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events
that may prevent successful or timely completion of clinical development include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory authorities on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organization (&#8220;CRO&#8221;) and clinical trial
    sites;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or perceived lack of effectiveness of any product candidate during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects for the entire duration of applicable clinical studies (as study subjects may withdraw at any time due to adverse
    side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in its manufacturing process or product candidate formulation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorization s, such as INDs and any others that must be obtained, maintained, and/or satisfied to commence
    a clinical trial, including &#8220;clinical holds&#8221; or delays requiring suspension or termination of a trial by a regulatory
    agency, such as the FDA, before or after a trial is commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature or timing of studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing pre-clinical studies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of its CROs, or other third-party contractors to comply with all contractual requirements or to perform their services in a timely
    or acceptable manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure, or the failure of any individuals, entities, or organizations involved in one or more aspects of our clinical development
    activities, to comply with all applicable FDA or other regulatory requirements relating to the conduct of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    concerns and additional difficulties associated with cannabinoid products, generally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow its clinical protocols; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the clinical trials of any of our current or future therapeutic candidates do not produce favorable results or are found to have
been conducted in violation of the FDA&#8217;s or other regulatory body&#8217;s standards governing such studies, our ability to request
and obtain regulatory approval for the therapeutic candidate may be adversely impacted, which could have a material adverse effect on
our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop, obtain regulatory approval for and commercialize MYMD-1, Supera-CBD or other future product candidates, or
if we experience significant delays in doing so, our business will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested a substantial amount of effort and financial resources in MYMD-1 and Supera-CBD. We plan to initiate Phase 2 clinical
trials for treatment of diabetes, rheumatoid arthritis, aging and multiple sclerosis with MYMD-1 and IND-enabling pre-clinical
studies of Supera-CBD to enable submission of an Investigational New Drug (&#8220;IND&#8221;) application for a Phase 1 in healthy
volunteers followed by clinical trials in epilepsy, addiction and anxiety disorders. In order to conduct human clinical trials, we
are required obtain approval from Institutional Review Boards (&#8220;IRBs&#8221;) or Ethics committees. IRBs are independent
committee organizations that operate in compliance with U.S. federal regulations (including, but not limited to 21 C.F.R. Parts 50
and 56, and 45 C.F.R. Part 46) in order to help protect the rights of research subjects under the federal Health Insurance
Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;). IRBs provide expertise in examining research for its ethical
implications, including research involving vulnerable populations, such as pediatrics, critically ill, and cognitively impaired
participants. There is no guarantee that an IRB will approve our current product candidates for human clinical trials. Without IRB
approval, the Company would not be able to perform clinical research on humans and our products would not be able to move through
the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate product revenue will depend heavily on the successful development and eventual commercialization of MYMD-1, Supera-CBD
and our other product candidates, which may never occur. We currently generate no revenue from sales of any product and we may never
be able to develop or commercialize a marketable product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our programs and product candidates will require further clinical and/or pre-clinical development, regulatory approval in multiple
jurisdictions, obtaining pre-clinical, clinical and commercial manufacturing supply, capacity and expertise, building of a commercial
organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. MYMD-1 and
Supera-CBD and our other product candidates must be authorized for marketing by the FDA and certain other foreign regulatory agencies
before we may commercialize any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our product candidates depends on multiple factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    completion of pre-clinical studies, including those compliant with Good Laboratory Practices (&#8220;GLP&#8221;) or GLP toxicology
    studies, biodistribution studies and minimum effective dose studies in animals, and successful enrollment and completion of clinical
    trials compliant with current Good Clinical Practices (&#8220;GCPs&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effective
    INDs and Clinical Trial Authorizations (&#8220;CTAs&#8221;) that allow commencement of our planned clinical trials or future clinical
    trials for our product candidates in relevant territories;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    from IRBs or Ethics committees to conduct human clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining relationships with contract research organizations (&#8220;CROs&#8221;), and clinical sites for the clinical development
    of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    clearance of products arriving from foreign countries, needed to perform clinical trials, through U.S. customs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintenance
    of arrangements with third-party contract manufacturing organizations (&#8220;CMOs&#8221;) for key materials used in our manufacturing
    processes and to establish backup sources for clinical and large-scale commercial supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">positive
    results from our clinical programs that are supportive of safety and efficacy and provide an acceptable risk-benefit profile for
    our product candidates in the intended patient populations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of regulatory approvals from applicable regulatory authorities, including those necessary for pricing and reimbursement of our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    and maintenance of patent and trade secret protection and regulatory exclusivity for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    launch of our product candidates, if and when approved, whether alone or in collaboration with others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our product candidates, if and when approved, by patients, patient advocacy groups, third-party payors and the general medical
    community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    effective competition against other therapies available in the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    and maintenance of adequate reimbursement from third-party payors for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to acquire or in-license additional product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prosecution,
    maintenance, enforcement and defense of intellectual property rights and claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintenance
    of a continued acceptable safety profile of our product candidates following approval, including meeting any post-marketing commitments
    or requirements imposed by or agreed to with applicable regulatory authorities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    factors surrounding the approval process, such as government shutdowns, political instability or global pandemics such as the outbreak
    of the novel strain of coronavirus, COVID-19.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability
to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals
for our product candidates, we may not be able to continue our operations.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not have the resources to conduct clinical protocols sufficient to yield data suitable for publication in peer-reviewed journals
and our inability to do so in the future could have an adverse effect on marketing our products effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for our products targeted for use by hospital laboratory professionals and healthcare providers to be widely adopted, we would
have to conduct clinical protocols that are designed to yield data suitable for publication in peer-reviewed journals. These studies
are often time-consuming, labor-intensive and expensive to execute. We have not previously had the resources to effectively implement
such clinical programs within our clinical development activities and may not be able to do so in the future. In addition, if a protocol
is initiated, the results of such protocol may ultimately not support the anticipated positioning and benefit proposition for the product.
Either of these scenarios could hinder our ability to market our products, and revenue may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Success
in pre-clinical studies and earlier clinical trials for our product candidates may not be indicative of the results that may be obtained
in later clinical trials, including our Phase 2 clinical trial for MYMD-1, which may delay or prevent obtaining regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. Success in pre-clinical studies and early clinical trials may not be predictive of results in later-stage
clinical trials, and successful results from early or small clinical trials may not be replicated or show as favorable an outcome in
later-stage or larger clinical trials, even if successful. We will be required to demonstrate through adequate and well-controlled clinical
trials that our product candidates are safe and effective for their intended uses before we can seek regulatory approvals for their commercial
sale. The conduct of Phase 2 and Phase 3 trials, and the submission of a New Drug Application (&#8220;NDA&#8221;) is a complicated process.
We have not previously conducted any clinical trials, and have limited experience in preparing, submitting and supporting regulatory
filings. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials and other requirements
in a way that leads to NDA submission and approval of any product candidate we are developing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies in the pharmaceutical industry have suffered significant setbacks in late-stage clinical trials after achieving positive results
in early-stage development, and there is a high failure rate for product candidates proceeding through clinical trials. In addition,
different methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different
statistical results. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may
not be sufficient to support approval by the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted
in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our
partners, which could delay, limit or prevent regulatory approval. If our study data do not consistently or sufficiently demonstrate
the safety or efficacy of any of our product candidates, including MYMD-1 and Supera-CBD, to the satisfaction of the FDA or foreign regulatory
authorities, then the regulatory approvals for such product candidates could be significantly delayed as we work to meet approval requirements,
or, if we are not able to meet these requirements, such approvals could be withheld or withdrawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary pre-clinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval
to commercialize a product candidate and the approval may be for a narrower indication than we seek.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commercialization in the United States, MYMD-1, Supera-CBD and our other product candidates must be approved by the FDA pursuant to
an NDA for their respective target indication(s). The process of obtaining marketing approvals, both in the U.S. and abroad, is expensive
and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,
complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent
us from commercializing the product candidate. We have not received approval to market MYMD-1, Supera-CBD or any of our other product
candidates from regulatory authorities in any jurisdiction. We have limited experience in submitting and supporting the applications
necessary to gain marketing approvals, and, in the event regulatory authorities indicate that we may submit such applications, we may
be unable to do so as quickly and efficiently as desired. Securing marketing approval requires the submission of extensive pre-clinical
and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s
safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process
to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only
moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude
our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval
process and may refuse to accept or file any application or may decide that our data is insufficient for approval and require additional
pre-clinical, clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing
could delay, limit or prevent marketing approval of a product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of MYMD-1, Supera-CBD or our other product candidates may be delayed or refused for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, that our product candidates
    are safe and effective for any of their proposed indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    populations studied in clinical trials may not be sufficiently broad or representative to assure efficacy and safety in the populations
    for which we seek approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
    authorities for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other
    comparable submission in foreign jurisdictions or to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    facilities of third-party manufacturers with which we contract or procure certain service or raw materials, may not be adequate to
    support approval of our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates meet their pre-specified safety and efficacy endpoints in clinical trials, the regulatory authorities may not
complete their review processes in a timely manner and may not consider such the clinical trial results sufficient to grant, or we may
not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends
non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation
from future legislation or administrative action, or changes in regulatory authority policy during the period of product development,
clinical trials and the review process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations
in the form of narrow indications, warnings, contraindications or Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;). These
regulatory authorities may also grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory
authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.
Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and adversely affect our business,
financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
health crises, such as the COVID-19 pandemic, could have a material adverse impact the execution of our planned clinical
trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Phase 2 clinical trial for MYMD-1 currently in progress has been and may continue to be affected by the pandemic.  Protocols put into place for COVID-19 have delayed and may continue to delay patient enrollment in our current and
planned clinical trials. Any such
delays to our planned Phase 2 and Phase 3 clinical trials for MYMD-1 could impact the use and sufficiency of our existing cash reserves,
and we may be required to raise additional capital earlier than we had previously planned. We may be unable to raise additional capital
if and when needed, which may result in further delays or suspension of our development plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
infections and deaths related to COVID-19 have disrupted certain healthcare and healthcare regulatory systems globally. Lingering
effects from such disruptions and/or any similar issues in the future could divert healthcare resources away from, or materially
delay review by, the FDA and comparable foreign regulatory agencies. There is substantial uncertainty in connection with the extent to which the pandemic may impact or disrupt development
plans and/or operations, generally, in the future. Any elongation or de-prioritization of our clinical
trials or delay in regulatory review resulting from such disruptions could materially adversely affect the development and study of
our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently utilize third parties to, among other things, manufacture raw materials and our product candidates, components, parts, and
consumables, and to perform quality testing. If either we or any third-party in the supply chain for materials used in the production
of its product candidates are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted,
limiting our ability to manufacture product candidates for our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could
be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with
regulatory requirements or if it experiences unanticipated problems with our product candidates, when and if any of them are approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates and the activities associated with their development and potential commercialization, including their testing, manufacturing,
recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by
the FDA and other U.S. and international regulatory authorities. These requirements include submissions of safety and other post-marketing
information and reports, registration and listing requirements, requirements relating to manufacturing, including current Good Manufacturing
Practices (&#8220;cGMPs&#8221;), quality control, quality assurance and corresponding maintenance of records and documents, including
periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to providers
and recordkeeping. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced
inspections by the FDA and other regulatory authorities for compliance with cGMPs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of any approved product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing
processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on such product candidates, manufacturers or manufacturing processes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the labeling or marketing of a product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on product distribution or use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    or untitled letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of any approved product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
    of product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed in a manner consistent
with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding
use of their products. For example, under applicable FDA marketing regulations, prescription drug promotions must be consistent with
and not contrary to approved labeling, present a &#8220;fair balance&#8221; between the product&#8217;s risks and benefits, be truthful
and not false or misleading, and be sufficiently substantiated with appropriate documentary evidence, among numerous other requirements.
If we promote our products that are approved for marketing in the United States, if any, in a manner inconsistent with FDA-approved labeling
or otherwise not in compliance with FDA regulations, we may be subject to enforcement action. Violations of the Federal Food, Drug, and
Cosmetic Act (&#8220;FD&amp;C Act&#8221;) relating to the promotion of prescription drugs may lead to investigation or prosecution by
the DOJ or other applicable agencies and could give rise to ancillary violations of federal and state healthcare fraud and abuse laws,
as well as state consumer protection laws and similar laws in international jurisdictions. Additionally, our marketing activities relating
to any products we may commercialize in the United States in the future may also be subject to enforcement by the FTC and/or state attorneys
general, and we may face consumer class-action liability if our marketing practices are actually or allegedly misleading or deceptive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the requirements applicable to approved drug products, we may also be subject to enforcement action in connection with any
promotion of an investigational new drug. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, may
not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation
or otherwise promote the therapeutic candidate. Sponsors must strike the often difficult balance of communicating sufficient information about its product candidates
to inform investors and engaging in valid scientific exchanges with the medical community without crossing the often-difficult-to-ascertain
line into &#8220;promotion,&#8221; which is not defined by regulation but is generally interpreted broadly by FDA. Accordingly, if FDA finds any of our communications regarding MyMD-1 or Supera-CBD to be promotional,
we may be subject to a wide range of enforcement actions, and our candidates&#8217; prospects for regulatory approval may be adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above could give rise to material reputational harm to our business and our current, and any future, product candidates
we may develop and may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response. The FDA&#8217;s and
other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit
or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we have obtained, and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the
U.S.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
market and sell MYMD-1, Supera-CBD or our other product candidates in other jurisdictions, we must obtain separate marketing approvals
and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional
testing. The time and data required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory
approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries
outside the U.S., we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that
country. Failure to obtain foreign regulatory approvals or non-compliance with foreign regulatory requirements could result in significant
delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market
will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be
adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any
of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product
candidate and our business prospects could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
development program for Supera-CBD, a synthetic analog of CBD, is in its infancy and subject to substantial uncertainty and may not
yield commercial results and is subject to significant regulatory risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are only in the pre-clinical stage of development for Supera-CBD, which is essentially the earliest stage of a
candidate&#8217;s development process and must be followed by regulatory submissions (such as, an IND application and FDA&#8217;s acceptance
thereof), IRB approval, as well as the complex, onerous clinical-trial process (which must be conducted in accordance with FDA&#8217;s
IND regulations), and ultimately, NDA submission, the approval of which is not guaranteed. There
can be no assurance that our development program for Supera-CBD, a synthetic analog of CBD, will be successful, or that any research
and development and product testing efforts will result in commercially saleable products, or that the market will accept or respond
positively to products based on Supera-CBD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Federal
Regulation of CBD</b>. The market for cannabinoids is heavily regulated. Synthetic cannabinoids may be viewed as qualifying as controlled
substances under the federal Controlled Substances Act of 1970 (CSA) and may be subject to a high degree of regulation including, among
other things, certain registration, licensing, manufacturing, security, record keeping, reporting, import, export, inspection by DEA
clinical and non-clinical studies, insurance and other requirements administered by the U.S. Drug Enforcement Administration (DEA) and/or
the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State
Regulation of CBD. </b>Individual states and countries have also established controlled substance laws and regulations, which may differ
from U.S. federal law. States have also developed CBD-specific laws and regulations that govern a wide range of CBD-related activities,
from cultivation to processing to marketing. There is substantial variation among states&#8217; CBD laws, and we will have to devote
substantial time, expenses, and resources toward compliance, and such laws are also subject to ongoing evolution and, thus, must be actively
monitored. We or our business partners may be required to obtain separate state or country registrations, permits or licenses in order
to be able to develop produce, sell, store and transport cannabinoids.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance
is Complex and Costly</b>. Complying with laws and regulations relating to cannabinoids is evolving, complex and expensive, and may divert
management&#8217;s attention and resources from other aspects of our business. Failure to maintain compliance with such laws and regulations
may result in regulatory action that could have a material adverse effect on our business, results of operations and financial condition.
The DEA, FDA or state agencies may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those
registrations. In certain circumstances, violations could lead to criminal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
trials</b>. Because synthetic CBD products may be regulated as controlled substances in the U.S., to conduct clinical trials in the U.S.,
each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that will
allow those sites to handle and dispense products based on Supera-CBD and to obtain product from our manufacturer. If the DEA delays
or denies the grant of a research registration to one or more research sites, the clinical trial could be significantly delayed, and
we could lose clinical trial sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negative
public perception of cannabis-related businesses, misconceptions about the nature of our business or Supera-MD, and regulatory uncertainties
relating to the legality of cannabinoids could each have a material adverse effect on our business, financial condition, and results
of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the cannabinoid industry is highly dependent upon consumer perception regarding the safety, efficacy, quality, and legality of
cannabinoids, whether naturally derived or synthetic. Consumer perception of cannabinoid products can be significantly influenced by
scientific research or findings, regulatory investigations, litigation, media attention, and other publicity regarding the consumption
of CBD products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention,
or other research findings or publicity will be favorable to the CBD market or Supera-CBD, in particular. Our dependence upon consumer
perceptions with regard to Supera-CBD, particularly once it is approved for commercialization, if ever, means that adverse scientific
research reports, findings, regulatory proceedings, litigation, media attention, or other publicity relating to cannabinoid products,
generally, or any particular cannabinoid products or derivatives, in particular, regardless of merit or accuracy, could have a material
adverse effect on our business, the development of, or ultimate commercial demand for (if applicable), Supera-CBD. Such adverse publicity
or other negative media attention could arise even if the adverse effects reportedly associated with such products resulted from consumers&#8217;
failure to consume such products appropriately or as directed. Any adverse publicity or other similar occurrences affecting consumer
perception may have a material adverse impact on our reputation, perception of Supera-CBD, and our ability to obtain the necessary regulatory
approvals for Supera-CBD and its prospective commercial viability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization and Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
commercial success of our product candidates, including MYMD-1 and Supera-CBD, will depend upon their degree of market acceptance by
providers, patients, patient advocacy groups, third-party payors and the general medical community.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
with the requisite approvals from the FDA and other regulatory authorities internationally, the commercial success of our product candidates
will depend, in part, on the acceptance of providers, patients and third-party payors of our product candidates, as medically necessary,
cost-effective and safe. Any product that we commercialize may not gain acceptance by providers, patients, patient advocacy groups, third-party
payors and the general medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant
product revenue and may not become profitable. The degree of market acceptance of MYMD-1, Supera-CBD and our other product candidates,
if approved for commercial sale, will depend on several factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy, durability and safety of such product candidates as demonstrated in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential and perceived advantages of product candidates over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment relative to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which the product candidate is approved by the FDA or the European Commission;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of providers to prescribe new therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    labeling or product insert requirements of the FDA or other regulatory authorities, including any limitations or warnings contained
    in a product&#8217;s approved labeling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of marketing and distribution support;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    quality of our relationships with patient advocacy groups;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
    concerning our product candidates or competing products and treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient
    third-party payor coverage and adequate reimbursement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a potential product displays a favorable efficacy and safety profile in pre-clinical studies and clinical trials, market acceptance
of the product will not be fully known until after it is launched.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate
coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our
ability to generate product revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish or sustain coverage and adequate reimbursement for our product candidates from third-party payors, the adoption
of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market
or sell those product candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that coverage and reimbursement by third-party payors will be essential for most patients to be able to afford these treatments.
Accordingly, sales of MYMD-1, Supera-CBD and our other product candidates will depend substantially, both domestically and internationally,
on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party
payors. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing
sufficient to realize a sufficient return on our investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., third-party payors,
including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent
to which new drugs will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older, disabled or suffering
from end-stage renal disease. The Medicaid program, which varies from state to state, covers certain individuals and families who have
limited financial means. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental
payors develop their coverage and reimbursement policies for drugs. One payor&#8217;s determination to provide coverage for a drug product,
however, does not assure that other payors will also provide coverage for the drug product. Further, a payor&#8217;s decision to provide
coverage for a drug product does not imply that an adequate reimbursement rate will be approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to government and private payors, professional organizations such as the American Medical Association (&#8220;AMA&#8221;), can
influence decisions about coverage and reimbursement for new products by determining standards for care. In addition, many private payors
contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement
for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement
or utilization of our product candidates. Even if favorable coverage and reimbursement status is attained for one or more product candidates
for which our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure
on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European
Union, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries,
pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product.
To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness
of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower
than in the U.S. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional
foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the U.S., the reimbursement for our product candidates may be reduced compared with the U.S. and may
be insufficient to generate commercially reasonable revenues and profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors, in the U.S. and internationally, to cap or reduce healthcare costs may cause
such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or
provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of
our product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health
maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription
drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected
to the entry of new products into the healthcare market. Recently there have been instances in which third-party payors have refused
to reimburse treatments for patients for whom the treatment is indicated in the FDA-approved product labeling. Even if we are successful
in obtaining FDA approvals to commercialize our product candidates, we cannot guarantee that we will be able to secure reimbursement
for all patients for whom treatment with our product candidates is indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties on which we depend to conduct our planned pre-clinical studies or clinical trials, do not perform as contractually required,
fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects
on our business, financial condition, results of operations and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third party CROs, CMOs, consultants and others to design, conduct, supervise and monitor key activities relating to, discovery,
manufacturing, pre-clinical studies and clinical trials of our product candidates, and we intend to do the same for future activities
relating to existing and future programs. Because we rely on third parties and do not have the ability to conduct all required testing,
discovery, manufacturing, preclinical studies or clinical trials independently, we have less control over the timing, quality and other
aspects of discovery, manufacturing, pre-clinical studies and clinical trials than we would if we conducted them on our own. These investigators,
CROs, CMOs and consultants are not our employees, and we have limited control over the amount of time and resources that they dedicate
to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which
may draw time and resources from our programs. The third parties we contract with might not be diligent or timely in conducting our discovery,
manufacturing, pre-clinical studies or clinical trials, resulting in discovery, manufacturing, pre-clinical studies or clinical trials
being delayed or unsuccessful, in whole or in part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry
out their contractual duties, satisfy legal and regulatory requirements for the conduct of pre-clinical studies or clinical trials or
meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible
for ensuring that each of our pre-clinical studies and clinical trials is conducted in accordance with the general investigational plan
and protocols for the trial, as well as in accordance with GLP, GCPs and other applicable laws, regulations and standards. Our reliance
on third parties that we do not control does not relieve us of these responsibilities and requirements. The FDA and other regulatory
authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these
third parties fails to comply with applicable GCPs, the clinical data generated in its clinical trials may be deemed unreliable and the
FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving its marketing
applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any
of our clinical trials have complied with GCPs. In addition, our clinical trials must be conducted with product produced in accordance
with cGMPs. Our failure to comply with these regulations may require us to repeat clinical trials, which could delay or prevent the receipt
of regulatory approvals. Any such event could have an adverse effect on our business, financial condition, results of operations and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition in an environment of rapid pharmacological change and it is possible that our competitors may achieve regulatory
approval before us or develop therapies that are more advanced or effective than ours, which may harm our business, financial condition
and our ability to successfully market or commercialize MYMD-1, Supera-CBD and our other product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, competition and a strong emphasis on
intellectual property. We are aware of several companies focused on developing immunometabolic treatments in various indications as well
as several companies addressing other treatments for anti-aging, anxiety and depression. We may also face competition from large and
specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research
institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing
and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
companies are focused on developing treatments for immunometabolic dysregulation in treatment of autoimmune disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our potential competitors, alone or with their strategic partners, may have substantially greater financial, technical and other resources
than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in
the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors.
Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors
also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which
could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally,
new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party
manufacturers encounter such difficulties, our ability to provide supply of MYMD-1, Supera-CBD or our other product candidates for clinical
trials, our ability to obtain marketing approval, or our ability to provide supply of our product candidates for patients, if approved,
could be delayed or stopped.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to establish manufacturing relationships with a limited number of suppliers to manufacture raw materials, the drug substance and
finished product of any product candidate for which we are responsible for pre-clinical or clinical development. Each supplier may require
licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing
approval, a manufacturer and its processes are required to be qualified by the FDA prior to regulatory approval. If supply from the approved
vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified
through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the U.S. may also require
additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is
likely to result in a delay in our desired clinical and commercial timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing drugs is complex, highly regulated and subject to multiple risks. Manufacturing drugs is highly susceptible
to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency
in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal
manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral
or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended
period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover,
if the FDA determines that our CMOs are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may
deny NDA approval until the deficiencies are corrected or we replace the manufacturer in our NDA with a manufacturer that is in compliance.
In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive
FDA requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures
conform to cGMP requirements. As such, our CMOs are subject to continual review and periodic inspections to assess compliance with cGMPs.
Furthermore, although we do not have day-to-day control over the operations of our CMOs, we are responsible for ensuring compliance with
applicable laws and regulations, including cGMPs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others,
cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing
practices, lot consistency and timely availability of raw materials. Even if our collaborators obtain regulatory approval for any of
our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable
to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch
of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials
or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial
condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be adversely affected if healthcare reform measures substantially change the market for medical care or healthcare coverage in
the U.S.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2010, President Obama signed the &#8220;Patient Protection and Affordable Care Act&#8221; (P.L. 111-148) (the &#8220;ACA&#8221;)
and on March 30, 2010, he signed the &#8220;Health Care and Education Reconciliation Act&#8221; (P.L. 111-152), collectively commonly
referred to as the &#8220;Healthcare Reform Law.&#8221; The Healthcare Reform Law included a number of new rules regarding health insurance,
the provision of healthcare, conditions to reimbursement for healthcare services provided to Medicare and Medicaid patients, and other
healthcare policy reforms. Through the law-making process, substantial changes have been and continue to be made to the current system
for paying for healthcare in the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage
and to contain or reduce healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and drugs,
and imposing additional taxes, fees, and rebate obligations on pharmaceutical and medical device companies). This legislation was one
of the most comprehensive and significant reforms ever experienced by the U.S. in the healthcare industry and has significantly changed
the way healthcare is financed by both governmental and private insurers. This legislation has impacted the scope of healthcare insurance
and incentives for consumers and insurance companies, among others. Additionally, the Healthcare Reform Law&#8217;s provisions were designed
to encourage providers to find cost savings in their clinical operations. Pharmaceuticals represent a significant portion of the cost
of providing care. This environment has caused changes in the purchasing habits of consumers and providers and resulted in specific attention
to the pricing negotiation, product selection and utilization review surrounding pharmaceuticals. This attention may result in our current
commercial products, products we may commercialize or promote in the future, and our therapeutic candidates, being chosen less frequently
or the pricing being substantially lowered. At this stage, it is difficult to estimate the full extent of the direct or indirect impact
of the Healthcare Reform Law on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
structural changes could entail further modifications to the existing system of private payors and government programs (such as Medicare,
Medicaid, and the State Children&#8217;s Health Insurance Program), creation of government-sponsored healthcare insurance sources, or
some combination of both, as well as other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement
for prescribed drugs and pharmaceuticals, including our current commercial products, those we and our development or commercialization
partners are currently developing or those that we may commercialize or promote in the future. If reimbursement for the products we currently
commercialize or promote, any product we may commercialize or promote, or approved therapeutic candidates is substantially reduced or
otherwise adversely affected in the future, or rebate obligations associated with them are substantially increased, it could have a material
adverse effect on our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extending
medical benefits to those who currently lack coverage will likely result in substantial costs to the U.S. federal government, which may
force significant additional changes to the healthcare system in the U.S. Much of the funding for expanded healthcare coverage may be
sought through cost savings. While some of these savings may come from realizing greater efficiencies in delivering care, improving the
effectiveness of preventive care and enhancing the overall quality of care, much of the cost savings may come from reducing the cost
of care and increased enforcement activities. Cost of care could be reduced further by decreasing the level of reimbursement for medical
services or products (including our current commercial products, our development or commercialization partners or any product we may
commercialize or promote, or those therapeutic candidates currently being developed by us), or by restricting coverage (and, thereby,
utilization) of medical services or products. In either case, a reduction in the utilization of, or reimbursement for our current commercial
products, any product we may commercialize or promote, or any therapeutic candidate, or for which we receive marketing approval in the
future, could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
states and private entities initially mounted legal challenges to the Healthcare Reform Law, in particular, the ACA, and they continue
to litigate various aspects of the legislation. On July 26, 2012, the U.S. Supreme Court generally upheld the provisions of the ACA at
issue as constitutional. However, the U.S. Supreme Court held that the legislation improperly required the states to expand their Medicaid
programs to cover more individuals. As a result, states have a choice as to whether they will expand the number of individuals covered
by their respective state Medicaid programs. Some states have not expanded their Medicaid programs and have chosen to develop other cost-saving
and coverage measures to provide care to currently uninsured individuals. Many of these efforts to date have included the institution
of Medicaid-managed care programs. The manner in which these cost-saving and coverage measures are implemented could have a material
adverse effect on our reputation, business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the healthcare regulatory environment has seen significant changes in recent years and is still in flux. Legislative initiatives to modify,
limit, replace, or repeal the ACA and judicial challenges have continued. We cannot predict the impact on our business of future legislative
and legal challenges to the ACA or other aspects of the Healthcare Reform Law or other changes to the current laws and regulations. The
financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the policies
reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation. From time
to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions
governing coverage, reimbursement, and marketing of pharmaceutical products. In addition, third-party payor coverage and reimbursement
policies are often revised or interpreted in ways that may significantly affect our business and our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
his time in office, former President Trump supported the repeal of all or portions of the ACA. President Trump also issued an executive
order in which he stated that it is his administration&#8217;s policy to seek the prompt repeal of the ACA and in which he directed executive
departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to
the maximum extent permitted by law. Congress has enacted legislation that repeals certain portions of the ACA, including but not limited
to the Tax Cuts and Jobs Act, passed in December 2017, which included a provision that eliminates the penalty under the ACA&#8217;s individual
mandate, effective January 1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things,
repealed the Independent Payment Advisory Board (which was established by the ACA and was intended to reduce the rate of growth in Medicare
spending).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in December 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the ACA is, therefore,
invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded the case back to the
lower court to reassess whether and how such holding affects the validity of the rest of the ACA. The Fifth Circuit&#8217;s decision
on the individual mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court held that the plaintiffs (comprised
of the state of Texas, as well as numerous other states and certain individuals) did not have standing to challenge the constitutionality
of the ACA&#8217;s individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s decision and instructed the district court
to dismiss the case. As a result, the ACA will remain in-effect in its current form for the foreseeable future; however, we cannot predict
what additional challenges may arise in the future, the outcome thereof, or the impact any such actions may have on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden administration also introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on
January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health
insurance coverage through the ACA marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive
order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On the legislative front, the
American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid drug
rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, beginning January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021,
HHS released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and
sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take
to advance these principles. And, in August 2022, the Inflation Reduction Act (&#8220;IRA&#8221;) was signed into law, which will, among other things,
allow U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to negotiate the selling price of certain drugs and biologics that
the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) reimburses under Medicare Part&#160;B and Part&#160;D, although
only high-expenditure single-source drugs that have been approved for at least 7&#160;years (11&#160;years for biologics) can be selected
by CMS for negotiation, with the negotiated price taking effect two&#160;years after the selection&#160;year. The negotiated prices, which
will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in October&#160;2023, the IRA will also penalize
drug manufacturers that increase prices of Medicare Part&#160;B and Part&#160;D drugs at a rate greater than the rate of inflation. The
IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial&#160;years.
Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends
enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan&#160;year 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is uncertainty as to what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the
U.S. or the effect of any future legislation or regulation. Furthermore, we cannot predict what actions the Biden administration will
implement in connection with the Health Reform Law. However, it is possible that such initiatives could have an adverse effect on our
ability to obtain approval and/or successfully commercialize products in the U.S. in the future, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that
we have failed to comply, the agency can institute a wide variety of enforcement actions which may materially affect our business operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that
we have failed to comply, with one or more applicable requirements the agency can institute a wide variety of enforcement actions, ranging
from a public warning letter to more severe sanctions such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    injunctions and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall,
    detention or seizure of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issuance of public notices or warnings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions, partial suspension or total shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    MyMD&#8217;s requests for a 510(k) clearance of new products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing
    a 510(k) clearance already granted; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to comply with applicable requirements could lead to an enforcement action that may have an adverse effect on our financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA&#8217;s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels,
ability to hire and retain key personnel, statutory, regulatory and policy changes and global health concerns.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of
user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition, government funding
of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid
and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved
by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for
35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the
FDA, have had to furlough critical employees and stop critical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government
funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions could
significantly impact the ability of the FDA and other agencies to fulfill their functions and could greatly impact healthcare and the
pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing
facilities and, subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing
facilities. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19
pandemic. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing
facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories
of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all
regulatory activities. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to
the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory
authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability
of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse
effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations and relationships with future customers, providers and third-party payors will be subject to applicable anti-kickback, fraud
and abuse and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil penalties,
contractual damages, reputational harm and diminished profits and future earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which
we obtain marketing approval. Our future arrangements with providers, third-party payors and customers will subject us to broadly applicable
fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we market, sell and distribute any product candidates for which we obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions
under applicable U.S. federal and state healthcare laws and regulations include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits, among other things, persons and entities from knowingly and willfully
    soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either
    the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made
    under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the
    AKS or specific intent to violate it in order to have committed a violation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    false claims laws, including the federal False Claims Act, imposes criminal and civil penalties, including through civil whistleblower
    or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government,
    claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money
    to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation
    of the AKS constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    imposes criminal and civil liability for, among other things, knowingly and willfully executing or attempting to execute a scheme
    to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the AKS, a person
    or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payment Sunshine Act of 2010 (&#8220;PPSA&#8221;) requires applicable manufacturers of covered drugs, devices,
    biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance
    Program, with specific exceptions, to report payments and other transfers of value provided during the previous year to physicians,
    as defined by such law, certain other healthcare providers starting in 2022 (for payments made in 2021), and teaching hospitals,
    as well as certain ownership and investment interests held by such physicians and their immediate family, which includes annual data
    collection and reporting obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;
    and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
    state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and
    the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related
    to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates from government-funded healthcare
programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings,
and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom
we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government-funded healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of its third-party vendors, collaborators, or other contractors may be subject to various federal
and state confidentiality and privacy laws in the United States and abroad and could sustain system failures, security breaches, or other
disruptions, any of which could have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
international, national, federal, provincial and state laws, including state privacy laws (such as the California Consumer Privacy Act),
state security breach notification and information security laws, and federal and state consumer protection laws govern the collection,
use, and disclosure of personal information. In addition, most healthcare providers who may, in the future, prescribe and dispense our
products in the United States and research institutions in the United States with whom we may collaborate in the future are &#8220;covered
entities&#8221; subject to privacy and security requirements under HIPAA. Among other things, HITECH makes HIPAA&#8217;s privacy and
security standards directly applicable to business associates, independent contractors, or agents of covered entities that receive or
obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new
tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and
gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. We could be subject to a wide range
of penalties and sanctions under HIPAA, including criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose
individually identifiable health information maintained by a covered entity in a manner that is not authorized or permitted by HIPAA.
Failure to comply with applicable HIPAA requirements or other current and future privacy laws and regulations could result in governmental
enforcement actions (including the imposition of significant penalties), criminal and civil liability, and/or adverse publicity that
negatively affects our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we rely on our internal and third-party provided information technology systems and applications to support our operations and to maintain
and process company information including personal information, confidential business information and proprietary information. If these
information technology systems are subject to cybersecurity attacks, or are otherwise compromised, due to cyberattacks, human error or
malfeasance, system errors or otherwise, it may adversely impact our business, disrupt our operations, or lead to the loss, theft, destruction,
corruption, or compromise of our information or that of our collaborators, study subjects, or other third-party contractors, as applicable.
Such information technology or security events could also lead to legal liability, regulatory investigations or enforcement actions,
loss of business, negative media coverage, and reputational damage. While we seek to protect our information technology systems from
these types of incidents, the healthcare sector continues to see a high frequency of cyberattacks and increasingly sophisticated threat
actors, and our systems and the information maintained within those systems remain potentially vulnerable to data security incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the above-described cyber or other security-related incidents may trigger notification obligations to affected individuals and government
agencies, legal claims or proceedings, and liability under foreign, federal, provincial and state laws that protect the privacy and security
of personal information. Our proprietary and confidential information may also be accessed. Any one of these events could cause our business
to be materially harmed and our results of operations may be adversely impacted. Finally, as cyber threats continue to evolve, and privacy
and cybersecurity laws and regulations continue to develop, we may need to invest additional resources to implement new compliance measures,
strengthen our information security posture, or respond to cyber threats and incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success largely depends on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect
our proprietary rights and technology, and we may not be able to ensure their adequate protection.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in large part on obtaining and maintaining patent, trademark, trade secret and other intellectual property
protection of our proprietary technologies and product candidates, which include MYMD-1, Supera-CBD and the other product candidates
we have in development, their respective components, formulations, combination therapies, methods used to manufacture them and methods
of treatment, as well as successfully defending our patents and other intellectual property rights against third-party challenges. Our
ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our
product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover
these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope
of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar
or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications
at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is
also possible that we will fail to identify patentable aspects of our research and development activities before it is too late to obtain
patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent
applications, or to maintain the patents, covering technology that we may license from or license to third parties and may be reliant
on our licensors or licensees to do so. Our pending and future patent applications may not result in issued patents. Even if patent applications
we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with adequate protection,
prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents
that we hold or in-license may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether
any of our platform advances and product candidates will be protectable or remain protected by valid and enforceable patents. In addition,
our existing patents and any future patents we obtain may not provide an adequate scope of protection or otherwise may not be enforceable
to prevent others from using our technology or from developing competing products and technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success and future revenue growth will depend, in part, on our ability to protect our intellectual property. We will primarily rely on
patent, copyright, trademark and trade secret laws, as well as nondisclosure agreements and other methods, to protect our proprietary
technologies or processes. It is possible that competitors or other unauthorized third parties may obtain, copy, use or disclose proprietary
technologies and processes, despite efforts by us to protect our proprietary technologies and processes. While we hold rights in
several patents, there can be no assurances that any additional patents will be issued, or additional rights will be granted, to us.
Even if new patents are issued, the claims allowed may not be sufficiently broad to adequately protect our technology and processes.
Our competitors may also be able to develop similar technology independently or design around the patents to which we have rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
MyMD has 16 issued U.S. patents, 50 foreign patents, four pending U.S. patent applications, and 15 foreign patent applications pending
in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea, which if issued are expected to expire
between 2036 and 2041. Although we expect to obtain additional patents and in-licenses in the future, there is no guarantee that we will
be able to successfully obtain such patents or in-licenses in a timely manner or at all. Further, any of our rights to existing patents,
and any future patents issued to us, may be challenged, invalidated or circumvented. As such, any rights granted under these patents
may not provide us with meaningful protection. Even if foreign patents are granted, effective enforcement in foreign countries may not
be available. If our patents or rights to patents do not adequately protect our technology or processes, competitors may be able to offer
products similar to our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
potential strategy of obtaining rights to key technologies through in-licenses may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future growth of our business may depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates
and technologies. We cannot assure that we will be able to in-license or acquire the rights to any product candidates or technologies
from third parties on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, our agreements with certain of our third-party research partners provide that improvements developed in the course of our relationship
with a given partner may be owned solely by either us or our third-party research partner, or jointly between us and the third party.
If we determine that exclusive rights to such improvements owned solely by a research partner or other third party with whom we collaborate
are necessary to commercialize our drug candidates or maintain our competitive advantage, we may need to obtain an exclusive license
from such third party in order to use the improvements and continue developing, manufacturing or marketing our drug candidates. We may
not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from
commercializing our drug candidates or allow our competitors or others the opportunity to access technology that is important to our
business. We also may need the cooperation of any co-owners of our intellectual property in order to enforce such intellectual property
against third parties, and such cooperation may not be provided to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the in-licensing and acquisition of these technologies is a highly competitive area, and a number of more established companies
are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established
companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization
capabilities. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may
be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights
to suitable product candidates or technologies, our business and prospects could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we rely upon know-how and trade secret protection, as well as non-disclosure agreements and invention
assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially
where we do not believe patent protection is appropriate or obtainable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute
confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all
confidential information concerning our business or financial affairs developed or made known to the individual or entity during the
course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified
circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related
to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment
or proprietary information (or as otherwise permitted by applicable law), are our exclusive property. In the case of consultants and
other third parties, the agreements provide that all inventions conceived in connection with the services provided are our exclusive
property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to
our trade secrets or proprietary technology and processes. We have also adopted policies and conduct training that provides guidance
on our expectations, and our advice for best practices, in protecting our trade secrets. Despite these efforts, any of these parties
may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate
remedies for such breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate
precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These
measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access,
provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating
our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide
an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret
can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed
by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such
as our trade secrets, were to be disclosed or misappropriated, such as through a data breach, or if any of that information was independently
developed by a competitor, our competitive position could be harmed. Additionally, certain trade secret and proprietary information may
be required to be disclosed in submissions to regulatory authorities. If such authorities do not maintain the confidential basis of such
information or disclose it as part of the basis of regulatory approval, our competitive position could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Although we have no knowledge of any claims against
us, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary
information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending
against these claims, litigation could result in substantial costs and be a distraction to management. To date, none of our employees
have been subject to such claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-party
claims of intellectual property infringement may prevent, delay or otherwise interfere with our product discovery and development efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary
technologies without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of third
parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and
pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes
review, post grant review, and reexamination proceedings before the United States Patent and Trademark Office (&#8220;USPTO&#8221;) or
oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by
third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies
infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending
patent applications that are owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology
and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims
of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents
cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and
patent applications filed in our field, third parties may allege they have patent rights encompassing our product candidates, technologies
or methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of
issues, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement
    and other intellectual property claims that, regardless of merit, may be expensive and time-consuming to litigate and may divert
    our management&#8217;s attention from our core business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes
    on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to
    pay treble damages plus the patent owner&#8217;s attorneys&#8217; fees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court prohibiting us from developing, manufacturing, marketing, selling or importing our product candidates, or from using our proprietary
    technologies, unless the third-party licenses its product rights or proprietary technology to us, which it is not required to do
    in the U.S. and certain other countries, on commercially reasonable terms or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant
    cross-licenses to intellectual property rights for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that we redesign our product candidates or processes so they do not infringe, which may not be possible or may require
    substantial monetary expenditures and time; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities
    analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material
adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect
on our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are employing their proprietary technology without authorization, including by enforcing its patents against
us by filing a patent infringement lawsuit against us. In this regard, patents issued in the U.S. by law enjoy a presumption of validity
that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have identified all patents, published applications or published literature that affect our business by blocking our ability
to commercialize our products, by preventing the patentability of one or more aspects of our products to us or our licensors, or by covering
the same or similar technologies that may affect our ability to market our products. For example, we (or the licensor of a product to
us) may not have conducted a patent clearance search sufficient to identify potentially obstructing third party patent rights. Moreover,
patent applications in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however,
patent applications remain confidential in the U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance
as a U.S. patent. Patent applications filed in countries outside of the United States are not typically published until at least 18 months
from their first filing date. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual discoveries.
We cannot be certain that we or our licensors were the first to invent, or the first to file, patent applications covering our products.
We also may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the
first to invent the technology that is the subject of our patent applications. Competitors may have filed patent applications or received
patents and may obtain additional patents and proprietary rights that block or compete with our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore, there
may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods
for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue,
there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.
In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates,
or materials used in or formed during the manufacturing process, or any final product itself, the holders of those patents may be able
to block our ability to commercialize our product candidates unless we obtain a license under the applicable patents, or until those
patents were to expire or those patents are finally determined to be invalid or unenforceable. Similarly, if any third-party patent were
held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including
combination therapy or patient selection methods, the holders of that patent may be able to block our ability to develop and commercialize
a product candidate unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable.
In either case, a license may not be available on commercially reasonable terms, or at all, particularly if such patent is owned or controlled
by one of our primary competitors. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable
terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could significantly harm our
business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed
to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could
dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee time and resources from our business. In the event of a successful claim of
infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement,
obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require
substantial time and monetary expenditure. We cannot predict whether any license of this nature would be available at all or whether
it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses
from third parties to advance our research or allow commercialization of our product candidates and we may fail to obtain any of these
licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize
our product candidates, which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming
and unsuccessful and could result in a finding that such patents are unenforceable or invalid.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement
claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of
our patents is not valid, is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that
our patents do not cover the technology in question.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous
grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before
administrative bodies in the U.S. or abroad, even outside the context of litigation. These types of mechanisms include re-examination,
post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions
(e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer
cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which
we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of
invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and
perhaps all, of the patent protection on our product candidates. Defense of these types of claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversely,
we may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent
claims in re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings), or we may choose to challenge a third party&#8217;s patent in patent opposition
proceedings in the Canadian Intellectual Property Office (&#8220;CIPO&#8221;) the European Patent Office (&#8220;EPO&#8221;) or another
foreign patent office. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or
other resources. If we fail to obtain a favorable result at the USPTO, CIPO, EPO or other patent office then we may be exposed to litigation
by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, that perception could have a substantial adverse effect on the price of our Common Stock. Any of the foregoing
could have a material adverse effect on our business financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates
in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside
the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property
rights to the same extent as federal and state laws in the U.S. For example, patents covering therapeutic methods of treating humans
are not available in many foreign countries. Consequently, we may not be able to prevent third parties from practicing our inventions
in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions.
Competitors may use our technologies in jurisdictions where we do not have or have not obtained patent protection to develop their own
products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement
is not as strong as that in the U.S. These products may compete with our product candidates in jurisdictions where we do not have any
issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal and political systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents,
trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make
it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of
our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights
in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could be impossible or impractical due to sanctions or trade disputes between countries, could put our patents
at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may
not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime
of the patent. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment
and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in
many cases be cured by payment of a late fee or by other means in accordance with the applicable laws and rules, there are situations
in which noncompliance can result in irrevocable abandonment or lapse of the patent or patent application, resulting in partial or complete
loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent
application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees
and failure to properly legalize and submit formal documents. Were a noncompliance event to occur, our competitors might be able to enter
the market, which would have a material adverse effect on our business financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law in the U.S. and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability
to protect our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming
and inherently uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past
or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. For example, in March 2013, under the Leahy-Smith America Invents Act (&#8220;America
Invents Act&#8221;), the U.S. moved from a &#8220;first to invent&#8221; to a &#8220;first-inventor-to-file&#8221; patent system. Under
our &#8220;first-inventor-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file
a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention
earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect
the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes
continue to evolve as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act and
many of the substantive changes to patent law, including the &#8220;first-inventor-to-file&#8221; provisions, only became effective in
March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations
on the specific patents discussed in this filing have not been determined and would need to be reviewed. Moreover, the America Invents
Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
cases by the U.S. Supreme Court have held that certain methods of treatment or diagnosis are not patent-eligible. U.S. law regarding
patent-eligibility continues to evolve. While we do not believe that any of our patents will be found invalid based on these changes
to US patent law, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.
Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial
condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years
from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection
it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open
to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting our product candidates might expire before or shortly after our or our partners
commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S.
patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, (the
&#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation
for patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining
term of a patent beyond a total of 14 years from the date of product approval, only one patent per product may be extended and only those
claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. U.S. and ex-U.S. law concerning
patent term extensions and foreign equivalents continue to evolve. Even if we were to seek a patent term extension, it may not be granted
because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to
apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable
requirements. Moreover, the applicable time period of extension or the scope of patent protection afforded could be less than we request.
If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval
of competing products following our patent expiration sooner than expected, and our business, financial condition, results of operations
and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Series&#160;F Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of our Series F Preferred Stock are entitled to certain payments under the Certificate of Designation that may be paid in cash or in
shares of Common Stock depending on the circumstances. If we make these payments in cash, it may require the expenditure of a substantial
portion of our cash resources. If we make these payments in Common Stock, it may result in substantial dilution to the holders of our
Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Certificate of Designations (the &#8220;Certificate of Designation&#8221;) of our Series F Convertible Preferred Stock (&#8220;Series
F Preferred Stock&#8221;), we are required to redeem the shares of Series F Preferred Stock in 12 equal monthly installments, commencing
on July 1, 2023. Holders of our Series F Preferred Stock are also entitled to receive dividends, payable in arrears monthly, and dividends
payable on installment dates shall be paid as part of the applicable installment amount. Installment amounts are payable, at the company&#8217;s
election, in shares of Common Stock or, subject to certain limitations, in cash. Installment amounts paid in cash must be paid in the
amount of 105% of the applicable payment amount due. For an installment amounts paid in shares of Common Stock, the number of shares
of Common Stock shall be calculated by dividing the applicable payment amount due by the &#8220;installment conversion price.&#8221;
The installment conversion price shall be equal to the lower of (i) the Conversion Price (as defined in the Certificate of Designation)
in effect as of the applicable payment date and (ii) the greater of (A) 80% of the average of the three lowest closing prices of our
Common Stock during the thirty trading day period immediately prior to the date the payment is due or (B) the lower of (x) $0.4014 and
(y) 20% of the &#8220;Minimum Price&#8221; (as defined in Rule 5635 of the Rules of the Nasdaq Stock Market) on the date of the Stockholder
Approval (as defined below) (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other
similar events) or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to make payments due to the holders of our Series F Preferred Stock using shares of Common Stock is subject to certain limitations
set forth in the Certificate of Designation, including a limit on the number of shares that may be issued until the time, if any, that
our stockholders have approved the issuance of more than 19.9% of our outstanding shares of Common Stock in accordance with the rules
of the Nasdaq Stock Market (the &#8220;Stockholder Approval&#8221;). If we are unable to make installment payments in shares of Common
Stock, we may be forced to make such payments in cash. If we do not have sufficient cash resources to make these payments, we may need
to raise additional equity or debt capital, and we cannot provide any assurance that we will be successful in doing so. If are unable
to raise sufficient capital to meet our payment obligations, we may need to delay, reduce or eliminate certain research and development
programs or other operations, sell some or all of our assets or merge with another entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to make payments due to the holders of our Series F Preferred Stock using cash is also limited by the amount of cash we have
on hand at the time such payments are due as well as certain provisions of the New Jersey Business Corporations Act. Further, we intend
to make the installment payments due to holders of Series F Preferred Stock in the form of Common Stock to the extent allowed under the
Certificate of Designation and applicable law in order to preserve our cash resources. The issuance of shares of Common Stock to the
holders of our Series F Preferred Stock with increase the number of shares of Common Stock outstanding and could result in substantial
dilution to the existing holders of our Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Certificate of Designation for the Series&#160;F Preferred Stock and the warrants issued concurrently therewith contain anti-dilution
provisions that may result in the reduction of the conversion price of the Series&#160;F Preferred Stock or the exercise price of such
warrants in the future. These features may increase the number of shares of Common Stock being issuable upon conversion of the Series&#160;F
Preferred Stock or upon the exercise of the warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Certificate of Designation and the warrants issued concurrently with the Series&#160;F Preferred Stock (the &#8220;February 2023
Warrants&#8221;) contain anti-dilution provisions, which provisions require the lowering of the applicable conversion price or
exercise, as then in effect, to the purchase price of equity or equity-linked securities issued in subsequent offerings. If in the
future, while any of our Series&#160;F Preferred Stock or February&#160;2023 Warrants are outstanding, we issue securities for a
consideration per share of Common Stock (the &#8220;New Issuance Price&#8221;) that is less than the Conversion Price of our
Series&#160;F Preferred Stock or the exercise price of the February&#160;2023 Warrants, as then in effect, we will be required,
subject to certain limitations and adjustments as provided in the Certificate of Designation or the February&#160;2023 Warrants, to
reduce the Conversion Price or the exercise price to be equal to the New Issuance Price, which will result in a greater number of
shares of Common Stock being issuable upon conversion or exercise, as applicable, which in turn will increase the dilutive effect of
such conversion or exercise on existing holders of our Common Stock. It is possible that we will not have a sufficient number of
shares available to satisfy the conversion of the Series&#160;F Preferred Stock or the exercise of the February&#160;2023 Warrants
if we enter into a future transaction that reduces the applicable Conversion Price or exercise price. If we do not have a sufficient
number of available shares for any Series&#160;F Preferred Stock conversions or February&#160;2023 Warrant exercises, we may need to
seek shareholder approval to increase the number of authorized shares of our Common Stock, which may not be possible and will be
time consuming and expensive. The potential for such additional issuances may depress the price of our Common Stock regardless of
our business performance and may make it difficult for us to raise additional equity capital while any of our Series F Preferred
Stock or February&#160;2023 Warrants are outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the February 2023 Securities Purchase Agreement we are subject to certain restrictive covenants that may make it difficult to
procure additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement pursuant to which we issued the Series F Preferred Stock (&#8220;February 2023 SPA&#8221;) contains the
following restrictive covenants: (i)&#160;until all of the February&#160;2023 Warrants are exercised, we agreed not to enter into any
variable rate transactions; (ii)&#160;for approximately ten months after the execution of the February&#160;2023 SPA, we agreed not to
issue or sell any equity security or convertible security, subject to certain exceptions; and (iii)&#160;we agreed to offer to the investors
party to the February&#160;2023 SPA, until the later of no Series&#160;F Preferred Shares being outstanding and the maturity date of
the Series&#160;F Preferred Shares, the opportunity to participate in any subsequent securities offerings by us. If we require additional
funding while these restrictive covenants remain in effect, we may be unable to effect a financing transaction while remaining in compliance
with the terms of the February&#160;2023 SPA, or we may be forced to seek a waiver from the investors party to the February&#160;2023
SPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not receive approval from our stockholders, we will be unable to pay amounts due to the holders of our Series&#160;F Preferred
Stock in shares of Common Stock and we will be required to pay such amounts in cash, which may force us to divert cash from other uses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the February 2023 SPA, we are required to hold a meeting of our stockholders to seek approval under Nasdaq Listing Rule 5635(d) for the
sale, issuance or potential issuance by us of our Common Stock (or securities convertible into or exercisable for our Common Stock) in
excess of 7,894,001 shares, which is 20% of the shares of Common Stock outstanding immediately prior to the execution of the February&#160;2023
SPA. Certain stockholders, who beneficially held approximately 44% of our outstanding Common Stock as of the date of the February 2023
SPA, are party to a voting agreement pursuant to which, among other things, each such stockholder agreed, solely in their capacity as
a stockholder, to vote all of their shares of Common Stock in favor of the approval, and if an insufficient number of our remaining stockholders
vote in favor of the proposal we will be unable to issue shares of Common Stock in order to pay amounts due under the Certificate of
Designation to holders of our Series&#160;F Preferred Stock in shares of Common Stock. If we are unable to pay such amounts when due
in shares of Common Stock, we will have to satisfy our payment obligations by means of cash payments. If we do not have sufficient cash
resources to make these payments, we may need to delay, reduce or eliminate certain research and development programs or other operations,
sell some or all of our assets or merge with another entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offers
or availability for sale of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales of a significant number
of shares of our Common Stock in the public market could harm the market prices of our Common Stock and make it more difficult for us
to raise funds through future offerings of Common Stock or other securities. Our stockholders and the holders of our options and warrants
may sell substantial amounts of our Common Stock in the public market. In addition, we may be required to issue shares of Common Stock
to the holders of our Series&#160;F Preferred Stock upon conversion of shares of our Series F Preferred Stock and the payment of
the dividends thereunder in Common Stock as a result of the full ratchet anti-dilution price protection in the Certificate of Designation
if the effective Common Stock purchase price in a subsequent offering is less than the then current Series&#160;F Preferred Stock conversion
price, which in turn will increase the number of shares of Common Stock available for sale. See &#8220;Risk Factors&#8212;Risks Related
to Our Series&#160;F Preferred Stock&#8212;The Certificate of Designation for the Series F Preferred Stock and the warrants issued
concurrently contain anti-dilution provisions that may result in the reduction of the conversion price of the Series&#160;F Preferred
Stock or the exercise price of such warrants in the future. These features may increase the number of shares of Common Stock being issuable
upon conversion of the Series F Preferred Stock or upon the exercise of the warrants.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the fact that our stockholders can sell substantial amounts of our Common Stock in the public market, whether or not sales
have occurred or are occurring, could make it more difficult for us to raise additional financing through the sale of equity or equity-related
securities in the future at a time and price that we deem reasonable or appropriate, or at all.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
active trading market for our Common Stock may not be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing of our Common Stock on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) does not assure that a meaningful, consistent and liquid
trading market exists. An active trading market for shares of our Common Stock may not be sustained. If an active market for our Common Stock is not sustained, it may be difficult for investors to sell their shares either without depressing the market price for the shares
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
intended benefits of the Contribution Transaction may not be realized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Contribution Transaction poses risks for our ongoing operations, including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
                                            consummation of the Contribution Transaction, if Oravax is not successful in developing the
                                            COVID-19 Vaccine Candidate, we may not realize any value out of its ownership of Oravax shares;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            and expenses associated with any undisclosed or potential liabilities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, we may be unable to realize the full strategic and financial benefits originally anticipated from the Contribution
Transaction, and we cannot assure you that the Contribution Transaction will be accretive in the near term or at all. Furthermore, if
we fail to realize the intended benefits of the Contribution Transaction, the market price of our Common Stock could decline to the extent
that the market price reflects those benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to various internal control reporting requirements under the Sarbanes-Oxley Act. We can provide no assurance that we will
at all times in the future be able to report that our internal controls over financial reporting are effective.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we are required to comply with Section 404 (&#8220;Section 404&#8221;) of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;). In any given year, we cannot be certain as to the time of completion
of our internal control evaluation, testing and remediation actions or of their impact on our operations. Upon completion of this
process, we may identify control deficiencies of varying degrees of severity under applicable SEC and Public Company Accounting
Oversight Board (U.S.) rules and regulations. Our management, including our principal executive officer and principal financial officer, does not expect that our internal controls and disclosure controls will prevent all errors and all fraud. A
control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives
of the control system are met. In addition, the design of a control system must reflect the fact that there are resource constraints
and the benefit of controls must be relative to their costs. Because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, in our company have
been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple errors or mistakes. Further, controls can be circumvented by individual acts of some persons, by
collusion of two or more persons, or by management override of the controls. The design of any system of controls is also based in
part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in
achieving our stated goals under all potential future conditions. Over time, a control may be inadequate because of changes in
conditions, such as growth of the company or increased transaction volume, or the degree of compliance with the policies or
procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud
may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a public company, we are required to report, among other things, control deficiencies that constitute material weaknesses
or changes in internal controls that, or that are reasonably likely to, materially affect internal controls over financial reporting.
A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement of our annual consolidated financial statements will not be prevented
or detected on a timely basis. If we fail to comply with the requirements of Section 404 or if we report a material weakness, we might
be subject to regulatory sanction and investors may lose confidence in our consolidated financial statements, which may be inaccurate
if we fail to remedy such material weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which
could harm our operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company, including costs
associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act and the Dodd-Frank Act, as well as rules implemented
by the SEC and Nasdaq, impose a number of requirements on public companies, including with respect to corporate governance practices.
Our management and other personnel need to devote a substantial amount of time to these compliance and disclosure obligations. Moreover,
compliance with these rules and regulations has increased our legal, accounting and financial compliance costs and has made some activities
more time-consuming and costly. It is also more expensive for us to obtain director and officer liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our Common Stock. The
delisting could adversely affect the market liquidity of our Common Stock and the market price of our Common Stock could
decrease.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on The Nasdaq Capital Market. In order to maintain our listing, we must meet minimum financial and other requirements,
including requirements for a minimum amount of capital and a minimum price per share. We cannot assure you that we will continue to meet
the continued listing requirements in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Nasdaq delists our Common Stock from trading on its exchange, due to failure to meet its continued listing requirements, and we are not
able to list our Common Stock on another national securities exchange, we expect our securities could be quoted on an over-the-counter
market. If this were to occur, we could face significant material adverse consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our Common Stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity for our Common Stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our Common Stock is a &#8220;penny stock&#8221; which will require brokers trading in our Common Stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our Common Stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional equity securities in the future, which may result in dilution to existing investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. The combined
Company may, from time to time, sell additional equity securities in one or more transactions at prices and in a manner it determines.
If we sell additional equity securities, existing stockholders may be materially diluted. In addition, new investors could gain rights
superior to existing stockholders, such as liquidation and other preferences. In addition, the number of shares available for future
grant under our equity compensation plans may be increased in the future. In addition, the exercise or conversion of outstanding options
or warrants to purchase shares of capital stock may result in dilution to our stockholders upon any such exercise or conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of Common Stock are, and any Milestone Shares of our Common Stock that may be issued in the future, will be,
freely tradable without restrictions or further registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
except for shares subject to lock-up agreements, and any shares held by affiliates, as defined in Rule 144 under the Securities Act.
Rule 144 defines an affiliate as a person who directly, or indirectly through one or more intermediaries, controls, or is controlled
by, or is under common control with, the Company and would include persons such as our directors and executive officers and large shareholders.
In turn, resales, or the perception by the market that a substantial number of resales could occur, could have the effect of depressing
the market price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, we may be required
to issue an indeterminate number of shares of Common Stock to the holders of our Series F Preferred Stock and the February&#160;2023 Warrants
upon the conversion or exercise of either, as applicable. See &#8220;Risk Factors&#8212;Risks Related to Our Series F Preferred Stock&#8212;
Holders of our Series F Preferred Stock are entitled to certain payments under the Certificate of Designation that may be paid in cash
or in shares of Common Stock depending on the circumstances. If we make these payments in cash, it may require the expenditure of a substantial
portion of our cash resources. If we make these payments in Common Stock, it may result in substantial dilution to the holders of our
Common Stock.&#8221; and &#8220;Risk Factors&#8212;Risks Related to Our Series F Preferred Stock&#8212;The Certificate of Designation
for the Series F Preferred Stock and the warrants issued concurrently contain anti-dilution provisions that may result in the reduction
of the conversion price of the Series F Preferred Stock or the exercise price of such warrants in the future. These features may increase
the number of shares of Common Stock issuable upon conversion of the Series F Preferred Stock or upon the exercise of the warrants.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not anticipate paying cash dividends on our Common Stock and, accordingly, stockholders must rely on stock appreciation for any return
on their investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our Common Stock and do not
expect to do so in the foreseeable future. So long as any shares of Series&#160;F Preferred Stock are outstanding, as they are at this
time, we are not able to declare or pay any cash dividend or distribution on any of our capital stock (other than as required by the Certificate
of Designation) without the prior written consent of the Required Holders (as defined in the Certificate of Designation). The declaration
of dividends is further subject to the discretion of our board of directors and limitations under applicable law, and will depend on various
factors, including our operating results, financial condition, future prospects and any other factors deemed relevant our board of directors.
You should not rely on an investment in us if you require dividend income from your investment in us. The success of your investment will
likely depend entirely upon any future appreciation of the market price of our Common Stock, which is uncertain and unpredictable. There
is no guarantee that our Common Stock will appreciate in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our
Common Stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Common Stock relies in part on the availability of research and reports that third-party industry or financial
analysts publish about us. There are many large, publicly traded companies active in the life sciences and biopharmaceutical industries,
which may mean it will be less likely that we receive widespread analyst coverage. Furthermore, if one or more of the analysts who do
cover the Company (if any) downgrades our stock, our stock price would likely decline. If one or more of these analysts cease coverage
of the Company, we could lose visibility in the market, which in turn could cause our stock price to decline. Additionally, if securities
analysts publish negative evaluations of competitors in the life sciences and biopharmaceutical industries, the comparative effect could
cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have been subject to a number of securities litigations, and we may be subject to similar or other litigation in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been subject to a number of litigations as described elsewhere in these &#8220;Risk Factors&#8221; and in Note 9 to our consolidated
financial statements. In connection with certain of these litigations, we have entered into settlements of claims for significant monetary
damages. We may also be subject to judgements or enter into additional settlements of claims for significant monetary damages for the
securities litigations that we have yet to enter into settlement agreements. Defending against the current litigations is or can be time-consuming,
expensive and cause diversion of our management&#8217;s attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
that have experienced volatility in the market price of their stock have frequently been the objects of securities class action litigation.
We may be the target of this type of litigation in the future. Class action and derivative lawsuits could result in substantial costs
to us and cause a diversion of our management&#8217;s attention and resources, which could materially harm our financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to any litigation, our insurance may not reimburse us, or may not be sufficient to reimburse us, for the expenses or losses we
may suffer in contesting and concluding such lawsuit. Substantial litigation costs, including the substantial self-insured retention
that we are required to satisfy before any insurance applies to a claim, unreimbursed legal fees or an adverse result in any litigation
may adversely impact our business, operating results or financial condition. We believe that our directors&#8217; and officers&#8217;
liability insurance will cover our potential liability with respect to any securities class-action lawsuit; however, the insurer has
reserved its rights to contest the applicability of the insurance to such claims and the limits of the insurance may be insufficient
to cover any eventual liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to various internal control reporting requirements under the Sarbanes-Oxley Act. We can provide no assurance that we will
at all times in the future be able to report that our internal controls over financial reporting are effective.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we are required to comply with Section 404. In any given year, we cannot be certain as to the time of completion
of our internal control evaluation, testing and remediation actions or of their impact on our operations. Upon completion of this
process, we may identify control deficiencies of varying degrees of severity under applicable SEC and Public Company Accounting
Oversight Board (United States) rules and regulations. Our management, including our principal executive officer and principal financial
officer, does not expect that our internal controls and disclosure controls will prevent all errors and all fraud. A control system,
no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. In addition, the design of a control system must reflect the fact that there are resource constraints and the
benefit of controls must be relative to their costs. Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that all control issues and instances of fraud, if any, in us have been detected. These
inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of
simple errors or mistakes. Further, controls can be circumvented by individual acts of some persons, by collusion of two or more
persons, or by management override of the controls. The design of any system of controls is also based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our
stated goals under all potential future conditions. Over time, a control may be inadequate because of changes in conditions, such as
growth of the company or increased transaction volume, or the degree of compliance with the policies or procedures may deteriorate.
Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be
detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a public company, we are required to report, among other things, control deficiencies that constitute material weaknesses
or changes in internal controls that, or that are reasonably likely to, materially affect internal controls over financial reporting.
A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement of our annual consolidated financial statements will not be prevented
or detected on a timely basis. If we fail to comply with the requirements of Section 404 or if we report a material weakness, we might
be subject to regulatory sanction and investors may lose confidence in our consolidated financial statements, which may be inaccurate
if we fail to remedy such material weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which
could harm our operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company, including costs
associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act and the Dodd-Frank Act, as well as rules implemented
by the SEC and Nasdaq, impose a number of requirements on public companies, including with respect to corporate governance practices.
Our management and other personnel need to devote a substantial amount of time to these compliance and disclosure obligations. Moreover,
compliance with these rules and regulations has increased our legal, accounting and financial compliance costs and has made some activities
more time-consuming and costly. It is also more expensive for us to obtain director and officer liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
2. Properties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company leases as its corporate headquarters an office facility located at 855 North Wolfe Street, Suite 601, Baltimore, Maryland 20215.
The lease as amended has a twelve-month term beginning on December 1, 2022, which term shall automatically renew thereafter until termination
by either party upon 60 days&#8217; notice. The monthly rent is approximately $4,532 and will increase 3% on each anniversary of the
December 1, 2022 effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our current facilities are sufficient and adequate for our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we are a party to litigation and subject to claims incident to the ordinary course of business. Future litigation may be
necessary to defend ourselves and our customers by determining the scope, enforceability, and validity of third-party proprietary rights
or to establish our proprietary rights. For a discussion of material legal proceedings affecting us as of December 31, 2022, please read
Note 9 to the consolidated financial statements under &#8220;Litigation and Settlements,&#8221; which information is incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Part
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock began trading on the Nasdaq Capital Market under the symbol &#8220;AKER&#8221; on January 23, 2014. On April 19, 2021, the
symbol for our Common Stock changed to &#8220;MYMD.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 29, 2023, there were approximately 737 holders of record of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described herein, we have never paid any cash or other dividends to our stockholders and we do not plan to declare or pay any cash
or other dividends in the foreseeable future. On or around September 9, 2020, our Board declared a dividend of one preferred share purchase
right for each share of our Common Stock outstanding held by stockholders of record on September 21, 2020. We currently intend to retain
earnings, if any, for use in the operation and expansion of our business. Subject to the foregoing, the payment of cash dividends in
the future, if any, will be at the discretion of our Board and will depend on such factors as earning levels, contractual restrictions,
capital requirements, our overall financial condition and any other factors deemed relevant by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not repurchase any of our equity securities during the fourth quarter of the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
information set forth below should be read in conjunction with our consolidated financial statements and related notes thereto included
elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based on our current expectations,
assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties. Our actual results could differ
materially from those indicated in these forward-looking statements as a result of certain factors, including those discussed in Item
1 of this Annual Report on Form 10-K, entitled &#8220;Business,&#8221; under &#8220;Forward-Looking Statements&#8221; and Item 1A of
this Annual Report on Form 10-K, entitled &#8220;Risk Factors.&#8221; References in this discussion and analysis to &#8220;us,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; or &#8220;the Company&#8221; refer collectively to MyMD Pharmaceuticals, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements are prepared in accordance with GAAP. These accounting principles require us to make certain estimates, judgments
and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available
to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the
reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and
expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between
these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP
and does not require management&#8217;s judgment in its application. There are also areas in which management&#8217;s judgment in selecting
any available alternative would not produce a materially different result. The following discussion should be read in conjunction with
our financial statements and notes thereto appearing elsewhere in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report on Form 10-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (the
&#8220;SEC&#8221; and such reports, collectively, the &#8220;Filings&#8221;) contain or may contain forward-looking statements and information
that are based upon beliefs of, and information currently available to, the Company&#8217;s management as well as estimates and assumptions
made by Company&#8217;s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are
only predictions and speak only as of the date hereof. When used in the Filings, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; or the negative of these
terms and similar expressions as they relate to the Company or the Company&#8217;s management identify forward-looking statements. Such
statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions,
and other factors, including the risks relating to the Company&#8217;s business, industry, and the Company&#8217;s operations and results
of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States,
we do not intend to update any of the forward-looking statements to conform these statements to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
factors that could cause actual results to differ materially from the results and events anticipated or implied by such forward-looking
statements include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuation
    and volatility in market price of our Common Stock due to market and industry factors, as well as general economic, political and
    market conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of dilution on our shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to realize the intended benefits of the Merger (as defined below) and the Contribution Transaction (as defined below);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of our ability to realize the anticipated tax impact of the Merger;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome of litigation or other proceedings we may become subject to in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delisting
    of our Common Stock from the Nasdaq;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    availability and ability to continue to obtain sufficient funding to conduct planned research and development efforts and realize
    potential profits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and commercialize our product candidates, including MYMD-1, Supera-CBD and other future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the complexity of the regulatory landscape on our ability to seek and obtain regulatory approval for our product candidates,
    both within and outside of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    required investment of substantial time, resources and effort for successful clinical development and marketization of our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    we may face with maintaining regulatory approval, if achieved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential impact of changes in the legal and regulatory landscape, both within and outside of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the ongoing COVID-19 pandemic on the administration, funding and policies of regulatory authorities, both within and outside
    of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties to conduct pre-clinical and clinical trials and manufacture its product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the ongoing COVID-19 pandemic on our results of operations, business plan and the global economy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    we may face with respect to our product candidates achieving market acceptance by providers, patients, patient advocacy groups, third
    party payors and the general medical community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of pricing, insurance coverage and reimbursement status of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emerging
    competition and rapidly advancing technology in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, maintain and protect our trade secrets or other proprietary rights, operate without infringing upon the proprietary
    rights of others and prevent others from infringing on its proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain adequate cyber security and information systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to achieve the expected benefits and costs of the transactions related to the acquisition of Supera Pharmaceuticals, Inc.
    (&#8220;Supera&#8221;);</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively execute and deliver our plans related to commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emerging
    competition and rapidly advancing technology in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain adequate financing in the future on reasonable terms, as and when we need it;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    we may face in identifying, acquiring and operating new business opportunities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain and attract senior management and other key employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to quickly and effectively respond to new technological developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in political, economic or regulatory conditions generally and in the markets in which we operate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    compliance with all laws, rules, and regulations applicable to our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Merger and the Contribution Transaction described below that occurred on April 16, 2021, we have been focused on developing
and commercializing two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD-1
    is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including (but not limited
    to) multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related
    illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as
    TNF-&#945;, interleukin 6 (&#8220;IL-6&#8221;) and interleukin 17 (&#8220;IL-17&#8221;). MYMD-1 currently is being evaluated in
    patients with sarcopenia (age-related muscle loss). The company has significant intellectual property coverage to protect these autoimmune
    indications, as well as therapy as an anti-aging product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera-CBD
    is a synthetic analog of cannabidiol (&#8220;CBD&#8221;) being developed to treat various conditions, including, but not limited
    to, epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, and a monoamine oxidase enzyme (&#8220;MAO&#8221;)
    type B. Supera-CBD has shown tremendous promise in treating neuroinflammatory and neurodegenerative diseases, and will be a major
    focus as the Company moves forward.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights to Supera-CBD were previously owned by Supera and were acquired by MyMD Florida (as defined below) immediately prior to the closing
of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Closing
of the Merger and Reverse Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the previously announced Agreement and Plan of Merger and Reorganization, dated November 11, 2020 (the
&#8220;Original Merger Agreement&#8221;), as amended by Amendment No. 1 thereto, dated March 16, 2021 (the Original Merger
Agreement, as amended by Amendment No. 1, the &#8220;Merger Agreement&#8221;), by and among MyMD, a New Jersey corporation
previously known as Akers Biosciences, Inc., XYZ Merger Sub, Inc. (&#8220;Merger Sub&#8221;), and MyMD Pharmaceuticals (Florida),
Inc., a Florida corporation previously known as MyMD Pharmaceuticals, Inc. (&#8220;MyMD Florida&#8221;), Merger Sub was merged with
and into MyMD Florida, with MyMD Florida continuing after the merger as the surviving entity and a wholly owned subsidiary of the
Company (the &#8220;Merger&#8221;). At the effective time of the Merger, without any action on the part of any stockholder, each
issued and outstanding share of pre-Merger MyMD Florida&#8217;s Common Stock, par value $0.001 per share (the &#8220;MyMD Florida
Common Stock&#8221;), including shares underlying pre-Merger MyMD Florida&#8217;s outstanding equity awards, was converted into the
right to receive (x) 0.7718 shares (the &#8220;Exchange Ratio&#8221;) of the Company&#8217;s Common Stock, no par value per share
(the &#8220;Company Common Stock&#8221; or &#8220;Common Stock&#8221;), (y) an amount in cash, on a pro rata basis, equal to the aggregate cash proceeds received
by the Company from the exercise of any options to purchase shares of MyMD Florida Common Stock outstanding at the effective time of
the Merger assumed by the Company upon closing of the Merger prior to the second-year anniversary of the closing of the Merger (the
&#8220;Option Exercise Period&#8221;), such payment (the &#8220;Additional Consideration&#8221;), and (z) potential milestone
payment in shares of Company Common Stock up to the aggregate number of shares issued by the Company to pre-Merger MyMD Florida
stockholders at the closing of the Merger (the &#8220;Milestone Payments&#8221;) payable upon the achievement of certain market
capitalization milestone events (the &#8220;Milestone Events&#8221;) during the 36-month period immediately following the closing of
the Merger (the &#8220;Milestone Period&#8221;). The Milestone Events and corresponding Milestone Payments are set forth in the
table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Event</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Payment</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    capitalization of the combined company for at least ten (10) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#8220;First Milestone Event&#8221;).</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,000,000</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least 10 trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    capitalization of the combined company for at least 10 trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#8220;Second Milestone Event&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25,000,000</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least 10 trading days during any 20 consecutive trading day period during the Milestone
    Period.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25,000,000
    per each incremental increase</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the table above, &#8220;market capitalization&#8221; means, with respect to any trading day, the product of (i) the total
outstanding shares of the combined company Common Stock and (ii) the volume weighted average trading price for the combined company Common Stock for such trading day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the effective time of the Merger, the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company
Common Stock (the &#8220;Reverse Stock Split&#8221;). Upon completion of the Merger and the transactions contemplated in the Merger Agreement,
(i) the former MyMD Florida equity holders owned approximately 77.05% of the outstanding equity of the Company on a fully diluted basis,
assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common stock and including 4,188,315 shares
of Company Common Stock underlying options to purchase shares of MyMD Florida Common Stock assumed by the company at closing and after
adjustments based on the Company&#8217;s net cash at closing; and (ii) former Akers Biosciences, Inc. stockholders own approximately
22.95% of the outstanding equity of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of 4:05 pm Eastern Time on April 16, 2021, we filed an amendment to its Amended and Restated Certificate of Incorporation to effect
the Reverse Stock Split. As a result of the Reverse Stock Split, immediately following the effective time of the Merger, every two shares
of our Common Stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share
of our Common Stock. No fractional shares were issued in connection with the Reverse Stock Split. Each stockholder who did not have a
number of shares evenly divisible pursuant to the Reverse Stock Split ratio and who would otherwise be entitled to receive a fractional
share of our Common Stock was entitled to receive an additional share of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In
connection with the closing of the Merger, we changed our name to MyMD Pharmaceuticals, Inc. and our trading symbol on The Nasdaq Capital
Market to MYMD. For additional information concerning the Merger, please see Note 3 to the Company&#8217;s Consolidated Financial Statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Closing
of Contribution and Assignment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
acquired 100% of the membership interests of Cystron Biotech, LLC (&#8220;Cystron&#8221;) pursuant to a Membership Interest Purchase
Agreement, dated March 23, 2020 (as amended by Amendment No. 1 on May 14, 2020, the &#8220;MIPA&#8221;) from certain selling parties
(the &#8220;Cystron Sellers&#8221;). Cystron is a party to a License and Development Agreement (as amended and restated on March 19,
2020, in connection with our entry into the MIPA, the &#8220;License Agreement&#8221;) with Premas Biotech PVT Ltd. (&#8220;Premas&#8221;)
whereby Premas granted Cystron, amongst other things, an exclusive license with respect to Premas&#8217; genetically engineered yeast
(S. cerevisiae)-based vaccine platform, D-Crypt&#8482;, for the development of a vaccine against COVID-19 and other coronavirus infections.
We had partnered with Premas on this initiative as we sought to advance this COVID-19 vaccine candidate through the regulatory process,
both with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and the office of the drug controller in India. Premas was primarily
responsible for the development of the COVID-19 vaccine candidate through proof of concept and was entitled to receive milestone payments
upon achievement of certain development milestones through proof of concept.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 14, 2020, Premas had successfully completed its vaccine prototype and obtained transmission electron microscopic (TEM) images
of the recombinant virus like particle (VLP) assembled in yeast. In July 2020, animal studies for the COVID-19 vaccine candidate were
initiated in India. In addition, we announced that Premas had successfully completed the manufacturing process for the VLP vaccine candidate.
On August 27, 2020, we announced with Premas positive proof of concept results from the animal studies conducted during a four-week test
of the COVID-19 vaccine candidate in mice. On March 18, 2021, the Company and the Cystron Sellers, which are also shareholders of Oravax
Medical, Inc. (&#8220;Oravax&#8221;), entered into a Termination and Release Agreement terminating the MIPA effective upon consummation
of the Contribution Agreement (as defined below). In addition, the Cystron Sellers agreed to waive any change of control payment triggered
under the MIPA as a result of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the Contribution and Assignment Agreement, dated March 18, 2021 (the &#8220;Contribution Agreement&#8221;)
by and among the Company, Cystron, Oravax and, for the limited purpose set forth therein, Premas, the parties consummated the transactions
contemplated therein. Pursuant to the Contribution Agreement, effective upon the closing of the Merger, the Company agreed (i) to contribute
an amount in cash equal to $1,500,000 to Oravax and (ii) cause Cystron to contribute substantially all of the assets associated with
its business or developing and manufacturing Cystron&#8217;s COVID-19 vaccine candidate to Oravax (the &#8220;Contribution Transaction&#8221;).
In consideration for the Company&#8217;s commitment to consummate the Contribution Transaction, Oravax issued to the Company 390,000
shares of its capital stock (equivalent to 13% of Oravax&#8217;s outstanding capital stock on a fully diluted basis) and assumed all
of the obligations or liabilities in respect of the assets of Cystron (excluding certain amounts due to Premas), including the obligations
under the license agreement with Premas. In addition, Oravax agreed to pay future royalties to the Company equal to 2.5% of all net sales
of products (or combination products) manufactured, tested, distributed and/or marketed by Oravax or its subsidiaries. For additional
information concerning the Contribution Transaction, please see Note 3 to the Company&#8217;s Consolidated Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Contribution Transaction, Oravax is pursuing the development of the COVID-19 vaccine candidate. MyMD is currently evaluating several options
with respect to its interest in Oravax, including a potential distribution of Oravax shares to the MyMD shareholders. This would make
Oravax a publicly held company. MyMD&#8217;s interest in Oravax consists of 13% of Oravax&#8217;s outstanding shares of capital stock
and the rights to a 2.5% royalty on all future net sales. In addition, MyMD currently has the right to designate a member of the board
of directors of Oravax, pursuant to which Mr. Joshua Silverman, our Chairman of the Board, has been designated to serve as a director
of Oravax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Operations Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval
for, and successfully commercialize our MYMD-1 and Supera-CBD product candidates. The lengthy process of securing marketing approvals
for new drugs requires the expenditure of substantial resources. Any significant delay or failure to obtain regulatory approvals would
materially adversely affect our product candidate&#8217;s development efforts and our business overall. In addition, if we obtain regulatory
approval for MYMD-1 and/or Supera-CBD, we expect to incur significant expenses related to developing our commercialization capability
to support product sales, marketing, manufacturing and distribution activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our expenses will increase significantly as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    the development of our MYMD-1 and Supera-CBD;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    and continue research and preclinical and clinical development of potential new product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property as it pertains to MYMD-1 and Supera-CBD;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our infrastructure and facilities to accommodate our growing employee base and ongoing development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    agreements with contract research organizations, or CROs, and third-party contract manufacturing organizations, or CMOs, in connection
    with our Supera-CBD preclinical studies, MYMD-1 ongoing and planned clinical trials, Supera-CBD clinical trials and the development
    of our manufacturing capabilities for MYMD-1 and Supera-CBD;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    the large-scale manufacturing processes and capabilities for the commercialization of our MYMD-1 and Supera-CBD drug products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    marketing approvals for our MYMD-1 and Supera-CBD product candidates that successfully complete clinical trials and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure to commercialize MYMD-1 and Supera-CBD should we obtain marketing approval</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these anticipated expenditures, we will need substantial additional funding to support our continuing operations and pursue
our growth strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future.
If our research and development efforts with MYMD-1 and Supera-CBD are successful, we may generate revenue from product sales or through
license agreements with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses are broken into several components, including research and development and general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect operating expenses to increase as we progress through the various clinical trials in the development of MYMD-1 and Supera-CBD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses primarily consist of costs associated with the development of MYMD-1 and Supera-CBD. These costs include,
but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries,
    wages and benefits of the research and development staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual
    agreements with third parties including contract research organizations, preclinical activities and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
    consultants including fees and expenses; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
    supplies and equipment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    compliance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    application and maintenance costs to protect our intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
of our nine employees are principally involved in research and development activities for either MYMD-1 or Supera-CBD. Their salaries,
wages and benefits are captured as a component of research and development but not allocated to specific projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize third party contractors and consultants with expertise in specific research or development activities to perform work under the
supervision of our researchers. We believe this allows us to control costs and to progress through the development cycle and to utilize
our staff more efficiently.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is difficult to project with absolute accuracy the duration or final cost of the development of MYMD-1 and Super-CBD or if revenue will
be generated from the commercialization of these components. The process of achieving regulatory approval is very costly and time consuming.
A few of the many factors that contribute to costs of duration include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Size
    and scope of pre-clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    phases of clinical development and the stage of our product candidates in the cycle; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    subject trial costs; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of sites required for the trials and the availability of appropriate sites to perform the trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    time that is required to enroll the appropriate number of trial participants; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    time required to achieve the approval of regulatory agencies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of salaries, wages and benefits for our employees in the executive, legal and accounting
functions and third-party costs for legal, accounting, insurance, investor relations, stock market and board expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect general and administrative
expenses to decline over the near-term. We incurred significant non-recurring legal and accounting fees in 2021 associated with the Merger
with Akers Biosciences and we do not anticipate the addition of new general and administrative staff.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
treated as components of general and administrative expenses, we have chosen to disclose the following significant items separately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense and Accretion of Debt Discount (related party)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense and accretion of debt discount are the financing costs associated with the line-of-credit established between MYMD and The
Starwood Trust (the &#8220;Line of Credit&#8221;), which was terminated upon the closing of the Merger with Akers Biosciences and
paid in full along with the accumulated interest due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Based Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation includes the fair market value, as determined by Black-Scholes, of stock options issued to key staff and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Option Modification Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option modification expenses includes the re-valuation of the outstanding stock options that was performed in relation to the Merger
with Akers Biosciences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (Expense), net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net consists of interest and dividends earned on our cash, cash equivalents, and investments, gains on the sale marketable
securities, losses on equity investments, gains on the forgiveness of debt and an uninsured casualty loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Statements of Operations for the Fiscal Years Ended December 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD.
The following table summarized the results of operations for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">For the Year
    Ended <br /> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Description</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Change</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 46%; text-align: left">Research and Development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,067,422</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">6,745,104</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">34.4</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and Administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,520,150</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,420,092</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest Expense &amp; Accretion of Debt
    Discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">608,460</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(100.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock Based Compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">695,191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">100.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Stock Option Modifications</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,036,051</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(100.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Operating Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,282,763</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,809,707</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(47.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from Operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,282,763</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(28,809,707</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(47.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other Income (Expense), net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">85,427</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,079,338</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(107.9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,197,336</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(29,889,045</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(49.2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no revenue from operations during the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our research and development expenses for the years ended December 31, 2022 and 2021 as well as the percentage
of change year-over-year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">For the Year
    Ended <br /> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Description</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Change</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Salaries and Wages</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,087,574</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">808,554</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">34.5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Development Programs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,728,568</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,815,617</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(22.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">119,809</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34,790</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">244.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,121,848</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,057,702</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">289.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other Research and Development Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,623</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,441</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(66.2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Research and Development Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,067,422</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,745,104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">34.4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
and wages increased $279,020 during the year ended December 31, 2022. The increase is attributed to the full year costs of a staff member
added in May 2021 and  bonuses paid to three employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
program costs include those associated with pre-clinical development, clinical trials and other material and development programs.
Costs decreased $1,087,049 during the year ended December 31, 2022 as a result of the completion of pre-clinical toxicology studies,
the completion of Phase 1 clinical trials and the acquisition of base compounds for current and future trails.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
services costs increased $85,019 during the year ended December 31, 2022. These costs are primarily related to legal and patent related
fees associated with the protection of our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
expenses increased $3,064,146 during the year ended December 31, 2022. Regulatory expenses include clinical research organizations (CRO)
and regulatory consulting fees associated with Phase 2 clinical study designs, protocol preparations and the maintenance of the investigator
brochures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
research and development expenses declined $18,818 during the year ended December 31, 2022. These expenses include laboratory supplies,
training and travel for department personnel while working with third-party trial sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our administrative expenses for the years ended December 31, 2022 and 2021 as well as the percentage of change
year-over-year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">For the Years
    Ended<br /> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Description</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Change</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Personnel Costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,169,180</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,396,375</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(16.3</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional Service Costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,609,513</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,725,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock Market &amp; Investor Relations Costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">961,540</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">895,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">7.3</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other Administrative Costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,779,917</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,402,776</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(25.9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Administrative Expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,520,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,420,092</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel
costs decreased $227,195 during the year ended December 31, 2022. During the year ended December 31, 2021,  bonuses were included
in general and administrative expenses, regardless of the employee&#8217;s primary responsibilities. During the year ended December 31,
2022, these bonuses were allocated to the appropriate department based upon the employee&#8217;s responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
services costs decreased $115,687 during the year ended December 31, 2022. These costs included legal and accounting and specialized
consulting services related to the Merger as well as other legal and accounting services regularly incurred in the course of business.
The decrease is primarily related to non-recurring legal and accounting expenses recorded during the year ended December 31, 2021 that
were related to the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
market and investor relations costs increased $65,799 during the year ended December 31, 2022. These costs include the annual Nasdaq
listing fees, activities related to keeping the shareholder base informed through press releases, presentations and other communication
efforts and the costs of annual shareholder meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Other
administrative expenses decreased $622,859 during the year ended December 31, 2022. These costs include Board expenses, business insurance,
corporate travel and the settlement of shareholder litigation related to the Merger.&#160;We incurred significant decreases in costs
associated with the terminated aircraft lease, corporate travel and legal settlements which was offset by increases director&#8217;s
fees and business insurance costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
Expense and Accretion of Debt Discount</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Line of Credit included a requirement to issue one share of stock for each dollar borrowed. The fair market value, as determined using
Black-Scholes, was amortized over the remaining life of the Line of Credit. The Line of Credit also carried an annualized 5% interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Line of Credit was terminated on April 16, 2021 in connection with the Merger and was paid in full on April 28, 2021.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, stock-based compensation totaled $695,191. These expenses include stock options issued to staff and
service providers, restricted stock units and Common Stock warrants issued for services. During the year ended December 31, 2021, we
did not incur any stock-based compensation expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Modification Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, we did not incur any stock option modification expenses. During the year ended December 31, 2021, we
recorded $15,036,051 in stock option modification expenses related to the 4,188,315 pre-Merger MyMD Florida options that were assumed
by MyMD upon the consummation of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Income and Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our other income and expenses for the years ended December 31, 2022 and 2021 as well as the percentage of change
year-over-year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">For the Years
    Ended<br /> December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Description</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Change</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Interest and Dividend Income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(83,991</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(8,907</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">843.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on Debt Forgiveness</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(180,257</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(100.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(Gain)/Loss on FMV of Equity Investments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,793</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(106.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(Gain)/Loss on Investments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,964</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(39,597</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(115.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Uninsured Casualty (Gain)/Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,442</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,265,306</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(100.4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Other (Income)/Expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,427</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,079,338</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(107.9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net of expenses, totaled $85,427 for the year ended December 31, 2022, and other expenses, net of income, totaled $1,079,338
for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">During the year ended December 31, 2022 interest and dividend income, the
changes in fair value of our investments and realized gains from the sale of investments are primarily the result of rising interest rates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gain on debt forgiveness totaling $180,257 resulted from (i) $109,657 from the negotiated settlement of the amounts due under the related
party Line of Credit, aircraft lease and personal loans and (ii) $70,600 from the forgiveness of the Payroll Protection Program loans
received in 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, we identified an uninsured casualty loss of $1,265,306 related to wire fraud due to a compromised electronic
mail account. This incident began in late August 2021 and was discovered on October 26, 2021. The Company&#8217;s internal review of
disbursements made during the period of the incident did not identify any additional losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third-party forensic technology company&#8217;s investigation confirmed that we were a victim of wire fraud due to a compromised electronic
mail account. Following the incident, we have taken measures to enhance our electronic mail security and have modified our internal procedures
to ensure the authenticity of payment instructions. Despite these prophylactic measures, the risk of such cyber-attacks against us or
our third-party providers and business partners remain a serious issue. Cybersecurity incidents are pervasive, and the risks of cybercrime
are complex and continue to evolve. Although we are making significant efforts to maintain the security and integrity of our information
systems and are exploring various measures to manage the risk of a security breach or disruption, there can be no assurance that our
security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, we recovered $4,442 from the receiving financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, we had U.S. federal net operating loss carry forwards of approximately $107.1 million and $101.9 million,
respectively. Approximately $57.7 million of the U.S. federal net operating loss generated in tax years beginning before January 1, 2018
expire beginning with the year ending December 31, 2023 through 2037. The remaining U.S. federal net operating loss of approximately
$49.4 million does not expire, however it is limited to 80% of each subsequent year&#8217;s net income. As of December 31, 2022, and
2021, we had U.S. state net operating loss carry forwards of approximately $41.0 million and $38.2 million, respectively, some of which
expire beginning with the year ending December 31, 2023 through 2042.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 382 of the Code, use of our net operating loss carryforwards is limited if we experience a cumulative change in ownership of
greater than 50% in a moving three-year period. We experienced an ownership change as a result of the Merger and therefore our ability
to utilize our net operating loss carryforwards and certain credit carryforwards are limited. The limitation is determined by the fair
market value of our common stock outstanding immediately prior to the ownership change, multiplied by the applicable federal rate. It
is expected that the Merger caused our net operating loss carryforwards to be limited. However, the limitation had no impact on our financial
statements since we recorded a full valuation allowance for our deferred tax assets as of December 31, 2022 and 2021. (See Note 8 to
the Consolidated Financial Statements)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s cash and cash equivalents on hand was $749,090 and marketable securities were $4,086,902. The
Company has incurred net losses of $15,197,336 and $29,889,045 for the years ended December 31, 2022 and 2021, respectfully. As of December
31, 2022, the Company had working capital of $2,632,796 and a stockholders&#8217; equity of $14,695,056 including an accumulated deficit
of $93,758,904. During the year ended December 31, 2022, cash flows used in operating activities were $12,270,068, consisting primarily
of a net loss from operations of $15,197,336 offset by an increase in trade and other payables of $1,686,595, a decrease in prepaid expenses
of $540,560 and non-cash stock compensation expenses of $695,191. Since inception, the Company has met its liquidity requirements principally
through the sale of its Common Stock in public and private placements. See also &#8220;Recent Developments&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the Company&#8217;s current cash requirements for operations in conjunction with management&#8217;s strategic plan and
believes that the Company&#8217;s current financial resources as of the date of the issuance of these consolidated financial
statements, are sufficient to fund its current operating budget and contractual obligations as of December 31, 2022 as they fall due
within the next twelve-month period , alleviating any substantial doubt raised by the Company&#8217;s historical operating results and
satisfying its estimated liquidity needs for twelve months from the issuance of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net cash used by operating activities totaled $12,270,068 during the year ended December 31, 2022. Net cash used consisted principally
of the net loss from operations of $15,197,336 partially offset by an increase in trade and other payables of $1,686,595, a decrease
in prepaid expenses of $540,560 and non-cash stock compensation expenses of $695,191.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net cash used by operating activities totaled $19,516,475 during the year ended December 31, 2021. Net cash used consisted principally
of the net losses from operations of $29,889,045 and a decrease in trade and other payables of $4,268,961 partially offset by non-cash
option modification expenses of $15,036,051.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net cash provided by investing activities totaled $6,913,163 for the year ended December 31, 2022 as compared to cash provided by investing
activities totaling $19,850,625 during the year ended December 31, 2021. During the year ended December 31, 2022 we purchased securities
totaling $4,836,837 and sold securities totaling $11,750,000. During the year ended December 31, 2021 we purchased securities totaling
$13,403, sold securities totaling $18,483,176 and received $1,380,852 from the merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities during the year ended December 31, 2022 was $5,550,028 which consisted of the net proceeds
from the sale of Common Stock. Net cash provided by financing activities during the year ended December 31, 2021 was $73,533 which
consisted of the payoff of our Line of Credit totaling $3,062,444 offset by proceeds of $120,000 from the Line of Credit and
$1,826,137 from a Secured Promissory Note made to us by pre-Merger MyMD Florida which was paid off at the time of the Merger and net
proceeds of $1,189,840 from the exercise of warrants for Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">August&#160;2022
Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On
August 15, 2022, we entered into a securities purchase agreement (the &#8220;August&#160;2022&#160;SPA&#8221;) with certain
accredited and institutional investors pursuant to which we agreed to issue 1,411,764 shares of Common Stock (the
&#8220;August&#160;2022 Shares&#8221;) in a registered direct offering and unregistered warrants to purchase up to an aggregate of
1,411,764 shares of Common Stock in a concurrent private placement (the &#8220;August&#160;2022 Warrants&#8221;). The
August&#160;2022 Warrants have an exercise price of $5.25 per share, became exercisable six months following the date of issuance
and have a term of exercise equal to five years from the initial exercise date. We received net proceeds from the sale of the
August&#160;2022 Shares and the August&#160;2022 Warrants, after deducting fees and other estimated offering expenses payable by the
Company, of approximately $5.5 million. As of March 29, 2023, none of the August&#160;2022 Warrants have been exercised and
1,411,764 of the August&#160;2022 Warrants remain outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;US
GAAP&#8221;) requires management to make estimates and assumptions about future events that affect the amounts reported in the financial
statements and accompanying notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination
of estimates requires the exercise of judgment. Actual results inevitably will differ from those estimates, and such differences may
be material to the financial statements. The most significant accounting estimates inherent in the preparation of our financial statements
include estimates associated with revenue recognition, impairment analysis of intangibles and stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial position, results of operations and cash flows are impacted by the accounting policies we have adopted. In order to get a full
understanding of our financial statements, one must have a clear understanding of the accounting policies employed. A summary of our
critical accounting policies is presented within the notes to our consolidated financial statements appearing elsewhere in this Annual
Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make
estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent
assets and liabilities in our financial statements. These items are monitored and analyzed by us for changes in facts and circumstances,
and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events,
and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions
on an ongoing basis. Our actual results may materially differ from these estimates under different assumptions or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere
in this Annual Report on Form 10-K, we believe that the following accounting policies are those most significant to the judgments and
estimates used in the preparation of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. For the years ended December 31, 2022 and 2021, no liability for unrecognized
tax benefits was required to be reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no income tax benefit recorded for the losses for the years ended December 31, 2022 and 2021 since management determined that the
realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on
the net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
years from 2019 through 2022 remain subject to examination by federal and state jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-based
compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for share-based payments by recognizing compensation expense based upon the estimated fair value of the share-based payments
on the date of grant. We determine the estimated fair value of the share-based payments granted using the fair market value of the stock
in the case of restricted stock awards or Black-Scholes option pricing model in the case of stock options and recognize compensation
costs ratably over the requisite service period which approximates the vesting period using the graded method. To calculate the fair
value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying Common Stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause
significant adjustments to the valuation. We calculate our volatility assumptions using the actual changes in the market value of our
stock. Forfeitures are recognized as they occur. Our historical option exercises do not provide a reasonable basis to estimate an expected
term due to the lack of sufficient data. Therefore, we estimate the expected term by using the simplified method. The simplified method
calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate
is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The assumptions used
in determining the fair value of share-based awards represent our best estimates, but the estimates involve inherent uncertainties and
the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, our share-based
compensation expense could be materially different in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no significant known off balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2023 Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February&#160;21, 2023, we entered into a Securities Purchase Agreement (the &#8220;February&#160;2023 SPA&#8221;) with certain accredited
investors, pursuant to which we agreed to sell in a registered direct offering (the &#8220;February&#160;2023 Offering&#8221;) (i)&#160;an
aggregate of 15,000 shares (the &#8220;Series&#160;F Preferred Shares&#8221;) of our newly-designated Series F Convertible Preferred
Stock, with a stated value of $1,000 per Preferred Share and without par value (the &#8220;Series&#160;F Preferred Stock&#8221;), convertible
into shares of Common Stock (the &#8220;Series&#160;F Conversion Shares&#8221;) pursuant to the terms of the Certificate of Designations
of the Series&#160;F Preferred Stock (the &#8220;Certificate of Designation&#8221;), and (ii)&#160;6,651,885&#160;warrants (the &#8220;February&#160;2023
Warrants&#8221;) to acquire up to an aggregate of 6,651,885&#160;shares of Common Stock, subject to adjustment (the &#8220;February&#160;2023
Warrant Shares&#8221;). The Conversion Price (as defined below) is subject to customary adjustments for stock dividends, stock splits,
reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible,
exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
closing, we received net proceeds from the February&#160;2023 Offering of approximately $14.1&#160;million, after deducting various fees
and expenses. We intend to use the net proceeds from this offering for general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series&#160;F
Preferred Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Series&#160;F Preferred Shares are as set forth in the form of Certificate of Designation. The Series&#160;F Preferred
Shares will be convertible into the Conversion Shares at the election of the holder at any time at an initial conversion price of $2.255
(the &#8220;Conversion Price&#8221;). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications
and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable
or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). The Company
will be required to redeem the Series&#160;F Preferred Shares in 12 equal monthly installments, commencing on July 1, 2023. The amortization
payments due upon such redemption are payable, at the company&#8217;s election, in cash, or subject to certain limitations, in shares
of Common Stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) 80% of the average of the
three lowest closing prices of the Company&#8217;s Common Stock during the thirty trading day period immediately prior to the date the
amortization payment is due or (B) the Floor Price (as defined below). For purposes of the Certificate of Designation, the &#8220;Floor
Price&#8221; means the lower of (x) $0.4014 and (y) 20% of the &#8220;Minimum Price&#8221; (as defined in Rule 5635 of the Rules of the
Nasdaq Stock Market) on the date of the Nasdaq Stockholder Approval (as defined below) (subject to adjustment for stock splits, stock
dividends, stock combinations, recapitalizations or other similar events) or, in any case, such lower amount as permitted, from time
to time, by the Nasdaq Stock Market. The Company may require holders to convert their Series&#160;F Preferred Shares into Conversion
Shares if the closing price of the Common Stock exceeds $6.765 per share (subject to adjustment for stock splits, stock dividends, stock
combinations, recapitalizations or other similar events) for 20 consecutive trading days and the daily dollar trading volume of the Common
Stock exceeds $3,000,000 per day during the same period and certain equity conditions described in the Certificate of Designation are
satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Series&#160;F Preferred Shares will be entitled to dividends of 10% per annum, compounded monthly, which will be payable
in cash or shares of Common Stock at the Company&#8217;s option, in accordance with the terms of the Certificate of Designation. Upon
the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designation), the Series&#160;F Preferred
Shares will accrue dividends at the rate of 15% per annum. In connection with a Triggering Event, each holder of Series&#160;F Preferred
Shares will be able to require the Company to redeem in cash any or all of the holder&#8217;s Series&#160;F Preferred Shares at a premium
set forth in the Certificate of Designation. Upon conversion or redemption, the holders of the Series&#160;F Preferred Shares are also
entitled to receive a dividend make-whole payment. The holders of Series&#160;F Preferred Shares have no voting rights on account of
the Series&#160;F Preferred Shares, other than with respect to certain matters affecting the rights of the Series&#160;F Preferred Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, acquisition and investment
transactions, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends
pursuant to the Certificate of Designation), distributions or redemptions, and the transfer of assets, among other matters. There is
no established public trading market for the Series&#160;F Preferred Shares and the Company does not intend to list the Series&#160;F
Preferred Shares on any national securities exchange or nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
2023 Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
February 2023 Warrants are exercisable immediately upon issuance at an exercise price of $2.255 per share (the &#8220;Exercise Price&#8221;)
and expire five years from the date of issuance. The Exercise Price is subject to customary adjustments for stock dividends, stock splits,
reclassifications and the like, and subject to price-based adjustment, on a &#8220;full ratchet&#8221; basis, in the event of any issuances
of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Exercise
Price (subject to certain exceptions). There is no established public trading market for the February&#160;2023 Warrants and the Company
does not intend to list the February&#160;2023 Warrants on any national securities exchange or nationally recognized trading system</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq
Stockholder Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to issue Series&#160;F Conversion Shares and February&#160;2023 Warrant Shares using shares of Common Stock is subject to
certain limitations set forth in the Certificate of Designation, including a limit on the number of shares that may be issued until
the time, if any, that our stockholders have approved the issuance of more than 19.9% of our outstanding shares of Common Stock in
accordance with the Nasdaq Listing Rules (the &#8220;Nasdaq Stockholder Approval&#8221;). In the February&#160;2023 SPA we agreed to
seek the Nasdaq Stockholder Approval at a meeting of stockholders. Certain stockholders, who beneficially held approximately 44% of
our outstanding Common Stock as of the date of the February 2023 SPA, are party to a voting agreement pursuant to which, among other
things, each such stockholder agreed, solely in their capacity as a stockholder, to vote all of their shares of Common Stock in
favor of the approval of the Nasdaq Stockholder Approval and against any actions that could adversely affect our ability to perform
our obligations under the February&#160;2023 SPA. The voting agreement also places certain restrictions on the transfer of the
shares of Common Stock held by the signatories thereto.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Item
8. Financial Statements and Supplementary Data.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 8 is included at the end of this Annual Report on Form 10-K beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>Item
9A. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures
(as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) Rule 13a-15(e) and 15d-15(e)) as of the
end of the period covered by this Annual Report on Form 10-K, have concluded that, based on such evaluation, our disclosure controls
and procedures were effective to ensure that information required to be disclosed by us in the reports that we filed or submit under
the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms,
and is accumulated and communicated to our management, including our principal executive officer and principal financial officers as
appropriate to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Internal
Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f)
under the Exchange Act. Internal control over financial reporting refers to the process designed by, or under the supervision of, our
principal executive officer and principal financial officer, and effected by our board of directors, management and other personnel,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect our transactions and the disposition of our assets, (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP and that receipts and expenditures
are being made only in accordance with authorizations of our management and board of directors, and (iii) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect
on the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with policies and procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated the effectiveness of our internal control over financial reporting based on the 2013 framework in <i>Internal Control &#8212;
Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation management
concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant
to the Dodd-Frank Wall Street Reform and Consumer Protection Act, which permits us to provide only management&#8217;s report in this
Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Controls over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting that occurred during our last fiscal quarter ended December 31, 2022
that have materially affected, or are reasonably likely to affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>Item
10. Directors, Executive Officers, and Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the names, ages and positions of all of our directors and executive officers and the positions they hold as
of the date hereof. Our directors serve until their successors are elected and shall qualify. Executive officers are elected by our board
of directors (the &#8220;Board&#8221;) and serve at the discretion of the directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position
    with the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Chapman, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    President and Chief Medical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Kaplin, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Rivard, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Legal Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian
    Rhodes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    Eagle, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Schreiber</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Silverman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jude
    Uzonwanne</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill
    J. White</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a brief description of the background and business experience of each of our executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chris
Chapman, M.D.</i>, has been our director since April 16, 2021 and currently serves as our President and Chief Medical Officer. Dr. Chapman
previously served as President and Chief Medical Officer of MyMD Pharmaceuticals (Florida), Inc., a Florida corporation previously known
as MyMD Pharmaceuticals, Inc. (&#8220;MyMD Florida&#8221;) effective as of November 1, 2020. Prior to joining MYMD Florida and since
1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization
that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product
safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as
the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible
for the supervision of four fellow M.D.s and 10 drug safety specialists. Prior to his time at Organon, Dr. Chapman served as Director,
Medical Affairs, Drug Safety and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995-2003, where he grew the
division from no employees to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers
and supporting staff. Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific,
Inc.) from 2007-2016, including as a member of the Audit Committee from 2007-2014, chairperson of the Compensation Committee from 2007-2014,
and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert
and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects.
Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established
to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and
tuberculosis, which was organized in 2006. Dr. Chapman is a graduate of the Harvard Kennedy School of Cambridge, Massachusetts for financial
management in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his internship
in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown. Dr.
Chapman&#8217;s qualifications to sit on the Board include his extensive experience and leadership roles within the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adam
Kaplin, M.D., Ph.D.,</i> has been our Chief Scientific Officer since April 16, 2021. He previously served as Chief Scientific Officer
of MYMD Florida effective as of December 18, 2020. Since June 20, 2022, Dr. Kaplin has served as the President and Chief Scientific
Officer of Mira Pharmaceuticals, which is developing novel synthetic cannabinoid analogs for a range of neuropsychiatric conditions.
He has been an adjunct faculty member at Johns Hopkins since December 18, 2020, and he served as the Chief Psychiatric Consultant to
the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers from July 1, 2004 to December 18, 2020. Dr. Kaplin completed
his undergraduate training at Yale University and his M.D. and Ph.D. training at the Johns Hopkins School of Medicine. His research training
experience includes having trained in the labs of two Nobel Laureates and completed his Ph.D. and postdoctoral training in the Lab of
Solomon Snyder, M.D., who was the 2005 recipient of the National Medal of Science (the highest science honor in the United States).&#160;Dr.
Kaplin investigated the biological basis of the effects of the immune system on mood regulation and cognition, and he provided neuropsychiatric
care to patients afflicted with such comorbidities. His research is focused on understanding the biological basis of depression and dementia
and discovering new ways to diagnose prognosticate and treat these diseases.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><i>Paul
Rivard, Esq.</i> has been our Chief Legal Officer since March 22, 2023, and prior to that time he served as Executive Vice President
of Operations and General Counsel since April 16, 2021. He previously served as Executive Vice President of Operations and General
Counsel of MYMD Florida effective as of September 21, 2020. Prior to joining MYMD Florida, Mr. Rivard was a principal shareholder of
Banner Witcoff, a national law firm specializing in intellectual property law, from 2003&#8211;2020, and in that capacity also
served as Chair of the firm&#8217;s Prosecution Policies and Procedures Committee, developing and refining internal procedures,
workflow, and docketing practices to improve efficiencies and mitigate risk. Before becoming a principal shareholder, Mr. Rivard was
an associate at Banner Witcoff from 1998&#8211;2002. In addition, prior to his time at Banner Witcoff, Mr. Rivard served as a patent
examiner for the United States Patent and Trademark Office from 1992&#8211;1998. Mr. Rivard brings more than 20 years of experience
as intellectual property counsel for clients ranging from startups to Fortune 100 companies in the life sciences, chemical and
consumer product industries, including primary outside intellectual property counsel for MYMD Florida from 2014&#8211;2020. Since
May 2022, Mr. Rivard has also served as Executive Vice President and General Counsel of MIRA Pharmaceuticals, Inc., a privately held
company developing a synthetic cannabinoid analog for treating chronic pain and anxiety, and from November 2021 until May 2022
served as President of that company. Mr. Rivard received his Juris Doctor from Catholic University of America&#8217;s Columbus
School of Law, graduating cum laude in 1998, and his B.S. in Chemical Engineering from Clarkson University in 1992.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ian
Rhodes</i> has been our Interim Chief Financial Officer since February 1, 2021. Mr. Rhodes joined Brio Financial Group (&#8220;Brio&#8221;)
in January 2021. From March 2020 to December 2020, Mr. Rhodes served as the Interim CFO of Roadway Moving and Storage. From November
2018 to July 2019, he served as Interim CFO of Greyston Bakery and Foundation. From December 2016 to September 2018, Mr. Rhodes served
as President, CEO and Director of GlyEco, Inc., and served as CFO of GlyEco, Inc. from February 2016 to December 2016. From May 2014
to January 2016, he served as CFO of Calmare Therapeutics. Mr. Rhodes began his career at PricewaterhouseCoopers, where he worked for
15 years. Mr. Rhodes holds a Bachelor of Science degree in Business Administration with a concentration in Accounting from Seton Hall
University and is a licensed CPA in New York</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Craig
Eagle, M.D.</i> has been our director since April 16, 2021. Dr. Eagle is currently the Chief Medical Officer of Guardant Health, Inc.
since 2021. Previously, Dr. Eagle was Vice President of Oncology for Genentech, where he oversaw the medical programs across Genentech&#8217;s
oncology portfolio. Prior to his current role, Dr. Eagle worked in several positions at Pfizer from 2009 to 2019, including as the oncology
business lead in the United Kingdom and Canada, the global lead for Oncology Strategic Alliances and Partnerships based in New York,
and as the head of the Oncology Therapeutic Area Global Medical and Outcomes Group, including the U.S. oncology medical business. Through
his multiple roles at Pfizer, Dr. Eagle delivered significant business growth and was involved in multiple strategic acquisitions and
divestitures. In addition, while at Pfizer, Dr. Eagle oversaw extensive oncology clinical trial programs, multiple regulatory and payer
approvals across Pfizer&#8217;s oncology portfolio, health outcomes assessments and scientific collaborations with key global research
organizations like the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC), and
led worldwide development of several compounds including celecoxib, aromasin, irinotecan, dalteparin and ozagomicin. Dr. Eagle currently
serves as a member of the board of directors and chair of the Science and Policy Committee of Pierian Biosciences, a privately held life
sciences company. Dr. Eagle attended Medical School at the University of New South Wales, Sydney, Australia and received his general
internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal
Prince Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College
of Pathologists Australasia (FRCPA). After his training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to
develop a new monoclonal antibody to inhibit platelets before moving into the pharmaceutical industry. Dr. Eagle&#8217;s qualifications
to sit on the Board include his long and successful career in the international pharmaceutical industry, his senior executive experience
in areas such as business growth, strategic alliances and mergers and acquisition transactions, his experience as a member of both public
and private company boards in the healthcare and life science industries, and his wealth of oncology experience, including leading and
participating in scientific research, regulatory, pricing &amp; re-imbursement negotiations for compounds in therapeutic areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Christopher
C. Schreiber </i>has been our director since August 8, 2017 and he previously at various times as our Chief Executive Officer, President,
and Executive Chairman of the Board. Mr. Schreiber combines over 30 years of experience in the securities industry. As the Managing Director
of Capital Markets at Taglich Brothers, Inc., Mr. Schreiber builds upon his extensive background in capital markets, deal structures,
and syndications. Prior to his time at Taglich Brothers, Inc., he was a member of the board of directors of Paulson Investment Company,
a 40-year-old full-service investment banking firm. In addition, Mr. Schreiber serves as a director and partner of Long Island Express
North, an elite lacrosse training organization for teams and individuals.  Mr. Schreiber is a graduate of Johns Hopkins University, where he received a bachelor&#8217;s degree in political science. Mr. Schreiber&#8217;s qualifications to sit on the Board include his financial expertise and his experience with
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Joshua
Silverman</i> has been our director since September 6, 2018 and currently serves as Chairman of the Board. Prior to the completion of
the Merger, Mr. Silverman was also the lead independent director. Mr. Silverman currently serves as the managing member of Parkfield
Funding LLC. Mr. Silverman was the co-founder, and a principal and managing partner of Iroquois Capital Management, LLC (&#8220;Iroquois&#8221;),
an investment advisory firm. Since its inception in 2003 until July 2016, Mr. Silverman served as co-chief investment officer of Iroquois.
While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private
companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and
management. From 2000 to 2003, Mr. Silverman served as co-chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior
to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions.
Previously, Mr. Silverman served as assistant press secretary to the president of the United States. Mr. Silverman currently serves as
a director of Ayro Inc. and Petros Pharmaceutical, Inc., both of which are public companies. He previously served as a director of National
Holdings Corporation from July 2014 through August 2016 and as a director of Marker Therapeutics, Inc. from August 2016 until October
2018. Mr. Silverman received his B.A. from Lehigh University in 1992. Mr. Silverman&#8217;s qualifications to sit on the Board include
his experience as an investment banker, management consultant and as a director of numerous public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Jude
Uzonwanne </i>has been our director since April 16, 2021. Mr. Uzonwanne has been the Chief Executive Officer for Mira
Pharmaceuticals Inc. since June 2022. Mira is a US based biopharmaceutical company focused on developing an oral FDA approved
marijuana analog. Prior to Mira, he was the Chief Business Officer at a genetics-based healthcare company, 54gene from March 2021 to
June 2022. Prior to 54gene, he was a Principal with ZS Associates, Inc., a consulting and professional services firm, a position he
held from January 2021 to March 2021. Prior to joining ZS Associates, Mr. Uzonwanne was a Principal at IQVIA, Inc. from 2018 to
2020, where he served as the head of the firm&#8217;s US Financial Investors Consulting practice and as management consulting lead
for IQVIA&#8217;s service to a top-6 global pharmaceutical company and select emerging biopharmaceutical companies. Prior to joining
IQVIA, Mr. Uzonwanne served as Vice President (Associate Partner) at EY-Parthenon LLP from 2016 to 2018, where he managed teams
advising corporate and private equity investors on a range of commercial due diligence targets in healthcare strategies and advised
clients on growth accelerating strategies and investments. Prior to this role, Mr. Uzonwanne has worked for several other companies
including Bain &amp; Company, Dalberg Global Development Advisers, the Bill and Melinda Gates Foundation, and Monitor Group. Mr.
Uzonwanne is a graduate of Swarthmore College (double Honors B.A in Economics and Political Science). Mr. Uzonwanne&#8217;s
qualifications to sit on the Board include his experience as a corporate strategy and transaction services adviser in the healthcare
markets globally..&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bill
J. White</i> has been our director since August 8, 2017. Mr. White has more than 30 years of experience in financial management, operations
and business development. Most recently he has served as the chief financial officer for ProPhase Labs Inc. (Nasdaq: PRPH), and the chief
financial officer, chief operating officer, treasurer and secretary of Intellicheck, Inc., (Nasdaq: IDN). Prior to working at Intellicheck,
Inc., he served 11 years as the chief financial officer, chief operating officer, secretary and treasurer of FocusMicro, Inc. (&#8220;FM&#8221;).
As co-founder of FM, Mr. White played an integral role in growing the business from the company&#8217;s inception to leading its international
expansion into Dubai, UAE.&#160; Mr. White has broad domestic and international experience including managing rapid and significant growth,
import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic
planning, resource allocation, tax compliance and organization development. Prior to co-founding FM, he served 15 years in various financial
leadership positions in the government sector. Mr. White started his career in Public Accounting. Mr. White holds a Bachelor of Arts
in Business Administration from Washington State University and is a Certified Fraud Examiner. Mr. White was selected to serve on the
Board of Directors in part because of his significant financial and accounting experience with public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Family
Relationships</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships between any of our officers or directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance Reforms</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 28, 2020, the United States District Court for the District of New Jersey approved that certain Amended Stipulation and Agreement
of Settlement, dated October 1, 2019 (the &#8220;Settlement&#8221;) among the settling parties in connection with a consolidated shareholder
derivative action, Case No.: 2:18-cv-15992. Pursuant to the Settlement, effective as of July 21, 2020, we made various modifications
to our corporate governance and business ethics practices as further discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Ethics and Conduct, which applies to our Board, our executive officers and our employees, outlines the
broad principles of ethical business conduct we adopted, covering subject areas such as, compliance with applicable laws and regulations,
handling of books and records, public disclosure reporting, insider trading, conflicts of interest, competition and fair dealing, and
other violations. Our Code of Business Ethics and Conduct is available on our website at <span style="text-decoration: underline">www.mymd.com</span> in the &#8220;Corporate
Governance&#8221; section found under the &#8220;Investors&#8221; tab. Pursuant to the Settlement, we will conduct a review of our Code
of Business Ethics and Conduct on an annual basis and to monitor compliance. We intend to disclose any amendments to, or waivers from,
our Code of Business Ethics and Conduct at the same website address provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Settlement, we adopted a Whistleblower Policy to encourage employees, officers and directors to bring forward
ethical and legal violations. We have disclosed a copy of the Whistleblower Policy and intend to disclose any amendments to the Whistleblower
Policy at the same website address provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Settlement, we formed a Risk and Disclosure Committee, which is served by the members of the Audit Committee, which reviews our
ethics and risk program and internal controls over compliance and identifies and recommends to the Board any changes that it deemed necessary.
The Risk and Disclosure Committee also monitors compliance with our Code of Business Ethics and Conduct, reviews and evaluates our public
disclosures and disclosure controls and procedures and handle any whistleblower complaints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Composition and Committees </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation, as amended (the &#8220;Charter&#8221;), and our Amended and Restated Bylaws (&#8220;Bylaws&#8221;)
provide that our Board will consist of a number of directors to be determined from time to time solely by resolution of the Board, which
is currently set at seven directors. Vacancies or newly created directorships resulting from an increase in the authorized number of
directors elected by all of the stockholders having the right to vote as a single class may be filled by a majority of the directors
then in office, although less than a quorum, or by a sole remaining director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no formal policy regarding Board diversity. Our Board believes that each director should have a basic understanding of the principal
operational and financial objectives and plans and strategies of the Company, our results of operations and financial condition and relative
standing in relation to our competitors. We take into consideration the overall composition and diversity of the Board and areas of expertise
that director nominees may be able to offer, including business experience, knowledge, abilities and customer relationships. Generally,
we will strive to assemble a Board that brings to us a variety of perspectives and skills derived from business and professional experience
as we may deem are in our and our stockholders&#8217; best interests. In doing so, we will also consider candidates with appropriate
non-business backgrounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently listed on the Nasdaq Capital Market and therefore rely on the definition of independence set forth in the Nasdaq Listing
Rules (&#8220;Nasdaq Rules&#8221;). Under the Nasdaq Rules, a director will only qualify as an &#8220;independent director&#8221; if,
in the opinion of our Board, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. Based upon information requested from and provided by each director concerning his
background, employment, share ownership, and affiliations with other board members, shareholders, business, contractor and family relationships,
as well as the amount of the compensation we pay to each director, we have determined that Mr. Silverman, Mr. White, Dr. Eagle, and Mr.
Uzonwanne have no material relationships with us that would interfere with the exercise of independent judgment and are &#8220;independent
directors&#8221; as that term is defined in the Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Settlement, we also adopted amendments to our Bylaws to require that at least 50% of the Board will qualify as &#8220;independent
directors&#8221; under the Nasdaq Rules and that the Chairman of the Board will be an independent director. Currently, more than 50%
of the Board qualify as &#8220;independent directors&#8221; under the Nasdaq Rules. We are currently in compliance with these requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board delegates various responsibilities and authority to different Board committees. Committees regularly report on their activities
and actions to the full Board. Currently, the Board has established an Audit Committee, a Compensation Committee, a Nominating and Corporate
Governance Committee and a Risk and Disclosure Committee. Committee assignments are re-evaluated annually. Each of these committees operates
under a charter that has been approved by our Board. The current charter of each of these committees is available on our website at <span style="text-decoration: underline">www.mymd.com
</span>in the &#8220;Corporate Governance&#8221; section under &#8220;Investors.&#8221; Pursuant to the Settlement, we adopted several amendments
to the committee charters. We disclosed these amendments and intend to disclose any future amendments to the charters of these committees
at the same website address provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the membership of each of the Board committees listed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit<br />
    Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation<br />
    Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nomination<br />
    Corporate<br />
    Governance<br />
    Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    and<br />
    Disclosure<br />
    Committee</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Chapman, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    Eagle, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    C. Schreiber</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Silverman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jude
    Uzonwanne</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill
    J. White</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is responsible for, among other matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; text-indent: -17.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    the integrity of our financial reporting process, including critical accounting policies and estimates, and systems of internal controls
    regarding finance, accounting, legal and regulatory compliance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    the independence and performance of our independent auditors and our accounting personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    an avenue of communication among the independent auditors, management, our accounting personnel, and the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing
    and providing oversight for the independent auditors engaged to perform the audit of the financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the scope of the independent auditors&#8217; examination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the financial statements and the independent auditors&#8217; report;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    areas of potential significant financial risk and exposure to us, to the extent that there are any, and assess the steps management
    has taken to monitor such risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    compliance with legal and regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">soliciting
    recommendations from the independent auditors regarding internal controls and other matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resolving
    any disagreements between management and the auditors regarding financial reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report required by Item 407(d) of Regulation S-K, as required by the rules of the SEC;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    issues regarding accounting principles and financial statement presentation (including any significant changes in our selection or
    application of accounting principles); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the effectiveness of any special accounting steps adopted in light of identified significant and/or material control deficiencies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is composed of Bill J. White (Chair), Joshua Silverman, and Jude Uzonwanne. Our Board has determined that each of the
current members of the Audit Committee is independent in accordance with Nasdaq Rules and Rule 10A-3 under the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;). Our Board has also reviewed the education, experience and other qualifications
of each member of the Audit Committee. Based upon that review, our Board has determined that Mr. White qualifies as an &#8220;audit committee
financial expert,&#8221; as defined by the rules of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 16.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee is responsible for, among other matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -17.35pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reviewing and approving on an annual basis goals and objectives relevant
    to our Chief Executive Officer&#8217;s compensation, evaluating our Chief Executive Officer&#8217;s performance in light of those
    goals and objectives, and determining the compensation of our Chief Executive Officer based on this evaluation or recommending such
    goals, objectives and compensation of our Chief Executive Officer&#8217;s to the Board for its approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reviewing and approving on an annual basis the compensation of our
    executive officers other than our Chief Executive Officer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reviewing on an annual basis, the fees and equity compensation paid to the Company&#8217;s non-employee directors for service on the Board and Board
    committees and recommending any changes to the Board as necessary;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">selecting, retaining and terminating any compensation consultant to
    be used by the Compensation Committee or us to assist in the evaluation of the compensation of non-employee directors, the Chief
    Executive Officer or the other executive officers and approving such compensation consultant&#8217;s fees and other retention terms,
    and overseeing the work of such compensation consultant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reviewing, approving and, when appropriate, making recommendations
    to the Board for approval, incentive-compensation programs and equity-based plans and the adoption of or material changes in material
    employee benefit, bonus, severance and other compensation plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reviewing and approving and, when appropriate, recommending to the
    Board for approval, any employment agreements and change in control agreements for each of our executive officers and any other officers
    recommended by the Chief Executive Officer or the Board, which includes the ability to adopt, amend and terminate such agreements,
    arrangements or plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">determining and approving the options and other equity-based
    compensation to be granted to executive officers, including the Chief Executive Officer, and shall recommend to the Board for
    approval options and other equity-based compensation to be granted to non-employee directors, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">in conjunction with the Chief Executive Officer, determining the issuance
    of options and other equity-based compensation under the Company&#8217;s incentive compensation and other stock-based plans to all
    other officers and employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee is composed of Joshua Silverman (Chair), Craig Eagle, M.D., and Jude Uzonwanne. Our Board has determined that
each of the current members of the Compensation Committee is independent in accordance with Nasdaq Rules. The Compensation Committee
may delegate the determination with respect to persons other than officers to the Chief Executive Officer but will approve the aggregate
amount granted to all employees and all new hire grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating and Corporate Governance Committee is responsible for, among other matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the administration of our Code of Business Ethics and Conduct and related policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leading
    the search for and recommending individuals qualified to become members of the Board, and selecting director nominees to be presented
    for election by the shareholders at each annual meeting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring,
    in cooperation with the Compensation Committee, that no agreements or arrangements are made with directors or relatives of directors
    for providing professional or consulting services to us or our affiliate or individual officer or one of their affiliated, without
    appropriate review and evaluation for conflicts of interest;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring
    that Board members do not serve on more than six other for-profit public company boards that have a class of securities registered
    under the Exchange Act in addition to the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the Board&#8217;s committee structure and to recommend to the Board for its approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    recommendations received from shareholders for persons to be considered for nomination to the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    compliance with our corporate governance guidelines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and implementing an annual self-evaluation of the Board, both individually and as a Board, and of its committees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending changes to procedures whereby shareholders may communicate with the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
    the independence of directors annually and report to the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the Board for its approval, the leadership structure of the Board, including whether the Board should have an executive or non-executive
    Chairman, whether the roles of Chairman and Chief Executive Officer should combine, and whether a Lead Director of the Board should
    be appointed; provided that such structure shall be subject to the bylaws of the Company then in effect.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating and Corporate Governance Committee is composed of Jude Uzonwanne (Chair), Bill J. White, and Joshua Silverman. Each of the
current appointed Nominating and Corporate Governance Committee members is &#8220;independent&#8221; within the meaning of the Nasdaq
Stock Market Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk
and Disclosure Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Risk and Disclosure Committee is responsible for, among other matters:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the effectiveness of our Code of Ethics annually, including our ethics and risk program, and recommending to the Board any changes
    to our policies and internal controls as necessary;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    compliance with our Code of Ethics, and specifically reviewing and evaluating our public disclosures and annually reviewing and evaluating
    our disclosure controls and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving any waivers of provisions of the Code of Ethics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    any whistleblower complaints and ensuring that all whistleblower complaints are appropriately reviewed by the Risk and Disclosure
    Committee and that any appropriate remedial action if necessary is taken based on the results of its review; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring
    that non-retaliation policies are instituted and strictly complied with in order to protect any Company employee who reports a whistleblower
    complaint.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Risk and Disclosure Committee is composed of Bill J. White (Chair), Joshua Silverman and Jude Uzonwanne. Our Board has determined that
each of the current members of the Risk and Disclosure Committee is independent in accordance with Nasdaq Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material legal proceedings that would require disclosure under the federal securities laws that are material to an evaluation
of the ability or integrity of our directors or executive officers, or in which any director, officer, nominee or principal stockholder,
or any affiliate thereof, is a party adverse to us or has a material interest adverse to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance
with Section 16(a) of the Exchange Act</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our directors and officers, and persons who own more than ten percent of our Common Stock,
to file with the SEC initial reports of ownership and reports of changes in ownership of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely upon a review of copies of Section 16(a) reports and representations received by us from reporting persons, and without conducting
any independent investigation of our own, in fiscal year 2022, all Forms 3, 4 and 5 were timely filed with the SEC by such reporting
persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
following is a discussion of the material components of the executive compensation arrangements of our named executive officers,
comprised of (i) our principal executive officer, (ii) the two most highly compensated executive officers other than the principal
executive officer who were serving as executive officers at the end of the 2022 fiscal year and whose salary, as determined
by Regulation S-K, Item 402, exceeded $100,000 and (iii) up to two most highly compensated former executive officers who were no
longer serving as an executive officer at the end of the 2022 fiscal year (the individuals falling within categories (i), (ii) and
(iii) are collectively referred to as the &#8220;named executive officers&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers for 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Chapman, M.D., President and Chief Medical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Kaplin, M.D., Ph.D., Chief Scientific Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Rivard, Esq., Chief Legal Officer and Former Executive Vice President of Operations and General Counsel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of 4:05 pm Eastern Time on April 16, 2021, we filed an amendment to
our Amended and Restated Certificate of Incorporation to effect a Reverse Stock Split of the issued and outstanding shares of our Common
Stock, at a ratio of 1 for 2. The stock awards listed below have been adjusted to give effect to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
                                            and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards<sup>(2)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation<sup>(3)</sup></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Chapman, M.D.<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">261,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Medical Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121,540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,854,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,140,540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Kaplin, M.D., PhD<sup>(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">245,153</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,580</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">353,733</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,724</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,854,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,230,724</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Rivard, Esq.<sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,412</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,239</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Legal Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,618,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,843,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 48px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">In accordance with SEC rules, this column reflects the aggregate fair
    value of stock awards granted during the fiscal year ended December 31, 2021, computed as of their respective grant dates in accordance
    with Financial Accounting Standard Board Accounting Standards Codification (&#8220;FASB ASC&#8221;) Topic 718 for share-based compensation
    transactions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">In accordance with SEC rules, this column reflects the aggregate fair
    value of option awards granted during the fiscal year ended December 31, 2020, computed as of their respective grant dates in accordance
    with FASB ASC Topic 718 for share-based compensation transactions. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This column reflects the
    matching contribution paid to participants of the MyMD Pharmaceuticals 401(k) PS Plan (the &#8220;401(k) Plan&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Dr. Chapman was appointed President and Chief Medical Officer of MyMD
    effective April 16, 2021. Prior to the Merger, Dr. Chapman served as the President and Chief Medical Officer of MyMD Florida effective
    November 1, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Dr. Kaplin was appointed Chief Scientific Officer of MyMD effective
    April 16, 2021. Prior to the Merger, Dr. Kaplin served as Chief Scientific Officer of MyMD Florida effective December 18, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">On April 16, 2021, Mr. Rivard entered into an employment agreement,
    under which he would receive an annual salary of $165,000. On March 22, 2023, Mr. Rivard was appointed as Chief Legal Officer and his annual salary was increased to $275,000,
retroactively to January 1, 2023. Prior to the Merger, Mr. Rivard served as Executive Vice President of
    Operations and General Counsel of MyMD Florida effective September 21, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">On October 14, 2021, the Company granted 600,000 restricted stock units
    (&#8220;RSUs&#8221;) to each of Dr. Chapman and Dr. Kaplin..</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">On October 14, 2021, the Company granted 200,000 RSUs to Mr. Rivard.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into employment agreements with each of our Named Executive Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
of Chris Chapman, M.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Merger
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 1, 2020, MyMD Florida and Dr. Chapman entered into an employment agreement, which was subsequently amended by that certain First
Amendment to Employment Agreement, dated December 18, 2020, that certain Second Amendment to Employment Agreement dated January 8, 2021,
and that certain Third Amendment to Employment Agreement dated February 11, 2021 (such agreement, as amended, the &#8220;Chapman Employment
Agreement&#8221;), pursuant to which Dr. Chapman was appointed President and Chief Medical Officer of MyMD Florida. Under the Chapman
Employment Agreement, Dr. Chapman is entitled to an annual base salary of $165,000, payable monthly. Dr. Chapman is also eligible to
receive bonus compensation in the form of lump-sum cash payments made within 30 days following the completion of certain specified &#8220;Bonus
Events&#8221; (as defined in the Chapman Employment Agreement). The aggregate amount of bonus compensation payable to Dr. Chapman upon
achievement of all specified Bonus Events is $800,000. In addition, Dr. Chapman is eligible to receive additional bonus compensation
in connection with his annual performance, determined in the sole discretion of MyMD Florida&#8217;s board of directors. Pursuant to
and on the effective date of the Chapman Employment Agreement, Dr. Chapman was also granted options to purchase 250,000 shares of MyMD
Florida Common Stock, at an exercise price of $1.00 per share. (After giving effect to the Exchange Ratio and the Reverse Stock Split,
such MyMD Florida options became options to purchase 96,475 shares of the Company&#8217;s Common Stock at an exercise price of $2.59.)
Such options all vested immediately upon grant. The options had an original term of lasting until the earlier of (i) ten years from the
date of grant or (ii) the second-year anniversary of the effective date of a &#8220;Reorganization Event&#8221; as defined in the MyMD
Pharmaceuticals, Inc. Amended and Restated 2016 Equity Incentive Plan (as amended, the &#8220;MyMD Florida Incentive Plan&#8221;) (the
practical effect of which makes the term of such options expire on the second-year anniversary of the effective date of the merger, which
occurred on April 16, 2021). MyMD Florida also agreed to provide and cover the cost of health insurance and disability policies for Dr.
Chapman during the term of employment under the Chapman Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Chapman&#8217;s employment with MyMD Florida pursuant to the Chapman Employment Agreement commenced as of the effective date of the Chapman
Employment Agreement and was to continue for a period of two years, unless earlier terminated by either party, with such termination
effective upon the provision of written notice to the other party. In the event of termination of Dr. Chapman&#8217;s employment with
MyMD Florida for cause, MyMD Florida was to pay to Dr. Chapman his monthly base salary for a period of three months following the date
that notice of termination of employment is provided, which would be the full extent of MyMD Florida&#8217;s obligations with respect
to severance payments to Dr. Chapman under the Chapman Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chapman Employment Agreement also contains certain standard confidentiality, work for hire and assignment of inventions provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 2, 2020, Dr. Chapman received a discretionary grant of options to purchase 200,000 shares of MyMD Florida Common Stock, at an
exercise price of $1.00 per share. All such options vested immediately upon grant. The options had an original term of ten years from
the date of grant, subject to certain events described in the applicable award agreement, including Dr. Chapman&#8217;s, death, disability,
retirement or an &#8220;Event of Cause&#8221; (as defined in the applicable award agreement). In connection with the Merger Agreement,
certain terms of such options were amended. After giving effect to the Exchange Ratio and the Reverse Stock Split, such MyMD Florida
options became options to purchase 77,180 shares of the Company&#8217;s Common Stock at an exercise price of $2.59.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Merger
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the effective time of the Merger, the Board appointed Dr. Chapman to the offices of President and Chief Medical Officer on
the terms of the Chapman Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 24, 2021, the Company and Dr. Chapman entered into a Fourth Amendment to Employment Agreement. This agreement provided that
certain performance criteria applicable to Dr. Chapman&#8217;s bonus compensation under the Chapman Employment Agreement would be waived
and deemed to have been achieved, and that Dr. Chapman would be entitled to a bonus payment of $100,000 as a result. On August&#160;30,
2022, the Company and Dr. Chapman entered into a Fifth Amendment to amend one of the performance criteria under the Chapman Employment
Agreement, upon the achievement of which by the Company Dr. Chapman would be entitled to an additional bonus payment of $100,000. On
February 1, 2023, the Company and Dr. Chapman entered into a Sixth Amendment providing for Dr. Chapman&#8217;s annual base salary to
be set at $310,000, effective retroactively to January&#160;1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
of Adam Kaplin, M.D., Ph.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Merger
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
December 18, 2020, MyMD Florida and Dr. Kaplin entered into an employment agreement, which was subsequently amended by that certain First
Amendment to Employment Agreement, dated February 11, 2021 (such agreement, as amended, the &#8220;Kaplin Employment Agreement&#8221;),
pursuant to which Dr. Kaplin was appointed Chief Scientific Officer of MyMD Florida. Under the Kaplin Employment Agreement, Dr. Kaplin
is entitled to an annual base salary of $250,000, payable monthly. Dr. Kaplin is also eligible to receive bonus compensation in the form
of lump-sum cash payments made within 30 days following the completion of certain specified &#8220;Bonus Events&#8221; (as defined in
the Kaplin Employment Agreement). The aggregate amount of bonus compensation payable to Dr. Kaplin upon achievement of all specified
Bonus Events is $800,000. In addition, Dr. Kaplin is eligible to receive additional bonus compensation in connection with his annual
performance, determined in the sole discretion of MyMD Florida&#8217;s board of directors. On the effective date of the Kaplin Employment
Agreement, Dr. Kaplin received a signing bonus in the form of a lump-sum cash payment in the amount of $100,000 and was also granted
options to purchase 400,000 shares of MyMD Florida Common Stock, at an exercise price of $1.00 per share. (After giving effect to the
Exchange Ratio and the Reverse Stock Split, such MyMD Florida options became options to purchase 154,360 shares of the Company&#8217;s
Common Stock at an exercise price of $2.59.) Such options all vested immediately upon grant. The options had an original term of lasting
until the earlier of (i) ten years from the date of grant or (ii) the second-year anniversary of the effective date of a &#8220;Reorganization
Event&#8221; as defined in the MyMD Florida Incentive Plan (the practical effect of which makes the term of such options expire on the
second-year anniversary of the effective date of the merger, which occurred on April 16, 2021). MyMD Florida also agreed to provide and
cover the cost of health insurance and disability policies for Dr. Kaplin during the term of employment under the Kaplin Employment Agreement.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kaplin&#8217;s employment with MyMD Florida pursuant to the Kaplin Employment Agreement commenced on December 18, 2020 and was to continue
for a term of two years unless earlier terminated by either party, with such termination effective upon the provision of written notice
to the other party. In the event of termination of Dr. Kaplin&#8217;s employment with MyMD Florida for cause, MyMD Florida was to pay
to Dr. Kaplin his monthly base salary for a period of three months following the date that notice of termination of employment is provided,
which would be the full extent of MyMD Florida&#8217;s obligations with respect to severance payments to Dr. Kaplin under the Kaplin
Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Kaplin Employment Agreement also contained certain standard confidentiality, work for hire and assignment of inventions provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Merger
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the effective time of the Merger, the Board appointed Dr. Kaplin to the office of Chief Scientific Officer on the terms of
the Kaplin Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 24, 2021, the Company and Dr. Kaplin entered into a Second Amendment to Employment Agreement. This agreement provided that certain
performance criteria applicable to Dr. Kaplin&#8217;s bonus compensation under the Kaplin Employment Agreement would be waived and deemed
to have been achieved, and that Dr. Kaplin would be entitled to a bonus payment of $100,000 as a result. On August&#160;30, 2022, the
Company and Dr. Kaplin entered into a Third Amendment to amend one of the performance criteria under the Kaplin Employment Agreement,
upon the achievement of which by the Company Dr. Kaplin would be entitled to an additional bonus payment of $100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
of Paul Rivard, Esq.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Merger
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 21, 2020, MyMD Florida and Mr. Rivard entered into an employment agreement (such agreement, as amended, the &#8220;Rivard Employment
Agreement&#8221;), pursuant to which Mr. Rivard was appointed Executive Vice President of Operations and General Counsel of MyMD Florida.
Under the Rivard Employment Agreement, Mr. Rivard is entitled to an annual base salary of $165,000, payable monthly. Mr. Rivard is also
eligible to receive bonus compensation in the form of lump-sum cash payments made within 30 days following the completion of certain
specified &#8220;Bonus Events&#8221; (as defined in the Rivard Employment Agreement). The aggregate amount of bonus compensation payable
to Mr. Rivard upon achievement of all specified Bonus Events is $160,000. In addition, Mr. Rivard is eligible to receive additional bonus
compensation in connection with his annual performance, determined in the sole discretion of MyMD Florida&#8217;s board of directors.
On the effective date of the Rivard Employment Agreement, Mr. Rivard was granted options to purchase 200,000 shares of MyMD Florida Common Stock, at an exercise price of $1.00 per share. (After giving effect to the Exchange Ratio and the Reverse Stock Split, such MyMD Florida
options became options to purchase 77,180 shares of the Company&#8217;s Common Stock at an exercise price of $2.59.) Such options all
vested immediately upon grant. The options had an original term of lasting until the earlier of (i) ten years from the date of grant
or (ii) the second-year anniversary of the effective date of a &#8220;Reorganization Event&#8221; as defined in the MyMD Florida Incentive
Plan (the practical effect of which makes the term of such options expire on the second-year anniversary of the effective date of the
merger, which occurred on April 16, 2021). MyMD Florida also agreed to provide and cover the cost of health insurance and disability
policies for Mr. Rivard during the term of employment under the Rivard Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rivard&#8217;s employment with MyMD Florida pursuant to the Rivard Employment Agreement commenced on September 21, 2020 and was to continue
until terminated by either party, with such termination effective upon the provision of written notice to the other party. In the event
of termination of Mr. Rivard employment with MyMD Florida, MyMD Florida was to pay to Mr. Rivard his monthly base salary for a period
of three months following the date that notice of termination of employment is provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Rivard Employment Agreement also contained certain standard confidentiality, work for hire and assignment of inventions provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Merger
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the effective time of the Merger, the Board appointed Mr. Rivard to the office of Executive Vice President of Operations and
General Counsel on the terms of the Rivard Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On March 22, 2023, Mr. Rivard was appointed Chief
Legal Officer and his annual salary was increased to $275,000, retroactively to January 1, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the outstanding equity awards that have been previously awarded to each of our Named
Executive Officers and which remain outstanding as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Named</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Officer</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercisable</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercisable</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expiration
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>date<sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>units
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stock
                                            that</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>have
                                            not</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>vested</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
                                            value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
                                            shares or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>units
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stock
                                            that</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>have
                                            not</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>vested</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: left">Christopher Chapman, M.D.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">38,590</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(3)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2.59</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">4/16/2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">President, Chief Medical Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,180</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(4)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4/16/2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,180</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(5)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4/16/2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,475</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(6)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4/16/2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">n/a</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">600,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,854,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Adam Kaplin, M.D., PhD</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">154,360</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4/16/2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Scientific Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">n/a</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">600,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,854,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Paul Rivard, Esq</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,180</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(8)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4/16/2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Legal Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">n/a</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,618,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
All such options vested immediately upon grant. The options had an original term of lasting until the earlier of (i) ten years from the
date of grant or (ii) the second-year anniversary of the effective date of a &#8220;Reorganization Event&#8221; as defined in the MyMD
Florida Incentive Plan (the practical effect of which makes the term of such options expire on the second-year anniversary of the effective
date of the merger, which occurred on April 16, 2021).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Granted on October 14, 2021. These RSUs vest at various times based upon the market capitalization of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Granted on December 3, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Granted on December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Granted on August 3, 2020</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Granted on October 26, 2020</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Granted on December 18, 2020</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Granted on August 21, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

























































<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table presents
the total compensation for each person who served as a member of our Board during 2022. All compensation paid to Dr. Chapman during 2022
is reported under the Summary Compensation Table. Other than as set forth in the table and described more fully below, we did not pay
any compensation, reimburse any expense of, make any equity awards or non-equity awards to, or pay any other compensation to any of the
other members of our Board in such period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Name</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fees earned or paid in cash</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards<sup>(1)</sup></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">All Other Compensation<sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Silverman<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">216,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">216,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill J. White<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig Eagle, M.D<sup>(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jude Uzonwanne<sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Schreiber<sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">306,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">306,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">In accordance with SEC rules, this column reflects the aggregate fair
    value of stock awards granted during the fiscal year ended December 31, 2022, computed as of their respective grant dates in accordance
    with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for share-based compensation transactions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This column includes salaries
    and matching contributions paid to participants of the 401(k) Plan for non-executive employee members of the Board.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As of December 31, 2022, Mr. Silverman had 673,776 outstanding RSUs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As of December 31, 2022, Mr. White had 223,776 outstanding RSUs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As of December 31, 2022, Dr. Eagle had 150,000 outstanding RSUs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As of December 31, 2022, Mr. Uzonwanne had 150,000 outstanding RSUs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(7)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 24, 2020, Mr. Schreiber entered into an employment agreement with the Company, under which he would
                                    receive an annual salary of $300,000. Since then he has served the Company in various positions, and his employment agreement with
                                    the Company remains in effect. As of December 31, 2022, Mr. Schreiber had 238,238 outstanding RSUs.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Director Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
approved by the Compensation Committee of the Board on March 29, 2019, beginning in April 2019, each serving director who is not also
holding a position as an executive officer is paid $8,000 per month. On or around May 2020, the Compensation Committee of the Board approved
payments to Mr. Silverman of $18,000 per month, beginning in May 2020. All director fees were paid on a monthly basis. There was no other
compensation for directors during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Compensation Committee of the Board authorized the issuance of 2,795,000 restricted stock units with a fair market
value of $8.09 per RSU to the directors and key employees of the Company. These RSUs will vest in thirds when certain market capitalization
milestones are met and maintained for twenty consecutive trading sessions. Upon achievement of a vesting milestone, the expenses related
to the vested RSUs will be recorded at the fair market value of the Company&#8217;s Common Stock on the date of vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Equity Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, at the effective time of the Merger, the Company adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;),
which was approved by the Company&#8217;s stockholders on April 15, 2021. The 2021 Plan provides for the granting of incentive stock
options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other
awards which may be granted singly, in combination or in tandem, and which may be paid in cash or shares of Common Stock. At the effective
time of the Merger, the number of shares of Common Stock that were reserved for issuance pursuant to awards under the 2021 Plan was 7,228,184
shares. As of December 31, 2022, 4,078,977 shares remain available for issuance under the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose</i>.
The purpose of the 2021 Plan is to enable the Company to remain competitive and innovative in its ability to attract and retain the services
of key employees, key contractors, and non-employee directors of the Company or any of its subsidiaries. The 2021 Plan provides for the
granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units,
performance awards, and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares
of the Company&#8217;s Common Stock. The 2021 Plan is expected to provide flexibility to the Company&#8217;s compensation methods in
order to adapt the compensation of key employees, key contractors, and non-employee directors to a changing business environment, after
giving due consideration to competitive conditions and the impact of applicable tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effective
Date and Expiration</i>. The 2021 Plan was approved by the Company&#8217;s Board of Directors on March 18, 2021 (the &#8220;Plan Effective
Date&#8221;) and approved by the Company&#8217;s stockholders on April 15, 2021. The 2021 Plan will terminate on the tenth anniversary
of the Plan Effective Date, unless sooner terminated by the Company&#8217;s Board of Directors. No awards may be made under the 2021
Plan after its termination date, but awards made prior to the termination date may extend beyond that date in accordance with their terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share
Authorization</i>. At the effective time of the Merger, the number of shares of Common Stock that were reserved for issuance pursuant
to awards under the 2021 Plan was 7,228,184 shares, 100% of which may be delivered as incentive stock options. Shares to be issued may
be made available from authorized but unissued shares of the Company&#8217;s Common Stock, shares held by the Company in its treasury,
or shares purchased by the Company on the open market or otherwise. During the term of the 2021 Plan, the Company will at all times reserve
and keep enough shares available to satisfy the requirements of the 2021 Plan. If an award under the 2021 Plan is cancelled, forfeited,
or expires, in whole or in part, the shares subject to such forfeited, expired, or cancelled award may again be awarded under the 2021
Plan. Awards that may be satisfied either by the issuance of Common Stock or by cash or other consideration shall be counted against
the maximum number of shares that may be issued under the 2021 Plan only during the period that the award is outstanding or to the extent
the award is ultimately satisfied by the issuance of shares. An award will not reduce the number of shares that may be issued pursuant
to the 2021 Plan if the settlement of the award will not require the issuance of shares, as, for example, a stock appreciation right
that can be satisfied only by the payment of cash. Shares of Common Stock that are otherwise deliverable pursuant to an award under the
2021 Plan that are withheld in payment of the option price of an option or for payment of applicable employment taxes and/or withholding
obligations resulting from the award shall be treated as delivered to the award recipient and shall be counted against the maximum number
of shares of our Common Stock that may be issued under the 2021 Plan. Only shares forfeited back to the Company or cancelled on account
of termination, expiration, or lapse of an award shall again be available for grant of incentive stock options under the 2021 Plan but
shall not increase the maximum number of shares described above as the maximum number of shares of the Company&#8217;s Common Stock that
may be delivered pursuant to incentive stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration</i>.
The 2021 Plan is administered by the compensation committee of the Board or such other committee of the board as is designated by it
to administer the 2021 Plan (the &#8220;2021 Plan Administration Committee&#8221;). If necessary to satisfy the requirements of Rule
16b-3 promulgated under the Exchange Act, membership on the 2021 Plan Administration Committee shall be limited to those members of the
Board who are &#8220;non-employee directors&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act. At any time there is
no 2021 Plan Administration Committee to administer the 2021 Plan, any reference to the 2021 Plan Administration Committee is a reference
to the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2021 Plan Administration Committee will determine the persons to whom awards are to be made; determine the type, size, and terms of awards;
interpret the 2021 Plan; establish and revise rules and regulations relating to the 2021 Plan as well as any sub-plans for awards to
be made to eligible award recipients who are not resident in the United States; establish performance goals for awards and certify the
extent of their achievement; and make any other determinations that it believes are necessary for the administration of the 2021 Plan.
The 2021 Plan Administration Committee may delegate certain of its duties to one or more of the Company&#8217;s officers as provided
in the 2021 Plan. Notwithstanding the foregoing, to the extent necessary to satisfy the requirements of Rule 16b-3 promulgated under
the Exchange Act, any function relating to an award recipient subject to the reporting requirements of Section 16 of the Exchange Act
shall be performed solely by the 2021 Plan Administration Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the adoption of the 2021 Plan, awards granted under the 2018 Plan (as defined below) remained in full force and effect under the
terms and conditions of the 2018 Plan and in accordance with each award&#8217;s respective terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility</i>.
Employees (including any employee who is also a director or an officer), contractors, and non-employee directors of the Company or any
of its subsidiaries, whose judgment, initiative, and efforts contributed to or may be expected to contribute to the Company&#8217;s successful
performance, are eligible to participate in the 2021 Plan. As of the December 31, 2022, the Company had 9 employees, 0 contractors, and
4 non-employee directors who would be eligible for awards under the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. The 2021 Plan Administration Committee may grant either incentive stock options (&#8220;ISOs&#8221;) qualifying under Section
422 of the Code, or nonqualified stock options, provided that only employees of the Company and its subsidiaries (excluding subsidiaries
that are not corporations) are eligible to receive ISOs. Stock options may not be granted with an option price less than 100% of the
fair market value of a share of Common Stock on the date the stock option is granted. If an ISO is granted to an employee who owns or
is deemed to own more than 10% of the combined voting power of all classes of the Company&#8217;s stock (or of any parent or subsidiary),
the option price shall be at least 110% of the fair market value of a share of Common Stock on the date of grant. The 2021 Plan Administration
Committee will determine the terms of each stock option at the time of grant, including, without limitation, the methods by or forms
in which shares will be delivered to participants or registered in their names. The maximum term of each option, the times at which each
option will be exercisable, and provisions requiring forfeiture of unexercised options at or following termination of employment or service
generally are fixed by the 2021 Plan Administration Committee, except that the 2021 Plan Administration Committee may not grant stock
options with a term exceeding 10 years or, in the case of an ISO granted to an employee who owns or is deemed to own more than 10% of
the combined voting power of all classes of our stock (or of any parent or subsidiary), a term exceeding five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recipients
of stock options may pay the option price (i) in cash, check, bank draft, or money order payable to the order of the Company; (ii) by
delivering to the Company shares of the Company&#8217;s Common Stock (including restricted stock) already owned by the participant having
a fair market value equal to the aggregate option price and that the participant has not acquired from the Company within six months
prior to the exercise date; (iii) by delivering to the Company or its designated agent an executed irrevocable option exercise form,
together with irrevocable instructions from the participant to a broker or dealer, reasonably acceptable to the Company, to sell certain
of the shares purchased upon the exercise of the option or to pledge such shares to the broker as collateral for a loan from the broker
and to deliver to the Company the amount of sale or loan proceeds necessary to pay the purchase price; (iv) by requesting that Company
withhold the number of shares otherwise deliverable upon exercise of the stock option by the number of shares having an aggregate fair
market value equal to the aggregate option price at the time of exercise (<i>i.e.,</i> a cashless net exercise); and (v) by any other
form of valid consideration that is acceptable to the 2021 Plan Administration Committee in its sole discretion. No dividends or dividend
equivalent rights may be paid or granted with respect to any stock options granted under the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. The 2021 Plan Administration Committee is authorized to grant stock appreciation rights (&#8220;SARs&#8221;)
as a stand-alone award, or freestanding SARs, or in conjunction with options granted under the 2021 Plan, or tandem SARs. SARs entitle
a participant to receive an amount equal to the excess of the fair market value of a share of Common Stock on the date of exercise over
the fair market value of a share of our Common Stock on the date of grant. The exercise price of a SAR cannot be less than 100% of the
fair market value of a share of the Company&#8217;s Common Stock on the date of grant. The 2021 Plan Administration Committee will determine
the terms of each SAR at the time of the grant, including, without limitation, the methods by or forms in which shares will be delivered
to participants or registered in their names. The maximum term of each SAR, the times at which each SAR will be exercisable, and provisions
requiring forfeiture of unexercised SARs at or following termination of employment or service generally are fixed by the 2021 Plan Administration
Committee, except that no freestanding SAR may have a term exceeding 10 years and no tandem SAR may have a term exceeding the term of
the option granted in conjunction with the tandem SAR. Distributions to the recipient may be made in Common Stock, cash, or a combination
of both as determined by the 2021 Plan Administration Committee. No dividends or dividend equivalent rights may be paid or granted with
respect to any SARs granted under the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock and Restricted Stock Units</i>. The 2021 Plan Administration Committee is authorized to grant restricted stock and restricted stock
units. Restricted stock consists of shares of our Common Stock that may not be sold, assigned, transferred, pledged, hypothecated, encumbered,
or otherwise disposed of, and that may be forfeited in the event of certain terminations of employment or service, prior to the end of
a restricted period as specified by the 2021 Plan Administration Committee. Restricted stock units are the right to receive shares of
Common Stock at a future date in accordance with the terms of such grant upon the attainment of certain conditions specified by the 2021
Plan Administration Committee, which include a substantial risk of forfeiture and restrictions on their sale or other transfer by the
participant. The 2021 Plan Administration Committee determines the eligible participants to whom, and the time or times at which, grants
of restricted stock or restricted stock units will be made; the number of shares or units to be granted; the price to be paid, if any;
the time or times within which the shares covered by such grants will be subject to forfeiture; the time or times at which the restrictions
will terminate; and all other terms and conditions of the grants. Restrictions or conditions could include, but are not limited to, the
attainment of performance goals (as described below), continuous service with the Company, the passage of time, or other restrictions
and conditions. Except as otherwise provided in the 2021 Plan or the applicable award agreement, a participant shall have, with respect
to shares of restricted stock, all of the rights of a shareholder of the Company holding the class of Common Stock that is the subject
of the restricted stock, including, if applicable, the right to vote the Common Stock and the right to receive any dividends thereon,
provided that (i) any dividends with respect to such a restricted stock award may be withheld by the Company for the participant&#8217;s
account until such award is vested, subject to such terms as determined by the 2021 Plan Administration Committee, and (ii) any dividends
so withheld by the Company and attributable to any particular restricted stock award shall be distributed to such participant in cash
or, at the discretion of the 2021 Plan Administration Committee, in shares of the Company&#8217;s Common Stock having a fair market value
equal to the amount of such dividends, if applicable, upon vesting of the award. If, however, such restricted stock award is forfeited,
the participant&#8217;s rights as to such dividends will also be forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Awards</i>. The 2021 Plan Administration Committee may grant performance awards payable at the end of a specified performance period
in cash, shares of Common Stock, units, or other rights based upon, payable in, or otherwise related to the Company&#8217;s Common Stock.
Payment will be contingent upon achieving pre-established performance goals (as discussed below) by the end of the applicable performance
period. The 2021 Plan Administration Committee will determine the length of the performance period, the maximum payment value of an award,
and the minimum performance goals required before payment will be made, so long as such provisions are not inconsistent with the terms
of the 2021 Plan and, to the extent an award is subject to Section 409A of the Code, are in compliance with the applicable requirements
of Section 409A of the Code and any applicable regulations or guidance. In certain circumstances, the 2021 Plan Administration Committee
may, in its discretion, determine that the amount payable with respect to certain performance awards will be reduced from the maximum
amount of any potential awards. If the 2021 Plan Administration Committee determines, in its sole discretion, that the established performance
measures or objectives are no longer suitable because of a change in the Company&#8217;s business, operations, corporate structure, or
for other reasons that the 2021 Plan Administration Committee deems satisfactory, the 2021 Plan Administration Committee may modify the
performance measures or objectives and/or the performance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Goals</i>. Awards of restricted stock, restricted stock units, performance awards, and other awards under the 2021 Plan may be made subject
to the attainment of performance goals relating to one or more business criteria which shall consist of one or more or any combination
of the following criteria (&#8220;Performance Criteria&#8221;): cash (cash flow, cash generation or other cash measures); cost; revenues;
sales; ratio of debt to debt plus equity; net borrowing, credit quality or debt ratings; profit before tax; economic profit; earnings
before interest and taxes; earnings before interest, taxes, depreciation and amortization; gross margin; earnings per share (whether
on a pre-tax, after-tax, operational or other basis); operating earnings; capital expenditures; improvements in capital structure; expenses
(expense management, expense ratio, expense efficiency ratios, expense levels or other expense measures); economic value added; ratio
of operating earnings to capital spending or any other operating ratios; free cash flow; profit (net profit, gross profit, operating
profit, economic profit, profit margin or other corporate profit measures); net income (before or after taxes, operating income or other
income measures); net sales; net asset value per share; business expansion or consolidation (the accomplishment of mergers, acquisitions,
dispositions, public offerings or similar extraordinary business transactions); sales growth; price of the Company&#8217;s Common Stock;
return measures (including, without limitation, return on assets, capital, equity, investments or sales, and cash flow return on assets,
capital, equity, or sales); market share; inventory levels, inventory management, inventory turn or shrinkage; stock price or performance;
internal rate of return or increase in net present value; working capital targets relating to inventory and/or accounts receivable; service
or product delivery or quality; customer satisfaction; employee retention; safety standards; productivity measures; cost reduction measures;
strategic plan development and implementation; or total return to shareholders. Any Performance Criteria may be used to measure our performance
as a whole or of any of our business units and may be measured relative to a peer group or index. Any Performance Criteria may include
or exclude (i) events that are of an unusual nature or indicate infrequency of occurrence, (ii) gains or losses on the disposition of
a business; (iii) changes in tax or accounting regulations or laws; (iv) the effect of a merger or acquisition, as identified in the
Company&#8217;s quarterly and annual earnings releases; or (v) other similar occurrences. In all other respects, Performance Criteria
shall be calculated in accordance with the Company&#8217;s financial statements, under generally accepted accounting principles, or under
a methodology established by the 2021 Plan Administration Committee prior to the issuance of an award, which is consistently applied
and identified in the Company&#8217;s audited financial statements, including in footnotes, or the Compensation Discussion and Analysis
sections of the Company&#8217;s annual report and definitive proxy statement, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Awards</i>. The 2021 Plan Administration Committee may grant other forms of awards, based upon, payable in, or that otherwise relate
to, in whole or in part, shares of the Company&#8217;s Common Stock, if the 2021 Plan Administration Committee determines that such other
form of award is consistent with the purpose and restrictions of the 2021 Plan. The terms and conditions of such other form of award
shall be specified in the grant. Such other awards may be granted for no cash consideration, for such minimum consideration as may be
required by applicable law, or for such other consideration as may be specified in the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vesting,
Forfeiture and Recoupment, Assignment</i>. The 2021 Plan Administration Committee, in its sole discretion, may determine that an award
will be immediately vested, in whole or in part, or that all or any portion may not be vested until a date, or dates, subsequent to its
date of grant, or until the occurrence of one or more specified events, subject in any case to the terms of the 2021 Plan. If the 2021
Plan Administration Committee imposes conditions upon vesting, then, subsequent to the date of grant, the 2021 Plan Administration Committee
may, in its sole discretion, accelerate the date on which all or any portion of the award may be vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2021 Plan Administration Committee may impose on any award at the time of grant or thereafter, such additional terms and conditions as
the 2021 Plan Administration Committee determines, including terms requiring forfeiture of awards in the event of a participant&#8217;s
termination of employment or service. The 2021 Plan Administration Committee will specify the circumstances on which performance awards
may be forfeited in the event of a termination of service by a participant prior to the end of a performance period or settlement of
awards. Except as otherwise determined by the 2021 Plan Administration Committee, restricted stock will be forfeited upon a participant&#8217;s
termination of employment or service during the applicable restriction period. In addition, the Company may recoup all or any portion
of any shares or cash paid to a participant in connection with any award in the event of a restatement of the Company&#8217;s financial
statements as set forth in the Company&#8217;s clawback policy, if any, as such policy may be approved or modified by the Board from
time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
granted under the 2021 Plan generally are not assignable or transferable except by will or by the laws of descent and distribution, except
that the 2021 Plan Administration Committee may, in its discretion and pursuant to the terms of an award agreement, permit transfers
of nonqualified stock options or SARs to (i) the spouse (or former spouse), children, or grandchildren of the participant (&#8220;Immediate
Family Members&#8221;); (ii) a trust or trusts for the exclusive benefit of such Immediate Family Members; (iii) a partnership in which
the only partners are (a) such Immediate Family Members and/or (b) entities which are controlled by the participant and/or his or her
Immediate Family Members; (iv) an entity exempt from federal income tax pursuant to Section 501(c)(3) of the Code or any successor provision;
or (v) a split interest trust or pooled income fund described in Section 2522(c)(2) of the Code or any successor provision, provided
that (x) there shall be no consideration for any such transfer, (y) the applicable award agreement pursuant to which such nonqualified
stock options or SARs are granted must be approved by the 2021 Plan Administration Committee and must expressly provide for such transferability,
and (z) subsequent transfers of transferred nonqualified stock options or SARs shall be prohibited except those by will or the laws of
descent and distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adjustments
Upon Changes in Capitalization</i>. In the event that any dividend or other distribution (whether in the form of cash, shares of the
Company&#8217;s Common Stock, other securities or other property), recapitalization, stock split, reverse stock split, rights offering,
reorganization, merger, consolidation, split-up, spin-off, split-off, combination, subdivision, repurchase, or exchange of shares of
Common Stock or other securities of the Company, issuance of warrants or other rights to purchase shares of Common Stock or other securities
of the Company, or other similar corporate transaction or event affects the fair value of an award, then the 2021 Plan Administration
Committee shall adjust any or all of the following so that the fair value of the award immediately after the transaction or event is
equal to the fair value of the award immediately prior to the transaction or event: (i) the number of shares and type of Common Stock
(or the securities or property) which thereafter may be made the subject of awards; (ii) the number of shares and type of Common Stock
(or other securities or property) subject to outstanding awards; (iii) the number of shares and type of Common Stock (or other securities
or property) specified as the annual per-participant limit under the 2021 Plan; (iv) the option price of each outstanding stock option;
(v) the amount, if any, the Company pays for forfeited shares in accordance with the terms of the 2021 Plan; and (vi) the number of or
exercise price of shares then subject to outstanding SARs previously granted and unexercised under the 2021 Plan, to the end that the
same proportion of the Company&#8217;s issued and outstanding shares of Common Stock in each instance shall remain subject to exercise
at the same aggregate exercise price; provided, however, that the number of shares of Common Stock (or other securities or property)
subject to any award shall always be a whole number. Notwithstanding the foregoing, no such adjustment shall be made or authorized to
the extent that such adjustment would cause the 2021 Plan or any stock option to violate Section 422 of the Code or Section 409A of the
Code. All such adjustments must be made in accordance with the rules of any securities exchange, stock market, or stock quotation system
to which the Company is subject.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: sp_001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
or Discontinuance of the 2021 Plan</i>. The Board may, at any time and from time to time, without the consent of participants, alter,
amend, revise, suspend, or discontinue the 2021 Plan in whole or in part; provided, however, that (i) no amendment that requires shareholder
approval in order for the 2021 Plan and any awards under the 2021 Plan to continue to comply with Sections 421 and 422 of the Code (including
any successors to such sections or other applicable law) or any applicable requirements of any securities exchange or inter-dealer quotation
system on which our stock is listed or traded, shall be effective unless such amendment is approved by the requisite vote of our shareholders
entitled to vote on the amendment; and (ii) unless required by law, no action by the Board regarding amendment or discontinuance of the
2021 Plan may adversely affect any rights of any participants or obligations of the Company to any participants with respect to any outstanding
awards under the 2021 Plan without the consent of the affected participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Repricing of Stock Options or SARs</i>. The 2021 Plan Administration Committee may not, without the approval of our shareholders, &#8220;reprice&#8221;
any stock options or SARs. For purposes of the 2021 Plan, &#8220;reprice&#8221; means any of the following or any other action that has
the same effect: (i) amending a stock option or SAR to reduce its option price or exercise price, respectively; (ii) canceling a stock
option or SAR at a time when its option price or exercise price, respectively, exceeds the fair market value of a share of our Common Stock in exchange for cash or a stock option, SAR, award of restricted stock, or other equity award with an option price or exercise
price that is less than the option price or exercise price of the original stock option or SAR; or (iii) taking any other action that
is treated as a repricing under generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MyMD
Florida Pre-Merger Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, pre-Merger MyMD Florida adopted the MyMD Pharmaceuticals, Inc. Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016
Plan&#8221;). The MyMD Florida Incentive Plan provided for the issuance of up to 50,000,000 shares of pre-Merger MyMD Florida Common Stock. As of December 31, 2022, options to purchase 4,188,315 shares of Company Common Stock have been issued pursuant to
the plan and 0 shares of Company Common Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Merger Agreement, effective as of the effective time of the Merger,
the Company assumed pre-Merger MyMD Florida&#8217;s Second Amendment to Amended and Restated 2016 Stock Incentive Plan (collectively with
the 2016 Plan, the &#8220;MyMD Florida Incentive Plan&#8221;), assuming all of pre-Merger MyMD Florida&#8217;s rights and obligations
with respect to the options issued thereunder (except that the term of the option will be amended to expire on the second-year anniversary
of the effective time of closing). The assumed pre-Merger MyMD Florida&#8217;s options became a number of shares of Company Common Stock
equal to the product of (a) the number of shares of MyMD Florida Common Stock subject to such option, multiplied by (b) the Exchange Ratio
and rounding the resulting number down to the nearest whole share of Company Common Stock, at an exercise price per share of Company Common
Stock equal to the quotient of (i) the exercise price per share of MyMD Florida Common Stock subject to such option immediately prior
to the effective time of the merger divided by (ii) the Exchange Ratio and rounding the resulting exercise price up to the nearest whole
cent, and then subsequently adjusted for the reverse stock split of the MyMD Florida Common Stock. Upon the closing of the Merger, the
Company assumed all of pre-Merger MyMD Florida&#8217;s rights and obligations under pre-Merger MyMD Florida stock options that were outstanding
immediately prior to the effective time of the Merger, and no additional awards can be issued under the MyMD Florida Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MyMD Florida Incentive Plan authorized the grant of incentive stock options, non-qualified stock options, restricted stock, restricted
stock units, and other stock-based awards, or a combination of the foregoing. MyMD Florida granted only incentive stock options and non-qualified
stock options under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized
Shares</i>. A total of 50,000,000 shares of MyMD Florida Common Stock were authorized for the grant of awards under the MyMD Florida
Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Plan
Administration</i>. The MyMD Florida Incentive Plan was administered by the MyMD Florida board of directors. The MyMD Florida board had
the authority to grant awards under the plan and to adopt, amend, and repeal such administrative rules, guidelines, and practices relating
to the plan as it deemed advisable. The MyMD Florida board had the authority to determine the persons to whom and the dates on which
awards will be granted, the number of shares of Common Stock to be subject to each award, the time or times during the term of each award
within which all or a portion of such award may be exercised, the exercise price, the type of consideration to be paid, and the other
terms and provisions of each award, which need not be identical. The MyMD Florida board had the power to construe and interpret the MyMD
Florida Incentive Plan and awards granted under it. All decisions, determinations and interpretations by the MyMD Florida board regarding
the plan were to be final, binding and conclusive on all participants or other persons claiming rights under the plan or any award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Options.
</i>Options granted under the MyMD Florida Incentive Plan could (i) either be &#8220;incentive stock options&#8221; within the meaning
of Section 422 of the Code, or &#8220;nonqualified stock options,&#8221; and (ii) become vested upon such conditions as were determined
by the MyMD Florida board. Such vesting could be based on continued service to MyMD Florida over a certain period, the occurrence of
certain performance milestones, or other criteria as determined by the MyMD Florida board. Options granted under the MyMD Florida Incentive
Plan could be subject to different vesting terms. Options could not have an exercise price per share of less than 100% of the fair market
value of a share of MyMD Florida Common Stock on the date of grant or a term longer than 10 years. To the extent provided by the terms
of an option, a participant could satisfy any federal, state or local tax withholding obligation relating to the exercise of such option
by a cash payment upon exercise, by authorizing MyMD Florida to withhold a portion of the stock otherwise issuable to the participant
upon exercise, or by such other method as may be set forth in the option agreement or authorized by the MyMD Florida board. The treatment
of options under the MyMD Florida Incentive Plan upon a participant&#8217;s termination of employment with or service to MyMD Florida
was set forth in the applicable award agreement, which typically provided that the options would terminate 24 months after a termination
of employment or service. In connection with the Merger Agreement, on November 10, 2020, MyMD Florida amended each of the option grant
award agreements noted above to, among other things, revise the term of exercisability of such option to expire on the earlier of (i)
the 10th anniversary of the date of grant or (ii) the second anniversary of the effective date of a &#8220;Reorganization Event&#8221;
as defined in the MyMD Florida Incentive Plan. Accordingly, the term of each such option was amended to expire on the second anniversary
of the effective date of the Merger. Incentive stock options are not transferable except by will or by the laws of descent and distribution.
Non-qualified stock options are transferable to certain permitted transferees (as provided in the MyMD Florida Incentive Plan) to the
extent included in the option award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock and Restricted Stock Unit Awards.</i> Subject to certain limitations, the MyMD Florida board was authorized to grant awards of
restricted stock and restricted stock units, which are rights to receive shares of MyMD Florida Common Stock or cash, as determined by
the MyMD Florida board and as set forth in the applicable award agreement, upon the settlement of the restricted stock units at the end
of a specified time. The MyMD Florida board could impose any restrictions or conditions upon the vesting of restricted stock or restricted
stock unit awards, or that would provide for a delay in the settlement of a restricted stock unit award after it vests, that the committee
deemed appropriate and in accordance with the requirements of Section 409A of the Code. Dividend equivalents could be credited in respect
of shares covered by a restricted stock or a restricted stock unit award, as determined by the MyMD Florida board. At the discretion
of the MyMD Florida board, such dividend equivalents could be converted into additional shares covered by restricted stock or restricted
stock units, as applicable. If a restricted stock or restricted stock unit award recipient&#8217;s employment or service relationship
with MyMD Florida terminated, any unvested portion of the restricted stock or restricted stock unit award would be forfeited, unless
the participant&#8217;s award agreement provided otherwise. Restricted stock and restricted stock unit awards are generally not transferable
except (i) by will or by the laws of descent and distribution or (ii) to certain permitted transferees, to the extent provided in the
award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Stock-Based Awards</i>. The MyMD Florida Incentive Plan authorized the grant of other awards that are valued in whole or in part by reference
to, or are otherwise based on, shares of MyMD Florida Common Stock or other property, including awards entitling recipients to receive
shares of MyMD Florida Common Stock to be delivered in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain
Adjustments; Reorganization Events.</i> In connection with any stock split, reverse stock split, stock dividend, dividend in property
other than cash, recapitalization, share combination, share reclassification, spin-off, or other similar change in capitalization or
event, the MyMD Florida board would equitably adjust the type(s), class(es) and number of shares of stock subject to the MyMD Florida
Incentive Plan, and any outstanding awards would also be appropriately adjusted as to the type(s), class(es), number of shares and exercise
price per share of Common Stock subject to such awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a &#8220;Reorganization Event&#8221; (as defined in the MyMD Florida Incentive Plan) such as certain mergers or consolidations,
the MyMD Florida board could take any one or more of the following actions as to all or any (or any portion of) outstanding awards on
such terms as the board determines: (i) provide that awards will be assumed, or substantially equivalent awards will be substituted,
by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a participant, provide that all of
the participant&#8217;s unexercised awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised
by the participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that outstanding
awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an award shall lapse, in whole or in part
prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of MyMD Florida
Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event, make or provide
for a cash payment to participants with respect to each award held by a participant equal to (A) the number of shares of MyMD Florida
Common Stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately
prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the acquisition price in the Reorganization Event over
(II) the exercise price of such award and any applicable tax withholdings, in exchange for the termination of such award, (v) provide
that, in connection with a liquidation or dissolution of MyMD Florida, awards shall convey into the right to receive liquidation proceeds
(if applicable, net of the exercise price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. In
taking any of above actions, the MyMD Florida board would not be obligated by the MyMD Florida Incentive Plan to treat all awards of
the same type identically.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment,
Termination</i>. The MyMD Florida board could amend, alter, suspend, discontinue, or terminate the MyMD Florida Incentive Plan, provided
that no such amendment would adversely affect the rights of any participant without the participant&#8217;s consent. The MyMD Florida
Incentive Plan will terminate in 2026, unless earlier terminated earlier by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Company
Pre-Merger Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2014, we adopted the 2013 Stock Incentive Plan (the &#8220;2013 Plan&#8221;). The 2013 Plan was amended by the Board on January
9, 2015 and September 30, 2016, and such amendments were ratified by stockholders on December 7, 2018. The 2013 Plan provides for the
issuance of up to 2,162 shares of the Company&#8217;s Common Stock, and as of December 31, 2022 756 shares of Common Stock remain available
for grants under the 2013 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2016, the shareholders approved, and the Company adopted the 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;). &#160;The
2016 Plan provides for the issuance of up to 50,000,000 shares of the Company&#8217;s common stock. As of December 31, 2022, grants of
options to purchase 4,188,315 shares of Common Stock have been issued pursuant to the 2016 Plan, and 0 shares of Common Stock remain
available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2017, the stockholders approved, and the Company adopted the 2017 Stock Incentive Plan (&#8220;2017 Plan&#8221;). The 2017
Plan provides for the issuance of up to 3,516 shares of the Company&#8217;s Common Stock. The purpose of the 2017 Plan is to provide
additional incentive to those of our officers, employees, consultants and non-employee directors and our parents, subsidiaries and affiliates
whose contributions are essential to the growth and success of our business. As of December 31, 2022, grants of restricted stock and
options to purchase totaling 2,538 shares of Common Stock have been issued pursuant to the 2017 Plan and as of December 31, 2022, 978
shares of Common Stock remain available for grants under the 2017 Plan. The 2017 Plan provides for the issuance of shares of the Company&#8217;s
Common Stock through the grant of non-qualified options, incentive options, restricted stock and unrestricted stock to directors, officers,
consultants, attorneys, advisors and employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2018, the stockholders approved, and we adopted the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;) and on August
27, 2020, the stockholders approved, and we adopted an amendment to the plan to increase the number of shares of Common Stock available
for issuance pursuant to awards under the 2018 Plan by an additional 521,000 shares. The 2018 Plan, as amended, provides for the issuance
of up to 560,063 shares of the Company&#8217;s Common Stock. The purpose of the 2018 Plan is to provide additional incentive to those
of our officers, employees, consultants and non-employee directors and to promote the success of our business. As of December 31, 2022,
grants of RSUs to purchase 263,026 shares of Common Stock had been issued pursuant to the 2018 Plan, and 297,037 shares of Common Stock
remained available for issuance. The 2018 Plan provides for the issuance of shares of the Company&#8217;s Common Stock through the grant
of options, restricted stock, stock appreciation rights, other stock-based awards, performance compensation awards to directors, officers,
consultants, advisors and employees. In addition, the 2018 Plan provides the Compensation Committee of the Board with discretion to accelerate
the vesting and exercisability of outstanding awards upon the occurrence of a change of control (as defined in the 2018 Plan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 29, 2019, the Compensation Committee of the Board approved the grant of 2,601 RSUs to Mr. Schreiber. Each RSU had a grant date
fair value of $46.56 which was amortized on a straight-line basis over the vesting period into administrative expenses within our Consolidated
Statement of Comprehensive Loss. Such RSUs were granted under the 2018 Plan, and vested on January 1, 2020.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Compensation Committee of our Board approved the grant of 131,750 RSUs to Mr. Schreiber. Each RSU had a grant
date fair value of $4.48 which was amortized on a straight-line basis over the vesting period into administrative expenses within our
Consolidated Statement of Comprehensive Loss. Such RSUs were granted under the 2018 Plan, with 50% to vest on the first anniversary of
the date of grant, and the remaining 50% to vest on the second anniversary of the date of grant, provided that the RSUs would vest immediately
upon the occurrence of (i) a change in control, provided that Mr. Schreiber is employed or providing services to us and our affiliates
on the closing date of such change in control, (ii) Mr. Schreiber&#8217;s termination of employment or services to us and our affiliates
by reason of death or disability, or (iii) Mr. Schreiber&#8217;s termination of employment or services by us without cause. At our election,
the vested RSUs may be settled for cash. The RSUs accelerated and vested in full upon the closing of the Merger on April 16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the number of securities to be issued under the 2021 Plan, the 2013 Plan, the 2016 Plan, the 2017 Plan and the 2018 Plan (collectively, the &#8220;Equity Compensation Plans&#8221;) as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Plan Category</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of securities to be issued upon exercise of outstanding options, warrants and rights (a)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
    exercise price of outstanding options (b)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
                                            remaining available for future issuance under equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>compensation
                                            plans (excluding securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>reflected
                                            in column (a))</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,604,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,377,748</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity compensation
    plans not approved by security holders</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,604,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,377,748</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares available for issuance under the Equity Compensation Plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="item12_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of our voting securities as of March 29, 2023 by
(i) each person known to us to beneficially own five percent (5%) or more of any class of our voting securities; (ii) each of our
named executive officers and directors; and (iii) all of our named directors and executive officers as a group. The percentages of
voting securities beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial
ownership of securities. Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or
shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes
the power to dispose of or to direct the disposition of the security. Except as indicated in the footnotes to this table, to our
knowledge and subject to community property laws where applicable, each beneficial owner named in the table below has sole voting
and sole investment power with respect to all shares beneficially owned and each person&#8217;s address is c/o MyMD Pharmaceuticals,
Inc., 855 N. Wolfe Street, Suite 601, Baltimore, MD 21205. Percentage of Common Stock ownership is based on 39,470,009 shares of
Common Stock issued and outstanding as of March 29, 2023. Percentage of Series D Convertible Preferred Stock (the
&#8220;Series D Preferred Stock&#8221;) ownership is based on 72,992 shares of Series D Preferred Stock issued and outstanding as of
March 29, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of Common Stock beneficially owned by the principal stockholders and the percentage of shares outstanding, as set forth
below, take into account certain limitations on the exercise of warrants to purchase Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC. For the purpose of calculating the number of shares beneficially owned
by a stockholder and the percentage ownership of that stockholder, shares of Common Stock subject to options or warrants that are currently
exercisable or exercisable within sixty (60) days of March 29, 2023 by that stockholder are deemed outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares of Common Stock Beneficially Owned<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage of Class</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares of Series D Preferred Stock Beneficially Owned<sup>(2)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage of Class</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total Voting Power</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">5% Beneficial Owner</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Abbe / Iroquois Capital Investment Group LLC<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,667,622</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6.47</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6.46</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caroline Williams / Starwood Trust<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,020,182</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12.32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12.31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samuel Duffey<sup>(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,241,812</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.65</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.65</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Premas Biotech PVT Ltd.<sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">103,782</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72,992</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Named Executive Officers and Directors</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Silverman<sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">88,776</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill J White<sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">73,776</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig Eagle, M.D.<sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">482,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.21</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.21</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jude Uzonwanne<sup>(10)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">115,770</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher C Schreiber<sup>(11)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">88,238</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Chapman, M.D.<sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">289,425</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam Kaplin, M.D., PhD<sup>(13)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">154,360</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Rivard<sup>(14)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">179,360</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">All current executive officers and Directors as a group (9 persons)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,472,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Common Stock beneficially owned and the respective percentages of beneficial ownership of Common Stock assume the exercise of
    all options and other securities convertible into Common Stock beneficially owned by such person or entity currently exercisable
    or exercisable within 60 days of March 29, 2023, except as otherwise noted. Shares issuable pursuant to the exercise of
    stock options and other securities convertible into Common Stock exercisable within 60 days are deemed outstanding and held by the
    holder of such options or other securities for computing the percentage of outstanding Common Stock beneficially owned by such person
    but are not deemed outstanding for computing the percentage of outstanding Common Stock beneficially owned by any other person. Percentage
    of Common Stock ownership is based on 39,470,009 shares of Common Stock issued and outstanding as of March 29, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Series D  Preferred Stock beneficially owned and convertible into Common Stock and the respective percentages of beneficial
    ownership of Series D  Preferred Stock assume the exercise of all options and other securities convertible into Common
    Stock beneficially owned by such person or entity currently exercisable or exercisable within 60 days of March 29, 2023,
    except as otherwise noted. Shares issuable pursuant to the exercise of stock options and other securities convertible into Common
    Stock exercisable within 60 days are deemed outstanding and held by the holder of such options or other securities for computing
    the percentage of outstanding Common Stock beneficially owned by such person but are not deemed outstanding for computing the percentage
    of outstanding Common Stock beneficially owned by any other person. Percentage of Series D Preferred Stock ownership is based on
    72,992 shares of Series D Preferred Stock issued and outstanding as of March 29, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
information is based on a Schedule 13G/A (the &#8220;Schedule&#160;13G&#8221;) filed with the SEC on February&#160;14, 2023 by Iroquois
Capital Management, LLC (&#8220;Iroquois Capital&#8221;) and on information available to the Company. The principal business office is
125 Park Avenue, 25<sup>th </sup>Floor, New York, NY 10017. Iroquois Capital is the investment advisor for Iroquois Master Fund, Ltd.
(&#8220;IMF&#8221;). As directors of IMF, Kimberly Page and Richard Abbe make voting and investment decisions on behalf of IMF. As a
result of the foregoing, Ms. Page and Mr. Abbe may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange)
of the securities held by Iroquois Capital and IMF.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Schedule&#160;13G, IMF owns 31,384 shares of Common Stock and warrants to purchase 1,126,105 shares of Common Stock (all of which
are subject to a 9.99% beneficial ownership blocker). In connection with the February&#160;2023 Offering, we issued to IMF warrants to
purchase up to 2,217,295 shares of Common Stock, which warrants are subject to a 4.99% beneficial ownership blocker.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Abbe also has voting control and investment discretion over securities held by Iroquois Capital Investment Group LLC (&#8220;ICIG&#8221;).
As such, Mr. Abbe may be deemed to be the beneficial owner (as determined under Section 13(d) of the Exchange Act) of the securities
held by ICIG. ICIG owns 700,414 shares of Common Stock and warrants to purchase 645,039 shares of Common Stock (that are subject to a
9.99% beneficial ownership blocker). In connection with the February&#160;2023 Offering, we issued to ICIG additional warrants to purchase
up to 1,219,512 shares of Common Stock, which warrants are subject to a 4.99% beneficial ownership blocker. In addition, by virtue of
his position as a custodian or trustee of certain Accounts (The Samantha Abbe Irrevocable Trust, The Talia Abbe Irrevocable Trust and
The Bennett Abbe Irrevocable Trust), Mr. Abbe may be deemed to be the beneficial owner of the 115,770 shares of Common Stock held in
aggregate by such Accounts. In addition, by virtue of his position as trustee of the Abbe Berman Foundation, Mr. Abbe may be deemed to
be the beneficial owner of the 49,110 shares of Common Stock held by the Abbe Berman Foundation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            information is based on a Schedule 13D filed with the SEC on April 16, 2021 by Caroline Williams,
                                            Individually and as Trustee of the Starwood Trust (&#8220;Trust&#8221;). The Schedule 13D
                                            reports shared voting power for 3,747,210 shares of Common Stock and shared dispositive power
                                            for 3,747,210 shares of Common Stock. The Common Stock is held directly by the Trust. As
                                            trustee of the Trust, Ms. Williams makes voting and investment decisions on behalf of the
                                            Trust. As a result of the foregoing, Ms. Williams may be deemed to have beneficial ownership
                                            (as determined under Section 13(d) of the Exchange Act) of the securities held by The Starwood
                                            Trust. The principal business address of The Starwood Trust is 324 South Hyde Park Avenue,
                                            Suite 350, Tampa, Florida 33606. The Trust owns 2,471,479 shares of Common Stock and options
                                            to purchase 1,275,731 shares of Common Stock.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Williams individually owns 1,272,972 shares of Common Stock as such is deemed to have beneficial ownership.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    information is based on a Schedule 13D filed with the SEC on September 8, 2022 by Samuel Duffey, individually and as trustee of the
    Rachel Jean Williams 2021 Irrevocable Trust (&#8220;RJW Trust&#8221;). The Schedule 13D reports that Mr. Duffey holds sole voting
    and dispositive power over 968,841 shares of Common Stock, which includes (i) 775,891 shares of Common Stock and (ii) 192,950 shares
    of Common Stock that may be acquired by Mr. Duffey pursuant to options. Mr. Duffey holds shared voting and dispositive power with
    respect to 1,272,971 shares of Common Stock that are held by the Trust as its sole trustee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 23, 2020, Premas Biotech PVT., Ltd received 103,782 shares of Common Stock and 72,992 shares of Series D Preferred Stock as
    partial compensation for their rights to Cystron.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prabuddha
    Kundu has sole voting and dispositive power over the securities held for this account.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 15,000 shares of Common Stock held by Mr. Silverman and (ii) 73,776 restricted stock unit (&#8220;RSU&#8221;) awards to Mr. Silverman
    that are vested or scheduled to vest within 60 days of March 29, 2023. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    73,776 RSU awards to Mr. White that are vested or scheduled to vest within 60 days of March 29, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    482,375 shares of Common Stock issuable upon the exercise of options held by Dr. Eagle which vested immediately upon grant and expire
    April 16, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    115,770 shares of Common Stock issuable upon the exercise of options held by Mr. Uzonwanne exercisable within 60 days of March 29, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    88,238 RSU awards to Mr. Schreiber that are vested or scheduled to vest within 60 days of March 29, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Represents
                                            289,425 shares of Common Stock issuable upon the exercise of options held by Dr. Chapman which vested
                                            immediately upon grant and expire on April 23, 2023.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Represents
                                            154,360 shares of Common Stock issuable upon the exercise of options held by Dr. Kaplin which vested
                                            immediately upon grant and expire April 16, 2023.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 25,000 shares of Common Stock held by Mr. Rivard, (ii) 77,180 shares of Common Stock issuable upon the exercise of options
    held by Mr. Rivard which fully vested upon grant and expire on April 16, 2023 and (iii) 77,180 shares of Common Stock issuable upon
    the exercise of options held by The Paul &amp; Jennifer Rivard Revocable Living Trust (the &#8220;Rivard Trust&#8221;) which fully
    vested upon grant and expire on April 16, 2023. Mr. Rivard makes voting and investment decisions on behalf of the Rivard Trust. As
    a result of the foregoing, Mr. Rivard may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange
    Act) of securities held by the Rivard Trust.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="K_01"></span><b>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
with related persons are governed by our Code of Business Ethics and Conduct, which applies to all of our employees, as well as each
of our directors and certain persons performing services for us. This code covers a wide range of potential activities, including, among
others, conflicts of interest, self-dealing and related party transactions. Waiver of the policies set forth in this code will only be
permitted when circumstances warrant. Such waivers for directors and executive officers, or that provide a benefit to a director or executive
officer, may be made only by the Board, as a whole, or the Audit Committee and must be promptly disclosed as required by applicable law
or regulation. Absent such a review and approval process in conformity with the applicable guidelines relating to the particular transaction
under consideration, such arrangements are not permitted. All related party transactions for which disclosure is required to be provided
herein were approved in accordance with our Code of Business Ethics and Conduct and Whistleblower Policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than compensation agreements, and other arrangements which are described below and under &#8220;Item 11. Executive
Compensation&#8221; herein, since January 1, 2021, there has not been, and there is not currently proposed, any transaction or
series of similar transactions to which we were or will be a party in which the amount involved exceeded or will exceed the lesser
of $120,000 or the average of our total assets at year-end for the last two completed fiscal years and in which any director,
executive officer, holder of 5% or more of any class of our capital stock, or any member of their immediate family had or will have
a direct or indirect material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On August 17, 2022, pursuant to
a securities purchase agreement with certain institutional and accredited investors, dated August 15, 2022, the Company issued and sold,
in a registered direct offering (the &#8220;August RD&#8221;), an aggregate of 1,411,764 shares of its Common Stock at an offering price
of $4.25 per share and, in a concurrent private placement (together with the August&#160;RD, the &#8220;August Offerings&#8221;), 1,411,764&#160;unregistered
investor warrants to purchase up to 1,411,764 shares of its Common Stock at an exercise price of $5.25, for gross and net proceeds of
$5,999,997 and $5,550,028, respectively. In connection with the August&#160;Offering, we issued to Iroquois Capital Investment Group LLC
(&#8220;ICIG&#8221;) 235,294&#160;shares of Common Stock and warrants to purchase an additional 235,294&#160;shares of Common Stock. ICIG
is the beneficial owner of more than five percent of our Common Stock. In connection with the August&#160;Offering, we also issued to
Iroquois Master Fund Ltd., an affiliate of ICIG (&#8220;IMF&#8221;), 352,941&#160;shares of Common Stock and warrants to purchase an additional
352,941&#160;shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, in connection with
the February&#160;2023&#160;Offering we issued to ICIG 2,750 shares of our Series&#160;F Preferred Stock and warrants to purchase up to
1,219,512&#160;shares of Common Stock. In connection with the February&#160;2023 Offering we also issued to IMF 5,000 shares of Series&#160;F
Preferred Stock and warrants to purchase up to 2,217,295 shares of Common Stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transactions of MyMD Florida</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, in connection with the merger (the &#8220;Merger&#8221;) by and between XYZ Merger Sub Inc., a Florida
corporation and wholly owned subsidiary of the Company, and MyMD Pharmaceuticals (Florida), Inc., a Florida corporation formerly
known as MyMD Pharmaceuticals, Inc. (&#8220;MyMD Florida&#8221;), MyMD Florida entered into the Supera Asset Purchase Agreement,
pursuant to which MyMD Florida agreed to acquire from Supera substantially all of the assets (including all rights to Supera-1R) and
certain obligations of Supera in consideration of the issuance to Supera of an aggregate of 33,937,909 shares of MyMD Florida Common Stock. (After giving effect to the Exchange Ratio and the Reverse Stock Split, such shares of MyMD Florida Common Stock are
equivalent to 13,096,639 shares of  Company Common Stock.) Supera is owned principally by The Starwood Trust, a trust for
which MyMD Florida&#8217;s founder Jonnie R. Williams, Sr. was the settlor/grantor; Mr. Williams did not have voting or investment
power of the MyMD Florida shares held by the trust. Supera is a Florida corporation that was incorporated in September 2018 by Mr.
Williams and The Starwood Trust to develop and commercialize Supera-1R, and in December 2018, Mr. Williams assigned his rights and
intellectual property relating to Supera-1R to Supera. As partial consideration for such assignment, Supera has granted to SRQ
Patent Holdings II, a royalty with respect to product sales and other consideration arising from the assigned intellectual
property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, Supera entered into an Amended and Restated Confirmatory Patent Assignment and Royalty Agreement, with SRQ Patent
Holdings II under which Supera (or its successor) is obligated to pay to SRQ Patent Holdings II (or its designees) certain royalties
on product sales or other revenue received on products that incorporate or are covered by the intellectual property that was assigned
to Supera by Mr. Williams. The royalty is equal to 8% of the net sales price on products sales and, without duplication, 8% of milestone
revenue or sublicense compensation. This agreement was assumed by MyMD Florida in connection with the Supera Purchase and remained in
place following the Merger. SRQ Patent Holdings II is an affiliate of Mr. Williams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020 MyMD Florida entered into an Amended and Restated Confirmatory Patent Assignment and Royalty Agreement with SRQ Patent
Holdings under which MyMD Florida (or its successor) would be obligated to pay to SRQ Patent Holdings (or other designees) certain royalties
on product sales or other revenue received on products that incorporate or are covered by the intellectual property that was assigned
to MyMD Florida by SRQ Patent Holdings. The royalty is equal to 8% of the net sales price on product sales and, without duplication,
8% of milestone revenue or sublicense compensation. This agreement remained in place following the Merger. SRQ Patent Holdings is an
affiliate of Mr. Williams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, MyMD Florida, The Starwood Trust and Mr. Williams agreed to cancel options to purchase an aggregate of 31,300,000
of MyMD Florida Common Stock and terminate the underlying stock option award agreements. After giving effect to the Exchange Ratio
and the Reverse Stock Split, such options to purchase MyMD Florida Common Stock are equivalent to options to purchase 12,078,670
shares of  Company Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Upon the completion of the Merger,
all amounts due and owing with respect to the Line of Credit established between MyMD Florida and The Starwood Trust were paid off in
full.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="K_02"></span>Item
14. Principal Accountant Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Audit Fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">85,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">121,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Audit-Related Fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,720</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179,187</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax Fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">All Other Fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">169,136</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">326,687</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Fees</i>. This category includes the audit of our annual consolidated financial statements, reviews of our financial statements included
in our Form 10-Qs and services that are normally provided by our independent registered public accounting firm in connection with its
engagements for those years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit-Related
Fees</i>. This category consists of assurance and related services by our independent registered public accounting firm that are reasonably
related to the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221;
The services for the fees disclosed under this category include consents regarding equity issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Fees</i>. This category typically consists of professional services rendered by our independent registered public accounting firm for
tax compliance and tax advice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
Other Fees</i>. This category includes aggregate fees billed in each of the last two fiscal years for products and services provided
by the Morison Cogen LLP, other than the services reported in the categories above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Audit Committee&#8217;s pre-approval policies and procedures, the Audit Committee is required to pre-approve all fees paid to, and
all services performed by, our independent registered public accounting firm. At the beginning of each year, the Audit Committee pre-approves
the proposed services, including the nature, type and scope of services contemplated and the related fees to be rendered by our independent
registered public accounting firm during the year. In addition, Audit Committee pre-approval is also required for those engagements that
may arise during the course of the year that are outside the scope of the initial services and fees pre-approved by the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the services rendered by Morison Cogen LLP in 2022 were pre-approved by the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="K_03"></span><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="K_04"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Exhibit and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
The following documents are filed as part of this Annual Report on Form 10-K:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_06">Report
    of Independent Registered Public Accounting Firm</a> (PCAOB ID No: 00536)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_07">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_08">Consolidated Statements of Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_09">Consolidated Statements of Changes in Shareholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_10">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#K_11">Notes to Consolidated Financial Statements</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-7</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements Schedule </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.
Financial statement schedules have not been included because they are not applicable or the information is included in the financial
statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Index to Exhibits&#8221; for a description of our exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="K_05"></span><b>Item
16. Form 10-K Summary.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline">INDEX TO EXHIBITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br />
Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220021154/ex2-1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger and Reorganization, dated November 11, 2020, by and among Akers Biosciences, Inc., XYZ Merger Sub Inc., and MYMD Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221006399/ex2-2.htm" style="-sec-extract: exhibit">Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated March 16, 2021, by and among Akers Biosciences, Inc., XYZ Merger Sub Inc., and MyMD Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 2.2 to the Company&#8217;s Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on March 19, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation, effective April 16, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective April 16, 2021 (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex3-3.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of MyMD Pharmaceuticals, Inc., effective April 16, 2021 (incorporated herein by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">3.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/ex3-1.htm" style="-sec-extract: exhibit">Form of Certificate of Designations of Series F Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2023).</a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Description of Securities</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315218015028/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 31, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315219018575/ex4-9.htm" style="-sec-extract: exhibit">Form of Series C Convertible Preferred Stock Warrant Certificate (incorporated herein by reference to Exhibit 4.9 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on November 29, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315219018575/ex4-10.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant Certificate (incorporated herein by reference to Exhibit 4.10 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on November 29, 2019).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222008546/ex4-12.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant Certificate (incorporated herein by reference to Exhibit 4.12 to the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#160;31, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220006035/ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220008921/ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated herein by references to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 15, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220015448/ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 13, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220021908/ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 18, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220017489/ex4-1.htm" style="-sec-extract: exhibit">Rights Agreement dated as of September 9, 2020 between Akers Biosciences, Inc. and VStock Transfer, LLC as Rights Agent (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221006399/ex4-19.htm" style="-sec-extract: exhibit">Amendment No. 1 to Rights Agreement, dated as of March 18, 2021, by and between Akers Biosciences, Inc. and VStock Transfer, LLC, as Rights Agent (incorporated herein by reference to Exhibit 4.19 to the Company&#8217;s Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on March 19, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220021154/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant. of Akers Biosciences, Inc. (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220021154/ex4-2.htm" style="-sec-extract: exhibit">Form of Investor Warrant. of Akers Biosciences, Inc. (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.14</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222022611/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15, 2022).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.15</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February&#160;21, 2023).</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000114420413066143/v361739_ex10-14.htm" style="-sec-extract: exhibit">2013 Incentive Stock and Award Plan (incorporated herein by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on December 6, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000114420413066143/v361739_ex10-15.htm" style="-sec-extract: exhibit">Form of Nonqualified Stock Option Agreement (Non-Employee) (incorporated herein by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on December 6, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000114420413066143/v361739_ex10-16.htm" style="-sec-extract: exhibit">Form of Nonqualified Stock Option Agreement (Employee) (incorporated herein by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on December 6, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000114420413066143/v361739_ex10-17.htm" style="-sec-extract: exhibit">Form of Restricted Stock Agreement (incorporated herein by reference to Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on December 6, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000114420413066143/v361739_ex10-18.htm" style="-sec-extract: exhibit">Form of Incentive Stock Option (incorporated herein by reference to Exhibit 10.18 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on December 6, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000114420415001581/v398071_ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated 2013 Incentive Stock and Award Plan of the Company (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2015).</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315216013980/ex10-2.htm" style="-sec-extract: exhibit">First Amendment to the Amended and Restated 2013 Incentive Stock and Award Plan of the Company (incorporated by referenced to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 12, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315217003536/ex10-1.htm" style="-sec-extract: exhibit">Form of Placement Agency Agreement, dated March 30, 2017, by and between the Company and Joseph Gunnar and Co., LLC (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315217003536/ex10-2.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated March 30, 2017, by and between the Company and various purchasers. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315217003536/ex10-3.htm" style="-sec-extract: exhibit">Form Registration Rights Agreement, dated March 30, 2017, by and between the Company and various purchasers (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315217008993/ex10-1.htm" style="-sec-extract: exhibit">
2017 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed
with the Securities and Exchange Commission on August 11, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315218014374/ex10-1.htm" style="-sec-extract: exhibit">Form of Resignation Agreement of John J. Gormally (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 11, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315218015028/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated October 31, 2018, by and among the Company and the investors signatory thereto (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 31, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315218017217/ex10-1.htm" style="-sec-extract: exhibit">2018 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315219018575/ex10-29.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.29 to the Company&#8217;s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on November 29, 2019).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 100; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220001457/ex10-1.htm" style="-sec-extract: exhibit">Offer of Employment to Christopher C. Schreiber, dated January 31, 2020 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 31, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220004577/ex10-1.htm" style="-sec-extract: exhibit">Membership Interest Purchase Agreement, dated as of March 23, 2020, by and among the members of Cystron Biotech, LLC and the Company (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220004577/ex10-2.htm" style="-sec-extract: exhibit">Support Agreement, dated as of March 23, 2020, by and among the Company and certain of its stockholders (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220004577/ex10-3.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated as of March 23, 2020, by and among certain members of Cystron Biotech, LLC and the Company (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220004577/ex10-4.htm" style="-sec-extract: exhibit">Amended and Restated License and Development Agreement by and among Premas Biotech PVT Ltd and Cystron Biotech, LLC (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220006035/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220009092/ex10-8.htm" style="-sec-extract: exhibit">Amendment No.1 to the Membership Interest Purchase Agreement, dated May 14, 2020 (incorporated herein by reference to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220008921/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 15, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220013820/ex10-1.htm" style="-sec-extract: exhibit">CFO Consulting Agreement, dated as of July 21, 2020, between the Company and Brio Financial Group (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220014991/ex10-1.htm" style="-sec-extract: exhibit">Settlement Agreement and General, Release, dated as of August 3, 2020, by and among the Company and ChubeWorkx Guernsey Limited (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 07, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220014991/ex10-2.htm" style="-sec-extract: exhibit">Leak-Out and Support Agreement, dated as of August 3, 2020, by and among the Company and ChubeWorkx Guernsey Limited (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 07, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220015448/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 13, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220016946/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to the Akers Biosciences, Inc., 2018 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 28, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220021154/ex10-2.htm" style="-sec-extract: exhibit">Secured Promissory Note, dated November 11, 2020, by and between the Company and MYMD Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2020).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 101; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315220021154/ex10-3.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated November 11, 2020, by and between the Company and purchasers named therein (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221006399/ex10-48.htm" style="-sec-extract: exhibit">Contribution and Assignment Agreement, dated March 16, 2021, by and among Akers Biosciences, Inc., Cystron Biotech LLC, and Oravax Medical Inc. (incorporated herein by reference to Exhibit 10.48 to the Company&#8217;s Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on March 19, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221006399/ex10-49.htm" style="-sec-extract: exhibit">Termination and Release Agreement, dated March 16, 2021, by and among Akers Biosciences, Inc., Cystron Biotech LLC, Premas Biotech Pvt. Ltd., and the other parties signatory thereto (incorporated herein by reference to Exhibit 10.49 to the Company&#8217;s Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on March 19, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex10-3.htm" style="-sec-extract: exhibit">MyMD Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex10-4.htm" style="-sec-extract: exhibit">Form of Nonqualified Stock Option Agreement (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex10-5.htm" style="-sec-extract: exhibit">Form of Incentive Stock Option Agreement (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221009411/ex10-6.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-3.htm" style="-sec-extract: exhibit">Asset Purchase Agreement, dated November 11, 2020, by and between MyMD Pharmaceuticals, Inc. and Supera Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-8.htm" style="-sec-extract: exhibit">MyMD Pharmaceuticals (Florida) Inc. Second Amendment to Amended and Restated 2016 Stock Incentive Plan, dated July 1, 2019 (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-9.htm" style="-sec-extract: exhibit">Amended and Restated Confirmatory Patent Assignment and Royalty Agreement dated November 11, 2020, by and between SRQ Patent Holdings II, LLC and Supera Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.9 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-10.htm" style="-sec-extract: exhibit">Amended and Restated Confirmatory Patent Assignment and Royalty Agreement dated November 11, 2020, by and between SRQ Patent Holdings, LLC and MyMD Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.10 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-11.htm" style="-sec-extract: exhibit">Employment Agreement between Adam Kaplin and MyMD Pharmaceuticals (Florida), Inc., effective December 18, 2020 (incorporated herein by reference to Exhibit 10.11 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-12.htm" style="-sec-extract: exhibit">Amendment No. 1 to Employment Agreement between Adam Kaplin and MyMD Pharmaceuticals (Florida), Inc, dated February 11, 2021 (incorporated herein by reference to Exhibit 10.12 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-13.htm" style="-sec-extract: exhibit">Employment Agreement between Chris Chapman and MyMD Pharmaceuticals (Florida), Inc., effective November 1, 2020 (incorporated herein by reference to Exhibit 10.13 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-14.htm" style="-sec-extract: exhibit">Amendment No. 1 to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals (Florida), Inc., dated December 18, 2020 (incorporated herein by reference to Exhibit 10.14 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-15.htm" style="-sec-extract: exhibit">Amendment No. 2 to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals (Florida), Inc., dated January 8, 2021 (incorporated herein by reference to Exhibit 10.15 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2021).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 102; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-16.htm" style="-sec-extract: exhibit">Amendment
    No. 3 to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals (Florida), Inc., dated February 11, 2021 (incorporated
    herein by reference to Exhibit 10.16 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange
    Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-17.htm" style="-sec-extract: exhibit">Employment
    Agreement between Paul Rivard and MyMD Pharmaceuticals (Florida), Inc., dated September 21, 2020 (incorporated herein by reference
    to Exhibit 10.17 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18,
    2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-18.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to Employment Agreement between Paul Rivard and MyMD Pharmaceuticals (Florida), Inc., dated November 24, 2020 (incorporated
    herein by reference to Exhibit 10.18 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange
    Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex10-19.htm" style="-sec-extract: exhibit">Amendment
    No. 2 to Employment Agreement between Paul Rivard and MyMD Pharmaceuticals (Florida), Inc., dated December 18, 2020 (incorporated
    herein by reference to Exhibit 10.19 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange
    Commission on May 18, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50#+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222008546/ex10-66.htm" style="-sec-extract: exhibit">Amendment No. 4 to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals, Inc., dated November 24, 2021 (incorporated herein by reference to Exhibit 10.66 to the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#160;31, 2022).</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51#+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222008546/ex10-67.htm">Amendment No. 2 to Employment Agreement between Adam Kaplin and MyMD Pharmaceuticals, Inc., dated November 24, 2021 (incorporated herein by reference to Exhibit 10.67 to the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#160;31, 2022).</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222022611/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222031423/ex10-2.htm" style="-sec-extract: exhibit">Fifth Amendment to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals, Inc., dated August 30, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November&#160;10, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315222031423/ex10-3.htm" style="-sec-extract: exhibit">Third Amendment to Employment Agreement between Adam Kaplin and MyMD Pharmaceuticals, Inc., dated August 30, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November&#160;10, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315223003530/ex10-1.htm" style="-sec-extract: exhibit">Sixth Amendment to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals, Inc., dated January 1, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February&#160;3, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/ex10-1.htm" style="-sec-extract: exhibit">Form of Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February&#160;21, 2023).</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.57#</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0; text-align: justify; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1321834/000149315223008700/ex10-1.htm" style="-sec-extract: exhibit">Third Amendment to Employment Agreement between Paul Rivard, Esq. and MyMD Pharmaceuticals, Inc., dated March 22, 2023. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March&#160;23, 2023).</a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List
    of Subsidiaries of MyMD Pharmaceuticals, Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent
    of Morison Cogen LLP, Independent Registered Public Accounting Firm.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of the Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of the Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
    of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
    of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive
    Data Files of Financial Statements and Notes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">+ Filed herewith</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"># Management contract or compensatory plan or arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">** The schedules and exhibits to the Agreement and
Plan of Merger and Reorganization have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or
exhibit will be furnished to the SEC upon request.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MYMD
    PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher C. Chapman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    C. Chapman, M.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Medical Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher C. Chapman</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Medical Officer and Director </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    C. Chapman, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ian Rhodes</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian
    Rhodes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joshua Silverman</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Silverman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bill J. White</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill
    J. White</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher C. Schreiber</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    C. Schreiber</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jude Uzonwanne</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jude
    Uzonwanne</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Craig Eagle</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    Eagle, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_06">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID No: 00<span id="xdx_900_edei--AuditorFirmId_c20220101__20221231_znikq8j7NcSi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">536</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_07">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_08">Consolidated Statements of Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_09">Consolidated Statements of Changes in Shareholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_10">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#K_11">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="K_06"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
Pharmaceuticals, Inc. and Subsidiaries</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of MyMD Pharmaceuticals, Inc. and Subsidiaries (the Company) as of December
31, 2022 and 2021 and the related consolidated statements of comprehensive loss, changes in stockholders&#8217; equity, and cash flows
for each of the two years in the period ended December 31, 2022 and the related notes (collectively referred to as the consolidated financial
statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company as of December 31, 2022 and 2021 and the results of their operations and their cash flows for each of the two years in the
period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements
that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are
material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as
a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters
or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
Concern Assessment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 3 to the consolidated financial statements, historically, the Company has incurred net losses. Since its inception,
the Company has met its liquidity requirements principally through the sale of its common stock in public and private placements. The
Company believes that its current financial resources as of the date of issuance of the consolidated financial statements are sufficient
to fund its current operating budget and contractual obligations as of December 31, 2022 as they fall due in the next twelve-month period,
and as such have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt upon
the Company&#8217;s ability to continue as a going concern. In making such a determination, management prepared a short-term cash flow
projection. Management used significant assumptions in preparing the short-term cash flow projection, which included operating costs
and financing obligations.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
Pharmaceuticals, Inc. and Subsidiaries</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal considerations for our determination that performing procedures relating to the going concern assessment is a critical audit
matter are the significant judgments in management&#8217;s plans to fund its operating budget and contractual obligations. This required
a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate management&#8217;s conclusion
that it is probable the Company&#8217;s plans will be effectively implemented within twelve months after the date the consolidated financial
statements are issued and will provide the necessary cash flows to fund the Company&#8217;s operating budget and contractual obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of the reasonableness of key assumptions and estimates used by the management in the short-term cash flow projection in the light
    of its existing operating requirements and plans.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of the reasonableness of management&#8217;s plans on the cash flow requirements of the operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing
    the completeness, accuracy, and relevance of underlying data in the short-term cash flow projection.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of the adequacy of the Company&#8217;s disclosure of these circumstances in the consolidated financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Assessment
of Impairment for Investment in Oravax, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2 to the consolidated financial statements, the Company has elected to measure its investment in Oravax Medical, Inc.
as an equity security without a readily determinable fair value. Under this election, an equity security without a readily available
fair value is reflected at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions
for the identical or a similar investment of the same issuer. At each reporting period, the Company is required to make a qualitative
assessment considering impairment indicators to evaluate whether the investment is impaired. If deemed impaired, the Company is required
to estimate the fair value of the investment and recognize an impairment loss equal to the difference between the fair value of the investment
and its carry amount. As of December 31, 2022, the Company performed a qualitative assessment to evaluate whether the investment is impaired
and determined that the investment was not impaired and thus no adjustment to fair market value was required as of December 31, 2022.
In making such a determination, management prepared a detailed qualitative analysis considering various impairment indicators. Management
used significant judgment in their qualitative assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal considerations for our determination that performing procedures relating to the impairment assessment of investments in equity
securities without readily determinable fair value is a critical audit matter is the significant judgment by management in making the
qualitative assessment of whether investments in equity securities were impaired. This in turn led to significant auditor judgment and
effort in performing procedures to evaluate the reasonableness of significant judgments management applied in determining whether events
or changes in circumstances indicate that the carrying amount of the investment might not be recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analyzing
    management&#8217;s detailed qualitative analysis considering various impairment indicators that may indicate that the carrying amount
    of the investment might not be recoverable for reasonableness.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    management&#8217;s assessment of events or changes in circumstances for reasonableness.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
    management&#8217;s significant accounting policies related to the election to measure its investment in Oravax Medical, Inc. as an
    equity security without a readily determinable fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_903_edei--AuditorName_c20220101__20221231_zZbdp6YwyOC6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Morison Cogen LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20220101__20221231_zgKcfUXqido2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Blue
Bell, Pennsylvania</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MYMD
PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="K_07"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_z0QUSTxXay2i" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20221231_zmvYiSxnJfDg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20211231_zf91rc6vIkRf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_z2alHohorAL9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrentAbstract_i01B_zHNrhNFh7LN9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzwy8_zjvRc2UNh4t5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash
    Equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,090</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">555,967</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--MarketableSecuritiesCurrent_i02I_pp0p0_maACzwy8_zPjeQNyYl91f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,086,902</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,003,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_i02I_pp0p0_maACzwy8_zfljNs6fE6Ie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">565,787</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,106,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzwy8_maAzgHz_zyQe2vfemHg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,401,779</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,665,385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_i01B_z1bEnmmSiXIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Current
    Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0_maANzSIa_zKItc8i2TV3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Right-of-Use
    Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Goodwill_i02I_pp0p0_maANzSIa_zPfmAoIuRhAd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,498,539</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,498,539</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LongTermInvestments_i02I_pp0p0_maANzSIa_zNGJgY8XcTgg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Investment
    in Oravax, Inc.</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsNoncurrent_i02TI_pp0p0_mtANzSIa_maAzgHz_zOvcQTjaZ6ub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Non-Current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,138,201</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,147,548</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_pp0p0_mtAzgHz_zBHNDolnJ5ze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,539,980</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,812,933</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAbstract_iB_zlY32KvmUeS9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zeJGoqgqpyb3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzkpE_zSRwVt6N8mma" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade and Other Payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,673,221</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">986,626</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DueToOfficersOrStockholdersCurrent_i02I_pp0p0_maLCzkpE_zY0v5DDp7y6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due to MyMD Florida Shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,982</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzkpE_zc6AGbeSTje6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    Lease Liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,780</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,240</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzkpE_maLzq0v_zj4M38sbmFX3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,768,983</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,039,866</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zG0OuTougOxb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DueToOfficersOrStockholdersNoncurrent_i02I_pp0p0_maLNzX5T_z8bH9fpYpUW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due to MyMD Florida Shareholders,
    net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0104">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,982</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pp0p0_maLNzX5T_z8wKOPvpt00e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    Lease Liability, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,941</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,911</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtLNzX5T_maLzq0v_zssslogKoZU6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Non-Current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,941</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,893</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_pp0p0_mtLzq0v_maLASEzxQH_z1cd7oUGefz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,844,924</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,165,759</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzxQH_zINU1KynewC3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments and Contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_i01B_zNhSSHee8jl6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SHAREHOLDERS&#8217; EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_ziGQsqix5VHj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Preferred Stock, <span id="xdx_902_eus-gaap--PreferredStockNoParValue_iI_do_c20221231_z5q1BFLhjiIe" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockNoParValue_iI_do_c20211231_zFo9X192HUp3" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par
    value, <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_z2e3hjo8V9P1" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z9Kk4dndmMwh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> total preferred shares authorized</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_maSEz8zG_zy9Zj85nJqqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"></span> Series D Convertible Preferred Stock, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z6gg8N2teA81" title="Preferred stock, shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zkSmekvwyyP9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">211,353</ix:nonFraction></ix:nonFraction></span></span>
    shares designated, <span id="xdx_90C_eus-gaap--PreferredStockNoParValue_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zMliy6sdYpbj" title="Preferred stock, no par value"><span id="xdx_90F_eus-gaap--PreferredStockNoParValue_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zejhErTSCE5a" title="Preferred stock, no par value"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value and a stated value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zjRohFo7Yvea" title="Preferred stock, stated value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zqHEeqRL2nsd" title="Preferred stock, stated value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zWRXTqswNJ9" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z8l7qXQGLHji" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zpng9zAeDkec" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zm5KjXfIKI9b" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2022
    and December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_zaAPE7BgBMYh" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Preferred stock value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_pp0p0_maSEz8zG_zBX6PemyTXY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, <span id="xdx_90D_eus-gaap--CommonStockNoParValue_iI_do_c20221231_zAc8oPEyOTXg" title="Common stock, no par value"><span id="xdx_904_eus-gaap--CommonStockNoParValue_iI_do_c20211231_zL6HEGvuss61" title="Common stock, no par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zt708BODdOkk" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zVED1BRGBYub" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
    authorized <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zoFPwDbcM58l" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zNb7SskDHtki" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,470,009</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20211231_zkfByxpZBTDa" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zD8CBkHGs1vl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,673,110</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December 31, 2022 and December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,309,436</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,064,218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEz8zG_z1DTllClvMH8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">93,758,904</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">78,561,568</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzxQH_mtSEz8zG_zEfHNAd58Bud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Shareholders&#8217; Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,695,056</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,647,174</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzxQH_zGtTvvBiIpll" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Shareholders&#8217; Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,539,980</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,812,933</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MYMD
PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="K_08"></span><b>Consolidated
Statements of Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_z6KD1IRofDb5" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220101__20221231_zE65ebNJFhUf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_z03zfpXRU3Mj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzqet_zDmXSS4PjDEl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerProductAndServiceExtensibleList_iP3us-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20220101__20221231_z7S1fJq9lj4g" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23ProductMember"><span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerProductAndServiceExtensibleList_iP3us-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20210101__20211231_z5jeaKsAaefb" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23ProductMember"><span style="-sec-ix-hidden: xdx2ixbrl0189"><span style="-sec-ix-hidden: xdx2ixbrl0190">Product Revenue</span></span></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0187">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0188">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_msGPzqet_zRBvyLrKcBU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--TypeOfCostGoodOrServiceExtensibleList_iP3us-gaap--CostOfGoodsAndServicesSold_dxL_c20220101__20221231_zZqPfLWEIMAg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23ProductMember"><span id="xdx_907_eus-gaap--TypeOfCostGoodOrServiceExtensibleList_iP3us-gaap--CostOfGoodsAndServicesSold_dxL_c20210101__20211231_zw5WSbcrlwF4" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23ProductMember"><span style="-sec-ix-hidden: xdx2ixbrl0194"><span style="-sec-ix-hidden: xdx2ixbrl0195">Product Cost of Sales</span></span></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0192">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0193">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--GrossProfit_iT_pp0p0_mtGPzqet_maOILz1wz_zH0IdYBa4MPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_msOILz1wz_zfyOU01TTJLk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Administrative Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,520,150</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,420,092</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_msOILz1wz_zZ6rRGl9Avce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and Development Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,067,422</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,745,104</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--AccretionOfDebtDiscount_msOILz1wz_z6P38lrHZZR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of Debt Discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0206">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:AccretionOfDebtDiscount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">608,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_msOILz1wz_zBrvERMhA0xi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Based Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,191</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockOptionModificationExpenses_msOILz1wz_z5fEiw72OTo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock Option Modification
    Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:StockOptionModificationExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,036,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILz1wz_maILFCOzI1K_zUgeVTeiaaja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss from Operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,282,763</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">28,809,707</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zttIC9sWvCf1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other (Income) Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeInterestAndDividend_i01N_pp0p0_di_maNIEzmvh_zkNCNkCJaPk9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest and Dividend Income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,991</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,907</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--MarketableSecuritiesRealizedGainLoss_i01N_pp0p0_di_maNIEzmvh_zLthRvFc3qc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Gain)/Loss on Sales of Marketable Securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,964</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,597</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01N_pp0p0_di_maNIEzmvh_ztR8d3pOGQ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized (Gain)/Loss on Marketable Securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">42,793</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--GainOnDebtForgiveness_i01N_pp0p0_di_maNIEzmvh_zem0CWBZM5D" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on Debt Forgiveness</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:GainOnDebtForgiveness" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">180,257</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_ecustom--UninsuredCasualtyLosses_i01N_pp0p0_di_maNIEzmvh_zLIaCAL2vTL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Uninsured Casualty Losses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:UninsuredCasualtyLosses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,442</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:UninsuredCasualtyLosses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,265,306</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01NT_pp0p0_di_mtNIEzmvh_maILFCOzI1K_z0EkHNQqnyzg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Other (Income</span>) Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,427</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,079,338</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOzI1K_maNILzf6M_zYC3TfwHsNH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss Before Income Tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">29,889,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzf6M_z8468pjnIly8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income Tax Benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0243">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzf6M_zqQ9qyoqbNul" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">29,889,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zm5GgHVGkqXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic and Dilutive net
    loss per common share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.39</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.85</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zTMPdO1gRPFh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average basic
    and diluted common shares outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,825,763</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,017,244</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part to these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MYMD
PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="K_09"></span>Consolidated
Statement of Changes in Stockholders&#8217; Equity /(Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_114_zkFNeXOwt156" summary="xdx: Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesDConvertiblePreferredStockMember_zkrIsK2MJgmg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--CommonStockNoParValueMember_zy60vz0HwCH8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zyYBMCDClzR6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6PTd69fsCul" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z2EDHdv6mbkb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_zruwvjt9fyKk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Series D Convertible</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Series
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zF60SOmRPzQi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zy3dAq1aN7G4" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDijeWcdo8Fh" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,673,110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,064,218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="display: none; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,561,568</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,647,174</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zeVbtiyFlAk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zvbQboQmKEXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from private
    placement of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFYclXY3Iamg" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,764</ix:nonFraction></span> common shares, net of offering costs of $<span id="xdx_907_eus-gaap--PaymentsOfFinancingCosts_pdp0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3FFE68PaGBe" title="Payments of financing costs"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,500</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlLZ1HShWDcf" title="Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,764</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,550,028</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,550,028</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--ExerciseOfPrepaidEquityForwardContractsForCommonStock_zus8W235ETB5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of prepaid equity
    forward contracts for Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ExerciseOfPrepaidEquityForwardContractsForCommonStockShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn4CTxOiGr3a" title="Exercise of prepaid equity forward contracts for common stock" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">385,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zt14U63aMdma" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    &#8211; stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,342</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,342</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zOjBc5SYkgx1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    &#8211; restricted stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,997</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,997</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueCompensationOfWarrants_zegAOLi2oJUk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation &#8211; warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants" contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,851</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></span></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84851</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zJ3xqivW8tb3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zj5shWwd8SHf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM038oHTevuk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,470,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,309,436</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></span></span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,758,904</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,695,056</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesDConvertiblePreferredStockMember_zta7bCBuhC0b" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Series
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--CommonStockNoParValueMember_zsyyQZGIfK7a" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">No
    Par</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_ztkfmk8eEpO" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$0.0001</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zeTEGAqGxVf6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zmki5jGC9wq5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_zyhI8IPG9vhf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Series
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
                                            Par</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-In</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Series
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">No
    Par</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$0.0001</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquity_iS_z5Oie97ysZ7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z7XXNmkIe9dd" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ9cMeV4Ldgc" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,553,307</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,411,487</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,672,523</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,257,032</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zLAJGJHNrV8l" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ziKfi4XRwaq6" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP8b27Xu8bnd" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,553,307</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,411,487</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,672,523</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,257,032</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_zRrVrINs7yD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,889,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,889,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zu8KGOEqrpC" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reverse merger with Akers Biosciences Inc effective
    April 16, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zlg95qovN6o6" title="Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbV4z1f4hQl3" title="Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,335,627</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,332,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,477,358</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_zSoPLPHBrZ5c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of post-merger MyMD Pharmaceutical
    Inc common shares at an exchange ratio of <span id="xdx_90B_ecustom--ExchangeRatioPricePerShares_iI_pid_uUSDPShares_c20210416_zOkwx1is4Ryk" title="Exchange ratio price per shares"><ix:nonFraction name="MYMD:ExchangeRatioPricePerShares" contextRef="AsOf2021-04-16" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7718</ix:nonFraction></span> per pre-merger MyMD common share</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,415,491</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,411,487</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--ModificationTermsOfPreMergerStockOptions_zWY0A98JdAfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Modification of the terms of <span id="xdx_90B_ecustom--ModificationOfPreMergerStockOptionShares_pid_c20210101__20211231_zGt6D7oY2uv1" title="Modification of pre merger stock options"><ix:nonFraction name="MYMD:ModificationOfPreMergerStockOptionShares" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,188,315</ix:nonFraction></span> pre-merger
    MyMD stock options per the terms of the merger agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ModificationTermsOfPreMergerStockOptions" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,036,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ModificationTermsOfPreMergerStockOptions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,036,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zVXCDLLdHeg7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of per-merger MyMD stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqTjCWMFYBuk" title="Exercise of per-merger MyMD stock options, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,576</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--ExerciseOfPrepaidEquityForwardContractsForCommonStock_zjbki24By3r9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of prepaid equity forward contracts
    for Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ExerciseOfPrepaidEquityForwardContractsForCommonStockShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc9awtZjlZb" title="Exercise of prepaid equity forward contracts for common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,716</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zwOBOLCQFxz9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z14rKUn4rim5" title="Stock based compensation for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,826</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--ExerciseOfWarrantsForCommonStock_z1Ma4sVYNJTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants
    for Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ExerciseOfWarrantsForCommonStockShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlC0uFYcnVz7" title="Exercise of warrants for common stock, shares" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStockShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,058</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStock" contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189,840</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ExerciseOfWarrantsForCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189,840</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_437_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zJb5bh20Kxtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z3Drj1PKRIkf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt72SjP15VKd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,673,110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,064,218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,561,568</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,647,174</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_437_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zbJlf3vhQX2b" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z3JXlXKaTI1c" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0ThNJ5JIj" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,673,110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockNoParValueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,064,218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,561,568</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,647,174</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MYMD
PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="K_10"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_112_zoXJ8tN1JTld" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220101__20221231_z6XylBG796j6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20210101__20211231_zSMaKqshMoM1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zOiIyKDq5j76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating
    activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzrSZ_zhDsj4vCviO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss from ongoing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">29,889,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zircUnGqsfX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--AccruedInterestdividends_i02_pp0p0_maNCPBUzrSZ_zHbi2pT2rKpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued interest/dividends</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:AccruedInterestdividends" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,024</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_i02_pp0p0_maNCPBUzrSZ_z9qt9EMJWAz9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">608,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr>
  <tr id="xdx_408_eus-gaap--MarketableSecuritiesRealizedGainLoss_i02N_pp0p0_di_msNCPBUzrSZ_zipxHdzLXYD" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Gain)/loss on sale of marketable securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,964</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,597</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_ecustom--MarketableSecuritiesUnrealizedLoss_i02_pp0p0_maNCPBUzrSZ_zXiN9Od48V71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized (gain)/loss on marketable securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:MarketableSecuritiesUnrealizedLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:MarketableSecuritiesUnrealizedLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,793</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--GainOnForgivenessOfDebt_i02N_pp0p0_di_msNCPBUzrSZ_zhRIat2PaVY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on forgiveness of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="MYMD:GainOnForgivenessOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">180,258</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationAbstract_i02B_zakFF0psWzn6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockOptionModificationExpenses_i03_pp0p0_maNCPBUzrSZ_zimClEtTb2bd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Option modification expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:StockOptionModificationExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,036,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_i03_pp0p0_maNCPBUzrSZ_zWWMS5gk8GJ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options issued to key employees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">338,922</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockOptionPlanExpense_i03_pp0p0_maNCPBUzrSZ_zQc6KHsPGi3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options issued to non-employees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">105,420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i03_pp0p0_maNCPBUzrSZ_zmWRStqfXw06" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants issued for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,851</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RestrictedStockExpense_i03_pp0p0_maNCPBUzrSZ_zPuEETSzxLF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted stock units
    to non-employees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,997</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zbnXWZKlqKUk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in assets and liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_pp0p0_di_msNCPBUzrSZ_zcaXi8Zxvm0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">540,560</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">912,815</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_pp0p0_maNCPBUzrSZ_zR0nr4xyq3r2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade and other payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,686,595</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,268,961</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pp0p0_maNCPBUzrSZ_zitxanfnN9Za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,917</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">81</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzrSZ_maCCERCzEdr_zIwVgybkYCwg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used by operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,270,068</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">19,516,475</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zqZWuTiH8m45" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_pp0p0_di_msNCPBUzwvs_z7ylXgzQKfIf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of marketable securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,836,837</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,403</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_pp0p0_maNCPBUzwvs_zqHBdIyICAz3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of marketable securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,750,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,483,176</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_i01_pp0p0_maNCPBUzwvs_zxAP8K2f1Hyj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash received in
    business combination</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,380,852</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzwvs_maCCERCzEdr_zM2hwZffWwN4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,913,163</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,850,625</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zwudlXvb5k84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RepaymentsOfLinesOfCredit_i01N_pp0p0_di_msNCPBUzddD_zolvefDKBQT5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Repayment of the line of credit &#8211; related
    party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,062,444</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfDebt_i01_pp0p0_maNCPBUzddD_zC6ifKlo3et8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from borrowings</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromNotesPayable_i01_pp0p0_maNCPBUzddD_zjDzpqos7ncb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,826,137</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzddD_zPlgczB7vvyc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from issuance of Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,550,028</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromWarrantExercises_i01_pp0p0_maNCPBUzddD_zdxtpfCapcme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from the
    exercise of warrants for Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,189,840</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUzddD_maCCERCzEdr_z1PRKQiXfLY9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,550,028</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,533</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzEdr_zl7m42lp7lC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase in cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">193,123</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">407,683</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zD3071g1PkH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    at beginning of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">555,967</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">148,284</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zmTJJrxgAnti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,090</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">555,967</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z7AN4TCvNmm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental cash flow information</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--CashPaidForAbstract_i01B_zZoEl4JTSEZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i02_pp0p0_zLtnXnWnB0k2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,322</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,800</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i02_pp0p0_zzGiHjIGtqmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income Taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zU7LWNFHFiGh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental Schedule of
    Non-Cash Financing and Investing Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0_z02E1RHlnHF6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease right-of-use
    asset obtained in exchange for lease obligation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,196</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,387</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--OtherAssetInvestment_i01_pp0p0_zMS2poJqTO5d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Investment in Oravax
    Medical, Inc.</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:OtherAssetInvestment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part to these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MYMD
PHARMACEUTICALS, INC. AND SUBSIDIARIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="K_11"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zxTLcVBJ0tBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_826_zTzVHhwIEHw9">Organization and Description of Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
Pharmaceuticals, Inc., previously known as Akers Biosciences, Inc., is a New Jersey corporation (&#8220;MyMD&#8221;). These consolidated
financial statements include four wholly owned subsidiaries as of December 31, 2022, MyMD Pharmaceuticals (Florida), Inc. (&#8220;MyMD
Florida&#8221;), XYZ Merger Sub, Inc. (&#8220;Merger Sub&#8221;), Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation, (together,
the &#8220;Company&#8221;). All material intercompany transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
Florida was formed in 2014 and is a Florida-based clinical development stage biopharmaceutical company that is developing its product
candidate, MYMD-1, as an immuno regulator to treat autoimmune diseases, ageing-related diseases. Substantive operations began in 2016
and the Company&#8217;s Investigative New Drug application was filed with the U.S. Food and Drug Administration in December 2018. MyMD
Florida completed its first-in-human Phase 1 clinical trial in December 2019. A second Phase 1 dosing study was completed in December
2021. MYMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release
of numerous pro-inflammatory cytokines, such as TNF-&#945;, interleukin 6 (&#8220;IL-6&#8221;) and interleukin 17 (&#8220;IL-17&#8221;).
MYMD-1 currently is being evaluated in a multicenter Phase 2 clinical trial in patients with sarcopenia and frailty (age-related muscle
loss). MyMD Florida&#8217;s intellectual property portfolio consists of 16 U.S. granted patents, 15 granted foreign patents and 19 pending
applications (3 US, 16 foreign).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera
Pharmaceuticals, Inc. (&#8220;Supera&#8221;) was formed in September 2018 and is a Florida based development company that is developing
its product candidate &#8220;Supera-CBD&#8221; as an FDA-approved synthetic analog of naturally grown cannabidiols. Substantially all
of Supera&#8217;s research and development activities in 2020 and 2021 were related to intellectual property development and securing
patents, along with product manufacturing and planning initial pre-clinical development activities. During the year ended December 31,
2021, these activities included preclinical work on Supera-CBD confirming it effectiveness in treating anxiety. The preclinical data
was presented at the 4<sup>th</sup> Annual International Cannabinoid Summit describing the superior potency of Supera-CBD. Supera-CBD
preclinical genotoxicity studies were completed in February 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the previously announced Agreement and Plan of Merger and Reorganization, dated November 11, 2020 (the
&#8220;Original Merger Agreement&#8221;), as amended by Amendment No. 1 thereto, dated March 16, 2021 the Original Merger Agreement,
as amended by Amendment No. 1 (the &#8220;Merger Agreement&#8221;), by and among MyMD, Merger Sub and MyMD Florida, Merger Sub was
merged with and into MyMD Florida, with MyMD Florida continuing after the merger as the surviving entity and a wholly owned
subsidiary of MyMD (the &#8220;Merger&#8221;). At the effective time of the Merger, without any action on the part of any
stockholder, each issued and outstanding share of pre-Merger MyMD Florida&#8217;s Common Stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210416__dei--LegalEntityAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zNS7l0hS7sP9" title="Common Stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-04-16_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (the &#8220;MyMD Florida Common Stock&#8221;), including shares underlying pre-Merger MyMD Florida&#8217;s outstanding
equity awards, was converted into the right to receive (x) <span id="xdx_904_ecustom--ExchangeRatioPricePerShares_iI_c20210416__dei--LegalEntityAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zKCdjKC3jD72" title="Exchange ratio price per shares"><ix:nonFraction name="MYMD:ExchangeRatioPricePerShares" contextRef="AsOf2021-04-16_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7718</ix:nonFraction></span>
shares (the &#8220;Exchange Ratio&#8221;) of MyMD&#8217;s Common Stock, no par value per share (the &#8220;Company Common
Stock&#8221; or &#8220;Common Stock&#8221;), (y) an amount in cash, on a pro rata basis, equal to the aggregate cash proceeds received by the Company from the
exercise of any options to purchase shares of MyMD Florida Common Stock outstanding at the effective time of the Merger assumed by
the Company upon closing of the Merger prior to the second-year anniversary of the closing of the Merger (the &#8220;Option Exercise
Period&#8221;), such payment (the &#8220;Additional Consideration&#8221;), and (z) potential milestone payment in shares of Company
Common Stock up to the aggregate number of shares issued by the Company to pre-Merger MyMD Florida stockholders at the closing of
the Merger (the &#8220;Milestone Payments&#8221;) payable upon the achievement of certain market capitalization milestone events
during the 36-month period immediately following the closing of the Merger (the &#8220;Milestone Period&#8221;). Immediately
following the effective time of the Merger, the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company
Common Stock (the &#8220;Reverse Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, MyMD Florida entered into an Asset Purchase Agreement with Supera, a related company through common control, in which
Supera was acquired by MyMD Florida through the issuance of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--SuperaPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zOiuRU33FyH" title="Stock issued during period, shares, acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2021-04-122021-04-16_custom_SuperaPharmaceuticalsIncMember_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,937,909</ix:nonFraction></span> shares of pre-Merger MyMD Florida Common Stock. The Supera
entity was dissolved pursuant to this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Merger, the Company changed its name
to MyMD Pharmaceuticals, Inc. and the Company Common Stock, listed previously trading through the close of business on April 16, 2021
under the trading symbol &#8220;AKER&#8221;, commenced trading on The Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis,
under the trading symbol &#8220;MYMD&#8221; on April 19, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2022&#160;, the MyMD Florida subsidiary was dissolved and merged into the New Jersey corporation MyMD Pharmaceuticals, Inc.
pursuant to an Agreement and Plan of Merger dated April 8, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zW0BikXhfmdk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_828_zqI9LcEqYod5">Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkmU3qnbJNQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
<span id="xdx_86B_zK6C0KSyZTn1">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally
accepted in the United States of America (US GAAP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zXdssfkOSpne" title="Reverse stock split"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-2 reverse stock split</ix:nonNumeric></span> immediately following the effective time of the Merger. No fractional shares were issued
in connection with the Reverse Stock Split. Each stockholder who did not have a number of shares evenly divisible pursuant to the Reverse
Stock Split ratio and who would otherwise be entitled to receive a fractional share of Company Common Stock was entitled to receive an
additional share of Company Common Stock. The number of shares on equity related disclosures included in this Annual Report on Form
10-K, including the consolidated financial statements and accompanying notes, were retroactively adjusted to reflect the effects
of the Reverse Stock Split and the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zitK6G4H5AMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
<span id="xdx_861_zdVe4a17sanl">Use of Estimates and Judgments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that
affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ
from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation,
uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in
the financial statements is included in the following notes for recording research and development expenses, impairment of intangible
assets and the valuation of share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zkvkpJ9bLyAd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
<span id="xdx_863_zivmKWz9RRna">Functional and Presentation Currency</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements are presented in U.S. Dollars, which is the Company&#8217;s functional currency. All financial
information has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated
in Foreign Currencies, are recorded in the Consolidated Statements of Operations and Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zGYMLK4EOk27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
<span id="xdx_86D_z0DG4sjMaICg">Comprehensive Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;) 220 in reporting comprehensive
loss. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information
that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income
(loss), comprehensive loss is equal to net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zECjbfjPZ8v8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)
<span id="xdx_86B_zWALoFqnF9a">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that
are not restricted as to withdrawal date or use, to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7to1s1s5s2a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
<span id="xdx_86A_zT1m60PGwzpg">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables.
The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their
short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are
described as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company
    can access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology include:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices for similar assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices for identical or similar assets or liabilities in inactive markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    other than quoted prices that are observable for the asset or liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    that are derived principally from or corroborated by observable market data by correlation or other means</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of
    the asset or liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
asset or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is
significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of
unobservable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
Fair Value of Financial Instruments, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MarketableSecuritiesTextBlock"><p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zePSfj8Avsca">Schedule
of Marketable Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable
Securities:</i> Valued using quoted prices in active markets for identical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Significant
    Unobservable Inputs (Level 3)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" title="Marketable securities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,086,902</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" title="Marketable securities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" title="Marketable securities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" title="Marketable securities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,003,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Marketable securities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" title="Marketable securities" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zNrXGEf2wrHg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities are classified as available for sale and are valued at fair market value. Maturities of the securities are less than one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the Company held certain mutual funds, which, under FASB ASC 321-10, were considered equity
investments. As such, the change in fair value in the year ended December 31, 2022 and 2021 was a gain of $<span id="xdx_907_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_zctD79SBIhmg" title="Unrealized (gain)/loss on marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-012022-12-31_us-gaap_MutualFundMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958</ix:nonFraction></span>
and a loss of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_z2GifEoTIlXd" title="Unrealized (gain)/loss on marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31_us-gaap_MutualFundMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,793</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses resulting from the sales of marketable securities were losses of $<span id="xdx_904_eus-gaap--MarketableSecuritiesRealizedGainLoss_iN_di_c20220101__20221231_zyRZ8Lr5LD26" title="Gain/loss on sale of marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,964</ix:nonFraction></span> and gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20210101__20211231_zGhwhueFBAd2" title="Gain/loss on sale of marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,597</ix:nonFraction></span> for the years ended December
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from the sales of marketable securities were $<span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20220101__20221231_zpI1TG3QqZRa" title="Proceeds from the sales of marketable securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,750,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20211231_zj6x4w1Pb0R1" title="Proceeds from the sales of marketable securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,483,176</ix:nonFraction></span> in the years ended December 31, 2022 and 2021, respectively.
Purchases of marketable securities were $<span id="xdx_907_eus-gaap--PaymentsToAcquireMarketableSecurities_c20220101__20221231_z5v6kEXs9f41" title="Purchase of marketable securities"><ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,836,837</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--PaymentsToAcquireMarketableSecurities_c20210101__20211231_z9ETZImwdjKc" title="Purchase of marketable securities"><ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,403</ix:nonFraction></span> during the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:PrepaidExpensesPolicyTextBlock"><p id="xdx_84E_ecustom--PrepaidExpensesPolicyTextBlock_zEXSDCVqVF4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)
<span id="xdx_865_z0t40pOFMOdh">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses represent expenses paid prior to the date that the related services are rendered or used are comprised principally of prepaid
insurance and research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zw5YAmiRVZPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)
<span id="xdx_864_zpAtJtp7O5tk">Concentrations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial
institutions and accounts receivable. At times, the Company&#8217;s cash in banks is in excess of the FDIC insurance limit. The Company
has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:RiskManagementOfCashInvestmentsPolicyTextBlock"><p id="xdx_84A_ecustom--RiskManagementOfCashInvestmentsPolicyTextBlock_zcaEdiCpaNg9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)
<span id="xdx_862_zUAivk8x7WY8">Risk Management of Cash and Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy to minimize the Company&#8217;s capital resources to investment risks, prioritizing the preservation of
capital over investment returns. Investments are maintained in securities, primarily publicly traded, short-term money market funds based
on highly rated federal, state and corporate bonds, that minimize the risk to the Company&#8217;s capital resources and provide ready
access to funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s investment portfolios are regularly monitored for risk and are held with one brokerage firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_zBGp5lXsQcn6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)
<span id="xdx_867_zwGzmjRwRRr3">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other
than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company&#8217;s
ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for
using the cost method to the equity method of valuation in accordance with FASB ASC 323.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company&#8217;s ability to significantly
influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the
time of the investment based upon several factors including, but not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
    on the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participation
    in policy-making processes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    intra-entity transactions</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interchange
    of management personnel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technological
    dependencies</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extent
    of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational
and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the
cost method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with FASB ASC 321-10-35-2, the Company has elected to measure
its investment in Oravax Medical, Inc. (&#8220;Oravax&#8221;) (Note 3) as an equity security without a readily determinable fair value.
Under this election, an equity security without a readily available fair value is reflected at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
At each reporting period, the Company is required to make a qualitative assessment considering impairment indicators to evaluate whether
the investment is impaired. If deemed impaired, the Company is required to estimate the fair value of the investment and recognize an
impairment loss equal to the difference between the fair value of the investment and its carry amount. As of December 31, 2022, the Company
performed a qualitative assessment to evaluate whether the investment is impaired and determined that the investment was not impaired
and thus no adjustment to fair market value was required as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zs5s0t7t55Se" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(k)
<span id="xdx_86A_zwcA9esYL5El">Property, Plant and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, plant and equipment and are recognized within &#8220;other (income)/expense&#8221; in the Consolidated
Statements of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognized over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of
the lease term or their useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"><p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zs65nJ7AflJl">Schedule
of Estimated Useful Lives of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">12</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &amp; software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">Shorter of the remaining
    lease or estimated useful life</ix:nonNumeric></span></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zsRLLYi1iiY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8iJ02grMFA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(l)
<span id="xdx_868_zWIJmvX69zU4">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate
there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets
not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount,
other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge in the Consolidated Statements of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents
and Trade Secrets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propriety
protection for the Company&#8217;s products, technology and process is important to its competitive position. As of December 31, 2022,
the Company has 16 issued U.S. patents, 50 foreign patents, four pending U.S. patent applications and 15 foreign patent applications
pending in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea, which if issued are expected
to expire between 2036 and 2041. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade
secrets) using all legal remedies available to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records expenses related to the application for and maintenance of patents as a component of research and development expenses
on the Consolidated Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic
benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life and assessed for impairment when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Intangible Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization
and accumulated impairment losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amortization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zTy2vgZzxaS3" style="display: none">Schedule of Estimated Useful Lives of Intangible Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
    and trademarks</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">12</ix:nonNumeric></span>-<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_ztE2JQSh464l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z48w7DnfUcCb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(m)
<span id="xdx_86E_zYGyDOVSEZG3">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is evaluated annually for impairment or whenever we identify certain triggering events or circumstances that would more likely than not
reduce the fair value below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include,
among other things, unexpected adverse business conditions, economic factors (for example, the loss of key personnel), supply costs,
unanticipated competitive activities, and acts by governments and courts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_zT9j3kHsrBL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(n)
<span id="xdx_861_zXuh6y5Q4Z46">Recoverability of Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB ASC 360-10-35 &#8220;Impairment or Disposal of Long-lived Assets&#8221;, long-lived assets to be held and used are
analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable
or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and
circumstances have occurred that indicate possible impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges)
and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by
which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the
lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying
amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce
the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:RightOfUseAssetsPolicyTextBlock"><p id="xdx_845_ecustom--RightOfUseAssetsPolicyTextBlock_zPO69ayfdMkj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(o)
<span id="xdx_86E_zZdGfl5apCMh">Right-of-Use Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased a facility in Tampa, Florida (&#8220;Hyde Park&#8221;) under an operating lease (&#8220;Hyde Park Lease&#8221;) with annual
rentals of $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z5gXmVY3O0hi" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-07-012019-07-02_srt_MinimumMember_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,048</ix:nonFraction></span> to $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zcYov0cps7ya" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-07-012019-07-02_srt_MaximumMember_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,320</ix:nonFraction></span> plus certain operating expenses. The Hyde Park facility housed the MyMD Florida operations. The Hyde Park
Lease took effect on July 1, 2019 for a term of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zhkNz0gLpuz6" title="Lessee, operating lease, term of contract"><ix:nonNumeric contextRef="AsOf2019-07-02_custom_HydeParkFacilityMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">36</ix:nonNumeric></span> months to expire on <span id="xdx_90E_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20190701__20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z2htao554bs8" title="Lease expiration date"><ix:nonNumeric contextRef="From2019-07-012019-07-02_custom_HydeParkFacilityMember" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1">June 30, 2022</ix:nonNumeric></span>. The Company cancelled the Hyde Park lease in March
2022 without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased an aircraft under an operating lease (&#8220;Supera Aviation Lease&#8221;) with annual rentals of $<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20181020__20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zo4CJ5rwsPLb" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2018-10-202018-10-26_custom_SuperaAviationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></span> plus certain
operating expenses. The Supera Aviation Lease took effect on October 26, 2018 for a term of <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zE0qgmlf4I4h" title="Lessee, operating lease, term of contract"><ix:nonNumeric contextRef="AsOf2018-10-26_custom_SuperaAviationMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">36</ix:nonNumeric></span> months to expire on September 26, 2021.
The Company cancelled the Supera Aviation Lease in April 2021 without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased a facility in Baltimore, Maryland (&#8220;2020 Wolfe St&#8221;) under an operating lease (&#8220;2020 Baltimore Lease&#8221;)
with annual rentals of $<span id="xdx_90F_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zb3FRNgbwJah" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2020-11-052020-11-09_srt_MinimumMember_custom_TwoThousandTwentyBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></span> to $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zl95SSVy0kS1" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2020-11-052020-11-09_srt_MaximumMember_custom_TwoThousandTwentyBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,462</ix:nonFraction></span> plus certain operating expenses. The 2020 Baltimore Lease took effect on November 9, 2020 for
a term of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zfTeYsV7SaJd" title="Lessee, operating lease, term of contract"><ix:nonNumeric contextRef="AsOf2020-11-09_custom_TwoThousandTwentyBaltimoreMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">12</ix:nonNumeric></span> months with automatic renewals unless a sixty-day notice was provided. The initial term expired on <span id="xdx_90B_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20201105__20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_z3I38lbOJec5" title="Lease expiration date"><ix:nonNumeric contextRef="From2020-11-052020-11-09_custom_TwoThousandTwentyBaltimoreMember" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1">November 30, 2021</ix:nonNumeric></span>. On
November 17, 2021, the 2020 Baltimore Lease was cancelled without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases a facility in Baltimore, Maryland (&#8220;2021 Wolfe St&#8221;) under an operating lease (&#8220;2021 Baltimore
Lease&#8221;) with annual rentals of $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MinimumMember_zfuZTDSVVlR8" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,800</ix:nonFraction></span>
to $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MaximumMember_zYs1H5BkXeWd" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,016</ix:nonFraction></span>
plus certain operating expenses. The 2021 Baltimore Lease took effect on November 17, 2021 for a term of <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zljWYGaAuPp" title="Lessee operating lease term of contract"><ix:nonNumeric contextRef="AsOf2021-11-17_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">12</ix:nonNumeric></span>
months with automatic renewals unless a sixty-day notice is provided. The initial term expires on <span id="xdx_90C_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zILO0WYY40v6" title="Expiration date"><ix:nonNumeric contextRef="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1">November
30, 2022</ix:nonNumeric></span>. The lease renewed effective December 1, 2022 for a term of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20221201_zaWttHsZO1Ha" title="Lessee operating lease renewal term"><ix:nonNumeric contextRef="AsOf2022-12-01" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm">12</ix:nonNumeric></span> months with automatic renewals unless a sixty-day notice
is provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases a facility in Tampa, Florida (&#8220;Platt St&#8221;) under an operating lease (&#8220;Platt Street Lease&#8221;) with
annual rentals of $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MinimumMember_z15D2sxrM7xd" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,030</ix:nonFraction></span> to $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MaximumMember_zYXFjtctPI8e" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,259</ix:nonFraction></span> plus certain operating expenses. The Platt Street Lease took effect on April 1, 2022 for a term
of <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zsv3fWf9Zku" title="Term of contract"><ix:nonNumeric contextRef="AsOf2022-04-02_custom_PlattStreetMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">36</ix:nonNumeric></span> months. The initial term expires on <span id="xdx_903_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z72rUefeJsWk" title="Lease expiration date"><ix:nonNumeric contextRef="From2022-04-012022-04-02_custom_PlattStreetMember" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1">March 31, 2025</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019 (&#8220;Effective Date&#8221;), the Company adopted FASB ASC, Topic 842, Leases (&#8220;ASC 842&#8221;), which increases
transparency and comparability by recognizing a lessee&#8217;s rights and obligations resulting from leases by recording them on the
balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (&#8220;ROU&#8221;)
assets and related operating and finance lease liabilities on the balance sheet. The Company adopted the new guidance using the modified
retrospective approach on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the package of practical expedients permitted within the standard, which allows an entity to forgo reassessing (i) whether
a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition
of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and
impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has
also elected the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any
lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
contracts entered into on or after the Effective Date, at the inception of a contract, the Company will assess whether the contract is,
or contains, a lease. The Company&#8217;s assessment is based on: (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtained the right to substantially all the economic benefit from the use of the asset throughout the
period, and (iii) whether the Company has the right to direct the use of the asset. Leases entered into prior to January 1, 2020, which
were accounted for under ASC 840, were not reassessed for classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The Company
generally uses its incremental borrowing rate as the discount rate for leases, unless an interest rate is implicitly stated in the lease.
The present value of the lease payments is calculated using the incremental borrowing rate for operating leases, which was determined
using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term. The lease term for all the Company&#8217;s leases includes the non-cancellable period
of the lease plus any additional periods covered by either a Company option to extend the lease that the Company is reasonably certain
to exercise, or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zv4QhUpqTiz4" style="display: none">Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt Street</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hyde
                                                                                         Park</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Balance
    Sheet Location</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Right
    of Use</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,353</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,309</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,156</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,853</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,741</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,039</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,780</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,164</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,076</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,240</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable - net of
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,070</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,871</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,941</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,911</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,911</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zEOBmg0vkU17" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides details of the Company&#8217;s lease expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGRbxhBgiqMd" style="display: none">Schedule of Lease Expense</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br /> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br /> December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Platt Street</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Supera Aviation</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease Expenses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b><span style="font-family: Times New Roman, Times, Serif">Lease</span></b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Lease Costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,981</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,400</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,632</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31_custom_SuperaAviationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,026</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31_custom_TwoThousandTwentyBaltimoreMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,533</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,226</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AF_zu8WgHFyEU2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zTbeKs7NCWTd" style="display: none">Schedule of Other Information Related to Leases</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Hyde</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other
    Information</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Park
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating cash
    used</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" title="Operating cash used" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,622</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" title="Operating cash used" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" title="Operating cash used" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,602</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" title="Operating cash used" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,852</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Average remaining lease
    term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">27</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">23</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">25</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31_custom_HydeParkFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zDSTRTFLYxp9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the annual minimum lease payments of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z418TRZZeYi" style="display: none">Schedule of Operating Lease Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">For Years Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,485</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,005</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,103</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,348</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,451</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,814</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,814</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments, undiscounted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,402</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">105,868</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">157,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,591</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,549</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of future
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31_custom_PlattStreetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,811</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,910</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z9Pn8x1uCzk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zV1OPgbYY9Ac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(p)
<span id="xdx_8B3_z0X56l1bZbzi">Revenue Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that
a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services
transferred to the customer. The following five steps are applied to achieve that core principle:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the contract with the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the transaction price</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
    the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
    revenue when the company satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zFd0LdHOkWhh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(q)
<span id="xdx_866_zPNtZrlB5KGg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits are
recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized
is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized
tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and
measurement standards. For the years ended December 31, 2022 and 2021, no liability for unrecognized tax benefits was required to be
reported.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no income tax benefit recorded for the losses for the years ended December 31, 2022 and 2021 since management determined that the
realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on
the net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax years from 2019 through 2022 remain
subject to examination by federal and state jurisdictions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zSFd7GSZQV6i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(r)
<span id="xdx_869_zJi0VKddkhRa">Basic and Diluted Earnings per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings
per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the
period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 375.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed using the weighted average number of shares of Common Stock and dilutive potential Common Stock outstanding
during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss for the years ended December 31, 2022 and 2021, Common Stock equivalents were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAXNur76ujuj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
    the Years Ended <br /> December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,376,737</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,176,739</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Unvested Restricted Stock Units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_UnvestedRestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,795,000</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_UnvestedRestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,795,000</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,514,827</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,074,489</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">520,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Convertible Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_SeriesCPreferredConvertibleWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_SeriesCPreferredConvertibleWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Convertible Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_SeriesDPreferredConvertibleStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,496</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_SeriesDPreferredConvertibleStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,496</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    potentially dilutive shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,885,695</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,630,494</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zu08y11WuaG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzGyNqd81XN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(s)
<span id="xdx_86E_zGEQBYKSKSgd">Stock-based Payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) 718, &#8220;Compensation - Stock Compensation&#8221;, which requires the measurement and recognition of compensation
expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates
the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is
ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In June 2018,
the FASB issued ASU No. 2018-07, Compensation &#8211; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment
Accounting (the &#8220;2018 Update&#8221;). The amendments in the 2018 Update expand the scope of Topic 718 to include share-based payment
transactions for acquiring goods and services from nonemployees. Prior to the 2018 Update, Topic 718 applied only to share-based transactions
to employees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards
within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when
the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the
instruments have been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for forfeiture of stock-based awards as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zawq1TKJXW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(t) <span id="xdx_86C_z2UTNbnIjANg">Research and Development Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with FASB ASC 730, research and development costs are expensed
as incurred and consist of fees paid to third parties that conduct certain research and development activities on the Company&#8217;s
behalf.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zb2UcIdCu8jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(u)
<span id="xdx_861_z1m1wXwiQfC4">Recently Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, FASB issued ASU 2017-11, Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and
Hedging (Topic 815): The new guidance amends ASC 815 to exclude consideration of a down-round feature in the evaluation of whether an
instrument is indexed to an entity&#8217;s own stock under ASC 815-40-15-7C. That is, a down-round provision would not preclude an entity
from concluding that an instrument or feature that includes a down-round feature is indexed to the entity&#8217;s own stock. This guidance
applies to both freestanding financial instruments and embedded conversion options (e.g., in convertible instruments with beneficial
conversion features (BCFs) or cash conversion features (CCFs)). The ASU is effective for annual reporting periods beginning after December
15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this standard did not have a material impact on their
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, FASB issued ASU 2020-06, <i>Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211;
Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own
Equity</i>. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer&#8217;s accounting for convertible debt instruments. The new
guidance removes from U.S. GAAP the separation models for (1) convertible debt with a CCF and (2) convertible instruments with a BCF.
As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in
such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as
preferred stock. This ASU is effective for fiscal years beginning after December 15, 2021 and early adoption is allowed. The Company
early adopted this guidance as of January 1, 2021. The adoption of this standard did not have a material impact on their consolidated
financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50),
Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40),
Issuer&#8217;s Accounting for Certain Modifications or Exchanges or Freestanding Equity - Classified Written Call Options. </i>The amendments
in this Update clarify an issuer&#8217;s accounting for modifications or exchanges of freestanding equity - classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments are effective for all entities for
fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments
prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for
all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this Update in an interim
period, the guidance should be applied as of the beginning of the fiscal year that includes the interim period. The adoption of this
ASU had no material impact on the Company&#8217;s consolidated financial statements and related disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements Not Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial
Instruments (&#8220;ASU-2016-13&#8221;). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets
that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred
losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2022, including interim periods
within that fiscal year. The Company expects that there would be no material impact on the Company&#8217;s consolidated financial
statements upon the adoption of this ASU.</span></p>
</ix:nonNumeric><p id="xdx_858_zag03Euhqlva" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:RecentDevelopmentsAndManagementsPlansTextBlock"><p id="xdx_807_ecustom--RecentDevelopmentsAndManagementsPlansTextBlock_zZwzjwClXqgj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82B_z0HVwZ3uMkUf">Recent Developments, Liquidity and Management&#8217;s Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition
and Disposition of Cystron</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired <span id="xdx_907_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_dp_uPure_c20200323__us-gaap--BusinessAcquisitionAxis__custom--CystronBiotechLLCMember__us-gaap--TypeOfArrangementAxis__custom--MembershipInterestPurchaseAgreementMember_zHgOJjBbVoQ7" title="Acquired membership interests, percentage"><ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" contextRef="AsOf2020-03-23_custom_CystronBiotechLLCMember_custom_MembershipInterestPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the membership interests of Cystron pursuant to a Membership Interest Purchase Agreement, dated March 23, 2020
(as amended by Amendment No. 1 on May 14, 2020, the &#8220;MIPA&#8221;) from certain selling parties (the &#8220;Cystron Sellers&#8221;).
The acquisition of Cystron was accounted for as a purchase of an asset. Cystron is a party to a License and Development Agreement (as
amended and restated on March 19, 2020, in connection with our entry into the MIPA, the &#8220;License Agreement&#8221;) with Premas
Biotech PVT Ltd. (&#8220;Premas&#8221;) whereby Premas granted Cystron, amongst other things, an exclusive license with respect to Premas&#8217;
vaccine platform for the development of a vaccine against COVID-19 and other coronavirus infections. Cystron was incorporated on March
10, 2020. Since its formation and through the date of its acquisition by the Company, Cystron did not have any employees and its sole
asset consisted of the exclusive license from Premas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company and the Cystron Sellers, which are also shareholders of Oravax, entered into a Termination and Release Agreement
terminating the MIPA effective upon consummation of the Contribution Agreement. In addition, the Cystron Sellers agreed to waive any
change of control payment triggered under the MIPA as a result of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the Contribution and Assignment Agreement, dated March 18, 2021 (the &#8220;Contribution Agreement&#8221;)
by and among the Company, Cystron, Oravax and, for the limited purpose set forth therein, Premas, the parties consummated the transactions
contemplated therein. Pursuant to the Contribution Agreement, among other things, the Company caused Cystron to contribute substantially
all of the assets associated with its business of developing and manufacturing Cystron&#8217;s COVID-19 vaccine candidate to Oravax (the
&#8220;Contribution Transaction&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, all amounts due to Premas under the Contribution Agreement have been paid. (<i>Note: Pursuant to the Contribution
Agreement, a total of $<span id="xdx_90A_eus-gaap--PaymentsForProceedsFromInvestments_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember__dei--LegalEntityAxis__custom--PremasBiotechPVTLtdMember_zFAbnIXVSo5g" title="Amount owed on investments"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2021-01-012021-12-31_custom_ContributionAgreementMember_custom_PremasBiotechPVTLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span> was owed to Premas, of which $<span id="xdx_904_eus-gaap--PaymentsToAcquireInvestments_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember__dei--LegalEntityAxis__custom--PremasBiotechPVTLtdMember_z0vNCglhow93" title="Payments to investments"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2021-01-012021-12-31_custom_ContributionAgreementMember_custom_PremasBiotechPVTLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></span> was paid by pre-merger Akers Biosciences, Inc.</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Agreement
and Plan of Merger and Reorganization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, MyMD, Merger Sub, and MyMD Florida entered into the Merger Agreement (Note 1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PreMergerMember_zA9GsiDBMY3c" title="Business acquisition description"><ix:nonNumeric contextRef="From2021-04-122021-04-16_custom_MergerAgreementMember_custom_PreMergerMember" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity">Upon
completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesPostReverseStockSplits_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z8HZoWanW0W8" title="Issuance of post reverse stock split"><ix:nonFraction name="MYMD:StockIssuedDuringPeriodSharesPostReverseStockSplits" contextRef="From2021-04-122021-04-16_custom_MergerAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,553,307</ix:nonFraction></span>
post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio.
Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD
Florida held approximately <span id="xdx_900_ecustom--ExchangeRatioPercentage_dp_uPure_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zow1OeGQnp46" title="Exchange ratio percentage"><ix:nonFraction name="MYMD:ExchangeRatioPercentage" contextRef="From2021-04-122021-04-16_custom_MergerAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.05</ix:nonFraction></span>%
of the Company&#8217;s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants
to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210416__srt--StatementScenarioAxis__custom--PrefundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zBynsI6NHzq3" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-04-16_custom_PrefundedWarrantsMember_custom_MergerAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">986,486</ix:nonFraction></span>
shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of
pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company&#8217;s net cash
at closing. Holders of pre-Merger Company Common Stock held approximately 22.95% of the outstanding equity of the
Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315
MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment
of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of
the Merger</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 805, the Company accounted for the transaction as a reverse merger with Akers Biosciences, Inc. (&#8220;Akers&#8221;)
as the legal acquirer and pre-Merger MyMD Florida as the accounting acquirer. As a result of the transaction, the Company recognized
Goodwill totaling $<span id="xdx_90E_eus-gaap--Goodwill_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zVAUDm3eucu1" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,498,539</ix:nonFraction></span> based upon Akers&#8217; pre-merger market capitalization of $<span id="xdx_90A_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zy2QKP80b0G7" title="Pre market capitalization"><ix:nonFraction name="us-gaap:CapitalizationLongtermDebtAndEquity" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,477,346</ix:nonFraction></span> less net tangible assets of $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zyQaj3sWDpT9" title="Tangible asset"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,978,807</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Akers&#8217;
valuation was based upon <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_z3MCITwbgF05" title="Common shares outstanding"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,335,627</ix:nonFraction></span> common shares outstanding and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgGbIkVmypFa" title="Vested restricted stock unit"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">263,026</ix:nonFraction></span> vested restricted stock units (&#8220;RSU&#8217;) with a fair
market value of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsO1ai5oX2h3" title="Fair market value price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.94</ix:nonFraction></span> per share, the closing price of Akers common shares on the NASDAQ Stock Exchange on April 16, 2021.</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zbqmEkrbkShe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z16p5vmab1Rd">Schedule
of Net Assets Acquired to be Allocated to Goodwill</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Valuation
    <br /> Analysis</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210416__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zW1yQXyWjuLh" title="Total Consideration" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-04-162021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,477,346</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" title="Cash and Cash Equivalents" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,380,852</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" title="Marketable Securities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,480,524</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" title="Other Receivables" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,026,137</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" title="Prepaid Expenses" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,314</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in Oravax, Inc.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" title="Investment in Oravax, Inc." style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Trade and Other Payables</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zY7GpVztgPi2" title="Trade and Other Payables" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,601,020</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Tangible Assets
    Acquired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zDDkY4np7f3b" title="Net Tangible Assets Acquired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,978,807</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Excess of Purchase Price
    Over Net Assets Acquired to be Allocated to Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--Goodwill_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" title="Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,498,539</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zcY4Mi6aa8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of approximately <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220412__20220416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zEYBOl4W5f54" title="Percentage of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2022-04-122022-04-16_custom_MergerAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49.68</ix:nonFraction></span>% of outstanding shares of Company Common Stock are subject to lockup agreements pursuant to which such
stockholders have agreed, except in limited circumstances, not to transfer, grant an option with respect to, sell, exchange, pledge or
otherwise dispose of, or encumber, any shares of Company capital stock for 180 days following the effective time of the Merger. For the
subsequent 180 days after the initial 180-day lock-up period, any disposal of Company Common Stock must be only in accordance with the
volume limitations set forth in paragraph (2) of Rule 144 promulgated under the Securities Act of 1933, as amended (the &#8220;Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and conditions of the Merger Agreement, not later than 30 days after the Option Exercise Period, the Company will pay stockholders
of MyMD Florida the Additional Consideration from the exercise of any MyMD Florida options assumed by the Company prior to the second-year
anniversary of the Merger; provided, however, the amount of such payment will not exceed the maximum amount of cash consideration that
may be received by stockholders of MyMD Florida without affecting the intended tax consequences of the Merger. As of the date of this
report, there have been no exercises of the MyMD Florida options assumed by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Merger Agreement, the Company has agreed to pay contingent consideration in combined Company Common Stock to MYMD Florida
stockholders if the combined company meets certain market capitalization milestones, referred to as Milestone Events, during the period
commencing on the business day following the closing date of the merger and ending on the 36-month anniversary of such date, referred
to as the Milestone Period. The Milestone Events and corresponding Milestone Payments are set forth in the table below.</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:SummaryOfMilestoneEventsPaymentTableTextBlock"><p id="xdx_89D_ecustom--SummaryOfMilestoneEventsPaymentTableTextBlock_ztnzcd3FAXkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zX43G04cJwKi">Summary
of Milestone Events Payment</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Event</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Payment</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zxQO5DcJdaa1" title="Milestone Event"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodOneMember" name="MYMD:MilestoneEvent">Market
    capitalization of the combined company for at least ten (<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zbAkHFkCvoxj" title="Debt Instrument, Convertible, Threshold Trading Days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2022-01-012022-12-31_custom_MilestonePeriodOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Days">10</ix:nonFraction></span>) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#8220;First Milestone Event&#8221;)</ix:nonNumeric></span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zn71c3673dzf" title="Milestone Payment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodOneMember" name="MYMD:MilestonePayment">20,000,000</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z3mOcVEauQti" title="Milestone Event"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember" name="MYMD:MilestoneEvent">For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least <span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z9NFKzKila4b" title="Threshold trading days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Days">10</ix:nonFraction></span> trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company</ix:nonNumeric></span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_zUWfakWc2bji" title="Milestone Payment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember" name="MYMD:MilestonePayment">10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zy6Uzjofk6Yc" title="Milestone Event"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember" name="MYMD:MilestoneEvent">Market
    capitalization of the combined company for at least <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zFPZOxDxzhCl" title="Debt Instrument, Convertible, Threshold Trading Days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Days">10</ix:nonFraction></span> trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#8220;Second Milestone Event&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zwcfVRNmJXe8" title="Milestone Payment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember" name="MYMD:MilestonePayment">25,000,000</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zCIuwjWOFz48" title="Milestone Event"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodFourMember" name="MYMD:MilestoneEvent">For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zzgeveMfu8mk" title="Threshold trading days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2022-01-012022-12-31_custom_MilestonePeriodFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Days">10</ix:nonFraction></span> trading days during any 20 consecutive trading day period during the Milestone
    Period</ix:nonNumeric></span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90E_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zLtbp8KJU8Zi" title="Milestone Payment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MilestonePeriodFourMember" name="MYMD:MilestonePayment">25,000,000</ix:nonNumeric></span>
    per each incremental increase</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

</ix:nonNumeric><p id="xdx_8AB_zeLl3tVjuXa5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the table above, &#8220;market capitalization&#8221; means, with respect to any trading day, the product of (i) the total
outstanding shares of the combined Company Common Stock and (ii) the volume weighted average trading price for the combined Company Common Stock for such trading day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, none of the contingencies noted above have been met.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s cash on hand was $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zGYUUbapHN1l" title="Cash on hand"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,090</ix:nonFraction></span> and marketable securities were $<span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zpZRYnoBQKL1" title="Marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,086,902</ix:nonFraction></span>. The Company has incurred
a net loss from operations of $<span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iN_pp0p0_di_c20220101__20221231_zn8kAqDORv5i" title="Loss from operations"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span> for the year  ended December 31, 2022. As of December 31, 2022, the Company had working
capital of $<span id="xdx_907_ecustom--WorkingCapital_iI_pp0p0_c20221231_zSbUIQpbjj2l" title="Working capital"><ix:nonFraction name="MYMD:WorkingCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,632,796</ix:nonFraction></span> and stockholders&#8217; equity of $<span id="xdx_907_eus-gaap--StockholdersEquity_iI_pp0p0_c20221231_zJtLSahnDpAa" title="Stockholders&apos; equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,695,056</ix:nonFraction></span> including an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20221231_zJTz9YLatmjk" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">93,758,904</ix:nonFraction></span>. During the year
ended December 31, 2022, cash flows used in operating activities were $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20220101__20221231_zSt0Ad7AII2i" title="Net cash provided by operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,270,068</ix:nonFraction></span>, consisting primarily of a net loss of $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220101__20221231_z7gGCqXPkVS2" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,197,336</ix:nonFraction></span>
offset by non-cash share-based compensation of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220101__20221231_zCCseBi5deQc" title="Non cash share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,191</ix:nonFraction> </span> and an increase in trade and other payables of $<span id="xdx_90C_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_pp0p0_c20220101__20221231_zAGjxOI4MtNf" title="Increase in trade and other payables"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,686,595</ix:nonFraction></span> and a decrease in prepaid
expenses of $<span id="xdx_90D_ecustom--DecreaseInPrepaidExpense_c20220101__20221231_zl64mJLJ5Xtj" title="Decrease in prepaid expense"><ix:nonFraction name="MYMD:DecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,560</ix:nonFraction></span>. Since its inception, the Company has met its liquidity requirements principally through the sale of its Common Stock in public and private placements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the current cash requirements for operations in conjunction with management&#8217;s strategic plan and believes that
the Company&#8217;s current financial resources as of the date of the issuance of these consolidated financial statements are sufficient
to fund its current operating budget and contractual obligations as of December 31, 2022 as they fall due within the next twelve-month
period, alleviating any substantial doubt raised by the Company&#8217;s historical operating results and satisfying its estimated liquidity
needs for twelve months from the issuance of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80B_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zF3Gkqu4OxWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_827_zzofitw2FMx4">Trade and Other Payables</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLkHF2WSGX6f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other payables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zmu5VpD0hIN3">Schedule
of Trade and Other Payables</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20221231_zWFKnewnHzU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20211231_zBPCCn91pAcb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableTradeCurrent_iI_pp0p0_maAPAOAzNsj_zaPxxI4z5X0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable &#8211; Trade</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,356,555</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">867,518</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzNsj_zWsHh3J32ut6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,666</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzNsj_ziwHp0LUz5nb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables, Total</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,673,221</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">986,626</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zHX8XofOYbzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zrA97pS6VZy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82A_zjs9c7Jwh4Uh">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Secured
Promissory Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, concurrently with the execution of the Merger Agreement, the Company agreed to provide a bridge loan up to an aggregate
principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember_zJJ6Yt3FtJN7" title="Maximum principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span> to pre-Merger MyMD Florida pursuant to the Bridge Loan Note. Advances under the Bridge Loan Note (&#8220;Bridge
Loan Advances&#8221;) were made in the amounts and at the times as needed to fund MyMD Florida&#8217;s operating expenses. Bridge Loan
Advances accrue interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember_zVJlOmZFd6mg" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum, which may be increased to <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--StatementScenarioAxis__custom--EventOfDefaultMember_zziOZUn1ClEf" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember_custom_EventOfDefaultMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum upon occurrence of any event of default, from the date
of such default. The principal and the accrued interest thereon are to be repaid on the earliest of (a) April 15, 2022; (b); if the Merger
was consummated, then upon demand of the Company following the consummation of the Merger; or (c) the date on which the obligations under
the Bridge Loan Note are accelerated upon event of default as set forth in the Bridge Loan Note. The payment and performance of all obligations
under the Bridge Loan Note are secured by a first priority security interest in all of MyMD Florida&#8217;s right, title and interest
in and to its assets as collateral. The outstanding principal amount and the accrued interest of the Bridge Loan Note were convertible
into shares of MyMD Florida Common Stock in accordance with the terms of the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and December 31, 2021 MyMD had advanced MyMD Florida $<span id="xdx_90E_eus-gaap--AdvancesToAffiliate_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zfGlQKpqb7Ii" title="Advances to affiliate"><span id="xdx_908_eus-gaap--AdvancesToAffiliate_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zAXb6ORFthh5" title="Advances to affiliate"><ix:nonFraction name="us-gaap:AdvancesToAffiliate" contextRef="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AdvancesToAffiliate" contextRef="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></ix:nonFraction></span></span> under the Bridge Loan Note plus accrued interest
totaling $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_z4QyR6kPyiqj" title="Accrued interest"><span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zgB0v11mDtZf" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,137</ix:nonFraction></ix:nonFraction></span></span>. The balance of $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zjAwYpS9kbn9" title="Notes payable"><span id="xdx_906_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zn8mjVxf4YS1" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,026,137</ix:nonFraction></ix:nonFraction></span></span> as of December 31, 2022 and December 31, 2021, respectively, were eliminated on consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuQw2yYrSRTa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_825_zIymIP6YDXRg">Stock-based Payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
incentive Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2013
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (&#8220;2013 Plan&#8221;). The 2013 Plan was amended by the Board
on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides
for the issuance of up to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20140123__us-gaap--PlanNameAxis__custom--TwoThousandThirteenStockIncentivePlanMember_zujpekTuZSb5" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2014-01-23_custom_TwoThousandThirteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,162</ix:nonFraction></span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of restricted stock and options
to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedPlanMember_zWe5KItoIMxk" title="Share-based compensation arrangement by share-based payment award, shares purchased for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-01-012022-12-31_custom_AmendedPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,406</ix:nonFraction></span> shares of Common Stock have been issued pursuant to the 2013 Plan, and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--AmendedPlanMember_zMo031D5W25a" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_AmendedPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755</ix:nonFraction></span> shares of Common Stock remain available
for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2016
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2016, the shareholders approved, and the Company adopted the 2016 Stock Incentive Plan (&#8220;2016 Plan&#8221;). The 2016
Plan provides for the issuance of up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20161221__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_zky8YGjAAVJg" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-12-21_custom_TwoThousandAndSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of options
to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_ze4jzwGnmjb4" title="Share-based compensation arrangement by share-based payment award, shares purchased for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,188,315</ix:nonFraction></span> shares of Common Stock have been issued pursuant to the 2016 Plan, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_zQvnBXNVOmr4" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares of Common Stock remain available
for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2017
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2017, the shareholders approved, and the Company adopted the 2017 Stock Incentive Plan (&#8220;2017 Plan&#8221;). The 2017
Plan provides for the issuance of up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20170807__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zDwUPIQYPqVe" title="Number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2017-08-07_custom_TwoThousandAndSeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,516</ix:nonFraction></span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of restricted
stock and options to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zqW9Qk2yTAg5" title="Share based compensation arrangement by share based payment award shares purchased for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,538</ix:nonFraction></span> shares of Common Stock have been issued pursuant to the 2017 Plan, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zWuQY7XR92rk" title="Remaining shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">978</ix:nonFraction></span> shares of Common Stock
remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2018
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2018, the shareholders approved, and the Company adopted the 2018 Stock Incentive Plan (&#8220;2018 Plan&#8221;). On August
27, 2020, the 2019 Plan was modified to increase the total authorized shares. The 2018 Plan, as amended, provides for the issuance of
up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20181207__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zXwAcLzX7hZ5" title="Share based compensation arrangement by share based payment award number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2018-12-07_custom_TwoThousandAndEighteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">560,063</ix:nonFraction></span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of RSUs and restricted stock to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zcw8E6ociSI1" title="Share based compensation arrangement by share based payment award shares purchased for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">263,026</ix:nonFraction></span>
shares of Common Stock have been issued pursuant to the 2018 Plan, and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zGTGjOIsRTKi" title="Share based compensation arrangement by share based payment award number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">297,037</ix:nonFraction></span> shares of Common Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 126 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2021
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15, 2021, the shareholders approved, and the Company adopted the 2021 Stock Incentive Plan (&#8220;2021 Plan&#8221;). The 2021
Plan provides for the issuance of up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210415__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zPBhOV286lW9" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-04-15_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,228,184</ix:nonFraction></span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of RSUs
and stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zuSkjtTViWlg" title="Share-based compensation arrangement by share-based payment award, shares purchased for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,149,207</ix:nonFraction></span> shares of Common Stock have been issued pursuant to the 2021 Plan, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zZNwZIVmqg" title="Remaining shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,078,977</ix:nonFraction></span> shares of Common
Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKU7dP8dbSzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activities for MyMD stock options for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zhogll6lP7H8">Summary
of Stock Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zXMCfTt0c42h" title="Number of Shares, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,176,737</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkraZcEptGI5" title="Weighted Average Exercise Price, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zdXh6kDV7ztk" title="Weighted Average Grant Date Fair Value, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUesiIMkAwR5" title="Weighted Average Remaining Contractual Term (Years), Beginning"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.29</ix:nonNumeric></span></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zrU9x5VANKu" title="Aggregate Intrinsic Value, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,493,284</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zgw5BWoHTN81" title="Number of Shares, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zIuVXPcxzkXh" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.41</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zAmc9CVvaB5c" title="Weighted Average Grant Date Fair Value, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.41</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--WeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231_zGUCNxEruRXb" title="Weighted Average Remaining Contractual Term (Years), Granted"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="MYMD:WeightedAverageRemainingContractualTermGranted">5.80</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zz9wlBdJF9Fg" title="Number of Shares, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zDQNPuVB1EM4" title="Weighted Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zU3f8FWpT9j8" title="Weighted Average Grant Date Fair Value, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_znHg0YZgsh63" title="Number of Shares, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJbHi3RYI4ae" title="Weighted Average Exercise Price, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zlOrdKKXojV2" title="Weighted Average Grant Date Fair Value, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_z1ukftiBAJm" title="Number of Shares, Canceled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEuhLHZi1wfh" title="Weighted Average Exercise Price, Canceled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zA8NUICsMAn9" title="Weighted Average Grant Date Fair Value, Canceled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zNiHI3IoqRke" title="Number of Shares, Ending Balance" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8239;<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,476,737</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zeilo4IWirH3" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.64</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zIQMsZ9v8hMf" title="Weighted Average Grant Date Fair Value, Ending" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.64</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOAkMHVCEzE7" title="Weighted Average Remaining Contractual Term (Years), Ending"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.64</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z6DuQ00yoaR5" title="Number of Shares, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,376,737</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zkE7UZjWJfO" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.61</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_c20220101__20221231_zNltyrsJ5DJ9" title="Weighted Average Grant Date Fair Value, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.61</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z6Ga8wHrZmGe" title="Weighted Average Remaining Contractual Term (Years), Exercisable"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">0.52</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_z57thjqMWK5h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5XgdiqaIo7" title="Share-based payment award, options, grants in period, grant date intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.15</ix:nonFraction></span> for the Company&#8217;s common shares on December 31, 2022 and the closing stock price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqOLaxsJZqQ5" title="Share-based payment award, options, grants in period, grant date intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember98108171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.06</ix:nonFraction></span> for the Company&#8217;s common
shares on December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 279pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2022, the Company&#8217;s Compensation Committee approved the issuance of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaZFC9QM7tr" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> stock options under the 2021 Stock Incentive
Plan. These shares had a grant date fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zODikesMNY35" title="Weighted Average Grant Date Fair Value, Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></span> per share or a cumulative fair market value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zy4lACyTZfib" title="Cumulative fair market value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">717,660</ix:nonFraction></span> as calculated using Black-Scholes
(exercise price $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9cCu8I5Qv9h" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-01-28_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.96</ix:nonFraction></span> per share, stock price $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOgTUnzIjL67" title="Stock price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.96</ix:nonFraction></span> per share, volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDUBtKd2wC38" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">124.43</ix:nonFraction></span>%, discount rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4FVhkS9NWN6" title="Discount rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.74</ix:nonFraction></span>% and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zP6O40mI5097" title="Expected term::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl1054">seven</span></span>-year term). The
grant was segmented into four vesting tranches triggered by performance achievements and expire on <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTy4TPnm22u3" title="Share based payment award vesting expiration date"><ix:nonNumeric contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">January 28, 2029</ix:nonNumeric></span>. The Company is amortizing
the expenses over the vesting cycles of the individual tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2022, the Company granted <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPVhU1mUxvae" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> stock options under the 2021 Stock Incentive Plan to a third-party consultant in consideration
of services rendered. These shares had a grant date fair value of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPhNXqFw41c5" title="Weighted average grant date fair value, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></span> per share or a cumulative fair market value of $<span id="xdx_908_ecustom--CumulativeFairMarketValue_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6qtipIBTOZf" title="Cumulative fair market value"><ix:nonFraction name="MYMD:CumulativeFairMarketValue" contextRef="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,360</ix:nonFraction></span> as calculated
using Black-Scholes (exercise price $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfKcF5ZNusk7" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-21_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></span> per share, stock price $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWjsBjBkCR12" title="Stock price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></span> per share, volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMxMHrYkuaGj" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">130.51</ix:nonFraction></span>%, discount rate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNcpLktSkc2k" title="Discount rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.24</ix:nonFraction></span>% and <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zde9VwxFUttf" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1072">five</span></span>-year
term). The grant vested immediately and expire on June 21, 2027. The Company is amortizing the expense over twelve months, the term of
the consulting agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and 2021, the Company incurred stock option expenses totaling $<span id="xdx_90C_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3HuxmX5kY44" title="Stock option expenses"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember98108296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,342</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--StockOptionPlanExpense_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOFPPfSN5vfh" title="Stock option expenses"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember98108171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively. The unamortized
stock option expenses as of December 31, 2022 and 2021 totaled $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231_zqZOJAXWrIcg" title="Unamortized stock option expenses"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,847</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zVs8HqjlGux3" title="Unamortized stock option expenses"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Assumption
of MyMD Florida Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, pre-Merger MyMD Florida adopted the MyMD Pharmaceuticals, Inc. Amended and Restated 2016 Equity Incentive Plan (the
&#8220;2016 Plan&#8221;). The 2016 Plan provided for the issuance of up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20161231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zF9YGcEDF3La" title="Premerger common stock, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span>
shares of pre-Merger MyMD Florida Common Stock. As of December 31, 2022, options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221229__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z9uSWkESH62b" title="Options to purchase of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-12-292022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,188,315</ix:nonFraction></span>
shares of Company Common Stock have been issued pursuant to the plan and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zXDR8J6JeEB4" title="Remaining shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>
shares of Company Common Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, effective as of the effective time of the Merger, the Company assumed pre-Merger MyMD Florida&#8217;s Second
Amendment to Amended and Restated 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;), assuming all of pre-Merger MyMD Florida&#8217;s
rights and obligations with respect to the options issued thereunder. As of the effective date of the Merger, no additional awards could
be issued under the 2016 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 127 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the terms of the Merger Agreement, the Company assumed all of pre-Merger MyMD Florida&#8217;s rights and obligations
under pre-Merger MyMD Florida&#8217;s stock options that were outstanding immediately prior to the effective time of the Merger, and
each such stock option, whether or not vested, was converted into a stock option representing the right to purchase shares of Company
Common Stock, on terms substantially the same as those in effect immediately prior to the effective time, except that the number of shares
of Company Common Stock issuable and the exercise price per share of such stock options was adjusted by the Exchange Ratio. Additionally,
the number of shares and exercise price per share of Company Common Stock under the assumed pre-Merger MyMD Florida stock options was
further adjusted by the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assumed <span id="xdx_906_ecustom--NumberOfStockOptionsAssumed_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zTYyh4KAh2U"><ix:nonFraction name="MYMD:NumberOfStockOptionsAssumed" contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,188,315</ix:nonFraction></span> MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited
to, the amendment of such stock option to change the term of such stock option for a period expiring on April 16, 2023, the second-year
anniversary of the Merger). The Company recorded expenses of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zQe8kepESZRi"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,036,051</ix:nonFraction></span> for the assumption of the options and the modification of the
terms which is included on the Consolidated Statement of Comprehensive Loss for the year December 31, 2021. The Company utilized Black-Scholes
using an exercise price of $2.59, an issue date fair value of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zfdyZ2m0EG4k" title="Fair value"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.94</ix:nonFraction></span>, a volatility index of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_z27P0wXGAE3f" title="Volatility index"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">122.31</ix:nonFraction></span>% and a discount rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zIdSDqNS5RPa" title="discount rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.16</ix:nonFraction></span>% to determine
the fair value of the modification. The pre-Merger MyMD options were valued at $<span id="xdx_909_ecustom--OptionsMarketValue_iI_c20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zUVeZRaeIhW4" title="Options market value"><ix:nonFraction name="MYMD:OptionsMarketValue" contextRef="AsOf2021-04-16_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> on April 16, 2021, as there was no reliable method
of determining the fair value given the material events that had occurred since the last arms-length trade of common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Compensation Committee of the Board of Directors approved grants totaling <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3DYtwKM4pLh" title="Restricted stock units"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">394,680</ix:nonFraction></span> Restricted Stock Units to the
Company&#8217;s four directors. Each RSU had a grant date fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCkJwKg45tr6" title="Grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.48</ix:nonFraction></span> which shall be amortized on a straight-line basis over
the vesting period into administrative expenses within the Consolidated Statement of Comprehensive Loss. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK23X6shFLeh" title="Restricted stock units, description"><ix:nonNumeric contextRef="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">Such RSUs were granted under
the 2018 Plan, as amended. Fifty percent (50%) of each RSU will vest on the first anniversary date of the Grant and the remaining fifty
percent (50%) will vest on the second anniversary date; provided that the RSUs shall vest immediately upon the occurrence of (i) a change
in control, provided that the director is employed by or providing services to the Company and its affiliates on the closing date of
such change of control, or (ii) the director&#8217;s termination of employment of service by the Company was without cause</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, concurrently with the closing of the Merger, pursuant to the terms of the RSU Agreements between the Company and four
board of directors, the <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7wQDrx0zKz7" title="Number of stock option to purchase shares of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">394,680</ix:nonFraction></span> RSUs granted on September 11, 2020 under the 2018 Plan, as amended, accelerated and vested in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the terms of the RSU agreements, the Company, at the Company&#8217;s sole discretion, may settle the RSUs in cash, or part cash and part
Common Stock. As there is no intention to settle the RSUs in cash, the Company accounted for these RSUs as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-merger
Akers Biosciences, Inc. recorded expenses totaling $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIprk2eP8nkh" title="Premerger expenses totaling"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">979,758</ix:nonFraction></span> for the acceleration of the vesting of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6UiWYRg3mxa" title="Number of vesting shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">394,680</ix:nonFraction></span> RSUs, the holders immediately
surrendered <span id="xdx_909_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYRcjPBx5Vd" title="Number of restricted stock, net of tax withholdings"><ix:nonFraction name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,457</ix:nonFraction></span> RSUs with a fair market value of $<span id="xdx_909_eus-gaap--RestrictedStockValueSharesIssuedNetOfTaxWithholdings_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbXVtDuCoza" title="Restricted stock value, net of tax withholdings"><ix:nonFraction name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">688,913</ix:nonFraction></span> for the withholding of federal and state income taxes, as directed by the
holders, which was recorded as Payroll Taxes Payable on the date of the Merger. The withholding obligations were paid by the Company
on June 30, 2021. As of March 29, 2023, the vested RSUs have not been converted to common shares of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 128 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Compensation Committee of the Board of Directors approved grants totaling <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zSHHg4pMbPcd" title="Restricted stock units"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,795,000</ix:nonFraction></span> Restricted Stock Units to the
Company&#8217;s six directors and seven key employees. Each RSU had a grant date fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvvplYS3Vvwi" title="Grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.09</ix:nonFraction></span> which will be amortized upon vesting
into administrative expenses within the Consolidated Statement of Comprehensive Loss. Such RSUs were granted under the 2021
Plan. Vesting of each RSU is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_znzp6sMHQxzk" title="Restricted stock units vested, description"><ix:nonNumeric contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">One-third
    (33%) of each RSU will vest when the Company&#8217;s market capitalization is equal to or greater than $500,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z8Xe7i4mozN5" title="Restricted stock units vested, description"><ix:nonNumeric contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">One-third
    (33%) of each RSU will vest when the Company&#8217;s market capitalization is equal to or greater than $750,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zKNpU0DcyTH8" title="Restricted stock units vested, description"><ix:nonNumeric contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The
    remaining awarded units will vest when the Company&#8217;s market capitalization is equal to or greater than $1,000,000,000 for at
    least ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market
    value of the Common Stock equals or exceeds $5.00 during such trading day period</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event that (i) a change in control occurs or (ii) the participant incurs a termination of service by the Company without cause
    or due to the participant&#8217;s death or total and permanent disability, then all unvested units shall become vested units immediately
    upon the occurrence of such event.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, none of the vesting milestones have been met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2022, the Compensation Committee of the Board of Directors approved a grant of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_zxGgFHjXetni" title="Share based compensation arrangement by share based payment award equity instruments other than options grants in period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-272022-01-28_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,040</ix:nonFraction></span> RSUs to a sub-contractor with a grant
date fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_z3BviRjGGRR2" title="Grant date fair value price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-272022-01-28_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15,998</ix:nonFraction></span> and vested immediately. Such RSUs were granted under the 2021 Plan. The Company recorded expenses of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_zB72KGScdNUk" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,998</ix:nonFraction></span>
which is included Stock Based Compensation on the Consolidated Statement of Comprehensive Loss during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2022, the Compensation Committee of the Board of Directors approved a grant of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220706__20220707__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_zsAn9sxkLgq9" title="Restricted stock units, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-07-062022-07-07_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,167</ix:nonFraction></span> RSUs to a sub-contractor with a grant date
fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220706__20220707__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_z4zR9Gl9pdSa" title="Grant date fair value price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-062022-07-07_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150,000</ix:nonFraction></span> and vested immediately. Such RSUs were granted under the 2021 Plan. The Company recorded expenses of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_zKGVXwKA857e" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,587</ix:nonFraction></span>
which is included Stock Based Compensation on the Consolidated Statement of Comprehensive Loss during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zP6y0EIgRuv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the status of outstanding unvested restricted stock units outstanding as of December 31, 2022 and the changes for the
year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z2h1ggkmMNRa">Summary
of Restricted Stock Units Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Average</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number
    of</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Grant
    Date</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RSUs</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
    Value</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VanMWyalIj" title="Number of RSUs, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,795,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRJZ6TxhYHSg" title="Weighted Average Grant Date Fair Value, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.09</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za4oOKNcjzU" title="Number of RSUs, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,207</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhnwmuWgJ0hg" title="Weighted Average Grant Date Fair Value, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.06</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD88faltMzu6" title="Number of RSUs, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6roEJbUYSr6" title="Weighted Average Grant Date Fair Value, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJx5G7mIb8w6" title="Number of RSUs, Vested" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,207</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo9jdXvPZEre" title="Weighted Average Grant Date Fair Value, Vested" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.06</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5AL2xCNq7d" title="Number of RSUs, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbgsmnENAzKa" title="Weighted Average Grant Date Fair Value, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzdPEWqALCl9" title="Number of RSUs, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUyqnmMouUs7" title="Weighted Average Grant Date Fair Value, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUMpOav64Jpa" title="Number of RSUs, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,795,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUIeSvX75u73" title="Weighted Average Grant Date Fair Value, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.09</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zj4rzrtxNay6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the unamortized value of the RSUs was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrv0TPHS1Df9" title="Unamortized value"><span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPhOxFUackgc" title="Unamortized value"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,611,550</ix:nonFraction></ix:nonFraction></span></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRINVxicGu4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_825_z4rl4q9GFFDc">Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of preferred shares or preferred warrants are entitled to vote per share, as limited by the certificate of designation for
each class of preferred shares or warrants, at meetings of the Company. As of December 31, 2022, <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_z7ncAdrf2z9c" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span>
shares of Preferred Stock were authorized and four classes of Preferred Stock or Warrants are designated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 129 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
D Convertible Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2020, the Company designated <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zL3NL94lXDZg" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">211,353</ix:nonFraction></span>
Series D Convertible Preferred Shares, <span id="xdx_90E_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zuqjEpgTGVK2" title="Preferred stock, no par value"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></span>
par value with a stated value of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyLifY4w5sT8" title="Preferred stock value, per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
per share and filed the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock
(the &#8220;Series D Certificate of Designation&#8221;) with the Secretary of State of the State of New Jersey. Pursuant to the
Series D Certificate of Designation, in the event of the Company&#8217;s liquidation or winding up of its affairs, the holders of
its Series D Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) will be entitled to receive the same amount that a
holder of the Company&#8217;s Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes
any conversion limitations set forth in the Series D Certificate of Designation) to Common Stock which amounts shall be paid pari
passu with all holders of the Company&#8217;s Common Stock. Each share of Preferred Stock has a stated value equal to $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zoOK7jaAytye" title="Preferred stock value, per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
(the &#8220;Stated Value&#8221;), subject to increase as set forth in Section 7 of the Series D Certificate of
Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Preferred Stock is entitled at any time to convert any whole or partial number of shares of Preferred Stock into shares of
the Company&#8217;s Common Stock determined by dividing the Stated Value of the Preferred Stock being converted by the conversion price
of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zjeDksW4AeG3" title="Preferred stock, conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20200322__20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ztkVIdHSqtx2" title="Preferred stock, terms of conversion"><ix:nonNumeric contextRef="From2020-03-222020-03-24_custom_SeriesDConvertiblePreferredStockMember" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">A
holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company&#8217;s Common Stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company&#8217;s
Common Stock then issued and outstanding (with such ownership restriction referred to as the &#8220;Beneficial Ownership Limitation&#8221;).
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days after such notice to the Company.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Beneficial Ownership Limitation, on any matter presented to the Company&#8217;s stockholders for their action or consideration
at any meeting of the Company&#8217;s stockholders (or by written consent of stockholders in lieu of a meeting), each holder of Preferred
Stock will be entitled to cast the number of votes equal to the number of whole shares of the Company&#8217;s Common Stock into which
the shares of Preferred Stock beneficially owned by such holder are convertible as of the record date for determining stockholders entitled
to vote on or consent to such matter (taking into account all Preferred Stock beneficially owned by such holder). Except as otherwise
required by law or by the other provisions of the Company&#8217;s certificate of incorporation, the holders of Preferred Stock will vote
together with the holders of the Company&#8217;s Common Stock and any other class or series of stock entitled to vote thereon as a single
class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Preferred Stock shall be entitled to receive dividends as and when paid to the holders of the Company&#8217;s Common Stock
on an as-converted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zwYANJCRt7i9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,992</ix:nonFraction></span> shares of Series D Convertible Preferred Stock outstanding which represent <span id="xdx_900_ecustom--NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqrFqPYMGxA9" title="Underlying shares of common stock"><ix:nonFraction name="MYMD:NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,496</ix:nonFraction></span> underlying
shares of the Company Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, on April 16, 2021, the Company filed an amended and restated certificate of incorporation (the &#8220;A&amp;R
Charter&#8221;) with the Secretary of State of the State of New Jersey, which was approved by the Company&#8217;s stockholders on April
15, 2021. Among other things, the A&amp;R Charter (i) changed the Company&#8217;s name to MyMD Pharmaceuticals, Inc., (ii) increased
the number of shares of Company Common Stock available from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210415__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zO5Ntc4lkiH8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-04-15_custom_MergerAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares to a total of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z6ZiiAHLaxV2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-04-16_custom_MergerAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span> shares of the Company&#8217;s
Common Stock, (iii) changed the structure of the board of directors from a classified board of three classes to a non-classified board
of a single class, and (iv) simplified and consolidated various provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of common shares are entitled to one vote per share at meetings of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2021, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210210__20210211__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2pkCf3yGxa5" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-102021-02-11_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,216</ix:nonFraction></span> shares of Common Stock issued pursuant to that certain Securities Purchase Agreement, dated November 11, 2020,
by and between the Company and certain institutional and accredited investors were cancelled and <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210211__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zVON2Wc1Xtud" title="Warrants, issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-02-11_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,216</ix:nonFraction></span> prefunded warrants (as defined
therein) were issued at the request of a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 18, 2021, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210517__20210518__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zpZhpTUJuN4j" title="Number of shares, exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-05-172021-05-18_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,216</ix:nonFraction></span> prefunded warrants were exercised in exchange for <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210517__20210518__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSMh62Tcias1" title="Number of shares, exchange"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-05-172021-05-18_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,716</ix:nonFraction></span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2021, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210804__20210805__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqHyDjK6snW5" title="Shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-08-042021-08-05_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,826</ix:nonFraction></span> shares of Common Stock with a fair market value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210804__20210805__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjBJTUDN0aki" title="Fair market value of shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-08-042021-08-05_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,002</ix:nonFraction></span> for services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2021, holders of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211208__20211209_zIJcRz0Vwft7" title="Common stock options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-12-082021-12-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,576</ix:nonFraction></span> Common Stock options were exercised for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211208__20211209_zb6LcgDzfgkk" title="Common stock options, exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-12-082021-12-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,576</ix:nonFraction></span> shares of Common Stock at an exercise
price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20211209_z5N636Vl2Gb2" title="Common stock options, exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-09" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.59</ix:nonFraction></span> per common share. The net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20221231_zJM5rIRuICzj" title="Common stock options, proceeds"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,982</ix:nonFraction></span> is recorded as a current liability on the Consolidated Balance
Sheet as of December 31, 2022. The accumulated proceeds from the exercise of these stock options will be distributed to the former shareholders
of MyMD Florida per the terms of the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2022, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220215__20220216__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zqZlm6bGPqB8" title="Number of shares, exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-02-152022-02-16_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">385,135</ix:nonFraction></span> prefunded warrants were exercised in exchange for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220215__20220216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFvnn8dNU04" title="Number of shares, exchange"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-02-152022-02-16_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">385,135</ix:nonFraction></span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2022, pursuant to a securities purchase agreement with certain institutional and accredited investors, dated August 15, 2022,
the Company issued and sold in a registered direct offering (the &#8220;August Offering&#8221;) an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817_zIoV9F8vOmsc" title="Stock issued during period share new issues"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-08-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,764</ix:nonFraction></span> shares of its
Common Stock at an offering price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20220817_zW7pfVSQyK19" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-08-17" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.25</ix:nonFraction></span> per share and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817_z0wroB98M1Ph" title="Stock issued during period share new issues"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-08-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,764</ix:nonFraction></span> unregistered investor warrants to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220816__20220817_ziWAPPdqBsff" title="Stock issued during period share new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-08-162022-08-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,764</ix:nonFraction></span> shares
of its Common Stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220817_zleGxkNuJbCf" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-17" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span>, for gross and net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220816__20220817_zlxb5qpjevtg" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-08-162022-08-17" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,999,997</ix:nonFraction></span> and $<span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_c20220816__20220817_zQxS11gU6kee" title="Net proceeds from issuance of common stock"><ix:nonFraction name="MYMD:NetProceedsFromIssuanceOfCommonStock" contextRef="From2022-08-162022-08-17" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,550,028</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFkPcvMDqjg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zUHlIhuGm3Fb" style="display: none">Summary
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term
    (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCIUzgfiGM98" title="Number of Warrants, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,074,489</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zio4pID9j5P9" title="Weighted Average Exercise Price, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgZMHVNocLqk" title="Weighted Average Remaining Contractual Term (years), Beginning"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning">4.34</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeg1CBIpIr8" title="Aggregate Intrinsic Value, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,554,827</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTLF2wpCzQbj" title="Number of Warrants, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,029</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKIQSLNimS6" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.27</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVHdIWWxZGA9" title="Weighted Average Remaining Contractual Term (Years), Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted">4.88</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVR1fnyZgg8b" title="Number of Warrants, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkL8JJxHRuK8" title="Weighted Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbmMkCqfeAW" title="Number of Warrants, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z82sk2wBeyhg" title="Weighted Average Exercise Price, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhFq1YzDwA7j" title="Number of Warrants, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,691</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgxDyxsMcYk7" title="Weighted Average Exercise Price, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">222.55</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XINGBMFcWi" title="Number of Warrants, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,514,827</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwK4Ys4Rs7K3" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.93</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNsxEbOoXQE9" title="Weighted Average Remaining Contractual Term (years), Ending Balance"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">3.63</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOoihMVONPek" title="Aggregate Intrinsic Value, Ending" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLhYk0yV4iXf" title="Number of Warrants, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,514,827</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWwnM3AQmSE4" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.93</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSgelimLgNig" title="Weighted Average Remaining Contractual Term (years), Exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1">3.63</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLblHPE20cM6" title="Aggregate Intrinsic Value, Exercisable" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z4ObSUF6dT4l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP1hRM1LsrJ2" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.15</ix:nonFraction></span></span> for the Company&#8217;s common shares on December 31, 2022 and the closing stock price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1nzKe022WFc" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.06</ix:nonFraction></span> for the Company&#8217;s common
shares on December 31, 2021. All warrants were vested on date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2022, the Company issued warrants to purchase up to <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220706__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQU4EuaCiGK5" title="Issuance of common stock for warrants, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-062022-07-07_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,265</ix:nonFraction></span>
shares of its Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxbhXdYLFmB4" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-07_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.98</ix:nonFraction></span>
to a vendor for services. The cumulative fair market value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220706__20220707_zZo0ssnvcwl5" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-07-062022-07-07" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,233</ix:nonFraction></span>
as calculated using Black-Scholes (exercise price $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220707_zZEftDmBLzYf" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-07" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.98</ix:nonFraction></span>
per share, stock price $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20220707_zxNbr8MLHmwk" title="Stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-07" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>
per share, volatility of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_c20220707__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zSfbBke4HGfi" title="Stock price per share"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-07_us-gaap_MeasurementInputOptionVolatilityMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="Days">131.06</ix:nonFraction>%</span>,
discount rate of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_c20220707__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zr27joCNfuH2" title="Stock price per share"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-07_us-gaap_MeasurementInputDiscountRateMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="Days">3.07</ix:nonFraction>%</span>
and a <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaSbziPt8nS8" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1294">five</span></span>-
year term). The warrants will be exercisable at any time and from time to time, in whole or in part, following the date of issuance
and for a term of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsZjIKIhyoj2" title="Warrants term"><ix:nonNumeric contextRef="AsOf2022-07-07_us-gaap_WarrantMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm">five
years</ix:nonNumeric></span> from the effective date. The fair-market value of the warrants was amortized over the life of the service contract.
During the year ended December 31, 2022, the Company recognized $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoY4i4YTJ5Ya" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,851</ix:nonFraction></span>
in expense which is included in Stock-Based Compensation on the Consolidated Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2022, in connection with the August Offering, the Company issued unregistered investor warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zU2rx2PcFFb9" title="Issuance of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-08-17_srt_MaximumMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,764</ix:nonFraction></span>
shares of its Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmzNJKpmXTB8" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-17_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> (the &#8220;August Investor Warrants&#8221;) in a private placement. The August
Investor Warrants will be exercisable at any time and from time to time, in whole or in part, beginning six-months following the date
of issuance and for a term of five years from the initial exercise date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-funded
Common Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zuKyqluIE4Mf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the pre-funded warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zOnA9QjAv8f1" style="display: none">Summary
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term
    (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zc3R2h01hbg9" title="Number of Warrants, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">520,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zxS5jU9uZnCd" title="Weighted Average Exercise Price, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zkh9XShkctni" title="Aggregate Intrinsic Value, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,151,796</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5hesPOZ4O36" title="Number of Warrants, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zyX1PqfGIuSg" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zoobEKmUY3bd" title="Number of Warrants, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">385,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCF1LkSgZjYb" title="Weighted Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zmGL1uFNUSye" title="Number of Warrants, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zhtkgmIBblO9" title="Weighted Average Exercise Price, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJ5ZBbB6XP2i" title="Number of Warrants, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zV1cpsQwPWZ9" title="Weighted Average Exercise Price, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCIo0kSUXXjc" title="Number of Warrants, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5NgHI1oApo6" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z1z95icvQrb3" title="Aggregate Intrinsic Value, Ending" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zIh74WklD2L5" title="Number of Warrants, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zUOX35pfcVu" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJlRxnOtpnzi" title="Aggregate Intrinsic Value, Exercisable" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zUNuvOZ3Hywa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
pre-funded warrants were vested on date of grant and are exercisable at any time. The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying award and the closing stock price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zTNgxEfajyFj" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.15</ix:nonFraction></span> for the Company&#8217;s common shares
on December 31, 2022 and the closing stock price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zTR5X61Asx47" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.06</ix:nonFraction></span> for  Common Stock on December 31, 2021.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 131 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Convertible Preferred Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zVkcq8Siov2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zdD6CFV0UyG7" style="display: none">Summary
of Warrant Activity</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    (years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Balance
    at December 31, 2021</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zXkWw4XeT4F" title="Number of Warrants, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,500</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zH1xQdMrXnx" title="Weighted Average Exercise Price, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zie5Y6BR6nB" title="Weighted Average Remaining Contractual Term (years), Beginning"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning">2.94</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z2aslaOoKOL6" title="Aggregate Intrinsic Value, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zERsFR22gIZd" title="Number of Warrants, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zeFpboMFUfAl" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z8G5iHj4p9d5" title="Number of Warrants, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1358">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zcS46sSV1Mr1" title="Weighted Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziEddDLpqo79" title="Number of Warrants, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zpUx2CcZBGhi" title="Weighted Average Exercise Price, Forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canceled/Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zBNZcL8trjOh" title="Number of Warrants, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zECF6ZiIkEEl" title="Weighted Average Exercise Price, Cancelled/Expired" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Balance
    at December 31, 2022</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zmE1ebquwRm" title="Number of Warrants, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,500</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zl7MGpBgKCCj" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zKdJFCSU5F49" title="Weighted Average Remaining Contractual Term (years), Ending Balance"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">1.94</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziJdhv0QoMl2" title="Aggregate Intrinsic Value, Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercisable
    as of December 31, 2022</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zyMSKudRgTW" title="Number of Warrants, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,500</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zx7nCp5KYcv6" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zotenN2Co6c9" title="Weighted Average Remaining Contractual Term (years), Exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt-sec:duryear" name="MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1">1.94</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zDJfQPkARKA8" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zna53PEszS7b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zMeqrFdCFUS6" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.15</ix:nonFraction></span> for the Company&#8217;s common shares on December 31, 2022 and the closing stock price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z5g7fqKqwgEc" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.06</ix:nonFraction></span> for the Company&#8217;s common
shares on December 31, 2021. All Series C Convertible Preferred Stock Warrants were vested on date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zArKxzeQ08C" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82E_zio8C6qM5kVg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zoK1Q7XEWVH1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s income tax (benefit)/provision is as follows for the years ended December 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zsV0g3b1tHg3" style="display: none">Schedule
of Income Tax (Benefit)/Provision</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220101__20221231_z0prSLIoi1sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zC7VPToJc4J5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBziYA_zKJi3HzmnZik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBziYA_z8nfiAwm8a6k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,914,000</ix:nonFraction><span style="display: none; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,219,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBziYA_zJsR53boBvA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,914,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,219,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBziYA_zG4moYR3Z8L7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income Tax Benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zDd5Dk5LOvte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfOV2YvTSGj2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December
31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zASRnJr28zp7" style="display: none">Schedule
of Reconciliation of Income Tax Rate and Benefit from Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231_zwQqHj4CXgk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20210101__20211231_zdqzOJo8RcFc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zdMn1hw0DIsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Statutory U.S. Federal Income Tax
    Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zWbi3Sd1Hgt1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">New Jersey State income taxes, net of U.S.
    Federal tax effect</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">14.5</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">9.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_ziYTR5nYljZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustment to deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.1</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_zip9QRej0Chg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.7</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zIOZtTK0kCj2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">38.9</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zGeYYSEJhCW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zwE8UBpNacK5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the Company had U.S. federal net operating loss carry forwards of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZSg2HVDhAl4"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">107.1</ix:nonFraction></span>&#160;million and
$<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOyTyWjiEUO7" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">101.9</ix:nonFraction></span>&#160;million, respectively. Approximately $<span id="xdx_90D_ecustom--OperatingLossCarryforwarddSubjectToExpiration_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_za6FQW8laGX5" title="Net operating loss carry forwards subject to expiration"><ix:nonFraction name="MYMD:OperatingLossCarryforwarddSubjectToExpiration" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">57.7</ix:nonFraction></span>&#160;million of the U.S. federal net operating loss generated in tax years beginning
before January 1, 2018 expire beginning with the year ending&#160;<span id="xdx_901_ecustom--OperatingLossCarryforwardsExpirationDateDescription_dd_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zVMzX1U9362k" title="Expiration date description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember" name="MYMD:OperatingLossCarryforwardsExpirationDateDescription">December 31, 2023 through 2037</ix:nonNumeric></span>. The remaining U.S. federal net operating
loss of approximately $<span id="xdx_902_ecustom--OperatingLossCarryforwardsNotSubjectToExpiration_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zhhSkjQTwk5b" title="Net operating loss carry forwards not to expiration"><ix:nonFraction name="MYMD:OperatingLossCarryforwardsNotSubjectToExpiration" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">49.4</ix:nonFraction></span>&#160;million does not expire, however it is limited to&#160;<span id="xdx_905_ecustom--PercentageOfNetIncomeForEachSubsequentPeriod_dp_c20171229__20180102_zI3W4bYjVAE3" title="Percentage of net income"><ix:nonFraction name="MYMD:PercentageOfNetIncomeForEachSubsequentPeriod" contextRef="From2017-12-292018-01-02" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>%&#160;of each subsequent year&#8217;s net
income. As of December 31, 2022, and 2021, the Company had U.S. state net operating loss carry forwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zMAt34nYTMJ8"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">41.0</ix:nonFraction></span>&#160;million
and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zFi18RXRvQBd"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">38.2</ix:nonFraction></span>&#160;million, respectively, some of which expire beginning with the year ending&#160;<span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationDateDescription_dd_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ztYwTGwH4eEb"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember" name="MYMD:OperatingLossCarryforwardsExpirationDateDescription">December 31, 2023 through 2042</ix:nonNumeric></span>. U.S. federal
net operating losses of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231_zvr0dPnJFE7e" title="Net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span> million expired during 2022. The timing and manner in which the Company can utilize operating
loss carryforwards in any year may be limited by provisions of the Internal Revenue Code regarding changes in ownership of corporations.
Such limitation may have an impact on the ultimate realization of its carryforwards and future tax deductions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 382 of the Code, use of the Company&#8217;s net operating loss carryforwards is limited if the Company experiences a cumulative
change in ownership of greater than&#160;<span id="xdx_90B_ecustom--CumulativeChangeInOwnershipPercentage_iI_dp_c20221231_zmZzZHunlGU7"><ix:nonFraction name="MYMD:CumulativeChangeInOwnershipPercentage" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%&#160;in a moving three-year period. The Company experienced an ownership change as a result
of the Merger and therefore the Company&#8217;s ability to utilize its net operating loss and certain credit carryforwards are limited.
The limitation is determined by the fair market value of the Company&#8217;s common stock outstanding immediately prior to the ownership
change, multiplied by the applicable federal rate. It is expected that the Merger caused the Company&#8217;s net operating loss carryforwards
to be limited. However, the limitation had no impact on the Company&#8217;s financial statements since the Company recorded a full valuation
allowance for the deferred tax assets as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxtH4Vfy0KYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of the deferred tax assets and related valuation allowances as of December 31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zopZG5pvkGKe" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowances</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20221231_zgGUYS0jpUXj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_z5ettnnAHKyd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pp0p0_maDTALNzOrT_zU3gfbiIzQ71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserves
    and other</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">745,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">179,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzOrT_zu0aQFEYrbag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    operating loss carry-forwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,176,000</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,526,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_maDTALNzOrT_zzDvfhPEYTgj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,177,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTALNzOrT_zrptaCcKFBF4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">610,000</ix:nonFraction><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">610,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzOrT_zI6OYdLPDECf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,542,000</ix:nonFraction><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,021,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzOrT_zpkpTZXujqx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,250,000</ix:nonFraction></p>
</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,336,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzOrT_zatvi99tVnZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zFzZC2LH8FC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 132 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance for deferred tax assets increased by approximately $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20220101__20221231_z9U4ZHTKzpbi" title="Change in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.9</ix:nonFraction></span>&#160;million and $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20210101__20211231_zeogcwDYqs4"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">6.2</ix:nonFraction></span>&#160;million, for the years ended December
31, 2022 and 2021, respectively, due mainly to increases in the Company&#8217;s deferred tax asset related to its net operating loss
carryforward. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some
portion or all of the deferred tax assets may be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which the net operating losses and temporary differences become deductible. Management
considers projected future taxable income and tax planning strategies in making this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files
U.S. federal income tax returns and state income tax returns. Since the Company had losses in the past, all prior years that generated
net operating loss carryforwards are open and subject to audit examination in relation to the net operating loss generated from those
years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6ATT4wXUqZ3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_824_zj0qYknxvO17">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific
Advisory Board</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2021, the Company formed the Scientific Advisory Board to (i) provide strategic advice and make recommendations to management
regarding current and planned research and development programs, (ii) advise management regarding the scientific merit of technology
or products involved in licensing and acquisition opportunities and (iii) provide strategic advice to management regarding emerging science
and technology issues and trends. During the years ended December 31, 2022 and 2021, the Company incurred costs of $<span id="xdx_90E_eus-gaap--CostsAndExpenses_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxUcjzvT6mIb" title="Cost and expenses incurred"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--CostsAndExpenses_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zCiNHjwf9Th9" title="Cost and expenses incurred"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,000</ix:nonFraction></span>, respectively.
These expenses are included in Research and Development Expenses on the Consolidated Statement of Comprehensive Loss. The Scientific
Advisory Board was disbanded effective September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China and has reached multiple other
countries, resulting in government-imposed quarantines, travel restrictions and other public health safety measures, including in the
United States and India. On March 12, 2020, the WHO declared COVID-19 to be a global pandemic. The various precautionary measures taken
by many governmental authorities around the world in order to limit the spread of COVID-19 have had and may continue to have an adverse
effect on the global markets and global economy. Such government-imposed precautionary measures may have been relaxed in certain countries
or states, but there is no assurance that more strict measures will not be put in place again due to a resurgence in COVID-19 cases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 133 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate impact of the global COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet
know the full extent of potential delays or impacts on the Company&#8217;s business, vaccine development efforts, healthcare systems
or the global economy as a whole. However, the effects have had and will likely continue to have a material impact on the Company&#8217;s
operations, liquidity and capital resources, and the Company will continue to monitor the COVID-19 situation closely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe
and/or long-term disruptions in the Company&#8217;s operations may negatively impact the Company&#8217;s business, operating results
and financial condition in other ways as well. Specifically, the Company anticipates that the stress of COVID-19 on healthcare systems
generally around the globe may negatively impact regulatory authorities and the third parties that the Company may engage in connection
with the development and testing of its product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
anticipated economic consequences of the COVID-19 pandemic have adversely impacted financial markets, resulting in high share price volatility,
reduced market liquidity, and substantial declines in the market prices of the shares of most publicly traded companies, including MyMD.
Volatile or declining markets for equities could adversely affect the Company&#8217;s ability to raise capital when needed through the
sale of shares of Common Stock or other equity securities. Should these market conditions persist when the Company needs to raise capital,
and if the Company is able to sell shares of its Common Stock under then prevailing market conditions, it might have to accept lower
prices for its shares and issue a larger number of shares than might have been the case under better market conditions, resulting in
significant dilution of the interests of the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
and Settlements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Raymond
Akers Actions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2021, Raymond F. Akers, Jr., Ph.D. filed a lawsuit against MyMD Pharmaceuticals, Inc. (p/k/a Akers Biosciences, Inc.) in the
Superior Court of New Jersey, Law Division, Gloucester County (the &#8220;First Raymond Akers Action&#8221;). Mr. Akers asserts one common
law whistleblower retaliation claim against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Court granted MyMD Pharmaceutical, Inc.&#8217;s (&#8220;MyMD&#8217;s&#8221;) Motion to Dismiss Plaintiff&#8217;s
Amended Complaint and dismissed Plaintiff&#8217;s Amended Complaint. The Court indicated that Mr. Akers is &#8220;free to file another
complaint, however, tort-based &#8216;Pierce&#8217; allegations, and/or CEPA claims are barred by the statute of limitations.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2022, Mr. Akers filed a second action against MyMD in the Superior Court of New Jersey, Law Division, Gloucester County (the
&#8220;Second Raymond Akers Action&#8221;) again asserting one common law whistleblower retaliation claim against the Company. The Company
believes that the Second Raymond Akers Action is without merit and, moreover, was filed against the Court&#8217;s specific admonition
that Plaintiff does not attempt to circumvent the statute of limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 27, 2022, the Court granted-in-part and denied-in-part MyMD&#8217;s Motion to Dismiss Plaintiff&#8217;s Complaint. The Court reaffirmed
the ruling in the First Raymond Akers Action that any tort-based Pierce claims are time-barred. However, the Court denied the Motion
as it pertained to Plaintiff&#8217;s contract-based Pierce claim and &#8220;Repayment of Monies Owed&#8221; claim. On July 29, 2022,
MyMD filed its Answer, which included affirmative defenses. As of December 31, 2022, the Second Raymond Akers Action is in the discovery
phase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
legal fees incurred were expensed as and when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 134 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zlUBvMRuBGS" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_zwbBvqt7BbK9">Related Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taglich
Brothers, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2020, the Company</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retained Taglich Brothers,
Inc. (&#8220;Taglich Brothers&#8221;) on a non-exclusive basis as a consultant to render consulting services, assist with review, and
analysis of, financial planning and budgeting matters of the Company for a term of 12 months. Pursuant to the Consulting Agreement with
Taglich Brothers, the Company agreed to pay Taglich Brothers $<span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20201122__20201123__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TaglichBrothersIncMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z0h2UJLPq08f" title="Amounts paid by related party"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2020-11-222020-11-23_custom_TaglichBrothersIncMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per month. During the year ended December 31, 2021, the Company
paid $<span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TaglichBrothersIncMember_zIkmIpLWketa"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-01-012021-12-31_custom_TaglichBrothersIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span> for consulting services to Taglich Brothers, Inc. which is included in administrative expenses on the Consolidated Statement
of Comprehensive Loss. This agreement was cancelled on August 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Schreiber, a Director, is the Managing Director of Capital Markets at Taglich Brothers. Mr. Schroeder, a former Director was the Vice
President of Investment Banking at Taglich Brothers until his death on September 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SRQ
Patent Holdings and SRQ Patent Holdings II</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
is a party to two Amended and Restated Confirmatory Patent Assignment and Royalty Agreements, both dated November 11, 2020, with SRQ
Patent Holdings and SRQ Patent Holdings II, under which MyMD (or its successor) will be obligated to pay to SRQ Patent Holdings or SRQ
Patent Holdings II (or its designees) certain royalties on product sales or other revenue received on products that incorporate or are
covered by the intellectual property that was assigned to MyMD. The royalty is equal to 8% of the net sales price on product sales and,
without duplication, 8% of milestone revenue or sublicense compensation. SRQ Patent Holdings and SRQ Patent Holdings II are affiliates
of Mr. Jonnie Williams, Sr. No revenue has been received subject to these agreements as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mr.
Jonnie Williams, Sr.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an obligation to Mr. Williams, a shareholder, for various expenses incurred on behalf of the Company between 2016 and
2019. The balance due of $<span id="xdx_906_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--MrWilliamsMember_z72ITYnqcn42" title="Due to officer"><ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent" contextRef="AsOf2021-04-28_custom_MrWilliamsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,577</ix:nonFraction></span> was paid on April 28, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Supera
Aviation I, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the Company entered a three-year leasing agreement with Supera Aviation I, LLC, a company owned by a shareholder, for a
Gulfstream IV-SP aircraft with an annual leasing fee of $<span id="xdx_901_ecustom--AnnualLeasingFee_pp0p0_c20181001__20181031__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember_zJAF8JiXjkng" title="Annual leasing fee"><ix:nonFraction name="MYMD:AnnualLeasingFee" contextRef="From2018-10-012018-10-31_custom_SuperaAviationILLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></span>. The Company incurred expenses totaling $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember_zqAVZ0tIv394" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31_custom_SuperaAviationILLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span> for the year ended
December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, the Company reached a negotiated settlement with Supera Aviation I, LLC to retire the $<span id="xdx_905_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--TypeOfArrangementAxis__custom--NegotiatedSettlementMember_zgDpKLpbu15e" title="Due to related party retired"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-04-28_custom_SuperaAviationILLCMember_custom_NegotiatedSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">627,042</ix:nonFraction></span> debt due under the leasing
agreement for $<span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--TypeOfArrangementAxis__custom--NegotiatedSettlementMember_z3soMpqhEdUa" title="Total future minimum lease payments, undiscounted"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-04-28_custom_SuperaAviationILLCMember_custom_NegotiatedSettlementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">517,384</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lines
of credit payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, Supera entered into a revolving credit facility which allows for borrowings of up to $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkVbdHT89455" title="Maximum borrowing facility"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span> with a shareholder. The
facility had an initial term of <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationPeriod_c20181101__20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zKKXO1SaWGX7" title="Line of credit facility expiration period"><ix:nonNumeric contextRef="From2018-11-012018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod">38 months</ix:nonNumeric></span>, which was extended to <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationDate1_pp0p0_dd_c20181101__20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0jTa4d6m65a" title="Expiration date"><ix:nonNumeric contextRef="From2018-11-012018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:datemonthdayyearen" name="us-gaap:LineOfCreditFacilityExpirationDate1">December 31, 2022</ix:nonNumeric></span> at which time all outstanding borrowings and accrued
interest, if any, are due in full. Borrowings accrue interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z2RZPKkT0NL7" title="Borrowings accrue interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span> per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the pre-Merger MyMD entered into a revolving credit facility which allows for borrowings of up to $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zLworK7LEbcd" title="Borrowing capacity revolving credit facility"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-05-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> with a shareholder.
<span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_pp0p0_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z5fbcYgMbTWh" title="Line of credit facility, description"><ix:nonNumeric contextRef="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember" name="us-gaap:LineOfCreditFacilityDescription">The facility had an initial term of <span id="xdx_904_eus-gaap--DebtInstrumentTerm_pp0p0_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zd3OybZpaEa6" title="Initial term"><ix:nonNumeric contextRef="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">18 months</ix:nonNumeric></span></ix:nonNumeric></span>, which was extended to July 31, 2021 and further extended to December 31, 2022, at which
time all outstanding borrowings and accrued interest, if any, are due in full. Borrowings accrue interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zTs3baJuMuAe" title="Borrowings accrued interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-05-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span> per annum.
Pursuant to the terms of the agreement, the Company must issue a number of Common Stock options to the lender based on the total borrowings
under the facility, with each dollar borrowed requiring the issuance of one Common Stock option. Upon issuance, each Common Stock option
will immediately vest at an exercise price of $<span id="xdx_906_eus-gaap--StockOptionExercisePriceIncrease_pid_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zKa6jJFPxPQj" title="Stock options exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.59</ix:nonFraction></span>. The Company recorded accretion of the debt discount totaling $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zCUmSQSyI5C6" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zv9MDJyXYa8e" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-012021-12-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">608,460</ix:nonFraction></span>, respectively,
during the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, in accordance with the Merger, the Company paid $<span id="xdx_903_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210427__20210428__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyPJPG97Msd5" title="Amounts paid by related party"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-04-272021-04-28_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,208,426</ix:nonFraction></span>, inclusive of interest and net of the debt discount, to retire
the amounts due to the shareholder under the two lines of credit as of April 28, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjkUkq543CT5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_824_zpE55G3U0wlj">Employee Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified
employees of the Company (the &#8220;401(k) Plan&#8221;). Under the 401(k) Plan, the Company matches <span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20220101__20221231_zvDSC4GBp3mk" title="Employer matching contribution, percent of match"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction>%</span> up to a <span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20220101__20221231_zPQVDxRE627k" title="Employer matching contribution, percent of employees&apos; gross pay"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span> contribution, and
<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMatchesFiftyPercentMember_zSJ7oC6zJqb4" title="Employer matching contribution, percent of match"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="From2022-01-012022-12-31_custom_FourZeroOneKPlanMatchesFiftyPercentMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction>%</span> over a <span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMatchesFiftyPercentMember_zPLeJ7dKvQvc" title="Employer Matching Contribution, Percent of Employees&apos; Gross Pay"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="From2022-01-012022-12-31_custom_FourZeroOneKPlanMatchesFiftyPercentMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span> contribution, up to a maximum of <span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMaximumFivePercentMember_zaZ806lwcc1f" title="Employer matching contribution, percent of employees&apos; gross pay"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="From2022-01-012022-12-31_custom_FourZeroOneKPlanMaximumFivePercentMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company made matching contributions to the 401(k) Plan during the years ended December 31, 2022 and 2021 of $<span id="xdx_900_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zmL40eN5GMS" title="Contributions to employee"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,443</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zIORIKftZ8gg" title="Contributions to employee"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,514</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 135 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock"><p id="xdx_802_ecustom--PaycheckProtectionProgramLoanDisclosureTextBlock_zkAUboJurTXa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12&#8212;<span id="xdx_82E_zFZSPUXbwJIj">Paycheck Protection Program Loan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2020, the Company received loan proceeds in the amount of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromLoans_c20200415__20200416__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_zULpMKTuNrX9" title="Proceeds from loans"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,600</ix:nonFraction></span> under the Paycheck Protection Program (&#8220;PPP&#8221;).
The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), provides for loans to
qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued
interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities,
and maintains its payroll levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The
unforgiven portion of the PPP loan is payable over two years at an annual interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200415__20200416__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_znwExR090ZQ3" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction>%</span>, with a deferral of payments through the
date that the Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender. The Company was notified
on June 1, 2021 that the loan totaling $<span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210601__20210601__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_zpbE5QsBole6" title="Gain on debt forgiveness"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-06-012021-06-01_custom_PaycheckProtectionProgramLoansMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,600</ix:nonFraction></span> was forgiven which was recorded as a gain on debt forgiveness on the Consolidated Statement
of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="MYMD:PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock"><p id="xdx_808_ecustom--PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_zgiUuIUWrefa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13&#8212;<span><span id="xdx_821_zbmt1Y44aPG9">Patent Assignment and Royalty Agreement</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company entered into an agreement with the holders of certain intellectual property relating to the Company&#8217;s
current product candidate. Under the terms of the agreement, the counterparty assigned its rights and interest in certain patents to
the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as defined. The agreement is effective
until the later of (1) the date of expiration of the assigned patents or (2) the date of expiration of the last strategic partnership
or licensing agreement including the assigned patents. <span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20210101__20211231_zb74UuDN8Pn5" title="Revenue::XDX::-"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20220101__20221231_zf01aOEfKrXg" title="Revenue::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1540"><span style="-sec-ix-hidden: xdx2ixbrl1542">No</span></span></span></span> revenue has been received subject to these agreements as of December 31, 2022
and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zIjPUKwOlzf8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 &#8211; <span id="xdx_828_zPmZqcfL9Qti">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On February 23, 2023,
pursuant to a securities purchase agreement with certain institutional and accredited investors, dated February 21, 2023, the
Company issued and sold in a registered direct offering i) an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNaC7wvNgPui" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span>
shares of the Company&#8217;s newly-designated Series F Convertible Preferred Stock with a stated value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zoMYnRpoinxj" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>
per share, convertible into shares of Common Stock pursuant to the terms of the securities purchase agreement, and (ii) warrants to
acquire up to an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvEzXU1vShPc" title="Warrants to acquire common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,651,885</ix:nonFraction></span>
shares of Common Stock, subject to adjustment, for gross and net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zespgBy8OXNj" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span>
and $<span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcHiMIW3vxFh" title="Net proceeds"><ix:nonFraction name="MYMD:NetProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,041,500</ix:nonFraction></span>,
respectively.</p>

</ix:nonNumeric><p id="xdx_816_zhQA4aG7wSvc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHANGE
ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
description of the capital stock of MyMD Pharmaceuticals, Inc., a New Jersey
corporation (&ldquo;we,&rdquo; &ldquo;our&rdquo; and the &ldquo;Company&rdquo;) is intended as a summary and is qualified in its entirety
by reference to our amended and restated certificate of incorporation, as amended (the &ldquo;Amended and Restated Certificate of Incorporation&rdquo;)
and the amended and restated by-laws, as amended (the &ldquo;By-laws&rdquo;) as currently in effect, copies of which are filed as exhibits
to our Annual Report on Form 10-K and are incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our authorized capital stock consists of 550,000,000 shares, of which 500,000,00
are shares of Common Stock, without par value (the &ldquo;Common Stock&rdquo;), and 50,000,000 are shares of preferred stock, without
par value, 1,990,000 of which have been designated as Series C Convertible Preferred Stock (the &ldquo;Series C Preferred Stock&rdquo;),
211,353 of which have been designated as Series D Convertible Preferred Stock (the &ldquo;Series D Preferred Stock&rdquo;), 100,000 of
which have been designated as Series E Junior Participating Preferred Stock and 15,000 of which have been designated as Series&nbsp;F
Convertible Preferred Stock (the &ldquo;Series&nbsp;F Preferred Stock&rdquo;). As of March 29, 2023, there were 39,470,009 shares
of Common Stock issued and outstanding and no shares of Series C Convertible Preferred Stock or Series E Junior Participating Preferred
Stock issued and outstanding. As of March 29, 2023, there were 72,992 shares of Series D Preferred Stock issued and outstanding,
warrants to purchase Series C Preferred Stock convertible into 27,500 shares of Common Stock outstanding and 15,000 shares of Series&nbsp;F
Preferred Stock issued and outstanding.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
stockholder has one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. A stockholder may vote
in person or by proxy. Elections of directors are determined by a plurality of the votes cast and all other matters are decided by a
majority of the votes cast by those stockholders entitled to vote and present in person or by proxy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of Common Stock
will be able to elect all of our directors. Our Amended and Restated Certificate of Incorporation and By-laws provide that stockholder
actions may be affected at a duly called meeting of stockholders or pursuant to written consent of the majority of stockholders. A special
meeting of stockholders may be called by the president, chief executive officer or the board of directors pursuant to a resolution approved
by the majority of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of outstanding shares of Common Stock are entitled to receive dividends out of funds legally available at the times and in the
amounts that our board of directors may determine, provided that required dividends, if any, on preferred stock have been paid or provided
for. However, to date we have not paid or declared cash distributions or dividends on our Common Stock and do not currently intend to
pay cash dividends on our Common Stock in the foreseeable future. We intend to retain all earnings, if and when generated, to finance
our operations. The declaration of cash dividends in the future will be determined by the board of directors based upon our earnings,
financial condition, capital requirements and other relevant factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Preemptive or Similar Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our Common Stock do not have preemptive rights, and Common Stock is not convertible or redeemable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
to Receive Liquidation Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders and remaining after payment
to holders of preferred stock of the amounts, if any, to which they are entitled, are distributable ratably among the holders of our
Common Stock subject to any senior class of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Nasdaq Capital Market Listing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;MYMD&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transfer
Agent and Registrar</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our Common Stock is Securities Transfer Corporation, 13577 Feather Sound Drive, Suite&nbsp;500, Clearwater, Florida 33762.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options,
Warrants and RSUs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 29, 2023, we had 4,176,739 shares of Common Stock issuable upon exercise of outstanding options, 5,072,432 shares
of Common Stock issuable upon the exercise of warrants, and 135,135 shares of Common Stock issuable upon the exercise of pre-funded
warrants, 27,500 shares of Common Stock issuable upon the exercise of warrants to purchase Series C Preferred Stock and an aggregate
of 263,026 shares of Common Stock issuable upon settlement of vested restricted stock units (&ldquo;RSUs&rdquo;) and upon vesting
and settlement of outstanding unvested RSUs. There are 2,795,000 outstanding RSUs and no other outstanding warrants or options at
this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue any class of preferred stock in any series. Our board of directors has the authority, subject to limitations prescribed under
New Jersey law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in
each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations
and restrictions. Our board of directors can also increase or decrease the number of shares of any series, but not below the number of
shares of that series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion
rights that could adversely affect the voting power or other rights of the holders of the Common Stock. The issuance of preferred stock,
while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the
effect of delaying, deferring or preventing a change in control of the Company and may adversely affect the market price of Common Stock
and the voting and other rights of the holders of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
C Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 29, 2023, the Company has 27,500 warrants to purchase an aggregate of 27,500 shares of Series C Preferred Stock
outstanding, with an exercise price of $8.00 per share of Series C Preferred Stock (the &ldquo;Series C Warrants&rdquo;). The Series
C Warrants were issued on December 9, 2019 and expire on January 6, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rank</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock ranks (1) on parity with Common Stock on an &ldquo;as converted&rdquo; basis, (2) senior to any series of our
capital stock hereafter created specifically ranking by its terms junior to the Series C Preferred Stock, (3) on parity with any series
of our capital stock hereafter created specifically ranking by its terms on parity with the Series C Preferred Stock, and (4) junior
to any series of our capital stock hereafter created specifically ranking by its terms senior to the Series C Preferred Stock in each
case, as to dividends or distributions of assets upon our liquidation, dissolution or winding up whether voluntary or involuntary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of the Series C Preferred Stock is convertible into one (1) share of Common Stock, provided that the holder will be prohibited
from converting Series C Preferred Stock into shares of Common Stock if, as a result of such conversion, the holder would own more than
4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the shares of Common Stock
issuable upon conversion of the Series C Preferred Stock, or, at the election of a holder, together with its affiliates, would own more
than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the shares of Common Stock issuable upon conversion of the Series C Preferred Stock. The conversion rate of the Series C Preferred Stock is subject to proportionate
adjustments for stock splits, reverse stock splits and similar events, but is not subject to adjustment based on price anti-dilution
provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to stock dividends or distributions for which proportionate adjustments will be made, holders of Series C Preferred Stock are
entitled to receive dividends on shares of Series C Preferred Stock equal, on an as-if-converted-to-common-stock basis, to and in the
same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.
No other dividends are payable on shares of Series C Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided in the Certificate of Designation of Series C Convertible Preferred Stock (the &ldquo;Series C Certificate of Designation&rdquo;)
or as otherwise required by law, the holders of Series C Preferred Stock will have no voting rights. However, we may not, without the
consent of holders of a majority of the outstanding shares of Series C Preferred Stock, alter or change adversely the powers, preferences
or rights given to the Series C Preferred Stock, increase the number of authorized shares of Series C Preferred Stock, or enter into
any agreement with respect to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series C Preferred Stock
are entitled to receive, <I>pari passu</I> with the holders of Common Stock, out of the assets available for distribution to stockholders
an amount equal to such amount per share as would have been payable had all shares of Series C Preferred Stock been converted into Common Stock immediately before such liquidation, dissolution or winding up, without giving effect to any limitation on conversion as a result
of the beneficial ownership limitation, as described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Akers
does not plan on making an application to list the shares of Series C Preferred Stock on the Nasdaq, any national securities exchange
or other nationally recognized trading system. Our Common Stock issuable upon conversion of the Series C Preferred Stock is listed on
the Nasdaq under the symbol &ldquo;MYMD&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Failure
to Deliver Conversion Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to timely deliver shares of Common Stock upon conversion of the Series C Preferred Stock (the &ldquo;Series C Conversion Shares&rdquo;)
within the time period specified in the Series C Certificate of Designation (within two trading days after delivery of the notice of
conversion, or any shorter standard settlement period in effect with respect to trading market on the date notice is delivered), then
we are obligated to pay to the holder, as liquidated damages, an amount equal to $50 per trading day (increasing to $100 per trading
day after the third trading day and $200 per trading day after the tenth trading day) for each $5,000 of Series C Conversion Shares for
which the Series C Preferred Stock being converted are not timely delivered. If we make such liquidated damages payments, we are not
also obligated to make Series C Buy-In (as defined below) payments with respect to the same Series C Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
for Series C Buy-In on Failure to Timely Deliver Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to timely deliver the Series C Conversion Shares to the holder, and if after the required delivery date the holder is required
by its broker to purchase (in an open market transaction or otherwise) or the holder or its brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the holder of the Series C Conversion Shares which the holder anticipated receiving
upon such conversion or exercise (a &ldquo;Series C Buy-In&rdquo;), then we are obligated to (A) pay in cash to the holder the amount,
if any, by which (x) the holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock
so purchased exceeds (y) the amount obtained by multiplying (1) the number of Series C Conversion Shares that we were required to deliver
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the holder,
either reinstate the portion of the Series C Preferred Stock and equivalent number of Series C Conversion Shares for which such conversion
was not honored (in which case such conversion shall be deemed rescinded) or deliver to the holder the number of shares of Common Stock
that would have been issued had we timely complied with our conversion and delivery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Subsequent
Rights Offerings; Pro Rata Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we grant, issue or sell any Common Stock equivalents pro rata to the record holders of any class of shares of Common Stock (the &ldquo;Series
C Purchase Rights&rdquo;), then a holder of Series C Preferred Stock will be entitled to acquire, upon the terms applicable to such Series
C Purchase Rights, the aggregate Series C Purchase Rights which the holder could have acquired if the holder had held the number of shares
of Common Stock acquirable upon conversion of the Series C Preferred Stock (without regard to any limitations on conversion). If we declare
or make any dividend or other distribution of our assets (or rights to acquire our assets) to holders of Common Stock, then a holder
of Series C Preferred Stock is entitled to participate in such distribution to the same extent as if the holder had held the number of
shares of Common Stock acquirable upon complete conversion of the Series C Preferred Stock (without regard to any limitations on conversion).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
Transaction</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at any time while the Series C Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
person whereby such other person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making or party
to, such stock or share purchase agreement or other business combination) (each a &ldquo;Series C Preferred Stock Fundamental Transaction&rdquo;),
then upon any subsequent conversion of Series C Preferred Stock, the holder will receive, for each Series C Conversion Share that would
have been issuable upon such conversion immediately prior to the occurrence of such Series C Preferred Stock Fundamental Transaction
(without regard to the beneficial ownership limitation), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Series C Preferred Stock Alternate
Consideration&rdquo;) receivable as a result of such Series C Preferred Stock Fundamental Transaction by a holder of the number of shares
of Common Stock for which the Series C Preferred Stock is convertible immediately prior to such Series C Preferred Stock Fundamental
Transaction (without regard to the beneficial ownership limitation). For purposes of any such conversion, the determination of the conversion
ratio will be appropriately adjusted to apply to such Series C Preferred Stock Alternate Consideration based on the amount of Series
C Preferred Stock Alternate Consideration issuable in respect of one share of Common Stock in such Series C Preferred Stock Fundamental
Transaction. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Series C Preferred
Stock Fundamental Transaction, then the holder will be given the same choice as to the Series C Preferred Stock Alternate Consideration
it receives upon automatic conversion of the Series C Preferred Stock following such Series C Preferred Stock Fundamental Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
D Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rank</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series D Preferred Stock ranks (1) on parity with Common Stock on an &ldquo;as converted&rdquo; basis, (2) senior to any series of our
capital stock hereafter created specifically ranking by its terms junior to the Series D Preferred Stock, (3) on parity with any series
of our capital stock hereafter created specifically ranking by its terms on parity with the Series D Preferred Stock, and (4) junior
to any series of our capital stock hereafter created specifically ranking by its terms senior to the Series D Preferred Stock in each
case, as to dividends or distributions of assets upon our liquidation, dissolution or winding up whether voluntary or involuntary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Series D Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series D Preferred Stock
into shares of our Common Stock, determined by dividing the stated value equal to $0.01 by the conversion price of $0.01 per share. A
holder of Series D Preferred Stock is prohibited from converting Series D Preferred Stock into shares of Common Stock if, as a result
of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our Common Stock
then issued and outstanding (with such ownership restriction referred to as the &ldquo;Series D Beneficial Ownership Limitation&rdquo;)
immediately after giving effect to the issuance of the shares of Common Stock issuable upon conversion of the Series D Preferred Stock.
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days after such notice to us. The conversion rate of the Series D Preferred Stock
is subject to proportionate adjustments for stock splits, reverse stock splits and similar events, but is not subject to adjustment based
on price anti-dilution provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to stock dividends or distributions for which proportionate adjustments will be made, holders of Series D Preferred Stock are
entitled to receive dividends on shares of Series D Preferred Stock equal, on an as-if-converted-to-common-stock basis, to and in the
same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.
No other dividends are payable on shares of Series D Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Series D Beneficial Ownership Limitation, on any matter presented to our stockholders for their action or consideration at any
meeting of our stockholders (or by written consent of stockholders in lieu of a meeting), each holder, in its capacity as such, shall
be entitled to cast the number of votes equal to the number of whole shares of our Common Stock into which the Series D Preferred Stock
beneficially owned by such holder are convertible as of the record date for determining stockholders entitled to vote on or consent to
such matter (taking into account all Series D Preferred Stock beneficially owned by such holder). Except as otherwise required by law
or by the other provisions of the Certificate of Designation of Series D Convertible Preferred Stock (the &ldquo;Series D Certificate
of Designation&rdquo;), the holders of Series D Preferred Stock, in their capacity as such, shall vote together with the holders of our
Common Stock and any other class or series of stock entitled to vote thereon as a single class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series D Preferred Stock
are entitled to receive, <I>pari passu</I> with the holders of Common Stock, out of the assets available for distribution to stockholders
an amount equal to such amount per share as would have been payable had all shares of Series D Preferred Stock been converted into Common Stock immediately before such liquidation, dissolution or winding up, without giving effect to any limitation on conversion as a result
of the Series D Beneficial Ownership Limitation, as described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
D Preferred Stock is not listed on the Nasdaq, any national securities exchange or other nationally recognized trading system. Our Common Stock issuable upon conversion of the Series D Preferred Stock is listed on the Nasdaq under the symbol &ldquo;MYMD&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Failure
to Deliver Conversion Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to timely deliver shares of Common Stock upon conversion of the Series D Preferred Stock (the &ldquo;Series D Conversion Shares&rdquo;)
within the time period specified in the Series D Certificate of Designation (within two trading days after delivery of the notice of
conversion, or any shorter standard settlement period in effect with respect to trading market on the date notice is delivered), then
we are obligated to pay to the holder, as liquidated damages, an amount equal to $25 per trading day (increasing to $50 per trading day
on the third trading day and $100 per trading day on the sixth trading day) for each $5,000 of stated value of Series D Preferred Stock
being converted which are not timely delivered. If we make such liquidated damages payments, we are not also obligated to make Series
D Buy-In (as defined below) payments with respect to the same Series D Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
for Series D Buy-In on Failure to Timely Deliver Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to timely deliver the Series D Conversion Shares to the holder, and if after the required delivery date the holder is required
by its broker to purchase (in an open market transaction or otherwise) or the holder or its brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the holder of the Series D Conversion Shares which the holder anticipated receiving
upon such conversion or exercise (a &ldquo;Series D Buy-In&rdquo;), then we are obligated to (A) pay in cash to such holder (in addition
to any other remedies available to or elected by such holder) the amount, if any, by which (x) such holder&rsquo;s total purchase price
(including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number
of Series D Conversion Shares that such holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale
price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the
option of such holder, either reissue (if surrendered) the shares of Series D Preferred Stock equal to the number of shares of Series
D Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such holder the number
of Series D Conversion Shares that would have been issued if we had timely complied with its delivery requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
E Junior Participating Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, our board of directors declared a dividend of one preferred share purchase right (a &ldquo;Right&rdquo;) for each of
our issued and outstanding shares of Common Stock, payable to the stockholders of record on September 21, 2020. Each such Right entitles
the registered holder, subject to the terms of a Rights Agreement, dated as of September 9, 2020, between the Company and VStock Transfer,
LLC (the &ldquo;Rights Agreement&rdquo;), to purchase from the Company one one-thousandth of a share of the Company&rsquo;s Series E
Junior Participating Preferred Stock, no par value with a stated value of $0.001 (the &ldquo;Series E Preferred Stock&rdquo;), at $15.00,
subject to certain adjustments. Pursuant to the Agreement and Plan of Merger, dated November 11, 2020, by and among the Company, XYZ
Merger Sub Inc., a wholly owned subsidiary of the Company, and MyMD Pharmaceuticals, Inc. (&ldquo;MYMD&rdquo;), we agreed to take any
and all necessary action to terminate such shareholder rights plan prior to closing of the merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Rights will not be exercisable until the earlier to occur of (i) the tenth business day following a public announcement or filing that
a person has, or affiliates or associates of such person have, become an &ldquo;Acquiring Person,&rdquo; which is defined as a person,
or affiliates or associates of such person, who, at any time after the date of the Rights Agreement, has acquired, or obtained the right
to acquire, Beneficial Ownership of 10% or more of our outstanding shares of Common Stock, subject to certain exceptions, or (ii) the
tenth business day (or such later date as may be determined by action of our board of directors prior to such time as any person or group
of affiliated or associated persons becomes an Acquiring Person) after the commencement of, or announcement of an intention to commence,
a tender offer or exchange offer the consummation of which would result in any person becoming an Acquiring Person (the earlier of such
dates being called the &ldquo;Distribution Date&rdquo;). Beneficial Ownership, as defined in the Rights Agreement, includes certain interests
in securities created by derivatives contracts, which are beneficially owned, directly or indirectly, by a counterparty (or any of such
counterparty&rsquo;s affiliates or associates) under any derivatives contract to which such person or any of such person&rsquo;s affiliates
or associates is a receiving party (as such terms are defined in Rights Agreement), subject to certain limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
the Distribution Date, (i) the Rights will be evidenced by the Common Stock certificates (or, for uncertificated shares of Common
Stock, by the book-entry account that evidences record ownership of such shares) and will be transferred with, and only with, such
Common Stock, and (ii) new Common Stock certificates issued after September 21, 2020 will contain a legend incorporating the Rights
Agreement by reference (for book entry Common Stock, this legend will be contained in the notations in book entry accounts). Until
the earlier of the Distribution Date and the Expiration Date (defined below), the transfer of any shares of Common Stock outstanding
on September 21, 2020 will also constitute the transfer of the Rights associated with such shares of Common Stock. As
soon as practicable after the Distribution Date, VStock Transfer, LLC (the &ldquo;Rights Agent&rdquo;) will send by first-class,
insured, postage prepaid mail, to each record holder of the Common Stock as of the close of business on the Distribution Date
separate rights certificates evidencing the Rights (&ldquo;Right Certificates&rdquo;), and such Right Certificates alone will
evidence the Rights. We may choose book entry in lieu of physical certificates, in which case, references to &ldquo;Rights
Certificates&rdquo; shall be deemed to mean the uncertificated book entry representing the Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Rights, which are not exercisable until the Distribution Date, expire upon the earliest to occur of (i) the close of business on September
8, 2021; (ii) the time at which the Rights are redeemed or exchanged pursuant to the Rights Agreement; and (iii) the time at which the
Rights are terminated upon the closing of any merger or other acquisition transaction involving the Company pursuant to a merger or other
acquisition agreement that has been approved by our board of directors prior to any person becoming an Acquiring Person (the earliest
of (i), (ii), and (iii) is referred to as the &ldquo;Expiration Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series E Preferred Stock will be entitled to a preferential per share dividend rate equal to the greater of (i) $0.001 and (ii)
the sum of (1) 1,000 times the aggregate per share amount of all cash dividends, plus (2) 1,000 times the aggregate per share amount
(payable in kind) of all non-cash dividends or other distributions other than certain dividends or subdivisions of the outstanding shares
of Common Stock. Each shares of Series E Preferred Stock will entitle the holder thereof to a number of votes equal to 1,000 on all matters
submitted to a vote of our stockholders. In the event of any merger, consolidation or other transaction in which shares of Common Stock
are exchanged, each share of Series E Preferred Stock will be entitled to receive 1,000 times the amount received per one share of Common Stock. Pursuant to the Rights Agreement, the preferential rates noted above may be adjusted in the event that we (i) pay dividends in
Common Stock, (ii) subdivide the outstanding Common Stock or (iii) combine outstanding Common Stock into a smaller number of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price payable, and the number of shares of Series E Preferred Stock or other securities or property issuable, upon exercise
of the Rights are subject to adjustment from time to time to prevent dilution (i) in the event of a stock dividend, or a subdivision,
combination or reclassification of the Series E Preferred Stock, (ii) if the holders of the Series E Preferred Stock are granted certain
rights, options or warrants to subscribe for the applicable Series E Preferred Stock or securities convertible into the applicable Series
E Preferred Stock at less than the current market price of the applicable Series E Preferred Stock, or (iii) upon the distribution to
holders of Series E Preferred Stock of evidences of indebtedness, cash (excluding regular quarterly cash dividends), assets (other than
dividends payable in Series E Preferred Stock) or subscription rights or warrants (other than those referred to in (ii) immediately above).
The number of outstanding Rights and the number of one one-thousandths of a shares of Series E Preferred Stock issuable upon exercise
of each Right are also subject to adjustment in the event of a stock split, reverse stock split, stock dividends and other similar transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
some exceptions, no adjustment in the purchase price relating to a Right will be required until cumulative adjustments amount to at least
one percent (1%) of the purchase price relating to the Right. No fractional shares of Series E Preferred Stock are required to be issued
(other than fractions which are integral multiples of one one-thousandth of a share of Series E Preferred Stock) and, in lieu of the
issuance of fractional shares, we may make an adjustment in cash based on the market price of the Series E Preferred Stock on the trading
date immediately prior to the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that a person or group of affiliated or associated persons becomes an Acquiring Person, each holder of a Right will thereafter
have the right to receive, upon exercise, Common Stock (or, in certain circumstances, other securities, cash or other assets of the Company)
having a value equal to two (2) times the exercise price of the Right. Notwithstanding any of the foregoing, following the occurrence
of a person becoming an Acquiring Person, all Rights that are, or (under certain circumstances specified in the Rights Agreement) were,
beneficially owned by any Acquiring Person (or by certain related parties) will be null and void and any holder of such Rights (including
any purported transferee or subsequent holder) will be unable to exercise or transfer any such Rights. However, Rights are not exercisable
following the occurrence of a person becoming an Acquiring Person until the Distribution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that, after a person or a group of affiliated or associated persons has become an Acquiring Person, the Company is acquired
in a merger or other business combination transaction, or 50% or more of the Company&rsquo;s assets or earning power are sold, proper
provision will be made so that each holder of a Right will thereafter have the right to receive, upon the exercise of a Right that number
of shares of Common Stock of the person with whom the Company has engaged in the foregoing transaction (or its parent) that at the time
of such transaction have a market value of two (2) times the exercise price of the Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time before any person or group of affiliated or associated persons becomes an Acquiring Person, our board of directors may redeem
the Rights in whole, but not in part, at a price of $0.001 per Right (subject to certain adjustments) (the &ldquo;Redemption Price&rdquo;).
The redemption of the Rights may be made effective at such time, on such basis and with such conditions as our board of directors in
its sole discretion may establish. Immediately upon the action of the board of directors electing to redeem or exchange the Rights, the
right to exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may, at its option, at any time after the first occurrence of a Flip-in Event (as defined in the Rights Agreement),
exchange all or part of the then outstanding and exercisable Rights for shares of Common Stock at an exchange ratio of one share of Common Stock per Right, appropriately adjusted to reflect any stock split, stock dividend or similar transaction occurring after the effective
date. However, the board of directors shall not effect such an exchange at any time after any person, together with all affiliates and
associates of such person, becomes a beneficial owner of 50% or more of the outstanding shares of Common Stock. Immediately upon the
action of our board of directors to exchange the Rights, the Rights will terminate and the only right of the holders of Rights will be
to receive the number of shares of Common Stock equal to the number of Rights held by such holder multiplied by the exchange ratio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
a Right is exercised or exchanged, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without
limitation, the right to vote or to receive dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may amend or supplement the Rights Agreement without the approval of any holders of Rights at any time so long as
the Rights are redeemable. At any time the Rights are no longer redeemable, no such supplement or amendment may (i) adversely affect
the interests of the holders of Rights (other than an Acquiring Person or an affiliate or associate of an Acquiring Person), (ii) cause
the Rights Agreement to become amendable other than in accordance with Section 27 of the Rights Agreement, or (iii) cause the Rights
again to become redeemable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Series F Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following are the principal terms of the Series&nbsp;F
Preferred Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the Series&nbsp;F Preferred Stock
will be entitled to dividends of 10.0% per annum, compounded monthly, which will be payable in cash or shares of Common Stock at the
Company&rsquo;s option, in accordance with the terms of the certificate of designation of the Series&nbsp;F Preferred Stock (the
&ldquo;Series&nbsp;F Certificate of Designation&rdquo;). Upon the occurrence and during the continuance of a Triggering Event (as
defined in the Series&nbsp;F Certificate of Designation), shares of Series F Preferred Stock will accrue dividends at the rate of
15.0% per annum. Upon conversion or redemption, the holders of shares of Series&nbsp;F Preferred Stock are also entitled to receive
a dividend make-whole payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series&nbsp;F Preferred Stock has no voting rights,
except as required by law (including without limitation, the New Jersey Business Corporation Act (the &ldquo;BCA&rdquo;)) and as expressly
provided in the Series&nbsp;F Certificate of Designation. To the extent that under the BCA the vote of the holders of shares of Series&nbsp;F
Preferred Stock, voting separately as a class or series, as applicable, is required to authorize a given action of the Company, the affirmative
vote or consent of a majority of the outstanding shares of Series&nbsp;F Preferred Stock, voting together in the aggregate and not in
separate series unless required under the BCA, represented at a duly held meeting at which a quorum is presented or by written consent
of such majority (except as otherwise may be required under the BCA) shall constitute the approval of such action by both the class or
the series, as applicable. To the extent that under the BCA holders of shares of Series&nbsp;F Preferred Stock are entitled to vote on
a matter with holders of shares of Common Stock, voting together as one class, each share of Series&nbsp;F Preferred Stock shall entitle
the holder thereof to cast that number of votes per share as is equal to the number of shares of Common Stock into which it is then convertible
(subject to certain beneficial ownership limitations) using the record date for determining the stockholders of the Company eligible to
vote on such matters as the date as of which the Conversion Price is calculated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon any liquidation, dissolution or winding-up of
the Company, whether voluntary or involuntary, the each holder shares of the Series&nbsp;F Preferred Stock shall be entitled to receive
out of the assets, whether capital or surplus, of the Company an amount per share of Series&nbsp;F Preferred Stock equal to the greater
of (A) 125% of the stated value of such share of Series&nbsp;F Preferred Stock (plus any applicable make-whole amount, unpaid late charge
or other applicable amount) on the date of such payment and (B) the amount per share such holder would receive if such holder converted
such share of Series&nbsp;F Preferred Stock into Common Stock immediately prior to the date of such payment. All shares of capital stock
of the Company shall be junior in rank to all shares of Series&nbsp;F Preferred Stock with respect to the preferences as to payments
upon the liquidation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series&nbsp;F Preferred Stock is convertible into
shares of Common Stock (the &ldquo;Conversion Shares&rdquo;). The initial conversion price, subject to adjustment as set forth in the
Series&nbsp;F Certificate of Designation, is $2.255 (the &ldquo;Conversion Price&rdquo;). The Conversion Price can be adjusted as set
forth in the Series&nbsp;F Certificate of Designation for stock dividends and stock splits or the occurrence of a fundamental transaction
(generally including any reorganization, recapitalization or reclassification of the Common Stock, the sale, transfer or other disposition
of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more
than 50% of the outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented
by the outstanding Common Stock). The Conversion Price is also subject to &ldquo;full ratchet&rdquo; price-based adjustment in the event
of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable
Conversion Price (subject to certain exceptions). If any shares of Series&nbsp;F Preferred Stock are converted or reacquired by us, such
shares shall resume the status of authorized but unissued shares of Series&nbsp;F Preferred Stock of the Company and shall no longer be
designated as Series&nbsp;F Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will be required to redeem the shares
of Series&nbsp;F Preferred Stock in 12 equal monthly installments, commencing on July 1, 2023. The amortization payments due upon such
redemption are payable, at the company&rsquo;s election, in cash, or subject to certain limitations, in shares of Common Stock valued
at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) a 80% of the average of the three lowest closing prices
of the Company&rsquo;s Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due
or (B) the Floor Price (as defined below). For purposes of the Series&nbsp;F Certificate of Designation, the &ldquo;Floor Price&rdquo;
means the lower of (x) $0.4014 and (y) 20% of the &ldquo;Minimum Price&rdquo; (as defined in Rule 5635 of the Rules of the Nasdaq Stock
Market) on the date of the Stockholder Approval (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations
or other similar events) or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Stock Market; provided that
if the amount set forth in clause B is the lowest effective price, the Company will be required to pay the amortization payment in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Exchange Cap</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series&nbsp;F Preferred Stock will not be convertible
into shares of Common Stock in excess of 19.99% of the shares of Common Stock outstanding as of the date immediately prior to the date
of the prospectus supplement under which the shares of Series&nbsp;F Preferred Stock were registered (the &ldquo;Issuable Maximum&rdquo;)
except in the event that the Company (A)&nbsp;obtains the stockholder approval for issuances of shares of Common Stock in excess of the
Issuable Maximum or (&ldquo;Stockholder Approval&rdquo;) (B)&nbsp;obtains a written opinion from outside counsel to the Company that such
approval is not required. Until such approval or such written opinion is obtained, no holder of Series&nbsp;F Preferred Stock shall be
issued in the aggregate more shares of Common Stock than such holder&rsquo;s pro rata share of the Issuable Maximum. In the event that
after July&nbsp;1, 2023, the Company has not obtained the Stockholder Approval or is not otherwise permitted to issue shares in excess
of the Issuable Maximum, then a holder of Series&nbsp;F Preferred Stock may elect to have his or her shares of Series&nbsp;F Preferred
Stock redeemed for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Optional Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series&nbsp;F Preferred Stock can be converted
at the option of the holder at any time and from time to time after the original issuance date. Holders shall effect conversions by providing
us with the form of conversion notice (the &ldquo;Notice of Conversion&rdquo;) specifying the number of shares of Series&nbsp;F Preferred
Stock to be converted, the number of shares of Series&nbsp;F Preferred Stock owned subsequent to the conversion at issue and the date
on which such conversion is to be effected, which date may not be prior to the date the applicable holder delivers by email such Notice
of Conversion to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Mandatory Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If on any day after the issuance of the shares of
Series&nbsp;F Preferred Stock the closing price of the Common Stock has exceeded 300% of the Conversion Price per share (subject to adjustment
for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) for 20 consecutive trading days and
the daily dollar trading volume of the Common Stock has exceeded $3,000,000 per trading day during the same period and certain equity
conditions described in the Series&nbsp;F Certificate of Designation are satisfied (the &ldquo;Mandatory Conversion Date&rdquo;), we shall
deliver written notice of the Mandatory Conversion (as defined below) to all holders on the Mandatory Conversion Date and, on such Mandatory
Conversion Date, we shall convert all of each holder&rsquo;s shares of Series&nbsp;F Preferred Stock into Conversion Shares at the then
effective Conversion Price (the &ldquo;Mandatory Conversion&rdquo;). If any of the Equity Conditions shall cease to be satisfied at any
time on or after the Mandatory Conversion Date through and including the actual delivery of all of the Conversion Shares to the holders,
the Mandatory Conversion shall be deemed withdrawn and void ab initio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Beneficial Ownership Limitation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series&nbsp;F Preferred Stock cannot be converted
to Common Stock if the holder and its affiliates would beneficially own more than 4.99% or 9.99% at the election of the holder of the
outstanding Common Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%
upon notice to us, provided that any increase in this limitation will not be effective until 61 days after such notice from the holder
to us and such increase or decrease will apply only to the holder providing such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other
rights or preferences that could impede the success of any attempt to change our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies
and to discourage certain types of transactions that may involve an actual or threatened acquisition of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that
may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our
shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these
provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are subject to Section 14A-10A of the New Jersey Shareholders Protection Act, a type of anti-takeover statute designed to
protect stockholders against coercive, unfair or inadequate tender offers and other abusive tactics and to encourage any person contemplating
a business combination with the Company to negotiate with our board of directors for the fair and equitable treatment of all stockholders.
Subject to certain qualifications and exceptions, the statute prohibits an &ldquo;interested stockholder&rdquo; of a combined company
from effecting a business combination with the combined company for a period of five years unless its board of directors approved the
combination or transaction or series of related transactions that caused such person to become an interested stockholder prior to the
stockholder becoming an interested stockholder or after the stockholder becomes an interested stockholder if the subsequent business
combination is approved by (i) the combined company&rsquo;s board of directors (or a committee thereof consisting solely of persons independent
from the interested stockholder), and (ii) the affirmative vote of a majority of the voting stock not beneficially owned by such interested
stockholder. In addition, but not in limitation of the five-year restriction, the combined company may not engage at any time in a business
combination with any interested stockholder of the combined company unless the combination is approved by its board of directors (or
a committee thereof consisting solely of persons independent from such interested stockholder) prior to the consummation of the business
combination, and the combination receives the approval of a majority of the voting stock of the combined company not beneficially owned
by the interested stockholder if the transaction or series of related transactions which caused the interested stockholder to become
an interested stockholder was approved by the board of directors prior to the stockholder becoming an interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;interested shareholder&rdquo; is defined to include any beneficial owner of 10% or more of the voting power of the outstanding
voting stock of the corporation and any affiliate or associate of the corporation who within the prior five-year period has at any time
owned 10% or more of the voting power of the then outstanding stock of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;business combination&rdquo; is defined to include a broad range of transactions including, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    merger or consolidation of the corporation, or any of its subsidiaries, with the interested shareholder or any other corporation
    that is, or after the merger or consolidation, would be an affiliate or associate of the interested shareholder,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) to an interested
    shareholder or any affiliate or associate of the interested shareholder of (i) 10% or more of the aggregate market value of corporation&rsquo;s
    assets, (ii) 10% or more of the aggregate market value of all the corporation&rsquo;s outstanding stock, or (iii) representing 10%
    or more of the earning power or income of the corporation, determined on a consolidated basis; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issuance or transfer by the corporation, or any of its subsidiaries, (in one transaction or a series of transactions) to an interested
    shareholder or any affiliate or associate of the interested shareholder of 5% or more of the aggregate market value of the stock
    of the corporation, or any of its subsidiaries, except pursuant to an exercise of warrants or rights to purchase stock offered, or
    a dividend or distribution paid or made, pro rata to all stockholders of the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effect of the statute is to protect non-tendering, post-acquisition minority stockholders from mergers in which they will be &ldquo;squeezed
out&rdquo; after the merger, by prohibiting transactions in which an acquirer could favor itself at the expense of minority stockholders.
The statute generally applies to corporations that are organized under New Jersey law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries
of the Registrant<SUP>1</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction
    of Organization</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Akers
    Acquisition Sub, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Jersey</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bout
    Time Marketing Corporation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Jersey</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XYZ
    Merger Sub Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florida</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>This information is as of March 29, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-234447 and 333-235359), Form S-3 (File No. 333-217390, 333-234449, 333-238631, 333-248095 and 333-254698) and Form S-8 (File No.&nbsp;333-266019) of
MyMD Pharmaceuticals, Inc. of our report dated March 31, 2023 relating to the consolidated financial statements, which
appears in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
MORISON COGEN LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blue
Bell, Pennsylvania</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christopher C. Chapman, President and Chief Medical Officer, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of MyMD Pharmaceuticals, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher C. Chapman, M.D.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    C. Chapman, M.D.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Medical Officer (Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO<BR>
SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF<BR>
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Ian Rhodes, Interim Chief Financial Officer, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of MyMD Pharmaceuticals, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ian Rhodes</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian
    Rhodes</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer<BR>
    <I>(Principal Financial and Accounting Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Annual Report on Form 10-K of MyMD Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) for the period ended December
31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, the undersigned, Christopher
C. Chapman, M.D., as the President of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher C. Chapman, M.D.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    C. Chapman, M.D., President and Chief Medical Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure
document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO<BR>
18 U.S.C. SECTION 1350<BR>
AS ADOPTED PURSUANT TO SECTION 906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Annual Report on Form 10-K of MyMD Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) for the period ended December
31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, the undersigned, Ian
Rhodes, as the Interim Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ian Rhodes</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian
    Rhodes, Interim Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial and Accounting Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure
document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>















































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#G_0P:5_X&1_XU\MTM/^S8?S/\ _M.?\J_$^H_\ A+/#G_0P:5_X&1_XT?\
M"6>'/^A@TK_P,C_QKY=HH_LV'\S_  #^TY_RK\3ZC_X2OPY_T,&E?^!D?^-'
M_"5^'/\ H8-*_P# R/\ QKY<I:/[-A_,_P !?VI/^5?B?47_  E?AS_H8-*_
M\#(_\:/^$K\.?]#!I7_@9'_C7R[11_9L/YG^ ?VI/^5?B?47_"5^'/\ H/Z5
M_P"!D?\ C1_PE?AS_H/Z5_X&1_XU\O"BC^S(?S/\ _M2?\J_$^H?^$K\.?\
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MZ*/[+A_,_P  _M6?\J_$^G/^$J\._P#0?TO_ ,#(_P#&C_A*O#O_ $']+_\
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M_ /[7G_*OO9]-1>)=!GF2&+6]-DED8(B)=(2S'@ #/)-:E?,OAS_ )&O1?\
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M?_W^;_XFOH&BCZ[5\@^HTO/[SY^_X4QXH_YZ:?\ ]_F_^)H_X4QXH_YZ:?\
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M\4?WM/\ ^_[?_$U[W11_:%;R^X/[.H>?WG@O_"G_ !1_>T__ +_M_P#$T?\
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MM-LI?*NM0M(),9V2S*IQ]":N5Y[J-Q86_P 1]2-_I$^HJ;&#:L-D;G8<MR0
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MXK<] J.>>&VA::XE2*)?O/(P51]2:RK'4KS6;+2-2TY;9;*Y3S+E9BQD52O
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M[H::!IAMO/:XGEE:>XN'&#+*QRS$=O\ ZU:U%*51RW"-.,=N@4445!H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^F#KJ-H/^VZ_XT 7:*H'6])'75+(?]O"?XTJ:WI,DJ11ZG9/(Y"JJW"$L3T
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M+W_OXO\ \31_PJ?P[_STO?\ OXO_ ,37=44?7L3_ #L/JM'^5'"_\*G\._\
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M'!YZUT]%#KU6K.3^\?)'L%%%%9%#7BCDQO16QTW#-,^S0?\ /"/_ +X%2T4
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M7:*<,)AX2YH02?HA2KU9+EE)M>H4445T&04444 %%%% !1110 4444 %%%%
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MZQ4_Y]2_\E_^2-^BL#^R?$/_ $,W_DA'_C1_9/B'_H9O_)"/_&CV4/YU^/\
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M:J"C?WGIY&=1U$OW:3?F[?HR_P"?#_SU3_OH4>?#_P ]4_[Z%9'_  B&@_\
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M?O?_ ,B:_GP_\]4_[Z%'GP_\]4_[Z%9'_"(:#_T#D_[[;_&C_A$-!_Z!R?\
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M ,!'H_X2BT_Y\]1_\!'K;HK3GI?R_C_P#'V=?_GXO_ 5_F8G_"46G_/GJ/\
MX"/1_P )1:?\^>H_^ CUMT4<]+^7\?\ @![.O_S\7_@*_P S$_X2BT_Y\]1_
M\!'H_P"$HM/^?/4?_ 1ZVZ*.>E_+^/\ P ]G7_Y^+_P%?YF)_P )1:?\^>H_
M^ CT?\)1:?\ /GJ/_@(];=%'/2_E_'_@![.O_P _%_X"O\S$_P"$HM/^?/4?
M_ 1Z/^$HM/\ GSU'_P !'K;HHYZ7\OX_\ /9U_\ GXO_  %?YF)_PE%I_P ^
M>H_^ CT?\)1:?\^>H_\ @(];=%'/2_E_'_@![.O_ ,_%_P" K_,Q/^$HM/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M , %BD_L2_\  ?\ @FW16)GQ3_<T?_ON7_"FL?%A/RC10/<RFCV/]Y??_P
M?UG^Y+_P'_@F[16!_P 5=_U _P#R+5W3?[;\U_[4_L_R]OR?9=^<^^[M2E2Y
M5?F7W_\  '#$<TE'DDO5:?F:5%%%9'0%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !3)H8[B"2&9%>*12CHPR&!&"#3Z* &HBQ1K&BA44!54= !VI
MU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0O=-EO)Q)'
MJE]:CRRGEP&/;D_Q?,A.1]<>U5SHMP3G^WM4'^KZ&'^$8/\ RS_BZGWZ8K7I
MD<L<H)C=7"DJ=IS@CJ* ,P:+<!MW]NZH?FD.,Q8^88 _U?1>H]^N::=#N#&R
M?\)!JWS1A-V8<C!!W#]WU.,'V-;%% &4=&N#,9/[<U,#S3)LS%MQ_<_U?W?U
M]ZC&A7 B"?\ "0:MD1F/=NAR3NSN_P!7][M].W>M=Y$C7<[JHSC+'%,-U;A7
M8SQ!8SM<[QA3Z'THL!G_ -C3^9O_ +<U/'F(^W,6/E&"O^KZ-U/Z8IJZ)<*
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M/6K-%%9MW=V2%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_A$]7_Z'#4_^^4IZ>%-4!/F>+M68=MH0?T-=316GMI_TE_D5SLYG_A%;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM/\ OP*/^%R>+?\ GK:?]^!1]2J>0OKM+S/HJBOG7_A<GBW_ )ZVG_?@4?\
M"X_%O_/6T_[\"CZE5\@^O4O,^BJ*^=O^%Q^+?^>MI_WX%'_"X_%O_/6T_P#
M<4?4JOD'UZEYGT317SO_ ,+B\6?\];3_ ,!Q1_PN+Q9_SUM/^_ H^I5?(/KU
M+S/HBBOG?_A<7BS_ )[6G_@.*7_A</BS_GM:?^ XI_4JOD'UZEYGT/17SQ_P
MN'Q9_P ]K3_P'%'_  N'Q9_SVM/_  '%'U&KY"^OTO,^AZ*^>?\ A<'BS_GM
M:?\ @.*/^%P>+/\ GM:?^ XH^HU?(/K]+S/H:BOGG_A<'BS_ )[6G_@.*/\
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MT?/[@_L^MY?>>%4M>Z?\*5\.?\_VK?\ ?V/_ .-TO_"E?#G_ #_:M_W]C_\
MC=/Z_1\_N%_9];R^\\*I:]T_X4KX<_Y_M6_[^Q__ !NC_A2WAW_G^U;_ +^Q
M_P#QNCZ_1\_N#^SZ_E]YX917N?\ PI;P[_S_ &K?]_8__C='_"EO#O\ S_ZM
M_P!_8_\ XW3_ +0H^?W"_LZOY?>>&4M>Y?\ "EO#O_/_ *M_W]C_ /C='_"E
MO#O_ #_ZM_W]C_\ C=']H4?/[@_LZOY?>>&T5[G_ ,*7\._\_P#JO_?V/_XW
M1_PI?P[_ ,_^J_\ ?V/_ .-T?VA1\_N#^SJ_E]YX:**]R_X4OX=_Y_\ 5?\
MO['_ /&Z/^%+^'?^?_5?^_L?_P ;H_M"CY_<+^SJ_E]YX:*6O<?^%+^'?^?_
M %7_ +^Q_P#QNC_A3'A[_G_U7_O['_\ &Z?]H4?/[@_LZOY?>>'4M>X?\*8\
M/?\ /_JO_?V/_P"-T?\ "F/#W_/_ *K_ -_8O_C=']H4?/[@_LVOY?>>'T5[
MA_PICP]_S_ZK_P!_8O\ XW2_\*8\/?\ /_JO_?V/_P"-T?VC0\_N#^S:_E]Y
MX?17N'_"F/#W_/\ ZK_W]C_^-T?\*8\/?\_^J_\ ?V/_ .-T_P"T:'G]P?V;
M7\OO/#Z!7N'_  IGP]_S_P"J_P#?V/\ ^-T?\*9\/?\ /_JO_?V+_P"-T?VC
M0\_N%_9M?R^\\0HKV_\ X4SX>_Y_]5_[^Q?_ !NC_A3/A[_G_P!5_P"_L7_Q
MNC^T:'G]P?V;7\OO/$:*]N_X4SX>_P"?_5?^_L7_ ,;H_P"%,^'_ /G_ -5_
M[^Q?_&Z/[1H>?W!_9M?R^\\2HKV[_A37A_\ Y_\ 5?\ O[%_\;H_X4UX?_Y_
M]5_[^Q?_ !NG_:5#S^X7]F5_+[SQ&BO;O^%->'_^?_5?^_L7_P ;H_X4UX?_
M .?_ %7_ +^Q?_&Z/[2H>?W!_9E?R^\\2%%>V_\ "FO#_P#S_P"J_P#?R+_X
MW1_PIOP__P _^J_]_(O_ (W1_:5#S^X/[,K^7WGB5+7MG_"F_#__ #_ZK_W\
MB_\ C='_  IOP_\ \_\ JO\ W\B_^-T_[2H>?W"_LROY?>>)TM>U_P#"F_#_
M /S_ .J_]_(O_C='_"F] _Y_]5_[^1?_ !NC^TJ'G]P?V97\OO/%*6O:O^%-
MZ!_S_P"J_P#?R+_XW2_\*<T#_G_U7_OY%_\ &Z/[2H>?W!_9F(\OO/%**]K_
M .%.:!_S_P"J_P#?R+_XW1_PIS0/^?\ U7_OY%_\;H_M.AY_<']EXCR^\\4J
M[#)$-*N(FE42&1&1-G)QD'G\:]>_X4YH'_/_ *K_ -_(O_C='_"G- _Y_P#5
M?^_D7_QNAYE0??[@668A=OO/*/#G_(UZ+_V$+?\ ]&+7TU7"6/PGT/3]1M;V
M.]U-I+:9)D5Y(]I92",X0'&17=UYN.Q$*\TX=$>G@,/.A!QGU84445PG>%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *@ G # 2(  A$! Q$!_\0
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M #J*;DB@$^M #J*3/I29...U #J*;R:3?^!Z?C0 ^BF$G/!^N:7)]/\ /K0
MZBFY('J: 3TS]/>@!U%-SSUH!)./SH =12<X["DR: '44W)X]*,GUY]Z '44
MW)Y_K2@\9SQZT +132<=_P Z7/7- "T4SGG)QZ8HW&@!]%-SZFC)H =13<\=
M12@Y% "T4F<G&:3//]* '44W)^M&3CKTH =129_.C/;O0 M%-W?GZ4 YSSF@
M!U%-R<XI<YH 6BFY/J,^E+GWH 6BF@GO1G'?\Z '44W-&3WH =132<@X- ))
MZ_2@!U%,R0>?R[TO)) - #J*:#D4 GMS0 ZBF@^^:=0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4TG!IU)SF@#PR3Q/>^'_ (M:Y?7E
M]*='C8P&,ME5=A\OZU'X,\3:_HEMXAU'4&DOC%<PM+%(W^ICD/4#VS7?ZM\,
M=)U<ZJUS//G4KF.YDQCY60\ ?6FZIX4_LBQUZ[T>Q;4;G5(UC:T=PJ@!=H()
M_.@#F?B'XLOM3TC5[/2)'MK>TD@C2\C?&^1^<?3!%<KK_BG6;_0M"L[>_GCN
M=,=5U)T;!9BP !_"O2-#^&T4?P\M- U.>03&9;FXD0Y)<'(&?0<#\*L7'POT
M:=M582SHVIS1S3%>Q3H!0!S=SH-SXM^(VO6CZ[J-E%96T#0"WEVJ&*CD^M5K
M?7O%NI?"N]-E>Q?:;&6:"YOG^\43NON?6NIUOX80:OKT^K1:YJ5A+<1)%,EL
M^T.JC'/X5NVW@_3++PC)X:M$>&RDB:-F!RQSU8GN: $\%327'@K19Y)))97M
M$+.YRS<=_>O,_'OBJ\/C*YN;'5UMH/#PC:2V\S!N23\P [X%>NZ1I4>C:-:Z
M9 [-%:Q")';K@#K]:YRR^&/AR&*^^VV::A<7LC22W%R@:3YNP/;% %'5_'NJ
M+K5AIVA:;#>&\T\WJO))M"C&:P9O&_B#7=3\&7&F0)!!?2RI<0,_5TX;\!R:
MZW1_AY9:->6=RE[<S&TM7M(UD/&QO\*BB^&FG0:?I%M!?W<;Z7=/<PS _,2Y
MRP/MVH S_#WC/2],AU^ZU6>2U@BU0V^^1RX9\#[O' K+D^U_$?QIJ=I'KMU8
M:7I\*-;I:ML:4L,[S[5W.D>#M-TDZAE?M:WUR;EUG4,%;'85F>(_AQIVO:BF
MH6]Y>Z3>B,1/+8R;/,0=%(H Y7Q+9ZM%H'AG1;GQ')<23ZB8)+RT;#,G8$CN
M*L:5;ZEX;\<W/@\:]>7%C>V#3Q3SL&>U<<9!K>OOAAI5UX<L-&M;R[L8[.4S
MI-"^9"YZDDT[2/AII>F0W_VF\O=2NK^(P37=U(3($] >U '+Z%>WOA;Q/K]A
M=:A?-:V^GM-"EX^]KEQ_RT0]A4>NZE>V?P_\/:*=5:UU/6I=S74LF/+0G<3G
MTP0*Z:U^%NGQ03I<:G?74CPBWBEF;+0Q YV#VK2O? .CZGKUMJFH1_:UM;46
MT-K,H:)0.^/6@#C]*^(EUIOPWCN5$>I:C97PTZ4;^)#G ;/O2:_XZ\1R:#XF
ML#91Z?K&FQQR;DDW#RW]#ZUT,_PJT22XN6MY);.VN)8IC;0 *@=.A K0O_ 6
MG:G?:Y=7$LV=8MTMYESP@7H1[T <]I_B"XM_%.B)K"&.<Z,;FX=)<HH ZE<<
MFJOB?Q@GBFYT+1_#6L/;VVIW#17%Y&,, HSM&>_%=3I_@2TL=3T_4'O+BZGL
M[0V8\XY$D9_O>M3Z_P"!]&U_2UL7M_L@C?S89;7Y'C?U7% ',3:)J?A+0O$D
M*>)I[ZU%D9((I7#3P/ZY]*YD6FI>#M#\-^*[?Q!?W4EY/#%<VES)O617Z[1[
M5WND_#33M,T_4X)+^]O+K48C#/=W,FZ39Z#TJGHOPFT[3+ZSN+K5=2U*.S.Z
MVM[F3,<9'3B@#$\46^I6/BZW-AKM]>:[=7B-%:0\16]M_$''TSS6)J^JZL?&
MMY>1ZG>^3#J<=NE\C_Z+"AQNC9>YKOD^&HA\176MV_B#4(KJYD#R8P<J#]WZ
M4ZY^%^E7.KR79N[M+2:X%U-8*_[F24?Q$4 -\3?$O2M&LM12QG2\U2R52UK@
MC.2!U_&L9OB-XG2:[M&\/0?:H+,7Y G^58>O)QUKL]?\(:9K^EW-E+"ENUP
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M+H?Q-U>^N-#GU#18[?3=7E:"%TERP=3U(]*]2KCK?X>:=;V.A6JW,Y71IC-
MV>6)ZAJ[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH */PHHH 2E_"BB@!.*.*6B@ XHHHH /PH_"BB@ _"DI:* $XI?PHHH /P
MI*6B@ XHHHH /PH_"BB@!*.*6B@ HHHH **** $XHXI:* "BBB@!.*.*6B@
M_"BBB@ HHHH /PH_"BB@ _"DI:* $HI:* $XHXI:* $HI:* $XI:** $XI:*
M* "DXI:* #\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDSP>*
M %HI-PY]J,T +12;L4;J %HHS10 4444 %%%% !1110 4444 %%%% !1110
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M33)$F,\<L<1P.,OT_G71MTXKA==\#WFHZE>ZC8ZHMK=3R1/"6C+",ICK]<4
M==J-ZNF6$MTT4LH3_EG$NYF/M6+;^,K"X\.7VLF&=$L=RSPL!O5AU&:HR>%-
M:FLGN9M?<:WY30K<QJ5B0'OL]?>I+3P?-%X'N/#LUU 7E4AIT0C?GJS9ZDT
M,T/XD:/K7VG>DUB8(5F/VC&"AZ$$5I_\)?HXO1!]I'E?9C<BXS^[V9]?6N6G
M^%%L+2YM+&\%O;S+$Q4J6(E3OD_PGTI)OA5%-I@LCJ!3;!L&Q3@/D'/TXZ4
M=E)XJT.*"UF?4H!%='$+9X8],4J>)=%DFN8DU&!FM5W38;A!]:X6Y^$[SV-I
M;)JD<:Q'?*OEDKOW9W+Z5-<_"TW-S?.VHK!#<1;3'!&1N;CEO7IVH [_ $_4
M[/5+87-C<)/"3C<ASS5T5S7A#PROA726M!*)))',CE1A<FND7IT_6@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F_K3J;0!DW7
MB31[2Z^SSWZ)*#@C!P#[U<GOK2".*26YB196"H6; <GH!7G_ (I)@\<6T+;6
MM)%5C&@ "G/5S[]JW/&D&F_V;I<%RX@Q>QFW*Q[@&]..E &TVOZ0AEW:E OD
MOY4F6^ZQ[?6M)3N4,&RI&0?:O%-3TK3+;4=3=-4CWK=A6@2(R!BPY8^X_*NB
MUZ'3]/O="GT_5Y6O6N88WB%R?G0@#[F?2@#TL=*!4<\PAADD()5%+$#VKG=
M\:V'B'4);.TCE62-=Q+XQ42J).P^6YU%%(#2U8@HHHH **** "BBB@ HHHH
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MZ&)'4T4W/3FESFD,=13<GVR*7-,!:*** "BBB@ HHHH **** "BBB@ HHHH
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MFW62X(:/))#^_P!*'N"V-SPW<^)I%U<(H:19OE^U+M4-D[@,=1C%:G@/SO[
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MGY3N],?K70?#^5I_#\TK0O"SW<K-$YY4D]*R?#M_XHN(=3,5O&\RRYVW,8C
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M8_ICGCO6QXFM=%CO?#[V=\9;P7D(6-IRQVX'\/;BA#9ZA1110 4444 %%%%
M!1110 48HHH YOQ'X>M]2L9KB)3'>QH3#)'P<CI7G_@.^UV[N+JT\3W4T-V&
MS92R##<>_<5[#BLS6M'AU:V\ML),AW12@<HW^%;0K6CRO_AC2-2^C,BZ!O)%
MANXUCU%%PC]$N%/H?Z5X[!%';?%:6T*WUQI)<J4?<%67';Z5ZC:WDJ7!T?5(
M\7"G*QLV/,_VXF_I7+7.NS+XKFLY$F>(_NW7R\,%'\7^][UDE*BVTKI@XU%K
M#;J>B^']2,R&QGDWS1#,;GK*G8_4="*Z$5YA'=3QRQF.16NHLO;RC@7 ]#Z/
MCJ*[O1=9@UO3TNH&PWW9(VX:-QU!':DFFKHAI+;8U:*0'(S2T""BBB@ JO<^
M?Y9^S%/,_P!OI5BF'K[XI>8'DVE#XG?\+,N1=.O]C<_?YBV]MOO7I>H"X_L:
MYVX^T>4V"G'-":OI\MV;..[B:X&08@W-6Y9%AB>61@J*,LQ["DI)O0+-;GGU
MM<ZG:16\FFK=K;M"OVQY5W%'_O =ZD&L^+L-<?91C?L$0CQ\N/\ 6'_"NOL]
M:L-0#&VN595&XEAMP/7GM5[S$W8,B[L9QGG'K57 Y31-0U^\U61+E66PBB)C
M=H\-,W],4>$/[2&I7WVTS%&&[]X>%;/3ZXKJ3-'M!$D9!!(^;.14-EJ=G?LZ
MVLRR%#AN,&@"\**** "HWY!YQQ4E1N"<@8Z=Z /.D\(Z#H_BFTU*YUV::]FE
M+0"=MW)_A!'05>\?:G&ODZ:29)9%\Q8(TS)D?Q ]J?I?@^[_ +3DU'49(5E2
M??"J+N3;]#T-1^,+N>+7;50UQ;0&W<_:;:W$K,W]P^@H$;7@R2TE\,6KV<)B
MB;)*,VX[N^?>L3Q\FL37ND1Z;?VUO&9@7BE?:[G/8]P/2MWP?)-)X8M&FMQ
MY!X";21GJ1ZFL'Q^D,EUI<=Q/Y,32C>P@WLG/W@W:DP*WA33M6D36$M]32WD
M\[:SAO.RXSEL=L\5M_#])(] E2:3S)1=RAWVXW'/)Q7->%]/T:>#5HY]5>.,
M.%#(QMSM!.&+<9R2:Z+X>1QP^'9(H7,L:W4H1]V[<,]<]ZI@CKZ*2EI#"BBC
M- !1110 48HHH 0]:R[[2A/+]KM'^S7J=)!T;V8=Q6H>M)@47L!XY\0[[0$U
M+38_$%G<6VJEP%D@&4D&>_J*VFM6TN[6>QC^SJR9DM,?*1CAD/I[5V^JZ%IF
MM(@U"RBN#&<HSKDJ?8UEW5I/9VX@NHVOM/\ X)%_UL/^-%2%.I&T5:1K3JVT
M9P?C][?Q%X(NOL\4O]IVS 1B+Y9(\]?JAK7^"^ZU\'#3;N>87L4C.\$W6,'H
M5]5JGXCLY-/L3?6DL,]HS;!.#B2,'^%O4?6J^D7\NHVD,?GK:ZI;-FRNQ]QP
M/X'/=3^E<D:WLY^Q:^952$>6_P"6QZ^O6G5SWAOQ&FM));SQ_9=4M_EN+9CT
M/]Y?53V-=!GGUS768"T449H ****  UQWCVY\4V_AR[?PW;1O<J 5;=E\=\#
MUKL#4$\\5O&9)W6- ?O,<"DVEJP5V<=\.KSQ==^'K=_$]NB3ECAG.)"O;(J[
MXEN7AU6QCDN;FWLBKES"3EFQP#QZUTD%Q%<IYD,J2)G&Y&R*AO+^SLM@NYHX
M]Y^4/WH5GL%K;G$#Q1XAL[4J]F99E^58VC.YU_OD^F*GD\4Z_#-)!-9*S1=&
M6,[9\]AZ8KN(WCEC$D;(Z,,A@<Y'M2@KD9QGMGO3 XV_U+6Y/"<-TX:*ZDE^
M98UQL7/&?0UTNARSS:):/=%S.T8+E^N?>K%S=06D/F7#I''GJQ[U.CI(BNC*
MR$9!'0T /'2BBB@ HHHH **** $Q[TT @_C3Z;B@#S#7($TC4GTR]UJVBL[N
MZ6[#/N-QG=PJ\^O'TKTM=I10"?N\$]:X;Q+X>U?5-;2<6$$R* !()BNX Y 8
M=L>U=M;K*EO&LH4.  0O3- 'D.IK;1/J:3QWLETNH8!EF"D+@DX..!C/%:?B
M.^T274- M[.R9+S[7 WFM#CY,#^.M3XA)#8V4+PV<&;FX5II9(M^67H#[GI6
M9XSUG5571$_X1YS&+N%D<,!N;CY1Z4 >IYHS7('Q/XB_Z%*Z_P"_J_XT?\)/
MXC_Z%&Z_[^K0!U^:,UR'_"3^(_\ H4;K_OZM5)?&^LPZC#8/X5NA<S*61?-7
MD#J>M '=9HS7(?\ "3^(L9_X1&Z_[^K_ (T?\)/XC_Z%&Z_[^K_C0!UV:,UR
M'_"3>(^O_"(W./\ KJO^-5(?'.L7&HW%C%X5NC<6ZJTB^:O /3O0!W>:,UR'
M_"3^(_\ H4;K_OZO^-'_  D_B/\ Z%&Z_P"_JT ==Q36!]:Y,>)O$62/^$2N
ML#TE7_&JEAXXUC4HY7M/"US(L4K0O^]7AEX(ZT =)J^BV6LVOD7D88@_)(IP
M\9]0:\CN)?$FE?$<1W$=S<:9"OE&Y2'+&/W]37H7_"3>(O\ H4;K_OZO^-(W
MB3Q#C/\ PB%P<]?WJUM1Q#I75MS2,W$QYK&UO[9I+*1"N<YB.!GMD=5;WK/T
MV_O-+UHS[=MVPQ*F<)>*.^>SC]:T=1O;S9->W'@JXB\I2[RQ2A6 ')/!K#N(
MM<US38[FQT.ZDMY4#QB5E)Q[-FLO9J4KQ=KC]V1Z1:>*M%NEC"ZA"DKD PNV
M'5O0CUK9!.[!%?.::+XOM/%=LK:%(^)%E8@ ].VZO7_^$F\1*#CPE<\?]-5_
MQJZE)PM=K7L3.*6QU^:,^U<5<^,]7L$CEO\ PQ<P6Q=4>4R*=N3Z5V8.<'KG
MD5F0.JM>6ZW<#1,[(#W0X-6>U0W%Q';1^9*VU>F<9I;Z M#B+3X<+!K[:B=2
MD9"Y8*!AAGWKK[JR\W2Y;-9#EHB@9N?Q-<[;?$30;CQ3<Z$+D>?#&'+]F/=0
M/45TMS>)!ILMX@+JD9<#H325'D*E)RW.2;PCJ,\=K+-+;I-9Q"*.-<[)5]'J
M+_A KSRI"NJ$3M)OW@M]W^YU^[6G!XL\MX$U*V\B2XA\VW6)LF0'MCUJ4>-M
M%,I3SV"J=C.5X+?W?K5$D.B^%)K#5I;^YG5UDC*) ,[8<]EYJ;0/#DFD:G<7
M<LRL'4QQHO15SFK-CXGL+_4%LH1+]IVEG0K_ *L>]4;WQ7);SW-LFGL9HYA&
MBNV XV[LT =4#2U1TR^&I:?!>(I591G'H>E7J "D(S2T4 -/& 3UKD?%,5]8
MW\>K6TMLT'DFW>*ZE\M 3_%GUKKS7*^-;.\U'3%LX=.-W$SASL895ATRIX(H
M M^$4CB\,VJ17PO57/[X'(SGD#V%97C1+8:GHKW$MZJ-/L'D8V'_ '\]16CX
M/L+C3="CM9;0VP0DJK')&?;H*T]1T^VO(D>YB\W[,WFQ(./F H X#06\+K;:
ML+VUG%MYH(^TG>I3)V[<=LYXKH?AV;=O#;FT %L;J7RL<#;GBL#PAJL<,>KR
M)HWGDS;RMJ-S#)/RG=TQ_6I?"'B:>WTF=%\/:G+F[E/R*N!STZ]J&(Z3Q)XK
M_P"$=N+2-K&6X6X?8&0_=-:,>MVC+EG93@$@CI6++XF><J9/"VJ/M.5W1IP?
MSI?^$HE/7POJISURB?XU?-"UK:FCE"UDM34U'Q%9Z?I\MXQ=TC&6"KSBH=(\
M5:=JU@EW$[1QO]T2+@GWK+N_% %G,;CPOJ8A5"9,QIC;CGOZ5%I_B>%M.@:R
M\+:BUJ4S&1&N-OYT[PY=AWAR['5+JEDW2X2G?VE9_P#/PGYUSO\ PD;G_F4]
M3_[]I_C2'Q#GKX3U/_OVG^-1H1='2K?6K_=GC/\ P*I1-&1D.I'UKB;_ ,4V
M>GVCW5YX7U&*!<;G,:\9X'>GKJT; ,OA350#R,!?\:+*X>[U.DBUW3KC4&L8
MKN-KI>L8/-:.X?A7G,$5I!J\VIQ>&-82:88)4*-OZUH'6;A5Q'HNOICMA2/Y
MU<XQZ%S4/LL[4MMZGB@\CC\J\H\3ZGJ$UWIC_9]<MB\^S&U0'[XX-=(/$FLQ
M+LBT'47P,9=5R?UH=/2Z8.&FY'\0O"\^J^&+M=(@Q?M@[$.T2<^GK7(Z#X3U
M_3?#$;WMF_V@L6>#.>/IV-=/J'BGQ.]G*MEX:O8K@_=E8*0#[C-2:-XI\0QV
M:IJOAN_DN!RTD87:1[<UJHN5&UD_7<TIRG3C9/0Y*[U%6:*YC:6TU&UXC>4%
M74?W#_>6O0/#'C&WUFV2.[9(+P+\REN&]Q69J^M:5J,R:;J/AF]ENIT+I&8U
MW$#J0<^]<%XB\(R/:RMH^FZU;<#$4N&4?0YS7/&"NDW8GD4WIH>Z1W$<V?*D
M1\<':V<5+S7C?PPDU?POIUW!>Z/J=T\K[P44$#VY-=Z/%MQC_D6M6X_V5_QJ
MJL8QE:+NC.4>5V.HSBC-8>B^(X]9N[BT-E<V=Q;@,\<X .#T/!K;[U!(N:YG
MQ1X8;7K61(KMX969>&.4X]JZ8U@:SXOT70EG^WWJQ/ F]X\'./K4N'/[I47R
MNZ*?A/PF_AZTVS7;RR!R<*?E.?:K6MZ9=W.JV5W;00SB!'1TE;'WAC(S1HGC
M+0_$,5LUC>*\DZ[ECP<CV-6=5UA[&]MK2"U:XGG!8*#T ZT*')HA2;>YRK^#
M=;2W,$%^ QY\X.1L7.3&!_6I7\)ZVDTBP7G[@G]P#(<VY[L/6MZ'Q=HTEN)W
MNA'P=P8'Y2/X2?6I%\5:,RJ5O%Y/(VG(^OI5",J7PQ=?\(W#9!Q+>1R&1G=\
M\GOS70:+82:;H]M9RRF62-,,Y[FJTGB"S&BSZI;[[F"(G[B\M]*KP>*(I]1A
MM1:RK'*P02GH'QG;0!T(I:0=*6@ HHHH **** "BBB@ I#2T4 0RK&8F,JJR
M+\S;QD#'>N1O/%.@:IXFTS0@([R1R9@X? B9>0?<UV; %2#T/%8]QX;T>[NH
M[N73X/M* JLJKM89X[4 4=!\6+KFN:GIWV1[<V;[5:0\S#^\/:NE7D<5F:?H
M.G:7=3W-I;A)IS^\<G.:U!TZ4 07EU#96[7%Q*L4*<L[=!7(VGB_0]6U_4'M
MXUG?2H"RW*O]X'[P%=G*B21E9%5D(Y##(K(_X1?15NI;E-.ACEE&V0H,;A[X
MH A\,^(?^$BL)9S:O:RQMM,9<-@=0<CVK?!XK/TK1[+1K4V^GPB&(L6*YSDU
M;21)5WQL' XRIS0!5U+4;;3(1-=2K'N;;'N.-S=A7+0>*+>'1M8\0?V0T=_;
MOY4T,;AFDQ]WD5V$]M#<QF*>%94;((9<BL,>&/#EC:O9>3%%%+D,C2XW;J -
M#0=576M&MM150AG7<R!L[3Z?45J=NM4-.MK&SM19V&P0V_R;(SG:??WJ7[9:
M@'=<Q HXC;YP,-V!]Z *.LZW#I,$@39+>["\=N7"F3'O7-CQ;9Z1H=C=V>EG
M=J$C2S1*P'EG/SDGN<]JZ:[M](UN.>SE\BZ(&UT5@63\N15.7PKX=,$5K):P
MB. JZ(7QM(Z'K0!NV\JW$*3*3LD4,OT(S4A^Z<5#)+%;1;Y9$CB4=3P!Z<TB
M3Q22M$DJ.Z %E4\C/0XH Y[Q)XEAT^&2VCM?[0;(2XA#A2BL.^>I/I4-SXG@
MT36]%T&&P:.WNHP1*3A8<]%/O6QJWAW2];,7VZVWF-Q(I4X((]<=::WAG27O
M(;Q[7S)X#NC9F)Q2L!KY/;G^E!XP>E.'3F@C-,#D=4\0VMUJ-II:V/\ :%I<
M2^7),)!A&'MUX[U/9^+([SQ1-HPM61$RJ3[ARPZC'45=N_#&DWNIPZC-:_Z3
M$"$9#M 'K@=ZDM?#NF66HR7]O:A+J10K/G)P* -8=!2$ @@X/UH'2J>H/>):
MNUC%'+.!\JR-M4T6U!:[&3!X(\/VVMG5X=-C6_W%O.[Y-;D\,=Q!)#*-R2#:
MPZ9%>:V4_P 1SXRN89?LSV42^8$)PC _PAO45WUW-=1:%/,RB.Y6$MB/YMK>
MWK53OW*E'E*:^$],$/EE)&8 ;)'<EDQT"GM0?"6C-#Y1LLH7WD;CRW][ZUS=
MOKVHV(M/L\TEW!- #=33 E;>3_ T\>-=:"F9M*_=;_*  )8<??\ ]VI).KL-
M!T_3;E[JVC/VB08:1FR6%)>Z!I]]YAGB8-(VXN&P0<8K)T'7]3U367M98(UM
M85YN A G/8KZ56N+K65M-6Q=LSPWD>PB/HAZJ/6@#K[:WBM8(X(EV(B[5'M4
M]1QDLB,23D _I4E !1110 4GX4M% "4TC+9/..E/HH PM3U;2/#5M<3SM;V^
M%,C1KA6E/MZFL5O%.E^'-#TRYM;.=HM5EW(H/W2W4L>PKH]6T#2];0IJ-A#<
MC;M^<<X]C69)X)T:2SMK/RYOL]M@1QJ_  [?2@1T2L'16'.[G@T_\:;&@C14
M4850  .P%24#.;\3>*-&T:PF2_G$AE(@:WC/SG=QT[=:A_X2&PT74=.T&&VF
M$;QJ!(#E8MWW035[5_"NAZXV=0TZ&9\YWG[P(J/_ (1+23J5K?-%*TUM_J]S
M\#'3(HZ6#H;PZXI3G'>F#!SD]?SI2<<\GOQ0!R^O:WID\UOI5S;O=6MU*(GG
MC8;(G!X!J>#Q3;3>+9O#D<$BR01AS*W"M[+ZFI+KPCH][?PW<ML5EB;S/W;%
M58^I'<BGV_AG3;;5QJBK(]TJ;0[OG'O]: -I2<<GFFR2+$A=V"HO)8G  ]Z4
M'@9Q[\TV98WB9) I1N&#=Z5@.;N-6T_5/$=GIDEK)(H!N+:[5OW9<=1Q5C0_
M%=OKU_=VL4$L1@.59^DBY(R/Q%+_ ,(AI(U0:A'%)%.J[5$;D*/<#UJ;2_#F
MG:-<7,]E&RO<'YV+9Q]*8&R!QUS4-Q<0VR&2XE6*-?XV. /K4G4=1[U%<007
M,)CN$62(XW*PR#0!R\.LV&H>(KF[DL;F.?3+=BDYZ.AY.![XK1\,>(XO%&E?
M;X89(!O*^4Y^9<=_QIEMX/TRUN;N6)[H&Z;=*GFY7VP/2KFC:)8Z#:O;V2,$
M=RS%VR2: U-3&1UJM=WL5C$9+B15'1 3RQQT'O5L=*JWME;7L7EW,:R+GY<]
M0?44DK:(#E;7Q)8"RU'Q"=,N(;I66W>-OO2G^$"NDT?5(]8TN"^B5D649*-U
M4]Q63!X)TF'27TX/=/:LS,5:7)!/O6UIMC;:780V-JI2")=J G)I@7.U8NO>
M&M+\2:>]CJ5LLD,A&\J,-QTYZULUS/B_4-<LM%NI=%M-UQ" ZLW(8#J,4XWO
MH-1;=BUX?\*Z1X7LA::9:K'&&+ MRP)]ZFU318M3N(+AYI89H 0K1^A&#^E9
M'@K4_$&HZ+;7&N6@CGN,OE>-H[<58\0W]S;ZI86L=[]D@E1V>4KGD#C\*4KW
M!JV@DG@G1Y08]CK#D.8@?E,G][ZT^7P9I4T\LW[U6GP)L-_K .@K"B\>7L-D
M))M/\QU?RMH)#R'/#XQPM3MX[NX5G6;3@9+4?O%#']X?1..:!'40:1:V^CG2
MXMRVVTJ.>0#56'PU96^HI>1M*2G*QEOEW#^+ZU4FU74Y_"#ZI&L4%R5WJA&X
M!?0CUJ>ROKZ3Q(;69T-J;1)57;@[CUH Z 4M(M+0 4444 %%%% !1110 444
M4 %&.<T44 &**** "DVBEHH :1E#]*\YBL?%<7AZZTFWLS;R)*TB3K-S,F<[
M0?X37I%-VG/7B@#R.YG\6V7B+2+&YDOI&DVL#%S'&N>5<CACCO6EXO\ #>J:
MYK5[!;JV\^3-!*20J;3T!]:]*V^](%]^.U 'DL&B>*/#>E2S)(PU2^O4+B([
ME8-PQ/I@4R?X?>(3KA82+)8-<I<R9D.9)%/#'\*]>V8Q[=*3;B@#S?1/#6M6
MNJF5+&+3YH6E+7N[=]HW=,CVJWJGAV\@N]7U"7S)VNK%8BR,?];D8*KV%=_M
MI-G3I@?SH XS5],U#Q'X!DTE[=H[K;'&=[8W8 RV:J^ ?#.LZ+J5_>:R5>:Z
MC1=P;/"\ >U=\%P<GK1B@ Q1M!I:* "BBB@!,"C I:* $%,/7@#/O3ZJ7]H;
MVU:#SI8=W\<9P10%NA*9(VD,0D4R#DJ#R*5V5$9WVA0,MD]![UP-K\.+J#Q5
M<:G)KUZ;>1 %4/\ -GW/3%=G<V#OHTUG&Y=VB**SGDGW-)7ZESC%:)W'6EQ8
M7<;?9)()4/)V8(/UJWA<C  SVQ7#?\(WJ[QVDB1);>1 (9HHG -Q[Y'2HQX7
M\2!9)$U'_2&DQS+P(L?=^OO3,SO%"Q@*  !TQZ5!+?VD2OYEU"FTA6)8=3VK
MG-#T+5+?6S>7T[&U"$00^9N\H_UI+_0;R-M3:PLX)OMLJL3(WW!MPQ />@9U
M:,KA71@RD<$'(J6J6F6BV>G6]JJLJQH!@G./QJ[0 4444 %%%% !1110 A /
M448%+10 8HHHH *:0.33J,4 <CXHOKG3-=TB\6"ZFLU++*+<;L$]"1Z5A:EX
MD\6VE[J$J6VRVCC9U5XOD2/&0X;J6]J]) (&,TUHU=2C@,A&"K#(- 'G>E^(
M]3UGP!J6HK<F5TFV17")L)3*Y('XFN?NK#Q7)K,L5HU\=-FNDF23>>%'&T>Q
MZU[#';0Q0^2D,21]T1 %_*I , *. .F* /*=2O?%>OV-[#!O7^SKQ(T>$;?.
M8'.?H 0*SX[77?L(N->M]4DCFN_-DBMV.Y,@@ 8[9Q7L<<,<"%845!UP!WJ3
MGGGK0!PX@\1S>#)+*7? YM6*3QMF8-GY5(]<=33M)U"[L==BBN7G>(V,"2JV
M3MF.?Y]Z[8#!IGDIO+A5R>IQR: /)_&%CXKF\2:@NF?:_LEVB1[E; CV\DC\
ML?C7J6FB0:7:"4,)!$H;=USCG-6<'UI<4 &T8Q1M%+10 4FT<^]+10 F*,<4
MM% #33"P(.<8]ZDQFN6\4:'KNK6=S#IVKBV61<(FW&/QH?D5%*4K-V1TV0 /
M0= *K7?V+:IO/(Z_+YN.OM7.^$_#_B'1]/M(-2UG[2L:X>,KD_3=4WB/3YY]
M4L+E+(W<$2.CH&P<D8!H7F*:2>C.@%O [>8L4;':%W[?X?3-*UK S!F@C)!X
MRO2N#.D^+;>W%O!._F8Q&X?Y4C)Y4_[7O4KZ=XLAG>*.>5XAQ V\?*>Y;U%
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MP0. ?I3Z* $'%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%)D<^U "T49%)D4 +129%+0 449HH ****
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MVL5GHS:=Y)2.<7_!9,<E,=Q7/S>%KVPL-4B@T^XN;1=6%P8&8L]S&1SS]>U
M'ITU[:P6HNI;F&.#&?-9P%QZYHM;VVOXA-97,5Q'_?B<,/TKSC4_#.KWOPML
MM'\AS=-.A,9&3%&6SR,]A6$WAKQ5H>CW=EIT,ZS->YN)K8?++'CY2B]O?WH
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M[BOL>*] '2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9]/>C=D9!R#T-<]XR0OX=GG1)IC$-RQ1,1O^N.:H^!8%.G27*EAO.W9EMGU
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M80W,LRJ^Z3K\QK*;G%^ZBXJ#7O,UKBXBM+:2XFDVQ1KN9O052LM;T^_5GAN
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MB1("<#9QS3\S,V;+PIIMAJ$5]'YC7$0VJS-T7L*TGTVWDNYKEPWF30^0W/\
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MAWQ;>>;(NHW2:E 8EE$MI&28F8GY"!7;+I]HK[EM(0QXSL%%IIMG8*ZV=K#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/AZQ/#^<X/9I2:UA14W8S/BTC3H"OEV<0([[<FKFQ0NT*-OL.E28HI -  X
MP*9)&DG#*"/I4M&*5D-,Q;?P_9VD\L]OOCEE.696JR5O(1PPF4<GLU:&!Z4A
MZ5FJ26PW-O<Y#4;?PW=:]$^HVV-0;&"WMTKH'TZV.'CS">S1G%2SZ?:7,PEE
M@1Y%Z$BF&R:/FWF:/_9ZBHC&2DWN6Y1:20SR-0B_U=RLB]EE']17GWC:QUFZ
MU^V>'3DF14&9$C#8Y]37H?FW<6/-A60>J=:J77B"TLYX()A(LDS;5&VG.7G8
M=.3B[HT[4%;6$/\ >V $>AQ4]-7!&1WIU:QM:Z,6[O46BBBJ C=E5"S$!5&3
MFN-U?XG>&M$\06^C75X3<38^=.53/3)KM'564JP!!X(KE=2^'GAC5M:@U6[T
MR-KJ#&,<*?3([TGY@=)!/%<H&@E61?536)'XKM///G02P6YE:(7$F-I8>OI6
M[#!%;H$BC6-1T"C%<^_@ZRECEAGGFDMGD:58CC"L>I]Z'N&A<_X2;1]T:&_C
M5G. #QCZ^E*?$>DYYO4R'\L#G);V]:S3X%TMOM!E>:5KF/RY2<?,O;Z8I]OX
M,T^"ZMIQ-([VY_<!L85?3WI@7#X@M5U]-)".9N[=AQFMRL/_ (1RT.N#5=\G
MG;MVWMGZUMB@!:0]:6D- '#?$ZWO;G1;9=/AU"2<39'V-]I''5O5:F^'46I6
MWA<KJJLEPLA;!4AL>_K6GXHUZ30;6"6/8S2OL"-W)Z8/;\:@\+SZI+I%VVK7
M1%QN8JS)CRACCZT <RESJ5_\04%O>74=F)0S0%=D;( <CU)SBO2)"JHY?&P#
M+?3UKS#0 LGB#3)3JM_),9'S<7,1\NXZ_+&?\]*]/;[ARN1CIUI,#Q>;5_"U
MW<7RVFFFX>*Z.7EN"I9 ><>@R?N]ZZ?6M4TRYUW0[:#3YHKC[6K>:8=HQM/?
MO7.7M_(TUT$LK>:,7@=;G[&5WL#Q&1ZUU>OZCJ<^JZ';SZ08+87:D3F0<G:>
M O44^@CNG(7+,>!UJE#K.G7+NL-[#(R'#*''%7F4'((RN,$>M8.E>$M+TB>[
MEA@#/<R%VW#IFJBH]2XJ/4V3=08SY\?_ 'T*P[KQ=96OB"#1VCD:XN!E"OW<
M=^:UO[+LMNTVZ8J%]!TQ[E)VME\U!A7[BG'D6Y4>1;F@D@.<$?3-2?A6?_8]
MIN+!7!/<.:8='BSE9IU^CFE9=R;+N:?XT=JS?[,D ^2^G7ZD&FBUU-/]7>(X
M'9UZTK+N%EW-//%(<8KFM?N?$=KI,TNGP027*_=P>OX5-I&JW0TV ZM%+'=,
M!YA$9V@U7)I<?)I<EU&P>&634]/S'=*N70?=F [$>OH:XOPAXGN_&>H:G_Q+
M#I=Y9MPV#B49QM<'K7H\5W;3C]S,CD=E;FLZ^TP2R+=V!6"]CY#*.)!Z-50<
M>5J2)3EN<O\ :7T?4Q*J-'"&VSP,/N@]<>JUS.K3MI?Q-@U-+XQXVK! /NRP
MMUKT5DM?$5N\-PK07L7RNO\ &G^*FO/#?V]AXD_X1_5(89Y$;R8+C&3"&Z<^
MG-<$W[&SZ,Z:2YW=*[ZH]&OHY+*9=:T\%T91]IA7I(G]X#U%;%O/%=0)/$X:
M-QD$?UKFO#<\MA.^DW1.U#MB.<[?8_7M5Q%&@:GMR1IUX^1_TRD_P-=*:>QS
M223T.BHIGXT\=*8@HHHH *C=E12[$!1U)Z"I*:Z*Z%74,IZ@B@#BKWXG^&;'
MQ1'H$MZ?M+D#S%&44GH":Z]9HI(3+'(KH.K#FN;N_AWX7O/$$>MRZ7&UXG3'
M"D^I'K72K''''Y<2JB]E7BC45DC"M_%UG(8Y+F&6U@EW>5,^-K[3STJX?$FD
M"1$-_&&?IS_/TK./@RS> 6\]S/)%&6:!3C]TQ.<CU--;P-I4T5PDCR.;@8E;
M@$G.?PH&:8\0Z3(Z1B[5WD?8J <L?IZ>],B\0VTFO/I&V3SUSENW%5;/PE86
M>HV^H!Y'GMUV1%L<+Z59C\.6<>MMJRO(9F8G;GC)]Z -M>G6EIJ]/ZTZ@ HH
MHH **** "H'L[>29)Y(4>5/NNPR14]% '/>,3"GA>]-Q \\6T;DC.&Z]<]L5
MS_AB.QC\6%(+B>^86*E)WF\P1*?X#QQ7<W)B6)S.RB+!#[NA!]:\\\%W6H1^
M)+BTF6SAL\-^[AB"?-GY<G^+B@#T=HHY,>8BMCIN&<4>3%S^[3DY/RCFJ][?
MVVFP+->3K%&S! 6[D] *SY?%NA0B<R:E"OV>012<_=8]* ,OX@<:9I8QQ_:,
M/'YUV%<;X^D233=**.K ZA"00>W/-=AYB#JP!^M #J*;YB?WU_.CS$_OK^=
M#L48IOF*<_,,#WH\Q/[Z_G0 ZBF^8G]]?SI/-C'\:_G0 ^BF^8O]X?G1YB?W
MU_.@!U%-\Q/[Z_G1YB?WU_.@!V**;YB]V4?C1YB?WU_.BP"X%)BCS$_OK^=(
M9$ SO7\Z '$5!-:P3LC2Q*[(<J2.E3;U[LH/UI-Z?WU_.I<4]T-.PHI:;YB?
MWU_.CS%_O#\Z:5MA/4?129I<TP(I698V94WL!D*.]>=ZWXWURQ\0)91:<$C)
M4;60L6S[BO1VQ4)CB+[F1"W<E1FLJD)2V*BTMR*PN9[F'?/;&W8]%)SQ7'?\
M)3J%F&OI)!<Q?:G@:UC3YE4=Q].YKN^<"J26FGBYD:."W$S<28 R1[U:5D)O
M4Y:3QXZ22I_9Q?[.GF3-&^1M_P!GU-2Q^-GGN+2&'3]S7; Q'?@*O^UZ'VKJ
M8["S2,(EM"H'&%0 "D2PM8F9UMHE=FW$A.I]?K5".<?7[^'Q@FG% \,DGEA%
M'W5QDL377]*K>1 DYG\M!-CE\#<1[FI4D61 Z,&0]&!XH DHQ110!#/:6]R%
M$\*2;3E=XS@TR]5#8SAT+IY;951R1CI5DG%-8@ DG '4T >5Z$NF_P!H>'VB
MDN9S([$6C7&[[*1G&5Q]:]0?HQ YQQBO.#=WEM\0!]D6P@L))@962-<R(1R2
M_P!<<=:])QD@X!'K2>P'D4MGKTB7!MXM1CC-Z3Y<DB[MV?E<'N.O%=%KT>N#
M5="-Y-;/9_:U^5%^<MM/>L;Q'X?N=/CG:2Y1(+C42\*2RD'YL88$>F#Q[UKZ
M]I=U;ZOH5Y)K4MQ&;M1Y!P%'RGD4^@'?X.?K2X%-\Q#T=?SH\Q/[Z_G0 [%&
M*;YB?WU_.C>G]X8'O0 ['%'%-$B?WU_.E\Q/[Z_G19 +Q2'UI/,3^^OYT;T_
MO#GIS2]  J&%!12N" ?K1YB8^^OYT;T_OK^=,+LHW.E6<ZG,01B/O)\I%<]H
M7A[5='N+Z8ZD\_FR?NHYCD*O]#76[ES]]?SI"R ?ZQ1[Y%7&;2L7&;2L<[?B
M;>L\L+6EVGW+F/YE/LWM7':@_@_5O%"6FI(T&O3_ "C8?E+8X(KU+]WT\Q,=
MP2.:Y74OA[X=U3Q$NN3*RWBKC*28&>Q^HJX>QG=5EZ#C5E!WAHWN9<_VK3D5
M+YBSP?(LYZE>P;W]#6SI^K1:M;OI>I##NO[N4=)!ZCT854N]-U6RR'NEOK8<
M*SJ"Q7^Z_K]:YD6EQ:&:XTT"15;)M!)EHSZKGD"N?V;CJMC6\)KL=WI6JQVD
MHT?4;F%+V(XBW.!YZ=F%="#@"OGG7KO3-<\4VMQJ%K=0WB[(W._ @(/!3ZU[
M_;RH;>,EU^Z.I]J49MNPJ^%G12E+J6**C\U!_&OYT\'FK.<6H9I'CC9D0NP'
M"#O4N<TF: /.+_QSKEOXF%@NG 1%P-NPEC[9Z5WEM/+-;&6:!H'Y^1NU2F.-
MV),:,2<_,M/Q@ =_>L8PE%W;+E)-:(X.'Q9?V<$%Y/*MX+AG5K=5P8B#@'/8
M>M69?'QB,I;36:.W7,S(<@\X^7UKJ8;/3@THAAM\L") JC)SUS4B65K&BJMK
M$J@<#:.*V,SFK3QD]WJUI816&Z2X&[>'^54]S_>]J6+7[_\ X3 Z:Z*\+2,F
MU?X%'1C72QV5I V8[:)#G<,+WI1#;Q3//Y<2RD99\#=CW]J!DZ]^*=3$=6&5
M.1ZCH:?0 4444 %%%% !1110!!<01W$;PS1B2-QM92."*S;+PQH^G7'VBVLE
M27.0Q8G!_$ULT4 <9XC\!0^()UF.JWT+B59=H8%,@^E9TOPR+F5UU3$FXK S
M1 [4)^8,/XC[UZ'VXIC[MK;#AL<9H X'Q/\ #JTU2VLQ:J[7$<L?FNTS+E%Z
MX&>M:O\ PK_PV6*B*?<.H^U/G^=9MWI'C ^+]-U.2>VN;&V#!HHF*'GVZ&IO
M"VB:MIWBK5[^[1UMKH[@7DW$MGC:.P H O#X>>'C_P L;C_P)?\ QH/P\\/
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M4)+SS6MWE!ML73\)CZ^M:8^'OAX](;@_]O+_ .-<U)X>U]_!$.EFRERLIE,
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M[MDDDF2+S ;MR1][_8_V:Z[^U; LB?;("SG"C>.30=4L1C-W"?G\O <9W>E
M'/>(M'OKG46GLA(P-JR$;R 3Z?4U?\+VUQ:6,YGA>W664O%"YR8U]*MW.M6-
MO?264LV)HHO/8;20J^M6K&^@U&RBN[9B\,HW*Q&.* +?:B@=** "D(!!SR*6
MB@##'A718[W[6NGIYH)8<G!/KC.*V@..E.HH YKQ5X8/B,6@2Z%NT#'DKNRI
MQD?7BLCQ!\/M/U2ZL9XD=G2<-,QG(^0#' S7:S"0QN(6"R$?*Q&0#V-<-_9/
MBY/&UIJMS+;W=E#"8]D+%.3U)7I0!J?\(!X<=O\ 5S$CJ!<O_C2_\*\\/?\
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M(HP?W?\ >_\ K5/?ZS>P:Q<V4:6\<:6WG1S2O@9[Y]J -?3K46.G6]J'WB)
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B0.NQN.J^GTJ_BC% %:TM(;&W6W@7;&O09SBK%+BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #F G # 2(  A$! Q$!_\0
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MS+?;D(\LKG.,]1P>GI5S1O$>EZ]ID&H6%VC031F9=_R-L!(+%3R!D'FO,X_
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M2K"$WR@*<MGH#[<9JHQYG8YL576'I.=KOHEU;V1THU?3O,VF]M]V<?ZP=:O
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M@U*QU;356[GN)$ :2)Y"<-)N 53ZX4]>M<]2OR2Y5%NQ4(2G=VTU_ ](HS7
M'4I)KB$_;[^UT^16,<BKDG;C<S==J@G'US5FVM9[B=HFUV] "[XW4JRR(>C
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M]!_TIO\ <'\S4N>.:X:S34[UI#!JPNI0 QC;A)%R<A2.5(.1S56ZN=0%W#!
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MZ9-JFI7@CNI(K6)]C7,6$DED';(_A4]?4\=*G6.ZU8O97+QI?6+;))!P)8V
MR0.VY3^!K>T^RCT^QBM(\E8UQN/5CW)]R<FL+7)QI>L/=H2&N;&2-?0R(<K^
M/S'\JUC1A"/*EH1&HYSY5\M/ZW)](LQ>:5J$D@!6^DD"C'2,#8H^F!^M1VVM
MNNAZ:D<1GU"=!&L6<?,O#,Q[*"#D_AWK9TNU%EI5K;=?*B52?4XYJKINB0Z9
M<W4X=I))G)4L/]6A.=B^V23]36JBU:Q#G%N5^^GY&=.FHV;V\&H7<=Y:7K^3
M+F/8T98'&TCMGCGFK%N'T/1KF[O%5[D\D(?O'[J*/KQ^)JYK]L]QHERL7^N1
M?,C_ -Y3N'\JSUG'B#5+/RMILK-5GE)'WI67*+^ .X_45#A'GYNO0J+YHWZ=
M?EM]X+H4J^'9(I&4ZC(WVEI%&/WP.X8]A@+]*R;C39Y-'TV[G1H;VXOA-*'/
M^K9P0 ?IA17<BL;Q0"-"EE3&Z*2.3GV=2?TS52IIJP4J\^=+JW_2]"WIMJUK
M9HLI!G<[Y6'.7/7\.U6I(HYHRCHK*PP01GBHY[ZUM81)<7,4*D9S(X7^=5=8
MU+^S]'EOH8_M#*H,<:G_ %A/  /OFBT5&QA:<I:;MF5: QZ@T4P/_$OB9VD(
M^\",(?\ OG/Y5$8IH/!UC=P*6G@Q<XQ_>R6X^C'\JOZU=QW'A>2:$C=>1+''
MCJQ?@#/XUL00I!;QQ* %10H'L!64:,4G%=3>51Q2DUUV]-_S.<NKFVT6&UU!
M&62V^S.IDSPQQO4_4G/YU'X,@FLTN8;@L99&$TFX\AW 8CVQG'X5+=>&%F?[
M/'>2QVCR>:;8HK(,,"0N>0"?YU:!,.OWF 3M6*0@<_*05/'X5A5IN#C.VS_X
M<T]I%TW!.[>_RV_,TECMK .8XL&:0NP1<EF/4_I6=>6TDMP]U8W(MPXV765^
M; Z,H_O=LGM]*TT*SW6\'<D:\'W/_P!;^=/DM8Y94D8?,I[=_K6CYZB;C:W3
M_.YPN$;69R#RS:7K]I9Z?9+)O@DD>)Y,-C(Z$_Q'WK5\,V(A@GO'M6MI+AR1
M"XPT:#(53^I_&H"JO\2%8'+1Z<<CTRXKJ !TJZ%-16G1LZJTU&$815KI?J&*
M7%+170<HF**6B@"K>6=O?6[07,22Q/C<CC(.#FHIE U*U&,C8_'Y5?JC/_R%
M+7_<D_I30[NUBA?N;7Q#I]S_ ,LYDDMWSVXW@_\ CI_.H;%4UO4I]0D3?91H
M;>W#K\L@/WW'J#]T>P/K6AJ^E0:O:I;SEU19%D^0X)P>GT/0^QJ[%$D,2QQJ
M%11@ #  ]!4V=S3VB45;?;Y&5;>'K*ST^ZLH%?RKG=OWMN(!&  3V X [53T
M*QOI9$O-80BXMA]G@0\C X,OU;]!^-=)BC HY4+VTK-/KUZ_TS%U#2KFXU..
M[M+LVNZ/RIRJ!F9<Y&,\ @YY]ZSHO#,MMK5F5N'FT^%GF*SD,ZRGIAO3J<>M
M=;@48&*B=*$_B0XUIQ5EVL9,FBV\NO1:J6;S$CV>6/NL>S'W )'XUBV5G<'Q
M=-;E"-/BE>\1@.#(0%*_@<M^-=?QQ5.QZW7_ %W;^E7RJS"-:233UTMZ%S':
MLF?0-/N;]KN>(RE@!Y;',>?[VWH3TY/I6O0?K2<5+=&:DX[.Q@ZG ^G7D.J6
M=NT@0>3<11+\SQGH0.Y4\_0FF6 DU36WOYK6:"&V3RX%G3:6=OO/CZ87\ZZ#
M;Z]*,<<4^4M5=+6UVOY%34+-+ZPN+<C E0KGT/8UA:'-+K&H"YGP!9P+"Z>D
M^<O^6!^==1CI56ULK>S,WD1JAFD,CX[L>IJ7!2W6@XU.6#77I^OX&%;:?"^N
MZC:NSHR.MS"Z-M90XPV/;(-2:7:!?$=X_FO+]GB6,N_5G<[C_P".A!^%&K22
MZ?XAM;Z&UGN/-A:"1(5W$<[E/H.01D^M7-!M9H;.::YA\JXN9GFD3<#MSP!D
M>P%+DC?8UE.7)S7W27^?Y&H\:R1LCJ&1A@@C((K%MO#=M:74$L<UP8;<DQ6[
MR;HT)&,C// SCGO6Z*7BK:3.>,Y132>YQ<JG^U7\/J2J2W@N2!_SRQO/X;QB
MI]/L/[/\5W%K(?\ 1)0UU:(>@=N) /<=<?[1KH6T^V;4UU QC[4L1A#Y_@)S
MC\ZKZO8-?V@:W=8[R!A+!(W17'K[$<'V-9RIIZOH='MT_=6B:L_7N<G%!+;V
MM_:3 K80RO*S=F(_@^G&3^ JYINARW_@:TBAF^SW+M]ICD'\!9B?_0215+49
MM2^TW]E_9LSRR+YQ6 AT)(P.>."P[CH*[>RMQ:V,$(_Y9QJOY"N+!TGS2<NF
MB]+ES7L*?NO5N_?H85^D6C:Q970PENMG+"1T'R@,/T#5IZ! 8=!M%;[S1^8W
M^\WS']35#Q;IDVJ65M';C,J7"L1ZH>''_?)-= J!0 .@&!7HI:F-2:=..NO^
M6WYF?<:/:2Z?>VT4*1"Z#&0HN-S$?>^O2H]-E_M?P_%YXPTD1CE'HP^5OU!K
M5)R*P)8+G1[Z2YL8'GL[ER\T"D;HW[NF>Q[C\12:^XF$G)<M]=T4]!M[EO$-
MQ)=@>9;PA#CU8\'_ +Y4'_@56?&=NSZ";J/ ELI4N%)_V3S^A-6/#RRR"^O)
MHI8GN;EF"2KM8* %7(^@J_J5NEWIMS;R %)4*-]#Q6<:2]GRHUE5M74GTM_P
M3'B0:CI5WJ,0R\KB2(XY(3&W^1_.K_\ ;E@UJ)4N4=G7<L:'<Q..F!S4'AN9
M/[+CL2GE7%F!#-$>JD#@_0CD'WK4\NWB)8(BL%)R  <4E"22:?J14<>=QL]'
MIZ')6.FRWUG?3P?)>Q3(82W&UT4$@^Q+,#]:O2^&HKC2+J2^2.YU*>-B\K+G
M8V.%3T4=OSJ_X9CVZ+'+CYKAWF8^NYB1^F*UB-P(]1BKA!**152O+G:71_U\
MC'TFUBG,&K[F9YK:/"GHOR\D>YZ?A4M[I_F7B3VTGD7)4@N%R&''##O4?ADD
M:'#$Q):%WB.?]EB!^F*FFU2RCNI5-U%OM8V>9 PW(,9R10H1<=41)SYVHZVT
M^06M@MDT]Q+,9I6&-Q0+M4=@!VSS6)H$*)>V990PN;+SAN'\0D+9^O[RJT=[
M?6MIJDEY*_F7EHUY$C?\LN-NP?0;#]2:TKB--+N=!D9PL<43P.3Z>7G/_CE3
M&,8I**LE_F;<LE>-[W_1&IJ.J0Z=Y2LKR3S-MAAC&6D/7CT'J3P*Y'Q#8WR6
M<>IW*J+Y[R-@J-D11J"53/YD^I-=%H=N]R6UBZR;BZ'[M6&/)B_A4?7J?<^U
M.\2@'38F(!47,6X'N"V/ZT54Y4V9QLI<BZZ-_P"1EPRIJ'CJ"=0&6"!D1AV^
M4$_^ABNIB_X^)OJO\JX[PM;O;:I;Q299Q;2NSYSG,@4?HGZ5V,8_TB?_ (#_
M "J,,VX<SZZF4HN*2>]BQ111720%%%% !65J\EP&MHH,8E=ED#,5!7:>XYZX
MZ<UJU4O+5+CRG<X,#^8OUP1_6@#GM1!.D7EO%M5[B1( $+'[S '[W?&>G%=#
M<6ZRZ?+;_P +1E/PQBLW[*-0N8#YNT6LRR$!M^X@'@D_7-;1&1BIMJS1RLHI
M>ISO@K=)X<CG?.Z9V;GV.W^E:MQI=I<WUO>3PB2:WSY;-_#GK[=JFL[2"QMD
MMK>,1Q)G:HYQDY/ZFK&:(QLDF.I4YJCFM+_D5-2M/MVG7%LI ,L3(">@)'!K
M*3PZ]U%C5[Z:Z+)M:%&,<0X[!<$_B:Z&@TVDR54DE9,YW4F^R3:9,HVI'>&(
MX[*RD#^E6/#2,='6XDSYES(\S9_VF./TQ46O6=Q?Z!?0VH#76XM#DXPP(Q6O
M9P+:V<,"\+&BJ/P&*5O>9I*2=)+K?_@D]8VMZ0FKM;1.VSRI%G!QG.U@2/QK
M:J%O^/Q?^N9_F*JU]&90DX/FCN3 8&*,4M%!(QE# @U2TK2K;1[,6MJK",,S
M?,<DDG/6K]!I6ZC3:5N@F#Q6?K%M]KTJXMAC,RE!GU(P*TJKW/W%_P!]?YTT
MKA%N+370QM-T%?),VJ)'<7TT865F7*H,8V)Z ?KUK,LR]Q+INBMDO83N92>Z
M1CY#^.Y:[%LUGQZ3!%K4^J+D32PK$P[8!SGZ_P" J7':QM&M?F<OEZ_\,8&F
MV\AU_P#L=D/V737:Y0GH0_\ JP/IE_R%=?Q3=B@[@!N/&<<TX4XQLB*E3G:?
M]>;^9$W_ !]Q_P"ZW]*I# \2MSR]J./HQ_QJZW_'W'_NM_2J<S%/$%KSP\$B
MX^A4U,]D*'7T9=B@2+<$4*&.XX]:SM5O9K6^T](VPDDI\[_<QC^9%:QKB/%]
MS<+XATNW@9@L@8.%[\$C/XJ*RJODI^[IM^9MA:7MJG+Y/\$7=/;S_B%JS;>(
M;:% WU))'Z5U8ZUR_AUUN-=UBX49#&,!O48S_6NHJZ3O"_K^8L4K5%'LE^0M
M%%%:G.%%%% !5&;_ )"EK_N2?TJ]5*;_ )"EK_N2?TIH"Y12T4@"BBB@ HHH
MH .U4K'K=?\ 7PW]*N]JI6/_ "]?]?#?THZ,"[1110 4444 %%%% $ _X^W_
M -Q?YFIJB'_'VW_7,?S-34 %%%% "44M% #=H#;L#)[TM+10!!)_Q\0?\"_E
M4]0R_P#'Q!_P+^534 %)2T4 (*@N_P#CW?\ #^=6*KW?_'L_X?SH6X%&^T6"
M\N5N1)/!.$V%[>386'7!]<=OK59O"NG.A\P3/.1@W#3-YO\ WUG].GM6]1BE
M9%JK-:)E>TMDL[2&VBSY<*!%R<G &!4_:G4E,AN[N<D-0N+-=3L[50U[)>F.
MW5N@WJ&W'V R:MMX9TY[:WLYXO-*EI&F)Q(SY!+$^YZCI5N+1DC\13ZL9&9Y
M(EC5".%QU(]R,#\*T''^DQ<_PM_2DH]S>=6S7LW;9OUL8?BG3[FZM[-[./?+
M'<(K@#_EDQ ?].?PJYK>D#6+6&W:0QJDR.Q SN4'E?Q'%:] [XHY41[:=HI=
M+_B- VC &![5C^*-P\/7#KRR-&XS[.IK:K*\1(7\/7Z@9/D,1CV&:4OA8J3M
M43?=%>SC1?$UR40*B6L:X48&2SDUK1?\?$_U7^59.D-YNK:G)G('E*/^_8/]
M:UXO^/B?ZK_*B.VA57XK>2)Z***HR"BBB@ IDG$;?3UQ3Z9)G8V,YQVH H6#
MF2:8L6)' .\-Q^'_ .NM'%4+'_7R_(RGC[P S[\5H4 %%%% !1110!7MQQ)_
MUT:K%06_23_KHU3T/< J _\ 'XO_ %S/\Q4]0G_C\7_KF?YB@":BBB@ HHHH
M *@NON+_ +Z_SJ>H+K[B_P"^O\Z%N!/1BCO10 F*,4M% %=_^/N+_=;^E4;_
M "-5TR3. 7="/7*G_"K[?\?4?^ZW]*I:J5CEL)68*%N%&3[@C^M14^'^NY=/
MXOO_ "-'/-<)KDIDUN]EP=MK$C@CJ,2)G],UJ^*M5>QNM*MHY)(Q=7(61HS@
MJF.OYD56_L]I+C78'D\V7[*%,FW&2VYNGKTK&H^>7*NG^1V8>/LE[27VEI]Z
M3)O"$#VUWK,+G(CN553ZC8#_ %%=77-^$IA=0WUTO2>X+C_OE1_2NDQ6U.*C
M%)'/BFW5DWOI^2%HHHJS **** "J4W_(4M?]R3^E7:I3?\A2U_W)/Z4T!=HH
MHI %%%% !1110 =JI6/_ "]?]?#?TJ[VJE8_\O7_ %\-_2CHP+M%%% !1110
M 4444 0C_C[;_KF/YFIJA'_'VW_7,?S-34, HHHH **** "BBB@""3_CX@_X
M%_*IZ@D_X^(/^!?RJ>@ HHHH *KW?_'L_P"'\ZL57N_^/9_P_G0MP+%%%% !
M1BBB@ Q4+_\ 'U%_NM_2IJA?_CZB_P!UOZ4 34444 )534D\W3+I/[T3C]#5
MNHYAF%U]5(_2ACB]4<YX-9Y[2[N7;<9)5Y^D:BN@B_X^9_JO\JYWP'')'X7B
M:4C>\LA./9BO]*Z*+_7S_4?RJ8?"C;$Z5I+L[?<6****HP"BBB@ J&X&8).,
M_*>V?TJ:H+K;]EEW9V[3GK_3F@"II\9CEERJKO ; 39^G]:TJSM/QYTI!4@@
M?=!'\ZT: "BBB@ HHKEM4UZYTW7'#[3:1P&0QJ,LPQGC_:)X H Z*WZ2?]=&
MJ>J&F745[8+=0G,4WSKGK@]C[]JOT/< J$_\?B_]<S_,5-4)_P"/Q?\ KF?Y
MB@":BBB@ HHHH *@NON+_OK_ #I\LJ0Q-)(=J(I9B>P%9MAJL&M:1;W]NLB)
M*X^20892&P01V--;@:W>BCO12 ***QO$=Y<V&EM-:LJMN +'D@>PH TF_P"/
MJ/\ W6_I6/XN@:;PW<E&VO&4E5L]"K YK)U#Q-,RM';XCNK8HLS8RK;@#\GJ
M >#Z&NCOHGN]#GC<*));=@0O(R5[4IJ\;%TI<LXR[-'*7B-X@U+;]V:*TD4#
MLL@ S_X\P_*M;PQ-_:*ZC>MR)Y$ ]@(U&/SS46@,+O5X[M=H!T^)FVC&7<DL
M3[_**U=$TE='M)K97#*]Q)*,#& S9Q^%8TX-:G96JQY'#M:WEJ[E/P=:266B
M+;RJRR(S@AA@_?;'Z8KHJ@B_X^9O^ _RJ?-;I65CBJ3<Y.3W8M%%%!(4444
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MV]&>.WF)W')/'!]ZZ#%4+JP6>[2Y!'F1PO&H('\7\NE &?;VTUU#;W"+M1[
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M?CSM@\S;TW8YQ^- $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!2U.*.?3;B*61HT>,JSIU48ZBN!&GZ!876G6]
MQJU\TH4E(%#8D&7Y(']WD^V*[[4GGCTZ=[6%9IPA,<;=&/85Q]I<^(IWL#)X
M<LDE(.Z>1<>2 6XQU&1C\S7+*,OK$9=+/H_SV'[>R]CKKKY:%C2TTY=4NO[/
MO[B27[-AXIPV$CPN7'?)^4CUYK'CCT+^R,#Q)??9LCGYM^_ PV/0+\OIGWK?
MA^V-?W'V_38+:/RP4N(24,K<;8R0<D#Y@<\'BL])-2%G@^$K;[3Y?^I ^01Y
M&1C^\6Y^@]JZA%[2(]/%[:?9KVX:7&81)&0'79U/J2,\GT]JH:K#HPOI6N=5
MNH96=]RQQE0,$YX]AD_AFM731>+/']HTBWAB9RTK1Q%2C;1@#UY &??VJK=G
M59=197\/VEP@D(\YHNJ[LCK^ _7I0!7U6+3!I5J+G7+NU@"J B+M;.YL-@=.
MX_"NRL/+_L^V\DL8O*386ZE<#&?>N7D2ZFUZWM$\+6_]GH1$US,H.U023M'I
MG;C\:[!5"J%4  #  ["@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 'I3:=1B@!*7%%% "8HQ2T4 )BEHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )> G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRD9,41< H&;L3D8^O- '3T5SUKXNT^]U<:= )]S,Z0S-'B.9D^^%;OCG\JW
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M+:Y_X,YO_BJ/^$2MO^@MKG_@SF_^*KH** .?_P"$2MO^@MKG_@SF_P#BJ/\
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M":X;0=<B\3:GI\,\]E>(=+^U2HBJVR;S  ?]GC/%=RI!48H 6BBB@#(\5?\
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M073I):0/"$89 !CV#;W'/)]:HF_\1VJZ?:331R37-O+--<"'[GEG)PO3+!E
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M-ISZC&/QJ<Z9J 32K>0PR+!=&:2=."J\D<'N2<?C71;!^5&WIUX[T /HHHH
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M=XH>W$$KQR*9X_,#81EVD9&",@BH]&\;WFHZS:0S6EJMG?22QP+%+NGB*?\
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M_<;^5 '#"&.'X3:5Y<:(&CL"=B@9/F1<G'>N^KA9/^22Z1_UQT__ -&Q5W5
M#7.$)Y_ 5Y?XVNH=2UN.-+F588D-O<QF&7INW-M*\'<0%)]!7J+_ '37G'Q
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MI_Z"*S/$4T5QX)U>:&19(I-.F9&4Y!!C."#6GIW_ "#+7_KBG_H(H LT444
M%%%% !1110 4444 %%%% !111D>M !7.^!_^1)TC_KB/YFNAR,XR,USW@?\
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MBB@ HHHH P+K^Q= N[O5;^>*$WKHCM+R"R@X"CKTJCKFI:-J?@S4YXI7GLT
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M.[W(C:%6#G&S:<[5(XS[5WNG?\@VU_ZXI_Z"*I>*O^10UK_KPG_]%M5[3O\
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M!X6:Y&=3UK4[TG[RB7R8S]47BNEP*, =J ,JQ\-:+I^/LNF6R'^\4W'\S6J
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MUC3+;X@P+<:C:0LFF2QL))U4JYEC(4@G@XYKHM2TRPU& QWMG#<*1C]XH)_
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MKHZY[QDH7PQ+C_GYM?\ T?'70T %%%% !1110 4444 %%%% !6!;?\C[J?\
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MO^;;M;ZXXIU<2? >F'Q)&XL3_9HLV4H+J3'F[Q@XW9^[GFM3_A!?#G_0./\
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MDK2FZ474@W93Y.-W/S4 =K@>E&!Z5SW_  @OAS_H''_P(E_^*H_X07PY_P!
MX_\ @1+_ /%4 =#@>E-9MH^Z3]!6!_P@OAS_ *!Q_P# B7_XJLS6? NERV &
MGV)6?SX22+J13L$B[QDM_<W#'O0!V>!_D4H'^<5SH\"^&\?\@X_]_P"7_P"*
MI?\ A!?#G_0./_@1+_\ %4 =#@?Y%1N""2-WX5S[>"/#0S_Q+B<=?](DX_\
M'JH:AX4\,F*\M+6"-;Y+5I$3[7(&3((5C\W R.IH DN_ \5[XF36Y-0G'[U)
M6M?L\?EMMQC=\N2>/O=1V-:'A[_D->)?7[>G_HB*L#PYX>\(ZKI,(A$-Y<PP
MHETT=W(^)-O.2&YR0>:Z_2-&T_1;>2'3K5;=)'WN Q8LV ,DDDG@#\J -"BB
MB@ HHHH **:6 />C>.?:@!U% .1FB@ HHHH *R?$OGGP[J"6H8W#6[B,+U)P
M>GO6M32,MF@#SWP.;&37VET>*-+)-+@BN/*3://!'#?[0&<]Z]"4Y]::D2H,
M*BKDY.T 9-/ P.: %IK L,4ZB@!BIM8GCGTI]%(QPI- ";A06!'!_&LK6M6_
ML>WMKAH"\<ES' Y#8\O><;O?DBL"7Q];*^NHMK(6TUT2++_\?)+[/E]/GR/P
MH [  !@V.!W J7/UK'MO$FDW%^VG"_@%]&I,D(;[I RPST..]4;CQKI(L_/T
M^XCO2MS# ZHQ4KYCA=W/4<]J .GHK"F\9>'H%1I-5A"NS(K<D$J<-T'0'C/2
MKVH:UINE6@NKZ[CA@8A58G.XGH!CK^% '%?$*-FUO16GNH+:P6.<//<P^;$L
MA V@@\;CR ?KWKH_"4CR^$M+:2V^RR&V7, ! 3VP>1Z\U4_X2RRO_$=CH^GK
M%?"XA-S)-Y@V11YP, CDD]O8UH-XDT^WEU-;J00)IK()I'SM^89&/SQ0!N#I
M2;O8UD0^*=$FO6LH]2@:Y5-Y3.. ,GD\<#G':J$_C;0SIUS>VEY'=+;["ZQY
M!VLX7=R.1SU'I0!T;+O''0TY%VH%[ 8XK'N_%N@Z?=FTN]3ACN GF>6<YQC/
M8=<<XZT3>+M @6T:75;=5NUWP')PZYQGV&3WH V2P7KQ[T Y%95QKVEQ:HFF
MR7T*7D@RD1SEN,CVSCG%.\/:Q%KVB0:C$CQK+N^1^64@D8/Y4 :3*6_^O0B[
M0?<TZB@ HHHH YKQ[ID6J>$;Y)O-(BC,@2-B-Y X!QU'M7&>)9M#F%EI<L<$
M>I7FGPK-?7666TA '* _\M"<XQCU/2O5G7< , ^QJ-K='/SQQGW*@T );!%C
MC5&+*$&TL<DCUJ>FJN/_ *U.H **"<#--W #- #J*0$&EH **** "BBB@ HH
MHH \_P#&/E6WB*2XO+2:XMKC29;2#9 TH,Q8G;@ X)!'/ZUUWAZWFM/#>F6]
MSD3Q6L:2 G)#!0"*OLA)R#3AT&: %HHHH 8\>^G 8Z]:6B@!"P%(7 (R#S^E
M##+"N/U?QNND66K2-8R2W&GW2P+ K<S!E#;A^&X_\!H [ _,..#^M(B!!VXX
MXKG1XRTZ*\NUN76&SMHH7-TS9#/(,A !R3C!_&K-UXMT"VM+:YFU2!(;G/E-
MR=V.IP!D8]Z -L$''O2US\/BO3QJEU9W,L<'ES1Q1.6SYQ=0PP/\BKNF>(=)
MUF6:+3[V.X>$ NJ@C )QGD<C(ZB@#0E!,+A3AB" 1ZUY;X*AO[37--MF^T2R
MQ"Y%]%/:A%M<M\I23;\Q8]>3GK7<W'B[0(+BZMI-3@\^U1GECW<@*,GGH2!V
MJA;^+E?P8OB:ZLS#;L%*1K+N8HSA02<=?FH ZH,#2DX&:QKCQ/HME+-%<ZC%
M') B22*<Y4/]W@#J?3K3+CQCX>MK6WN9M4A6&X!,3#)W => ,C'?/2@#:+#'
M%-\OY@>.*Q8O%&FM>:A$\JQQ6$<<LDQ/R%7&013[/QAX>U"=8;75;>21HS*!
MDCY1R3R.WIUH VZ;O&<5DVGBK0[ZVN;BVU&*2*U7=,PR-@]>1TXJI'XOTF[O
M-,M[2Y%PFHM*D4B9PK1@$J1C(//?'2@#HZC:,L.<=>]2#I10 #@4444 ,9#D
MD'!KBI]*T_2_%>L7<MF[6MQI6^[*AG,S>8V1W.<= *[BF,I+9P"* ."\"3V^
MHZG=ZGY3VMPUND$-B+:2,6\"_=#,P =_ITZ5WZC Q3=AYZ<TY00.>M "T444
M %%%% '*>,O%P\,0VL%O:/?:I?2&.TM$."Y[DGT&1^=85YXL\8^&X$U#Q)H5
MF=*+ 3RV<^Z2W![D?Q"D\3216GQC\+7-X=EN\$T43M]T28Z9[$Y KKO%&M:=
MX>T"YU'507M8P%:-5#M)G^$*>"30!KV\B36\<L9RCJ&4^H/(J2H+.5)[&"6)
M#'&\:LJ,,%01D CM4Q('4T +13=ZGH12[AC.: %HIN]<XS3@<C(H **** "B
MBB@ H-%% &7XATIM:T&\L$=4EEC/E.W19!RC'Z, :Y:/P!<(WAMS=Q%[ [M0
M)R?M)^]QQ_?)/-=[10!YDOPTOC<2VTES;FR\RXE2?>YES*#T7@ \\G)R*A_X
M5CJ5YI<EI>7-I"QBAMP\+NQ*(X+,"0-I('"CH>]>ITE 'F4_@#7O[-L;5+JP
MEFLXGMH;K+Q2+'NRI; (;CJI&"><UT^M:%J,XT:[L7M9;W3'+;+H$1RYC*-]
MT<'G(XKIJ6@#A_#?@>ZT7Q"NKS7$#R26TB3I$"%\QY3)\H/\(SCUX%77\/ZH
M^OW$YDM/L$MW!= $MO\ D7#*1C'/!SFNKHH \U@^'.HP7TJI<VAMUN)KF"=R
MS2!I <#9C:,$]<G([5'!X!U]%NYGGL/M#VL4,8::1]SQRK("QVC"G;C '&:]
M.HH Y$>%[^>^L[N[>T+0ZA+>,%!/RLN%4''4>M<W-\--4"[([BSE6>W:WF$K
MN!&#*[@J /F&'Q@XY%>I44 <C/X4NY_L^9K?,6HQ71<@DF-(R@'^]T]JU/">
MEWFB^';?3;TP&2W+*K0L2&7<2#R.#STK:HH **** "BBB@ HHHH **0D 9-&
MX$X!YH #T]:X3Q!XMU^V\:Q^&]"TFSNYFL_M1>XG,>!G![>XKO*\Z?GX^Q?]
M@1__ $,4 6-/\::K9^(+/1O%>BIILEZ<6MS!/YL4CC^$GL3V%=YD5YQ\5'2X
MD\,Z= 0VHS:FC0(/O #[S>PQWKT;OGM0 ZBBFEU R30 ZBDW#UHW#.,\T +1
M2;AZTF]<XSS0 ZB@'(S10 4444 %%%% "'Z9KE+WP@UYXVCUIY8S9>1B2V(Y
M>4!E5O3[KL/RKK** /-H_AWJ5OX?MH!>V\^HV]]]I#,65)$4;44L!E2%QSCK
M5=_AMJT,-O);SV33,DT=Q"TCJBB1@V5;!+8QR#C/M7J-% 'FUM\.M5T[Q'%K
M%CJ5J"D26Q@DC)1HO+"L<=CD @9Z<$UI^#O"NJZ#J-Q+=/:I:F$1);V\C,I8
M,3O&X908/W02*[:B@#SJX\ ZE>6[:3/)8?V6MQ-<K,H;SW+@_*PQ@<GDYY'%
M;=WX:O9/ $.AQ2P->PV]NBN^1&7B*'MR =OZUU5% '"ZOX0U;5+(2&:U%['J
M/VU%W,%9,8"%P,@@9YP:RI?AYK?V%+>&[L@D@F\Z(.Z*KR$?-N W. !T. 3S
M7I])0!PMAX0UFT81/-8M#(EKYS MUB&& &.0< C-17?P_N;N-X1<V\4<EW>W
M#,BG<!,N%_$=_:N_I: //-(\#ZM:8DFDL4D06T0"N\F^..0,Y)(ZD#@8P,]:
MT4\*:A:^)4U6WDM"OVZ:9HR67]W(BJ3D#ELKG'3FNRHH **** "BBB@ HHHH
M **0L!UH#!AD4 +1110 4444 8GB/PSI_BG3_L6IPL\8;?&R-M=&]5/45SUG
M\+].BO+>XU+4=2U=;9@\$-Y+NC1AT.T=<>]=Y10 BC"CC'M374MGKGL:?10!
MPTOB?6;73_$MQ<V"Q2V&PVL$>97(8#!;'4\YP.E4[7Q7JMXEO80W-I)JMS=>
M0?-MFC^R@(7)9"?FSCCM757N@"Z;5"MY<0-?B/YX#M:(J  5/X"LL^""VZ[D
MU6X;5C<+<"^" %2JE0 G3;M)&/>@#1\-:G-J^CB:[1$NHI9;>?RSE2Z,5)7/
M8XS69I&H^+=8TJWU"$:''%<)O1'68L!VR<]:O0^%5MM-MK*WU;4[;R=[R2P.
MBM.['<S/E3SDDC&.IK @;4[?X+QRZ-YYU)-._P!'\E-TA?/4#G)_"@#?V^,O
M[^@?]\3?XTF/&&,^9H'_ 'Q-_C7GWA!?'>M:1>0:\+[SENX_*^W1M"&3:Q;E
M #C./TK82]\8Z1#;6WDH\$=LTDKW,1?##>3\_0!<*!D\C'J< '4X\8_\]- _
M[XF_QHQXQ_YZ:!_WQ-_C7/:;XGUG4],N8X[6:[$HEC@N8X"@W X.[DXXYZ\]
MJ9I&H>+O.CLI+6:*W6WBB\R2W.Z-L1@L2>&QESU[<XH Z3'C'_GIH'_?$W^-
M!_X3 ?\ +30/^^)O\:J>(3K_ -N6+28&:,0).90<*\BO@Q^VY3^E8]]J?BU-
M1O+2*TN&M$.$=;<[N,'(;HP/3CGCH* .C/\ PF _Y::!_P!\3?XTN/&)_CT'
M_OB;_&LS0]1\4WUV8M0BC@C$XRZ6S#"88LF3CT7##(Y-96KV>NZQ?W2VC.98
MI;D.K.RK'@+Y6,$?,5Y&>,]: .GQXQSC?H&?]R;_ !HQXQS]_0/^^)O\:J:F
M-8>QLK.Q-WYLL?V:XN77:T>%#&0^YQM!'&32R7=^MGI+W >/4Y;F)C&,[#N!
M#)^"AB1ZC- %O9XR_OZ!_P!\3?XT;/&7]_0/^^)O\:Z/(]:3(]: .=V>,O[^
M@?\ ?$W^-&SQE_?T#_OB;_&NCHH YS9XR_OZ!_WQ-_C1L\9?W] _[XF_QKHZ
M* .<V>,O[^@?]\3?XT;/&7]_0/\ OB;_ !KHZ* .<V>,O[^@?]\3?XT;/&7]
M_0/^^)O\:Z.B@#G-GC+^_H'_ 'Q-_C1L\9?W] _[XF_QKHZ* .<V>,O[^@?]
M\3?XT;/&7]_0/^^)O\:Z.B@#G-GC+^_H'_?$W^-&SQE_?T#_ +XF_P :Z.B@
M#D]2NO&&G:9=7S_V"ZVT+S%0DP)"J3CK[5T5BYGM;>X*X,D2OCTR,XJIXG_Y
M%/6?^O&?_P!%M5K2_P#D$V7_ %P3_P!!% %H]*Y+Q!X!LM?UM-8DO;ZUNTA\
M@-:R;/DSG%==10!R>A> -&T'4O[23[3=ZAC:+F[E,C*#UQGI75\\<4M%  >E
M<_XDFU*WLXY+.]M;&W0L]U=W*AO*0#C /!)/%= >E<WXF\+_ /"1+:(][/;I
M;2B78@#*[#IN!ZX]#0!S,?BOQ'=Z;)=11VMK)8:=]NN8Y8S^_!9]H'=<JA;V
M+ =JL/XNU/<=:40?V+'>?9'@V'S2-OS29]=PQM]*U+KP6+]U>XU:_,CV_P!F
MNW7:INHMQ(5N./O$9'8FI#X*M'U+[3]HN!:F<7)L,@1&4+MW=,^^.YH IZ!K
MNLSZI8+J1MGMM3@DG@2%2&@*G[I/\0*]_6K"+K>J:QK"PZZ;&"SN1#'$MI')
M\OE(^26YZL:2V\!V,3$7=Q>7L*(8[>&24J(4+;L!EP>H]>G%2>$]/@TZ]\06
MMHACACU ;069S_J(CU8DGKZT 6/[&\0?]#9+_P" $/\ A1_8WB#_ *&R7_P!
MA_PKA_ GAOQWIWCR^O=<N97TYQ)OWW&]9B3\FU?X<?A6]?V7BN+6[N33_.%O
M).SQ;94VEOD +AN=@&[A><T ;7]CZ_G_ )&V3_P A_PI/['U\''_  ELF?\
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M YW^Q?$/_0UR_P#@!#_A1_8OB'_H:Y?_   A_P *Z*B@#G?[%\0_]#7+_P"
M$/\ A1_8OB'_ *&N7_P A_PKHJ* .=_L7Q#_ -#7+_X 0_X4?V+XA_Z&N7_P
M A_PKHJ* .=_L7Q#_P!#7+_X 0_X4?V+XA_Z&N7_ , (?\*Z*B@#G?[%\0_]
M#7+_ . $/^%']B^(?^AKE_\  "'_  KHJ* .=_L7Q#_T-<O_ ( 0_P"%']B^
M(?\ H:Y?_ "'_"NBHH YPZ)XA/\ S-<OU^P0_P"%6/"MW=WFBE[V<3SQW,\)
ME"!-P25D!P.!PHK;K \'_P#(%G_["%Y_Z424 ;]%%% !1110 4444 %%%% !
M1110 &N?\#?\B3I'_7N/YFN@-<GX8OK?3?A[IMY>3I!;16H:25S@*,]30!IZ
M_J$UFMDD,@C\^X"-(0" HR2/QQC\:X__ (6'<);VQDT^&0R.JNR3'!4A,GD#
MD;^1R1CIZ=%-XF\/ZA:DQ3+?B*>,&.%"S!_O)QQSQG\*O66H:7J&G07D*1FW
MDD94S& =PSNX['*MGZ4 <;%\1[F.+:F@G=Y^S9'*H"IC/7ID]AU]JN6'B_4I
M1<1BV^U3I,V$<B/]VKD?* /O?=&*ZJQN=/U*V2:T$$L3@2A@@P?0_7BG7-]9
M6.FW.H2M'Y5JC23-& 2H W-TH Q/#_BZXUN_E@DTX6BHX"M+,,L#N&,?WOES
MCT-8NJ^)-:MY]0_LZ\BN;9)UMS*VU! Y;D*3G@+U9@1GIQ74Q>(-%EF AFCR
MT,=T7$>%"2'"L3V)_K5=_$_AZ-KX&:,B" 3S$19#1DX##CG)H C;Q));V&A2
M,L32:AL#F:01LH*Y)"GW_F*2YU6Y@\;V]C%<1M;3?+-"L8W(=H(8\9.?4' Z
M'FK=KKNCZAJ"6FQC*2RPF6WPK,!DA">X'./:KUO?V5UJ5Q:PNC7ELJB7"\J#
MT&30!R]YXYEM[^XM8+""9$W!9S.0J;3@K(<':3V'/2G+XKN;JTL;^RTU;AKA
M5=(G?&P'8I(;!Y#2<^RFNCN-!TR[LFLY[&%H"^\IMQEO4^IJW#;P6L,4,$"(
MD2[(PH V@= * .<MO$<NHZ5J3!DM+V"W6=8AAF'[O?T/)';.*Z'3;DW>F6ET
M5"&>%)"OH64' _.B>QMKJ-HYX$8.NUSM )7TJPJ!550  !Q@<?04 2T444 %
M%%% !1110 4444 %%%% !1110 4444 97B?_ )%/6?\ KQG_ /1;5:TO_D$V
M7_7!/_0157Q/_P BGK/_ %XS_P#HMJM:7_R";+_K@G_H(H MT444 %%%&: "
MBBB@ HHHH *Y_P /D?VQXE_["*_^B(JZ"N>T$@:MXF)P -07_P!$14 =#D>M
M<#JWB+5;2\OGMANDBO&B%L\3N'C6,%0-OW2[-C)]*U-)\8PZM?V\ L+FW@O%
M=K*Y?!2X"_>(QROMGK6C!?V)N[^6-"LD4RV]P^WJ0!@GV&[^= '%3>//$"37
MNW3(PL,J*FZTER5+.",9^8@*"#D#YJ)_%_B*\%\@TZ2U\AT,>V)\D%@-K>O'
M.17<Z?K-IJN3:,7 9U) Z;3C/X]0?2K(O;=IIH%F1YX5#R1JV64=LCM0!QFJ
M^*/$-C8&Z@TZ">*20+'^ZD/E#YP=_=LE0 0!C=WK2U76)QX7>\EDGAG9U58K
M6(^8&/2,D@]^K8Q4MKXTTR[CLV@6Y8W232!!'\R",X;<.QST%'_"9Z0^I16B
MLSB:.61)PO[MO+^\ >YZ_B#0!BZ+J.O_ /"70V=_</-;&W(;9$=F0F=W3&">
M,YY(Z"M >)+Z^TOQ$+*#%W9;OLI4,2XV\-@J,\YZ9Z?G+9^.;"\$+):7<=N_
MEJ)FC^1&?[H;^[]:VEU.W&M)I0#FY: W&0GR[00.3ZY/Z4 <Q9:]?6G@PWMU
M,?M;7+0QSW,3,IR3@[0 Q'&.QJG:>.-4N=4CLI;2**29FC$(B<R(0/E=B>,,
M>W4=Z[V>"*=HO,C5_*<.F[^%A_$/IS^=,CT^TCO9+Q+>-;F0;6E ^9A]: .2
M?Q!XACANKE[2$V \S8T<3B4#:Y'4G)!51TYW^U;%KJ;3Z[8+!(9(+FS9W7D;
M""/FP?4DC\*W>H../UQ4<<$*W)F6-!*5V%P.<9SC^M %BBBB@ HHHH ****
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MT =#1110 4444 %%%% !1110 4444 %%%% !1110 5@>#_\ D"S_ /80O/\
MTHDK?K \'_\ (%G_ .PA>?\ I1)0!OT444 %%%% !7%>-WU:"\TZZL;:_N((
M1,3%9 EC/M B+@=4SG-=K61X@U7^QM*GO5MY[AE!Q'"F\@X."1Z<<T <MX0T
MV]T[7)82+XPK9*+V6=V*3W98,2F>N!D$CCM7?KG:,]:X_P +^,)]?OK:!K1H
M%?3_ +2YDC9"7WA?ESU7!KJW<@XR!WSG&!ZT 345P-SK_B"PL_$DEU);_:8)
M8$MDB4E(1)M'.>6/.355]4UV+63X7?5W:1[Q(QJ'E*)1&T32$8QMSE,=.AH
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MY$$0WG+?(/F/J?6L3PZBKJWB1550!J"X &!_J(JZ&L#P_P#\ACQ+_P!A%?\
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M +"*_P#HB*@#?HHHH **** "BBB@ HHHH **** "BBB@ KG_  =_R!)O^O\
MO/\ THDKH*Y_P=_R!)O^O^\_]*)* .@HHHH **** "BBB@ HHHH **** "BB
MB@ K \'_ /(%G_["%Y_Z425OU@>#_P#D"S_]A"\_]*)* -^BBB@ HHHH \\\
M4>']9UW4%G_LM(VMWQ'/!J)B=U# KN^4CJ,CTKJM%L/[/T"WLI;5(=B;&B\S
MS![Y)ZY[UG>*#?27^E6UA=R64]S))&LX=2@(7=AD(._(4\<?6FZS%K\?A[52
M^IV?G&-3"\$9MRN"-V79B,D9 /&": +Z+I&E:S%##9)!=W$?WX;?"E0>C,!@
M<]C6VGW1BO,OAU<WO]HNEQ/(D!@,?DW5ZLSR2!\@H Q/RKD$]S7IR_=% "T4
MA)[4A8^G_P!>@!QKG_ W_(DZ1_U[C^9K?SFL#P-_R).D?]>X_F: .@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-
M%!H XNV_Y)SX@_WM3_\ 1DM=3I?_ "";+_K@G_H(KEK;_DG/B#_>U/\ ]&2U
MU.E_\@FR_P"N"?\ H(H LOG8<5YEK/A;6=:U5K^72$B>0;9DM]3*+,,;?F^7
MKCY3CJ*].;D5R6K?VG-XOM;73;YK1OLQE<R8DBD ;!4Q]<].01UH WXK2)M/
MCMI;6(QI&J^00&1<#@#/7'K5/3FTJWU6YL;&T\BXP))BD!1&]/FQM)Y[5@>+
MTUN/PLPN+V&5Q.#+]D/V1FB.<*K,QP<X[C-+\.[J[GLI_M4[8VQ!(9;E99 5
M0*[_ "DX4L.!GU/>@#N:**9O/IG_  H ?13 Q/:F^8^.5'IF@"6L#P__ ,AC
MQ+_V$5_]$15M^9ZC'MZUB>'_ /D,>)?^PBO_ *(BH WZ*** "BBB@ HHHH *
M*** "BBB@ HHHH *Y_P=_P @2;_K_O/_ $HDKH*Y_P '?\@2;_K_ +S_ -*)
M* .@HHHH **** "BBB@ HHHH **** "BBB@ K \'_P#(%G_["%Y_Z425OU@>
M#_\ D"S_ /80O/\ THDH WZ*** "BBB@#@?$OB33[?5++4+RTU6"#2;B1I'^
MQ$I)E&3@Y_VN*T-?N;'7_AW=7!G:RLKF .LES$4VC<"-R]>< 8Z\USMS97^L
M>(TOI-9LKJ*2ZDM["TNK1RD4B EL+T)PIY.>G%=5KC"#PA='7%^UD*HE2V&W
M>Q90NW/3G')H X?0M)7Q!X@CN[>"PL);;R6,<$$B817SO4G^(_=QZ'FO75.1
MQ7!^$-?N-2UJ>WF34HE-L72.\FCD&5?8V-G(.>N:[M!A * .=\9:S=Z+I4<U
MA%ONI;A($/EEP@;.6('7&/UK!MO%6KZDL%GI=U937?D37,\LL#1[=C!?+*=5
M;)Y)KL-9TJ35+>-8+Z:RGBD$D<T78CL1_$ISR#6"W@)52.2WU>[AOOWOGW85
M2TPEP7XZ#H,>F* -;2_$%I>:'IVH7$]O:_:X%E"2RA<$@$@9ZX-0>!3N\#Z0
M1T-N/YFKB>'=*6PL[*2QMYX+2,10B>)9-J@ <9'? S5/P* O@?1P!@"W  _.
M@#H:*** "BBB@ HHHH **** "BB@\#- !13/,.>GY&@.<CY>U #Z*87QV]J!
M*IS[<'VH ?1110 4444 %%%% !1110 4444 %!I"<5B^*?$EOX5\/SZQ=6\T
M\,+(K)"!N.Y@.,D#O0!BVQ_XMQX@^NI_^C):ZK2_^039?]<$_P#017D_AGXA
M:=K_ (=\0:';VMU'.;34+WS'V[-C,S <'.<..WK7K&E_\@FR_P"N"?\ H(H
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M9\/)J3+>0SM:ZE ,P742_,O^RP_B7V- &UOYZ=Z=7.:1KSO=#2M:B6SU4<J
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MI^C:^+^XDT^^@-EJL*YEMF.0R_WT/\2_3IWH W*0G% 8=,TQW1 S,< #)^E
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M34TG>(GRXK>W6)!D8)8\EOTQ0!TE%%% $>& P*"I)YY'I4E% $>TX K$\/\
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M /HMJM:7_P @FR_ZX)_Z"*J^)_\ D4]9_P"O&?\ ]%M5K2_^039?]<$_]!%
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M*==?LY2]S# 5.FXXDD5,_P"LZC.<>U:(TWQ/_P!#):_^"P?_ !R@!PLO$_\
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M-&I_U?&0#^% &CVHJ'S#O*@\C'Z]ZBN;V*S@>>>9(XD94+,> 6( !]R2!^-
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MHK4I"TKI(LS@'.]=AVE/F;.0*]KVBC:/2@#@+W3;V?4[74XTO&O(]2BA,F6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" &@ 9,# 2(  A$! Q$!_\0
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MI\+P6N\(FZ2<-T/IBNNKPO289=)G\/\ BQ@RW6J7KK,S$_,C'CBO<1SSW(H
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MB8+A6/(QT)^HK)\*I_PD/Q"U?Q"?FM[0?9;<]CCJ10!WMO$L$$<*#"1J%7Z
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MJ:.H^M.\-_Z[4?\ KL/Y5I'X&+J;QZ5Q_P 1U7^Q(7P-RSK@]QS78=JYCQ]
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MK#/4UNR?ZMOI6">I^M4<(4444#"BBB@!8_\ 6+_O"M\"L"/_ %B_[PKH!TH
MCF&87'?::Y#P "(M15AAENGR#VYKL6&5/TKD_!Q U+65Z'[0<CTK.7Q)G72?
M[F:]#K <G%.%- YS3JT.1;"TE+2&@ S4-V?]#G_ZYM_*I:CF >"13T*D'\J
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MUK>'1B*Y Z"3^E8OC9Q(FCEB-K7*$CUK=T'C[8/28UO#:?R.:JN6A%>IJO\
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M_#?^OU'_ *[?TI@ZCZT_PW_K]1_Z[?TK2/P,1O4'I12&LP.*L,Q_$N]4<!H
M3[FNTKBI1]D^):,.?M4.#[8KM0:B'7U.O%:N#[I"FJM^WEV$['C"'G\*M5D^
M)IS;>'KR52 PC.,U3V.>DKS2\S)^'J8T-Y.TDS$'UYKJ)5$D3H>0P(K#\$VX
MM_#-I\I!<;B#ZFM['O4Q^%&N(E>LWYGEWA.S%I\1+J @8CW%0.V:[S1/OWW_
M %W-9$.AWL'CV34HXT%I)%ACWS6QH0^>]_Z[FG1CRTY(WQ]95IQE?HD:C?ZM
MOH:P>];S_P"K;Z&L$_>-4< 4444 %%%% "Q_ZQ?]X5OCI6!'_K%_WA70#I0
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MU*.WN-/>WAG)$+L>3CKD5/H?W[[_ *[FKC\+ U'_ -6WT-8-;S_ZMOH:P:@
MHHHH **** %C_P!8O^\*Z =*Y^/_ %B_[PKH!TH #TJM>1+-9S1-T9"#CZ59
M/2H)H]\+IN(W C([9J9;%1W.<\ R;M":(](9G0?G73GD''7H*XGP+_Q+]0U3
M2'8EXIBX)[@]Z[88 R:4'>*-\7%*L[;,Y"Z_XF/Q!MD/*6,18CW-=:ZAU96
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M:Y;6M)NO[.T"W0LD\UX9)95C!V$\Y(KJM5MGM=$CADD\UED4M)C&3GT%5'=
M;B?<7Z"L6Y_X^)/K6TGW%^@K%N?^/B3ZU($5%%% !1110,!U'UI_AO\ U^H_
M]=OZ4P=1]:?X:_U^H_\ 78?RK2/P,1O4&B@]*S ;5+5[5;S3+BW89#H?Y5=[
MTU@""#SGC%)JZL.$G&2:Z,\Y^&,.+[4'=BTD3>7R.@%>D"JMI86UFSM;PK&7
M.6P,9-6A2A'E5CHQ5?V]1S'44@IU4<PE9.A_?OO^O@UK5DZ']Z^_Z[FKC\+
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MM+?4])\0ZA;-I=PR7LBE+I "B\8R?I5_Q1I6H77AO[-N^VW N$92% ( ;DT
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MMHM-87-S.(\@EE;ICFIK^;4?[2@AM[2-H-P+2LW('?BK&KR3Q6+&WMDN&/\
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MJ_V?_P )9IXO#(LQ7]QM/!/H:L)_K%_WAQZU6U$./&-ENEB,93Y8V7)4^H-
M&]J$4<EC,),8VG)-5M *'2(UC8,JY ([TNN0I/H]PDDAC4KU!P1^-0^&8]FA
M6\8*D 'E3G_)H CTF]DGU:[M7G\P0'I]:;JFK74&J6]C;6C,78%I\<!<\BH/
M#]C):ZWJ4A0&-VRLA;))]"*T[_2FOKJWN%NI83"P)5>C =C0 _5I+F.Q8VL*
MRL>H9L #US3M+^T?V?%]J*M+CG:<CVYJ:ZMDO+:2WER$D&#M.#BDLK-+"V2V
MBW&-!@;CDT 5K'2$LKZXNUFD8SG)5CPOTHU#1X]0F@F:22-X&RNTXS]:TZ*
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MJ/[+D_YZUHAER.1STP>M.H S/[+D_P">U5)XO*D,9.2.];@(/3M6/??\?CT
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(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0 G # 2(  A$! Q$!_\0
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M))%VO\Y(/OSWKH ,4M(3B@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MR*T$+$'>,<T[O2 Q;4:K</<*;^,>5(4_U0]*L_9M4Q_R$(_^_-&G?\?&H?\
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M451U\?\ $@O?^N1JY9_\>=O_ -<U_D* )Z*** "BBB@ HHHH **** "BBB@
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MW0 4444 %%%% !1110 9I,C&:1^PKF+OQWH-J94>[<LK%$ C.)6'&U#W.>*
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M\AEE6WW>9EB0<]QC% &WX$LYVL[K6+S4X-0N]2<.\EN,(BJ,*H';WK*U\_\
M%[_"X_Z<)_ZU=\!AWU7Q!=1:?<V-E<SH\44Z[<M@[B!V%4]>_P"2X>&/^O"?
M^M 'H$D0='1UW(PP1]>M5+'3;73%D6UC*"1MS#-7VY(^M9.F)J2F]%^RD&4F
M#']VDP,O2HC'XXU9BFP/!&57  QSR,5<\4:G_9VC32(BRNPP$+;>.YKD?A[?
M:_>^,?$7]O0F)H]JPY7&4R<?IBND\9QQOHY+[^N-RQ[CCKVZ?6KC\1E5<N1V
M.!%O/+&I+%G;YC$[[@ >@K8\&V_VO4)[JW$>8LPL"N YZUDS[KU$MX)/($P4
MR3@\A1T KT33=,DTS3A$L<;JV"57C QZTZ%6NXSEB':[LEY'F83#QG75:[=E
M^/49%>QZ2M]*T$C8ER(XAG:,"B?7'/F/%;L&1-Z;^,C./QJ*.WD?[62#+"]R
M28U;&T8'%85WH>HSB.XM9I&=)BYB?A5QSMSZ'I6E*,7K(]5\UCJ;/4S-<0PS
M1@S,,G9]WZUN!AT_*N7T32YXD=KT-'-/)YB(#D1CT!KI8XPH R21ZUG4M?0I
M7ZDM4=9'_$FO/^N3?RJ]5+6/^0->_P#7%OY5 QVF\:7:?]<5_E69K&CWFHW"
M2VU^855-A3L>>M:6F_\ ()M.Y\E/Y"F:EJ5OI5K]JN21'N"\#UXH S-8TVS@
M\.SQ,[P1HI?>C;<M[U/X;9F\,:<<[G\@<GN:I^,O$^F^&O#K7VI[C;R_(-J[
MN3TXJSX>G63PI83+\R-;AP,8)'6A;V#:[.)\=:\9=772+,S2W<:;F6+I&>H.
M:\[&MZM;7PEF+)<!O]6IPI4=B:[+39);J]O+ZXMP9Y[AEVH<[$!P.:RKS3)=
M<\7V]I;0Q2+$ TJN>,5[F6XW#>UGA7'6*NV>)*OB98E**5G=+Y=SJO!27DMW
MIEQJ$JR+-YC1 <E>,\FO35"H"%4* <\5R<4:Z3J.DP6\6Z!8WP(U [>E:5Y/
M=VX:16!4J6\PG ^F/6O*KR=2HVM#V8_"C::5$&XL /4FA) Z;P01ZBN76XNI
M5CMSY<D<F624'D\<YK7AED9?)B@Q"@!#@]363CRHHU:*:N<#=UIU2!FZ_P#\
M@"]_ZY&K=G_QY6Y_Z9K_ "%5-?\ ^0#>_P#7(U;L_P#CRM_^N:_R% $]%%%
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M/N+:*XB*3QI(A(.U^1Q26J&WM((2<^7&%)'J!67+KDRW44:6$I1V"EB.1[T
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M_$F.-(T\<VP5%"C_ $3L.E 'I]-(/I7FG_"(_$S_ *'NV_\  2E_X1+XE_\
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M37@BDV^9&C[3D;E!P?44VV@2UMXK>//EQ($7Z 8J:@!,4M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %5+[3K34H/(O;>*XBSG;(NX9]:MT4 9;^'](>S%FVF6AME.5B\H;0?7%
M6+'3;/3H##96T-NAY*Q(%!_*KE% $#6Z-,LQ4&11M#$<@5,!2T4 %%%% !11
M10 4444 %%&:* "@\"BD;[IH ,TM<IHGCC3]:\3ZAH<".)K/JQ'7USZ5U8.:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!112-]T]?PH 3>,9'/TI<@'DUC>(-:AT#3OMD\$\V3L"0)N8G^@K-B\=Z7-K
M5AIL23&6\A$P9N$0'GD^M %2T_Y+%J7_ &#8OYFNW%<)IT\-Q\8-2:&5)%&G
M1 E&#<Y/I7="@!:::=28H X"[^+&BV?CN/PLT%PUPSB)I@ORAST&.X]Z[]>G
MO63+X=TB75TU9M,MFU%!A;EHP7'XUK*,+R: %HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"*
M6B@#D/%?AW5-;U/2VM9[>*T@D+S;URX..-IK"@\,ZAX?T&YO[F]\F]:[679:
MG"$9"@-ZY%>EXK"\7@#PW/T^_'_Z$* -F(EHD8]2 ?TJ6HX/]1'_ +H_E3R<
M4 +13%D5^58,/8YI] !1110 444=: "BBB@ HHI-P]10 M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I2$^E)G'TH QO$
M6AMK^D/IWVZXLTD(W20<.1G.!6;+X(LY[VTGENI62VVMY0"A6(&,GC./:NL
M%)@'@B@#S[0M,L=*^+.IV]C;+!&=/C<A>Y).37H0[5Q-I_R6+4O^P;%_,UVP
MH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QA_R+<_^_'_ .A"MW-8
M7C#_ )%N?_?C_P#0A0!M0?ZF/_='\J25G$;F(;GVDJ#TS2P?ZF/_ '1_*GD
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MX=#CUKI$^[0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (W )Y_\ UUY?;RWEYXB36+FYN5U"
M&[,$-I]G^18=V.N.XYS7I[8W<C(SFN @L]=74C;7,5W)<F_,\=XK 1>3G[I_
MX#2 ]"'6L/QA_P BW/\ [\?_ *$*W .<\BL/QA_R+<_^_'_Z$*8&S"?W$?\
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MC&TMG<)*L;F-RAZ,.H-6E%<IX,\&1^#8KZ*&^FNDO)C,PDZ*QZUUBY[_ *4
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M2Q:B/^H9%_,UVQ8*,L0 .Y-<39_\EBU'_L&Q?S-=?=VL5Y;O;SKOBD&&7U%
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M!M?#WAR^M8[FWM$DAD&4<.^&'YUHV&BV&F2,]G!Y1;KAB?YF@#0!SVI:04M
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THH/0T
M4=4U"VTS39[Z\F\FVB0EY,9VCUKSZ3Q1KD=I'<>%C)XDAE?.)8_+"J3_ 'N_
MXUU'B[5)=(@M+@V=Q<6)ES>""+S#LQT*^AK(\)VFA:O$-4TLBSN#(SR16LA7
M S\NY#QF@#M[1Y9+6)YX_+E907CSG8<<BIZ8F<<]>]/H 0]#67K^H1:7HEU>
M3V]Q<11H=\=NI9V!] *U&Z&N6\23ZQ;:E8W.GVK7EG;AGN((7'F,Q'RC;W%
M'#^&]6UZ]N"OA(L;,N"\.JW"NT8SR% .X'ZUZ]&25!;&['./6N'\*OH?B"Y6
M_ET]8->M"3<(8C$Z$GC('!XKNU'% "TAZ4M(W2@##\4ZP^AZ*]U"J27+LL5M
M$YX>1N #46A:^U\?L6HVYLM509DM7;[_ /M(>ZT_Q!?3V\]E#%I/]H"5BV,@
M;"HR"/>LFUU;2O%/B*&UGTF]@U'3E\X23Q^6T?; /<&@#M%Z4M(OW1FEH :V
M.]<(FC^(+>_U3Q!9SEKN68@:?.W[IXEZ8]&ZUVUVCR6LR1MLD9"%;T..#7!F
MP\<Z)IIFAUJ+4Y@AWVTZ#<"3P5(]J .STN_&I:?'=+#)"6'S12KAD;N*T!TJ
MK8K*+& W#$SF-?,)_O8Y_6K0H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 1LXXJF=/M7O%O&MH6N ,><4^<#ZU=HQ0 BY YI:** "BD/
M ZUDZAX@LK#3KF]:82+ XC=4;)5\X"GTYH G.E6AUD:L8O\ 31%Y(?/1,YQ5
M\=*Y_P /^)H==MR7B^RW!=E6,OG<!U93W'O70+TH 6BBB@ HHHH *:W&.F*,
MG)'2J&K2WB:9.-/"&^V?N0Y&"W:@!;O3;+49()KJ!)7@8O$2.E66MX9"&:&,
MM_M*.*Y;3?%WV+R]/\4^78ZN%4,5!\J?)ZQGO].U=<&W $'@C- "C@8I:**
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MTVU2V69MTBQDX)^G;\*TQTXH 6FOC:<G [TZJ]ZTR6<K6\8DF"DHC' 8^F:
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MB:!P.K9/(]Z /2='L8['3(+>.".(!<E8C\I)ZGWK3J- 0,=O<8J2@!K''/\
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K&((02=SD ,X'WB!U-3TU1CZ=J=0 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'VZ?D;AD=L4@->BL<7\_]X?E2_;I_P"\/RI@:]%8_P!OG_O#\J/M]Q_>'Y4
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MYH U=,_UE[_UW/\ (5HCH*S-)+,UYE=I\\\9SV%:@Z4 %0RQ^85SR ?6IJ*
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M]O9715/M,A\J=MO&1W^N*ZO0M<FM6BLKV0O;@;$E;AE/OZBN?:X:6UNH8/\
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MBBB@ [K]:^DM)_Y!%G_UQ3^5?-O=?K7TEI/_ ""+/_KBG\J +E%%% !1110
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M>S9$BKDD>E7%U">XU=72U!AA^ZLGRMSU(S7,IRB[&UD]A=-O[33X3%=32K*
M"))UY8>@K-U6T;5=<L+F2W:*&1]B.>21UY],UIZKJ^G7"Q0R;E(E!+/']WVJ
M?6KUVL%:UB?Y75EEQPN.^*A.2U0A-0T.!8!/IT8@NX,LA3C=[&L;1]:%C;73
M7:.;B23^'G+>]:,VH7TEB'NT^R0.GSR1C)6L>#2;\Z2\K3+%%&WF1LPRSCU-
M."37OL+6.@TT"[LH;DSR&:-BVTGA2>HQ65XY<M-9VY&Z)\NX/<] *U-)\.K9
MD3"\=S)AF':L/XC1F9[&*.4Q2@E]WMC%*'+[30(ZLXV^4QW%O;J^+>;^#/(I
M\UE;0@2!"'4_*YZAO6J\A*VZVCVK?:A_J)%.?,)JY<VZHR0W$DDA2(&8GC9G
M^'_Z]=NJ.EV>@ND6":[$Z7$\BQ02;%5.,GN:MV_A.&%A.KYNHG)1F.X,ON*K
MV,TU@'E8+&C<N%&05['%6[=M2US5?,M[B.V%NN8V0Y6<?TJ;LQE[IDZXEI-K
MZ1Q(J[ %GYX!/3CTI9Q)H]E/H]_C:</'_=8>@IMHPN/$>H?;(E#SC (Z!A_*
MIX;>34]<CL-5E=Q K;..3Z<UKTL3OJC-D2'["TVF6\N]4_TA2<@#VKHO")@N
M] GBD$<KAV#1A<%0>XJG%IEUH>M%K1UN(Y4+&.4XR!V]Z@UVWLX+V&:SE:WG
MG!,D4;8P0..E*3YERHGE=PN8UTVZGL?M+I;D!E 7/![&J/\ 9$T-[$T4?G6P
M^Z4.6 -7]&M[*]UB!K]W*;3G?D!B!T)K=L@NFZH\&EP$^:VZ8(-WEJ/>E*;A
MH7J4=.B:W=5E61;57+C*DMG&,D?RKF;[5+>Z9K9E($3ML<]67/ /O7HLFLR7
M&J/:R6,GEQ."DP7;N'<'UJKJW@^*[NA?Z:(TDWDO!)]T_P#UZSA6L[L=W>QY
MO]D=H6D@&P\*S'@G-=;X0BDA\3:7'.8P%8A,#D\'K6G9^$;B:_>34(HA"(]B
M@-\P;LU6?#_A_5;/Q%97%U' T49(+ Y(X.#15K*28WRI'I0^O>G4T'DC'>E%
M>;U,!:***8!1110 4444 %%%% "&N5\=1B3P^N1EQ,FP8!&[/&<D?I75-TKC
M_%@2[U*PLIK>]EC4-.!: %@ZD8)R>G- %_PNUXUAY=U;6\07E7MW+(Y/4<\Y
M&*VH[JWEFDBCF226+_6(K E?J*J:,3_9ZDQ7,>23MN% ?\A5?3]*-CK>HW<<
M<:Q7(3;CJ6&<YH LZ7_K;W_KN?Y"M(=*S-*+EKPLN/WY_D*TAT% &#XP_P"1
M>D_ZZ+_.N&KM_&3K'X>D=V"J'4DDX'6O.VU?3UN$A^U1EG7*L&&/Q- %FX_X
M]9O]PUZ?I/\ R";/_KBO\J\@36;*[M;@F>*,J"N"_7Z5Z_I)!TBS(.08EP?P
MH NT444 %%%-/7UH =FBL6[DUH:_:1V<,)TTJ6N)&/S9[ 5LB@!:*** *-__
M ,N__745;8'!V@$\X!Z&JE__ ,N__745</6@#S:W%D/'<:.K"'[060[?W?VC
M!W -ZX[5Z2N.?KS7FBRPZ?\ $(KJ(M(EEG,D)E4Y)(Q\N"5!]SBNR\0WL=AH
MD]U-=O:Q*03+$,L<GH/KTH VSTJG9_\ 'Q>?]=?Z"O.3KFO6DT,<^I"1P(FM
MC&NY9][8*MCJ5%>B6#!IKOGD2X/Y"@#&^('_ ")6H?[H_G7A Z5[M\0?^1*U
M#_='\Z\)'2@ HHHH .Z_6OI+2?\ D$6?_7%/Y5\V]U^M?26D_P#((L_^N*?R
MH N4444 %%,\Q.N]?KFE\Q/[R_G0 ZBF^8G]X?G2>8G]Y?SH ?56\ZVW_79?
MZU84@\@@CVJM>=;?_KLM 'DGQCD\G7](DXRL)(S]:X-IK>XE$L<AMYR.X^6N
MX^-)QKVE<9Q QY_WC7FJ[GR!PQ].E>YA%>C$XZCM(FE;S,9(8^U3F-4@0,"3
MPP ZXJ**Y,4,B>4C%B")!U'TI)96FG$C.?; YQ729ZDLWEKM59<1R?,T2]$J
M,7$@B6'^%,[=PYP?6E,I:$6JA5C+[BVWDD^IJQ%/+87D4Z11G[.Q",5RI.._
MK1L.Q'9P;I8SP-T@4,3WKW*P\+V9L8OM)9V:,9VG'_ZZ\7TN'[=JL1R%9Y,Y
MQA<FO9=%U"^%B\4@AF6WR 5D 8@5P8V4K+E.S#1([;PY'9ZVA68G8I>(^O\
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MQR0!WS6=XZC5;>*[.#Y3;2.Y4\?SJ#3M8FUG4K=C$-J-N,"'!'^T3_2M'Q?
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MW-VVO:=)!*ESIEP_RR*>4.#Q]#7(X26YS<C6YVW<TM-']:=4$!1110 4444
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M8^&M:>"4WEU9[I00$\S'EUZ)8W%O;6,$+W$9:- I(/!Q50:[HC7<]N;JW62
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MQ(PCY!S]TU]$:5J%HNE6BFX0$0J",^U2Q2:5<2B&+[)([)O"J 25/?Z5:%O
M!_J8_P#OF@!AU&S'_+Q'^=5]0U"T.FW0%PF3$P'/L:IWVMZ5IUU);W$6#$%:
M0B/(4-TS5L7NE;I@9K4&$!I%)'R ^M 'SIALL-C\L?X3ZT<_W'_[X-?17VG1
MS:/<(UJ\*+O+* >.M-2]T:121): B/S65@H*KZD4 ?._/]Q_^^31@D?<?U/R
M&OH.YU31+6$S2"'RA#Y^]8P0R9QD>M*-3T0DAFMD V<R*%!+#('UH P/AK>6
M\/@^)9951O,8X;@UU%Q>6TSVZ1S*[>:IP#5:SUC0KQ"8)[4J)C!V&9!U J];
MR6-RS&V,,AB;:Q3'RGTH X;XK^&EU;18M24XFLCDD#/R'K7B<\+P2;2K$D?*
M0IP:^KG174JZJP/4$9!J V-H1@VL)'N@KKH8MTH\MKHRE24M3Y:0%58[7RW7
MY#4EK \LH18Y"Y("_*:^HOL%I_SZP?\ ?L4@L;13E;2 'U$8K=YC?:)*H>9X
M)_PB\BZA&MT@$!7<2!S^5>IZ/-I2:9#;6[*JA>488.:ZK[+$3O,*%NF2HH%I
M;@_ZB+V^45RU\0ZNYO!*&QRM\+FXE^PV5TI$B$,I'3\:D\/P?8K.6V5"&CDP
M[ ??/K74""-3N6-0WK@4OEJ!A0,>F*QYK*QK[2YRLVHHEQ<:;9PL9VY&%^0$
M]S1_9MT%M':X+RPG<4(^5O85U*PHK%A&@8]2!3RB_P!T4<V@>T/.Y[ZWO?&%
MOL>6U9%(F<C&X^@K4U=(]00V-GMDNN'+..%'N:ZMK6!VW-#&3UR5!IR6\2$E
M8D4GJ0.HJN>VHG,\FDM;FVNI+*>U;SS@$Q\@BNL\.P1V&F.'!BD9B9-P[5UQ
MA3?OV+O[-@9H:)&^\BL3UR*J=;F%S*YQ6F7;7OB:>\B@=[50(PY&,'VSUKH+
MM9$O';!VL!MP.E:RQ)&,(JJ.P P!3L>V:SYB92N<X]N1+N,;D ?* *J6]I<F
M>2\FNL+NPD2<HH%==CVIOE* 1L7'7I1S#N><0PF6XFT^[$AAF<R07*9RC_7T
MJC%!>O>R174<TLMOE%+@E?KZ5ZIY2XQM7\A2^6.?E7/J15JM8?.><I;O""1:
MN<#G<IQGUI4M9W&/+E)VGG%>C;!C[HQZ8I=H[J/RJOK#[$W/-_L\_)2&0[>^
MSI52-)FNP# ^YVR"5/)^O:O4]H'10/H*;Y2_W5 ^G2FL0^PCS?R3'+N%M-\P
MP0%[TD=JS2^2T3DL.-R]*]*V+_=7\J3RUZ[1^5'UA]AW/+9XY$5D\F7CC.W-
M5XM*U2[D5XM*E*#E688!->M>6N/NK^5*5].*/K#[!<\LM8I4FD:2VDCE!_>H
MR'&?:M7P_%+'K5JNQQ'DDY7C.*[XQJ>64$^XH"*.P_*IE7<E8!V.:6D[TM8B
M"BBB@ HHHH **** "BBB@ HHHH **** $/TK+UC24U:*"*4G9%,LI7^]CM6K
M33[?E0!P[> B+B!OM<;10,VQ6!! +9SD=6]ZSH_!NHWFIK+A+,69!BD= ?-8
M-G+8Z\5<U[3]937II;$7!M(%%\$0Y\Z11M$8_'FL:YN_%ZSV\%LEY'!+'^\7
MR=WWQG.>Q!XH OCX9S"%D.I(P90K!D( (!&01SWKLM%T=='@DC!62223>S[<
M$].OK7%6EWXM2X$*R731B#8GF0\GC[Y/KGM7>Z=;SV]A;Q3W#7,JH \S@!G/
MJ10!>KC[WP2ES-+=)<^5=/<M-YFW/RD8(QZ^]=C2<T ><3^#+G2[%OLB1W<K
M$KMP2,'/S,#W]ZM#P)<RBVW:@D4*$2&/;DA\#(S[8KHK*+68M3U*2ZEC>S)S
M;1J#NZ5Q%GH^O">PLG^UFQCNC=2ER3YF\D;"?1?ZT :B_#YCJ@NY[V)T,J2,
MNT_O-I)Y[=^U;6I^&(-1UN+4C<B,+;M#)&!PW]P_\!-<UJ6BZV^D7V)KMY8K
MM(K-%R,0J<_CGIFJL4>K7.N2ZGJ5E??9)IXF> JS!0N0<** -<_#X;+!8[J,
M>0 6<J<LV22>.N?>HI/AP'NGE%ZI#QA<'(,?&/E'09[UH^';;7Q:.PF$%L;E
MVABNE+2"(G@>W'2K>A6EU;^(M>:5IY+>26-X&E/ !4;@OMF@#<LK1+*SBMHD
M551=N%&!]:M444 %%%% !0>E%% &?JVGC5-+FLF.T2@ G'H<US%]X%\\/'!<
MQ);B99DC<'KC!#$=1W%=N>E<7XLTO4;W4K9-/DGCBNT*7,D9X0)\P_,\4 9%
MYX)O+W4_LB*L5M&=PNF7+$A5P,]<9%7SX$NY;>X$VI1O-.^^3*':?;U%8T^H
M>+D%O<6EK=PO))O>$Q;MP'R[2>W3-6$F\4VLL217%[(J&0@RPD^8Q)X;T &,
M4 =+X4\)KX;6?,ZSR2J '"X( [9KICGWK(\,#4/^$?LWU65Y+V1 \N]=I4GM
MBMF@#F]2\+1ZAJ%U?&7;._EF(E<A2GJ.X-<[J/@::(2W$+?:I!,LJJ"2TG.2
M'!X(]J]%;[IXS6-Y.L?\)*LAFB_LOR"#&%^;=D=Z .2T'P7J<&BQV]S=PVXE
M/F31A3E2,@ =AUZ4K?#5Y-56\FU)'4 J1LP77(.T]L<5G^(;7Q&T^M6EK;WC
MPW=T)XIHS_JPC+\H^O/Y5I7WAW4I(=3C-S?/;B*,VD:D@H[D;\'OM_3- '1:
MUX>&K'3MDZV\-L^)8PO$L6.4]AP*P9?A_))I45D-2$D:322[W!/!.5 QZ=*S
M#8^(&^TW%XEVT,=NEJD*9RRHPR_N2/Y5TVFP:FYO&TMOLUF9%\A;I&/&/FP#
MTH Q(_ABT15A?HRJ6PA4A<'O@?Q>]=GHFDIHNG1V<6T[22SJN-Y)SS65!9W\
M7CXW#R3R6KV #$M^[$F[G [5U(H *,4M% "44M% "44M% !1110 4?A110 ?
MA1110 4444 )12T4 'X4444 )12T4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1129H 6BDS2T %%&:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BC-% !12=>]&1ZT +129]Z7.: "BBB@ HHHH **** "B
MBB@ HHHH **** "BB@T %%)FC(H 6BDHS2N M%)^-% "T4F?>C-,!:*3-)F@
M!U%)1F@!:*3-% "T449H **,T4 %%%(3[T +129]Z/QHN M%)FB@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7.>)_%]IX6:R2XM+NZEO'*0
MQVR;F9NO2NC8X&:\T^*EI<RWOAVYBLK^Y@M[EGG^P?ZU5QV/:@#L= U\Z]:R
M3C3;VQV/MV7<>QF^E;=<CX%N(KC39A%::Q J2D_\34YD/T]JZZ@#%EU3R7W7
M-[!;(\_D0AU'SMVYS4L%Z;A0T.HVS\D8P!T.#W]:S;W0TUP%)F54BNF=N.<X
MP"/0BLO2/ ]UIDT9ENHKDJ69IF4ACDYV_0]Z .OVW9'_ !]1X]?+Z_K566^$
M,LL,FIVZR1)O=2G*KZ]:TE7:H]AR!VK"UKP]'J<D\H*1O)"(]^,%B#GD^E &
MA;337<*S6]Y')$WW6\OK4_E7N?\ CXC_ ._=4=$LSI>F1VLUPDCJ225& ,]A
M6IYJ#JXH A\N]_Y^(_\ OW1Y=[_S\1_]^ZF\Y?[P^N:/-3D;AD=>: (?+O?^
M?B/_ +]TFR\'6XCXZ_NZL>8F/O#\Z3S$(^\/SH SYKM[>1(IM0MTE<%E4IR0
M.O>EM;F6]B\VVO8I$/&X1X%5=9T>+598)#)&C1JZ[L<_,,<4_P /:5+I-D8)
M60Y;Y53HH QQ]: +_E7O_/Q'_P!^Z/+O?^?B/_OW5O%)CWH H,]U!/"'E1TD
M?:0$QVJ\>E5;O_7VO_73^E6FZ'U&: .)L_B1:7^J/966C:I.J7)M7N(X<QJP
M.#D^U6M0\8G3]5O[!K!R]N(1"Q; F:0X'T />N>\ >%+F.YU._OI]2M)!JDL
MD< DVQR+G@E>X-=K>>'-.U"YGN9XF\Z=$1F#8*A#E<>F#0!S\7Q ,DKQC3CO
MM65+X;_]66;:-OJ,UU,<MS<3W"Q2I&L3[1E,D\"LM/!&C(8\0O\ *0TGS?ZT
M@Y&[UYYK2TZ)5N+Y1N_U^>3["@"QLO,_\?$>/^N=!BO?^?F/_OW_ /7K.\6W
M,UEX8OKBWD,<J1Y5AVKQ=?&'B/:/^)O/^E 'O/E7O_/RG_?O_P"O3'^UQL ;
ME3GTBKPG_A,/$7_06GH_X2_Q#G/]K3Y^M 'NH:[Q_KU_[]&C?=?\_ _[\UX4
M?&/B/'_(7GZ<UZM=ZCK+:1I$6F O>7$(=Y&7*CY>,_C0!OA[D_\ +P.?^F)H
MWW..;@<>D58[P>(5T>Y^V3I-<%P4%J-I"]QS4$L/B&273$B:6/"XG?<,#GG/
MOB@#H-UUS^_'''$7_P!>C?<_\_"_]^C7.:/;>(HM9M#>R.ULL3"0MSD\\Y_*
MNQH H;[G< ;E1G@9B[U)Y=[_ ,_$?_?NK#QA\9SP<BG8H J^7>_\_,?_ '[J
M.9KN! [3QL-P!&S%7JJZA_QZ_P# A_.@!E]=FT5F)58U4NS-T '4UP,WQ7M&
MGC%M9W?V%Y1$NHO ?(=CQA3]>]=?XHLWU'1[RQB8))<6[1*Q[$UX?J<WBH:+
MIGANUTO4+>[TI5BDV(#;N >6)]<4XJ[ ]E_MR[R /*Y]JRM0\4ZI#I]U/"(]
MT4@525SD8Y&*PI]2N[5K>#/F>9&I#].<<\U3M;]TM;VU*2-)(X)#C[IKLC26
M]BY69J67C;7;O'^I7=P!Y>35^T\2^(+J.220VUNB.4RZY)QWK)L;B'[7#<?9
M3&%C*LY'&?2M%)H=/TYGN4(MR^[(Y//:FX1[ HI*Y=M?%UT(9$NGB-S&Q 4+
MC<.Q IC^)=91(VD58_,?&?+R *Y2*&6YU%=0DA#032[8_P"\H[5NZ\\Z6\20
MJ6RV"RG./:ATXI[%)(T[[Q7=6-H2TD3R'[CJ./RK,M/'6I_:XUG-N8V;!*KC
M%9EO9K]H$%Z75<93/3\Z5K&%M6$$3 H1N.!T]J?LX6V$XN^AUC>*9S=1PQRP
MLS@G JPNN7A/&SKCD8KG&TBU!W(FR4?=8'H:J7.N7%FKQO:&6:->J]#Z5G[.
M+V-'%):G9V.NW-Q<S1N8R% VX'4]Q6A]OF']T^X%<!H<M_<0F2X?RY(G)!08
M89['\*W[6ZEAF$<LAFC8@ GJI_K652E;8QY>IT4=],TBJ0,$X-4?%'B>#PMI
MTFH7:,UNC*A"#+$L<"I8@?/0<=:Y;XMV-UJ7@R\M;*"2>9Y(<)%]_ 89-8DF
MY/XOBM]>T_1GB<7-_$9H3C@*!GFM3^T9O[JUYE#X:FTOXC^';BW%]<6RV4@G
MFG?>L3$#C/:O0L4 6_[1F_N+1_:$IX*+53 S7,^-=>.BZ2(H2PNKH%(RO\([
MFM*=/GE83=D3Z[\2K729_LUM&MY<(W[Y4/"#TSZU0MOBU"[(+C3)8U8XW+SM
M'J?:O,["S47,,<C96695D;UR>M:5W';Z?J-Y:!Q+;+(0&'4CT^M>BL+32L]S
M!5'<]P@U8W$$<\)1HY%#(1T-2?VC+S@+BO*=-U;4M-TV&TAN2D87<HD7<5SV
MK6TSQRWV@VVI0%@#@7$8_F*XYX9ILW3N>@'49A_"M)_:,W]U:IIM=%D1@\;#
M(=3D&E(YKF:L[#+?]I3?W5H_M*;^ZM4Z* +9U*?^ZM26]]++.J,J@&J&*FLO
M^/Q/K0!M4M)WI: "BBB@ HHHH **** "BBB@ /--P:=5>[O;:PA\ZZF6*/.-
MS= : )\?_KIHD0OLW#=Z9YI(YXIHQ)%(DB-T9&R#^(KF-"T;5=.\1:E>WTRS
MQ70R) W(YX4#L ,4 ;FG<FZ[_OC5[%9^E-O6Y.TK^^/!K1H 3%1R1+(5W9^4
MYJ6LN^\0:3IDS0WE_##*J[RC-SB@#0V(.-HYYZ5E:[?2Z?:1M;1;YI) @ 7-
M7[*]M]1LX[JV?S()!E&]14Q7)!(!(.1D=* .>BN=;>PNWN;..)E7]T4')]3C
MUQ5.ZOM6&F0FWBG\Y<D$QC+_ -W=Z=ZZ_!I>: .#T^_\3_VAI\=U:L8C(3<-
MM&-I]*[H1K_=%.&:6@"-HE(.  <8S3E7:H Z#BG44 %%%% %.\_U]K_UT_I5
MDD?-5:\_U]K_ -=/Z5/-Q$Y R0"<9QF@#GGUK54UF.WFL+58)#^[0S_OC[XZ
M?K71JP//K7G>@6Z-JLFIZC/;1F.8K!#-,'91_L\Y_,5UWB#5SHNCRWRQ>:P9
M452<9).!G\Z -C<*H6'_ !]7Q]9L?H*X^W^(,EP@:/303"4%V/,P4W-M&VNP
ML#FZO3C_ );<8[\"@#.\;_\ (H:C_P!<Z\!7[H^E>_>-_P#D4-1_ZYUX"OW1
M]* %HHHH 1ONG\Z^C=#7.A:><#/V=/Y5\Y-]TU]'Z%_R =/_ .O=/Y4 7MO.
M:-OTXIU% #2O-.HHH ****  U4U#_CT/^\/YU;-5+_\ X]??</YT 5]2<":)
M<C<0<+ZXZUB02S#7KP XMVB4'GGCO6QJ,"F\CF)^95(7VSUK U&633[T7C+O
MAE41*J_PGU:M((#)F@M;QW5()$BBD/D2'G:>_P"&:GTFW5(9'E"O,[GS9"/O
M8Z?A2PD"W&!A22<#UJM=WC:=*MPNW:P(8'H:Z%)O0Z.5**8U;%/,F)+!68[4
MSD*/I3]KW)-E)$'95SNSU'TJO8Z@K95GWEB27'05!=7D!OY5E66)60+O0?,!
MZBK2=[#DTXZ!IUG/-.Z1R*MO#+E,'/-:41N+N=9Y=BI$Q55 Z^YJEHMS;V;W
M$3N,*VY7/'F#VJ[8W,36K/O" .V0QZ42N3%JQ:GACN(C'*NY3^8^E8VE1F'5
M+B$A<(O!SS6C-JEI"FXRAW'15[UC1)<WVH-/;E(I'[%_F_*E%/9C<DGH= [*
MJ%V(P.YKE[S5U9Y2JC8SC#8Y.*T9HB))DU"\8NB@+&O?-9]WH;QVID,P557+
M(%SQ[U<4HO4)2;6AKV%[-,TEPUL6W !C'P/_ *]7[.>2\OEAC0Q^4P:3?P<4
MS3E4:= %Z!1R!3)YO)UO3OF(:1B#COZ9K*=FVT#NHG51$>=&0.-W'UJ>])%W
MD'! ZBH8_P#CX7&/O#(J6_\ ^/H_2N1[G/U*^3M(!."<D9ZTE%+0 @'(]S7F
M7C>5[WQ"8PXV01A.?7OBO2KFX6UMI9VX6-"YS[5XXUZUW>7-PX_>2R[@3T K
MMP<;OF(F-DT^6T:"YMD=U5@^,=Q2R1KJ.HR7#Q_9HV8LX!S@]:T+4RW-PTJ,
MX2(X\L#(:K;.$NAYT1A8=4*X-=CG<E01)'###)%]LC+12+OVKP2/7-= D>C:
MAI8M8GBC0=8I.&!^O>N?5=Q$>R0R'[IZXHAD@M[@M?V;S!N J\;?>L9Q;U-8
MZ&[IUNFD74D<%[NPH(0R97%=):74-[;+/#(K)T)'8^E<=JFCP"W2[@98[=L9
MR>15[2IYU"S1%8TC^3RP,"0>XKFG335R[<VQU/O28ID,RSPJZ\9ZCT/I4@KE
MVT(:LP J:S'^F)]:BJ:S_P"/M/K2 V.]+2=S2T %%%% !1110 4444 %%%%
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M"[ND?F;Y%C)*9" \%O;'K75-TXZUS?B.TU>Z:-;",2PR1F*5=X4)D@EL'[W
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M/TH CEP(GQQQS@=?K7J=E_QY6_\ US7^5>62\POCTKU.R_X\K?\ ZYK_ "H
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M+PW-PTOV>57+*H.-PZ&J2ZQ>0)+:JVY",#VSVJ]J+12:-%=HV7CX"#'RCO\
M6I]&BT^>V#QP$S@?.']?6K3M&Y-G<QK#;',D5POEJ#A^:Z_1O)74;7RR "3M
MP>HQ63JL44DD;K$K-NP^#VK2L=-2U\0V,T18QG@*?X>*SJ23C=E.6ECM_6EI
M*6N,S"BBB@ HHHH **** "BBB@!#TKBO&MQ;M=6%C<2W<:<W"FVA\S++_>'I
MS7;'I47E+YGF[%WXQN[T 9?AZ=+C2(Y8V=U+$YDA\IO^^:BT_1UT_7=3O8X
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MJ15KD%CIUNEQ)/M5V#D*PZ*/I5[PT(VUYI%P3O(X'3BGWFG,UN9(93#)(P&
MO'7O5O1])N+?589RR*JD[E3D-Q2<_=M<?,N6QV.:=31R*=7.8!1110 4444
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MQ+L7EBI[BL[3_ =O:7WVN>[:XE8Y<-& I//0?C6?=^!;&[G%[)K>8@2J9VD
M]US^'3VH Z:'6O#\ZL1=VY,<8E92W*J?6HX=9T2YM(KR(AH)IS LF.-W]!Q6
M'!X*L[97,FJQ8E3,;%5SDXY]QQ5VZ\/6 \,7>CWVJJK/+YKSC:C1N3D$#M0
M^W\5>'YV16C>+F0L9$QL"=S]>U6AXB\-[I0;N!4CC65G)^7:QP/QJK/X/MKJ
M.YFM;O#744<8? (&WN,>O>L^?X>6ES%;P_V@#+:8VY0$;\YY% '465]I%W=&
M*SE@EF11(0ASA3T.:UATK"\/^&XO#T+PP-O$A4LQ4*>!CM6Z!@4 %(PR*6B@
M" VT4C*\D*,R_=+*"1]*0VT.2QAC)[DJ*L4C9VG'6@#)N[[3;&Y6"X2./,32
M[R@V[5QG^=4+[Q7X=L+6WG>:"07#!8EB4,6SW^G%6M9\/_VM,DYFV21Q%5XR
M V002/PKF;WP#9SRR--JRQR,4DN_E7!P201_=Y/;K0!TPUW0O,\IY[5)?+\P
MH0.%QFH4\3^&Y)%2.ZMF!C:7>%&T =<GL?:J$W@NTNK)[>*\99 P/FHH+J=H
M'X#BJ%G\.(+6UGC&H;Q,6:1C&/O'I^5 &W>^*/#UI%:N9[>4W3JD*Q@$DDX_
M#FMMX8(XGD>&,A02?D%<:OP[C,T,IO2A\R.2=8XP%?8<J%_NUVTL1DA>,]&7
M;^% &/'KN@L8EDEMHI)$,@1P 0!ZU!;>*?#URD\J20B"%MKS,H"Y]JH77@&&
M=&C>^<6S[7D4("2Z_=(/I[=Z(? D>&:ZOC,TDHD8B(*#CH,=,4 :R^(/#K"+
M9=VA\U24P!R!_6EC\0>'Y/*'VJU5I4WJK@ [?\@USTO@:R2Z%S_:JI;13^8Z
M,JX5O3/;KTIMUX)TV=S<W&JQK#,OS,%4$L,X*GL.>E &]:^)-$O;2[NK55FA
MM)!'(RQ]R<9'MS2KXAT=I+A!&!]GG$,A,8P#C.?I573M"MM*TO48+C4HG-XI
M=Y=JH$4K@$#\JH6O@6T>V@:SU>4K':M;[T(.]B02[>I[4 :R^)_#+R1*EW:,
M)0S!@!M 7KGTZU<M=7T2\FACM+BVEDF4O'Y8!R!UKE?^%;6)L'TZ34F:21VF
M8[1N.<8X]!M%;WAWPG!H$SS+(LLTBX9A&% .220!TZT =#@$\@<'C-.VKZ#\
MJ,&EH ;M7^Z/RII0'JJD>F*DI.: (_*3NB_E2B*/^XN/I3Z* NR,Q(>J+[\4
M@@B'"QH![**EHHU#4B-O$>L:'ZJ*7RDZ;%QW^6I,4N.: U(C#&WWHT)]2HI!
M!$K96- ?914U% R+RH\$;%YZ\=:00ITV(!Z!:EHHNQ7&"*,8.Q<CT%*5!Z@'
MZBGTE $/V:$Y_<Q\]?EZTT6=L/\ EA'QT^4<58Q1BB["[L0FV@8',,9^JBF_
M8[?G%O%@]?E%6,48HNPU9$D$2?<B1>,<**4Q(5QL4CT(J7%%+4"'R(]Q/EID
M]3BD:VA9MS1(3Z[14])3NP(C;Q-UC0_\!%(;6 ]88\_[HJ:BB['=D#6ENW#0
MQD>ZB@6D"D%8(QCI\@XJ>BB[%J1^6/[JX],4JQJ#P@'N!3Z6@ HHHH ****
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F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '+ 6@# 2(  A$! Q$!_\0
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M]: .@HKG+[QQX<TW4!876J0I<9VXSP#[U9U3Q-I&BVL=Q?7\21R_ZOYN6^E
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MY9-*O$N%C.' ZJ: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*GX'H*,#T% #/-3U/Y4>:GJ?RI^!Z"C ]!0 SS4]3^5'FIZG\J?@>@HP/04
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5Q'>NW^(_P#Q]6WTKB.]?7Y7_NT3X3-_]YD!HHHKTCR@HHHH **** "BBB@
MHHHH !VKO_AK_J;W_>%< .U=_P##7_4WO^\*\K-_]W?J>QDW^]1/0.XI:3N*
M6ODD?;BT444QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_O"CRT]!1Y:>@H -Z_WA1O7^\*/+3T%'EIZ"@ WK_>%&]?[PH\M/04>6GH*
M#>O]X4;U_O"CRT]!1Y:>@H -Z_WA1O7^\*/+3T%'EI_=% "J<]#3J0 #@8I:
M "BBB@ HHHH " :3 I:* "BBB@ I#2TAH \V^(__ !]6WTKB.]=O\1_^/JV^
ME<1WKZ_*_P#=HGPF;_[S(#1117I'E!1110 4444 %%%% !1110 #M7?_  U_
MU-[_ +PK@!VKO_AK_J;W_>%>5F_^[OU/8R;_ 'J)Z!W%+2=Q2U\DC[<6BBBF
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D-+2&@#S;XC_\?5M]*XCO7;_$?_CZMOI7$=Z^ORO_ ':)\)F_
M^\R T445Z1Y04444 %%%% !1110 4444  [5W_PU_P!3>_[PK@!VKO\ X:_Z
MF]_WA7E9O_N[]3V,F_WJ)Z!W%+2=Q2U\DC[<6BBBF,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+32: /
M-_B/_P ?5M]*XCO7;_$?_CZMOI7$=Z^ORO\ W:)\)F_^\R"B@T5Z1Y04444
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M%8MAX<GM+ZRF(@ A3#LHYS[4 =2.E!Q0*" >HH ;D?WA1D?WA1Y*>E-,2>E
M'G/Q'(^U6WTKB:[;XC ?:K;Z5Q/>OK\L_P!VB?"9O_O,@/6B@T5Z1Y04444
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MB_G1Y\?_ #T7\Z\O\Z7_ )ZO_P!]4>=-_P ]7_.C^V%_*/\ M)?RGJ'GQ_\
M/1?SH^T1_P#/1/SKR_SIO^>K_G1Y\W_/9_SH_MA?RB_M-?RGJ'GQ_P#/1?SH
M-Q&/^6B_G7E_G3?\]7_[ZH\Z7_GJ_P"=']L+^4/[37\IZ=]HCSPX_.G>=&S8
M#J3V&:\O\Z7_ )ZO^=6=.DD;5;<&1R"V#S50S12ER\I4,PO+EY3TL,/[PH+
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MOS@_=K:E!3W-:4.=ZF2L3R$K$C.PZ@"ED@FB \V-ESTR*TM.EB6>]991%O\
MN.:@O$NHUB>:X%Q%D'([UJZ$;7N:JEI<IF&58P[1.%;H2*38WEB3'RG@'UK>
M,L5VLBI/O$RA8XQ_!ZFLZ_20X6&%OLL0V@_S:B6']WF3"5#2Z*%%''K17(TS
MDU"K6FG_ (FMM_OU5JSIO_(4MO\ ?K:A=U8LTHW]JG<].3[HIU-7[H^E.K[&
M.Q]0@HHHI@%%%% !1110 4444 %%%% !2&EI#0!YM\1_^/JV^E<1WKM_B/\
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '+ :<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"S1117U)\2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444:#L%%%%):B84444Q!1110
M 4444 %%%% !1112"_0****>P]@HHHH?DPMW"BBB@ HHHH ****!!1110 44
M44 %%%% PHHHHNEN%T%%%%%F%T]@HHHH!!1110 4444 %%%% !1110*X4444
M#"BBB@ HHHH **** "BBD/7'KVHN!5^V-_:R6/DX5D+;_I5=]3N@)9DM4-I%
M((V;^+%6WAD.K0W&,1+&RD^]4/)O8(9[+[+O627Y9L\;3ZUS2<DSL@H-$LFI
M7+M<26L"/;PX+2-UK3BC>:%)8H92CC<"%S6+]FN;-;FUBMS-'.<!\_=SZUT5
MEJ5]86,%I'< )"@4<4DY]!SC31%]GG_YX2_]\4?9Y_\ GA+_ -\5<_MS4O\
MGY_\=H_MW4O^?G]!6EZASOV93^SS_P#/"7_OBC[//_SPE_[XJY_;NI?\_/Z"
MC^W=2_Y^?THO4"U,I_9Y_P#GA+_WQ1]GG_YX2_\ ?%7/[=U+_GY_\=H_MW4O
M^?G_ ,=HYJH<M,I_9Y_^>$O_ 'Q1]GG_ .>$O_?%7/[=U+_GY_2C^W=2_P"?
MG_QVB]4+4RG]GG_YX2_]\4?9Y_\ GA)_WQ5S^W=2[W/_ ([1_;NH_P#/P/\
MOFB]0'[-+0I&&< DP2 #U2D\J0?\LVY]JO'6-0D!1Y^#[4?:)\#]Z37E8_-9
M8.24EN>[E>0K,(N<96L4?*D/_+-_^^:=Y$^,^1+^"5;>ZN$0NLI!'>@:[J6!
M_I.,#^[6F S%XQ-Q6QAFN4QR]J,G>Y4^SS_\^\O_ 'Q1]GG_ .?>7_OBKG]N
MZE_S\_I1_;NI?\_/Z5Z-ZIY/+3*?V>?_ )]Y?^^*/L\__/"7_OBKG]NZE_S\
M_I1_;NI#_EY_2B]4+4RG]GG_ .>$G_?%'V>?_GA+_P!\5<&NZC_S\#_OFE_M
MS4NUQ^E'-5[!:GW*7V>?_GA+_P!\4?9Y_P#GWE_[XJY_;NI?\_/Z4G]NZE_S
M\_\ CM%ZO8+4NY4^SS_\\)?^^*/L\_\ SPE_[XJY_;NI?\_/Z4?V[J7_ #\_
MI1>J*U(I_9Y\C]Q-U_N4&&4#YH7!)ZLM7/[=U+_GYS^%9VN:SJ,NG8-PPP^,
MKP:4I5(J[+A3A-V1)Y,G_/,_E1Y,Q/RQ,?8"N8_M*^_Y^Y?SK3T#4K[^TAFY
M=@1T8YK%XII7M<[%@4K:FIY,G:-QZY%'E2GCRS^57GN+@N296Y/-(9Y>?WAX
MKQ7Q$N?DY3Z!<*2=/VCD4O(G*_ZB3_OFE^SS_P#/"7_OBKG]M:B@P)^/I1_;
MFI?\_'Z"O?A4J3BI+J?*U:=.$G%]"G]GG_YX2_\ ?%'V>?\ YXR_]\5<_MS4
MO^?C]*/[<U'_ )^1_P!\U5ZNQE:F4_L\_P#SPD_[XH^SS_\ /O)_WS5S^W-1
M_P"?@?\ ?-']N:E_S\#_ +YHO5'RTRG]GG_Y]Y?^^:/L\_\ SPE_[XJW_;FI
M?\_/_CM+_;FH_P#/S_X[1S5!6IE/[//C'D2?]\4QD=!\Z,I]",5?_MS4?^>X
M_*JMS=37;;IWW-C&:<5/J*7+T(11116IF@HHHH&%%%% !1110 4#@@^E%%&O
M00F. .?>ER>>H)[YZ444M1[;!U&,D#OCO24M%&H;A1111KU$%'-%%.PPYHYH
MHHL%PH%%'I3TL)+47!QG'Z48;T_2L_5[B:%(C%(5SZ5D_P!H7G_/R_YURU*Z
MCH=U/"N:N=.BG=DK5KCH*PM'N)IVD$LF[ K=/:OD>(9\U2+/N^%J?)3DADH_
M<M]*JCI^%6Y?]2WTJH.GX5W<-_#(\SB_^)$*6BBOJ3XJXJJ68#.,U ;RS5BK
M7"@@X(JQ'_K!SBN5N0/M4O8[CR17/6J..QUX:C&IN=#]NLCTN!4P*LH*'<#S
MFN2QG'&#GTKL+2-&MXMV<[!6#QJA'FGHCJ_LZ52?+35V-%'.:L&&/WIDJJAX
MS44,TH5Y<JD/$9+BJ%+VM:.A%1117I'DA5'5S_H'_ Q5ZJ.K_P#'A_P,5E6^
M$WPWQF!6GH7_ "$Q]*S*T]!_Y"8^E>;+X6>XMT=.W7/O2'H32GO]:0_=-?"2
M_COU/TB/^[+T_0IGK11_%17Z7AU^ZB?C>+?[^?J%%%%;/1MF"U=@P<'VI<,,
M<'GVK"O[VYCO9%29P![U6.H7@#'[0_3@USRQ"BSNC@G*',=,01D'@BDJ"S=I
M+.)Y&9G(Y)J>MXR4E<XZD'!V844451(4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%'K0(R]<_U<-8_:MC7?]7!6-FO-J_$SW,/
M\"-?0?OR_2NB'05SN@_?E^E=".@^E?+9[\43[+ASX)#9?]4WTJJ.GX5:E_U+
M?2JHZ?A7I<-?PY'C\8_Q8BT445]2?%#H_P#6+]:Y6Y_X^Y_]XUU4?^L7ZURM
MS_Q]S_[QKDQ)Z.!W(O\ &NPLO]3'_N"N/_QKL++_ %,?^X*\/-/]W9]+D_\
MOD2R*AGZU,.HJ&?K7A9)_O2/H>(O^1>R&BBBOT0_* JAK'_'A_P,5?JAK'_'
MA_P,5G6^ WPW\0P:T]!_Y"0^E9E:>@_\A(?2O+ELSW.J.G/?ZTA^Z:4]_K2'
MH:^%E_'?J?I$/]U7H4S]^B@_>HK]+PW\*)^.8O\ CS]0HHHK=]3G6YSNH_\
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M<IWK38_N4[L:_,LP_P!ZEZG[%EE_J</0CN>B?2H"3CK4]ST3Z5 >E??Y8O\
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MA_\ W8^,XJ_WP****]X^9"BBB@ HHHH **** "BBB@0444468TNX4-_JY/\
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M:HJ5!(T]M,"3R>^?TH/$<O\ NG%%#?ZN3_=-*I9Q%3;YSDB!EO7-.C&98_\
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M.?8-7R.,P5>==R4=#[K 9CAH891<M;$US_!]*@J0NTX&Z/RR.Q-)Y9]17VF
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M1GY'_H:IW4EYMCEO(ECCB?(C3EI6[8KGGMJ=]/96,^V42Q&V,$SZEN_?W,G
M7!ZBMR2.SL/,O)%1,X#R8[^GU--6]N7CG=['R9E7<D3L,O[5GZ@\5S;I?EG-
MO*/)G@S\RMV('J*RNDKHTFG.5I;"WVK,]J8Y+&19& :-/^>BTVVA2YED@9MP
MN8MS,N=L)'0?6I+-+J>>.UO"N+(Y1@.9 >G-;/ &  !UP!WJXTW+5F=6JH*R
M(XH1&D(<AY$7'F8J3M[]S1ZCL>U%="@D<+FY;A1115$A1110,**** "BBB@
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MQD=[&&I M;"-(U"B)@2<[:L>'6+Z:^X-_KB ']_Z5ID*5P44A?F QP#2G@]
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MUP,_E0><_*/4<?>HSGFG3IN(5JRE'0****U, HHHH .P]Z/E]?E'WB.U*/\
M6#Z5CR,P2]()SD#K4R8X*YK!@W*D-]*<1CBL'4G:PM0UJQB+;<D5EVVJ7SW&
M&N7-3SE^S1V.,<D8QQ1C'J>W%<@FJWQ#9N7_ -95B#4;QM5V&=RNT\4^8?LT
M=1@XZ8 Z&DV]/X1VK"U:ZG31[=UE8,2<D5F6U_=27UJKSN5QT)I.8>R1V'7
M.,]C28.._!YQ7/1W]U_9MTWG-N4\'TJ.&_NFN[-3.Q5@NX>M5S:"4$=,67.T
ML 1T%*1@\\'UKD]1N)DU"^*R,"K+CGI6SHD\L]H3*Y?ZTHRNPE!+4TJ***LS
MN%%%% !1110 4444 PHHHH#H%%%% !1110 4444""BBB@84444@"BBBF 444
I4 %%%% !1110 4444 %%%% !1110(**** "BBBD,****8!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" %E 5L# 2(  A$! Q$!_\0
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MPC2KK]RG^K;^'VJ'PN,>&[,?[']30!K4444 %)BEHH *3'M2T4 -/ /TKF/
M_P#QZZGZ?;Y*Z.Y$QMW%N0),?*6Z9KF/A_YPT[4%N"#*+V3=CIF@#K:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"GJW_(*NO^N3?RJKX7_Y%RS_ -S^IJUJW_(*
MNO\ KF?Y55\+_P#(N6?^Y_4T :U%%% !16;J^J/I<"SB RQ _O"#C:/6H]*\
M16.M1LUC)N8#[C#!H UJ3^5<<_B/5K2XFAF6*X.,9C^["Q/ )[U*NOZDUT=)
M C^W*Q)E(^4J!G\Z .L/0_2N8\#_ /'KJ?\ U_R5J:7J\=YIB7%PZ0N<JVXX
M&163X%8-::F596'V^3E3D4 =51110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 E(:,U2U&^^Q0!@,L3@5E4JQI1<
MI.R0TKEZBH()A/$LB]"*GJH34XJ4=F#0M%%%6(**** *>K?\@JZ_ZYG^55?"
M_P#R+EG_ +G]35K5O^05=?\ 7(_RJKX7_P"1<L_]S^IH UJ*** .-\5O</J-
ML?,46\>?W3QYWMV/N*U=$MS<Z>9IE"SL"H98PA0>@JGXJN=\*P+:F1LG+A<L
MGN!5_P +C_B3(&GFF(8Y:9<,/PH K6GA*.VM9K5[V:6&3D!NH.<YS3SX4@-L
M$^TR^?NW?:,_/],UT%% &5_PCNFM:Q6\]N)DA'RE^361X!BC@L=1BB0(BWT@
M4#L*ZL]#]*Y?P/\ \>NI_P#7_)0!U-%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4AI:0T !.!29%!Z5F:EJ1M&1$Y8GD5C5
MJQI1YI#2N79IEA&.K'[J^M4WT[[9B2Y8@_W0>!5BVA! F8[W;OZ5:Q@=:B4(
MUH6DKIAL5[6T2SB\N,DC.>:LBD%+6T(1A%1BM$#%HHHJQ!1110!3U;_D%77_
M %S/\JJ^%_\ D7+/_<_J:M:M_P @JZ_ZYG^55?"__(N6?^Y_4T :U%%% '+^
M(K>W74[*YN)IH4)*M(C'"CT_&KOAF5);&?RT8*LS ,QSO_VJR/%K^("SQ6T(
M:P9>6C7<^>];/AE;=-%B%N[LO\7F=<T ;'>EIH/K@'O2;O3F@".X>9+=S!&'
MDQ\JDX!-<S\/VE?3M0:>,1R->R%E!R ?:NJ/&2<#BN9\#?\ 'MJG_7_)0!U-
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E&
M:*:3CZ=Z0#)91%&7;C'ZUGKIR79,]QG<_0>E3#-[<@_\L8SP>S&KV*PG3A6T
MDKH=[$<$"P1+&G05+116T8J*LA"T4450!1110 4444 4]6_Y!5U_US;^55?"
M_P#R+EG_ +G]35K5O^05=?\ 7-OY55\+_P#(N6?^X?YF@#6HHHH Y35/$MY;
MZE):V<%N41Q$7EDP=Q[X[@5JZ#?27MG()PGG0R&-VC^ZQ'<5D^)DT"!WENE@
M-^P&T/G/UP*V]&ALH-.C_L\)Y#_-E3G)H R7\3S_ &;5I5L6#6+;57J6]ZCB
M\2W4UI"L$<4]W,3A0V H SS6D=#"-?207+)+=L&W8SL_"J/_  B3A3.E^4OF
M8L9U0#@]1B@#6TK4TU#3H[IBL;-D,I/0BL?P-S::ETYOI.^:NGPQ8RZ=#93&
M1EBS\RM@DGJ:S?A[;1V>F7]M%NV17LBKN.30!UU%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 W-5+F1I9!;1]3]X^@J2YG$*
M#'+-PHI+6 PIN;F1N6-9RUT EBB6) B# 4<5)0./I15I %%+10 4444P"BBB
M@ HHHH IZM_R"KK_ *YG^55?"_\ R+EG_N?U-6M6_P"05=?]<C_*JOA?_D7+
M/_<_J: -:BBB@#DKJ.?2-:N[R;36OX;D?*ZX)3V.>@J_X4B9+":4[%6:9G6)
M#D1C^[6'XKL9;V_D$>M(#L'^@R/M'USZUT7AF2.318O+@6 *2I53W]: -?\
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M75QE2"/44N:R#H\MMSI]V\(Z^6W*FF_VI>VC;+^T.W_GK%R/Q]*+D\M]C8R
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M7DC,KCJ!WK?L+*#3[1+6W3;&@P!5EAZ'%*!QS4J*3;-YUZM2"A*5TN@HYYH
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M ;5%8O\ PE^A?\_Z_P#?#?X4?\)?H7_/^O\ WPW^% &U16+_ ,)?H7_/^O\
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M7_(-N/\ KF?Y52\+_P#(NVG^Z?YFKNI?\@VX_P"N9_E5+PO_ ,B[:?[I_F:
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MO_\ H.W/_?(_QH_L&_\ ^@[<_P#?(_QHHH /[!O_ /H.W/\ WR/\:/[!O_\
MH.W/_?(_QHHH /[!O_\ H.W/_?(_QH_L&_\ ^@[<_P#?(_QHHH /[!O_ /H.
MW/\ WR/\:/[!O_\ H.W/_?(_QHHH /[!O_\ H.W/_?(_QH_L&_\ ^@[<_P#?
M(_QHHH /[!O_ /H.W/\ WR/\:/[!O_\ H.W/_?(_QHHH /[!O_\ H.W/_?(_
MQH_L&_\ ^@[<_P#?(_QHHH /[!O_ /H.W/\ WR/\:/[!O_\ H.W/_?(_QHHH
M /[!O_\ H.W/_?(_QH_L&_\ ^@[<_P#?(_QHHH /[!O_ /H.W/\ WR/\:/[!
MO_\ H.W/_?(_QHHH /[!O_\ H.W/_?(_QH_L&_\ ^@[<_P#?(_QHHH /[!O_
M /H.W/\ WR/\:/[!O_\ H.W/_?(_QHHH /[!O_\ H.W/_?(_QH_L&_\ ^@[<
M_P#?(_QHHH /[!O_ /H.W/\ WR/\:/[!O_\ H.W/_?(_QHHH /[!O_\ H.W/
M_?(_QH_L&_\ ^@[<_P#?(_QHHH /[!O_ /H.W/\ WR/\:/[!O_\ H.W/_? _
MQHHH 8_AV\GB:.37+DJPVGY0,C\ZV=+LUL-.AM48LL:X!/4T44 6Z*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>mymd-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamMebP9z5Z8eekhvWB8bXnafyshH46yaS1kzY0mQdMN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:MYMD="http://mymd.com/20221231" elementFormDefault="qualified" targetNamespace="http://mymd.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://mymd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" id="StatementsOfComprehensiveLossParenthetical">
	  <link:definition>00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" id="StatementOfChangesInStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - Consolidated Statement of Changes in Stockholders' Equity /(Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" id="StatementOfChangesInStockholdersEquityDeficitParenthetical">
	  <link:definition>00000007 - Statement - Consolidated Statement of Changes in Stockholders' Equity /(Deficit) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
	  <link:definition>00000009 - Disclosure - Organization and Description of Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" id="RecentDevelopmentsLiquidityAndManagementsPlans">
	  <link:definition>00000011 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
	  <link:definition>00000012 - Disclosure - Trade and Other Payables</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000013 - Disclosure - Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/Stock-basedPayments" id="Stock-basedPayments">
	  <link:definition>00000014 - Disclosure - Stock-based Payments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/Equity" id="Equity">
	  <link:definition>00000015 - Disclosure - Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000017 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - Related Parties</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000019 - Disclosure - Employee Benefit Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/PaycheckProtectionProgramLoan" id="PaycheckProtectionProgramLoan">
	  <link:definition>00000020 - Disclosure - Paycheck Protection Program Loan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" id="PatentAssignmentAndRoyaltyAgreement">
	  <link:definition>00000021 - Disclosure - Patent Assignment and Royalty Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" id="RecentDevelopmentsLiquidityAndManagementsPlansTables">
	  <link:definition>00000025 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
	  <link:definition>00000026 - Disclosure - Trade and Other Payables (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/Stock-basedPaymentsTables" id="Stock-basedPaymentsTables">
	  <link:definition>00000027 - Disclosure - Stock-based Payments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/EquityTables" id="EquityTables">
	  <link:definition>00000028 - Disclosure - Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000029 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" id="OrganizationAndDescriptionOfBusinessDetailsNarrative">
	  <link:definition>00000030 - Disclosure - Organization and Description of Business (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" id="ScheduleOfMarketableSecuritiesDetails">
	  <link:definition>00000031 - Disclosure - Schedule of Marketable Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" id="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" id="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails">
	  <link:definition>00000033 - Disclosure - Schedule of Estimated Useful Lives of Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" id="ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails">
	  <link:definition>00000034 - Disclosure - Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" id="ScheduleOfLeaseExpenseDetails">
	  <link:definition>00000035 - Disclosure - Schedule of Lease Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" id="ScheduleOfOtherInformationRelatedToLeasesDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Other Information Related to Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" id="ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails">
	  <link:definition>00000037 - Disclosure - Schedule of Operating Lease Minimum Lease Payments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000038 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000039 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" id="ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails">
	  <link:definition>00000040 - Disclosure - Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" id="SummaryOfMilestoneEventsPaymentDetails">
	  <link:definition>00000041 - Disclosure - Summary of Milestone Events Payment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" id="RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative">
	  <link:definition>00000042 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" id="ScheduleOfTradeAndOtherPayablesDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Trade and Other Payables (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" id="SummaryOfStockOptionsActivityDetails">
	  <link:definition>00000045 - Disclosure - Summary of Stock Options Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" id="SummaryOfRestrictedStockUnitsActivityDetails">
	  <link:definition>00000046 - Disclosure - Summary of Restricted Stock Units Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" id="Stock-basedPaymentsDetailsNarrative">
	  <link:definition>00000047 - Disclosure - Stock-based Payments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SummaryOfWarrantActivityDetails" id="SummaryOfWarrantActivityDetails">
	  <link:definition>00000048 - Disclosure - Summary of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" id="ScheduleOfIncomeTaxBenefitprovisionDetails">
	  <link:definition>00000050 - Disclosure - Schedule of Income Tax (Benefit)/Provision (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" id="ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails">
	  <link:definition>00000051 - Disclosure - Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" id="ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails">
	  <link:definition>00000052 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000054 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000055 - Disclosure - Related Parties (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
	  <link:definition>00000056 - Disclosure - Employee Benefit Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" id="PaycheckProtectionProgramLoanDetailsNarrative">
	  <link:definition>00000057 - Disclosure - Paycheck Protection Program Loan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" id="PatentAssignmentAndRoyaltyAgreementDetailsNarrative">
	  <link:definition>00000058 - Disclosure - Patent Assignment and Royalty Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://mymd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000059 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="mymd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mymd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mymd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mymd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="MYMD_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_CommonStockNoParValueMember" name="CommonStockNoParValueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MyMDPharmaceuticalsFloridaIncMember" name="MyMDPharmaceuticalsFloridaIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SuperaPharmaceuticalsIncMember" name="SuperaPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_HydeParkFacilityMember" name="HydeParkFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SuperaAviationMember" name="SuperaAviationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandTwentyBaltimoreMember" name="TwoThousandTwentyBaltimoreMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandTwentyOneBaltimoreMember" name="TwoThousandTwentyOneBaltimoreMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PlattStreetMember" name="PlattStreetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PreFundedWarrantsToPurchaseCommonStockMember" name="PreFundedWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SeriesCPreferredConvertibleWarrantsMember" name="SeriesCPreferredConvertibleWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SeriesDPreferredConvertibleStockMember" name="SeriesDPreferredConvertibleStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_CystronBiotechLLCMember" name="CystronBiotechLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MembershipInterestPurchaseAgreementMember" name="MembershipInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ContributionAgreementMember" name="ContributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PremasBiotechPVTLtdMember" name="PremasBiotechPVTLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PreMergerMember" name="PreMergerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_AkersBiosciencesIncMember" name="AkersBiosciencesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MilestonePeriodOneMember" name="MilestonePeriodOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MilestonePeriodTwoMember" name="MilestonePeriodTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MilestonePeriodThreeMember" name="MilestonePeriodThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MilestonePeriodFourMember" name="MilestonePeriodFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_BridgeLoanNoteMember" name="BridgeLoanNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_EventOfDefaultMember" name="EventOfDefaultMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandThirteenStockIncentivePlanMember" name="TwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_AmendedPlanMember" name="AmendedPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandAndSixteenStockIncentivePlanMember" name="TwoThousandAndSixteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" name="TwoThousandAndSeventeenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandAndEighteenStockIncentivePlanMember" name="TwoThousandAndEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" name="TwoThousandAndSixteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MyMDFloridaStockOptionsMember" name="MyMDFloridaStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" name="JanuaryTwentyEightTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_JulySevenTwoThousandTwentyTwoMember" name="JulySevenTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PreFundedCommonStockWarrantsMember" name="PreFundedCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SeriesCConvertiblePreferredStockWarrantsMember" name="SeriesCConvertiblePreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_TaglichBrothersIncMember" name="TaglichBrothersIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MrWilliamsMember" name="MrWilliamsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SuperaAviationILLCMember" name="SuperaAviationILLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_NegotiatedSettlementMember" name="NegotiatedSettlementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" name="FourZeroOneKPlanMatchesFiftyPercentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_FourZeroOneKPlanMaximumFivePercentMember" name="FourZeroOneKPlanMaximumFivePercentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PaycheckProtectionProgramLoansMember" name="PaycheckProtectionProgramLoansMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_InstitutionalAndAccreditedInvestorsMember" name="InstitutionalAndAccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SeriesFConvertiblePreferredStockMember" name="SeriesFConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_AccretionOfDebtDiscount" name="AccretionOfDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_StockOptionModificationExpenses" name="StockOptionModificationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_GainOnDebtForgiveness" name="GainOnDebtForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_UninsuredCasualtyLosses" name="UninsuredCasualtyLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" name="ExerciseOfPrepaidEquityForwardContractsForCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" name="ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" name="StockIssuedDuringPeriodValueCompensationOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" name="IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ModificationTermsOfPreMergerStockOptions" name="ModificationTermsOfPreMergerStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ExerciseOfWarrantsForCommonStock" name="ExerciseOfWarrantsForCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ExerciseOfWarrantsForCommonStockShares" name="ExerciseOfWarrantsForCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ExchangeRatioPricePerShares" name="ExchangeRatioPricePerShares" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ModificationOfPreMergerStockOptionShares" name="ModificationOfPreMergerStockOptionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_AccruedInterestdividends" name="AccruedInterestdividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MarketableSecuritiesUnrealizedLoss" name="MarketableSecuritiesUnrealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_GainOnForgivenessOfDebt" name="GainOnForgivenessOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_CashPaidForAbstract" name="CashPaidForAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_OtherAssetInvestment" name="OtherAssetInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" name="DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock" name="RecentDevelopmentsAndManagementsPlansTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_DisclosurePaycheckProtectionProgramLoanAbstract" name="DisclosurePaycheckProtectionProgramLoanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" name="PaycheckProtectionProgramLoanDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" name="DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" name="PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PrepaidExpensesPolicyTextBlock" name="PrepaidExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock" name="RiskManagementOfCashInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_RightOfUseAssetsPolicyTextBlock" name="RightOfUseAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" name="ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" name="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock" name="SummaryOfMilestoneEventsPaymentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MilestoneEvent" name="MilestoneEvent" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" name="StockIssuedDuringPeriodSharesPostReverseStockSplits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ExchangeRatioPercentage" name="ExchangeRatioPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_DecreaseInPrepaidExpense" name="DecreaseInPrepaidExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_WeightedAverageRemainingContractualTermGranted" name="WeightedAverageRemainingContractualTermGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_CumulativeFairMarketValue" name="CumulativeFairMarketValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_NumberOfStockOptionsAssumed" name="NumberOfStockOptionsAssumed" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_OptionsMarketValue" name="OptionsMarketValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" name="NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_OperatingLossCarryforwarddSubjectToExpiration" name="OperatingLossCarryforwarddSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_OperatingLossCarryforwardsExpirationDateDescription" name="OperatingLossCarryforwardsExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" name="PercentageOfNetIncomeForEachSubsequentPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MYMD_AnnualLeasingFee" name="AnnualLeasingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>mymd-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mymd.com/role/Cover" xlink:href="mymd-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/BalanceSheets" xlink:href="mymd-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/BalanceSheetsParenthetical" xlink:href="mymd-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfComprehensiveLoss" xlink:href="mymd-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" xlink:href="mymd-20221231.xsd#StatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" xlink:href="mymd-20221231.xsd#StatementOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="mymd-20221231.xsd#StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfCashFlows" xlink:href="mymd-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="mymd-20221231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPolicies" xlink:href="mymd-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/TradeAndOtherPayables" xlink:href="mymd-20221231.xsd#TradeAndOtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/NotesPayable" xlink:href="mymd-20221231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPayments" xlink:href="mymd-20221231.xsd#Stock-basedPayments" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Equity" xlink:href="mymd-20221231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxes" xlink:href="mymd-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/CommitmentsAndContingencies" xlink:href="mymd-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RelatedParties" xlink:href="mymd-20221231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EmployeeBenefitPlan" xlink:href="mymd-20221231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PaycheckProtectionProgramLoan" xlink:href="mymd-20221231.xsd#PaycheckProtectionProgramLoan" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" xlink:href="mymd-20221231.xsd#PatentAssignmentAndRoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SubsequentEvents" xlink:href="mymd-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesPolicies" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesTables" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/TradeAndOtherPayablesTables" xlink:href="mymd-20221231.xsd#TradeAndOtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPaymentsTables" xlink:href="mymd-20221231.xsd#Stock-basedPaymentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EquityTables" xlink:href="mymd-20221231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxesTables" xlink:href="mymd-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:href="mymd-20221231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="mymd-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:href="mymd-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:href="mymd-20221231.xsd#ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" xlink:href="mymd-20221231.xsd#ScheduleOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:href="mymd-20221231.xsd#ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="mymd-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:href="mymd-20221231.xsd#ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" xlink:href="mymd-20221231.xsd#SummaryOfMilestoneEventsPaymentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfTradeAndOtherPayablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/NotesPayableDetailsNarrative" xlink:href="mymd-20221231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" xlink:href="mymd-20221231.xsd#Stock-basedPaymentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfWarrantActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EquityDetailsNarrative" xlink:href="mymd-20221231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:href="mymd-20221231.xsd#ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxesDetailsNarrative" xlink:href="mymd-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="mymd-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RelatedPartiesDetailsNarrative" xlink:href="mymd-20221231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="mymd-20221231.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" xlink:href="mymd-20221231.xsd#PaycheckProtectionProgramLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:href="mymd-20221231.xsd#PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SubsequentEventsDetailsNarrative" xlink:href="mymd-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AccretionOfDebtDiscount" xlink:label="loc_MYMDAccretionOfDebtDiscount" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_MYMDAccretionOfDebtDiscount" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockOptionModificationExpenses" xlink:label="loc_MYMDStockOptionModificationExpenses" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_MYMDStockOptionModificationExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaapInvestmentIncomeInterestAndDividend" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterestAndDividend" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_GainOnDebtForgiveness" xlink:label="loc_MYMDGainOnDebtForgiveness" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_MYMDGainOnDebtForgiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_UninsuredCasualtyLosses" xlink:label="loc_MYMDUninsuredCasualtyLosses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_MYMDUninsuredCasualtyLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AccruedInterestdividends" xlink:label="loc_MYMDAccruedInterestdividends" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MYMDAccruedInterestdividends" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MarketableSecuritiesUnrealizedLoss" xlink:label="loc_MYMDMarketableSecuritiesUnrealizedLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MYMDMarketableSecuritiesUnrealizedLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_GainOnForgivenessOfDebt" xlink:label="loc_MYMDGainOnForgivenessOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MYMDGainOnForgivenessOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockOptionModificationExpenses" xlink:label="loc_MYMDStockOptionModificationExpenses" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MYMDStockOptionModificationExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaapProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000009 - Disclosure - Organization and Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" xlink:title="00000011 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/TradeAndOtherPayables" xlink:title="00000012 - Disclosure - Trade and Other Payables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPayments" xlink:title="00000014 - Disclosure - Stock-based Payments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/Equity" xlink:title="00000015 - Disclosure - Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - Related Parties" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/EmployeeBenefitPlan" xlink:title="00000019 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/PaycheckProtectionProgramLoan" xlink:title="00000020 - Disclosure - Paycheck Protection Program Loan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" xlink:title="00000021 - Disclosure - Patent Assignment and Royalty Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:title="00000025 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/TradeAndOtherPayablesTables" xlink:title="00000026 - Disclosure - Trade and Other Payables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPaymentsTables" xlink:title="00000027 - Disclosure - Stock-based Payments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/EquityTables" xlink:title="00000028 - Disclosure - Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="00000030 - Disclosure - Organization and Description of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:title="00000031 - Disclosure - Schedule of Marketable Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:title="00000032 - Disclosure - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of Estimated Useful Lives of Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:title="00000034 - Disclosure - Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" xlink:title="00000035 - Disclosure - Schedule of Lease Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:title="00000036 - Disclosure - Schedule of Other Information Related to Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:title="00000037 - Disclosure - Schedule of Operating Lease Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000038 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:title="00000040 - Disclosure - Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" xlink:title="00000041 - Disclosure - Summary of Milestone Events Payment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:title="00000042 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:title="00000043 - Disclosure - Schedule of Trade and Other Payables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/NotesPayableDetailsNarrative" xlink:title="00000044 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" xlink:title="00000045 - Disclosure - Summary of Stock Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" xlink:title="00000046 - Disclosure - Summary of Restricted Stock Units Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" xlink:title="00000047 - Disclosure - Stock-based Payments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000048 - Disclosure - Summary of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/EquityDetailsNarrative" xlink:title="00000049 - Disclosure - Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:title="00000050 - Disclosure - Schedule of Income Tax (Benefit)/Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:title="00000051 - Disclosure - Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:title="00000052 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000053 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000054 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000055 - Disclosure - Related Parties (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000056 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" xlink:title="00000057 - Disclosure - Paycheck Protection Program Loan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:title="00000058 - Disclosure - Patent Assignment and Royalty Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mymd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000059 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>mymd-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mymd.com/role/Cover" xlink:href="mymd-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/BalanceSheets" xlink:href="mymd-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/BalanceSheetsParenthetical" xlink:href="mymd-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfComprehensiveLoss" xlink:href="mymd-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" xlink:href="mymd-20221231.xsd#StatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" xlink:href="mymd-20221231.xsd#StatementOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="mymd-20221231.xsd#StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfCashFlows" xlink:href="mymd-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="mymd-20221231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPolicies" xlink:href="mymd-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/TradeAndOtherPayables" xlink:href="mymd-20221231.xsd#TradeAndOtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/NotesPayable" xlink:href="mymd-20221231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPayments" xlink:href="mymd-20221231.xsd#Stock-basedPayments" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Equity" xlink:href="mymd-20221231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxes" xlink:href="mymd-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/CommitmentsAndContingencies" xlink:href="mymd-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RelatedParties" xlink:href="mymd-20221231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EmployeeBenefitPlan" xlink:href="mymd-20221231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PaycheckProtectionProgramLoan" xlink:href="mymd-20221231.xsd#PaycheckProtectionProgramLoan" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" xlink:href="mymd-20221231.xsd#PatentAssignmentAndRoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SubsequentEvents" xlink:href="mymd-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesPolicies" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesTables" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/TradeAndOtherPayablesTables" xlink:href="mymd-20221231.xsd#TradeAndOtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPaymentsTables" xlink:href="mymd-20221231.xsd#Stock-basedPaymentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EquityTables" xlink:href="mymd-20221231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxesTables" xlink:href="mymd-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:href="mymd-20221231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="mymd-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:href="mymd-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:href="mymd-20221231.xsd#ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" xlink:href="mymd-20221231.xsd#ScheduleOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:href="mymd-20221231.xsd#ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="mymd-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:href="mymd-20221231.xsd#ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" xlink:href="mymd-20221231.xsd#SummaryOfMilestoneEventsPaymentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfTradeAndOtherPayablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/NotesPayableDetailsNarrative" xlink:href="mymd-20221231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" xlink:href="mymd-20221231.xsd#Stock-basedPaymentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfWarrantActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EquityDetailsNarrative" xlink:href="mymd-20221231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:href="mymd-20221231.xsd#ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxesDetailsNarrative" xlink:href="mymd-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="mymd-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RelatedPartiesDetailsNarrative" xlink:href="mymd-20221231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="mymd-20221231.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" xlink:href="mymd-20221231.xsd#PaycheckProtectionProgramLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:href="mymd-20221231.xsd#PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SubsequentEventsDetailsNarrative" xlink:href="mymd-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseCurrent_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_50" xlink:to="loc_us-gaapGoodwill_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_50" xlink:to="loc_us-gaapLongTermInvestments_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_50" xlink:to="loc_us-gaapAssetsNoncurrent_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_50" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesNoncurrent_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_50" xlink:to="loc_us-gaapCommitmentsAndContingencies_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_50" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_50" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockNoParValueMember" xlink:label="loc_MYMDCommonStockNoParValueMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockNoParValueMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" xlink:label="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStock_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" xlink:label="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStockShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStockShares_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" xlink:label="loc_MYMDStockIssuedDuringPeriodValueCompensationOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDStockIssuedDuringPeriodValueCompensationOfWarrants_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" xlink:label="loc_MYMDIssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDIssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ModificationTermsOfPreMergerStockOptions" xlink:label="loc_MYMDModificationTermsOfPreMergerStockOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDModificationTermsOfPreMergerStockOptions_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfWarrantsForCommonStock" xlink:label="loc_MYMDExerciseOfWarrantsForCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfWarrantsForCommonStock_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfWarrantsForCommonStockShares" xlink:label="loc_MYMDExerciseOfWarrantsForCommonStockShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfWarrantsForCommonStockShares_70" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPricePerShares" xlink:label="loc_MYMDExchangeRatioPricePerShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExchangeRatioPricePerShares_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ModificationOfPreMergerStockOptionShares" xlink:label="loc_MYMDModificationOfPreMergerStockOptionShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDModificationOfPreMergerStockOptionShares_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000009 - Disclosure - Organization and Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" xlink:title="00000011 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/TradeAndOtherPayables" xlink:title="00000012 - Disclosure - Trade and Other Payables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPayments" xlink:title="00000014 - Disclosure - Stock-based Payments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/Equity" xlink:title="00000015 - Disclosure - Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - Related Parties" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/EmployeeBenefitPlan" xlink:title="00000019 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/PaycheckProtectionProgramLoan" xlink:title="00000020 - Disclosure - Paycheck Protection Program Loan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" xlink:title="00000021 - Disclosure - Patent Assignment and Royalty Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:title="00000025 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/TradeAndOtherPayablesTables" xlink:title="00000026 - Disclosure - Trade and Other Payables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPaymentsTables" xlink:title="00000027 - Disclosure - Stock-based Payments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/EquityTables" xlink:title="00000028 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="loc_MYMDCommonStockWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="loc_MYMDPreFundedCommonStockWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPreFundedCommonStockWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="00000030 - Disclosure - Organization and Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:label="loc_MYMDMyMDPharmaceuticalsFloridaIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MYMDMyMDPharmaceuticalsFloridaIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaPharmaceuticalsIncMember" xlink:label="loc_MYMDSuperaPharmaceuticalsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDSuperaPharmaceuticalsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AssetPurchaseAgreementMember" xlink:label="loc_MYMDAssetPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDAssetPurchaseAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPricePerShares" xlink:label="loc_MYMDExchangeRatioPricePerShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MYMDExchangeRatioPricePerShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:title="00000031 - Disclosure - Schedule of Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapMarketableSecurities_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:title="00000032 - Disclosure - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of Estimated Useful Lives of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PatentsAndTrademarksMember" xlink:label="loc_MYMDPatentsAndTrademarksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_MYMDPatentsAndTrademarksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:title="00000034 - Disclosure - Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" xlink:title="00000035 - Disclosure - Schedule of Lease Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationMember" xlink:label="loc_MYMDSuperaAviationMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSuperaAviationMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyBaltimoreMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyBaltimoreMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:title="00000036 - Disclosure - Schedule of Other Information Related to Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:title="00000037 - Disclosure - Schedule of Operating Lease Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000038 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_UnvestedRestrictedStockUnitsMember" xlink:label="loc_MYMDUnvestedRestrictedStockUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDUnvestedRestrictedStockUnitsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WarrantsToPurchaseCommonStockMember" xlink:label="loc_MYMDWarrantsToPurchaseCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDWarrantsToPurchaseCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedWarrantsToPurchaseCommonStockMember" xlink:label="loc_MYMDPreFundedWarrantsToPurchaseCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDPreFundedWarrantsToPurchaseCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCPreferredConvertibleWarrantsMember" xlink:label="loc_MYMDSeriesCPreferredConvertibleWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDSeriesCPreferredConvertibleWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDPreferredConvertibleStockMember" xlink:label="loc_MYMDSeriesDPreferredConvertibleStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDSeriesDPreferredConvertibleStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMutualFundMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationMember" xlink:label="loc_MYMDSuperaAviationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSuperaAviationMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyBaltimoreMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyBaltimoreMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRent_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_240" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:title="00000040 - Disclosure - Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AkersBiosciencesIncMember" xlink:label="loc_MYMDAkersBiosciencesIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDAkersBiosciencesIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill_30" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" xlink:title="00000041 - Disclosure - Summary of Milestone Events Payment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodOneMember" xlink:label="loc_MYMDMilestonePeriodOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodTwoMember" xlink:label="loc_MYMDMilestonePeriodTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodThreeMember" xlink:label="loc_MYMDMilestonePeriodThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodFourMember" xlink:label="loc_MYMDMilestonePeriodFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestoneEvent" xlink:label="loc_MYMDMilestoneEvent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MYMDMilestoneEvent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePayment" xlink:label="loc_MYMDMilestonePayment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MYMDMilestonePayment_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:title="00000042 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CystronBiotechLLCMember" xlink:label="loc_MYMDCystronBiotechLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDCystronBiotechLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreMergerMember" xlink:label="loc_MYMDPreMergerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDPreMergerMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AkersBiosciencesIncMember" xlink:label="loc_MYMDAkersBiosciencesIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDAkersBiosciencesIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MembershipInterestPurchaseAgreementMember" xlink:label="loc_MYMDMembershipInterestPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMembershipInterestPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ContributionAgreementMember" xlink:label="loc_MYMDContributionAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDContributionAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PremasBiotechPVTLtdMember" xlink:label="loc_MYMDPremasBiotechPVTLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MYMDPremasBiotechPVTLtdMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrefundedWarrantsMember" xlink:label="loc_MYMDPrefundedWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_MYMDPrefundedWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" xlink:label="loc_MYMDStockIssuedDuringPeriodSharesPostReverseStockSplits_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDStockIssuedDuringPeriodSharesPostReverseStockSplits_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPercentage" xlink:label="loc_MYMDExchangeRatioPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExchangeRatioPercentage_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="loc_us-gaapCapitalizationLongtermDebtAndEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalizationLongtermDebtAndEquity_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WorkingCapital" xlink:label="loc_MYMDWorkingCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDWorkingCapital_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DecreaseInPrepaidExpense" xlink:label="loc_MYMDDecreaseInPrepaidExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDDecreaseInPrepaidExpense_130" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:title="00000043 - Disclosure - Schedule of Trade and Other Payables (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/NotesPayableDetailsNarrative" xlink:title="00000044 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_BridgeLoanNoteMember" xlink:label="loc_MYMDBridgeLoanNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MYMDBridgeLoanNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_EventOfDefaultMember" xlink:label="loc_MYMDEventOfDefaultMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_MYMDEventOfDefaultMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:label="loc_MYMDMyMDPharmaceuticalsFloridaIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_MYMDMyMDPharmaceuticalsFloridaIncMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesToAffiliate" xlink:label="loc_us-gaapAdvancesToAffiliate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAdvancesToAffiliate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" xlink:title="00000045 - Disclosure - Summary of Stock Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" xlink:title="00000046 - Disclosure - Summary of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" xlink:title="00000047 - Disclosure - Stock-based Payments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandThirteenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandThirteenStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandThirteenStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AmendedPlanMember" xlink:label="loc_MYMDAmendedPlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDAmendedPlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSixteenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndSixteenStockIncentivePlanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndSixteenStockIncentivePlanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndSeventeenStockIncentivePlanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndSeventeenStockIncentivePlanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndEighteenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndEighteenStockIncentivePlanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndEighteenStockIncentivePlanMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndTwentyOneStockIncentivePlanMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndTwentyOneStockIncentivePlanMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndSixteenEquityIncentivePlanMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndSixteenEquityIncentivePlanMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDFloridaStockOptionsMember" xlink:label="loc_MYMDMyMDFloridaStockOptionsMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MYMDMyMDFloridaStockOptionsMember_290" xlink:type="arc" order="292" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" xlink:label="loc_MYMDJanuaryTwentyEightTwoThousandTwentyTwoMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_MYMDJanuaryTwentyEightTwoThousandTwentyTwoMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_JulySevenTwoThousandTwentyTwoMember" xlink:label="loc_MYMDJulySevenTwoThousandTwentyTwoMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_MYMDJulySevenTwoThousandTwentyTwoMember_400" xlink:type="arc" order="402" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_450" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_450" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_450" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CumulativeFairMarketValue" xlink:label="loc_MYMDCumulativeFairMarketValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDCumulativeFairMarketValue_450" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense_450" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_450" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NumberOfStockOptionsAssumed" xlink:label="loc_MYMDNumberOfStockOptionsAssumed_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDNumberOfStockOptionsAssumed_450" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_450" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_450" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_450" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_450" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OptionsMarketValue" xlink:label="loc_MYMDOptionsMarketValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDOptionsMarketValue_450" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_450" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_450" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_450" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings_450" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_450" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_450" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_450" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000048 - Disclosure - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="loc_MYMDCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="loc_MYMDPreFundedCommonStockWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPreFundedCommonStockWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_MYMDSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_100" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/EquityDetailsNarrative" xlink:title="00000049 - Disclosure - Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrefundedWarrantsMember" xlink:label="loc_MYMDPrefundedWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPrefundedWarrantsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="loc_MYMDCommonStockWarrantsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockWarrantsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="loc_MYMDPreFundedCommonStockWarrantsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPreFundedCommonStockWarrantsMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_MYMDSecuritiesPurchaseAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSecuritiesPurchaseAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue_350" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_350" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_350" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion_350" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_350" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" xlink:label="loc_MYMDNumberOfCommonStockSharesRepresentByPreferredStockOutstanding_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_MYMDNumberOfCommonStockSharesRepresentByPreferredStockOutstanding_350" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_350" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_350" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_350" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_350" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_350" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_350" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_350" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_350" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_350" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_350" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_350" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_350" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_350" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_MYMDNetProceedsFromIssuanceOfCommonStock_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_MYMDNetProceedsFromIssuanceOfCommonStock_350" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_350" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_350" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_350" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_350" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_350" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:title="00000050 - Disclosure - Schedule of Income Tax (Benefit)/Provision (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:title="00000051 - Disclosure - Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:title="00000052 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000053 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwarddSubjectToExpiration" xlink:label="loc_MYMDOperatingLossCarryforwarddSubjectToExpiration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDOperatingLossCarryforwarddSubjectToExpiration_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwardsExpirationDateDescription" xlink:label="loc_MYMDOperatingLossCarryforwardsExpirationDateDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDOperatingLossCarryforwardsExpirationDateDescription_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_MYMDOperatingLossCarryforwardsNotSubjectToExpiration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDOperatingLossCarryforwardsNotSubjectToExpiration_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" xlink:label="loc_MYMDPercentageOfNetIncomeForEachSubsequentPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDPercentageOfNetIncomeForEachSubsequentPeriod_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CumulativeChangeInOwnershipPercentage" xlink:label="loc_MYMDCumulativeChangeInOwnershipPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDCumulativeChangeInOwnershipPercentage_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000054 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostsAndExpenses_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000055 - Disclosure - Related Parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TaglichBrothersIncMember" xlink:label="loc_MYMDTaglichBrothersIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MYMDTaglichBrothersIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ConsultingAgreementMember" xlink:label="loc_MYMDConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDConsultingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NegotiatedSettlementMember" xlink:label="loc_MYMDNegotiatedSettlementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDNegotiatedSettlementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MrWilliamsMember" xlink:label="loc_MYMDMrWilliamsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_MYMDMrWilliamsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationILLCMember" xlink:label="loc_MYMDSuperaAviationILLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_MYMDSuperaAviationILLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrentAndNoncurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrentAndNoncurrent_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AnnualLeasingFee" xlink:label="loc_MYMDAnnualLeasingFee_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_MYMDAnnualLeasingFee_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationPeriod_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaapLineOfCreditFacilityDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityDescription_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_140" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000056 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaapRetirementPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaapRetirementPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRetirementPlanNameAxis" xlink:to="loc_us-gaapRetirementPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaapRetirementPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRetirementPlanNameAxis" xlink:to="loc_us-gaapRetirementPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" xlink:label="loc_MYMDFourZeroOneKPlanMatchesFiftyPercentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRetirementPlanNameDomain" xlink:to="loc_MYMDFourZeroOneKPlanMatchesFiftyPercentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_FourZeroOneKPlanMaximumFivePercentMember" xlink:label="loc_MYMDFourZeroOneKPlanMaximumFivePercentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRetirementPlanNameDomain" xlink:to="loc_MYMDFourZeroOneKPlanMaximumFivePercentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercent_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" xlink:title="00000057 - Disclosure - Paycheck Protection Program Loan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PaycheckProtectionProgramLoansMember" xlink:label="loc_MYMDPaycheckProtectionProgramLoansMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MYMDPaycheckProtectionProgramLoansMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:title="00000058 - Disclosure - Patent Assignment and Royalty Agreement (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mymd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000059 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_MYMDSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_InstitutionalAndAccreditedInvestorsMember" xlink:label="loc_MYMDInstitutionalAndAccreditedInvestorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MYMDInstitutionalAndAccreditedInvestorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesFConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesFConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesFConvertiblePreferredStockMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_MYMDNetProceedsFromIssuanceOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_MYMDNetProceedsFromIssuanceOfCommonStock_50" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>mymd-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="MYMD_SeriesDConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesDConvertiblePreferredStockMember" xlink:to="MYMD_SeriesDConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockNoParValueMember" xlink:label="MYMD_CommonStockNoParValueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CommonStockNoParValueMember" xlink:to="MYMD_CommonStockNoParValueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_CommonStockNoParValueMember_lbl" xml:lang="en-US">Common stock No Par Value [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:label="MYMD_MyMDPharmaceuticalsFloridaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:to="MYMD_MyMDPharmaceuticalsFloridaIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MyMDPharmaceuticalsFloridaIncMember_lbl" xml:lang="en-US">MyMD Pharmaceuticals (Florida), Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaPharmaceuticalsIncMember" xlink:label="MYMD_SuperaPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SuperaPharmaceuticalsIncMember" xlink:to="MYMD_SuperaPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SuperaPharmaceuticalsIncMember_lbl" xml:lang="en-US">Supera Pharmaceuticals Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AssetPurchaseAgreementMember" xlink:label="MYMD_AssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AssetPurchaseAgreementMember" xlink:to="MYMD_AssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember" xlink:label="us-gaap_MutualFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MutualFundMember_lbl" xml:lang="en-US">Mutual Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="MYMD_HydeParkFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_HydeParkFacilityMember" xlink:to="MYMD_HydeParkFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_HydeParkFacilityMember_lbl" xml:lang="en-US">Hyde Park Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationMember" xlink:label="MYMD_SuperaAviationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SuperaAviationMember" xlink:to="MYMD_SuperaAviationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SuperaAviationMember_lbl" xml:lang="en-US">Supera Aviation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyBaltimoreMember" xlink:label="MYMD_TwoThousandTwentyBaltimoreMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandTwentyBaltimoreMember" xlink:to="MYMD_TwoThousandTwentyBaltimoreMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandTwentyBaltimoreMember_lbl" xml:lang="en-US">2020 Baltimore [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="MYMD_TwoThousandTwentyOneBaltimoreMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:to="MYMD_TwoThousandTwentyOneBaltimoreMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandTwentyOneBaltimoreMember_lbl" xml:lang="en-US">2021 Baltimore [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="MYMD_PlattStreetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PlattStreetMember" xlink:to="MYMD_PlattStreetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PlattStreetMember_lbl" xml:lang="en-US">Platt Street [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PatentsAndTrademarksMember" xlink:label="MYMD_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PatentsAndTrademarksMember" xlink:to="MYMD_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_UnvestedRestrictedStockUnitsMember" xlink:label="MYMD_UnvestedRestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_UnvestedRestrictedStockUnitsMember" xlink:to="MYMD_UnvestedRestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_UnvestedRestrictedStockUnitsMember_lbl" xml:lang="en-US">Unvested Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WarrantsToPurchaseCommonStockMember" xlink:label="MYMD_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_WarrantsToPurchaseCommonStockMember" xlink:to="MYMD_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedWarrantsToPurchaseCommonStockMember" xlink:label="MYMD_PreFundedWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PreFundedWarrantsToPurchaseCommonStockMember" xlink:to="MYMD_PreFundedWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PreFundedWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Pre-funded Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCPreferredConvertibleWarrantsMember" xlink:label="MYMD_SeriesCPreferredConvertibleWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesCPreferredConvertibleWarrantsMember" xlink:to="MYMD_SeriesCPreferredConvertibleWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SeriesCPreferredConvertibleWarrantsMember_lbl" xml:lang="en-US">Series C Preferred Convertible Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDPreferredConvertibleStockMember" xlink:label="MYMD_SeriesDPreferredConvertibleStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesDPreferredConvertibleStockMember" xlink:to="MYMD_SeriesDPreferredConvertibleStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SeriesDPreferredConvertibleStockMember_lbl" xml:lang="en-US">Series D Preferred Convertible Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CystronBiotechLLCMember" xlink:label="MYMD_CystronBiotechLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CystronBiotechLLCMember" xlink:to="MYMD_CystronBiotechLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_CystronBiotechLLCMember_lbl" xml:lang="en-US">Cystron Biotech LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MembershipInterestPurchaseAgreementMember" xlink:label="MYMD_MembershipInterestPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MembershipInterestPurchaseAgreementMember" xlink:to="MYMD_MembershipInterestPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MembershipInterestPurchaseAgreementMember_lbl" xml:lang="en-US">Membership Interest Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ContributionAgreementMember" xlink:label="MYMD_ContributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ContributionAgreementMember" xlink:to="MYMD_ContributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ContributionAgreementMember_lbl" xml:lang="en-US">Contribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PremasBiotechPVTLtdMember" xlink:label="MYMD_PremasBiotechPVTLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PremasBiotechPVTLtdMember" xlink:to="MYMD_PremasBiotechPVTLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PremasBiotechPVTLtdMember_lbl" xml:lang="en-US">Premas Biotech PVT Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="MYMD_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MergerAgreementMember" xlink:to="MYMD_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreMergerMember" xlink:label="MYMD_PreMergerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PreMergerMember" xlink:to="MYMD_PreMergerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PreMergerMember_lbl" xml:lang="en-US">Pre Merger [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrefundedWarrantsMember" xlink:label="MYMD_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PrefundedWarrantsMember" xlink:to="MYMD_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AkersBiosciencesIncMember" xlink:label="MYMD_AkersBiosciencesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AkersBiosciencesIncMember" xlink:to="MYMD_AkersBiosciencesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_AkersBiosciencesIncMember_lbl" xml:lang="en-US">Akers Biosciences, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodOneMember" xlink:label="MYMD_MilestonePeriodOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodOneMember" xlink:to="MYMD_MilestonePeriodOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MilestonePeriodOneMember_lbl" xml:lang="en-US">Milestone Period One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodTwoMember" xlink:label="MYMD_MilestonePeriodTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodTwoMember" xlink:to="MYMD_MilestonePeriodTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MilestonePeriodTwoMember_lbl" xml:lang="en-US">Milestone Period Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodThreeMember" xlink:label="MYMD_MilestonePeriodThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodThreeMember" xlink:to="MYMD_MilestonePeriodThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MilestonePeriodThreeMember_lbl" xml:lang="en-US">Milestone Period Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodFourMember" xlink:label="MYMD_MilestonePeriodFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodFourMember" xlink:to="MYMD_MilestonePeriodFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MilestonePeriodFourMember_lbl" xml:lang="en-US">Milestone Period Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_BridgeLoanNoteMember" xlink:label="MYMD_BridgeLoanNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_BridgeLoanNoteMember" xlink:to="MYMD_BridgeLoanNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_BridgeLoanNoteMember_lbl" xml:lang="en-US">Bridge Loan Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_EventOfDefaultMember" xlink:label="MYMD_EventOfDefaultMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_EventOfDefaultMember" xlink:to="MYMD_EventOfDefaultMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_EventOfDefaultMember_lbl" xml:lang="en-US">Event of Default [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandThirteenStockIncentivePlanMember" xlink:label="MYMD_TwoThousandThirteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandThirteenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandThirteenStockIncentivePlanMember_lbl" xml:lang="en-US">2013 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AmendedPlanMember" xlink:label="MYMD_AmendedPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AmendedPlanMember" xlink:to="MYMD_AmendedPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_AmendedPlanMember_lbl" xml:lang="en-US">Amended Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSixteenStockIncentivePlanMember" xlink:label="MYMD_TwoThousandAndSixteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndSixteenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndSixteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandAndSixteenStockIncentivePlanMember_lbl" xml:lang="en-US">2016 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:label="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember_lbl" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndEighteenStockIncentivePlanMember" xlink:label="MYMD_TwoThousandAndEighteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndEighteenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndEighteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandAndEighteenStockIncentivePlanMember_lbl" xml:lang="en-US">2018 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:to="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2016 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDFloridaStockOptionsMember" xlink:label="MYMD_MyMDFloridaStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MyMDFloridaStockOptionsMember" xlink:to="MYMD_MyMDFloridaStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MyMDFloridaStockOptionsMember_lbl" xml:lang="en-US">MyMD Florida Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" xlink:label="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" xlink:to="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">January 28, 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_JulySevenTwoThousandTwentyTwoMember" xlink:label="MYMD_JulySevenTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_JulySevenTwoThousandTwentyTwoMember" xlink:to="MYMD_JulySevenTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_JulySevenTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">July 7, 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SecuritiesPurchaseAgreementMember" xlink:label="MYMD_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SecuritiesPurchaseAgreementMember" xlink:to="MYMD_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="MYMD_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CommonStockWarrantsMember" xlink:to="MYMD_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="MYMD_PreFundedCommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PreFundedCommonStockWarrantsMember" xlink:to="MYMD_PreFundedCommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PreFundedCommonStockWarrantsMember_lbl" xml:lang="en-US">Pre-funded Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="MYMD_SeriesCConvertiblePreferredStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:to="MYMD_SeriesCConvertiblePreferredStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SeriesCConvertiblePreferredStockWarrantsMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TaglichBrothersIncMember" xlink:label="MYMD_TaglichBrothersIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TaglichBrothersIncMember" xlink:to="MYMD_TaglichBrothersIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_TaglichBrothersIncMember_lbl" xml:lang="en-US">Taglich Brothers Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ConsultingAgreementMember" xlink:label="MYMD_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ConsultingAgreementMember" xlink:to="MYMD_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MrWilliamsMember" xlink:label="MYMD_MrWilliamsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MrWilliamsMember" xlink:to="MYMD_MrWilliamsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MrWilliamsMember_lbl" xml:lang="en-US">Mr Williams [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationILLCMember" xlink:label="MYMD_SuperaAviationILLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SuperaAviationILLCMember" xlink:to="MYMD_SuperaAviationILLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SuperaAviationILLCMember_lbl" xml:lang="en-US">Supera Aviation I, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NegotiatedSettlementMember" xlink:label="MYMD_NegotiatedSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NegotiatedSettlementMember" xlink:to="MYMD_NegotiatedSettlementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_NegotiatedSettlementMember_lbl" xml:lang="en-US">Negotiated Settlement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" xlink:label="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" xlink:to="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember_lbl" xml:lang="en-US">401 K Plan Matches 50% [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_FourZeroOneKPlanMaximumFivePercentMember" xlink:label="MYMD_FourZeroOneKPlanMaximumFivePercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_FourZeroOneKPlanMaximumFivePercentMember" xlink:to="MYMD_FourZeroOneKPlanMaximumFivePercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_FourZeroOneKPlanMaximumFivePercentMember_lbl" xml:lang="en-US">401 K Plan Maximum 5% [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PaycheckProtectionProgramLoansMember" xlink:label="MYMD_PaycheckProtectionProgramLoansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PaycheckProtectionProgramLoansMember" xlink:to="MYMD_PaycheckProtectionProgramLoansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PaycheckProtectionProgramLoansMember_lbl" xml:lang="en-US">Paycheck Protection Program Loans [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_InstitutionalAndAccreditedInvestorsMember" xlink:label="MYMD_InstitutionalAndAccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_InstitutionalAndAccreditedInvestorsMember" xlink:to="MYMD_InstitutionalAndAccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_InstitutionalAndAccreditedInvestorsMember_lbl" xml:lang="en-US">Institutional and Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesFConvertiblePreferredStockMember" xlink:label="MYMD_SeriesFConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesFConvertiblePreferredStockMember" xlink:to="MYMD_SeriesFConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SeriesFConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series F Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease Right-of-Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Investment in Oravax, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Non-Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade and Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US">Due to MyMD Florida Shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent_lbl" xml:lang="en-US">Due to MyMD Florida Shareholders, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease Liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, no par value, 500,000,000 shares authorized 39,470,009 and 37,673,110 issued and outstanding as of December 31, 2022 and December 31, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred stock, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Product Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Product Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AccretionOfDebtDiscount" xlink:label="MYMD_AccretionOfDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AccretionOfDebtDiscount" xlink:to="MYMD_AccretionOfDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_AccretionOfDebtDiscount_lbl" xml:lang="en-US">Accretion of Debt Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockOptionModificationExpenses" xlink:label="MYMD_StockOptionModificationExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockOptionModificationExpenses" xlink:to="MYMD_StockOptionModificationExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_StockOptionModificationExpenses_lbl" xml:lang="en-US">Stock Option Modification Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (Income) Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Interest and Dividend Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xml:lang="en-US">(Gain)/Loss on Sales of Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized (Gain)/Loss on Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_GainOnDebtForgiveness" xlink:label="MYMD_GainOnDebtForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_GainOnDebtForgiveness" xlink:to="MYMD_GainOnDebtForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MYMD_GainOnDebtForgiveness_lbl" xml:lang="en-US">Gain on Debt Forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_UninsuredCasualtyLosses" xlink:label="MYMD_UninsuredCasualtyLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_UninsuredCasualtyLosses" xlink:to="MYMD_UninsuredCasualtyLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MYMD_UninsuredCasualtyLosses_lbl" xml:lang="en-US">Uninsured Casualty Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other (Income) Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss Before Income Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and Dilutive net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average basic and diluted common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" xlink:label="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" xlink:to="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock_lbl" xml:lang="en-US">Exercise of prepaid equity forward contracts for Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" xlink:label="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" xlink:to="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares_lbl" xml:lang="en-US">Exercise of prepaid equity forward contracts for common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation &#8211; stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock-based compensation &#8211; restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" xlink:label="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" xlink:to="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants_lbl" xml:lang="en-US">Stock-based compensation &#8211; warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Reverse merger with Akers Biosciences Inc effective April 16, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" xlink:label="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" xlink:to="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_lbl" xml:lang="en-US">Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ModificationTermsOfPreMergerStockOptions" xlink:label="MYMD_ModificationTermsOfPreMergerStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ModificationTermsOfPreMergerStockOptions" xlink:to="MYMD_ModificationTermsOfPreMergerStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ModificationTermsOfPreMergerStockOptions_lbl" xml:lang="en-US">Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of per-merger MyMD stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of per-merger MyMD stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock based compensation for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock based compensation for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfWarrantsForCommonStock" xlink:label="MYMD_ExerciseOfWarrantsForCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfWarrantsForCommonStock" xlink:to="MYMD_ExerciseOfWarrantsForCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ExerciseOfWarrantsForCommonStock_lbl" xml:lang="en-US">Exercise of warrants for Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfWarrantsForCommonStockShares" xlink:label="MYMD_ExerciseOfWarrantsForCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfWarrantsForCommonStockShares" xlink:to="MYMD_ExerciseOfWarrantsForCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ExerciseOfWarrantsForCommonStockShares_lbl" xml:lang="en-US">Exercise of warrants for common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payments of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPricePerShares" xlink:label="MYMD_ExchangeRatioPricePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExchangeRatioPricePerShares" xlink:to="MYMD_ExchangeRatioPricePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ExchangeRatioPricePerShares_lbl" xml:lang="en-US">Exchange ratio price per shares</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ModificationOfPreMergerStockOptionShares" xlink:label="MYMD_ModificationOfPreMergerStockOptionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ModificationOfPreMergerStockOptionShares" xlink:to="MYMD_ModificationOfPreMergerStockOptionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ModificationOfPreMergerStockOptionShares_lbl" xml:lang="en-US">Modification of pre merger stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss from ongoing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AccruedInterestdividends" xlink:label="MYMD_AccruedInterestdividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AccruedInterestdividends" xlink:to="MYMD_AccruedInterestdividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_AccruedInterestdividends_lbl" xml:lang="en-US">Accrued interest/dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Accretion of debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_2_lbl" xml:lang="en-US">(Gain)/loss on sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MarketableSecuritiesUnrealizedLoss" xlink:label="MYMD_MarketableSecuritiesUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MarketableSecuritiesUnrealizedLoss" xlink:to="MYMD_MarketableSecuritiesUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MarketableSecuritiesUnrealizedLoss_lbl" xml:lang="en-US">Unrealized (gain)/loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_GainOnForgivenessOfDebt" xlink:label="MYMD_GainOnForgivenessOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_GainOnForgivenessOfDebt" xlink:to="MYMD_GainOnForgivenessOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MYMD_GainOnForgivenessOfDebt_lbl" xml:lang="en-US">Gain on forgiveness of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock based compensation:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockOptionModificationExpenses" xlink:to="MYMD_StockOptionModificationExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_StockOptionModificationExpenses_2_lbl" xml:lang="en-US">Option modification expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Options issued to key employees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Options issued to non-employees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted stock units to non-employees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xml:lang="en-US">Net cash received in business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of the line of credit &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Net proceeds from borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Net proceeds from note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from the exercise of warrants for Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CashPaidForAbstract" xlink:label="MYMD_CashPaidForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CashPaidForAbstract" xlink:to="MYMD_CashPaidForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental Schedule of Non-Cash Financing and Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right-of-use asset obtained in exchange for lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OtherAssetInvestment" xlink:label="MYMD_OtherAssetInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OtherAssetInvestment" xlink:to="MYMD_OtherAssetInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_OtherAssetInvestment_lbl" xml:lang="en-US">Investment in Oravax Medical, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:label="MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract_lbl" xml:lang="en-US">Recent Developments Liquidity And Managements Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_RecentDevelopmentsAndManagementsPlansTextBlock" xlink:label="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock" xlink:to="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock_lbl" xml:lang="en-US">Recent Developments, Liquidity and Management&#8217;s Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Trade and Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosurePaycheckProtectionProgramLoanAbstract" xlink:label="MYMD_DisclosurePaycheckProtectionProgramLoanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_DisclosurePaycheckProtectionProgramLoanAbstract" xlink:to="MYMD_DisclosurePaycheckProtectionProgramLoanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_DisclosurePaycheckProtectionProgramLoanAbstract_lbl" xml:lang="en-US">Paycheck Protection Program Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:label="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:to="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock_lbl" xml:lang="en-US">Paycheck Protection Program Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" xlink:label="MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" xlink:to="MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract_lbl" xml:lang="en-US">Patent Assignment And Royalty Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" xlink:label="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" xlink:to="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Patent Assignment and Royalty Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Judgments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional and Presentation Currency</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrepaidExpensesPolicyTextBlock" xlink:label="MYMD_PrepaidExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PrepaidExpensesPolicyTextBlock" xlink:to="MYMD_PrepaidExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_PrepaidExpensesPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock" xlink:label="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock" xlink:to="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock_lbl" xml:lang="en-US">Risk Management of Cash and Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy" xlink:label="us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy" xlink:to="us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_lbl" xml:lang="en-US">Recoverability of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_RightOfUseAssetsPolicyTextBlock" xlink:label="MYMD_RightOfUseAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_RightOfUseAssetsPolicyTextBlock" xlink:to="MYMD_RightOfUseAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_RightOfUseAssetsPolicyTextBlock_lbl" xml:lang="en-US">Right-of-Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">(p) Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Earnings per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Property Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" xlink:label="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" xlink:to="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US">Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Information Related to Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Minimum Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Assets Acquired to be Allocated to Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock" xlink:label="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock" xlink:to="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock_lbl" xml:lang="en-US">Summary of Milestone Events Payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Trade and Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Restricted Stock Units Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax (Benefit)/Provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Related Valuation Allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Stock issued during period, shares, acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property, plant and equipment, useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible assets estimated, useful lives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Lease Right of Use</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Lease Payable, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Lease Payable - net of current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Lease Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash used</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Unrealized (gain)/loss on marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_3_lbl" xml:lang="en-US">Gain/loss on sale of marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2_lbl" xml:lang="en-US">Proceeds from the sales of marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Term of contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee operating lease renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US">Investment in Oravax, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Trade and Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net Tangible Assets Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestoneEvent" xlink:label="MYMD_MilestoneEvent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestoneEvent" xlink:to="MYMD_MilestoneEvent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MilestoneEvent_lbl" xml:lang="en-US">Milestone Event</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Threshold trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePayment" xlink:label="MYMD_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePayment" xlink:to="MYMD_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_MilestonePayment_lbl" xml:lang="en-US">Milestone Payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Acquired membership interests, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Amount owed on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Payments to investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xml:lang="en-US">Business acquisition description</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" xlink:label="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" xlink:to="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits_lbl" xml:lang="en-US">Issuance of post reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPercentage" xlink:label="MYMD_ExchangeRatioPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExchangeRatioPercentage" xlink:to="MYMD_ExchangeRatioPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ExchangeRatioPercentage_lbl" xml:lang="en-US">Exchange ratio percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationLongtermDebtAndEquity" xlink:to="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xml:lang="en-US">Pre market capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Tangible asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3_lbl" xml:lang="en-US">Common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested restricted stock unit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair market value price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Percentage of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash on hand</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WorkingCapital" xlink:label="MYMD_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_WorkingCapital" xlink:to="MYMD_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash provided by operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Non cash share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase in trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DecreaseInPrepaidExpense" xlink:label="MYMD_DecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_DecreaseInPrepaidExpense" xlink:to="MYMD_DecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_DecreaseInPrepaidExpense_lbl" xml:lang="en-US">Decrease in prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable &#8211; Trade</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Trade and other payables, Total&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Maximum principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesToAffiliate" xlink:label="us-gaap_AdvancesToAffiliate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesToAffiliate_lbl" xml:lang="en-US">Advances to affiliate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WeightedAverageRemainingContractualTermGranted" xlink:label="MYMD_WeightedAverageRemainingContractualTermGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_WeightedAverageRemainingContractualTermGranted" xlink:to="MYMD_WeightedAverageRemainingContractualTermGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_WeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares, Canceled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Canceled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Canceled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Number of RSUs, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Number of RSUs, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Number of RSUs, Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Premerger common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Number of stock option to purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Remaining shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Cumulative fair market value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Share based payment award vesting expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CumulativeFairMarketValue" xlink:label="MYMD_CumulativeFairMarketValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CumulativeFairMarketValue" xlink:to="MYMD_CumulativeFairMarketValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_CumulativeFairMarketValue_lbl" xml:lang="en-US">Cumulative fair market value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionPlanExpense_2_lbl" xml:lang="en-US">Stock option expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unamortized value</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NumberOfStockOptionsAssumed" xlink:label="MYMD_NumberOfStockOptionsAssumed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NumberOfStockOptionsAssumed" xlink:to="MYMD_NumberOfStockOptionsAssumed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_NumberOfStockOptionsAssumed_lbl" xml:lang="en-US">Number of stock options assumed</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Volatility index</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xml:lang="en-US">discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OptionsMarketValue" xlink:label="MYMD_OptionsMarketValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OptionsMarketValue" xlink:to="MYMD_OptionsMarketValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_OptionsMarketValue_lbl" xml:lang="en-US">Options market value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Restricted stock units vested, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US">Number of vesting shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US">Number of restricted stock, net of tax withholdings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Restricted stock value, net of tax withholdings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Restricted stock units, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Grant date fair value price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of Warrants, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants, Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Warrants, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred stock, conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Preferred stock, terms of conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" xlink:label="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" xlink:to="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_lbl" xml:lang="en-US">Underlying shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Issuance of common stock for warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Number of shares, exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Fair market value of shares issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Common stock options, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Common stock options, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Common stock options, proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Issuance of warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:label="MYMD_NetProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:to="MYMD_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory U.S. Federal Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">New Jersey State income taxes, net of U.S. Federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Adjustment to deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Reserves and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwarddSubjectToExpiration" xlink:label="MYMD_OperatingLossCarryforwarddSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OperatingLossCarryforwarddSubjectToExpiration" xlink:to="MYMD_OperatingLossCarryforwarddSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_OperatingLossCarryforwarddSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carry forwards subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwardsExpirationDateDescription" xlink:label="MYMD_OperatingLossCarryforwardsExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OperatingLossCarryforwardsExpirationDateDescription" xlink:to="MYMD_OperatingLossCarryforwardsExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_OperatingLossCarryforwardsExpirationDateDescription_lbl" xml:lang="en-US">Expiration date description</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carry forwards not to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" xlink:label="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" xlink:to="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod_lbl" xml:lang="en-US">Percentage of net income</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CumulativeChangeInOwnershipPercentage" xlink:label="MYMD_CumulativeChangeInOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CumulativeChangeInOwnershipPercentage" xlink:to="MYMD_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_CumulativeChangeInOwnershipPercentage_lbl" xml:lang="en-US">Cumulative change in ownership percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Cost and expenses incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Amounts paid by related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to officer</link:label>
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AnnualLeasingFee" xlink:label="MYMD_AnnualLeasingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AnnualLeasingFee" xlink:to="MYMD_AnnualLeasingFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_AnnualLeasingFee_lbl" xml:lang="en-US">Annual leasing fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related party retired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Borrowing capacity revolving credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xml:lang="en-US">Line of credit facility expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Borrowings accrued interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="us-gaap_LineOfCreditFacilityDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDescription" xlink:to="us-gaap_LineOfCreditFacilityDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityDescription_lbl" xml:lang="en-US">Line of credit facility, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Initial term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Stock options exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Employer matching contribution, percent of employees' gross pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contributions to employee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on debt forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to acquire common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:to="MYMD_NetProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MYMD_NetProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesDConvertiblePreferredStockMember" xlink:to="MYMD_SeriesDConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SeriesDConvertiblePreferredStockMember_doc" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" xlink:to="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_doc" xml:lang="en-US">Number of common stock shares represent by preferred stock outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MergerAgreementMember" xlink:to="MYMD_MergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MergerAgreementMember_doc" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SecuritiesPurchaseAgreementMember" xlink:to="MYMD_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PrefundedWarrantsMember" xlink:to="MYMD_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PrefundedWarrantsMember_doc" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:to="MYMD_NetProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_NetProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Net proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CommonStockWarrantsMember" xlink:to="MYMD_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments forfeited in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of non-option equity outstanding and currently exercisable under the non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_doc" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PreFundedCommonStockWarrantsMember" xlink:to="MYMD_PreFundedCommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PreFundedCommonStockWarrantsMember_doc" xml:lang="en-US">Pre Funded Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock" xlink:to="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_RecentDevelopmentsAndManagementsPlansTextBlock_doc" xml:lang="en-US">Recent developments and managements plans text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CystronBiotechLLCMember" xlink:to="MYMD_CystronBiotechLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_CystronBiotechLLCMember_doc" xml:lang="en-US">Cystron Biotech LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MembershipInterestPurchaseAgreementMember" xlink:to="MYMD_MembershipInterestPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MembershipInterestPurchaseAgreementMember_doc" xml:lang="en-US">Membership Interest Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ContributionAgreementMember" xlink:to="MYMD_ContributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ContributionAgreementMember_doc" xml:lang="en-US">Contribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PremasBiotechPVTLtdMember" xlink:to="MYMD_PremasBiotechPVTLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PremasBiotechPVTLtdMember_doc" xml:lang="en-US">Premas Biotech PVT Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:to="MYMD_SeriesCConvertiblePreferredStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SeriesCConvertiblePreferredStockWarrantsMember_doc" xml:lang="en-US">Series C Convertible Preferred Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" xlink:to="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits_doc" xml:lang="en-US">Issuance of post reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExchangeRatioPercentage" xlink:to="MYMD_ExchangeRatioPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ExchangeRatioPercentage_doc" xml:lang="en-US">Exchange ratio percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AkersBiosciencesIncMember" xlink:to="MYMD_AkersBiosciencesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_AkersBiosciencesIncMember_doc" xml:lang="en-US">Akers Biosciences, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OperatingLossCarryforwarddSubjectToExpiration" xlink:to="MYMD_OperatingLossCarryforwarddSubjectToExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_OperatingLossCarryforwarddSubjectToExpiration_doc" xml:lang="en-US">Operating loss carryforward subject to expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OperatingLossCarryforwardsExpirationDateDescription" xlink:to="MYMD_OperatingLossCarryforwardsExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_OperatingLossCarryforwardsExpirationDateDescription_doc" xml:lang="en-US">Operating Loss Carryforwards Expiration Date Description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_OperatingLossCarryforwardsNotSubjectToExpiration_doc" xml:lang="en-US">Operating Loss Carryforwards Not Subject to Expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" xlink:to="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PercentageOfNetIncomeForEachSubsequentPeriod_doc" xml:lang="en-US">Percentage of net income for each subsequent period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CumulativeChangeInOwnershipPercentage" xlink:to="MYMD_CumulativeChangeInOwnershipPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_CumulativeChangeInOwnershipPercentage_doc" xml:lang="en-US">Cumulative change in ownership percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MrWilliamsMember" xlink:to="MYMD_MrWilliamsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MrWilliamsMember_doc" xml:lang="en-US">Mr Williams [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AnnualLeasingFee" xlink:to="MYMD_AnnualLeasingFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_AnnualLeasingFee_doc" xml:lang="en-US">Annual leasing fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SuperaAviationILLCMember" xlink:to="MYMD_SuperaAviationILLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SuperaAviationILLCMember_doc" xml:lang="en-US">Supera Aviation I, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NegotiatedSettlementMember" xlink:to="MYMD_NegotiatedSettlementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_NegotiatedSettlementMember_doc" xml:lang="en-US">Negotiated Settlement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" xlink:to="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_FourZeroOneKPlanMatchesFiftyPercentMember_doc" xml:lang="en-US">401 K Plan Matches 50% [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_FourZeroOneKPlanMaximumFivePercentMember" xlink:to="MYMD_FourZeroOneKPlanMaximumFivePercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_FourZeroOneKPlanMaximumFivePercentMember_doc" xml:lang="en-US">401 K Plan Maximum 5% [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:to="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock_doc" xml:lang="en-US">Paycheck Protection Program Loan Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PaycheckProtectionProgramLoansMember" xlink:to="MYMD_PaycheckProtectionProgramLoansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PaycheckProtectionProgramLoansMember_doc" xml:lang="en-US">Paycheck Protection Program Loans [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" xlink:to="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_doc" xml:lang="en-US">Patent Assignment and Royalty Agreement Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock" xlink:to="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock_doc" xml:lang="en-US">Summary of milestone events payment table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestoneEvent" xlink:to="MYMD_MilestoneEvent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MilestoneEvent_doc" xml:lang="en-US">Milestone Event.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodOneMember" xlink:to="MYMD_MilestonePeriodOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MilestonePeriodOneMember_doc" xml:lang="en-US">Milestone Period One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePayment" xlink:to="MYMD_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MilestonePayment_doc" xml:lang="en-US">Milestone Payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodTwoMember" xlink:to="MYMD_MilestonePeriodTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MilestonePeriodTwoMember_doc" xml:lang="en-US">Milestone Period Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AccretionOfDebtDiscount" xlink:to="MYMD_AccretionOfDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_AccretionOfDebtDiscount_doc" xml:lang="en-US">Accretion of debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockOptionModificationExpenses" xlink:to="MYMD_StockOptionModificationExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_StockOptionModificationExpenses_doc" xml:lang="en-US">Stock option modification expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_GainOnDebtForgiveness" xlink:to="MYMD_GainOnDebtForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_GainOnDebtForgiveness_doc" xml:lang="en-US">Gain on debt forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_UninsuredCasualtyLosses" xlink:to="MYMD_UninsuredCasualtyLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_UninsuredCasualtyLosses_doc" xml:lang="en-US">Uninsured Casualty Losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodThreeMember" xlink:to="MYMD_MilestonePeriodThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MilestonePeriodThreeMember_doc" xml:lang="en-US">Milestone Period Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MilestonePeriodFourMember" xlink:to="MYMD_MilestonePeriodFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MilestonePeriodFourMember_doc" xml:lang="en-US">Milestone Period Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_WorkingCapital" xlink:to="MYMD_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" xlink:to="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants_doc" xml:lang="en-US">Stock issued during period value compensation of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CommonStockNoParValueMember" xlink:to="MYMD_CommonStockNoParValueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_CommonStockNoParValueMember_doc" xml:lang="en-US">Common stock No Par Value [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_BridgeLoanNoteMember" xlink:to="MYMD_BridgeLoanNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_BridgeLoanNoteMember_doc" xml:lang="en-US">Bridge Loan Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ModificationTermsOfPreMergerStockOptions" xlink:to="MYMD_ModificationTermsOfPreMergerStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ModificationTermsOfPreMergerStockOptions_doc" xml:lang="en-US">Modification Terms Of Pre Merger Stock Options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_EventOfDefaultMember" xlink:to="MYMD_EventOfDefaultMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_EventOfDefaultMember_doc" xml:lang="en-US">Event of Default [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfWarrantsForCommonStock" xlink:to="MYMD_ExerciseOfWarrantsForCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ExerciseOfWarrantsForCommonStock_doc" xml:lang="en-US">Exercise of warrants for common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:to="MYMD_MyMDPharmaceuticalsFloridaIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MyMDPharmaceuticalsFloridaIncMember_doc" xml:lang="en-US">MyMD Pharmaceuticals (Florida), Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" xlink:to="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare_doc" xml:lang="en-US">Issuance of post-merger common share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" xlink:to="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares_doc" xml:lang="en-US">Exercise of prepaid equity forward contracts for common stock shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfWarrantsForCommonStockShares" xlink:to="MYMD_ExerciseOfWarrantsForCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ExerciseOfWarrantsForCommonStockShares_doc" xml:lang="en-US">Exercise of warrants for common stock shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandThirteenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandThirteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandThirteenStockIncentivePlanMember_doc" xml:lang="en-US">2013 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AmendedPlanMember" xlink:to="MYMD_AmendedPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_AmendedPlanMember_doc" xml:lang="en-US">Amended Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndSixteenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndSixteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandAndSixteenStockIncentivePlanMember_doc" xml:lang="en-US">2016 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandAndSeventeenStockIncentivePlanMember_doc" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndEighteenStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndEighteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandAndEighteenStockIncentivePlanMember_doc" xml:lang="en-US">2018 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExchangeRatioPricePerShares" xlink:to="MYMD_ExchangeRatioPricePerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ExchangeRatioPricePerShares_doc" xml:lang="en-US">Exchange ratio price per shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AccruedInterestdividends" xlink:to="MYMD_AccruedInterestdividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_AccruedInterestdividends_doc" xml:lang="en-US">Accrued interest dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MarketableSecuritiesUnrealizedLoss" xlink:to="MYMD_MarketableSecuritiesUnrealizedLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MarketableSecuritiesUnrealizedLoss_doc" xml:lang="en-US">Marketable Securities Unrealized Loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_GainOnForgivenessOfDebt" xlink:to="MYMD_GainOnForgivenessOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_GainOnForgivenessOfDebt_doc" xml:lang="en-US">Gain on forgiveness of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember_doc" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CashPaidForAbstract" xlink:to="MYMD_CashPaidForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_CashPaidForAbstract_doc" xml:lang="en-US">Cash paid for abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OtherAssetInvestment" xlink:to="MYMD_OtherAssetInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_OtherAssetInvestment_doc" xml:lang="en-US">Other asset investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancelled/Expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_WeightedAverageRemainingContractualTermGranted" xlink:to="MYMD_WeightedAverageRemainingContractualTermGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_WeightedAverageRemainingContractualTermGranted_doc" xml:lang="en-US">Weighted average remaining contractual term granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_CumulativeFairMarketValue" xlink:to="MYMD_CumulativeFairMarketValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_CumulativeFairMarketValue_doc" xml:lang="en-US">Cumulative fair market value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:to="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandAndSixteenEquityIncentivePlanMember_doc" xml:lang="en-US">2016 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_NumberOfStockOptionsAssumed" xlink:to="MYMD_NumberOfStockOptionsAssumed_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_NumberOfStockOptionsAssumed_doc" xml:lang="en-US">Number of stock options assumed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_MyMDFloridaStockOptionsMember" xlink:to="MYMD_MyMDFloridaStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_MyMDFloridaStockOptionsMember_doc" xml:lang="en-US">MyMD Florida Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_OptionsMarketValue" xlink:to="MYMD_OptionsMarketValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_OptionsMarketValue_doc" xml:lang="en-US">Options market value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" xlink:to="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember_doc" xml:lang="en-US">January 28, 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_JulySevenTwoThousandTwentyTwoMember" xlink:to="MYMD_JulySevenTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_JulySevenTwoThousandTwentyTwoMember_doc" xml:lang="en-US">July 7, 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercises in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xml:lang="en-US">share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercises in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SuperaPharmaceuticalsIncMember" xlink:to="MYMD_SuperaPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SuperaPharmaceuticalsIncMember_doc" xml:lang="en-US">Supera Pharmaceuticals Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_AssetPurchaseAgreementMember" xlink:to="MYMD_AssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_AssetPurchaseAgreementMember_doc" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PrepaidExpensesPolicyTextBlock" xlink:to="MYMD_PrepaidExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PrepaidExpensesPolicyTextBlock_doc" xml:lang="en-US">Prepaid Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock" xlink:to="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock_doc" xml:lang="en-US">Risk Management of Cash Investments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PatentsAndTrademarksMember" xlink:to="MYMD_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PatentsAndTrademarksMember_doc" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_RightOfUseAssetsPolicyTextBlock" xlink:to="MYMD_RightOfUseAssetsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_RightOfUseAssetsPolicyTextBlock_doc" xml:lang="en-US">Right of use assets [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_HydeParkFacilityMember" xlink:to="MYMD_HydeParkFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_HydeParkFacilityMember_doc" xml:lang="en-US">Hyde Park Facility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SuperaAviationMember" xlink:to="MYMD_SuperaAviationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SuperaAviationMember_doc" xml:lang="en-US">Supera Aviation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandTwentyBaltimoreMember" xlink:to="MYMD_TwoThousandTwentyBaltimoreMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandTwentyBaltimoreMember_doc" xml:lang="en-US">2020 Baltimore [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:to="MYMD_TwoThousandTwentyOneBaltimoreMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TwoThousandTwentyOneBaltimoreMember_doc" xml:lang="en-US">2021 Baltimore [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PlattStreetMember" xlink:to="MYMD_PlattStreetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PlattStreetMember_doc" xml:lang="en-US">Platt Street [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_doc" xml:lang="en-US">Schedule of condensed consolidated balance sheet information related to operating lease [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of Other Information Related to Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_DecreaseInPrepaidExpense" xlink:to="MYMD_DecreaseInPrepaidExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_DecreaseInPrepaidExpense_doc" xml:lang="en-US">Decrease in prepaid expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" xlink:to="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock_doc" xml:lang="en-US">Exercise of prepaid equity forward contracts for common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ModificationOfPreMergerStockOptionShares" xlink:to="MYMD_ModificationOfPreMergerStockOptionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ModificationOfPreMergerStockOptionShares_doc" xml:lang="en-US">Modification of pre merger stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of Estimated Useful Lives of Property Plant and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" xlink:to="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_doc" xml:lang="en-US">Schedule of Estimated Useful Lives of Intangible Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_WarrantsToPurchaseCommonStockMember" xlink:to="MYMD_WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PreFundedWarrantsToPurchaseCommonStockMember" xlink:to="MYMD_PreFundedWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PreFundedWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Pre-funded Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PreMergerMember" xlink:to="MYMD_PreMergerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_PreMergerMember_doc" xml:lang="en-US">Pre Merger [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesCPreferredConvertibleWarrantsMember" xlink:to="MYMD_SeriesCPreferredConvertibleWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SeriesCPreferredConvertibleWarrantsMember_doc" xml:lang="en-US">Series C Preferred Convertible Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_UnvestedRestrictedStockUnitsMember" xlink:to="MYMD_UnvestedRestrictedStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_UnvestedRestrictedStockUnitsMember_doc" xml:lang="en-US">Unvested Restricted Stock Units [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesDPreferredConvertibleStockMember" xlink:to="MYMD_SeriesDPreferredConvertibleStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SeriesDPreferredConvertibleStockMember_doc" xml:lang="en-US">Series D Preferred Convertible Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_InstitutionalAndAccreditedInvestorsMember" xlink:to="MYMD_InstitutionalAndAccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_InstitutionalAndAccreditedInvestorsMember_doc" xml:lang="en-US">Institutional And Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SeriesFConvertiblePreferredStockMember" xlink:to="MYMD_SeriesFConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_SeriesFConvertiblePreferredStockMember_doc" xml:lang="en-US">Series F Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_TaglichBrothersIncMember" xlink:to="MYMD_TaglichBrothersIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_TaglichBrothersIncMember_doc" xml:lang="en-US">Taglich Brothers Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ConsultingAgreementMember" xlink:to="MYMD_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MYMD_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_2_lbl" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_3_lbl" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_GainOnDebtForgiveness" xlink:to="MYMD_GainOnDebtForgiveness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_GainOnDebtForgiveness_3_lbl" xml:lang="en-US">GainOnDebtForgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_UninsuredCasualtyLosses" xlink:to="MYMD_UninsuredCasualtyLosses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_UninsuredCasualtyLosses_3_lbl" xml:lang="en-US">UninsuredCasualtyLosses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_GainOnForgivenessOfDebt" xlink:to="MYMD_GainOnForgivenessOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_GainOnForgivenessOfDebt_3_lbl" xml:lang="en-US">GainOnForgivenessOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:to="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock_3_lbl" xml:lang="en-US">PaycheckProtectionProgramLoanDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_PrepaidExpensesPolicyTextBlock" xlink:to="MYMD_PrepaidExpensesPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_PrepaidExpensesPolicyTextBlock_3_lbl" xml:lang="en-US">PrepaidExpensesPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>mymd-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mymd.com/role/Cover" xlink:href="mymd-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/BalanceSheets" xlink:href="mymd-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/BalanceSheetsParenthetical" xlink:href="mymd-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfComprehensiveLoss" xlink:href="mymd-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" xlink:href="mymd-20221231.xsd#StatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" xlink:href="mymd-20221231.xsd#StatementOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="mymd-20221231.xsd#StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/StatementsOfCashFlows" xlink:href="mymd-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="mymd-20221231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPolicies" xlink:href="mymd-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/TradeAndOtherPayables" xlink:href="mymd-20221231.xsd#TradeAndOtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/NotesPayable" xlink:href="mymd-20221231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPayments" xlink:href="mymd-20221231.xsd#Stock-basedPayments" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Equity" xlink:href="mymd-20221231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxes" xlink:href="mymd-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/CommitmentsAndContingencies" xlink:href="mymd-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RelatedParties" xlink:href="mymd-20221231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EmployeeBenefitPlan" xlink:href="mymd-20221231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PaycheckProtectionProgramLoan" xlink:href="mymd-20221231.xsd#PaycheckProtectionProgramLoan" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" xlink:href="mymd-20221231.xsd#PatentAssignmentAndRoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SubsequentEvents" xlink:href="mymd-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesPolicies" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesTables" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/TradeAndOtherPayablesTables" xlink:href="mymd-20221231.xsd#TradeAndOtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPaymentsTables" xlink:href="mymd-20221231.xsd#Stock-basedPaymentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EquityTables" xlink:href="mymd-20221231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxesTables" xlink:href="mymd-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:href="mymd-20221231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="mymd-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:href="mymd-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:href="mymd-20221231.xsd#ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" xlink:href="mymd-20221231.xsd#ScheduleOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:href="mymd-20221231.xsd#ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="mymd-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="mymd-20221231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:href="mymd-20221231.xsd#ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" xlink:href="mymd-20221231.xsd#SummaryOfMilestoneEventsPaymentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:href="mymd-20221231.xsd#RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfTradeAndOtherPayablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/NotesPayableDetailsNarrative" xlink:href="mymd-20221231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" xlink:href="mymd-20221231.xsd#Stock-basedPaymentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SummaryOfWarrantActivityDetails" xlink:href="mymd-20221231.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EquityDetailsNarrative" xlink:href="mymd-20221231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:href="mymd-20221231.xsd#ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:href="mymd-20221231.xsd#ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/IncomeTaxesDetailsNarrative" xlink:href="mymd-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="mymd-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/RelatedPartiesDetailsNarrative" xlink:href="mymd-20221231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="mymd-20221231.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" xlink:href="mymd-20221231.xsd#PaycheckProtectionProgramLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:href="mymd-20221231.xsd#PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mymd.com/role/SubsequentEventsDetailsNarrative" xlink:href="mymd-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AccretionOfDebtDiscount" xlink:label="loc_MYMDAccretionOfDebtDiscount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_MYMDAccretionOfDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockOptionModificationExpenses" xlink:label="loc_MYMDStockOptionModificationExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_MYMDStockOptionModificationExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaapInvestmentIncomeInterestAndDividend" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterestAndDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_GainOnDebtForgiveness" xlink:label="loc_MYMDGainOnDebtForgiveness" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_MYMDGainOnDebtForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_UninsuredCasualtyLosses" xlink:label="loc_MYMDUninsuredCasualtyLosses" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_MYMDUninsuredCasualtyLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="loc_us-gaapRevenueFromContractWithCustomerProductAndServiceExtensibleList" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:label="loc_us-gaapTypeOfCostGoodOrServiceExtensibleList" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapTypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockNoParValueMember" xlink:label="loc_MYMDCommonStockNoParValueMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_MYMDCommonStockNoParValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock" xlink:label="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares" xlink:label="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStockShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfPrepaidEquityForwardContractsForCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants" xlink:label="loc_MYMDStockIssuedDuringPeriodValueCompensationOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDStockIssuedDuringPeriodValueCompensationOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" xlink:label="loc_MYMDIssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDIssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ModificationTermsOfPreMergerStockOptions" xlink:label="loc_MYMDModificationTermsOfPreMergerStockOptions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDModificationTermsOfPreMergerStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfWarrantsForCommonStock" xlink:label="loc_MYMDExerciseOfWarrantsForCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfWarrantsForCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExerciseOfWarrantsForCommonStockShares" xlink:label="loc_MYMDExerciseOfWarrantsForCommonStockShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExerciseOfWarrantsForCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity /(Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPricePerShares" xlink:label="loc_MYMDExchangeRatioPricePerShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExchangeRatioPricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ModificationOfPreMergerStockOptionShares" xlink:label="loc_MYMDModificationOfPreMergerStockOptionShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDModificationOfPreMergerStockOptionShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AccruedInterestdividends" xlink:label="loc_MYMDAccruedInterestdividends" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MYMDAccruedInterestdividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MarketableSecuritiesUnrealizedLoss" xlink:label="loc_MYMDMarketableSecuritiesUnrealizedLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MYMDMarketableSecuritiesUnrealizedLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_GainOnForgivenessOfDebt" xlink:label="loc_MYMDGainOnForgivenessOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MYMDGainOnForgivenessOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaapShareBasedCompensationAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockOptionModificationExpenses" xlink:label="loc_MYMDStockOptionModificationExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_MYMDStockOptionModificationExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaapProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CashPaidForAbstract" xlink:label="loc_MYMDCashPaidForAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_MYMDCashPaidForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDCashPaidForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDCashPaidForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OtherAssetInvestment" xlink:label="loc_MYMDOtherAssetInvestment" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_MYMDOtherAssetInvestment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000009 - Disclosure - Organization and Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans" xlink:title="00000011 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:label="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_RecentDevelopmentsAndManagementsPlansTextBlock" xlink:label="loc_MYMDRecentDevelopmentsAndManagementsPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="loc_MYMDRecentDevelopmentsAndManagementsPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/TradeAndOtherPayables" xlink:title="00000012 - Disclosure - Trade and Other Payables">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPayments" xlink:title="00000014 - Disclosure - Stock-based Payments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/Equity" xlink:title="00000015 - Disclosure - Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - Related Parties">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/EmployeeBenefitPlan" xlink:title="00000019 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/PaycheckProtectionProgramLoan" xlink:title="00000020 - Disclosure - Paycheck Protection Program Loan">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosurePaycheckProtectionProgramLoanAbstract" xlink:label="loc_MYMDDisclosurePaycheckProtectionProgramLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:label="loc_MYMDPaycheckProtectionProgramLoanDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosurePaycheckProtectionProgramLoanAbstract" xlink:to="loc_MYMDPaycheckProtectionProgramLoanDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement" xlink:title="00000021 - Disclosure - Patent Assignment and Royalty Agreement">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" xlink:label="loc_MYMDDisclosurePatentAssignmentAndRoyaltyAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" xlink:label="loc_MYMDPatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosurePatentAssignmentAndRoyaltyAgreementAbstract" xlink:to="loc_MYMDPatentAssignmentAndRoyaltyAgreementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrepaidExpensesPolicyTextBlock" xlink:label="loc_MYMDPrepaidExpensesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDPrepaidExpensesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock" xlink:label="loc_MYMDRiskManagementOfCashInvestmentsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDRiskManagementOfCashInvestmentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_RightOfUseAssetsPolicyTextBlock" xlink:label="loc_MYMDRightOfUseAssetsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDRightOfUseAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_MYMDPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" xlink:label="loc_MYMDScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="loc_MYMDScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="loc_MYMDScheduleOfOtherInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MYMDScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables" xlink:title="00000025 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Tables)">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:label="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock" xlink:label="loc_MYMDSummaryOfMilestoneEventsPaymentTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="loc_MYMDSummaryOfMilestoneEventsPaymentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/TradeAndOtherPayablesTables" xlink:title="00000026 - Disclosure - Trade and Other Payables (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPaymentsTables" xlink:title="00000027 - Disclosure - Stock-based Payments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/EquityTables" xlink:title="00000028 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="loc_MYMDCommonStockWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="loc_MYMDPreFundedCommonStockWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPreFundedCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="00000030 - Disclosure - Organization and Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:label="loc_MYMDMyMDPharmaceuticalsFloridaIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MYMDMyMDPharmaceuticalsFloridaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaPharmaceuticalsIncMember" xlink:label="loc_MYMDSuperaPharmaceuticalsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDSuperaPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AssetPurchaseAgreementMember" xlink:label="loc_MYMDAssetPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPricePerShares" xlink:label="loc_MYMDExchangeRatioPricePerShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MYMDExchangeRatioPricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:title="00000031 - Disclosure - Schedule of Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapMarketableSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:title="00000032 - Disclosure - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of Estimated Useful Lives of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PatentsAndTrademarksMember" xlink:label="loc_MYMDPatentsAndTrademarksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_MYMDPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:title="00000034 - Disclosure - Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfLeaseExpenseDetails" xlink:title="00000035 - Disclosure - Schedule of Lease Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationMember" xlink:label="loc_MYMDSuperaAviationMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSuperaAviationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyBaltimoreMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" xlink:title="00000036 - Disclosure - Schedule of Other Information Related to Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails" xlink:title="00000037 - Disclosure - Schedule of Operating Lease Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000038 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_UnvestedRestrictedStockUnitsMember" xlink:label="loc_MYMDUnvestedRestrictedStockUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDUnvestedRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WarrantsToPurchaseCommonStockMember" xlink:label="loc_MYMDWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedWarrantsToPurchaseCommonStockMember" xlink:label="loc_MYMDPreFundedWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDPreFundedWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCPreferredConvertibleWarrantsMember" xlink:label="loc_MYMDSeriesCPreferredConvertibleWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDSeriesCPreferredConvertibleWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDPreferredConvertibleStockMember" xlink:label="loc_MYMDSeriesDPreferredConvertibleStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MYMDSeriesDPreferredConvertibleStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMutualFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_HydeParkFacilityMember" xlink:label="loc_MYMDHydeParkFacilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDHydeParkFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationMember" xlink:label="loc_MYMDSuperaAviationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSuperaAviationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyBaltimoreMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandTwentyOneBaltimoreMember" xlink:label="loc_MYMDTwoThousandTwentyOneBaltimoreMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDTwoThousandTwentyOneBaltimoreMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PlattStreetMember" xlink:label="loc_MYMDPlattStreetMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDPlattStreetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLoss_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails" xlink:title="00000040 - Disclosure - Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:label="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AkersBiosciencesIncMember" xlink:label="loc_MYMDAkersBiosciencesIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDAkersBiosciencesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails" xlink:title="00000041 - Disclosure - Summary of Milestone Events Payment (Details)">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:label="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodOneMember" xlink:label="loc_MYMDMilestonePeriodOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodTwoMember" xlink:label="loc_MYMDMilestonePeriodTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodThreeMember" xlink:label="loc_MYMDMilestonePeriodThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePeriodFourMember" xlink:label="loc_MYMDMilestonePeriodFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMilestonePeriodFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestoneEvent" xlink:label="loc_MYMDMilestoneEvent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MYMDMilestoneEvent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MilestonePayment" xlink:label="loc_MYMDMilestonePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MYMDMilestonePayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative" xlink:title="00000042 - Disclosure - Recent Developments, Liquidity and Management&#8217;s Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:label="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CystronBiotechLLCMember" xlink:label="loc_MYMDCystronBiotechLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDCystronBiotechLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreMergerMember" xlink:label="loc_MYMDPreMergerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDPreMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AkersBiosciencesIncMember" xlink:label="loc_MYMDAkersBiosciencesIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_MYMDAkersBiosciencesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MembershipInterestPurchaseAgreementMember" xlink:label="loc_MYMDMembershipInterestPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMembershipInterestPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ContributionAgreementMember" xlink:label="loc_MYMDContributionAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDContributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PremasBiotechPVTLtdMember" xlink:label="loc_MYMDPremasBiotechPVTLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MYMDPremasBiotechPVTLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrefundedWarrantsMember" xlink:label="loc_MYMDPrefundedWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_MYMDPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits" xlink:label="loc_MYMDStockIssuedDuringPeriodSharesPostReverseStockSplits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDStockIssuedDuringPeriodSharesPostReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ExchangeRatioPercentage" xlink:label="loc_MYMDExchangeRatioPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDExchangeRatioPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="loc_us-gaapCapitalizationLongtermDebtAndEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalizationLongtermDebtAndEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WorkingCapital" xlink:label="loc_MYMDWorkingCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DecreaseInPrepaidExpense" xlink:label="loc_MYMDDecreaseInPrepaidExpense" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MYMDDecreaseInPrepaidExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:title="00000043 - Disclosure - Schedule of Trade and Other Payables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/NotesPayableDetailsNarrative" xlink:title="00000044 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_BridgeLoanNoteMember" xlink:label="loc_MYMDBridgeLoanNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MYMDBridgeLoanNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_EventOfDefaultMember" xlink:label="loc_MYMDEventOfDefaultMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_MYMDEventOfDefaultMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDPharmaceuticalsFloridaIncMember" xlink:label="loc_MYMDMyMDPharmaceuticalsFloridaIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_MYMDMyMDPharmaceuticalsFloridaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesToAffiliate" xlink:label="loc_us-gaapAdvancesToAffiliate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAdvancesToAffiliate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfStockOptionsActivityDetails" xlink:title="00000045 - Disclosure - Summary of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_WeightedAverageRemainingContractualTermGranted" xlink:label="loc_MYMDWeightedAverageRemainingContractualTermGranted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_MYMDWeightedAverageRemainingContractualTermGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails" xlink:title="00000046 - Disclosure - Summary of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/Stock-basedPaymentsDetailsNarrative" xlink:title="00000047 - Disclosure - Stock-based Payments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandThirteenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandThirteenStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AmendedPlanMember" xlink:label="loc_MYMDAmendedPlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDAmendedPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSixteenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndSixteenStockIncentivePlanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndSixteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndSeventeenStockIncentivePlanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndSeventeenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndEighteenStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndEighteenStockIncentivePlanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndEighteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndTwentyOneStockIncentivePlanMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndTwentyOneStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_MYMDTwoThousandAndSixteenEquityIncentivePlanMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MYMDTwoThousandAndSixteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MyMDFloridaStockOptionsMember" xlink:label="loc_MYMDMyMDFloridaStockOptionsMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MYMDMyMDFloridaStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember" xlink:label="loc_MYMDJanuaryTwentyEightTwoThousandTwentyTwoMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_MYMDJanuaryTwentyEightTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_JulySevenTwoThousandTwentyTwoMember" xlink:label="loc_MYMDJulySevenTwoThousandTwentyTwoMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_MYMDJulySevenTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CumulativeFairMarketValue" xlink:label="loc_MYMDCumulativeFairMarketValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDCumulativeFairMarketValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NumberOfStockOptionsAssumed" xlink:label="loc_MYMDNumberOfStockOptionsAssumed" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDNumberOfStockOptionsAssumed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OptionsMarketValue" xlink:label="loc_MYMDOptionsMarketValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MYMDOptionsMarketValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000048 - Disclosure - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="loc_MYMDCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="loc_MYMDPreFundedCommonStockWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPreFundedCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_MYMDSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MYMDSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/EquityDetailsNarrative" xlink:title="00000049 - Disclosure - Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesDConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PrefundedWarrantsMember" xlink:label="loc_MYMDPrefundedWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CommonStockWarrantsMember" xlink:label="loc_MYMDCommonStockWarrantsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PreFundedCommonStockWarrantsMember" xlink:label="loc_MYMDPreFundedCommonStockWarrantsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDPreFundedCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesCConvertiblePreferredStockWarrantsMember" xlink:label="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MYMDSeriesCConvertiblePreferredStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MergerAgreementMember" xlink:label="loc_MYMDMergerAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_MYMDSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding" xlink:label="loc_MYMDNumberOfCommonStockSharesRepresentByPreferredStockOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_MYMDNumberOfCommonStockSharesRepresentByPreferredStockOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_MYMDNetProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_MYMDNetProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails" xlink:title="00000050 - Disclosure - Schedule of Income Tax (Benefit)/Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails" xlink:title="00000051 - Disclosure - Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails" xlink:title="00000052 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000053 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwarddSubjectToExpiration" xlink:label="loc_MYMDOperatingLossCarryforwarddSubjectToExpiration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDOperatingLossCarryforwarddSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwardsExpirationDateDescription" xlink:label="loc_MYMDOperatingLossCarryforwardsExpirationDateDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDOperatingLossCarryforwardsExpirationDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_MYMDOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PercentageOfNetIncomeForEachSubsequentPeriod" xlink:label="loc_MYMDPercentageOfNetIncomeForEachSubsequentPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDPercentageOfNetIncomeForEachSubsequentPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_CumulativeChangeInOwnershipPercentage" xlink:label="loc_MYMDCumulativeChangeInOwnershipPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_MYMDCumulativeChangeInOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000054 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000055 - Disclosure - Related Parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_TaglichBrothersIncMember" xlink:label="loc_MYMDTaglichBrothersIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MYMDTaglichBrothersIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_ConsultingAgreementMember" xlink:label="loc_MYMDConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NegotiatedSettlementMember" xlink:label="loc_MYMDNegotiatedSettlementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDNegotiatedSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_MrWilliamsMember" xlink:label="loc_MYMDMrWilliamsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_MYMDMrWilliamsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SuperaAviationILLCMember" xlink:label="loc_MYMDSuperaAviationILLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_MYMDSuperaAviationILLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_AnnualLeasingFee" xlink:label="loc_MYMDAnnualLeasingFee" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_MYMDAnnualLeasingFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaapLineOfCreditFacilityDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000056 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaapRetirementPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaapRetirementPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanNameAxis" xlink:to="loc_us-gaapRetirementPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_FourZeroOneKPlanMatchesFiftyPercentMember" xlink:label="loc_MYMDFourZeroOneKPlanMatchesFiftyPercentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanNameDomain" xlink:to="loc_MYMDFourZeroOneKPlanMatchesFiftyPercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_FourZeroOneKPlanMaximumFivePercentMember" xlink:label="loc_MYMDFourZeroOneKPlanMaximumFivePercentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanNameDomain" xlink:to="loc_MYMDFourZeroOneKPlanMaximumFivePercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" xlink:title="00000057 - Disclosure - Paycheck Protection Program Loan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosurePaycheckProtectionProgramLoanAbstract" xlink:label="loc_MYMDDisclosurePaycheckProtectionProgramLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosurePaycheckProtectionProgramLoanAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_PaycheckProtectionProgramLoansMember" xlink:label="loc_MYMDPaycheckProtectionProgramLoansMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MYMDPaycheckProtectionProgramLoansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative" xlink:title="00000058 - Disclosure - Patent Assignment and Royalty Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract" xlink:label="loc_MYMDDisclosurePatentAssignmentAndRoyaltyAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MYMDDisclosurePatentAssignmentAndRoyaltyAgreementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mymd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000059 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SecuritiesPurchaseAgreementMember" xlink:label="loc_MYMDSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MYMDSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_InstitutionalAndAccreditedInvestorsMember" xlink:label="loc_MYMDInstitutionalAndAccreditedInvestorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MYMDInstitutionalAndAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_SeriesFConvertiblePreferredStockMember" xlink:label="loc_MYMDSeriesFConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MYMDSeriesFConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="mymd-20221231.xsd#MYMD_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_MYMDNetProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_MYMDNetProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913465024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MyMD
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001321834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2983783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">855
                                            N. Wolfe Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
                                            601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baltimore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">848-8698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Shares
    of Common Stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MYMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,298,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,470,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Morison Cogen LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Blue
Bell, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912402864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 749,090<span></span>
</td>
<td class="nump">$ 555,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">4,086,902<span></span>
</td>
<td class="nump">11,003,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expenses</a></td>
<td class="nump">565,787<span></span>
</td>
<td class="nump">1,106,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,401,779<span></span>
</td>
<td class="nump">12,665,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease Right-of-Use Assets</a></td>
<td class="nump">139,662<span></span>
</td>
<td class="nump">149,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,498,539<span></span>
</td>
<td class="nump">10,498,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investment in Oravax, Inc.</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-Current Assets</a></td>
<td class="nump">12,138,201<span></span>
</td>
<td class="nump">12,147,548<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">17,539,980<span></span>
</td>
<td class="nump">24,812,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade and Other Payables</a></td>
<td class="nump">2,673,221<span></span>
</td>
<td class="nump">986,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to MyMD Florida Shareholders</a></td>
<td class="nump">29,982<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease Liability</a></td>
<td class="nump">65,780<span></span>
</td>
<td class="nump">53,240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,768,983<span></span>
</td>
<td class="nump">1,039,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersNoncurrent', window );">Due to MyMD Florida Shareholders, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease Liability, net of current portion</a></td>
<td class="nump">75,941<span></span>
</td>
<td class="nump">95,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">75,941<span></span>
</td>
<td class="nump">125,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,844,924<span></span>
</td>
<td class="nump">1,165,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, no par value, 500,000,000 shares authorized 39,470,009 and 37,673,110 issued and outstanding as of December 31, 2022 and December 31, 2021</a></td>
<td class="nump">108,309,436<span></span>
</td>
<td class="nump">102,064,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(93,758,904)<span></span>
</td>
<td class="num">(78,561,568)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">14,695,056<span></span>
</td>
<td class="nump">23,647,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">17,539,980<span></span>
</td>
<td class="nump">24,812,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="nump">$ 144,524<span></span>
</td>
<td class="nump">$ 144,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913375088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">39,470,009<span></span>
</td>
<td class="nump">37,673,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">39,470,009<span></span>
</td>
<td class="nump">37,673,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">211,353<span></span>
</td>
<td class="nump">211,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">72,992<span></span>
</td>
<td class="nump">72,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">72,992<span></span>
</td>
<td class="nump">72,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913429296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Product Cost of Sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative Expenses</a></td>
<td class="nump">5,520,150<span></span>
</td>
<td class="nump">6,420,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expenses</a></td>
<td class="nump">9,067,422<span></span>
</td>
<td class="nump">6,745,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_AccretionOfDebtDiscount', window );">Accretion of Debt Discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">608,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation</a></td>
<td class="nump">695,191<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_StockOptionModificationExpenses', window );">Stock Option Modification Expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,036,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(15,282,763)<span></span>
</td>
<td class="num">(28,809,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Income) Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and Dividend Income</a></td>
<td class="num">(83,991)<span></span>
</td>
<td class="num">(8,907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">(Gain)/Loss on Sales of Marketable Securities</a></td>
<td class="nump">5,964<span></span>
</td>
<td class="num">(39,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (Gain)/Loss on Marketable Securities</a></td>
<td class="num">(2,958)<span></span>
</td>
<td class="nump">42,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_GainOnDebtForgiveness', window );">Gain on Debt Forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(180,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_UninsuredCasualtyLosses', window );">Uninsured Casualty Losses</a></td>
<td class="num">(4,442)<span></span>
</td>
<td class="nump">1,265,306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other (Income) Expenses</a></td>
<td class="num">(85,427)<span></span>
</td>
<td class="nump">1,079,338<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss Before Income Tax</a></td>
<td class="num">(15,197,336)<span></span>
</td>
<td class="num">(29,889,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (15,197,336)<span></span>
</td>
<td class="num">$ (29,889,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and Dilutive net loss per common share</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average basic and diluted common shares outstanding</a></td>
<td class="nump">38,825,763<span></span>
</td>
<td class="nump">35,017,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_AccretionOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_AccretionOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_GainOnDebtForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on debt forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_GainOnDebtForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_StockOptionModificationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option modification expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_StockOptionModificationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_UninsuredCasualtyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uninsured Casualty Losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_UninsuredCasualtyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775917566048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible Enumeration]</a></td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914280032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity /(Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series D Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common stock No Par Value [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,004<span></span>
</td>
<td class="nump">$ 43,411,487<span></span>
</td>
<td class="num">$ (48,672,523)<span></span>
</td>
<td class="num">$ (5,257,032)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,553,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(29,889,045)<span></span>
</td>
<td class="num">(29,889,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock', window );">Exercise of prepaid equity forward contracts for Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares', window );">Exercise of prepaid equity forward contracts for common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Reverse merger with Akers Biosciences Inc effective April 16, 2021</a></td>
<td class="nump">$ 144,524<span></span>
</td>
<td class="nump">42,332,834<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,477,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares</a></td>
<td class="nump">72,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,335,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare', window );">Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43,415,491<span></span>
</td>
<td class="num">$ (4,004)<span></span>
</td>
<td class="num">(43,411,487)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ModificationTermsOfPreMergerStockOptions', window );">Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,036,051<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,036,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of per-merger MyMD stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of per-merger MyMD stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock based compensation for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">90,002<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock based compensation for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExerciseOfWarrantsForCommonStock', window );">Exercise of warrants for Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,189,840<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,189,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExerciseOfWarrantsForCommonStockShares', window );">Exercise of warrants for common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 144,524<span></span>
</td>
<td class="nump">102,064,218<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(78,561,568)<span></span>
</td>
<td class="nump">23,647,174<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">72,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,673,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,197,336)<span></span>
</td>
<td class="num">(15,197,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,550,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,550,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock', window );">Exercise of prepaid equity forward contracts for Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares', window );">Exercise of prepaid equity forward contracts for common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation &#8211; stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">444,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">444,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation &#8211; restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">165,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">165,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants', window );">Stock-based compensation &#8211; warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 84,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of per-merger MyMD stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 144,524<span></span>
</td>
<td class="nump">$ 108,309,436<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (93,758,904)<span></span>
</td>
<td class="nump">$ 14,695,056<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">72,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,470,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of prepaid equity forward contracts for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of prepaid equity forward contracts for common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ExerciseOfWarrantsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ExerciseOfWarrantsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ExerciseOfWarrantsForCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ExerciseOfWarrantsForCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of post-merger common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ModificationTermsOfPreMergerStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification Terms Of Pre Merger Stock Options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ModificationTermsOfPreMergerStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value compensation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913451872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity /(Deficit) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ModificationOfPreMergerStockOptionShares', window );">Modification of pre merger stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,188,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="nump">$ 449,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ModificationOfPreMergerStockOptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of pre merger stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ModificationOfPreMergerStockOptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912192688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from ongoing operations</a></td>
<td class="num">$ (15,197,336)<span></span>
</td>
<td class="num">$ (29,889,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_AccruedInterestdividends', window );">Accrued interest/dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">608,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">(Gain)/loss on sale of marketable securities</a></td>
<td class="nump">5,964<span></span>
</td>
<td class="num">(39,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MarketableSecuritiesUnrealizedLoss', window );">Unrealized (gain)/loss on marketable securities</a></td>
<td class="num">(2,958)<span></span>
</td>
<td class="nump">42,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_GainOnForgivenessOfDebt', window );">Gain on forgiveness of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(180,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock based compensation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_StockOptionModificationExpenses', window );">Option modification expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,036,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Options issued to key employees</a></td>
<td class="nump">338,922<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Options issued to non-employees</a></td>
<td class="nump">105,420<span></span>
</td>
<td class="nump">90,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Warrants issued for services</a></td>
<td class="nump">84,851<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock units to non-employees</a></td>
<td class="nump">165,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">540,560<span></span>
</td>
<td class="num">(912,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade and other payables</a></td>
<td class="nump">1,686,595<span></span>
</td>
<td class="num">(4,268,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">1,917<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="num">(12,270,068)<span></span>
</td>
<td class="num">(19,516,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(4,836,837)<span></span>
</td>
<td class="num">(13,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">11,750,000<span></span>
</td>
<td class="nump">18,483,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Net cash received in business combination</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,380,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">6,913,163<span></span>
</td>
<td class="nump">19,850,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of the line of credit &#8211; related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,062,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds from borrowings</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net proceeds from note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,826,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of Common Stock</a></td>
<td class="nump">5,550,028<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from the exercise of warrants for Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,189,840<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,550,028<span></span>
</td>
<td class="nump">73,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">193,123<span></span>
</td>
<td class="nump">407,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">555,967<span></span>
</td>
<td class="nump">148,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">749,090<span></span>
</td>
<td class="nump">555,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">13,322<span></span>
</td>
<td class="nump">271,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Schedule of Non-Cash Financing and Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">53,196<span></span>
</td>
<td class="nump">141,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_OtherAssetInvestment', window );">Investment in Oravax Medical, Inc.</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_AccruedInterestdividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_AccruedInterestdividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_GainOnForgivenessOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_GainOnForgivenessOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_MarketableSecuritiesUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities Unrealized Loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_MarketableSecuritiesUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_OtherAssetInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other asset investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_OtherAssetInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_StockOptionModificationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option modification expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_StockOptionModificationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775919340672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zxTLcVBJ0tBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_826_zTzVHhwIEHw9">Organization and Description of Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
Pharmaceuticals, Inc., previously known as Akers Biosciences, Inc., is a New Jersey corporation (&#8220;MyMD&#8221;). These consolidated
financial statements include four wholly owned subsidiaries as of December 31, 2022, MyMD Pharmaceuticals (Florida), Inc. (&#8220;MyMD
Florida&#8221;), XYZ Merger Sub, Inc. (&#8220;Merger Sub&#8221;), Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation, (together,
the &#8220;Company&#8221;). All material intercompany transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
Florida was formed in 2014 and is a Florida-based clinical development stage biopharmaceutical company that is developing its product
candidate, MYMD-1, as an immuno regulator to treat autoimmune diseases, ageing-related diseases. Substantive operations began in 2016
and the Company&#8217;s Investigative New Drug application was filed with the U.S. Food and Drug Administration in December 2018. MyMD
Florida completed its first-in-human Phase 1 clinical trial in December 2019. A second Phase 1 dosing study was completed in December
2021. MYMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release
of numerous pro-inflammatory cytokines, such as TNF-&#945;, interleukin 6 (&#8220;IL-6&#8221;) and interleukin 17 (&#8220;IL-17&#8221;).
MYMD-1 currently is being evaluated in a multicenter Phase 2 clinical trial in patients with sarcopenia and frailty (age-related muscle
loss). MyMD Florida&#8217;s intellectual property portfolio consists of 16 U.S. granted patents, 15 granted foreign patents and 19 pending
applications (3 US, 16 foreign).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supera
Pharmaceuticals, Inc. (&#8220;Supera&#8221;) was formed in September 2018 and is a Florida based development company that is developing
its product candidate &#8220;Supera-CBD&#8221; as an FDA-approved synthetic analog of naturally grown cannabidiols. Substantially all
of Supera&#8217;s research and development activities in 2020 and 2021 were related to intellectual property development and securing
patents, along with product manufacturing and planning initial pre-clinical development activities. During the year ended December 31,
2021, these activities included preclinical work on Supera-CBD confirming it effectiveness in treating anxiety. The preclinical data
was presented at the 4<sup>th</sup> Annual International Cannabinoid Summit describing the superior potency of Supera-CBD. Supera-CBD
preclinical genotoxicity studies were completed in February 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the previously announced Agreement and Plan of Merger and Reorganization, dated November 11, 2020 (the
&#8220;Original Merger Agreement&#8221;), as amended by Amendment No. 1 thereto, dated March 16, 2021 the Original Merger Agreement,
as amended by Amendment No. 1 (the &#8220;Merger Agreement&#8221;), by and among MyMD, Merger Sub and MyMD Florida, Merger Sub was
merged with and into MyMD Florida, with MyMD Florida continuing after the merger as the surviving entity and a wholly owned
subsidiary of MyMD (the &#8220;Merger&#8221;). At the effective time of the Merger, without any action on the part of any
stockholder, each issued and outstanding share of pre-Merger MyMD Florida&#8217;s Common Stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210416__dei--LegalEntityAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zNS7l0hS7sP9" title="Common Stock, par value">0.001</span>
per share (the &#8220;MyMD Florida Common Stock&#8221;), including shares underlying pre-Merger MyMD Florida&#8217;s outstanding
equity awards, was converted into the right to receive (x) <span id="xdx_904_ecustom--ExchangeRatioPricePerShares_iI_c20210416__dei--LegalEntityAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zKCdjKC3jD72" title="Exchange ratio price per shares">0.7718</span>
shares (the &#8220;Exchange Ratio&#8221;) of MyMD&#8217;s Common Stock, no par value per share (the &#8220;Company Common
Stock&#8221; or &#8220;Common Stock&#8221;), (y) an amount in cash, on a pro rata basis, equal to the aggregate cash proceeds received by the Company from the
exercise of any options to purchase shares of MyMD Florida Common Stock outstanding at the effective time of the Merger assumed by
the Company upon closing of the Merger prior to the second-year anniversary of the closing of the Merger (the &#8220;Option Exercise
Period&#8221;), such payment (the &#8220;Additional Consideration&#8221;), and (z) potential milestone payment in shares of Company
Common Stock up to the aggregate number of shares issued by the Company to pre-Merger MyMD Florida stockholders at the closing of
the Merger (the &#8220;Milestone Payments&#8221;) payable upon the achievement of certain market capitalization milestone events
during the 36-month period immediately following the closing of the Merger (the &#8220;Milestone Period&#8221;). Immediately
following the effective time of the Merger, the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company
Common Stock (the &#8220;Reverse Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, MyMD Florida entered into an Asset Purchase Agreement with Supera, a related company through common control, in which
Supera was acquired by MyMD Florida through the issuance of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--SuperaPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zOiuRU33FyH" title="Stock issued during period, shares, acquisitions">33,937,909</span> shares of pre-Merger MyMD Florida Common Stock. The Supera
entity was dissolved pursuant to this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Merger, the Company changed its name
to MyMD Pharmaceuticals, Inc. and the Company Common Stock, listed previously trading through the close of business on April 16, 2021
under the trading symbol &#8220;AKER&#8221;, commenced trading on The Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis,
under the trading symbol &#8220;MYMD&#8221; on April 19, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2022&#160;, the MyMD Florida subsidiary was dissolved and merged into the New Jersey corporation MyMD Pharmaceuticals, Inc.
pursuant to an Agreement and Plan of Merger dated April 8, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918152320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zW0BikXhfmdk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_828_zqI9LcEqYod5">Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkmU3qnbJNQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
<span id="xdx_86B_zK6C0KSyZTn1">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally
accepted in the United States of America (US GAAP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zXdssfkOSpne" title="Reverse stock split">1-for-2 reverse stock split</span> immediately following the effective time of the Merger. No fractional shares were issued
in connection with the Reverse Stock Split. Each stockholder who did not have a number of shares evenly divisible pursuant to the Reverse
Stock Split ratio and who would otherwise be entitled to receive a fractional share of Company Common Stock was entitled to receive an
additional share of Company Common Stock. The number of shares on equity related disclosures included in this Annual Report on Form
10-K, including the consolidated financial statements and accompanying notes, were retroactively adjusted to reflect the effects
of the Reverse Stock Split and the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zitK6G4H5AMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
<span id="xdx_861_zdVe4a17sanl">Use of Estimates and Judgments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that
affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ
from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation,
uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in
the financial statements is included in the following notes for recording research and development expenses, impairment of intangible
assets and the valuation of share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zkvkpJ9bLyAd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
<span id="xdx_863_zivmKWz9RRna">Functional and Presentation Currency</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements are presented in U.S. Dollars, which is the Company&#8217;s functional currency. All financial
information has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated
in Foreign Currencies, are recorded in the Consolidated Statements of Operations and Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zGYMLK4EOk27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
<span id="xdx_86D_z0DG4sjMaICg">Comprehensive Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;) 220 in reporting comprehensive
loss. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information
that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income
(loss), comprehensive loss is equal to net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zECjbfjPZ8v8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)
<span id="xdx_86B_zWALoFqnF9a">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that
are not restricted as to withdrawal date or use, to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7to1s1s5s2a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
<span id="xdx_86A_zT1m60PGwzpg">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables.
The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their
short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are
described as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company
    can access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology include:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices for similar assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices for identical or similar assets or liabilities in inactive markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    other than quoted prices that are observable for the asset or liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    that are derived principally from or corroborated by observable market data by correlation or other means</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of
    the asset or liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
asset or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is
significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of
unobservable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
Fair Value of Financial Instruments, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zePSfj8Avsca">Schedule
of Marketable Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable
Securities:</i> Valued using quoted prices in active markets for identical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Significant
    Unobservable Inputs (Level 3)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif">4,086,902</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif">11,003,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zNrXGEf2wrHg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities are classified as available for sale and are valued at fair market value. Maturities of the securities are less than one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the Company held certain mutual funds, which, under FASB ASC 321-10, were considered equity
investments. As such, the change in fair value in the year ended December 31, 2022 and 2021 was a gain of $<span id="xdx_907_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_zctD79SBIhmg" title="Unrealized (gain)/loss on marketable securities">2,958</span>
and a loss of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_z2GifEoTIlXd" title="Unrealized (gain)/loss on marketable securities">42,793</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses resulting from the sales of marketable securities were losses of $<span id="xdx_904_eus-gaap--MarketableSecuritiesRealizedGainLoss_iN_di_c20220101__20221231_zyRZ8Lr5LD26" title="Gain/loss on sale of marketable securities">5,964</span> and gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20210101__20211231_zGhwhueFBAd2" title="Gain/loss on sale of marketable securities">39,597</span> for the years ended December
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from the sales of marketable securities were $<span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20220101__20221231_zpI1TG3QqZRa" title="Proceeds from the sales of marketable securities">11,750,000</span> and $<span id="xdx_90D_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20211231_zj6x4w1Pb0R1" title="Proceeds from the sales of marketable securities">18,483,176</span> in the years ended December 31, 2022 and 2021, respectively.
Purchases of marketable securities were $<span id="xdx_907_eus-gaap--PaymentsToAcquireMarketableSecurities_c20220101__20221231_z5v6kEXs9f41" title="Purchase of marketable securities">4,836,837</span> and $<span id="xdx_90B_eus-gaap--PaymentsToAcquireMarketableSecurities_c20210101__20211231_z9ETZImwdjKc" title="Purchase of marketable securities">13,403</span> during the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--PrepaidExpensesPolicyTextBlock_zEXSDCVqVF4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)
<span id="xdx_865_z0t40pOFMOdh">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses represent expenses paid prior to the date that the related services are rendered or used are comprised principally of prepaid
insurance and research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zw5YAmiRVZPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)
<span id="xdx_864_zpAtJtp7O5tk">Concentrations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial
institutions and accounts receivable. At times, the Company&#8217;s cash in banks is in excess of the FDIC insurance limit. The Company
has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--RiskManagementOfCashInvestmentsPolicyTextBlock_zcaEdiCpaNg9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)
<span id="xdx_862_zUAivk8x7WY8">Risk Management of Cash and Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy to minimize the Company&#8217;s capital resources to investment risks, prioritizing the preservation of
capital over investment returns. Investments are maintained in securities, primarily publicly traded, short-term money market funds based
on highly rated federal, state and corporate bonds, that minimize the risk to the Company&#8217;s capital resources and provide ready
access to funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s investment portfolios are regularly monitored for risk and are held with one brokerage firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_zBGp5lXsQcn6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)
<span id="xdx_867_zwGzmjRwRRr3">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other
than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company&#8217;s
ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for
using the cost method to the equity method of valuation in accordance with FASB ASC 323.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company&#8217;s ability to significantly
influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the
time of the investment based upon several factors including, but not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
    on the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participation
    in policy-making processes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    intra-entity transactions</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interchange
    of management personnel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technological
    dependencies</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extent
    of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational
and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the
cost method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with FASB ASC 321-10-35-2, the Company has elected to measure
its investment in Oravax Medical, Inc. (&#8220;Oravax&#8221;) (Note 3) as an equity security without a readily determinable fair value.
Under this election, an equity security without a readily available fair value is reflected at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
At each reporting period, the Company is required to make a qualitative assessment considering impairment indicators to evaluate whether
the investment is impaired. If deemed impaired, the Company is required to estimate the fair value of the investment and recognize an
impairment loss equal to the difference between the fair value of the investment and its carry amount. As of December 31, 2022, the Company
performed a qualitative assessment to evaluate whether the investment is impaired and determined that the investment was not impaired
and thus no adjustment to fair market value was required as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zs5s0t7t55Se" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(k)
<span id="xdx_86A_zwcA9esYL5El">Property, Plant and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, plant and equipment and are recognized within &#8220;other (income)/expense&#8221; in the Consolidated
Statements of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognized over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of
the lease term or their useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zs65nJ7AflJl">Schedule
of Estimated Useful Lives of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives">12</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &amp; software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives">5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives">Shorter of the remaining
    lease or estimated useful life</span></span></td></tr>
  </table>

<p id="xdx_8A6_zsRLLYi1iiY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8iJ02grMFA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(l)
<span id="xdx_868_zWIJmvX69zU4">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate
there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets
not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount,
other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge in the Consolidated Statements of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents
and Trade Secrets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propriety
protection for the Company&#8217;s products, technology and process is important to its competitive position. As of December 31, 2022,
the Company has 16 issued U.S. patents, 50 foreign patents, four pending U.S. patent applications and 15 foreign patent applications
pending in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea, which if issued are expected
to expire between 2036 and 2041. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade
secrets) using all legal remedies available to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records expenses related to the application for and maintenance of patents as a component of research and development expenses
on the Consolidated Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic
benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life and assessed for impairment when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Intangible Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization
and accumulated impairment losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amortization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zTy2vgZzxaS3" style="display: none">Schedule of Estimated Useful Lives of Intangible Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
    and trademarks</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives">12</span>-<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives">17</span></span></td></tr>
  </table>
<p id="xdx_8A4_ztE2JQSh464l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z48w7DnfUcCb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(m)
<span id="xdx_86E_zYGyDOVSEZG3">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is evaluated annually for impairment or whenever we identify certain triggering events or circumstances that would more likely than not
reduce the fair value below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include,
among other things, unexpected adverse business conditions, economic factors (for example, the loss of key personnel), supply costs,
unanticipated competitive activities, and acts by governments and courts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_zT9j3kHsrBL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(n)
<span id="xdx_861_zXuh6y5Q4Z46">Recoverability of Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB ASC 360-10-35 &#8220;Impairment or Disposal of Long-lived Assets&#8221;, long-lived assets to be held and used are
analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable
or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and
circumstances have occurred that indicate possible impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges)
and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by
which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the
lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying
amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce
the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--RightOfUseAssetsPolicyTextBlock_zPO69ayfdMkj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(o)
<span id="xdx_86E_zZdGfl5apCMh">Right-of-Use Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased a facility in Tampa, Florida (&#8220;Hyde Park&#8221;) under an operating lease (&#8220;Hyde Park Lease&#8221;) with annual
rentals of $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z5gXmVY3O0hi" title="Payments for Rent">22,048</span> to $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zcYov0cps7ya" title="Payments for Rent">23,320</span> plus certain operating expenses. The Hyde Park facility housed the MyMD Florida operations. The Hyde Park
Lease took effect on July 1, 2019 for a term of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zhkNz0gLpuz6" title="Lessee, operating lease, term of contract">36</span> months to expire on <span id="xdx_90E_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20190701__20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z2htao554bs8" title="Lease expiration date">June 30, 2022</span>. The Company cancelled the Hyde Park lease in March
2022 without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased an aircraft under an operating lease (&#8220;Supera Aviation Lease&#8221;) with annual rentals of $<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20181020__20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zo4CJ5rwsPLb" title="Payments for Rent">600,000</span> plus certain
operating expenses. The Supera Aviation Lease took effect on October 26, 2018 for a term of <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zE0qgmlf4I4h" title="Lessee, operating lease, term of contract">36</span> months to expire on September 26, 2021.
The Company cancelled the Supera Aviation Lease in April 2021 without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased a facility in Baltimore, Maryland (&#8220;2020 Wolfe St&#8221;) under an operating lease (&#8220;2020 Baltimore Lease&#8221;)
with annual rentals of $<span id="xdx_90F_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zb3FRNgbwJah" title="Payments for Rent">24,000</span> to $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zl95SSVy0kS1" title="Payments for Rent">25,462</span> plus certain operating expenses. The 2020 Baltimore Lease took effect on November 9, 2020 for
a term of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zfTeYsV7SaJd" title="Lessee, operating lease, term of contract">12</span> months with automatic renewals unless a sixty-day notice was provided. The initial term expired on <span id="xdx_90B_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20201105__20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_z3I38lbOJec5" title="Lease expiration date">November 30, 2021</span>. On
November 17, 2021, the 2020 Baltimore Lease was cancelled without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases a facility in Baltimore, Maryland (&#8220;2021 Wolfe St&#8221;) under an operating lease (&#8220;2021 Baltimore
Lease&#8221;) with annual rentals of $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MinimumMember_zfuZTDSVVlR8" title="Payments for rent">52,800</span>
to $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MaximumMember_zYs1H5BkXeWd" title="Payments for rent">56,016</span>
plus certain operating expenses. The 2021 Baltimore Lease took effect on November 17, 2021 for a term of <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zljWYGaAuPp" title="Lessee operating lease term of contract">12</span>
months with automatic renewals unless a sixty-day notice is provided. The initial term expires on <span id="xdx_90C_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zILO0WYY40v6" title="Expiration date">November
30, 2022</span>. The lease renewed effective December 1, 2022 for a term of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20221201_zaWttHsZO1Ha" title="Lessee operating lease renewal term">12</span> months with automatic renewals unless a sixty-day notice
is provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases a facility in Tampa, Florida (&#8220;Platt St&#8221;) under an operating lease (&#8220;Platt Street Lease&#8221;) with
annual rentals of $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MinimumMember_z15D2sxrM7xd" title="Payments for Rent">22,030</span> to $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MaximumMember_zYXFjtctPI8e" title="Payments for rent">23,259</span> plus certain operating expenses. The Platt Street Lease took effect on April 1, 2022 for a term
of <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zsv3fWf9Zku" title="Term of contract">36</span> months. The initial term expires on <span id="xdx_903_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z72rUefeJsWk" title="Lease expiration date">March 31, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019 (&#8220;Effective Date&#8221;), the Company adopted FASB ASC, Topic 842, Leases (&#8220;ASC 842&#8221;), which increases
transparency and comparability by recognizing a lessee&#8217;s rights and obligations resulting from leases by recording them on the
balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (&#8220;ROU&#8221;)
assets and related operating and finance lease liabilities on the balance sheet. The Company adopted the new guidance using the modified
retrospective approach on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the package of practical expedients permitted within the standard, which allows an entity to forgo reassessing (i) whether
a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition
of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and
impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has
also elected the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any
lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
contracts entered into on or after the Effective Date, at the inception of a contract, the Company will assess whether the contract is,
or contains, a lease. The Company&#8217;s assessment is based on: (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtained the right to substantially all the economic benefit from the use of the asset throughout the
period, and (iii) whether the Company has the right to direct the use of the asset. Leases entered into prior to January 1, 2020, which
were accounted for under ASC 840, were not reassessed for classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The Company
generally uses its incremental borrowing rate as the discount rate for leases, unless an interest rate is implicitly stated in the lease.
The present value of the lease payments is calculated using the incremental borrowing rate for operating leases, which was determined
using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term. The lease term for all the Company&#8217;s leases includes the non-cancellable period
of the lease plus any additional periods covered by either a Company option to extend the lease that the Company is reasonably certain
to exercise, or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zv4QhUpqTiz4" style="display: none">Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt Street</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hyde
                                                                                         Park</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Balance
    Sheet Location</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Right
    of Use</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,662</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,156</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,853</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,741</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,076</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53,240</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable - net of
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,070</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,941</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,911</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,911</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zEOBmg0vkU17" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides details of the Company&#8217;s lease expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGRbxhBgiqMd" style="display: none">Schedule of Lease Expense</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Platt Street</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Supera Aviation</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease Expenses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b><span style="font-family: Times New Roman, Times, Serif">Lease</span></b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Lease Costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,251</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,981</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">54,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,632</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,533</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">202,226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AF_zu8WgHFyEU2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zTbeKs7NCWTd" style="display: none">Schedule of Other Information Related to Leases</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Hyde</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other
    Information</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Park
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating cash
    used</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">4,622</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">19,628</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">51,602</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">75,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Average remaining lease
    term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term">27</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term">23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term">25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A5_zDSTRTFLYxp9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the annual minimum lease payments of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z418TRZZeYi" style="display: none">Schedule of Operating Lease Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">For Years Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,485</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,005</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,348</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments, undiscounted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,868</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">157,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of future
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,811</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,721</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_z9Pn8x1uCzk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zV1OPgbYY9Ac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(p)
<span id="xdx_8B3_z0X56l1bZbzi">Revenue Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that
a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services
transferred to the customer. The following five steps are applied to achieve that core principle:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the contract with the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the transaction price</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
    the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
    revenue when the company satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zFd0LdHOkWhh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(q)
<span id="xdx_866_zPNtZrlB5KGg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits are
recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized
is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized
tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and
measurement standards. For the years ended December 31, 2022 and 2021, no liability for unrecognized tax benefits was required to be
reported.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no income tax benefit recorded for the losses for the years ended December 31, 2022 and 2021 since management determined that the
realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on
the net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax years from 2019 through 2022 remain
subject to examination by federal and state jurisdictions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zSFd7GSZQV6i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(r)
<span id="xdx_869_zJi0VKddkhRa">Basic and Diluted Earnings per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings
per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the
period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 375.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed using the weighted average number of shares of Common Stock and dilutive potential Common Stock outstanding
during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss for the years ended December 31, 2022 and 2021, Common Stock equivalents were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAXNur76ujuj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
    the Years Ended <br/> December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,376,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,176,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Unvested Restricted Stock Units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,795,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,795,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,074,489</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">520,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Convertible Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Convertible Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,496</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,496</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    potentially dilutive shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,885,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,630,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zu08y11WuaG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzGyNqd81XN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(s)
<span id="xdx_86E_zGEQBYKSKSgd">Stock-based Payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) 718, &#8220;Compensation - Stock Compensation&#8221;, which requires the measurement and recognition of compensation
expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates
the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is
ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In June 2018,
the FASB issued ASU No. 2018-07, Compensation &#8211; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment
Accounting (the &#8220;2018 Update&#8221;). The amendments in the 2018 Update expand the scope of Topic 718 to include share-based payment
transactions for acquiring goods and services from nonemployees. Prior to the 2018 Update, Topic 718 applied only to share-based transactions
to employees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards
within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when
the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the
instruments have been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for forfeiture of stock-based awards as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zawq1TKJXW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(t) <span id="xdx_86C_z2UTNbnIjANg">Research and Development Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with FASB ASC 730, research and development costs are expensed
as incurred and consist of fees paid to third parties that conduct certain research and development activities on the Company&#8217;s
behalf.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zb2UcIdCu8jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(u)
<span id="xdx_861_z1m1wXwiQfC4">Recently Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, FASB issued ASU 2017-11, Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and
Hedging (Topic 815): The new guidance amends ASC 815 to exclude consideration of a down-round feature in the evaluation of whether an
instrument is indexed to an entity&#8217;s own stock under ASC 815-40-15-7C. That is, a down-round provision would not preclude an entity
from concluding that an instrument or feature that includes a down-round feature is indexed to the entity&#8217;s own stock. This guidance
applies to both freestanding financial instruments and embedded conversion options (e.g., in convertible instruments with beneficial
conversion features (BCFs) or cash conversion features (CCFs)). The ASU is effective for annual reporting periods beginning after December
15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this standard did not have a material impact on their
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, FASB issued ASU 2020-06, <i>Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211;
Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own
Equity</i>. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer&#8217;s accounting for convertible debt instruments. The new
guidance removes from U.S. GAAP the separation models for (1) convertible debt with a CCF and (2) convertible instruments with a BCF.
As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in
such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as
preferred stock. This ASU is effective for fiscal years beginning after December 15, 2021 and early adoption is allowed. The Company
early adopted this guidance as of January 1, 2021. The adoption of this standard did not have a material impact on their consolidated
financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50),
Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40),
Issuer&#8217;s Accounting for Certain Modifications or Exchanges or Freestanding Equity - Classified Written Call Options. </i>The amendments
in this Update clarify an issuer&#8217;s accounting for modifications or exchanges of freestanding equity - classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments are effective for all entities for
fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments
prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for
all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this Update in an interim
period, the guidance should be applied as of the beginning of the fiscal year that includes the interim period. The adoption of this
ASU had no material impact on the Company&#8217;s consolidated financial statements and related disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements Not Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial
Instruments (&#8220;ASU-2016-13&#8221;). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets
that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred
losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2022, including interim periods
within that fiscal year. The Company expects that there would be no material impact on the Company&#8217;s consolidated financial
statements upon the adoption of this ASU.</span></p>
<p id="xdx_858_zag03Euhqlva" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918261344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Developments, Liquidity and Management&#8217;s Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract', window );"><strong>Recent Developments Liquidity And Managements Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_RecentDevelopmentsAndManagementsPlansTextBlock', window );">Recent Developments, Liquidity and Management&#8217;s Plans</a></td>
<td class="text"><p id="xdx_807_ecustom--RecentDevelopmentsAndManagementsPlansTextBlock_zZwzjwClXqgj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82B_z0HVwZ3uMkUf">Recent Developments, Liquidity and Management&#8217;s Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition
and Disposition of Cystron</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired <span id="xdx_907_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_dp_uPure_c20200323__us-gaap--BusinessAcquisitionAxis__custom--CystronBiotechLLCMember__us-gaap--TypeOfArrangementAxis__custom--MembershipInterestPurchaseAgreementMember_zHgOJjBbVoQ7" title="Acquired membership interests, percentage">100</span>% of the membership interests of Cystron pursuant to a Membership Interest Purchase Agreement, dated March 23, 2020
(as amended by Amendment No. 1 on May 14, 2020, the &#8220;MIPA&#8221;) from certain selling parties (the &#8220;Cystron Sellers&#8221;).
The acquisition of Cystron was accounted for as a purchase of an asset. Cystron is a party to a License and Development Agreement (as
amended and restated on March 19, 2020, in connection with our entry into the MIPA, the &#8220;License Agreement&#8221;) with Premas
Biotech PVT Ltd. (&#8220;Premas&#8221;) whereby Premas granted Cystron, amongst other things, an exclusive license with respect to Premas&#8217;
vaccine platform for the development of a vaccine against COVID-19 and other coronavirus infections. Cystron was incorporated on March
10, 2020. Since its formation and through the date of its acquisition by the Company, Cystron did not have any employees and its sole
asset consisted of the exclusive license from Premas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company and the Cystron Sellers, which are also shareholders of Oravax, entered into a Termination and Release Agreement
terminating the MIPA effective upon consummation of the Contribution Agreement. In addition, the Cystron Sellers agreed to waive any
change of control payment triggered under the MIPA as a result of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, pursuant to the Contribution and Assignment Agreement, dated March 18, 2021 (the &#8220;Contribution Agreement&#8221;)
by and among the Company, Cystron, Oravax and, for the limited purpose set forth therein, Premas, the parties consummated the transactions
contemplated therein. Pursuant to the Contribution Agreement, among other things, the Company caused Cystron to contribute substantially
all of the assets associated with its business of developing and manufacturing Cystron&#8217;s COVID-19 vaccine candidate to Oravax (the
&#8220;Contribution Transaction&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, all amounts due to Premas under the Contribution Agreement have been paid. (<i>Note: Pursuant to the Contribution
Agreement, a total of $<span id="xdx_90A_eus-gaap--PaymentsForProceedsFromInvestments_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember__dei--LegalEntityAxis__custom--PremasBiotechPVTLtdMember_zFAbnIXVSo5g" title="Amount owed on investments">1,500,000</span> was owed to Premas, of which $<span id="xdx_904_eus-gaap--PaymentsToAcquireInvestments_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember__dei--LegalEntityAxis__custom--PremasBiotechPVTLtdMember_z0vNCglhow93" title="Payments to investments">1,200,000</span> was paid by pre-merger Akers Biosciences, Inc.</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Agreement
and Plan of Merger and Reorganization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, MyMD, Merger Sub, and MyMD Florida entered into the Merger Agreement (Note 1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PreMergerMember_zA9GsiDBMY3c" title="Business acquisition description">Upon
completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesPostReverseStockSplits_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z8HZoWanW0W8" title="Issuance of post reverse stock split">28,553,307</span>
post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio.
Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD
Florida held approximately <span id="xdx_900_ecustom--ExchangeRatioPercentage_dp_uPure_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zow1OeGQnp46" title="Exchange ratio percentage">77.05</span>%
of the Company&#8217;s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants
to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210416__srt--StatementScenarioAxis__custom--PrefundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zBynsI6NHzq3" title="Warrants to purchase">986,486</span>
shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of
pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company&#8217;s net cash
at closing. Holders of pre-Merger Company Common Stock held approximately 22.95% of the outstanding equity of the
Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315
MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment
of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of
the Merger</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 805, the Company accounted for the transaction as a reverse merger with Akers Biosciences, Inc. (&#8220;Akers&#8221;)
as the legal acquirer and pre-Merger MyMD Florida as the accounting acquirer. As a result of the transaction, the Company recognized
Goodwill totaling $<span id="xdx_90E_eus-gaap--Goodwill_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zVAUDm3eucu1" title="Goodwill">10,498,539</span> based upon Akers&#8217; pre-merger market capitalization of $<span id="xdx_90A_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zy2QKP80b0G7" title="Pre market capitalization">42,477,346</span> less net tangible assets of $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zyQaj3sWDpT9" title="Tangible asset">31,978,807</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Akers&#8217;
valuation was based upon <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_z3MCITwbgF05" title="Common shares outstanding">8,335,627</span> common shares outstanding and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgGbIkVmypFa" title="Vested restricted stock unit">263,026</span> vested restricted stock units (&#8220;RSU&#8217;) with a fair
market value of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsO1ai5oX2h3" title="Fair market value price per share">4.94</span> per share, the closing price of Akers common shares on the NASDAQ Stock Exchange on April 16, 2021.</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zbqmEkrbkShe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z16p5vmab1Rd">Schedule
of Net Assets Acquired to be Allocated to Goodwill</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Valuation
    <br/> Analysis</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210416__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zW1yQXyWjuLh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total Consideration"><span style="font-family: Times New Roman, Times, Serif">42,477,346</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and Cash Equivalents"><span style="font-family: Times New Roman, Times, Serif">1,380,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">29,480,524</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other Receivables"><span style="font-family: Times New Roman, Times, Serif">3,026,137</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expenses"><span style="font-family: Times New Roman, Times, Serif">192,314</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in Oravax, Inc.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment in Oravax, Inc."><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Trade and Other Payables</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zY7GpVztgPi2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and Other Payables"><span style="font-family: Times New Roman, Times, Serif">(3,601,020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Tangible Assets
    Acquired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zDDkY4np7f3b" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Tangible Assets Acquired"><span style="font-family: Times New Roman, Times, Serif">31,978,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Excess of Purchase Price
    Over Net Assets Acquired to be Allocated to Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--Goodwill_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill"><span style="font-family: Times New Roman, Times, Serif">10,498,539</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zcY4Mi6aa8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of approximately <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220412__20220416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zEYBOl4W5f54" title="Percentage of common stock">49.68</span>% of outstanding shares of Company Common Stock are subject to lockup agreements pursuant to which such
stockholders have agreed, except in limited circumstances, not to transfer, grant an option with respect to, sell, exchange, pledge or
otherwise dispose of, or encumber, any shares of Company capital stock for 180 days following the effective time of the Merger. For the
subsequent 180 days after the initial 180-day lock-up period, any disposal of Company Common Stock must be only in accordance with the
volume limitations set forth in paragraph (2) of Rule 144 promulgated under the Securities Act of 1933, as amended (the &#8220;Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and conditions of the Merger Agreement, not later than 30 days after the Option Exercise Period, the Company will pay stockholders
of MyMD Florida the Additional Consideration from the exercise of any MyMD Florida options assumed by the Company prior to the second-year
anniversary of the Merger; provided, however, the amount of such payment will not exceed the maximum amount of cash consideration that
may be received by stockholders of MyMD Florida without affecting the intended tax consequences of the Merger. As of the date of this
report, there have been no exercises of the MyMD Florida options assumed by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Merger Agreement, the Company has agreed to pay contingent consideration in combined Company Common Stock to MYMD Florida
stockholders if the combined company meets certain market capitalization milestones, referred to as Milestone Events, during the period
commencing on the business day following the closing date of the merger and ending on the 36-month anniversary of such date, referred
to as the Milestone Period. The Milestone Events and corresponding Milestone Payments are set forth in the table below.</span></p>

<p id="xdx_89D_ecustom--SummaryOfMilestoneEventsPaymentTableTextBlock_ztnzcd3FAXkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zX43G04cJwKi">Summary
of Milestone Events Payment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Event</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Payment</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zxQO5DcJdaa1" title="Milestone Event">Market
    capitalization of the combined company for at least ten (<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zbAkHFkCvoxj" title="Debt Instrument, Convertible, Threshold Trading Days">10</span>) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#8220;First Milestone Event&#8221;)</span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zn71c3673dzf" title="Milestone Payment">20,000,000</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z3mOcVEauQti" title="Milestone Event">For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least <span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z9NFKzKila4b" title="Threshold trading days">10</span> trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company</span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_zUWfakWc2bji" title="Milestone Payment">10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zy6Uzjofk6Yc" title="Milestone Event">Market
    capitalization of the combined company for at least <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zFPZOxDxzhCl" title="Debt Instrument, Convertible, Threshold Trading Days">10</span> trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#8220;Second Milestone Event&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zwcfVRNmJXe8" title="Milestone Payment">25,000,000</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zCIuwjWOFz48" title="Milestone Event">For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zzgeveMfu8mk" title="Threshold trading days">10</span> trading days during any 20 consecutive trading day period during the Milestone
    Period</span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90E_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zLtbp8KJU8Zi" title="Milestone Payment">25,000,000</span>
    per each incremental increase</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<p id="xdx_8AB_zeLl3tVjuXa5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the table above, &#8220;market capitalization&#8221; means, with respect to any trading day, the product of (i) the total
outstanding shares of the combined Company Common Stock and (ii) the volume weighted average trading price for the combined Company Common Stock for such trading day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, none of the contingencies noted above have been met.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s cash on hand was $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zGYUUbapHN1l" title="Cash on hand">749,090</span> and marketable securities were $<span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zpZRYnoBQKL1" title="Marketable securities">4,086,902</span>. The Company has incurred
a net loss from operations of $<span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iN_pp0p0_di_c20220101__20221231_zn8kAqDORv5i" title="Loss from operations">15,197,336</span> for the year  ended December 31, 2022. As of December 31, 2022, the Company had working
capital of $<span id="xdx_907_ecustom--WorkingCapital_iI_pp0p0_c20221231_zSbUIQpbjj2l" title="Working capital">2,632,796</span> and stockholders&#8217; equity of $<span id="xdx_907_eus-gaap--StockholdersEquity_iI_pp0p0_c20221231_zJtLSahnDpAa" title="Stockholders' equity">14,695,056</span> including an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20221231_zJTz9YLatmjk" title="Accumulated deficit">93,758,904</span>. During the year
ended December 31, 2022, cash flows used in operating activities were $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20220101__20221231_zSt0Ad7AII2i" title="Net cash provided by operating activities">12,270,068</span>, consisting primarily of a net loss of $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220101__20221231_z7gGCqXPkVS2" title="Net loss">15,197,336</span>
offset by non-cash share-based compensation of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220101__20221231_zCCseBi5deQc" title="Non cash share based compensation">695,191 </span> and an increase in trade and other payables of $<span id="xdx_90C_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_pp0p0_c20220101__20221231_zAGjxOI4MtNf" title="Increase in trade and other payables">1,686,595</span> and a decrease in prepaid
expenses of $<span id="xdx_90D_ecustom--DecreaseInPrepaidExpense_c20220101__20221231_zl64mJLJ5Xtj" title="Decrease in prepaid expense">540,560</span>. Since its inception, the Company has met its liquidity requirements principally through the sale of its Common Stock in public and private placements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the current cash requirements for operations in conjunction with management&#8217;s strategic plan and believes that
the Company&#8217;s current financial resources as of the date of the issuance of these consolidated financial statements are sufficient
to fund its current operating budget and contractual obligations as of December 31, 2022 as they fall due within the next twelve-month
period, alleviating any substantial doubt raised by the Company&#8217;s historical operating results and satisfying its estimated liquidity
needs for twelve months from the issuance of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_RecentDevelopmentsAndManagementsPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent developments and managements plans text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_RecentDevelopmentsAndManagementsPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918114304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and Other Payables</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zF3Gkqu4OxWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_827_zzofitw2FMx4">Trade and Other Payables</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLkHF2WSGX6f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other payables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zmu5VpD0hIN3">Schedule
of Trade and Other Payables</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20221231_zWFKnewnHzU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20211231_zBPCCn91pAcb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableTradeCurrent_iI_pp0p0_maAPAOAzNsj_zaPxxI4z5X0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable &#8211; Trade</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,356,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">867,518</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzNsj_zWsHh3J32ut6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">119,108</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzNsj_ziwHp0LUz5nb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables, Total</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,673,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">986,626</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zHX8XofOYbzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918166768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zrA97pS6VZy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82A_zjs9c7Jwh4Uh">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Secured
Promissory Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2020, concurrently with the execution of the Merger Agreement, the Company agreed to provide a bridge loan up to an aggregate
principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember_zJJ6Yt3FtJN7" title="Maximum principal amount">3,000,000</span> to pre-Merger MyMD Florida pursuant to the Bridge Loan Note. Advances under the Bridge Loan Note (&#8220;Bridge
Loan Advances&#8221;) were made in the amounts and at the times as needed to fund MyMD Florida&#8217;s operating expenses. Bridge Loan
Advances accrue interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember_zVJlOmZFd6mg" title="Interest rate">5</span>% per annum, which may be increased to <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--StatementScenarioAxis__custom--EventOfDefaultMember_zziOZUn1ClEf" title="Interest rate">8</span>% per annum upon occurrence of any event of default, from the date
of such default. The principal and the accrued interest thereon are to be repaid on the earliest of (a) April 15, 2022; (b); if the Merger
was consummated, then upon demand of the Company following the consummation of the Merger; or (c) the date on which the obligations under
the Bridge Loan Note are accelerated upon event of default as set forth in the Bridge Loan Note. The payment and performance of all obligations
under the Bridge Loan Note are secured by a first priority security interest in all of MyMD Florida&#8217;s right, title and interest
in and to its assets as collateral. The outstanding principal amount and the accrued interest of the Bridge Loan Note were convertible
into shares of MyMD Florida Common Stock in accordance with the terms of the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and December 31, 2021 MyMD had advanced MyMD Florida $<span id="xdx_90E_eus-gaap--AdvancesToAffiliate_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zfGlQKpqb7Ii" title="Advances to affiliate"><span id="xdx_908_eus-gaap--AdvancesToAffiliate_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zAXb6ORFthh5" title="Advances to affiliate">3,000,000</span></span> under the Bridge Loan Note plus accrued interest
totaling $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_z4QyR6kPyiqj" title="Accrued interest"><span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zgB0v11mDtZf" title="Accrued interest">26,137</span></span>. The balance of $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zjAwYpS9kbn9" title="Notes payable"><span id="xdx_906_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zn8mjVxf4YS1" title="Notes payable">3,026,137</span></span> as of December 31, 2022 and December 31, 2021, respectively, were eliminated on consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918212000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Payments</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuQw2yYrSRTa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_825_zIymIP6YDXRg">Stock-based Payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
incentive Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2013
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (&#8220;2013 Plan&#8221;). The 2013 Plan was amended by the Board
on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides
for the issuance of up to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20140123__us-gaap--PlanNameAxis__custom--TwoThousandThirteenStockIncentivePlanMember_zujpekTuZSb5" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">2,162</span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of restricted stock and options
to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedPlanMember_zWe5KItoIMxk" title="Share-based compensation arrangement by share-based payment award, shares purchased for award">1,406</span> shares of Common Stock have been issued pursuant to the 2013 Plan, and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--AmendedPlanMember_zMo031D5W25a" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">755</span> shares of Common Stock remain available
for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2016
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2016, the shareholders approved, and the Company adopted the 2016 Stock Incentive Plan (&#8220;2016 Plan&#8221;). The 2016
Plan provides for the issuance of up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20161221__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_zky8YGjAAVJg" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">50,000,000</span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of options
to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_ze4jzwGnmjb4" title="Share-based compensation arrangement by share-based payment award, shares purchased for award">4,188,315</span> shares of Common Stock have been issued pursuant to the 2016 Plan, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_zQvnBXNVOmr4" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">0</span> shares of Common Stock remain available
for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2017
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2017, the shareholders approved, and the Company adopted the 2017 Stock Incentive Plan (&#8220;2017 Plan&#8221;). The 2017
Plan provides for the issuance of up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20170807__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zDwUPIQYPqVe" title="Number of shares authorized">3,516</span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of restricted
stock and options to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zqW9Qk2yTAg5" title="Share based compensation arrangement by share based payment award shares purchased for award">2,538</span> shares of Common Stock have been issued pursuant to the 2017 Plan, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zWuQY7XR92rk" title="Remaining shares available for issuance">978</span> shares of Common Stock
remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2018
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2018, the shareholders approved, and the Company adopted the 2018 Stock Incentive Plan (&#8220;2018 Plan&#8221;). On August
27, 2020, the 2019 Plan was modified to increase the total authorized shares. The 2018 Plan, as amended, provides for the issuance of
up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20181207__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zXwAcLzX7hZ5" title="Share based compensation arrangement by share based payment award number of shares authorized">560,063</span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of RSUs and restricted stock to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zcw8E6ociSI1" title="Share based compensation arrangement by share based payment award shares purchased for award">263,026</span>
shares of Common Stock have been issued pursuant to the 2018 Plan, and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zGTGjOIsRTKi" title="Share based compensation arrangement by share based payment award number of shares available for grant">297,037</span> shares of Common Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2021
Stock Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15, 2021, the shareholders approved, and the Company adopted the 2021 Stock Incentive Plan (&#8220;2021 Plan&#8221;). The 2021
Plan provides for the issuance of up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210415__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zPBhOV286lW9" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">7,228,184</span> shares of the Company&#8217;s Common Stock. As of December 31, 2022, grants of RSUs
and stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zuSkjtTViWlg" title="Share-based compensation arrangement by share-based payment award, shares purchased for award">3,149,207</span> shares of Common Stock have been issued pursuant to the 2021 Plan, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zZNwZIVmqg" title="Remaining shares available for issuance">4,078,977</span> shares of Common
Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKU7dP8dbSzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activities for MyMD stock options for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zhogll6lP7H8">Summary
of Stock Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zXMCfTt0c42h" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of Shares, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">4,176,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkraZcEptGI5" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">2.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zdXh6kDV7ztk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">2.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"/></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUesiIMkAwR5" title="Weighted Average Remaining Contractual Term (Years), Beginning">1.29</span></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zrU9x5VANKu" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">14,493,284</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zgw5BWoHTN81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zIuVXPcxzkXh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">3.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zAmc9CVvaB5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif">3.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--WeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231_zGUCNxEruRXb" title="Weighted Average Remaining Contractual Term (Years), Granted">5.80</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zz9wlBdJF9Fg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zDQNPuVB1EM4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zU3f8FWpT9j8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_znHg0YZgsh63" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJbHi3RYI4ae" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zlOrdKKXojV2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_z1ukftiBAJm" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Canceled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEuhLHZi1wfh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Canceled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zA8NUICsMAn9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Canceled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zNiHI3IoqRke" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Ending Balance">&#8239;<span style="font-family: Times New Roman, Times, Serif">4,476,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zeilo4IWirH3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zIQMsZ9v8hMf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"><span style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOAkMHVCEzE7" title="Weighted Average Remaining Contractual Term (Years), Ending">0.64</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z6DuQ00yoaR5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercisable"><span style="font-family: Times New Roman, Times, Serif">4,376,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zkE7UZjWJfO" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_c20220101__20221231_zNltyrsJ5DJ9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z6Ga8wHrZmGe" title="Weighted Average Remaining Contractual Term (Years), Exercisable">0.52</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_z57thjqMWK5h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5XgdiqaIo7" title="Share-based payment award, options, grants in period, grant date intrinsic value">1.15</span> for the Company&#8217;s common shares on December 31, 2022 and the closing stock price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqOLaxsJZqQ5" title="Share-based payment award, options, grants in period, grant date intrinsic value">6.06</span> for the Company&#8217;s common
shares on December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 279pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2022, the Company&#8217;s Compensation Committee approved the issuance of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaZFC9QM7tr" title="Number of shares issued">200,000</span> stock options under the 2021 Stock Incentive
Plan. These shares had a grant date fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zODikesMNY35" title="Weighted Average Grant Date Fair Value, Granted">3.59</span> per share or a cumulative fair market value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zy4lACyTZfib" title="Cumulative fair market value">717,660</span> as calculated using Black-Scholes
(exercise price $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9cCu8I5Qv9h" title="Exercise price">3.96</span> per share, stock price $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOgTUnzIjL67" title="Stock price">3.96</span> per share, volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDUBtKd2wC38" title="Volatility rate">124.43</span>%, discount rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4FVhkS9NWN6" title="Discount rate">1.74</span>% and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zP6O40mI5097" title="Expected term::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl1054">seven</span></span>-year term). The
grant was segmented into four vesting tranches triggered by performance achievements and expire on <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTy4TPnm22u3" title="Share based payment award vesting expiration date">January 28, 2029</span>. The Company is amortizing
the expenses over the vesting cycles of the individual tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2022, the Company granted <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPVhU1mUxvae" title="Number of shares issued">100,000</span> stock options under the 2021 Stock Incentive Plan to a third-party consultant in consideration
of services rendered. These shares had a grant date fair value of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPhNXqFw41c5" title="Weighted average grant date fair value, granted">2.30</span> per share or a cumulative fair market value of $<span id="xdx_908_ecustom--CumulativeFairMarketValue_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6qtipIBTOZf" title="Cumulative fair market value">199,360</span> as calculated
using Black-Scholes (exercise price $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfKcF5ZNusk7" title="Exercise price">2.30</span> per share, stock price $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWjsBjBkCR12" title="Stock price">2.30</span> per share, volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMxMHrYkuaGj" title="Volatility rate">130.51</span>%, discount rate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNcpLktSkc2k" title="Discount rate">3.24</span>% and <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zde9VwxFUttf" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1072">five</span></span>-year
term). The grant vested immediately and expire on June 21, 2027. The Company is amortizing the expense over twelve months, the term of
the consulting agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and 2021, the Company incurred stock option expenses totaling $<span id="xdx_90C_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3HuxmX5kY44" title="Stock option expenses">444,342</span> and $<span id="xdx_909_eus-gaap--StockOptionPlanExpense_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOFPPfSN5vfh" title="Stock option expenses">0</span>, respectively. The unamortized
stock option expenses as of December 31, 2022 and 2021 totaled $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231_zqZOJAXWrIcg" title="Unamortized stock option expenses">113,847</span> and $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zVs8HqjlGux3" title="Unamortized stock option expenses">0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Assumption
of MyMD Florida Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, pre-Merger MyMD Florida adopted the MyMD Pharmaceuticals, Inc. Amended and Restated 2016 Equity Incentive Plan (the
&#8220;2016 Plan&#8221;). The 2016 Plan provided for the issuance of up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20161231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zF9YGcEDF3La" title="Premerger common stock, shares">50,000,000</span>
shares of pre-Merger MyMD Florida Common Stock. As of December 31, 2022, options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221229__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z9uSWkESH62b" title="Options to purchase of common stock">4,188,315</span>
shares of Company Common Stock have been issued pursuant to the plan and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zXDR8J6JeEB4" title="Remaining shares available for issuance">0</span>
shares of Company Common Stock remain available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, effective as of the effective time of the Merger, the Company assumed pre-Merger MyMD Florida&#8217;s Second
Amendment to Amended and Restated 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;), assuming all of pre-Merger MyMD Florida&#8217;s
rights and obligations with respect to the options issued thereunder. As of the effective date of the Merger, no additional awards could
be issued under the 2016 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the terms of the Merger Agreement, the Company assumed all of pre-Merger MyMD Florida&#8217;s rights and obligations
under pre-Merger MyMD Florida&#8217;s stock options that were outstanding immediately prior to the effective time of the Merger, and
each such stock option, whether or not vested, was converted into a stock option representing the right to purchase shares of Company
Common Stock, on terms substantially the same as those in effect immediately prior to the effective time, except that the number of shares
of Company Common Stock issuable and the exercise price per share of such stock options was adjusted by the Exchange Ratio. Additionally,
the number of shares and exercise price per share of Company Common Stock under the assumed pre-Merger MyMD Florida stock options was
further adjusted by the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assumed <span id="xdx_906_ecustom--NumberOfStockOptionsAssumed_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zTYyh4KAh2U">4,188,315</span> MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited
to, the amendment of such stock option to change the term of such stock option for a period expiring on April 16, 2023, the second-year
anniversary of the Merger). The Company recorded expenses of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zQe8kepESZRi">15,036,051</span> for the assumption of the options and the modification of the
terms which is included on the Consolidated Statement of Comprehensive Loss for the year December 31, 2021. The Company utilized Black-Scholes
using an exercise price of $2.59, an issue date fair value of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zfdyZ2m0EG4k" title="Fair value">4.94</span>, a volatility index of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_z27P0wXGAE3f" title="Volatility index">122.31</span>% and a discount rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zIdSDqNS5RPa" title="discount rate">0.16</span>% to determine
the fair value of the modification. The pre-Merger MyMD options were valued at $<span id="xdx_909_ecustom--OptionsMarketValue_iI_c20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zUVeZRaeIhW4" title="Options market value">0</span> on April 16, 2021, as there was no reliable method
of determining the fair value given the material events that had occurred since the last arms-length trade of common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Compensation Committee of the Board of Directors approved grants totaling <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3DYtwKM4pLh" title="Restricted stock units">394,680</span> Restricted Stock Units to the
Company&#8217;s four directors. Each RSU had a grant date fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCkJwKg45tr6" title="Grant date fair value">4.48</span> which shall be amortized on a straight-line basis over
the vesting period into administrative expenses within the Consolidated Statement of Comprehensive Loss. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK23X6shFLeh" title="Restricted stock units, description">Such RSUs were granted under
the 2018 Plan, as amended. Fifty percent (50%) of each RSU will vest on the first anniversary date of the Grant and the remaining fifty
percent (50%) will vest on the second anniversary date; provided that the RSUs shall vest immediately upon the occurrence of (i) a change
in control, provided that the director is employed by or providing services to the Company and its affiliates on the closing date of
such change of control, or (ii) the director&#8217;s termination of employment of service by the Company was without cause</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2021, concurrently with the closing of the Merger, pursuant to the terms of the RSU Agreements between the Company and four
board of directors, the <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7wQDrx0zKz7" title="Number of stock option to purchase shares of common stock">394,680</span> RSUs granted on September 11, 2020 under the 2018 Plan, as amended, accelerated and vested in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the terms of the RSU agreements, the Company, at the Company&#8217;s sole discretion, may settle the RSUs in cash, or part cash and part
Common Stock. As there is no intention to settle the RSUs in cash, the Company accounted for these RSUs as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-merger
Akers Biosciences, Inc. recorded expenses totaling $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIprk2eP8nkh" title="Premerger expenses totaling">979,758</span> for the acceleration of the vesting of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6UiWYRg3mxa" title="Number of vesting shares">394,680</span> RSUs, the holders immediately
surrendered <span id="xdx_909_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYRcjPBx5Vd" title="Number of restricted stock, net of tax withholdings">139,457</span> RSUs with a fair market value of $<span id="xdx_909_eus-gaap--RestrictedStockValueSharesIssuedNetOfTaxWithholdings_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbXVtDuCoza" title="Restricted stock value, net of tax withholdings">688,913</span> for the withholding of federal and state income taxes, as directed by the
holders, which was recorded as Payroll Taxes Payable on the date of the Merger. The withholding obligations were paid by the Company
on June 30, 2021. As of March 29, 2023, the vested RSUs have not been converted to common shares of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Compensation Committee of the Board of Directors approved grants totaling <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zSHHg4pMbPcd" title="Restricted stock units">2,795,000</span> Restricted Stock Units to the
Company&#8217;s six directors and seven key employees. Each RSU had a grant date fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvvplYS3Vvwi" title="Grant date fair value">8.09</span> which will be amortized upon vesting
into administrative expenses within the Consolidated Statement of Comprehensive Loss. Such RSUs were granted under the 2021
Plan. Vesting of each RSU is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_znzp6sMHQxzk" title="Restricted stock units vested, description">One-third
    (33%) of each RSU will vest when the Company&#8217;s market capitalization is equal to or greater than $500,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z8Xe7i4mozN5" title="Restricted stock units vested, description">One-third
    (33%) of each RSU will vest when the Company&#8217;s market capitalization is equal to or greater than $750,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zKNpU0DcyTH8" title="Restricted stock units vested, description">The
    remaining awarded units will vest when the Company&#8217;s market capitalization is equal to or greater than $1,000,000,000 for at
    least ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market
    value of the Common Stock equals or exceeds $5.00 during such trading day period</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event that (i) a change in control occurs or (ii) the participant incurs a termination of service by the Company without cause
    or due to the participant&#8217;s death or total and permanent disability, then all unvested units shall become vested units immediately
    upon the occurrence of such event.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, none of the vesting milestones have been met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2022, the Compensation Committee of the Board of Directors approved a grant of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_zxGgFHjXetni" title="Share based compensation arrangement by share based payment award equity instruments other than options grants in period">4,040</span> RSUs to a sub-contractor with a grant
date fair value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_z3BviRjGGRR2" title="Grant date fair value price per share">15,998</span> and vested immediately. Such RSUs were granted under the 2021 Plan. The Company recorded expenses of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_zB72KGScdNUk" title="Share based compensation">15,998</span>
which is included Stock Based Compensation on the Consolidated Statement of Comprehensive Loss during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2022, the Compensation Committee of the Board of Directors approved a grant of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220706__20220707__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_zsAn9sxkLgq9" title="Restricted stock units, granted">50,167</span> RSUs to a sub-contractor with a grant date
fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220706__20220707__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_z4zR9Gl9pdSa" title="Grant date fair value price per share">150,000</span> and vested immediately. Such RSUs were granted under the 2021 Plan. The Company recorded expenses of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_zKGVXwKA857e" title="Share based compensation">138,587</span>
which is included Stock Based Compensation on the Consolidated Statement of Comprehensive Loss during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zP6y0EIgRuv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the status of outstanding unvested restricted stock units outstanding as of December 31, 2022 and the changes for the
year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z2h1ggkmMNRa">Summary
of Restricted Stock Units Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Average</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number
    of</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Grant
    Date</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RSUs</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
    Value</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VanMWyalIj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">2,795,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRJZ6TxhYHSg" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">8.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za4oOKNcjzU" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Granted"><span style="font-family: Times New Roman, Times, Serif">54,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhnwmuWgJ0hg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif">3.06</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD88faltMzu6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6roEJbUYSr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJx5G7mIb8w6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"><span style="font-family: Times New Roman, Times, Serif">(54,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo9jdXvPZEre" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"><span style="font-family: Times New Roman, Times, Serif">3.06</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5AL2xCNq7d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbgsmnENAzKa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzdPEWqALCl9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUyqnmMouUs7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUMpOav64Jpa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">2,795,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUIeSvX75u73" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">8.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zj4rzrtxNay6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the unamortized value of the RSUs was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrv0TPHS1Df9" title="Unamortized value"><span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPhOxFUackgc" title="Unamortized value">22,611,550</span></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914373440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRINVxicGu4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_825_z4rl4q9GFFDc">Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of preferred shares or preferred warrants are entitled to vote per share, as limited by the certificate of designation for
each class of preferred shares or warrants, at meetings of the Company. As of December 31, 2022, <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_z7ncAdrf2z9c" title="Preferred stock, shares authorized">50,000,000</span>
shares of Preferred Stock were authorized and four classes of Preferred Stock or Warrants are designated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
D Convertible Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2020, the Company designated <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zL3NL94lXDZg" title="Preferred stock, shares authorized">211,353</span>
Series D Convertible Preferred Shares, <span id="xdx_90E_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zuqjEpgTGVK2" title="Preferred stock, no par value">no</span>
par value with a stated value of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyLifY4w5sT8" title="Preferred stock value, per share">0.01</span>
per share and filed the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock
(the &#8220;Series D Certificate of Designation&#8221;) with the Secretary of State of the State of New Jersey. Pursuant to the
Series D Certificate of Designation, in the event of the Company&#8217;s liquidation or winding up of its affairs, the holders of
its Series D Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) will be entitled to receive the same amount that a
holder of the Company&#8217;s Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes
any conversion limitations set forth in the Series D Certificate of Designation) to Common Stock which amounts shall be paid pari
passu with all holders of the Company&#8217;s Common Stock. Each share of Preferred Stock has a stated value equal to $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zoOK7jaAytye" title="Preferred stock value, per share">0.01</span>
(the &#8220;Stated Value&#8221;), subject to increase as set forth in Section 7 of the Series D Certificate of
Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Preferred Stock is entitled at any time to convert any whole or partial number of shares of Preferred Stock into shares of
the Company&#8217;s Common Stock determined by dividing the Stated Value of the Preferred Stock being converted by the conversion price
of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zjeDksW4AeG3" title="Preferred stock, conversion price">0.01</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20200322__20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ztkVIdHSqtx2" title="Preferred stock, terms of conversion">A
holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company&#8217;s Common Stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company&#8217;s
Common Stock then issued and outstanding (with such ownership restriction referred to as the &#8220;Beneficial Ownership Limitation&#8221;).
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days after such notice to the Company.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Beneficial Ownership Limitation, on any matter presented to the Company&#8217;s stockholders for their action or consideration
at any meeting of the Company&#8217;s stockholders (or by written consent of stockholders in lieu of a meeting), each holder of Preferred
Stock will be entitled to cast the number of votes equal to the number of whole shares of the Company&#8217;s Common Stock into which
the shares of Preferred Stock beneficially owned by such holder are convertible as of the record date for determining stockholders entitled
to vote on or consent to such matter (taking into account all Preferred Stock beneficially owned by such holder). Except as otherwise
required by law or by the other provisions of the Company&#8217;s certificate of incorporation, the holders of Preferred Stock will vote
together with the holders of the Company&#8217;s Common Stock and any other class or series of stock entitled to vote thereon as a single
class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Preferred Stock shall be entitled to receive dividends as and when paid to the holders of the Company&#8217;s Common Stock
on an as-converted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zwYANJCRt7i9" title="Preferred stock, shares outstanding">72,992</span> shares of Series D Convertible Preferred Stock outstanding which represent <span id="xdx_900_ecustom--NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqrFqPYMGxA9" title="Underlying shares of common stock">36,496</span> underlying
shares of the Company Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, on April 16, 2021, the Company filed an amended and restated certificate of incorporation (the &#8220;A&amp;R
Charter&#8221;) with the Secretary of State of the State of New Jersey, which was approved by the Company&#8217;s stockholders on April
15, 2021. Among other things, the A&amp;R Charter (i) changed the Company&#8217;s name to MyMD Pharmaceuticals, Inc., (ii) increased
the number of shares of Company Common Stock available from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210415__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zO5Ntc4lkiH8" title="Common stock, shares authorized">100,000,000</span> shares to a total of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z6ZiiAHLaxV2" title="Common stock, shares authorized">500,000,000</span> shares of the Company&#8217;s
Common Stock, (iii) changed the structure of the board of directors from a classified board of three classes to a non-classified board
of a single class, and (iv) simplified and consolidated various provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of common shares are entitled to one vote per share at meetings of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2021, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210210__20210211__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2pkCf3yGxa5" title="Number of shares issued">466,216</span> shares of Common Stock issued pursuant to that certain Securities Purchase Agreement, dated November 11, 2020,
by and between the Company and certain institutional and accredited investors were cancelled and <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210211__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zVON2Wc1Xtud" title="Warrants, issued">466,216</span> prefunded warrants (as defined
therein) were issued at the request of a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 18, 2021, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210517__20210518__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zpZhpTUJuN4j" title="Number of shares, exercised">466,216</span> prefunded warrants were exercised in exchange for <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210517__20210518__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSMh62Tcias1" title="Number of shares, exchange">466,716</span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2021, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210804__20210805__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqHyDjK6snW5" title="Shares issued for services">16,826</span> shares of Common Stock with a fair market value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210804__20210805__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjBJTUDN0aki" title="Fair market value of shares issued for services">90,002</span> for services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2021, holders of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211208__20211209_zIJcRz0Vwft7" title="Common stock options">11,576</span> Common Stock options were exercised for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211208__20211209_zb6LcgDzfgkk" title="Common stock options, exercised">11,576</span> shares of Common Stock at an exercise
price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20211209_z5N636Vl2Gb2" title="Common stock options, exercise price">2.59</span> per common share. The net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20221231_zJM5rIRuICzj" title="Common stock options, proceeds">29,982</span> is recorded as a current liability on the Consolidated Balance
Sheet as of December 31, 2022. The accumulated proceeds from the exercise of these stock options will be distributed to the former shareholders
of MyMD Florida per the terms of the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2022, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220215__20220216__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zqZlm6bGPqB8" title="Number of shares, exercised">385,135</span> prefunded warrants were exercised in exchange for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220215__20220216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFvnn8dNU04" title="Number of shares, exchange">385,135</span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2022, pursuant to a securities purchase agreement with certain institutional and accredited investors, dated August 15, 2022,
the Company issued and sold in a registered direct offering (the &#8220;August Offering&#8221;) an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817_zIoV9F8vOmsc" title="Stock issued during period share new issues">1,411,764</span> shares of its
Common Stock at an offering price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20220817_zW7pfVSQyK19" title="Share price">4.25</span> per share and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817_z0wroB98M1Ph" title="Stock issued during period share new issues">1,411,764</span> unregistered investor warrants to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220816__20220817_ziWAPPdqBsff" title="Stock issued during period share new issues">1,411,764</span> shares
of its Common Stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220817_zleGxkNuJbCf" title="Exercise price">5.25</span>, for gross and net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220816__20220817_zlxb5qpjevtg" title="Proceeds from issuance of common stock">5,999,997</span> and $<span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_c20220816__20220817_zQxS11gU6kee" title="Net proceeds from issuance of common stock">5,550,028</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFkPcvMDqjg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zUHlIhuGm3Fb" style="display: none">Summary
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term
    (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCIUzgfiGM98" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">5,074,489</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zio4pID9j5P9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">5.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgZMHVNocLqk" title="Weighted Average Remaining Contractual Term (years), Beginning">4.34</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeg1CBIpIr8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">9,554,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTLF2wpCzQbj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif">1,450,029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKIQSLNimS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">5.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVHdIWWxZGA9" title="Weighted Average Remaining Contractual Term (Years), Granted">4.88</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVR1fnyZgg8b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkL8JJxHRuK8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbmMkCqfeAW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z82sk2wBeyhg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhFq1YzDwA7j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif">(9,691</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgxDyxsMcYk7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif">222.55</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XINGBMFcWi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwK4Ys4Rs7K3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">4.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNsxEbOoXQE9" title="Weighted Average Remaining Contractual Term (years), Ending Balance">3.63</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOoihMVONPek" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLhYk0yV4iXf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWwnM3AQmSE4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif">4.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSgelimLgNig" title="Weighted Average Remaining Contractual Term (years), Exercisable">3.63</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLblHPE20cM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_z4ObSUF6dT4l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP1hRM1LsrJ2" title="Class of warrant or right, exercise price of warrants or rights">1.15</span></span> for the Company&#8217;s common shares on December 31, 2022 and the closing stock price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1nzKe022WFc" title="Class of warrant or right, exercise price of warrants or rights">6.06</span> for the Company&#8217;s common
shares on December 31, 2021. All warrants were vested on date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2022, the Company issued warrants to purchase up to <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220706__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQU4EuaCiGK5" title="Issuance of common stock for warrants, shares">38,265</span>
shares of its Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxbhXdYLFmB4" title="Warrant exercise price per share">5.98</span>
to a vendor for services. The cumulative fair market value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220706__20220707_zZo0ssnvcwl5" title="Fair value of warrants">93,233</span>
as calculated using Black-Scholes (exercise price $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220707_zZEftDmBLzYf" title="Warrant exercise price per share">5.98</span>
per share, stock price $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20220707_zxNbr8MLHmwk" title="Stock price per share">2.99</span>
per share, volatility of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_c20220707__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zSfbBke4HGfi" title="Stock price per share">131.06%</span>,
discount rate of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_c20220707__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zr27joCNfuH2" title="Stock price per share">3.07%</span>
and a <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaSbziPt8nS8" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1294">five</span></span>-
year term). The warrants will be exercisable at any time and from time to time, in whole or in part, following the date of issuance
and for a term of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsZjIKIhyoj2" title="Warrants term">five
years</span> from the effective date. The fair-market value of the warrants was amortized over the life of the service contract.
During the year ended December 31, 2022, the Company recognized $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoY4i4YTJ5Ya" title="Stock-based compensation">84,851</span>
in expense which is included in Stock-Based Compensation on the Consolidated Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2022, in connection with the August Offering, the Company issued unregistered investor warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zU2rx2PcFFb9" title="Issuance of warrant">1,411,764</span>
shares of its Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmzNJKpmXTB8" title="Class of warrant or right, exercise price of warrants or rights">5.25</span> (the &#8220;August Investor Warrants&#8221;) in a private placement. The August
Investor Warrants will be exercisable at any time and from time to time, in whole or in part, beginning six-months following the date
of issuance and for a term of five years from the initial exercise date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-funded
Common Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zuKyqluIE4Mf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the pre-funded warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zOnA9QjAv8f1" style="display: none">Summary
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term
    (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zc3R2h01hbg9" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">520,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zxS5jU9uZnCd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zkh9XShkctni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">3,151,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5hesPOZ4O36" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zyX1PqfGIuSg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zoobEKmUY3bd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif">(385,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCF1LkSgZjYb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zmGL1uFNUSye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zhtkgmIBblO9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJ5ZBbB6XP2i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zV1cpsQwPWZ9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCIo0kSUXXjc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5NgHI1oApo6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z1z95icvQrb3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif">155,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zIh74WklD2L5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zUOX35pfcVu" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJlRxnOtpnzi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif">155,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A9_zUNuvOZ3Hywa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
pre-funded warrants were vested on date of grant and are exercisable at any time. The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying award and the closing stock price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zTNgxEfajyFj" title="Share price">1.15</span> for the Company&#8217;s common shares
on December 31, 2022 and the closing stock price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zTR5X61Asx47" title="Share price">6.06</span> for  Common Stock on December 31, 2021.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Convertible Preferred Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zVkcq8Siov2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zdD6CFV0UyG7" style="display: none">Summary
of Warrant Activity</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    (years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Balance
    at December 31, 2021</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zXkWw4XeT4F" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zH1xQdMrXnx" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zie5Y6BR6nB" title="Weighted Average Remaining Contractual Term (years), Beginning">2.94</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z2aslaOoKOL6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zERsFR22gIZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zeFpboMFUfAl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z8G5iHj4p9d5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1358">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zcS46sSV1Mr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziEddDLpqo79" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zpUx2CcZBGhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canceled/Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zBNZcL8trjOh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zECF6ZiIkEEl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Balance
    at December 31, 2022</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zmE1ebquwRm" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zl7MGpBgKCCj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zKdJFCSU5F49" title="Weighted Average Remaining Contractual Term (years), Ending Balance">1.94</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziJdhv0QoMl2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercisable
    as of December 31, 2022</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zyMSKudRgTW" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zx7nCp5KYcv6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zotenN2Co6c9" title="Weighted Average Remaining Contractual Term (years), Exercisable">1.94</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zDJfQPkARKA8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8AD_zna53PEszS7b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zMeqrFdCFUS6" title="Share price">1.15</span> for the Company&#8217;s common shares on December 31, 2022 and the closing stock price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z5g7fqKqwgEc" title="Share price">6.06</span> for the Company&#8217;s common
shares on December 31, 2021. All Series C Convertible Preferred Stock Warrants were vested on date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914375920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zArKxzeQ08C" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82E_zio8C6qM5kVg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zoK1Q7XEWVH1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s income tax (benefit)/provision is as follows for the years ended December 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zsV0g3b1tHg3" style="display: none">Schedule
of Income Tax (Benefit)/Provision</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220101__20221231_z0prSLIoi1sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zC7VPToJc4J5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBziYA_zKJi3HzmnZik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBziYA_z8nfiAwm8a6k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(5,914,000<span style="display: none; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,219,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBziYA_zJsR53boBvA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,914,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,219,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBziYA_zG4moYR3Z8L7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income Tax Benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zDd5Dk5LOvte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfOV2YvTSGj2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December
31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zASRnJr28zp7" style="display: none">Schedule
of Reconciliation of Income Tax Rate and Benefit from Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231_zwQqHj4CXgk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20210101__20211231_zdqzOJo8RcFc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zdMn1hw0DIsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Statutory U.S. Federal Income Tax
    Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(21.0</p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.0)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zWbi3Sd1Hgt1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">New Jersey State income taxes, net of U.S.
    Federal tax effect</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(14.5</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_ziYTR5nYljZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustment to deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(4.1</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_zip9QRej0Chg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zIOZtTK0kCj2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">38.9</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zGeYYSEJhCW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">0.0</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


<p id="xdx_8A6_zwE8UBpNacK5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the Company had U.S. federal net operating loss carry forwards of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZSg2HVDhAl4">107.1</span>&#160;million and
$<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOyTyWjiEUO7" title="Net operating loss carry forwards">101.9</span>&#160;million, respectively. Approximately $<span id="xdx_90D_ecustom--OperatingLossCarryforwarddSubjectToExpiration_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_za6FQW8laGX5" title="Net operating loss carry forwards subject to expiration">57.7</span>&#160;million of the U.S. federal net operating loss generated in tax years beginning
before January 1, 2018 expire beginning with the year ending&#160;<span id="xdx_901_ecustom--OperatingLossCarryforwardsExpirationDateDescription_dd_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zVMzX1U9362k" title="Expiration date description">December 31, 2023 through 2037</span>. The remaining U.S. federal net operating
loss of approximately $<span id="xdx_902_ecustom--OperatingLossCarryforwardsNotSubjectToExpiration_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zhhSkjQTwk5b" title="Net operating loss carry forwards not to expiration">49.4</span>&#160;million does not expire, however it is limited to&#160;<span id="xdx_905_ecustom--PercentageOfNetIncomeForEachSubsequentPeriod_dp_c20171229__20180102_zI3W4bYjVAE3" title="Percentage of net income">80</span>%&#160;of each subsequent year&#8217;s net
income. As of December 31, 2022, and 2021, the Company had U.S. state net operating loss carry forwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zMAt34nYTMJ8">41.0</span>&#160;million
and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zFi18RXRvQBd">38.2</span>&#160;million, respectively, some of which expire beginning with the year ending&#160;<span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationDateDescription_dd_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ztYwTGwH4eEb">December 31, 2023 through 2042</span>. U.S. federal
net operating losses of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231_zvr0dPnJFE7e" title="Net operating loss">3.8</span> million expired during 2022. The timing and manner in which the Company can utilize operating
loss carryforwards in any year may be limited by provisions of the Internal Revenue Code regarding changes in ownership of corporations.
Such limitation may have an impact on the ultimate realization of its carryforwards and future tax deductions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 382 of the Code, use of the Company&#8217;s net operating loss carryforwards is limited if the Company experiences a cumulative
change in ownership of greater than&#160;<span id="xdx_90B_ecustom--CumulativeChangeInOwnershipPercentage_iI_dp_c20221231_zmZzZHunlGU7">50</span>%&#160;in a moving three-year period. The Company experienced an ownership change as a result
of the Merger and therefore the Company&#8217;s ability to utilize its net operating loss and certain credit carryforwards are limited.
The limitation is determined by the fair market value of the Company&#8217;s common stock outstanding immediately prior to the ownership
change, multiplied by the applicable federal rate. It is expected that the Merger caused the Company&#8217;s net operating loss carryforwards
to be limited. However, the limitation had no impact on the Company&#8217;s financial statements since the Company recorded a full valuation
allowance for the deferred tax assets as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxtH4Vfy0KYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of the deferred tax assets and related valuation allowances as of December 31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zopZG5pvkGKe" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowances</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20221231_zgGUYS0jpUXj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_z5ettnnAHKyd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pp0p0_maDTALNzOrT_zU3gfbiIzQ71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserves
    and other</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">745,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzOrT_zu0aQFEYrbag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    operating loss carry-forwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">26,176,000</p><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,526,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_maDTALNzOrT_zzDvfhPEYTgj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,177,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTALNzOrT_zrptaCcKFBF4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">610,000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">610,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzOrT_zI6OYdLPDECf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,542,000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,021,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzOrT_zpkpTZXujqx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(34,250,000</p>
</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28,336,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzOrT_zatvi99tVnZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p id="xdx_8A6_zFzZC2LH8FC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance for deferred tax assets increased by approximately $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20220101__20221231_z9U4ZHTKzpbi" title="Change in valuation allowance">5.9</span>&#160;million and $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20210101__20211231_zeogcwDYqs4">6.2</span>&#160;million, for the years ended December
31, 2022 and 2021, respectively, due mainly to increases in the Company&#8217;s deferred tax asset related to its net operating loss
carryforward. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some
portion or all of the deferred tax assets may be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which the net operating losses and temporary differences become deductible. Management
considers projected future taxable income and tax planning strategies in making this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files
U.S. federal income tax returns and state income tax returns. Since the Company had losses in the past, all prior years that generated
net operating loss carryforwards are open and subject to audit examination in relation to the net operating loss generated from those
years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913325344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6ATT4wXUqZ3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_824_zj0qYknxvO17">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific
Advisory Board</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2021, the Company formed the Scientific Advisory Board to (i) provide strategic advice and make recommendations to management
regarding current and planned research and development programs, (ii) advise management regarding the scientific merit of technology
or products involved in licensing and acquisition opportunities and (iii) provide strategic advice to management regarding emerging science
and technology issues and trends. During the years ended December 31, 2022 and 2021, the Company incurred costs of $<span id="xdx_90E_eus-gaap--CostsAndExpenses_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxUcjzvT6mIb" title="Cost and expenses incurred">148,000</span> and $<span id="xdx_900_eus-gaap--CostsAndExpenses_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zCiNHjwf9Th9" title="Cost and expenses incurred">174,000</span>, respectively.
These expenses are included in Research and Development Expenses on the Consolidated Statement of Comprehensive Loss. The Scientific
Advisory Board was disbanded effective September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China and has reached multiple other
countries, resulting in government-imposed quarantines, travel restrictions and other public health safety measures, including in the
United States and India. On March 12, 2020, the WHO declared COVID-19 to be a global pandemic. The various precautionary measures taken
by many governmental authorities around the world in order to limit the spread of COVID-19 have had and may continue to have an adverse
effect on the global markets and global economy. Such government-imposed precautionary measures may have been relaxed in certain countries
or states, but there is no assurance that more strict measures will not be put in place again due to a resurgence in COVID-19 cases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate impact of the global COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet
know the full extent of potential delays or impacts on the Company&#8217;s business, vaccine development efforts, healthcare systems
or the global economy as a whole. However, the effects have had and will likely continue to have a material impact on the Company&#8217;s
operations, liquidity and capital resources, and the Company will continue to monitor the COVID-19 situation closely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe
and/or long-term disruptions in the Company&#8217;s operations may negatively impact the Company&#8217;s business, operating results
and financial condition in other ways as well. Specifically, the Company anticipates that the stress of COVID-19 on healthcare systems
generally around the globe may negatively impact regulatory authorities and the third parties that the Company may engage in connection
with the development and testing of its product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
anticipated economic consequences of the COVID-19 pandemic have adversely impacted financial markets, resulting in high share price volatility,
reduced market liquidity, and substantial declines in the market prices of the shares of most publicly traded companies, including MyMD.
Volatile or declining markets for equities could adversely affect the Company&#8217;s ability to raise capital when needed through the
sale of shares of Common Stock or other equity securities. Should these market conditions persist when the Company needs to raise capital,
and if the Company is able to sell shares of its Common Stock under then prevailing market conditions, it might have to accept lower
prices for its shares and issue a larger number of shares than might have been the case under better market conditions, resulting in
significant dilution of the interests of the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
and Settlements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Raymond
Akers Actions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2021, Raymond F. Akers, Jr., Ph.D. filed a lawsuit against MyMD Pharmaceuticals, Inc. (p/k/a Akers Biosciences, Inc.) in the
Superior Court of New Jersey, Law Division, Gloucester County (the &#8220;First Raymond Akers Action&#8221;). Mr. Akers asserts one common
law whistleblower retaliation claim against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Court granted MyMD Pharmaceutical, Inc.&#8217;s (&#8220;MyMD&#8217;s&#8221;) Motion to Dismiss Plaintiff&#8217;s
Amended Complaint and dismissed Plaintiff&#8217;s Amended Complaint. The Court indicated that Mr. Akers is &#8220;free to file another
complaint, however, tort-based &#8216;Pierce&#8217; allegations, and/or CEPA claims are barred by the statute of limitations.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2022, Mr. Akers filed a second action against MyMD in the Superior Court of New Jersey, Law Division, Gloucester County (the
&#8220;Second Raymond Akers Action&#8221;) again asserting one common law whistleblower retaliation claim against the Company. The Company
believes that the Second Raymond Akers Action is without merit and, moreover, was filed against the Court&#8217;s specific admonition
that Plaintiff does not attempt to circumvent the statute of limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 27, 2022, the Court granted-in-part and denied-in-part MyMD&#8217;s Motion to Dismiss Plaintiff&#8217;s Complaint. The Court reaffirmed
the ruling in the First Raymond Akers Action that any tort-based Pierce claims are time-barred. However, the Court denied the Motion
as it pertained to Plaintiff&#8217;s contract-based Pierce claim and &#8220;Repayment of Monies Owed&#8221; claim. On July 29, 2022,
MyMD filed its Answer, which included affirmative defenses. As of December 31, 2022, the Second Raymond Akers Action is in the discovery
phase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
legal fees incurred were expensed as and when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918219360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zlUBvMRuBGS" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_zwbBvqt7BbK9">Related Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taglich
Brothers, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2020, the Company</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retained Taglich Brothers,
Inc. (&#8220;Taglich Brothers&#8221;) on a non-exclusive basis as a consultant to render consulting services, assist with review, and
analysis of, financial planning and budgeting matters of the Company for a term of 12 months. Pursuant to the Consulting Agreement with
Taglich Brothers, the Company agreed to pay Taglich Brothers $<span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20201122__20201123__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TaglichBrothersIncMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z0h2UJLPq08f" title="Amounts paid by related party">10,000</span> per month. During the year ended December 31, 2021, the Company
paid $<span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TaglichBrothersIncMember_zIkmIpLWketa">80,000</span> for consulting services to Taglich Brothers, Inc. which is included in administrative expenses on the Consolidated Statement
of Comprehensive Loss. This agreement was cancelled on August 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Schreiber, a Director, is the Managing Director of Capital Markets at Taglich Brothers. Mr. Schroeder, a former Director was the Vice
President of Investment Banking at Taglich Brothers until his death on September 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SRQ
Patent Holdings and SRQ Patent Holdings II</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MyMD
is a party to two Amended and Restated Confirmatory Patent Assignment and Royalty Agreements, both dated November 11, 2020, with SRQ
Patent Holdings and SRQ Patent Holdings II, under which MyMD (or its successor) will be obligated to pay to SRQ Patent Holdings or SRQ
Patent Holdings II (or its designees) certain royalties on product sales or other revenue received on products that incorporate or are
covered by the intellectual property that was assigned to MyMD. The royalty is equal to 8% of the net sales price on product sales and,
without duplication, 8% of milestone revenue or sublicense compensation. SRQ Patent Holdings and SRQ Patent Holdings II are affiliates
of Mr. Jonnie Williams, Sr. No revenue has been received subject to these agreements as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mr.
Jonnie Williams, Sr.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an obligation to Mr. Williams, a shareholder, for various expenses incurred on behalf of the Company between 2016 and
2019. The balance due of $<span id="xdx_906_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--MrWilliamsMember_z72ITYnqcn42" title="Due to officer">14,577</span> was paid on April 28, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Supera
Aviation I, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the Company entered a three-year leasing agreement with Supera Aviation I, LLC, a company owned by a shareholder, for a
Gulfstream IV-SP aircraft with an annual leasing fee of $<span id="xdx_901_ecustom--AnnualLeasingFee_pp0p0_c20181001__20181031__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember_zJAF8JiXjkng" title="Annual leasing fee">600,000</span>. The Company incurred expenses totaling $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember_zqAVZ0tIv394" title="Operating lease expense">150,000</span> for the year ended
December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, the Company reached a negotiated settlement with Supera Aviation I, LLC to retire the $<span id="xdx_905_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--TypeOfArrangementAxis__custom--NegotiatedSettlementMember_zgDpKLpbu15e" title="Due to related party retired">627,042</span> debt due under the leasing
agreement for $<span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--TypeOfArrangementAxis__custom--NegotiatedSettlementMember_z3soMpqhEdUa" title="Total future minimum lease payments, undiscounted">517,384</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lines
of credit payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, Supera entered into a revolving credit facility which allows for borrowings of up to $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkVbdHT89455" title="Maximum borrowing facility">1,000,000</span> with a shareholder. The
facility had an initial term of <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationPeriod_c20181101__20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zKKXO1SaWGX7" title="Line of credit facility expiration period">38 months</span>, which was extended to <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationDate1_pp0p0_dd_c20181101__20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0jTa4d6m65a" title="Expiration date">December 31, 2022</span> at which time all outstanding borrowings and accrued
interest, if any, are due in full. Borrowings accrue interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z2RZPKkT0NL7" title="Borrowings accrue interest rate percentage">5%</span> per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the pre-Merger MyMD entered into a revolving credit facility which allows for borrowings of up to $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zLworK7LEbcd" title="Borrowing capacity revolving credit facility">5,000,000</span> with a shareholder.
<span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_pp0p0_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z5fbcYgMbTWh" title="Line of credit facility, description">The facility had an initial term of <span id="xdx_904_eus-gaap--DebtInstrumentTerm_pp0p0_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zd3OybZpaEa6" title="Initial term">18 months</span></span>, which was extended to July 31, 2021 and further extended to December 31, 2022, at which
time all outstanding borrowings and accrued interest, if any, are due in full. Borrowings accrue interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zTs3baJuMuAe" title="Borrowings accrued interest rate">5%</span> per annum.
Pursuant to the terms of the agreement, the Company must issue a number of Common Stock options to the lender based on the total borrowings
under the facility, with each dollar borrowed requiring the issuance of one Common Stock option. Upon issuance, each Common Stock option
will immediately vest at an exercise price of $<span id="xdx_906_eus-gaap--StockOptionExercisePriceIncrease_pid_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zKa6jJFPxPQj" title="Stock options exercise price">2.59</span>. The Company recorded accretion of the debt discount totaling $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zCUmSQSyI5C6" title="Amortization of debt discount">0</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zv9MDJyXYa8e" title="Amortization of debt discount">608,460</span>, respectively,
during the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, in accordance with the Merger, the Company paid $<span id="xdx_903_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210427__20210428__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyPJPG97Msd5" title="Amounts paid by related party">3,208,426</span>, inclusive of interest and net of the debt discount, to retire
the amounts due to the shareholder under the two lines of credit as of April 28, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918152320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjkUkq543CT5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_824_zpE55G3U0wlj">Employee Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified
employees of the Company (the &#8220;401(k) Plan&#8221;). Under the 401(k) Plan, the Company matches <span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20220101__20221231_zvDSC4GBp3mk" title="Employer matching contribution, percent of match">100%</span> up to a <span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20220101__20221231_zPQVDxRE627k" title="Employer matching contribution, percent of employees' gross pay">3%</span> contribution, and
<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMatchesFiftyPercentMember_zSJ7oC6zJqb4" title="Employer matching contribution, percent of match">50%</span> over a <span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMatchesFiftyPercentMember_zPLeJ7dKvQvc" title="Employer Matching Contribution, Percent of Employees' Gross Pay">3%</span> contribution, up to a maximum of <span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMaximumFivePercentMember_zaZ806lwcc1f" title="Employer matching contribution, percent of employees' gross pay">5%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company made matching contributions to the 401(k) Plan during the years ended December 31, 2022 and 2021 of $<span id="xdx_900_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zmL40eN5GMS" title="Contributions to employee">41,443</span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zIORIKftZ8gg" title="Contributions to employee">16,514</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775918193632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_DisclosurePaycheckProtectionProgramLoanAbstract', window );"><strong>Paycheck Protection Program Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock', window );">Paycheck Protection Program Loan</a></td>
<td class="text"><p id="xdx_802_ecustom--PaycheckProtectionProgramLoanDisclosureTextBlock_zkAUboJurTXa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12&#8212;<span id="xdx_82E_zFZSPUXbwJIj">Paycheck Protection Program Loan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 16, 2020, the Company received loan proceeds in the amount of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromLoans_c20200415__20200416__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_zULpMKTuNrX9" title="Proceeds from loans">70,600</span> under the Paycheck Protection Program (&#8220;PPP&#8221;).
The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), provides for loans to
qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued
interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities,
and maintains its payroll levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The
unforgiven portion of the PPP loan is payable over two years at an annual interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200415__20200416__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_znwExR090ZQ3" title="Debt interest rate">1%</span>, with a deferral of payments through the
date that the Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender. The Company was notified
on June 1, 2021 that the loan totaling $<span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210601__20210601__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_zpbE5QsBole6" title="Gain on debt forgiveness">70,600</span> was forgiven which was recorded as a gain on debt forgiveness on the Consolidated Statement
of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_DisclosurePaycheckProtectionProgramLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_DisclosurePaycheckProtectionProgramLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paycheck Protection Program Loan Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914373440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent Assignment and Royalty Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract', window );"><strong>Patent Assignment And Royalty Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock', window );">Patent Assignment and Royalty Agreement</a></td>
<td class="text"><p id="xdx_808_ecustom--PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_zgiUuIUWrefa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13&#8212;<span><span id="xdx_821_zbmt1Y44aPG9">Patent Assignment and Royalty Agreement</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company entered into an agreement with the holders of certain intellectual property relating to the Company&#8217;s
current product candidate. Under the terms of the agreement, the counterparty assigned its rights and interest in certain patents to
the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as defined. The agreement is effective
until the later of (1) the date of expiration of the assigned patents or (2) the date of expiration of the last strategic partnership
or licensing agreement including the assigned patents. <span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20210101__20211231_zb74UuDN8Pn5" title="Revenue::XDX::-"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20220101__20221231_zf01aOEfKrXg" title="Revenue::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1540"><span style="-sec-ix-hidden: xdx2ixbrl1542">No</span></span></span></span> revenue has been received subject to these agreements as of December 31, 2022
and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Assignment and Royalty Agreement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914958816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zIjPUKwOlzf8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 &#8211; <span id="xdx_828_zPmZqcfL9Qti">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On February 23, 2023,
pursuant to a securities purchase agreement with certain institutional and accredited investors, dated February 21, 2023, the
Company issued and sold in a registered direct offering i) an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNaC7wvNgPui" title="Number of shares issued">15,000</span>
shares of the Company&#8217;s newly-designated Series F Convertible Preferred Stock with a stated value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zoMYnRpoinxj" title="Number of shares issued, value">1,000</span>
per share, convertible into shares of Common Stock pursuant to the terms of the securities purchase agreement, and (ii) warrants to
acquire up to an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvEzXU1vShPc" title="Warrants to acquire common stock">6,651,885</span>
shares of Common Stock, subject to adjustment, for gross and net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zespgBy8OXNj" title="Gross proceeds">15,000,000</span>
and $<span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcHiMIW3vxFh" title="Net proceeds">14,041,500</span>,
respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912529216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkmU3qnbJNQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
<span id="xdx_86B_zK6C0KSyZTn1">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally
accepted in the United States of America (US GAAP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zXdssfkOSpne" title="Reverse stock split">1-for-2 reverse stock split</span> immediately following the effective time of the Merger. No fractional shares were issued
in connection with the Reverse Stock Split. Each stockholder who did not have a number of shares evenly divisible pursuant to the Reverse
Stock Split ratio and who would otherwise be entitled to receive a fractional share of Company Common Stock was entitled to receive an
additional share of Company Common Stock. The number of shares on equity related disclosures included in this Annual Report on Form
10-K, including the consolidated financial statements and accompanying notes, were retroactively adjusted to reflect the effects
of the Reverse Stock Split and the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Judgments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zitK6G4H5AMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
<span id="xdx_861_zdVe4a17sanl">Use of Estimates and Judgments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that
affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ
from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation,
uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in
the financial statements is included in the following notes for recording research and development expenses, impairment of intangible
assets and the valuation of share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional and Presentation Currency</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zkvkpJ9bLyAd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
<span id="xdx_863_zivmKWz9RRna">Functional and Presentation Currency</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements are presented in U.S. Dollars, which is the Company&#8217;s functional currency. All financial
information has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated
in Foreign Currencies, are recorded in the Consolidated Statements of Operations and Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zGYMLK4EOk27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
<span id="xdx_86D_z0DG4sjMaICg">Comprehensive Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;) 220 in reporting comprehensive
loss. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information
that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income
(loss), comprehensive loss is equal to net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zECjbfjPZ8v8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)
<span id="xdx_86B_zWALoFqnF9a">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that
are not restricted as to withdrawal date or use, to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7to1s1s5s2a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
<span id="xdx_86A_zT1m60PGwzpg">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables.
The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their
short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are
described as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company
    can access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology include:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices for similar assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices for identical or similar assets or liabilities in inactive markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    other than quoted prices that are observable for the asset or liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    that are derived principally from or corroborated by observable market data by correlation or other means</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of
    the asset or liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
asset or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is
significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of
unobservable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
Fair Value of Financial Instruments, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zePSfj8Avsca">Schedule
of Marketable Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable
Securities:</i> Valued using quoted prices in active markets for identical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Significant
    Unobservable Inputs (Level 3)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif">4,086,902</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif">11,003,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zNrXGEf2wrHg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities are classified as available for sale and are valued at fair market value. Maturities of the securities are less than one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the Company held certain mutual funds, which, under FASB ASC 321-10, were considered equity
investments. As such, the change in fair value in the year ended December 31, 2022 and 2021 was a gain of $<span id="xdx_907_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_zctD79SBIhmg" title="Unrealized (gain)/loss on marketable securities">2,958</span>
and a loss of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_z2GifEoTIlXd" title="Unrealized (gain)/loss on marketable securities">42,793</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses resulting from the sales of marketable securities were losses of $<span id="xdx_904_eus-gaap--MarketableSecuritiesRealizedGainLoss_iN_di_c20220101__20221231_zyRZ8Lr5LD26" title="Gain/loss on sale of marketable securities">5,964</span> and gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20210101__20211231_zGhwhueFBAd2" title="Gain/loss on sale of marketable securities">39,597</span> for the years ended December
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from the sales of marketable securities were $<span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20220101__20221231_zpI1TG3QqZRa" title="Proceeds from the sales of marketable securities">11,750,000</span> and $<span id="xdx_90D_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20211231_zj6x4w1Pb0R1" title="Proceeds from the sales of marketable securities">18,483,176</span> in the years ended December 31, 2022 and 2021, respectively.
Purchases of marketable securities were $<span id="xdx_907_eus-gaap--PaymentsToAcquireMarketableSecurities_c20220101__20221231_z5v6kEXs9f41" title="Purchase of marketable securities">4,836,837</span> and $<span id="xdx_90B_eus-gaap--PaymentsToAcquireMarketableSecurities_c20210101__20211231_z9ETZImwdjKc" title="Purchase of marketable securities">13,403</span> during the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_PrepaidExpensesPolicyTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p id="xdx_84E_ecustom--PrepaidExpensesPolicyTextBlock_zEXSDCVqVF4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)
<span id="xdx_865_z0t40pOFMOdh">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses represent expenses paid prior to the date that the related services are rendered or used are comprised principally of prepaid
insurance and research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zw5YAmiRVZPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)
<span id="xdx_864_zpAtJtp7O5tk">Concentrations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial
institutions and accounts receivable. At times, the Company&#8217;s cash in banks is in excess of the FDIC insurance limit. The Company
has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock', window );">Risk Management of Cash and Investments</a></td>
<td class="text"><p id="xdx_84A_ecustom--RiskManagementOfCashInvestmentsPolicyTextBlock_zcaEdiCpaNg9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)
<span id="xdx_862_zUAivk8x7WY8">Risk Management of Cash and Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy to minimize the Company&#8217;s capital resources to investment risks, prioritizing the preservation of
capital over investment returns. Investments are maintained in securities, primarily publicly traded, short-term money market funds based
on highly rated federal, state and corporate bonds, that minimize the risk to the Company&#8217;s capital resources and provide ready
access to funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s investment portfolios are regularly monitored for risk and are held with one brokerage firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_zBGp5lXsQcn6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)
<span id="xdx_867_zwGzmjRwRRr3">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other
than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company&#8217;s
ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for
using the cost method to the equity method of valuation in accordance with FASB ASC 323.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company&#8217;s ability to significantly
influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the
time of the investment based upon several factors including, but not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representation
    on the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participation
    in policy-making processes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    intra-entity transactions</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interchange
    of management personnel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technological
    dependencies</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extent
    of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational
and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the
cost method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with FASB ASC 321-10-35-2, the Company has elected to measure
its investment in Oravax Medical, Inc. (&#8220;Oravax&#8221;) (Note 3) as an equity security without a readily determinable fair value.
Under this election, an equity security without a readily available fair value is reflected at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
At each reporting period, the Company is required to make a qualitative assessment considering impairment indicators to evaluate whether
the investment is impaired. If deemed impaired, the Company is required to estimate the fair value of the investment and recognize an
impairment loss equal to the difference between the fair value of the investment and its carry amount. As of December 31, 2022, the Company
performed a qualitative assessment to evaluate whether the investment is impaired and determined that the investment was not impaired
and thus no adjustment to fair market value was required as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zs5s0t7t55Se" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(k)
<span id="xdx_86A_zwcA9esYL5El">Property, Plant and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, plant and equipment and are recognized within &#8220;other (income)/expense&#8221; in the Consolidated
Statements of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognized over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of
the lease term or their useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zs65nJ7AflJl">Schedule
of Estimated Useful Lives of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives">12</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &amp; software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives">5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives">Shorter of the remaining
    lease or estimated useful life</span></span></td></tr>
  </table>

<p id="xdx_8A6_zsRLLYi1iiY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8iJ02grMFA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(l)
<span id="xdx_868_zWIJmvX69zU4">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate
there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets
not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount,
other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge in the Consolidated Statements of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents
and Trade Secrets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propriety
protection for the Company&#8217;s products, technology and process is important to its competitive position. As of December 31, 2022,
the Company has 16 issued U.S. patents, 50 foreign patents, four pending U.S. patent applications and 15 foreign patent applications
pending in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea, which if issued are expected
to expire between 2036 and 2041. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade
secrets) using all legal remedies available to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records expenses related to the application for and maintenance of patents as a component of research and development expenses
on the Consolidated Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic
benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life and assessed for impairment when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Intangible Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization
and accumulated impairment losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amortization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zTy2vgZzxaS3" style="display: none">Schedule of Estimated Useful Lives of Intangible Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
    and trademarks</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives">12</span>-<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives">17</span></span></td></tr>
  </table>
<p id="xdx_8A4_ztE2JQSh464l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z48w7DnfUcCb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(m)
<span id="xdx_86E_zYGyDOVSEZG3">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is evaluated annually for impairment or whenever we identify certain triggering events or circumstances that would more likely than not
reduce the fair value below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include,
among other things, unexpected adverse business conditions, economic factors (for example, the loss of key personnel), supply costs,
unanticipated competitive activities, and acts by governments and courts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy', window );">Recoverability of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_zT9j3kHsrBL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(n)
<span id="xdx_861_zXuh6y5Q4Z46">Recoverability of Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB ASC 360-10-35 &#8220;Impairment or Disposal of Long-lived Assets&#8221;, long-lived assets to be held and used are
analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable
or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and
circumstances have occurred that indicate possible impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges)
and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by
which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the
lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying
amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce
the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_RightOfUseAssetsPolicyTextBlock', window );">Right-of-Use Assets</a></td>
<td class="text"><p id="xdx_845_ecustom--RightOfUseAssetsPolicyTextBlock_zPO69ayfdMkj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(o)
<span id="xdx_86E_zZdGfl5apCMh">Right-of-Use Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased a facility in Tampa, Florida (&#8220;Hyde Park&#8221;) under an operating lease (&#8220;Hyde Park Lease&#8221;) with annual
rentals of $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z5gXmVY3O0hi" title="Payments for Rent">22,048</span> to $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zcYov0cps7ya" title="Payments for Rent">23,320</span> plus certain operating expenses. The Hyde Park facility housed the MyMD Florida operations. The Hyde Park
Lease took effect on July 1, 2019 for a term of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zhkNz0gLpuz6" title="Lessee, operating lease, term of contract">36</span> months to expire on <span id="xdx_90E_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20190701__20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z2htao554bs8" title="Lease expiration date">June 30, 2022</span>. The Company cancelled the Hyde Park lease in March
2022 without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased an aircraft under an operating lease (&#8220;Supera Aviation Lease&#8221;) with annual rentals of $<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20181020__20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zo4CJ5rwsPLb" title="Payments for Rent">600,000</span> plus certain
operating expenses. The Supera Aviation Lease took effect on October 26, 2018 for a term of <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zE0qgmlf4I4h" title="Lessee, operating lease, term of contract">36</span> months to expire on September 26, 2021.
The Company cancelled the Supera Aviation Lease in April 2021 without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased a facility in Baltimore, Maryland (&#8220;2020 Wolfe St&#8221;) under an operating lease (&#8220;2020 Baltimore Lease&#8221;)
with annual rentals of $<span id="xdx_90F_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zb3FRNgbwJah" title="Payments for Rent">24,000</span> to $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zl95SSVy0kS1" title="Payments for Rent">25,462</span> plus certain operating expenses. The 2020 Baltimore Lease took effect on November 9, 2020 for
a term of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zfTeYsV7SaJd" title="Lessee, operating lease, term of contract">12</span> months with automatic renewals unless a sixty-day notice was provided. The initial term expired on <span id="xdx_90B_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20201105__20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_z3I38lbOJec5" title="Lease expiration date">November 30, 2021</span>. On
November 17, 2021, the 2020 Baltimore Lease was cancelled without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases a facility in Baltimore, Maryland (&#8220;2021 Wolfe St&#8221;) under an operating lease (&#8220;2021 Baltimore
Lease&#8221;) with annual rentals of $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MinimumMember_zfuZTDSVVlR8" title="Payments for rent">52,800</span>
to $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MaximumMember_zYs1H5BkXeWd" title="Payments for rent">56,016</span>
plus certain operating expenses. The 2021 Baltimore Lease took effect on November 17, 2021 for a term of <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zljWYGaAuPp" title="Lessee operating lease term of contract">12</span>
months with automatic renewals unless a sixty-day notice is provided. The initial term expires on <span id="xdx_90C_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zILO0WYY40v6" title="Expiration date">November
30, 2022</span>. The lease renewed effective December 1, 2022 for a term of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20221201_zaWttHsZO1Ha" title="Lessee operating lease renewal term">12</span> months with automatic renewals unless a sixty-day notice
is provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases a facility in Tampa, Florida (&#8220;Platt St&#8221;) under an operating lease (&#8220;Platt Street Lease&#8221;) with
annual rentals of $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MinimumMember_z15D2sxrM7xd" title="Payments for Rent">22,030</span> to $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MaximumMember_zYXFjtctPI8e" title="Payments for rent">23,259</span> plus certain operating expenses. The Platt Street Lease took effect on April 1, 2022 for a term
of <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zsv3fWf9Zku" title="Term of contract">36</span> months. The initial term expires on <span id="xdx_903_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z72rUefeJsWk" title="Lease expiration date">March 31, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019 (&#8220;Effective Date&#8221;), the Company adopted FASB ASC, Topic 842, Leases (&#8220;ASC 842&#8221;), which increases
transparency and comparability by recognizing a lessee&#8217;s rights and obligations resulting from leases by recording them on the
balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (&#8220;ROU&#8221;)
assets and related operating and finance lease liabilities on the balance sheet. The Company adopted the new guidance using the modified
retrospective approach on January 1, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the package of practical expedients permitted within the standard, which allows an entity to forgo reassessing (i) whether
a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition
of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and
impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has
also elected the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any
lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
contracts entered into on or after the Effective Date, at the inception of a contract, the Company will assess whether the contract is,
or contains, a lease. The Company&#8217;s assessment is based on: (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtained the right to substantially all the economic benefit from the use of the asset throughout the
period, and (iii) whether the Company has the right to direct the use of the asset. Leases entered into prior to January 1, 2020, which
were accounted for under ASC 840, were not reassessed for classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The Company
generally uses its incremental borrowing rate as the discount rate for leases, unless an interest rate is implicitly stated in the lease.
The present value of the lease payments is calculated using the incremental borrowing rate for operating leases, which was determined
using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term. The lease term for all the Company&#8217;s leases includes the non-cancellable period
of the lease plus any additional periods covered by either a Company option to extend the lease that the Company is reasonably certain
to exercise, or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zv4QhUpqTiz4" style="display: none">Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt Street</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hyde
                                                                                         Park</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Balance
    Sheet Location</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Right
    of Use</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,662</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,156</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,853</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,741</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,076</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53,240</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable - net of
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,070</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,941</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,911</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,911</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zEOBmg0vkU17" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides details of the Company&#8217;s lease expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGRbxhBgiqMd" style="display: none">Schedule of Lease Expense</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Platt Street</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Supera Aviation</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease Expenses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b><span style="font-family: Times New Roman, Times, Serif">Lease</span></b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Lease Costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,251</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,981</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">54,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,632</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,533</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">202,226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AF_zu8WgHFyEU2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zTbeKs7NCWTd" style="display: none">Schedule of Other Information Related to Leases</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Hyde</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other
    Information</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Park
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating cash
    used</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">4,622</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">19,628</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">51,602</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">75,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Average remaining lease
    term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term">27</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term">23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term">25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A5_zDSTRTFLYxp9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the annual minimum lease payments of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z418TRZZeYi" style="display: none">Schedule of Operating Lease Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">For Years Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,485</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,005</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,348</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments, undiscounted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,868</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">157,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of future
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,811</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,721</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_z9Pn8x1uCzk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">(p) Revenue Recognition</a></td>
<td class="text"><p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zV1OPgbYY9Ac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(p)
<span id="xdx_8B3_z0X56l1bZbzi">Revenue Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that
a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services
transferred to the customer. The following five steps are applied to achieve that core principle:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the contract with the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the transaction price</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
    the transaction price to the performance obligations in the contract</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
    revenue when the company satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zFd0LdHOkWhh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(q)
<span id="xdx_866_zPNtZrlB5KGg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits are
recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized
is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized
tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and
measurement standards. For the years ended December 31, 2022 and 2021, no liability for unrecognized tax benefits was required to be
reported.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no income tax benefit recorded for the losses for the years ended December 31, 2022 and 2021 since management determined that the
realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on
the net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax years from 2019 through 2022 remain
subject to examination by federal and state jurisdictions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings per Share of Common Stock</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zSFd7GSZQV6i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(r)
<span id="xdx_869_zJi0VKddkhRa">Basic and Diluted Earnings per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings
per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the
period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 375.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed using the weighted average number of shares of Common Stock and dilutive potential Common Stock outstanding
during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss for the years ended December 31, 2022 and 2021, Common Stock equivalents were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAXNur76ujuj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
    the Years Ended <br/> December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,376,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,176,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Unvested Restricted Stock Units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,795,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,795,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,074,489</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">520,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Convertible Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Convertible Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,496</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,496</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    potentially dilutive shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,885,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,630,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zu08y11WuaG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Payments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzGyNqd81XN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(s)
<span id="xdx_86E_zGEQBYKSKSgd">Stock-based Payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) 718, &#8220;Compensation - Stock Compensation&#8221;, which requires the measurement and recognition of compensation
expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates
the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is
ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In June 2018,
the FASB issued ASU No. 2018-07, Compensation &#8211; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment
Accounting (the &#8220;2018 Update&#8221;). The amendments in the 2018 Update expand the scope of Topic 718 to include share-based payment
transactions for acquiring goods and services from nonemployees. Prior to the 2018 Update, Topic 718 applied only to share-based transactions
to employees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards
within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when
the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the
instruments have been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for forfeiture of stock-based awards as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zawq1TKJXW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(t) <span id="xdx_86C_z2UTNbnIjANg">Research and Development Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with FASB ASC 730, research and development costs are expensed
as incurred and consist of fees paid to third parties that conduct certain research and development activities on the Company&#8217;s
behalf.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zb2UcIdCu8jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(u)
<span id="xdx_861_z1m1wXwiQfC4">Recently Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, FASB issued ASU 2017-11, Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and
Hedging (Topic 815): The new guidance amends ASC 815 to exclude consideration of a down-round feature in the evaluation of whether an
instrument is indexed to an entity&#8217;s own stock under ASC 815-40-15-7C. That is, a down-round provision would not preclude an entity
from concluding that an instrument or feature that includes a down-round feature is indexed to the entity&#8217;s own stock. This guidance
applies to both freestanding financial instruments and embedded conversion options (e.g., in convertible instruments with beneficial
conversion features (BCFs) or cash conversion features (CCFs)). The ASU is effective for annual reporting periods beginning after December
15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this standard did not have a material impact on their
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, FASB issued ASU 2020-06, <i>Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211;
Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own
Equity</i>. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer&#8217;s accounting for convertible debt instruments. The new
guidance removes from U.S. GAAP the separation models for (1) convertible debt with a CCF and (2) convertible instruments with a BCF.
As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in
such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as
preferred stock. This ASU is effective for fiscal years beginning after December 15, 2021 and early adoption is allowed. The Company
early adopted this guidance as of January 1, 2021. The adoption of this standard did not have a material impact on their consolidated
financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50),
Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40),
Issuer&#8217;s Accounting for Certain Modifications or Exchanges or Freestanding Equity - Classified Written Call Options. </i>The amendments
in this Update clarify an issuer&#8217;s accounting for modifications or exchanges of freestanding equity - classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments are effective for all entities for
fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments
prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for
all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this Update in an interim
period, the guidance should be applied as of the beginning of the fiscal year that includes the interim period. The adoption of this
ASU had no material impact on the Company&#8217;s consolidated financial statements and related disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements Not Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial
Instruments (&#8220;ASU-2016-13&#8221;). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets
that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred
losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2022, including interim periods
within that fiscal year. The Company expects that there would be no material impact on the Company&#8217;s consolidated financial
statements upon the adoption of this ASU.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_PrepaidExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_PrepaidExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_RightOfUseAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_RightOfUseAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Management of Cash Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for planned major maintenance activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=16397424&amp;loc=d3e949-110221<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908599296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zePSfj8Avsca">Schedule
of Marketable Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable
Securities:</i> Valued using quoted prices in active markets for identical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Significant
    Unobservable Inputs (Level 3)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif">4,086,902</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif">11,003,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives of Property Plant and Equipment</a></td>
<td class="text"><p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zs65nJ7AflJl">Schedule
of Estimated Useful Lives of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives">12</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &amp; software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives">5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives">Shorter of the remaining
    lease or estimated useful life</span></span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock', window );">Schedule of Estimated Useful Lives of Intangible Assets</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zTy2vgZzxaS3" style="display: none">Schedule of Estimated Useful Lives of Intangible Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    years)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
    and trademarks</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives">12</span>-<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives">17</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock', window );">Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zv4QhUpqTiz4" style="display: none">Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt Street</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hyde
                                                                                         Park</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Balance
    Sheet Location</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Right
    of Use</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,662</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,156</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,853</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,741</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,780</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,076</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53,240</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Payable - net of
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,070</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,941</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,911</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,911</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides details of the Company&#8217;s lease expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGRbxhBgiqMd" style="display: none">Schedule of Lease Expense</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended<br/> December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Platt Street</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Supera Aviation</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hyde Park</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021 Baltimore</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease Expenses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b><span style="font-family: Times New Roman, Times, Serif">Lease</span></b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Lease Costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,251</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,981</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">54,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,632</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,533</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">202,226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock', window );">Schedule of Other Information Related to Leases</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zTbeKs7NCWTd" style="display: none">Schedule of Other Information Related to Leases</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Hyde</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other
    Information</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Park
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating cash
    used</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">4,622</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">19,628</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">51,602</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"><span style="font-family: Times New Roman, Times, Serif">75,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Average remaining lease
    term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term">27</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term">23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term">25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate">10.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Minimum Lease Payments</a></td>
<td class="text"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the annual minimum lease payments of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z418TRZZeYi" style="display: none">Schedule of Operating Lease Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Platt</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021 Baltimore</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Street
    Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">For Years Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,485</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,005</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,348</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments, undiscounted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,868</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">157,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of future
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,811</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,721</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAXNur76ujuj" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
    the Years Ended <br/> December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,376,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,176,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Unvested Restricted Stock Units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,795,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,795,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,074,489</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">520,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Convertible Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Convertible Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,496</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,496</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    potentially dilutive shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,885,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,630,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Estimated Useful Lives of Property Plant and Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of condensed consolidated balance sheet information related to operating lease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Estimated Useful Lives of Intangible Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Information Related to Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912369168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Developments, Liquidity and Management&#8217;s Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract', window );"><strong>Recent Developments Liquidity And Managements Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired to be Allocated to Goodwill</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zbqmEkrbkShe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z16p5vmab1Rd">Schedule
of Net Assets Acquired to be Allocated to Goodwill</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Valuation
    <br/> Analysis</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210416__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zW1yQXyWjuLh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total Consideration"><span style="font-family: Times New Roman, Times, Serif">42,477,346</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and Cash Equivalents"><span style="font-family: Times New Roman, Times, Serif">1,380,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">29,480,524</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other Receivables"><span style="font-family: Times New Roman, Times, Serif">3,026,137</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expenses"><span style="font-family: Times New Roman, Times, Serif">192,314</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in Oravax, Inc.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment in Oravax, Inc."><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Trade and Other Payables</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zY7GpVztgPi2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and Other Payables"><span style="font-family: Times New Roman, Times, Serif">(3,601,020</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Tangible Assets
    Acquired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zDDkY4np7f3b" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Tangible Assets Acquired"><span style="font-family: Times New Roman, Times, Serif">31,978,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Excess of Purchase Price
    Over Net Assets Acquired to be Allocated to Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--Goodwill_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill"><span style="font-family: Times New Roman, Times, Serif">10,498,539</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock', window );">Summary of Milestone Events Payment</a></td>
<td class="text"><p id="xdx_89D_ecustom--SummaryOfMilestoneEventsPaymentTableTextBlock_ztnzcd3FAXkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zX43G04cJwKi">Summary
of Milestone Events Payment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Event</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milestone
    Payment</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zxQO5DcJdaa1" title="Milestone Event">Market
    capitalization of the combined company for at least ten (<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zbAkHFkCvoxj" title="Debt Instrument, Convertible, Threshold Trading Days">10</span>) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#8220;First Milestone Event&#8221;)</span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zn71c3673dzf" title="Milestone Payment">20,000,000</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z3mOcVEauQti" title="Milestone Event">For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least <span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z9NFKzKila4b" title="Threshold trading days">10</span> trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company</span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_zUWfakWc2bji" title="Milestone Payment">10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zy6Uzjofk6Yc" title="Milestone Event">Market
    capitalization of the combined company for at least <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zFPZOxDxzhCl" title="Debt Instrument, Convertible, Threshold Trading Days">10</span> trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#8220;Second Milestone Event&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zwcfVRNmJXe8" title="Milestone Payment">25,000,000</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zCIuwjWOFz48" title="Milestone Event">For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zzgeveMfu8mk" title="Threshold trading days">10</span> trading days during any 20 consecutive trading day period during the Milestone
    Period</span>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90E_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zLtbp8KJU8Zi" title="Milestone Payment">25,000,000</span>
    per each incremental increase</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of milestone events payment table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775917564144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Trade and Other Payables</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLkHF2WSGX6f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other payables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zmu5VpD0hIN3">Schedule
of Trade and Other Payables</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20221231_zWFKnewnHzU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20211231_zBPCCn91pAcb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableTradeCurrent_iI_pp0p0_maAPAOAzNsj_zaPxxI4z5X0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts Payable &#8211; Trade</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,356,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">867,518</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzNsj_zWsHh3J32ut6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">119,108</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzNsj_ziwHp0LUz5nb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables, Total</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,673,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">986,626</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914404624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKU7dP8dbSzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activities for MyMD stock options for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zhogll6lP7H8">Summary
of Stock Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zXMCfTt0c42h" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of Shares, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">4,176,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkraZcEptGI5" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">2.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zdXh6kDV7ztk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">2.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"/></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUesiIMkAwR5" title="Weighted Average Remaining Contractual Term (Years), Beginning">1.29</span></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zrU9x5VANKu" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">14,493,284</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zgw5BWoHTN81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zIuVXPcxzkXh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">3.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zAmc9CVvaB5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif">3.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--WeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231_zGUCNxEruRXb" title="Weighted Average Remaining Contractual Term (Years), Granted">5.80</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zz9wlBdJF9Fg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zDQNPuVB1EM4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zU3f8FWpT9j8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_znHg0YZgsh63" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJbHi3RYI4ae" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zlOrdKKXojV2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_z1ukftiBAJm" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Canceled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEuhLHZi1wfh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Canceled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zA8NUICsMAn9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Canceled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zNiHI3IoqRke" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Ending Balance">&#8239;<span style="font-family: Times New Roman, Times, Serif">4,476,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zeilo4IWirH3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zIQMsZ9v8hMf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"><span style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOAkMHVCEzE7" title="Weighted Average Remaining Contractual Term (Years), Ending">0.64</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z6DuQ00yoaR5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercisable"><span style="font-family: Times New Roman, Times, Serif">4,376,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zkE7UZjWJfO" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_c20220101__20221231_zNltyrsJ5DJ9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z6Ga8wHrZmGe" title="Weighted Average Remaining Contractual Term (Years), Exercisable">0.52</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zP6y0EIgRuv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the status of outstanding unvested restricted stock units outstanding as of December 31, 2022 and the changes for the
year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z2h1ggkmMNRa">Summary
of Restricted Stock Units Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Average</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number
    of</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Grant
    Date</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RSUs</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
    Value</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VanMWyalIj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">2,795,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRJZ6TxhYHSg" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">8.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za4oOKNcjzU" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Granted"><span style="font-family: Times New Roman, Times, Serif">54,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhnwmuWgJ0hg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="font-family: Times New Roman, Times, Serif">3.06</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD88faltMzu6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6roEJbUYSr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJx5G7mIb8w6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"><span style="font-family: Times New Roman, Times, Serif">(54,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo9jdXvPZEre" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"><span style="font-family: Times New Roman, Times, Serif">3.06</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5AL2xCNq7d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbgsmnENAzKa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzdPEWqALCl9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUyqnmMouUs7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUMpOav64Jpa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">2,795,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUIeSvX75u73" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">8.09</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908635456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFkPcvMDqjg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zUHlIhuGm3Fb" style="display: none">Summary
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term
    (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCIUzgfiGM98" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">5,074,489</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zio4pID9j5P9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">5.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgZMHVNocLqk" title="Weighted Average Remaining Contractual Term (years), Beginning">4.34</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeg1CBIpIr8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">9,554,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTLF2wpCzQbj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif">1,450,029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKIQSLNimS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">5.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVHdIWWxZGA9" title="Weighted Average Remaining Contractual Term (Years), Granted">4.88</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVR1fnyZgg8b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkL8JJxHRuK8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbmMkCqfeAW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z82sk2wBeyhg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhFq1YzDwA7j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif">(9,691</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgxDyxsMcYk7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif">222.55</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XINGBMFcWi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwK4Ys4Rs7K3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">4.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNsxEbOoXQE9" title="Weighted Average Remaining Contractual Term (years), Ending Balance">3.63</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOoihMVONPek" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLhYk0yV4iXf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"><span style="font-family: Times New Roman, Times, Serif">6,514,827</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWwnM3AQmSE4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif">4.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSgelimLgNig" title="Weighted Average Remaining Contractual Term (years), Exercisable">3.63</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLblHPE20cM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember', window );">Pre-funded Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zuKyqluIE4Mf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the pre-funded warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zOnA9QjAv8f1" style="display: none">Summary
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Term
    (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zc3R2h01hbg9" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">520,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zxS5jU9uZnCd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zkh9XShkctni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">3,151,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5hesPOZ4O36" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zyX1PqfGIuSg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zoobEKmUY3bd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif">(385,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCF1LkSgZjYb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zmGL1uFNUSye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zhtkgmIBblO9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Canceled/Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJ5ZBbB6XP2i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zV1cpsQwPWZ9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCIo0kSUXXjc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5NgHI1oApo6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z1z95icvQrb3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif">155,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    as of December 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zIh74WklD2L5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"><span style="font-family: Times New Roman, Times, Serif">135,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zUOX35pfcVu" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif">0.002</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJlRxnOtpnzi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif">155,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember', window );">Series C Convertible Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zVkcq8Siov2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zdD6CFV0UyG7" style="display: none">Summary
of Warrant Activity</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    (years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Balance
    at December 31, 2021</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zXkWw4XeT4F" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zH1xQdMrXnx" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zie5Y6BR6nB" title="Weighted Average Remaining Contractual Term (years), Beginning">2.94</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z2aslaOoKOL6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zERsFR22gIZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zeFpboMFUfAl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z8G5iHj4p9d5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1358">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zcS46sSV1Mr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziEddDLpqo79" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zpUx2CcZBGhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canceled/Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zBNZcL8trjOh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zECF6ZiIkEEl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Balance
    at December 31, 2022</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zmE1ebquwRm" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zl7MGpBgKCCj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zKdJFCSU5F49" title="Weighted Average Remaining Contractual Term (years), Ending Balance">1.94</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziJdhv0QoMl2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercisable
    as of December 31, 2022</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zyMSKudRgTW" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zx7nCp5KYcv6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zotenN2Co6c9" title="Weighted Average Remaining Contractual Term (years), Exercisable">1.94</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zDJfQPkARKA8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913359808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax (Benefit)/Provision</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zoK1Q7XEWVH1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s income tax (benefit)/provision is as follows for the years ended December 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zsV0g3b1tHg3" style="display: none">Schedule
of Income Tax (Benefit)/Provision</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220101__20221231_z0prSLIoi1sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zC7VPToJc4J5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBziYA_zKJi3HzmnZik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBziYA_z8nfiAwm8a6k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(5,914,000<span style="display: none; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,219,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBziYA_zJsR53boBvA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,914,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,219,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBziYA_zG4moYR3Z8L7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income Tax Benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfOV2YvTSGj2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December
31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zASRnJr28zp7" style="display: none">Schedule
of Reconciliation of Income Tax Rate and Benefit from Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231_zwQqHj4CXgk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20210101__20211231_zdqzOJo8RcFc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zdMn1hw0DIsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Statutory U.S. Federal Income Tax
    Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(21.0</p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.0)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zWbi3Sd1Hgt1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">New Jersey State income taxes, net of U.S.
    Federal tax effect</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(14.5</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_ziYTR5nYljZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustment to deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(4.1</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_zip9QRej0Chg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zIOZtTK0kCj2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">38.9</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zGeYYSEJhCW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">0.0</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Related Valuation Allowances</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxtH4Vfy0KYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of the deferred tax assets and related valuation allowances as of December 31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zopZG5pvkGKe" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowances</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20221231_zgGUYS0jpUXj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_z5ettnnAHKyd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pp0p0_maDTALNzOrT_zU3gfbiIzQ71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserves
    and other</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">745,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzOrT_zu0aQFEYrbag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    operating loss carry-forwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">26,176,000</p><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,526,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_maDTALNzOrT_zzDvfhPEYTgj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,177,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTALNzOrT_zrptaCcKFBF4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">610,000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">610,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzOrT_zI6OYdLPDECf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,542,000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><span style="font-family: Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,021,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzOrT_zpkpTZXujqx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    Allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(34,250,000</p>
</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28,336,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzOrT_zatvi99tVnZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1463">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913376048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExchangeRatioPricePerShares', window );">Exchange ratio price per shares</a></td>
<td class="nump">$ 0.7718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=MYMD_SuperaPharmaceuticalsIncMember', window );">Supera Pharmaceuticals Inc [Member] | Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, shares, acquisitions | shares</a></td>
<td class="nump">33,937,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MYMD_MyMDPharmaceuticalsFloridaIncMember', window );">MyMD Pharmaceuticals (Florida), Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExchangeRatioPricePerShares', window );">Exchange ratio price per shares</a></td>
<td class="nump">$ 0.7718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ExchangeRatioPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio price per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ExchangeRatioPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=MYMD_SuperaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=MYMD_SuperaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MYMD_MyMDPharmaceuticalsFloridaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MYMD_MyMDPharmaceuticalsFloridaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908636480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 4,086,902<span></span>
</td>
<td class="nump">$ 11,003,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912341408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, plant and equipment, useful lives</a></td>
<td class="text">Shorter of the remaining
    lease or estimated useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775919041840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives of Intangible Assets (Details) - Patents and Trademarks [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=MYMD_PatentsAndTrademarksMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated, useful lives</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=MYMD_PatentsAndTrademarksMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated, useful lives</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=MYMD_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=MYMD_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914249104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease Right of Use</a></td>
<td class="nump">$ 139,662<span></span>
</td>
<td class="nump">$ 149,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease Payable, current</a></td>
<td class="nump">65,780<span></span>
</td>
<td class="nump">53,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease Payable - net of current</a></td>
<td class="nump">75,941<span></span>
</td>
<td class="nump">95,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember', window );">Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease Right of Use</a></td>
<td class="nump">45,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease Payable, current</a></td>
<td class="nump">18,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease Payable - net of current</a></td>
<td class="nump">27,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember', window );">2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease Right of Use</a></td>
<td class="nump">94,309<span></span>
</td>
<td class="nump">136,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease Payable, current</a></td>
<td class="nump">47,039<span></span>
</td>
<td class="nump">41,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease Payable - net of current</a></td>
<td class="nump">$ 48,871<span></span>
</td>
<td class="nump">95,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember', window );">Hyde Park Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease Right of Use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease Payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease Payable - net of current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908580080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Lease Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease Costs</a></td>
<td class="nump">$ 77,632<span></span>
</td>
<td class="nump">$ 202,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember', window );">Hyde Park Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease Costs</a></td>
<td class="nump">6,251<span></span>
</td>
<td class="nump">25,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember', window );">Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease Costs</a></td>
<td class="nump">16,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember', window );">2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease Costs</a></td>
<td class="nump">$ 54,400<span></span>
</td>
<td class="nump">4,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SuperaAviationMember', window );">Supera Aviation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyBaltimoreMember', window );">2020 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_SuperaAviationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_SuperaAviationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914201456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Other Information Related to Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used</a></td>
<td class="nump">$ 75,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember', window );">Hyde Park Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used</a></td>
<td class="nump">$ 4,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember', window );">Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used</a></td>
<td class="nump">$ 19,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">27 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember', window );">2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used</a></td>
<td class="nump">$ 51,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">23 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913312912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Minimum Lease Payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 77,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">74,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">157,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">15,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">141,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember', window );">Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">22,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">23,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">51,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">5,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">45,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember', window );">2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">54,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">51,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">105,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">9,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 95,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908815072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">13,885,695<span></span>
</td>
<td class="nump">12,630,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">4,376,737<span></span>
</td>
<td class="nump">4,176,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">2,795,000<span></span>
</td>
<td class="nump">2,795,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">6,514,827<span></span>
</td>
<td class="nump">5,074,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_PreFundedWarrantsToPurchaseCommonStockMember', window );">Pre-funded Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">135,135<span></span>
</td>
<td class="nump">520,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_SeriesCPreferredConvertibleWarrantsMember', window );">Series C Preferred Convertible Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">27,500<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_SeriesDPreferredConvertibleStockMember', window );">Series D Preferred Convertible Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">36,496<span></span>
</td>
<td class="nump">36,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_PreFundedWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_PreFundedWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_SeriesCPreferredConvertibleWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_SeriesCPreferredConvertibleWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_SeriesDPreferredConvertibleStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MYMD_SeriesDPreferredConvertibleStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912663008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Nov. 17, 2021</div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Jul. 02, 2019</div></th>
<th class="th"><div>Oct. 26, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (gain)/loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,958<span></span>
</td>
<td class="num">$ (42,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">(Gain)/loss on sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,964<span></span>
</td>
<td class="num">(39,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Gain/loss on sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,964)<span></span>
</td>
<td class="nump">39,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from the sales of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="nump">18,483,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,836,837<span></span>
</td>
<td class="nump">13,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember', window );">Hyde Park Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SuperaAviationMember', window );">Supera Aviation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyBaltimoreMember', window );">2020 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember', window );">2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember', window );">Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Hyde Park Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2020 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 22,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Hyde Park Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2020 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2021 Baltimore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Platt Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 23,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (gain)/loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,958<span></span>
</td>
<td class="nump">$ 42,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_HydeParkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_SuperaAviationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_SuperaAviationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_TwoThousandTwentyOneBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_PlattStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908816560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Net Assets Acquired to be Allocated to Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,498,539<span></span>
</td>
<td class="nump">$ 10,498,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember', window );">Akers Biosciences, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Consideration</a></td>
<td class="nump">$ 42,477,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,380,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">29,480,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Other Receivables</a></td>
<td class="nump">3,026,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid Expenses</a></td>
<td class="nump">192,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Investment in Oravax, Inc.</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Trade and Other Payables</a></td>
<td class="num">(3,601,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net Tangible Assets Acquired</a></td>
<td class="nump">31,978,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill</a></td>
<td class="nump">$ 10,498,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908365536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Milestone Events Payment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>d</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodOneMember', window );">Milestone Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestoneEvent', window );">Milestone Event</a></td>
<td class="text">Market
    capitalization of the combined company for at least ten (10) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#8220;First Milestone Event&#8221;)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodTwoMember', window );">Milestone Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestoneEvent', window );">Milestone Event</a></td>
<td class="text">For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least 10 trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodThreeMember', window );">Milestone Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestoneEvent', window );">Milestone Event</a></td>
<td class="text">Market
    capitalization of the combined company for at least 10 trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#8220;Second Milestone Event&#8221;)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodFourMember', window );">Milestone Period Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestoneEvent', window );">Milestone Event</a></td>
<td class="text">For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least 10 trading days during any 20 consecutive trading day period during the Milestone
    Period<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">25,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_MilestoneEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_MilestoneEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MilestonePeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912712016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Developments, Liquidity and Management&#8217;s Plans (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2022</div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,498,539<span></span>
</td>
<td class="nump">$ 10,498,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,090<span></span>
</td>
<td class="nump">555,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086,902<span></span>
</td>
<td class="nump">11,003,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,197,336<span></span>
</td>
<td class="nump">29,889,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,695,056<span></span>
</td>
<td class="nump">23,647,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,257,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,758,904<span></span>
</td>
<td class="nump">78,561,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,270,068<span></span>
</td>
<td class="nump">19,516,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,197,336<span></span>
</td>
<td class="nump">29,889,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non cash share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,191<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase in trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686,595<span></span>
</td>
<td class="num">(4,268,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_DecreaseInPrepaidExpense', window );">Decrease in prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non cash share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_ContributionAgreementMember', window );">Contribution Agreement [Member] | Premas Biotech PVT Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Amount owed on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits', window );">Issuance of post reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,553,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ExchangeRatioPercentage', window );">Exchange ratio percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock</a></td>
<td class="nump">49.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember', window );">Merger Agreement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,486<span></span>
</td>
<td class="nump">986,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=MYMD_CystronBiotechLLCMember', window );">Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Acquired membership interests, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=MYMD_PreMergerMember', window );">Pre Merger [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon
completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307
post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio.
Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD
Florida held approximately 77.05%
of the Company&#8217;s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants
to purchase 986,486
shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of
pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company&#8217;s net cash
at closing. Holders of pre-Merger Company Common Stock held approximately 22.95% of the outstanding equity of the
Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315
MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment
of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of
the Merger<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember', window );">Akers Biosciences, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,498,539<span></span>
</td>
<td class="nump">$ 10,498,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationLongtermDebtAndEquity', window );">Pre market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,477,346<span></span>
</td>
<td class="nump">42,477,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Tangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,978,807<span></span>
</td>
<td class="nump">$ 31,978,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,335,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember', window );">Akers Biosciences, Inc [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_DecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in prepaid expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_DecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ExchangeRatioPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ExchangeRatioPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of post reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationLongtermDebtAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the total consolidated (as applicable) capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationLongtermDebtAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_ContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_ContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MYMD_PremasBiotechPVTLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MYMD_PremasBiotechPVTLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=MYMD_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=MYMD_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=MYMD_CystronBiotechLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=MYMD_CystronBiotechLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MembershipInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MembershipInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=MYMD_PreMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=MYMD_PreMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=MYMD_AkersBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912537296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Trade and Other Payables (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts Payable &#8211; Trade</a></td>
<td class="nump">$ 2,356,555<span></span>
</td>
<td class="nump">$ 867,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">316,666<span></span>
</td>
<td class="nump">119,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Trade and other payables, Total&#160;</a></td>
<td class="nump">$ 2,673,221<span></span>
</td>
<td class="nump">$ 986,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139776010349440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - Bridge Loan Note [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 11, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=MYMD_BridgeLoanNoteMember', window );">MyMD Pharmaceuticals (Florida), Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesToAffiliate', window );">Advances to affiliate</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">26,137<span></span>
</td>
<td class="nump">26,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 3,026,137<span></span>
</td>
<td class="nump">$ 3,026,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Maximum principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember', window );">Merger Agreement [Member] | Event of Default [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=MYMD_BridgeLoanNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=MYMD_BridgeLoanNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=MYMD_MyMDPharmaceuticalsFloridaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=MYMD_MyMDPharmaceuticalsFloridaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=MYMD_EventOfDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=MYMD_EventOfDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908968528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Options Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,176,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 20 days<span></span>
</td>
<td class="text">1 year 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,493,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_WeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="nump">11,576<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares, Canceled/Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Canceled/Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Canceled/Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,476,737<span></span>
</td>
<td class="nump">4,176,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,376,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value, Cancelled/Expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value, Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value, Exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_WeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_WeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908852768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Beginning Balance</a></td>
<td class="nump">2,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance</a></td>
<td class="nump">$ 8.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="nump">54,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod', window );">Number of RSUs, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="num">(54,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Number of RSUs, Cancelled/Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled/Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Ending Balance</a></td>
<td class="nump">2,795,000<span></span>
</td>
<td class="nump">2,795,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance</a></td>
<td class="nump">$ 8.09<span></span>
</td>
<td class="nump">$ 8.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercises in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercises in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775900628304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 17, 2022</div></th>
<th class="th"><div>Jul. 07, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Oct. 14, 2021</div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Sep. 11, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Dec. 07, 2018</div></th>
<th class="th"><div>Aug. 07, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 21, 2016</div></th>
<th class="th"><div>Jan. 23, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cumulative fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,550,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,420<span></span>
</td>
<td class="nump">$ 90,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized value</a></td>
<td class="nump">$ 113,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,191<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.51%<span></span>
</td>
<td class="nump">124.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
<td class="nump">1.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share based payment award vesting expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 28,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,342<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MYMD_MyMDFloridaStockOptionsMember', window );">MyMD Florida Stock Options [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_NumberOfStockOptionsAssumed', window );">Number of stock options assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,188,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,036,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value</a></td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility index</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_OptionsMarketValue', window );">Options market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,680<span></span>
</td>
<td class="nump">394,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Restricted stock units vested, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Such RSUs were granted under
the 2018 Plan, as amended. Fifty percent (50%) of each RSU will vest on the first anniversary date of the Grant and the remaining fifty
percent (50%) will vest on the second anniversary date; provided that the RSUs shall vest immediately upon the occurrence of (i) a change
in control, provided that the director is employed by or providing services to the Company and its affiliates on the closing date of
such change of control, or (ii) the director&#8217;s termination of employment of service by the Company was without cause<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of vesting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Number of restricted stock, net of tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Restricted stock value, net of tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | January 28, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | July 7, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Restricted stock units vested, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-third
    (33%) of each RSU will vest when the Company&#8217;s market capitalization is equal to or greater than $500,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Restricted stock units vested, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-third
    (33%) of each RSU will vest when the Company&#8217;s market capitalization is equal to or greater than $750,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Restricted stock units vested, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
    remaining awarded units will vest when the Company&#8217;s market capitalization is equal to or greater than $1,000,000,000 for at
    least ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market
    value of the Common Stock equals or exceeds $5.00 during such trading day period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized value</a></td>
<td class="nump">$ 22,611,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,611,550<span></span>
</td>
<td class="nump">$ 22,611,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Premerger common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_AmendedPlanMember', window );">Amended Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Premerger common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,188,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndSeventeenStockIncentivePlanMember', window );">2017 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Premerger common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Premerger common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="nump">297,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Premerger common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,228,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,149,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="nump">4,078,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,078,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cumulative fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_CumulativeFairMarketValue', window );">Cumulative fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Premerger common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of stock option to purchase shares of common stock</a></td>
<td class="nump">4,188,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_CumulativeFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative fair market value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_CumulativeFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_NumberOfStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock options assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_NumberOfStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_OptionsMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_OptionsMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MYMD_MyMDFloridaStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MYMD_MyMDFloridaStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=MYMD_JulySevenTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=MYMD_JulySevenTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_TwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_TwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_AmendedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_AmendedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_TwoThousandAndSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_TwoThousandAndSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_TwoThousandAndEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MYMD_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MYMD_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912635488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Beginning Balance | shares</a></td>
<td class="nump">5,074,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning', window );">Weighted Average Remaining Contractual Term (years), Beginning</a></td>
<td class="text">4 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning | $</a></td>
<td class="nump">$ 9,554,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted | shares</a></td>
<td class="nump">1,450,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 5.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Cancelled/Expired | shares</a></td>
<td class="num">(9,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Expired | $ / shares</a></td>
<td class="nump">$ 222.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Ending Balance | shares</a></td>
<td class="nump">6,514,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted Average Remaining Contractual Term (years), Ending Balance</a></td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Warrants, Exercisable | shares</a></td>
<td class="nump">6,514,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember', window );">Pre-funded Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Beginning Balance | shares</a></td>
<td class="nump">520,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 0.002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning | $</a></td>
<td class="nump">$ 3,151,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised | shares</a></td>
<td class="num">(385,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 0.002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Cancelled/Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Ending Balance | shares</a></td>
<td class="nump">135,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 0.002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending | $</a></td>
<td class="nump">$ 155,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Warrants, Exercisable | shares</a></td>
<td class="nump">135,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 0.002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 155,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember', window );">Series C Convertible Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Beginning Balance | shares</a></td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning', window );">Weighted Average Remaining Contractual Term (years), Beginning</a></td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Cancelled/Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Ending Balance | shares</a></td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted Average Remaining Contractual Term (years), Ending Balance</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Warrants, Exercisable | shares</a></td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of non-option equity outstanding and currently exercisable under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments forfeited in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term (Years), Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775907252288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 07, 2022 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 09, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 24, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 15, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for warrants, shares</a></td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Fair market value of shares issued for services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Common stock options, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Common stock options, proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issuance of warrant</a></td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 5.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 5,999,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,550,028<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 5,550,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,191<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issuance of warrant</a></td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price per share | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price per share | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding', window );">Underlying shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares, exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Fair market value of shares issued for services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember', window );">Pre-funded Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember', window );">Series C Convertible Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,353<span></span>
</td>
<td class="nump">211,353<span></span>
</td>
<td class="nump">211,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock value, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Preferred stock, terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A
holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company&#8217;s Common Stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company&#8217;s
Common Stock then issued and outstanding (with such ownership restriction referred to as the &#8220;Beneficial Ownership Limitation&#8221;).
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days after such notice to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,992<span></span>
</td>
<td class="nump">72,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares represent by preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_PreFundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MYMD_SeriesCConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MYMD_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139776010344784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Tax (Benefit)/Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(5,914,000)<span></span>
</td>
<td class="num">(6,219,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in Valuation Allowance</a></td>
<td class="nump">5,914,000<span></span>
</td>
<td class="nump">6,219,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775907476432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory U.S. Federal Income Tax Rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">New Jersey State income taxes, net of U.S. Federal tax effect</a></td>
<td class="num">(14.50%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Adjustment to deferred tax assets</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="nump">38.90%<span></span>
</td>
<td class="nump">20.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914685456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Related Valuation Allowances (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Reserves and other</a></td>
<td class="nump">$ 745,000<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">26,176,000<span></span>
</td>
<td class="nump">23,526,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Capitalized research and development</a></td>
<td class="nump">2,177,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">4,542,000<span></span>
</td>
<td class="nump">4,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(34,250,000)<span></span>
</td>
<td class="num">(28,336,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908816272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_PercentageOfNetIncomeForEachSubsequentPeriod', window );">Percentage of net income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,914,000<span></span>
</td>
<td class="nump">$ 6,219,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,100,000<span></span>
</td>
<td class="nump">101,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_OperatingLossCarryforwarddSubjectToExpiration', window );">Net operating loss carry forwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_OperatingLossCarryforwardsExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 31, 2023 through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carry forwards not to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000,000.0<span></span>
</td>
<td class="nump">$ 38,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_OperatingLossCarryforwardsExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 31, 2023 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_OperatingLossCarryforwarddSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_OperatingLossCarryforwarddSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_OperatingLossCarryforwardsExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Date Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_OperatingLossCarryforwardsExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Not Subject to Expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_PercentageOfNetIncomeForEachSubsequentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net income for each subsequent period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_PercentageOfNetIncomeForEachSubsequentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775913335872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Cost and expenses incurred</a></td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775914331616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2021</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 608,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Amounts paid by related party</a></td>
<td class="nump">$ 3,208,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Borrowings accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of credit facility, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The facility had an initial term of 18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Stock options exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">608,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=MYMD_MrWilliamsMember', window );">Mr Williams [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent', window );">Due to officer</a></td>
<td class="nump">14,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=MYMD_SuperaAviationILLCMember', window );">Supera Aviation I, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_AnnualLeasingFee', window );">Annual leasing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=MYMD_SuperaAviationILLCMember', window );">Supera Aviation I, LLC [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit facility expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">38 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Borrowings accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_NegotiatedSettlementMember', window );">Negotiated Settlement [Member] | Supera Aviation I, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party retired</a></td>
<td class="nump">627,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">$ 517,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MYMD_TaglichBrothersIncMember', window );">Taglich Brothers Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Amounts paid by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MYMD_TaglichBrothersIncMember', window );">Taglich Brothers Inc [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Amounts paid by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_AnnualLeasingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual leasing fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_AnnualLeasingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=MYMD_MrWilliamsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=MYMD_MrWilliamsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=MYMD_SuperaAviationILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=MYMD_SuperaAviationILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_NegotiatedSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_NegotiatedSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MYMD_TaglichBrothersIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MYMD_TaglichBrothersIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775908979184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions to employee</a></td>
<td class="nump">$ 41,443<span></span>
</td>
<td class="nump">$ 16,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=MYMD_FourZeroOneKPlanMatchesFiftyPercentMember', window );">401 K Plan Matches 50% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=MYMD_FourZeroOneKPlanMaximumFivePercentMember', window );">401 K Plan Maximum 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=MYMD_FourZeroOneKPlanMatchesFiftyPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=MYMD_FourZeroOneKPlanMatchesFiftyPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=MYMD_FourZeroOneKPlanMaximumFivePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=MYMD_FourZeroOneKPlanMaximumFivePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775919169248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Paycheck Protection Program Loan (Details Narrative) - Paycheck Protection Program Loans [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt forgiveness</a></td>
<td class="nump">$ 70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=MYMD_PaycheckProtectionProgramLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=MYMD_PaycheckProtectionProgramLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912407392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent Assignment and Royalty Agreement (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract', window );"><strong>Patent Assignment And Royalty Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139775912653568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Aug. 17, 2022</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,550,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,999,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,550,028<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,550,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to acquire common stock</a></td>
<td class="nump">6,651,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MYMD_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">14,041,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member] | Series F Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member] | Series F Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MYMD_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MYMD_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MYMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MYMD_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MYMD_InstitutionalAndAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MYMD_InstitutionalAndAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MYMD_SeriesFConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MYMD_SeriesFConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:MYMD="http://mymd.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mymd-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockNoParValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CommonStockNoParValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockNoParValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CommonStockNoParValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockNoParValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-04-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="AsOf2021-04-16_custom_MyMDPharmaceuticalsFloridaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MYMD:MyMDPharmaceuticalsFloridaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="From2021-04-122021-04-16_custom_SuperaPharmaceuticalsIncMember_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:SuperaPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-02_srt_MinimumMember_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-02_srt_MaximumMember_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="AsOf2019-07-02_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-02</instant>
        </period>
    </context>
    <context id="From2019-07-012019-07-02_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="From2018-10-202018-10-26_custom_SuperaAviationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SuperaAviationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-20</startDate>
            <endDate>2018-10-26</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-26_custom_SuperaAviationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SuperaAviationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-26</instant>
        </period>
    </context>
    <context id="From2020-11-052020-11-09_srt_MinimumMember_custom_TwoThousandTwentyBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-05</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="From2020-11-052020-11-09_srt_MaximumMember_custom_TwoThousandTwentyBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-05</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-09_custom_TwoThousandTwentyBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-09</instant>
        </period>
    </context>
    <context id="From2020-11-052020-11-09_custom_TwoThousandTwentyBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-05</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-17_custom_TwoThousandTwentyOneBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-02_custom_PlattStreetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-02_custom_PlattStreetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MYMD:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">MYMD:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PlattStreetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PlattStreetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:PlattStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SuperaAviationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SuperaAviationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandTwentyBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandTwentyOneBaltimoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:TwoThousandTwentyOneBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_HydeParkFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:HydeParkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:PreFundedWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:PreFundedWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesCPreferredConvertibleWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesCPreferredConvertibleWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesCPreferredConvertibleWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesCPreferredConvertibleWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesDPreferredConvertibleStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesDPreferredConvertibleStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesDPreferredConvertibleStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MYMD:SeriesDPreferredConvertibleStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-23_custom_CystronBiotechLLCMember_custom_MembershipInterestPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:CystronBiotechLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MembershipInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-23</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ContributionAgreementMember_custom_PremasBiotechPVTLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:ContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MYMD:PremasBiotechPVTLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-122021-04-16_custom_MergerAgreementMember_custom_PreMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:PreMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="From2021-04-122021-04-16_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-16_custom_PrefundedWarrantsMember_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="AsOf2021-04-16_custom_AkersBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-16_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-16</endDate>
        </period>
    </context>
    <context id="From2021-04-162021-04-16_custom_AkersBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">MYMD:AkersBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MilestonePeriodOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MilestonePeriodFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MilestonePeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-11</instant>
        </period>
    </context>
    <context id="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember_custom_EventOfDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">MYMD:EventOfDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-11</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">MYMD:MyMDPharmaceuticalsFloridaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">MYMD:MyMDPharmaceuticalsFloridaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:BridgeLoanNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2014-01-23_custom_TwoThousandThirteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-23</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AmendedPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AmendedPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-12-21_custom_TwoThousandAndSixteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-21</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-08-07_custom_TwoThousandAndSeventeenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-07_custom_TwoThousandAndEighteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-07</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-04-15_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-15</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_StockOptionMember98108171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-28_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-28</instant>
        </period>
    </context>
    <context id="From2022-01-272022-01-28_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-19</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-21_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="From2022-06-192022-06-21_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-19</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember98108296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2016-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="From2022-12-292022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-29</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MYMD:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MYMD:MyMDFloridaStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MYMD:MyMDFloridaStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-04-16_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MYMD:MyMDFloridaStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-10</startDate>
            <endDate>2020-09-11</endDate>
        </period>
    </context>
    <context id="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-15</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2022-01-272022-01-28_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JanuaryTwentyEightTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JanuaryTwentyEightTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-062022-07-07_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JulySevenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-07</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">MYMD:JulySevenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="From2020-03-222020-03-24_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-22</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-15_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-15</instant>
        </period>
    </context>
    <context id="AsOf2021-04-16_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="From2021-02-102021-02-11_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-10</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-11_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="From2021-05-172021-05-18_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-17</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2021-05-172021-05-18_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-17</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2021-08-042021-08-05_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="From2021-12-082021-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <startDate>2021-12-08</startDate>
            <endDate>2021-12-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="From2022-02-152022-02-16_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-16</endDate>
        </period>
    </context>
    <context id="From2022-02-152022-02-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="From2022-08-162022-08-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-08-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-062022-07-07_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-07</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-07_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-07</instant>
        </period>
    </context>
    <context id="From2022-07-062022-07-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-07</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <instant>2022-07-07</instant>
        </period>
    </context>
    <context id="AsOf2022-07-07_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-07</instant>
        </period>
    </context>
    <context id="AsOf2022-07-07_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-07</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-17_srt_MaximumMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="AsOf2022-08-17_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:SeriesCConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:SeriesCConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MYMD:SeriesCConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2017-12-292018-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2018-01-02</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-11-222020-11-23_custom_TaglichBrothersIncMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MYMD:TaglichBrothersIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-22</startDate>
            <endDate>2020-11-23</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TaglichBrothersIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MYMD:TaglichBrothersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-28_custom_MrWilliamsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:MrWilliamsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="From2018-10-012018-10-31_custom_SuperaAviationILLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SuperaAviationILLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-28_custom_SuperaAviationILLCMember_custom_NegotiatedSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:NegotiatedSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="AsOf2018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="From2018-11-012018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">MYMD:SuperaAviationILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-272021-04-28_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FourZeroOneKPlanMatchesFiftyPercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">MYMD:FourZeroOneKPlanMatchesFiftyPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FourZeroOneKPlanMaximumFivePercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">MYMD:FourZeroOneKPlanMaximumFivePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:PaycheckProtectionProgramLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-15</startDate>
            <endDate>2020-04-16</endDate>
        </period>
    </context>
    <context id="From2021-06-012021-06-01_custom_PaycheckProtectionProgramLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MYMD:PaycheckProtectionProgramLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MYMD:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001321834</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MYMD:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MYMD:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Days">
        <measure>utr:D</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001321834</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:DueToOfficersOrStockholdersCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0189">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0190">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0194">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0195">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:GrossProfit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:AccretionOfDebtDiscount
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:StockOptionModificationExpenses
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:GainOnDebtForgiveness
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0344"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ModificationTermsOfPreMergerStockOptions
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ModificationTermsOfPreMergerStockOptions
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ModificationTermsOfPreMergerStockOptions
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ModificationTermsOfPreMergerStockOptions
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfWarrantsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfWarrantsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfWarrantsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:ExerciseOfWarrantsForCommonStock
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:AccruedInterestdividends
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:GainOnForgivenessOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:StockOptionModificationExpenses
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedStockExpense
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:OtherAssetInvestment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31_custom_HydeParkFacilityMember"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2022-12-31_custom_HydeParkFacilityMember"
      id="xdx2ixbrl0742"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1002"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1004"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1006"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1008"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1010"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1012"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1014"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1016"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1018"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember"
      id="xdx2ixbrl1054">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember"
      id="xdx2ixbrl1072">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1146"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1148"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1154"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1156"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1158"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1160"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1248"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1250"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1252"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1254"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1266"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-07_us-gaap_WarrantMember"
      id="xdx2ixbrl1294">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      id="xdx2ixbrl1312"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      id="xdx2ixbrl1314"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      id="xdx2ixbrl1320"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      id="xdx2ixbrl1322"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      id="xdx2ixbrl1324"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      id="xdx2ixbrl1326"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1354"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1356"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1358"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1360"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1362"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1364"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1366"
      unitRef="Shares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1368"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1376"
      unitRef="USD"
      xsi:nil="true"/>
    <MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      id="xdx2ixbrl1384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1542"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-36268</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">MyMD Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">22-2983783</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">855                                             N. Wolfe Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite                                             601</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Baltimore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">21205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(856)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">848-8698</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Shares     of Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">MYMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">70298348</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-29" decimals="INF" unitRef="Shares">39470009</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">536</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Morison Cogen LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Blue Bell, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">749090</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">555967</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4086902</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11003071</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">565787</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1106347</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5401779</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12665385</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">139662</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">149009</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10498539</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10498539</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1500000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1500000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">12138201</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12147548</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17539980</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">24812933</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2673221</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">986626</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">29982</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">65780</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">53240</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2768983</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1039866</us-gaap:LiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">29982</us-gaap:DueToOfficersOrStockholdersNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">75941</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95911</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">75941</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">125893</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2844924</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1165759</us-gaap:Liabilities>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">211353</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">211353</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">39470009</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">39470009</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">37673110</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">37673110</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">108309436</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">102064218</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-93758904</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-78561568</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14695056</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">23647174</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17539980</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">24812933</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5520150</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6420092</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">9067422</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6745104</us-gaap:ResearchAndDevelopmentExpense>
    <MYMD:AccretionOfDebtDiscount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">608460</MYMD:AccretionOfDebtDiscount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">695191</us-gaap:ShareBasedCompensation>
    <MYMD:StockOptionModificationExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">15036051</MYMD:StockOptionModificationExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15282763</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-28809707</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">83991</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8907</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5964</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">39597</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2958</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-42793</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <MYMD:GainOnDebtForgiveness
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">180257</MYMD:GainOnDebtForgiveness>
    <MYMD:UninsuredCasualtyLosses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4442</MYMD:UninsuredCasualtyLosses>
    <MYMD:UninsuredCasualtyLosses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1265306</MYMD:UninsuredCasualtyLosses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">85427</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1079338</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-29889045</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-29889045</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">38825763</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">35017244</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">37673110</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">102064218</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-78561568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">23647174</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1411764</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">449500</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1411764</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">5550028</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5550028</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStockShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">385135</MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStockShares>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">444342</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">444342</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">165997</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">165997</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants
      contextRef="From2022-01-012022-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">84851</MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants>
    <MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">84851</MYMD:StockIssuedDuringPeriodValueCompensationOfWarrants>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">39470009</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">108309436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-93758904</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14695056</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">28553307</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">43411487</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-48672523</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-5257032</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">28553307</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">43411487</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-48672523</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-5257032</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-29889045</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-29889045</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8335627</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">42332834</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">42477358</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <MYMD:ExchangeRatioPricePerShares
      contextRef="AsOf2021-04-16"
      decimals="INF"
      unitRef="USDPShares">0.7718</MYMD:ExchangeRatioPricePerShares>
    <MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">43415491</MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare>
    <MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-4004</MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare>
    <MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-43411487</MYMD:IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare>
    <MYMD:ModificationOfPreMergerStockOptionShares
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">4188315</MYMD:ModificationOfPreMergerStockOptionShares>
    <MYMD:ModificationTermsOfPreMergerStockOptions
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">15036051</MYMD:ModificationTermsOfPreMergerStockOptions>
    <MYMD:ModificationTermsOfPreMergerStockOptions
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">15036051</MYMD:ModificationTermsOfPreMergerStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">11576</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStockShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">466716</MYMD:ExerciseOfPrepaidEquityForwardContractsForCommonStockShares>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16826</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">90002</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">90002</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <MYMD:ExerciseOfWarrantsForCommonStockShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">289058</MYMD:ExerciseOfWarrantsForCommonStockShares>
    <MYMD:ExerciseOfWarrantsForCommonStock
      contextRef="From2021-01-012021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">1189840</MYMD:ExerciseOfWarrantsForCommonStock>
    <MYMD:ExerciseOfWarrantsForCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1189840</MYMD:ExerciseOfWarrantsForCommonStock>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">37673110</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">102064218</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-78561568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">23647174</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">144524</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">37673110</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockNoParValueMember"
      decimals="0"
      unitRef="USD">102064218</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-78561568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">23647174</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-29889045</us-gaap:NetIncomeLoss>
    <MYMD:AccruedInterestdividends
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3024</MYMD:AccruedInterestdividends>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">608460</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5964</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">39597</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <MYMD:MarketableSecuritiesUnrealizedLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2958</MYMD:MarketableSecuritiesUnrealizedLoss>
    <MYMD:MarketableSecuritiesUnrealizedLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">42793</MYMD:MarketableSecuritiesUnrealizedLoss>
    <MYMD:GainOnForgivenessOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">180258</MYMD:GainOnForgivenessOfDebt>
    <MYMD:StockOptionModificationExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">15036051</MYMD:StockOptionModificationExpenses>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">338922</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">105420</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">90002</us-gaap:StockOptionPlanExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">84851</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:RestrictedStockExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">165997</us-gaap:RestrictedStockExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-540560</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">912815</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1686595</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4268961</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1917</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-81</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12270068</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-19516475</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4836837</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">13403</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">11750000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">18483176</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1380852</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">6913163</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19850625</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3062444</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1826137</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5550028</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1189840</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5550028</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">73533</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">193123</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">407683</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">555967</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">148284</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">749090</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">555967</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">13322</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">271800</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">53196</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">141387</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <MYMD:OtherAssetInvestment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1500000</MYMD:OtherAssetInvestment>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zxTLcVBJ0tBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_826_zTzVHhwIEHw9"&gt;Organization and Description of Business&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MyMD
Pharmaceuticals, Inc., previously known as Akers Biosciences, Inc., is a New Jersey corporation (&#x201c;MyMD&#x201d;). These consolidated
financial statements include four wholly owned subsidiaries as of December 31, 2022, MyMD Pharmaceuticals (Florida), Inc. (&#x201c;MyMD
Florida&#x201d;), XYZ Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;), Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation, (together,
the &#x201c;Company&#x201d;). All material intercompany transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MyMD
Florida was formed in 2014 and is a Florida-based clinical development stage biopharmaceutical company that is developing its product
candidate, MYMD-1, as an immuno regulator to treat autoimmune diseases, ageing-related diseases. Substantive operations began in 2016
and the Company&#x2019;s Investigative New Drug application was filed with the U.S. Food and Drug Administration in December 2018. MyMD
Florida completed its first-in-human Phase 1 clinical trial in December 2019. A second Phase 1 dosing study was completed in December
2021. MYMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release
of numerous pro-inflammatory cytokines, such as TNF-&#x3b1;, interleukin 6 (&#x201c;IL-6&#x201d;) and interleukin 17 (&#x201c;IL-17&#x201d;).
MYMD-1 currently is being evaluated in a multicenter Phase 2 clinical trial in patients with sarcopenia and frailty (age-related muscle
loss). MyMD Florida&#x2019;s intellectual property portfolio consists of 16 U.S. granted patents, 15 granted foreign patents and 19 pending
applications (3 US, 16 foreign).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supera
Pharmaceuticals, Inc. (&#x201c;Supera&#x201d;) was formed in September 2018 and is a Florida based development company that is developing
its product candidate &#x201c;Supera-CBD&#x201d; as an FDA-approved synthetic analog of naturally grown cannabidiols. Substantially all
of Supera&#x2019;s research and development activities in 2020 and 2021 were related to intellectual property development and securing
patents, along with product manufacturing and planning initial pre-clinical development activities. During the year ended December 31,
2021, these activities included preclinical work on Supera-CBD confirming it effectiveness in treating anxiety. The preclinical data
was presented at the 4&lt;sup&gt;th&lt;/sup&gt; Annual International Cannabinoid Summit describing the superior potency of Supera-CBD. Supera-CBD
preclinical genotoxicity studies were completed in February 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 16, 2021, pursuant to the previously announced Agreement and Plan of Merger and Reorganization, dated November 11, 2020 (the
&#x201c;Original Merger Agreement&#x201d;), as amended by Amendment No. 1 thereto, dated March 16, 2021 the Original Merger Agreement,
as amended by Amendment No. 1 (the &#x201c;Merger Agreement&#x201d;), by and among MyMD, Merger Sub and MyMD Florida, Merger Sub was
merged with and into MyMD Florida, with MyMD Florida continuing after the merger as the surviving entity and a wholly owned
subsidiary of MyMD (the &#x201c;Merger&#x201d;). At the effective time of the Merger, without any action on the part of any
stockholder, each issued and outstanding share of pre-Merger MyMD Florida&#x2019;s Common Stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210416__dei--LegalEntityAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zNS7l0hS7sP9" title="Common Stock, par value"&gt;0.001&lt;/span&gt;
per share (the &#x201c;MyMD Florida Common Stock&#x201d;), including shares underlying pre-Merger MyMD Florida&#x2019;s outstanding
equity awards, was converted into the right to receive (x) &lt;span id="xdx_904_ecustom--ExchangeRatioPricePerShares_iI_c20210416__dei--LegalEntityAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zKCdjKC3jD72" title="Exchange ratio price per shares"&gt;0.7718&lt;/span&gt;
shares (the &#x201c;Exchange Ratio&#x201d;) of MyMD&#x2019;s Common Stock, no par value per share (the &#x201c;Company Common
Stock&#x201d; or &#x201c;Common Stock&#x201d;), (y) an amount in cash, on a pro rata basis, equal to the aggregate cash proceeds received by the Company from the
exercise of any options to purchase shares of MyMD Florida Common Stock outstanding at the effective time of the Merger assumed by
the Company upon closing of the Merger prior to the second-year anniversary of the closing of the Merger (the &#x201c;Option Exercise
Period&#x201d;), such payment (the &#x201c;Additional Consideration&#x201d;), and (z) potential milestone payment in shares of Company
Common Stock up to the aggregate number of shares issued by the Company to pre-Merger MyMD Florida stockholders at the closing of
the Merger (the &#x201c;Milestone Payments&#x201d;) payable upon the achievement of certain market capitalization milestone events
during the 36-month period immediately following the closing of the Merger (the &#x201c;Milestone Period&#x201d;). Immediately
following the effective time of the Merger, the Company effected a 1-for-2 reverse stock split of the issued and outstanding Company
Common Stock (the &#x201c;Reverse Stock Split&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 16, 2021, MyMD Florida entered into an Asset Purchase Agreement with Supera, a related company through common control, in which
Supera was acquired by MyMD Florida through the issuance of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--SuperaPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zOiuRU33FyH" title="Stock issued during period, shares, acquisitions"&gt;33,937,909&lt;/span&gt; shares of pre-Merger MyMD Florida Common Stock. The Supera
entity was dissolved pursuant to this transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the closing of the Merger, the Company changed its name
to MyMD Pharmaceuticals, Inc. and the Company Common Stock, listed previously trading through the close of business on April 16, 2021
under the trading symbol &#x201c;AKER&#x201d;, commenced trading on The Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis,
under the trading symbol &#x201c;MYMD&#x201d; on April 19, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 8, 2022&#160;, the MyMD Florida subsidiary was dissolved and merged into the New Jersey corporation MyMD Pharmaceuticals, Inc.
pursuant to an Agreement and Plan of Merger dated April 8, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-04-16_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <MYMD:ExchangeRatioPricePerShares
      contextRef="AsOf2021-04-16_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="INF"
      unitRef="USDPShares">0.7718</MYMD:ExchangeRatioPricePerShares>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2021-04-122021-04-16_custom_SuperaPharmaceuticalsIncMember_custom_AssetPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">33937909</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zW0BikXhfmdk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_828_zqI9LcEqYod5"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkmU3qnbJNQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)
&lt;span id="xdx_86B_zK6C0KSyZTn1"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally
accepted in the United States of America (US GAAP).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company effected a &lt;span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zXdssfkOSpne" title="Reverse stock split"&gt;1-for-2 reverse stock split&lt;/span&gt; immediately following the effective time of the Merger. No fractional shares were issued
in connection with the Reverse Stock Split. Each stockholder who did not have a number of shares evenly divisible pursuant to the Reverse
Stock Split ratio and who would otherwise be entitled to receive a fractional share of Company Common Stock was entitled to receive an
additional share of Company Common Stock. The number of shares on equity related disclosures included in this Annual Report on Form
10-K, including the consolidated financial statements and accompanying notes, were retroactively adjusted to reflect the effects
of the Reverse Stock Split and the Exchange Ratio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zitK6G4H5AMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)
&lt;span id="xdx_861_zdVe4a17sanl"&gt;Use of Estimates and Judgments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that
affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ
from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation,
uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in
the financial statements is included in the following notes for recording research and development expenses, impairment of intangible
assets and the valuation of share-based payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zkvkpJ9bLyAd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)
&lt;span id="xdx_863_zivmKWz9RRna"&gt;Functional and Presentation Currency&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These consolidated financial statements are presented in U.S. Dollars, which is the Company&#x2019;s functional currency. All financial
information has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated
in Foreign Currencies, are recorded in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zGYMLK4EOk27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(d)
&lt;span id="xdx_86D_z0DG4sjMaICg"&gt;Comprehensive Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows Financial Accounting Standards Board Accounting Standards Codification (&#x201c;FASB ASC&#x201d;) 220 in reporting comprehensive
loss. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information
that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income
(loss), comprehensive loss is equal to net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zECjbfjPZ8v8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(e)
&lt;span id="xdx_86B_zWALoFqnF9a"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that
are not restricted as to withdrawal date or use, to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7to1s1s5s2a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(f)
&lt;span id="xdx_86A_zT1m60PGwzpg"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables.
The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their
short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are
described as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company
    can access.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the valuation methodology include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;quoted
    prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;quoted
    prices for identical or similar assets or liabilities in inactive markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs
    other than quoted prices that are observable for the asset or liability;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs
    that are derived principally from or corroborated by observable market data by correlation or other means&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
    the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of
    the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
asset or liability&#x2019;s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is
significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of
unobservable inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(f)
Fair Value of Financial Instruments, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zePSfj8Avsca"&gt;Schedule
of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Marketable
Securities:&lt;/i&gt; Valued using quoted prices in active markets for identical assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant
    Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,086,902&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,003,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zNrXGEf2wrHg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
securities are classified as available for sale and are valued at fair market value. Maturities of the securities are less than one year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the Company held certain mutual funds, which, under FASB ASC 321-10, were considered equity
investments. As such, the change in fair value in the year ended December 31, 2022 and 2021 was a gain of $&lt;span id="xdx_907_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_zctD79SBIhmg" title="Unrealized (gain)/loss on marketable securities"&gt;2,958&lt;/span&gt;
and a loss of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_z2GifEoTIlXd" title="Unrealized (gain)/loss on marketable securities"&gt;42,793&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses resulting from the sales of marketable securities were losses of $&lt;span id="xdx_904_eus-gaap--MarketableSecuritiesRealizedGainLoss_iN_di_c20220101__20221231_zyRZ8Lr5LD26" title="Gain/loss on sale of marketable securities"&gt;5,964&lt;/span&gt; and gains of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20210101__20211231_zGhwhueFBAd2" title="Gain/loss on sale of marketable securities"&gt;39,597&lt;/span&gt; for the years ended December
31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
from the sales of marketable securities were $&lt;span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20220101__20221231_zpI1TG3QqZRa" title="Proceeds from the sales of marketable securities"&gt;11,750,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20211231_zj6x4w1Pb0R1" title="Proceeds from the sales of marketable securities"&gt;18,483,176&lt;/span&gt; in the years ended December 31, 2022 and 2021, respectively.
Purchases of marketable securities were $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireMarketableSecurities_c20220101__20221231_z5v6kEXs9f41" title="Purchase of marketable securities"&gt;4,836,837&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--PaymentsToAcquireMarketableSecurities_c20210101__20211231_z9ETZImwdjKc" title="Purchase of marketable securities"&gt;13,403&lt;/span&gt; during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--PrepaidExpensesPolicyTextBlock_zEXSDCVqVF4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(g)
&lt;span id="xdx_865_z0t40pOFMOdh"&gt;Prepaid Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses represent expenses paid prior to the date that the related services are rendered or used are comprised principally of prepaid
insurance and research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zw5YAmiRVZPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(h)
&lt;span id="xdx_864_zpAtJtp7O5tk"&gt;Concentrations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial
institutions and accounts receivable. At times, the Company&#x2019;s cash in banks is in excess of the FDIC insurance limit. The Company
has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of December 31,
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--RiskManagementOfCashInvestmentsPolicyTextBlock_zcaEdiCpaNg9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(i)
&lt;span id="xdx_862_zUAivk8x7WY8"&gt;Risk Management of Cash and Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
is the Company&#x2019;s policy to minimize the Company&#x2019;s capital resources to investment risks, prioritizing the preservation of
capital over investment returns. Investments are maintained in securities, primarily publicly traded, short-term money market funds based
on highly rated federal, state and corporate bonds, that minimize the risk to the Company&#x2019;s capital resources and provide ready
access to funds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s investment portfolios are regularly monitored for risk and are held with one brokerage firm.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_zBGp5lXsQcn6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(j)
&lt;span id="xdx_867_zwGzmjRwRRr3"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other
than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company&#x2019;s
ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for
using the cost method to the equity method of valuation in accordance with FASB ASC 323.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company&#x2019;s ability to significantly
influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the
time of the investment based upon several factors including, but not limited to the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Representation
    on the Board of Directors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Participation
    in policy-making processes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Material
    intra-entity transactions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interchange
    of management personnel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Technological
    dependencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Extent
    of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational
and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the
cost method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In accordance with FASB ASC 321-10-35-2, the Company has elected to measure
its investment in Oravax Medical, Inc. (&#x201c;Oravax&#x201d;) (Note 3) as an equity security without a readily determinable fair value.
Under this election, an equity security without a readily available fair value is reflected at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
At each reporting period, the Company is required to make a qualitative assessment considering impairment indicators to evaluate whether
the investment is impaired. If deemed impaired, the Company is required to estimate the fair value of the investment and recognize an
impairment loss equal to the difference between the fair value of the investment and its carry amount. As of December 31, 2022, the Company
performed a qualitative assessment to evaluate whether the investment is impaired and determined that the investment was not impaired
and thus no adjustment to fair market value was required as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zs5s0t7t55Se" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(k)
&lt;span id="xdx_86A_zwcA9esYL5El"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, plant and equipment and are recognized within &#x201c;other (income)/expense&#x201d; in the Consolidated
Statements of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is recognized over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of
the lease term or their useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives for the current and comparative periods are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zs65nJ7AflJl"&gt;Schedule
of Estimated Useful Lives of Property Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
    years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment &amp;amp; software&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives"&gt;Shorter of the remaining
    lease or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zsRLLYi1iiY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
methods, useful lives and residual values are reviewed at each reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8iJ02grMFA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(l)
&lt;span id="xdx_868_zWIJmvX69zU4"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate
there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets
not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount,
other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge in the Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patents
and Trade Secrets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Propriety
protection for the Company&#x2019;s products, technology and process is important to its competitive position. As of December 31, 2022,
the Company has 16 issued U.S. patents, 50 foreign patents, four pending U.S. patent applications and 15 foreign patent applications
pending in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea, which if issued are expected
to expire between 2036 and 2041. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade
secrets) using all legal remedies available to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records expenses related to the application for and maintenance of patents as a component of research and development expenses
on the Consolidated Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patent
Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic
benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life and assessed for impairment when necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Intangible Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization
and accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amortization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zTy2vgZzxaS3" style="display: none"&gt;Schedule of Estimated Useful Lives of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
    years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
    and trademarks&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives"&gt;12&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_ztE2JQSh464l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z48w7DnfUcCb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(m)
&lt;span id="xdx_86E_zYGyDOVSEZG3"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is evaluated annually for impairment or whenever we identify certain triggering events or circumstances that would more likely than not
reduce the fair value below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include,
among other things, unexpected adverse business conditions, economic factors (for example, the loss of key personnel), supply costs,
unanticipated competitive activities, and acts by governments and courts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_zT9j3kHsrBL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(n)
&lt;span id="xdx_861_zXuh6y5Q4Z46"&gt;Recoverability of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB ASC 360-10-35 &#x201c;Impairment or Disposal of Long-lived Assets&#x201d;, long-lived assets to be held and used are
analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable
or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and
circumstances have occurred that indicate possible impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges)
and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by
which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the
lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying
amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce
the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--RightOfUseAssetsPolicyTextBlock_zPO69ayfdMkj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(o)
&lt;span id="xdx_86E_zZdGfl5apCMh"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased a facility in Tampa, Florida (&#x201c;Hyde Park&#x201d;) under an operating lease (&#x201c;Hyde Park Lease&#x201d;) with annual
rentals of $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z5gXmVY3O0hi" title="Payments for Rent"&gt;22,048&lt;/span&gt; to $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zcYov0cps7ya" title="Payments for Rent"&gt;23,320&lt;/span&gt; plus certain operating expenses. The Hyde Park facility housed the MyMD Florida operations. The Hyde Park
Lease took effect on July 1, 2019 for a term of &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zhkNz0gLpuz6" title="Lessee, operating lease, term of contract"&gt;36&lt;/span&gt; months to expire on &lt;span id="xdx_90E_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20190701__20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z2htao554bs8" title="Lease expiration date"&gt;June 30, 2022&lt;/span&gt;. The Company cancelled the Hyde Park lease in March
2022 without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased an aircraft under an operating lease (&#x201c;Supera Aviation Lease&#x201d;) with annual rentals of $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20181020__20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zo4CJ5rwsPLb" title="Payments for Rent"&gt;600,000&lt;/span&gt; plus certain
operating expenses. The Supera Aviation Lease took effect on October 26, 2018 for a term of &lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zE0qgmlf4I4h" title="Lessee, operating lease, term of contract"&gt;36&lt;/span&gt; months to expire on September 26, 2021.
The Company cancelled the Supera Aviation Lease in April 2021 without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased a facility in Baltimore, Maryland (&#x201c;2020 Wolfe St&#x201d;) under an operating lease (&#x201c;2020 Baltimore Lease&#x201d;)
with annual rentals of $&lt;span id="xdx_90F_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zb3FRNgbwJah" title="Payments for Rent"&gt;24,000&lt;/span&gt; to $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zl95SSVy0kS1" title="Payments for Rent"&gt;25,462&lt;/span&gt; plus certain operating expenses. The 2020 Baltimore Lease took effect on November 9, 2020 for
a term of &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zfTeYsV7SaJd" title="Lessee, operating lease, term of contract"&gt;12&lt;/span&gt; months with automatic renewals unless a sixty-day notice was provided. The initial term expired on &lt;span id="xdx_90B_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20201105__20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_z3I38lbOJec5" title="Lease expiration date"&gt;November 30, 2021&lt;/span&gt;. On
November 17, 2021, the 2020 Baltimore Lease was cancelled without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases a facility in Baltimore, Maryland (&#x201c;2021 Wolfe St&#x201d;) under an operating lease (&#x201c;2021 Baltimore
Lease&#x201d;) with annual rentals of $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MinimumMember_zfuZTDSVVlR8" title="Payments for rent"&gt;52,800&lt;/span&gt;
to $&lt;span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MaximumMember_zYs1H5BkXeWd" title="Payments for rent"&gt;56,016&lt;/span&gt;
plus certain operating expenses. The 2021 Baltimore Lease took effect on November 17, 2021 for a term of &lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zljWYGaAuPp" title="Lessee operating lease term of contract"&gt;12&lt;/span&gt;
months with automatic renewals unless a sixty-day notice is provided. The initial term expires on &lt;span id="xdx_90C_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zILO0WYY40v6" title="Expiration date"&gt;November
30, 2022&lt;/span&gt;. The lease renewed effective December 1, 2022 for a term of &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20221201_zaWttHsZO1Ha" title="Lessee operating lease renewal term"&gt;12&lt;/span&gt; months with automatic renewals unless a sixty-day notice
is provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases a facility in Tampa, Florida (&#x201c;Platt St&#x201d;) under an operating lease (&#x201c;Platt Street Lease&#x201d;) with
annual rentals of $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MinimumMember_z15D2sxrM7xd" title="Payments for Rent"&gt;22,030&lt;/span&gt; to $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MaximumMember_zYXFjtctPI8e" title="Payments for rent"&gt;23,259&lt;/span&gt; plus certain operating expenses. The Platt Street Lease took effect on April 1, 2022 for a term
of &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zsv3fWf9Zku" title="Term of contract"&gt;36&lt;/span&gt; months. The initial term expires on &lt;span id="xdx_903_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z72rUefeJsWk" title="Lease expiration date"&gt;March 31, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2019 (&#x201c;Effective Date&#x201d;), the Company adopted FASB ASC, Topic 842, Leases (&#x201c;ASC 842&#x201d;), which increases
transparency and comparability by recognizing a lessee&#x2019;s rights and obligations resulting from leases by recording them on the
balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (&#x201c;ROU&#x201d;)
assets and related operating and finance lease liabilities on the balance sheet. The Company adopted the new guidance using the modified
retrospective approach on January 1, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company elected the package of practical expedients permitted within the standard, which allows an entity to forgo reassessing (i) whether
a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition
of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and
impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has
also elected the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any
lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
contracts entered into on or after the Effective Date, at the inception of a contract, the Company will assess whether the contract is,
or contains, a lease. The Company&#x2019;s assessment is based on: (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtained the right to substantially all the economic benefit from the use of the asset throughout the
period, and (iii) whether the Company has the right to direct the use of the asset. Leases entered into prior to January 1, 2020, which
were accounted for under ASC 840, were not reassessed for classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The Company
generally uses its incremental borrowing rate as the discount rate for leases, unless an interest rate is implicitly stated in the lease.
The present value of the lease payments is calculated using the incremental borrowing rate for operating leases, which was determined
using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term. The lease term for all the Company&#x2019;s leases includes the non-cancellable period
of the lease plus any additional periods covered by either a Company option to extend the lease that the Company is reasonably certain
to exercise, or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis
over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zv4QhUpqTiz4" style="display: none"&gt;Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt Street&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Hyde
                                                                                         Park&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Right
    of Use&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94,309&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;139,662&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,156&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Payable, current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,780&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,164&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,076&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53,240&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Payable - net of
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,070&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,941&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zEOBmg0vkU17" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following provides details of the Company&#x2019;s lease expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zGRbxhBgiqMd" style="display: none"&gt;Schedule of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Hyde Park&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Platt Street&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Supera Aviation&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Hyde Park&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease Expenses&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;Lease Costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,981&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;54,400&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;77,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,533&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202,226&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AF_zu8WgHFyEU2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zTbeKs7NCWTd" style="display: none"&gt;Schedule of Other Information Related to Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Hyde&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    Information&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Park
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Street
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating cash
    used&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,622&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,628&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,602&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,852&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average remaining lease
    term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zDSTRTFLYxp9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the annual minimum lease payments of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z418TRZZeYi" style="display: none"&gt;Schedule of Operating Lease Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Street
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,485&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,005&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,103&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,814&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,814&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,868&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;157,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,591&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,958&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,549&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of future
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,811&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,910&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,721&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z9Pn8x1uCzk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zV1OPgbYY9Ac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(p)
&lt;span id="xdx_8B3_z0X56l1bZbzi"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will recognize revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that
a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services
transferred to the customer. The following five steps are applied to achieve that core principle:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the contract with the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine
    the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate
    the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize
    revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zFd0LdHOkWhh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(q)
&lt;span id="xdx_866_zPNtZrlB5KGg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#x2019;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management&#x2019;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax benefits are
recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized
is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#x201c;unrecognized
tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and
measurement standards. For the years ended December 31, 2022 and 2021, no liability for unrecognized tax benefits was required to be
reported.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was no income tax benefit recorded for the losses for the years ended December 31, 2022 and 2021 since management determined that the
realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on
the net deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax years from 2019 through 2022 remain
subject to examination by federal and state jurisdictions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zSFd7GSZQV6i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(r)
&lt;span id="xdx_869_zJi0VKddkhRa"&gt;Basic and Diluted Earnings per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings
per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the
period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 375.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
net loss per share is computed using the weighted average number of shares of Common Stock and dilutive potential Common Stock outstanding
during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company reported a net loss for the years ended December 31, 2022 and 2021, Common Stock equivalents were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zAXNur76ujuj" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;For
    the Years Ended &lt;br/&gt; December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,376,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,176,739&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Unvested Restricted Stock Units&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,795,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,795,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,074,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;520,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series C Preferred Convertible Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series D Preferred Convertible Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    potentially dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,885,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,630,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zu08y11WuaG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzGyNqd81XN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(s)
&lt;span id="xdx_86E_zGEQBYKSKSgd"&gt;Stock-based Payments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) 718, &#x201c;Compensation - Stock Compensation&#x201d;, which requires the measurement and recognition of compensation
expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates
the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is
ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In June 2018,
the FASB issued ASU No. 2018-07, Compensation &#x2013; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment
Accounting (the &#x201c;2018 Update&#x201d;). The amendments in the 2018 Update expand the scope of Topic 718 to include share-based payment
transactions for acquiring goods and services from nonemployees. Prior to the 2018 Update, Topic 718 applied only to share-based transactions
to employees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards
within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when
the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the
instruments have been satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected to account for forfeiture of stock-based awards as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zawq1TKJXW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;(t) &lt;span id="xdx_86C_z2UTNbnIjANg"&gt;Research and Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with FASB ASC 730, research and development costs are expensed
as incurred and consist of fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s
behalf.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zb2UcIdCu8jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(u)
&lt;span id="xdx_861_z1m1wXwiQfC4"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2017, FASB issued ASU 2017-11, Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and
Hedging (Topic 815): The new guidance amends ASC 815 to exclude consideration of a down-round feature in the evaluation of whether an
instrument is indexed to an entity&#x2019;s own stock under ASC 815-40-15-7C. That is, a down-round provision would not preclude an entity
from concluding that an instrument or feature that includes a down-round feature is indexed to the entity&#x2019;s own stock. This guidance
applies to both freestanding financial instruments and embedded conversion options (e.g., in convertible instruments with beneficial
conversion features (BCFs) or cash conversion features (CCFs)). The ASU is effective for annual reporting periods beginning after December
15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this standard did not have a material impact on their
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, FASB issued ASU 2020-06, &lt;i&gt;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013;
Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own
Equity&lt;/i&gt;. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer&#x2019;s accounting for convertible debt instruments. The new
guidance removes from U.S. GAAP the separation models for (1) convertible debt with a CCF and (2) convertible instruments with a BCF.
As a result, after adopting the ASU&#x2019;s guidance, entities will not separately present in equity an embedded conversion feature in
such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as
preferred stock. This ASU is effective for fiscal years beginning after December 15, 2021 and early adoption is allowed. The Company
early adopted this guidance as of January 1, 2021. The adoption of this standard did not have a material impact on their consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50),
Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40),
Issuer&#x2019;s Accounting for Certain Modifications or Exchanges or Freestanding Equity - Classified Written Call Options. &lt;/i&gt;The amendments
in this Update clarify an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity - classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments are effective for all entities for
fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments
prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for
all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this Update in an interim
period, the guidance should be applied as of the beginning of the fiscal year that includes the interim period. The adoption of this
ASU had no material impact on the Company&#x2019;s consolidated financial statements and related disclosure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements Not Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial
Instruments (&#x201c;ASU-2016-13&#x201d;). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets
that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred
losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2022, including interim periods
within that fiscal year. The Company expects that there would be no material impact on the Company&#x2019;s consolidated financial
statements upon the adoption of this ASU.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_858_zag03Euhqlva" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkmU3qnbJNQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)
&lt;span id="xdx_86B_zK6C0KSyZTn1"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally
accepted in the United States of America (US GAAP).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company effected a &lt;span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zXdssfkOSpne" title="Reverse stock split"&gt;1-for-2 reverse stock split&lt;/span&gt; immediately following the effective time of the Merger. No fractional shares were issued
in connection with the Reverse Stock Split. Each stockholder who did not have a number of shares evenly divisible pursuant to the Reverse
Stock Split ratio and who would otherwise be entitled to receive a fractional share of Company Common Stock was entitled to receive an
additional share of Company Common Stock. The number of shares on equity related disclosures included in this Annual Report on Form
10-K, including the consolidated financial statements and accompanying notes, were retroactively adjusted to reflect the effects
of the Reverse Stock Split and the Exchange Ratio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-01-01to2022-12-31">1-for-2 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zitK6G4H5AMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)
&lt;span id="xdx_861_zdVe4a17sanl"&gt;Use of Estimates and Judgments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that
affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ
from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation,
uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in
the financial statements is included in the following notes for recording research and development expenses, impairment of intangible
assets and the valuation of share-based payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zkvkpJ9bLyAd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)
&lt;span id="xdx_863_zivmKWz9RRna"&gt;Functional and Presentation Currency&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These consolidated financial statements are presented in U.S. Dollars, which is the Company&#x2019;s functional currency. All financial
information has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated
in Foreign Currencies, are recorded in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zGYMLK4EOk27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(d)
&lt;span id="xdx_86D_z0DG4sjMaICg"&gt;Comprehensive Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows Financial Accounting Standards Board Accounting Standards Codification (&#x201c;FASB ASC&#x201d;) 220 in reporting comprehensive
loss. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information
that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income
(loss), comprehensive loss is equal to net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zECjbfjPZ8v8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(e)
&lt;span id="xdx_86B_zWALoFqnF9a"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that
are not restricted as to withdrawal date or use, to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7to1s1s5s2a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(f)
&lt;span id="xdx_86A_zT1m60PGwzpg"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables.
The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their
short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are
described as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company
    can access.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the valuation methodology include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;quoted
    prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;quoted
    prices for identical or similar assets or liabilities in inactive markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs
    other than quoted prices that are observable for the asset or liability;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs
    that are derived principally from or corroborated by observable market data by correlation or other means&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
    the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of
    the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
asset or liability&#x2019;s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is
significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of
unobservable inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(f)
Fair Value of Financial Instruments, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zePSfj8Avsca"&gt;Schedule
of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Marketable
Securities:&lt;/i&gt; Valued using quoted prices in active markets for identical assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant
    Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,086,902&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,003,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zNrXGEf2wrHg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
securities are classified as available for sale and are valued at fair market value. Maturities of the securities are less than one year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the Company held certain mutual funds, which, under FASB ASC 321-10, were considered equity
investments. As such, the change in fair value in the year ended December 31, 2022 and 2021 was a gain of $&lt;span id="xdx_907_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_zctD79SBIhmg" title="Unrealized (gain)/loss on marketable securities"&gt;2,958&lt;/span&gt;
and a loss of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--MutualFundMember_z2GifEoTIlXd" title="Unrealized (gain)/loss on marketable securities"&gt;42,793&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses resulting from the sales of marketable securities were losses of $&lt;span id="xdx_904_eus-gaap--MarketableSecuritiesRealizedGainLoss_iN_di_c20220101__20221231_zyRZ8Lr5LD26" title="Gain/loss on sale of marketable securities"&gt;5,964&lt;/span&gt; and gains of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20210101__20211231_zGhwhueFBAd2" title="Gain/loss on sale of marketable securities"&gt;39,597&lt;/span&gt; for the years ended December
31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
from the sales of marketable securities were $&lt;span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20220101__20221231_zpI1TG3QqZRa" title="Proceeds from the sales of marketable securities"&gt;11,750,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20211231_zj6x4w1Pb0R1" title="Proceeds from the sales of marketable securities"&gt;18,483,176&lt;/span&gt; in the years ended December 31, 2022 and 2021, respectively.
Purchases of marketable securities were $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireMarketableSecurities_c20220101__20221231_z5v6kEXs9f41" title="Purchase of marketable securities"&gt;4,836,837&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--PaymentsToAcquireMarketableSecurities_c20210101__20211231_z9ETZImwdjKc" title="Purchase of marketable securities"&gt;13,403&lt;/span&gt; during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_z8No9qmbRvqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2022 and December
31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zePSfj8Avsca"&gt;Schedule
of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Marketable
Securities:&lt;/i&gt; Valued using quoted prices in active markets for identical assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted
    Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted
    Prices for Similar Assets or Liabilities in Active Markets (Level 2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant
    Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj3lWZ7nMBeh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,086,902&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zztfrj6jgBAl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zShk8LKM8xr5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Marketable securities"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9bz3agyiZK6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,003,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zee3Ecbc2bw4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">4086902</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">11003071</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-012022-12-31_us-gaap_MutualFundMember"
      decimals="0"
      unitRef="USD">2958</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31_us-gaap_MutualFundMember"
      decimals="0"
      unitRef="USD">42793</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5964</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">39597</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">11750000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">18483176</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4836837</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">13403</us-gaap:PaymentsToAcquireMarketableSecurities>
    <MYMD:PrepaidExpensesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_ecustom--PrepaidExpensesPolicyTextBlock_zEXSDCVqVF4e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(g)
&lt;span id="xdx_865_z0t40pOFMOdh"&gt;Prepaid Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses represent expenses paid prior to the date that the related services are rendered or used are comprised principally of prepaid
insurance and research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MYMD:PrepaidExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zw5YAmiRVZPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(h)
&lt;span id="xdx_864_zpAtJtp7O5tk"&gt;Concentrations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial
institutions and accounts receivable. At times, the Company&#x2019;s cash in banks is in excess of the FDIC insurance limit. The Company
has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of December 31,
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <MYMD:RiskManagementOfCashInvestmentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--RiskManagementOfCashInvestmentsPolicyTextBlock_zcaEdiCpaNg9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(i)
&lt;span id="xdx_862_zUAivk8x7WY8"&gt;Risk Management of Cash and Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
is the Company&#x2019;s policy to minimize the Company&#x2019;s capital resources to investment risks, prioritizing the preservation of
capital over investment returns. Investments are maintained in securities, primarily publicly traded, short-term money market funds based
on highly rated federal, state and corporate bonds, that minimize the risk to the Company&#x2019;s capital resources and provide ready
access to funds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s investment portfolios are regularly monitored for risk and are held with one brokerage firm.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</MYMD:RiskManagementOfCashInvestmentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_zBGp5lXsQcn6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(j)
&lt;span id="xdx_867_zwGzmjRwRRr3"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other
than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company&#x2019;s
ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for
using the cost method to the equity method of valuation in accordance with FASB ASC 323.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company&#x2019;s ability to significantly
influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the
time of the investment based upon several factors including, but not limited to the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Representation
    on the Board of Directors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Participation
    in policy-making processes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Material
    intra-entity transactions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interchange
    of management personnel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Technological
    dependencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Extent
    of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational
and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the
cost method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In accordance with FASB ASC 321-10-35-2, the Company has elected to measure
its investment in Oravax Medical, Inc. (&#x201c;Oravax&#x201d;) (Note 3) as an equity security without a readily determinable fair value.
Under this election, an equity security without a readily available fair value is reflected at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
At each reporting period, the Company is required to make a qualitative assessment considering impairment indicators to evaluate whether
the investment is impaired. If deemed impaired, the Company is required to estimate the fair value of the investment and recognize an
impairment loss equal to the difference between the fair value of the investment and its carry amount. As of December 31, 2022, the Company
performed a qualitative assessment to evaluate whether the investment is impaired and determined that the investment was not impaired
and thus no adjustment to fair market value was required as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zs5s0t7t55Se" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(k)
&lt;span id="xdx_86A_zwcA9esYL5El"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, plant and equipment and are recognized within &#x201c;other (income)/expense&#x201d; in the Consolidated
Statements of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is recognized over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of
the lease term or their useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives for the current and comparative periods are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zs65nJ7AflJl"&gt;Schedule
of Estimated Useful Lives of Property Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
    years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment &amp;amp; software&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives"&gt;Shorter of the remaining
    lease or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zsRLLYi1iiY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
methods, useful lives and residual values are reviewed at each reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <MYMD:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89F_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_zXWNYZKgDiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives for the current and comparative periods are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zs65nJ7AflJl"&gt;Schedule
of Estimated Useful Lives of Property Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
    years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcRSKCAh0B59" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_za3Ub9BRz203" title="Property, plant and equipment, useful lives"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zPIkCJqTlx1e" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_znET3G9J5caj" title="Property, plant and equipment, useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment &amp;amp; software&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zA5E494Ersad" title="Property, plant and equipment, useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMtYpXYfkWj5" title="Property, plant and equipment, useful lives"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z2qh5A4FoIWb" title="Property, plant and equipment, useful lives"&gt;Shorter of the remaining
    lease or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MYMD:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MaximumMember">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">Shorter of the remaining
    lease or estimated useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8iJ02grMFA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(l)
&lt;span id="xdx_868_zWIJmvX69zU4"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate
there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets
not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount,
other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge in the Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patents
and Trade Secrets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Propriety
protection for the Company&#x2019;s products, technology and process is important to its competitive position. As of December 31, 2022,
the Company has 16 issued U.S. patents, 50 foreign patents, four pending U.S. patent applications and 15 foreign patent applications
pending in such jurisdictions as Australia, Canada, China, European Union, Israel, Japan and South Korea, which if issued are expected
to expire between 2036 and 2041. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade
secrets) using all legal remedies available to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records expenses related to the application for and maintenance of patents as a component of research and development expenses
on the Consolidated Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patent
Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic
benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life and assessed for impairment when necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Intangible Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization
and accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amortization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zTy2vgZzxaS3" style="display: none"&gt;Schedule of Estimated Useful Lives of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
    years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
    and trademarks&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives"&gt;12&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_ztE2JQSh464l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <MYMD:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock_zia3M0Pgs533" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that
they are available for use. The estimated useful lives for the current and comparative periods are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zTy2vgZzxaS3" style="display: none"&gt;Schedule of Estimated Useful Lives of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
    years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
    and trademarks&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_ziNYMg2Gmp56" title="Intangible assets estimated, useful lives"&gt;12&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zFfSLbc0zGod" title="Intangible assets estimated, useful lives"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</MYMD:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z48w7DnfUcCb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(m)
&lt;span id="xdx_86E_zYGyDOVSEZG3"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is evaluated annually for impairment or whenever we identify certain triggering events or circumstances that would more likely than not
reduce the fair value below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include,
among other things, unexpected adverse business conditions, economic factors (for example, the loss of key personnel), supply costs,
unanticipated competitive activities, and acts by governments and courts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy_zT9j3kHsrBL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(n)
&lt;span id="xdx_861_zXuh6y5Q4Z46"&gt;Recoverability of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB ASC 360-10-35 &#x201c;Impairment or Disposal of Long-lived Assets&#x201d;, long-lived assets to be held and used are
analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable
or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and
circumstances have occurred that indicate possible impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges)
and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by
which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the
lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying
amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce
the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy>
    <MYMD:RightOfUseAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_ecustom--RightOfUseAssetsPolicyTextBlock_zPO69ayfdMkj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(o)
&lt;span id="xdx_86E_zZdGfl5apCMh"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased a facility in Tampa, Florida (&#x201c;Hyde Park&#x201d;) under an operating lease (&#x201c;Hyde Park Lease&#x201d;) with annual
rentals of $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z5gXmVY3O0hi" title="Payments for Rent"&gt;22,048&lt;/span&gt; to $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20190701__20190702__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zcYov0cps7ya" title="Payments for Rent"&gt;23,320&lt;/span&gt; plus certain operating expenses. The Hyde Park facility housed the MyMD Florida operations. The Hyde Park
Lease took effect on July 1, 2019 for a term of &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zhkNz0gLpuz6" title="Lessee, operating lease, term of contract"&gt;36&lt;/span&gt; months to expire on &lt;span id="xdx_90E_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20190701__20190702__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z2htao554bs8" title="Lease expiration date"&gt;June 30, 2022&lt;/span&gt;. The Company cancelled the Hyde Park lease in March
2022 without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased an aircraft under an operating lease (&#x201c;Supera Aviation Lease&#x201d;) with annual rentals of $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20181020__20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zo4CJ5rwsPLb" title="Payments for Rent"&gt;600,000&lt;/span&gt; plus certain
operating expenses. The Supera Aviation Lease took effect on October 26, 2018 for a term of &lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20181026__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zE0qgmlf4I4h" title="Lessee, operating lease, term of contract"&gt;36&lt;/span&gt; months to expire on September 26, 2021.
The Company cancelled the Supera Aviation Lease in April 2021 without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased a facility in Baltimore, Maryland (&#x201c;2020 Wolfe St&#x201d;) under an operating lease (&#x201c;2020 Baltimore Lease&#x201d;)
with annual rentals of $&lt;span id="xdx_90F_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zb3FRNgbwJah" title="Payments for Rent"&gt;24,000&lt;/span&gt; to $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20201105__20201109__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zl95SSVy0kS1" title="Payments for Rent"&gt;25,462&lt;/span&gt; plus certain operating expenses. The 2020 Baltimore Lease took effect on November 9, 2020 for
a term of &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zfTeYsV7SaJd" title="Lessee, operating lease, term of contract"&gt;12&lt;/span&gt; months with automatic renewals unless a sixty-day notice was provided. The initial term expired on &lt;span id="xdx_90B_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20201105__20201109__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_z3I38lbOJec5" title="Lease expiration date"&gt;November 30, 2021&lt;/span&gt;. On
November 17, 2021, the 2020 Baltimore Lease was cancelled without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases a facility in Baltimore, Maryland (&#x201c;2021 Wolfe St&#x201d;) under an operating lease (&#x201c;2021 Baltimore
Lease&#x201d;) with annual rentals of $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MinimumMember_zfuZTDSVVlR8" title="Payments for rent"&gt;52,800&lt;/span&gt;
to $&lt;span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember__srt--RangeAxis__srt--MaximumMember_zYs1H5BkXeWd" title="Payments for rent"&gt;56,016&lt;/span&gt;
plus certain operating expenses. The 2021 Baltimore Lease took effect on November 17, 2021 for a term of &lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zljWYGaAuPp" title="Lessee operating lease term of contract"&gt;12&lt;/span&gt;
months with automatic renewals unless a sixty-day notice is provided. The initial term expires on &lt;span id="xdx_90C_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zILO0WYY40v6" title="Expiration date"&gt;November
30, 2022&lt;/span&gt;. The lease renewed effective December 1, 2022 for a term of &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20221201_zaWttHsZO1Ha" title="Lessee operating lease renewal term"&gt;12&lt;/span&gt; months with automatic renewals unless a sixty-day notice
is provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases a facility in Tampa, Florida (&#x201c;Platt St&#x201d;) under an operating lease (&#x201c;Platt Street Lease&#x201d;) with
annual rentals of $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MinimumMember_z15D2sxrM7xd" title="Payments for Rent"&gt;22,030&lt;/span&gt; to $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember__srt--RangeAxis__srt--MaximumMember_zYXFjtctPI8e" title="Payments for rent"&gt;23,259&lt;/span&gt; plus certain operating expenses. The Platt Street Lease took effect on April 1, 2022 for a term
of &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zsv3fWf9Zku" title="Term of contract"&gt;36&lt;/span&gt; months. The initial term expires on &lt;span id="xdx_903_eus-gaap--LeaseExpirationDate1_pp0p0_dd_c20220401__20220402__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z72rUefeJsWk" title="Lease expiration date"&gt;March 31, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2019 (&#x201c;Effective Date&#x201d;), the Company adopted FASB ASC, Topic 842, Leases (&#x201c;ASC 842&#x201d;), which increases
transparency and comparability by recognizing a lessee&#x2019;s rights and obligations resulting from leases by recording them on the
balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (&#x201c;ROU&#x201d;)
assets and related operating and finance lease liabilities on the balance sheet. The Company adopted the new guidance using the modified
retrospective approach on January 1, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company elected the package of practical expedients permitted within the standard, which allows an entity to forgo reassessing (i) whether
a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition
of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and
impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has
also elected the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any
lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
contracts entered into on or after the Effective Date, at the inception of a contract, the Company will assess whether the contract is,
or contains, a lease. The Company&#x2019;s assessment is based on: (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtained the right to substantially all the economic benefit from the use of the asset throughout the
period, and (iii) whether the Company has the right to direct the use of the asset. Leases entered into prior to January 1, 2020, which
were accounted for under ASC 840, were not reassessed for classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The Company
generally uses its incremental borrowing rate as the discount rate for leases, unless an interest rate is implicitly stated in the lease.
The present value of the lease payments is calculated using the incremental borrowing rate for operating leases, which was determined
using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term. The lease term for all the Company&#x2019;s leases includes the non-cancellable period
of the lease plus any additional periods covered by either a Company option to extend the lease that the Company is reasonably certain
to exercise, or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis
over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zv4QhUpqTiz4" style="display: none"&gt;Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt Street&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Hyde
                                                                                         Park&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Right
    of Use&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94,309&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;139,662&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,156&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Payable, current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,780&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,164&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,076&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53,240&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Payable - net of
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,070&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,941&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zEOBmg0vkU17" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following provides details of the Company&#x2019;s lease expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zGRbxhBgiqMd" style="display: none"&gt;Schedule of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Hyde Park&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Platt Street&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Supera Aviation&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Hyde Park&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease Expenses&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;Lease Costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,981&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;54,400&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;77,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,533&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202,226&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AF_zu8WgHFyEU2i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zTbeKs7NCWTd" style="display: none"&gt;Schedule of Other Information Related to Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Hyde&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    Information&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Park
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Street
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating cash
    used&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,622&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,628&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,602&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,852&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average remaining lease
    term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zDSTRTFLYxp9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the annual minimum lease payments of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z418TRZZeYi" style="display: none"&gt;Schedule of Operating Lease Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Street
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,485&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,005&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,103&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,814&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,814&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,868&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;157,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,591&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,958&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,549&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of future
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,811&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,910&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,721&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z9Pn8x1uCzk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MYMD:RightOfUseAssetsPolicyTextBlock>
    <us-gaap:PaymentsForRent
      contextRef="From2019-07-012019-07-02_srt_MinimumMember_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">22048</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2019-07-012019-07-02_srt_MaximumMember_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">23320</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-07-02_custom_HydeParkFacilityMember">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="From2019-07-012019-07-02_custom_HydeParkFacilityMember">2022-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="From2018-10-202018-10-26_custom_SuperaAviationMember"
      decimals="0"
      unitRef="USD">600000</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2018-10-26_custom_SuperaAviationMember">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2020-11-052020-11-09_srt_MinimumMember_custom_TwoThousandTwentyBaltimoreMember"
      decimals="0"
      unitRef="USD">24000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2020-11-052020-11-09_srt_MaximumMember_custom_TwoThousandTwentyBaltimoreMember"
      decimals="0"
      unitRef="USD">25462</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-11-09_custom_TwoThousandTwentyBaltimoreMember">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-11-052020-11-09_custom_TwoThousandTwentyBaltimoreMember">2021-11-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">52800</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">56016</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-11-17_custom_TwoThousandTwentyOneBaltimoreMember">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="From2021-11-152021-11-17_custom_TwoThousandTwentyOneBaltimoreMember">2022-11-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2022-12-01">P12M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">22030</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-04-012022-04-02_custom_PlattStreetMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">23259</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2022-04-02_custom_PlattStreetMember">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="From2022-04-012022-04-02_custom_PlattStreetMember">2025-03-31</us-gaap:LeaseExpirationDate1>
    <MYMD:ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_zuXwxOgH1yv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating leases are comprised of the 2021 Baltimore Lease and the Platt Street Lease on the Consolidated Balance
Sheet. The information related to these leases are presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zv4QhUpqTiz4" style="display: none"&gt;Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_z2JGgKboWYog" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zBhUp9SRH7w5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zhiqYUqQQVn7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z889WXOxtv48" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0N6jdSq1iNh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zLE475N4pNcg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt Street&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Hyde
                                                                                         Park&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_z6vSAtFzCtC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Right
    of Use&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94,309&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;139,662&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,156&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zbbu3KC6qs1l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Payable, current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,780&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,164&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,076&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53,240&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zehPe5wf4jUi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Payable - net of
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,070&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,941&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MYMD:ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">45353</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">94309</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">139662</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">12156</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">136853</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">149009</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">18741</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">47039</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">65780</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">12164</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">41076</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">53240</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">27070</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">48871</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">75941</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">95911</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95911</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zidgwOcdR6C4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following provides details of the Company&#x2019;s lease expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zGRbxhBgiqMd" style="display: none"&gt;Schedule of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_znyIIHvnUELb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zfGR3tXFBCPk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_z0Rldhcvlota" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zChVhZY2Udfg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SuperaAviationMember_zBWzFF2HMhd7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_z8206YIPKIO7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyBaltimoreMember_zs8N6N9fag2j" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zAM0YOZThfyk" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_z2tTJCq4C6E5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended&lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Hyde Park&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Platt Street&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Supera Aviation&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Hyde Park&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021 Baltimore&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease Expenses&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lease&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_ziZUqkebjW2l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;Lease Costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,981&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;54,400&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;77,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,533&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202,226&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">6251</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">16981</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">54400</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">77632</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31_custom_SuperaAviationMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">25026</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31_custom_TwoThousandTwentyBaltimoreMember"
      decimals="0"
      unitRef="USD">22667</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">4533</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">202226</us-gaap:OperatingLeaseCost>
    <MYMD:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_z8GkV8T8w7na" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zTbeKs7NCWTd" style="display: none"&gt;Schedule of Other Information Related to Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Hyde&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    Information&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Park
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Street
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating cash
    used&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zpt8hW2BktD2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,622&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zH9Jywc1gFH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,628&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zF0qtCq6WEMj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,602&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20220101__20221231_zp4zMGpbaVyj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Operating cash used"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,852&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average remaining lease
    term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zbrZDL2UYade" title="Weighted-average remaining lease term"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zuY3v1OBNKak" title="Weighted-average remaining lease term"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zlsmHb0UJ9v3" title="Weighted-average remaining lease term"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zehCMXi5vmM1" title="Weighted-average remaining lease term"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--HydeParkFacilityMember_zgWi4h4TtsPg" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zgH2mheX5Op6" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zES3dlSic98g" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zIEvRiJnaW6d" title="Weighted-average discount rate"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MYMD:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31_custom_HydeParkFacilityMember"
      decimals="0"
      unitRef="USD">4622</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">19628</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">51602</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">75852</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31_custom_PlattStreetMember">P27Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember">P23Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P25Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31_custom_HydeParkFacilityMember"
      decimals="INF"
      unitRef="Pure">0.100</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="INF"
      unitRef="Pure">0.100</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="INF"
      unitRef="Pure">0.100</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.100</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zc2r5dCKpcwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the annual minimum lease payments of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z418TRZZeYi" style="display: none"&gt;Schedule of Operating Lease Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231__us-gaap--TypeOfArrangementAxis__custom--PlattStreetMember_zi6KxxAXQ067" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyOneBaltimoreMember_zsj1EZzZM9n6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zohtxYmm1OBb" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Platt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021 Baltimore&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Street
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz4vV_zNysjfKxIC9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,485&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,005&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz4vV_zIZ8WoeZY178" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,103&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz4vV_zZXgjid7Gz5i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,814&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,814&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz4vV_zpUTr9AWOF7h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,868&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;157,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_zIWotGVZozM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,591&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,958&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,549&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zjGMJi6P7ob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of future
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,811&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,910&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,721&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">22485</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">54520</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">77005</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">23103</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">51348</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">74451</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">5814</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5814</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">51402</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">105868</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">157270</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">5591</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">9958</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15549</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31_custom_PlattStreetMember"
      decimals="0"
      unitRef="USD">45811</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyOneBaltimoreMember"
      decimals="0"
      unitRef="USD">95910</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">141721</us-gaap:OperatingLeaseLiability>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zV1OPgbYY9Ac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(p)
&lt;span id="xdx_8B3_z0X56l1bZbzi"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will recognize revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that
a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to
contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services
transferred to the customer. The following five steps are applied to achieve that core principle:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the contract with the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine
    the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate
    the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize
    revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zFd0LdHOkWhh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(q)
&lt;span id="xdx_866_zPNtZrlB5KGg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#x2019;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management&#x2019;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax benefits are
recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized
is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#x201c;unrecognized
tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and
measurement standards. For the years ended December 31, 2022 and 2021, no liability for unrecognized tax benefits was required to be
reported.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was no income tax benefit recorded for the losses for the years ended December 31, 2022 and 2021 since management determined that the
realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on
the net deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax years from 2019 through 2022 remain
subject to examination by federal and state jurisdictions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zSFd7GSZQV6i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(r)
&lt;span id="xdx_869_zJi0VKddkhRa"&gt;Basic and Diluted Earnings per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings
per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the
period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 375.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
net loss per share is computed using the weighted average number of shares of Common Stock and dilutive potential Common Stock outstanding
during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company reported a net loss for the years ended December 31, 2022 and 2021, Common Stock equivalents were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zAXNur76ujuj" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;For
    the Years Ended &lt;br/&gt; December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,376,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,176,739&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Unvested Restricted Stock Units&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,795,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,795,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,074,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;520,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series C Preferred Convertible Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series D Preferred Convertible Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    potentially dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,885,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,630,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zu08y11WuaG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zbhdPRqrVjnc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the following securities are excluded from the calculation of weighted average dilutive common shares
because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zAXNur76ujuj" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zBtWK7pgNyn8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zB8Mc0Melxyl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;For
    the Years Ended &lt;br/&gt; December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoHNCk9lojNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,376,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,176,739&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_z2pAJSt1ZSD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Unvested Restricted Stock Units&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,795,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,795,000&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z3NOGDlpZRd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,074,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsToPurchaseCommonStockMember_z7RK5RxOGz4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;520,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredConvertibleWarrantsMember_zBvu0Q3eKbg8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series C Preferred Convertible Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDPreferredConvertibleStockMember_zMvRtVoaQ7cj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series D Preferred Convertible Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyTVIVNZEnB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    potentially dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,885,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,630,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">4376737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">4176739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      unitRef="Shares">2795000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      unitRef="Shares">2795000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">6514827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">5074489</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">135135</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_PreFundedWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">520270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_SeriesCPreferredConvertibleWarrantsMember"
      decimals="INF"
      unitRef="Shares">27500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_SeriesCPreferredConvertibleWarrantsMember"
      decimals="INF"
      unitRef="Shares">27500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_SeriesDPreferredConvertibleStockMember"
      decimals="INF"
      unitRef="Shares">36496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_SeriesDPreferredConvertibleStockMember"
      decimals="INF"
      unitRef="Shares">36496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">13885695</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">12630494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzGyNqd81XN" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(s)
&lt;span id="xdx_86E_zGEQBYKSKSgd"&gt;Stock-based Payments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) 718, &#x201c;Compensation - Stock Compensation&#x201d;, which requires the measurement and recognition of compensation
expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates
the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is
ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In June 2018,
the FASB issued ASU No. 2018-07, Compensation &#x2013; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment
Accounting (the &#x201c;2018 Update&#x201d;). The amendments in the 2018 Update expand the scope of Topic 718 to include share-based payment
transactions for acquiring goods and services from nonemployees. Prior to the 2018 Update, Topic 718 applied only to share-based transactions
to employees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards
within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when
the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the
instruments have been satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected to account for forfeiture of stock-based awards as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zawq1TKJXW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;(t) &lt;span id="xdx_86C_z2UTNbnIjANg"&gt;Research and Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with FASB ASC 730, research and development costs are expensed
as incurred and consist of fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s
behalf.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zb2UcIdCu8jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(u)
&lt;span id="xdx_861_z1m1wXwiQfC4"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2017, FASB issued ASU 2017-11, Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and
Hedging (Topic 815): The new guidance amends ASC 815 to exclude consideration of a down-round feature in the evaluation of whether an
instrument is indexed to an entity&#x2019;s own stock under ASC 815-40-15-7C. That is, a down-round provision would not preclude an entity
from concluding that an instrument or feature that includes a down-round feature is indexed to the entity&#x2019;s own stock. This guidance
applies to both freestanding financial instruments and embedded conversion options (e.g., in convertible instruments with beneficial
conversion features (BCFs) or cash conversion features (CCFs)). The ASU is effective for annual reporting periods beginning after December
15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this standard did not have a material impact on their
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, FASB issued ASU 2020-06, &lt;i&gt;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013;
Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own
Equity&lt;/i&gt;. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer&#x2019;s accounting for convertible debt instruments. The new
guidance removes from U.S. GAAP the separation models for (1) convertible debt with a CCF and (2) convertible instruments with a BCF.
As a result, after adopting the ASU&#x2019;s guidance, entities will not separately present in equity an embedded conversion feature in
such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as
preferred stock. This ASU is effective for fiscal years beginning after December 15, 2021 and early adoption is allowed. The Company
early adopted this guidance as of January 1, 2021. The adoption of this standard did not have a material impact on their consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50),
Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40),
Issuer&#x2019;s Accounting for Certain Modifications or Exchanges or Freestanding Equity - Classified Written Call Options. &lt;/i&gt;The amendments
in this Update clarify an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity - classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments are effective for all entities for
fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments
prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for
all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in this Update in an interim
period, the guidance should be applied as of the beginning of the fiscal year that includes the interim period. The adoption of this
ASU had no material impact on the Company&#x2019;s consolidated financial statements and related disclosure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements Not Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial
Instruments (&#x201c;ASU-2016-13&#x201d;). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets
that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred
losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2022, including interim periods
within that fiscal year. The Company expects that there would be no material impact on the Company&#x2019;s consolidated financial
statements upon the adoption of this ASU.&lt;/span&gt;&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <MYMD:RecentDevelopmentsAndManagementsPlansTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_ecustom--RecentDevelopmentsAndManagementsPlansTextBlock_zZwzjwClXqgj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82B_z0HVwZ3uMkUf"&gt;Recent Developments, Liquidity and Management&#x2019;s Plans&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Acquisition
and Disposition of Cystron&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company acquired &lt;span id="xdx_907_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_dp_uPure_c20200323__us-gaap--BusinessAcquisitionAxis__custom--CystronBiotechLLCMember__us-gaap--TypeOfArrangementAxis__custom--MembershipInterestPurchaseAgreementMember_zHgOJjBbVoQ7" title="Acquired membership interests, percentage"&gt;100&lt;/span&gt;% of the membership interests of Cystron pursuant to a Membership Interest Purchase Agreement, dated March 23, 2020
(as amended by Amendment No. 1 on May 14, 2020, the &#x201c;MIPA&#x201d;) from certain selling parties (the &#x201c;Cystron Sellers&#x201d;).
The acquisition of Cystron was accounted for as a purchase of an asset. Cystron is a party to a License and Development Agreement (as
amended and restated on March 19, 2020, in connection with our entry into the MIPA, the &#x201c;License Agreement&#x201d;) with Premas
Biotech PVT Ltd. (&#x201c;Premas&#x201d;) whereby Premas granted Cystron, amongst other things, an exclusive license with respect to Premas&#x2019;
vaccine platform for the development of a vaccine against COVID-19 and other coronavirus infections. Cystron was incorporated on March
10, 2020. Since its formation and through the date of its acquisition by the Company, Cystron did not have any employees and its sole
asset consisted of the exclusive license from Premas.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2021, the Company and the Cystron Sellers, which are also shareholders of Oravax, entered into a Termination and Release Agreement
terminating the MIPA effective upon consummation of the Contribution Agreement. In addition, the Cystron Sellers agreed to waive any
change of control payment triggered under the MIPA as a result of the Merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 16, 2021, pursuant to the Contribution and Assignment Agreement, dated March 18, 2021 (the &#x201c;Contribution Agreement&#x201d;)
by and among the Company, Cystron, Oravax and, for the limited purpose set forth therein, Premas, the parties consummated the transactions
contemplated therein. Pursuant to the Contribution Agreement, among other things, the Company caused Cystron to contribute substantially
all of the assets associated with its business of developing and manufacturing Cystron&#x2019;s COVID-19 vaccine candidate to Oravax (the
&#x201c;Contribution Transaction&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, all amounts due to Premas under the Contribution Agreement have been paid. (&lt;i&gt;Note: Pursuant to the Contribution
Agreement, a total of $&lt;span id="xdx_90A_eus-gaap--PaymentsForProceedsFromInvestments_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember__dei--LegalEntityAxis__custom--PremasBiotechPVTLtdMember_zFAbnIXVSo5g" title="Amount owed on investments"&gt;1,500,000&lt;/span&gt; was owed to Premas, of which $&lt;span id="xdx_904_eus-gaap--PaymentsToAcquireInvestments_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember__dei--LegalEntityAxis__custom--PremasBiotechPVTLtdMember_z0vNCglhow93" title="Payments to investments"&gt;1,200,000&lt;/span&gt; was paid by pre-merger Akers Biosciences, Inc.&lt;/i&gt;)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Agreement
and Plan of Merger and Reorganization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 11, 2020, MyMD, Merger Sub, and MyMD Florida entered into the Merger Agreement (Note 1).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PreMergerMember_zA9GsiDBMY3c" title="Business acquisition description"&gt;Upon
completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued &lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesPostReverseStockSplits_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z8HZoWanW0W8" title="Issuance of post reverse stock split"&gt;28,553,307&lt;/span&gt;
post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio.
Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD
Florida held approximately &lt;span id="xdx_900_ecustom--ExchangeRatioPercentage_dp_uPure_c20210412__20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zow1OeGQnp46" title="Exchange ratio percentage"&gt;77.05&lt;/span&gt;%
of the Company&#x2019;s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants
to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210416__srt--StatementScenarioAxis__custom--PrefundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zBynsI6NHzq3" title="Warrants to purchase"&gt;986,486&lt;/span&gt;
shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of
pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company&#x2019;s net cash
at closing. Holders of pre-Merger Company Common Stock held approximately 22.95% of the outstanding equity of the
Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315
MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment
of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of
the Merger&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 805, the Company accounted for the transaction as a reverse merger with Akers Biosciences, Inc. (&#x201c;Akers&#x201d;)
as the legal acquirer and pre-Merger MyMD Florida as the accounting acquirer. As a result of the transaction, the Company recognized
Goodwill totaling $&lt;span id="xdx_90E_eus-gaap--Goodwill_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zVAUDm3eucu1" title="Goodwill"&gt;10,498,539&lt;/span&gt; based upon Akers&#x2019; pre-merger market capitalization of $&lt;span id="xdx_90A_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zy2QKP80b0G7" title="Pre market capitalization"&gt;42,477,346&lt;/span&gt; less net tangible assets of $&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zyQaj3sWDpT9" title="Tangible asset"&gt;31,978,807&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Akers&#x2019;
valuation was based upon &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_z3MCITwbgF05" title="Common shares outstanding"&gt;8,335,627&lt;/span&gt; common shares outstanding and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20210412__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgGbIkVmypFa" title="Vested restricted stock unit"&gt;263,026&lt;/span&gt; vested restricted stock units (&#x201c;RSU&#x2019;) with a fair
market value of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsO1ai5oX2h3" title="Fair market value price per share"&gt;4.94&lt;/span&gt; per share, the closing price of Akers common shares on the NASDAQ Stock Exchange on April 16, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zbqmEkrbkShe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z16p5vmab1Rd"&gt;Schedule
of Net Assets Acquired to be Allocated to Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Valuation
    &lt;br/&gt; Analysis&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210416__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zW1yQXyWjuLh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total Consideration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,477,346&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and Cash Equivalents"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,380,852&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,480,524&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other Receivables"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,026,137&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expenses"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,314&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investment in Oravax, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment in Oravax, Inc."&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade and Other Payables&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zY7GpVztgPi2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and Other Payables"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,601,020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Tangible Assets
    Acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zDDkY4np7f3b" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Tangible Assets Acquired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,978,807&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Excess of Purchase Price
    Over Net Assets Acquired to be Allocated to Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Goodwill_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,498,539&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zcY4Mi6aa8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of approximately &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220412__20220416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zEYBOl4W5f54" title="Percentage of common stock"&gt;49.68&lt;/span&gt;% of outstanding shares of Company Common Stock are subject to lockup agreements pursuant to which such
stockholders have agreed, except in limited circumstances, not to transfer, grant an option with respect to, sell, exchange, pledge or
otherwise dispose of, or encumber, any shares of Company capital stock for 180 days following the effective time of the Merger. For the
subsequent 180 days after the initial 180-day lock-up period, any disposal of Company Common Stock must be only in accordance with the
volume limitations set forth in paragraph (2) of Rule 144 promulgated under the Securities Act of 1933, as amended (the &#x201c;Act&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms and conditions of the Merger Agreement, not later than 30 days after the Option Exercise Period, the Company will pay stockholders
of MyMD Florida the Additional Consideration from the exercise of any MyMD Florida options assumed by the Company prior to the second-year
anniversary of the Merger; provided, however, the amount of such payment will not exceed the maximum amount of cash consideration that
may be received by stockholders of MyMD Florida without affecting the intended tax consequences of the Merger. As of the date of this
report, there have been no exercises of the MyMD Florida options assumed by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Merger Agreement, the Company has agreed to pay contingent consideration in combined Company Common Stock to MYMD Florida
stockholders if the combined company meets certain market capitalization milestones, referred to as Milestone Events, during the period
commencing on the business day following the closing date of the merger and ending on the 36-month anniversary of such date, referred
to as the Milestone Period. The Milestone Events and corresponding Milestone Payments are set forth in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--SummaryOfMilestoneEventsPaymentTableTextBlock_ztnzcd3FAXkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zX43G04cJwKi"&gt;Summary
of Milestone Events Payment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Milestone
    Event&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Milestone
    Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zxQO5DcJdaa1" title="Milestone Event"&gt;Market
    capitalization of the combined company for at least ten (&lt;span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zbAkHFkCvoxj" title="Debt Instrument, Convertible, Threshold Trading Days"&gt;10&lt;/span&gt;) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#x201c;First Milestone Event&#x201d;)&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zn71c3673dzf" title="Milestone Payment"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z3mOcVEauQti" title="Milestone Event"&gt;For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least &lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z9NFKzKila4b" title="Threshold trading days"&gt;10&lt;/span&gt; trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_zUWfakWc2bji" title="Milestone Payment"&gt;10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zy6Uzjofk6Yc" title="Milestone Event"&gt;Market
    capitalization of the combined company for at least &lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zFPZOxDxzhCl" title="Debt Instrument, Convertible, Threshold Trading Days"&gt;10&lt;/span&gt; trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#x201c;Second Milestone Event&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zwcfVRNmJXe8" title="Milestone Payment"&gt;25,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zCIuwjWOFz48" title="Milestone Event"&gt;For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zzgeveMfu8mk" title="Threshold trading days"&gt;10&lt;/span&gt; trading days during any 20 consecutive trading day period during the Milestone
    Period&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90E_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zLtbp8KJU8Zi" title="Milestone Payment"&gt;25,000,000&lt;/span&gt;
    per each incremental increase&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;p id="xdx_8AB_zeLl3tVjuXa5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
purposes of the table above, &#x201c;market capitalization&#x201d; means, with respect to any trading day, the product of (i) the total
outstanding shares of the combined Company Common Stock and (ii) the volume weighted average trading price for the combined Company Common Stock for such trading day.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022, none of the contingencies noted above have been met.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s cash on hand was $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zGYUUbapHN1l" title="Cash on hand"&gt;749,090&lt;/span&gt; and marketable securities were $&lt;span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zpZRYnoBQKL1" title="Marketable securities"&gt;4,086,902&lt;/span&gt;. The Company has incurred
a net loss from operations of $&lt;span id="xdx_90C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iN_pp0p0_di_c20220101__20221231_zn8kAqDORv5i" title="Loss from operations"&gt;15,197,336&lt;/span&gt; for the year  ended December 31, 2022. As of December 31, 2022, the Company had working
capital of $&lt;span id="xdx_907_ecustom--WorkingCapital_iI_pp0p0_c20221231_zSbUIQpbjj2l" title="Working capital"&gt;2,632,796&lt;/span&gt; and stockholders&#x2019; equity of $&lt;span id="xdx_907_eus-gaap--StockholdersEquity_iI_pp0p0_c20221231_zJtLSahnDpAa" title="Stockholders' equity"&gt;14,695,056&lt;/span&gt; including an accumulated deficit of $&lt;span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20221231_zJTz9YLatmjk" title="Accumulated deficit"&gt;93,758,904&lt;/span&gt;. During the year
ended December 31, 2022, cash flows used in operating activities were $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20220101__20221231_zSt0Ad7AII2i" title="Net cash provided by operating activities"&gt;12,270,068&lt;/span&gt;, consisting primarily of a net loss of $&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220101__20221231_z7gGCqXPkVS2" title="Net loss"&gt;15,197,336&lt;/span&gt;
offset by non-cash share-based compensation of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220101__20221231_zCCseBi5deQc" title="Non cash share based compensation"&gt;695,191 &lt;/span&gt; and an increase in trade and other payables of $&lt;span id="xdx_90C_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_pp0p0_c20220101__20221231_zAGjxOI4MtNf" title="Increase in trade and other payables"&gt;1,686,595&lt;/span&gt; and a decrease in prepaid
expenses of $&lt;span id="xdx_90D_ecustom--DecreaseInPrepaidExpense_c20220101__20221231_zl64mJLJ5Xtj" title="Decrease in prepaid expense"&gt;540,560&lt;/span&gt;. Since its inception, the Company has met its liquidity requirements principally through the sale of its Common Stock in public and private placements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the current cash requirements for operations in conjunction with management&#x2019;s strategic plan and believes that
the Company&#x2019;s current financial resources as of the date of the issuance of these consolidated financial statements are sufficient
to fund its current operating budget and contractual obligations as of December 31, 2022 as they fall due within the next twelve-month
period, alleviating any substantial doubt raised by the Company&#x2019;s historical operating results and satisfying its estimated liquidity
needs for twelve months from the issuance of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MYMD:RecentDevelopmentsAndManagementsPlansTextBlock>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="AsOf2020-03-23_custom_CystronBiotechLLCMember_custom_MembershipInterestPurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2021-01-012021-12-31_custom_ContributionAgreementMember_custom_PremasBiotechPVTLtdMember"
      decimals="0"
      unitRef="USD">1500000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2021-01-012021-12-31_custom_ContributionAgreementMember_custom_PremasBiotechPVTLtdMember"
      decimals="0"
      unitRef="USD">1200000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="From2021-04-122021-04-16_custom_MergerAgreementMember_custom_PreMergerMember">Upon
completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307
post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio.
Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD
Florida held approximately 77.05%
of the Company&#x2019;s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants
to purchase 986,486
shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of
pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company&#x2019;s net cash
at closing. Holders of pre-Merger Company Common Stock held approximately 22.95% of the outstanding equity of the
Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315
MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment
of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of
the Merger</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <MYMD:StockIssuedDuringPeriodSharesPostReverseStockSplits
      contextRef="From2021-04-122021-04-16_custom_MergerAgreementMember"
      decimals="INF"
      unitRef="Shares">28553307</MYMD:StockIssuedDuringPeriodSharesPostReverseStockSplits>
    <MYMD:ExchangeRatioPercentage
      contextRef="From2021-04-122021-04-16_custom_MergerAgreementMember"
      decimals="INF"
      unitRef="Pure">0.7705</MYMD:ExchangeRatioPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-04-16_custom_PrefundedWarrantsMember_custom_MergerAgreementMember"
      decimals="INF"
      unitRef="Shares">986486</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:Goodwill
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">10498539</us-gaap:Goodwill>
    <us-gaap:CapitalizationLongtermDebtAndEquity
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">42477346</us-gaap:CapitalizationLongtermDebtAndEquity>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">31978807</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember"
      decimals="INF"
      unitRef="Shares">8335627</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2021-04-122021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">263026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharePrice
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.94</us-gaap:SharePrice>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zbqmEkrbkShe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z16p5vmab1Rd"&gt;Schedule
of Net Assets Acquired to be Allocated to Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Valuation
    &lt;br/&gt; Analysis&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210416__20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zW1yQXyWjuLh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total Consideration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,477,346&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and Cash Equivalents"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,380,852&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,480,524&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other Receivables"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,026,137&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expenses"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,314&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investment in Oravax, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment in Oravax, Inc."&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade and Other Payables&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zY7GpVztgPi2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and Other Payables"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,601,020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Tangible Assets
    Acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_zDDkY4np7f3b" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Tangible Assets Acquired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,978,807&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Excess of Purchase Price
    Over Net Assets Acquired to be Allocated to Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Goodwill_c20210416__us-gaap--BusinessAcquisitionAxis__custom--AkersBiosciencesIncMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,498,539&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-04-162021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">42477346</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">1380852</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">29480524</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">3026137</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">192314</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">3601020</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">31978807</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="AsOf2021-04-16_custom_AkersBiosciencesIncMember"
      decimals="0"
      unitRef="USD">10498539</us-gaap:Goodwill>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2022-04-122022-04-16_custom_MergerAgreementMember"
      decimals="INF"
      unitRef="Pure">0.4968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <MYMD:SummaryOfMilestoneEventsPaymentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--SummaryOfMilestoneEventsPaymentTableTextBlock_ztnzcd3FAXkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zX43G04cJwKi"&gt;Summary
of Milestone Events Payment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Milestone
    Event&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Milestone
    Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zxQO5DcJdaa1" title="Milestone Event"&gt;Market
    capitalization of the combined company for at least ten (&lt;span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zbAkHFkCvoxj" title="Debt Instrument, Convertible, Threshold Trading Days"&gt;10&lt;/span&gt;) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#x201c;First Milestone Event&#x201d;)&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodOneMember_zn71c3673dzf" title="Milestone Payment"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z3mOcVEauQti" title="Milestone Event"&gt;For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least &lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_z9NFKzKila4b" title="Threshold trading days"&gt;10&lt;/span&gt; trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodTwoMember_zUWfakWc2bji" title="Milestone Payment"&gt;10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zy6Uzjofk6Yc" title="Milestone Event"&gt;Market
    capitalization of the combined company for at least &lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zFPZOxDxzhCl" title="Debt Instrument, Convertible, Threshold Trading Days"&gt;10&lt;/span&gt; trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#x201c;Second Milestone Event&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_908_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodThreeMember_zwcfVRNmJXe8" title="Milestone Payment"&gt;25,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--MilestoneEvent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zCIuwjWOFz48" title="Milestone Event"&gt;For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uDays_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zzgeveMfu8mk" title="Threshold trading days"&gt;10&lt;/span&gt; trading days during any 20 consecutive trading day period during the Milestone
    Period&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90E_ecustom--MilestonePayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MilestonePeriodFourMember_zLtbp8KJU8Zi" title="Milestone Payment"&gt;25,000,000&lt;/span&gt;
    per each incremental increase&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

</MYMD:SummaryOfMilestoneEventsPaymentTableTextBlock>
    <MYMD:MilestoneEvent contextRef="From2022-01-012022-12-31_custom_MilestonePeriodOneMember">Market
    capitalization of the combined company for at least ten (10) trading days during any 20 consecutive trading day period during the
    Milestone Period is equal to or greater than $500,000,000 (the &#x201c;First Milestone Event&#x201d;)</MYMD:MilestoneEvent>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="From2022-01-012022-12-31_custom_MilestonePeriodOneMember"
      decimals="INF"
      unitRef="Days">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <MYMD:MilestonePayment contextRef="From2022-01-012022-12-31_custom_MilestonePeriodOneMember">20,000,000</MYMD:MilestonePayment>
    <MYMD:MilestoneEvent contextRef="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember">For
    every $250,000,000 incremental increase in market capitalization of the combined company after the First Milestone Event to the extent
    such incremental increase occurs for at least 10 trading days during any 20 consecutive trading day period during the Milestone Period,
    up to a $1,000,000,000 market capitalization of the combined company</MYMD:MilestoneEvent>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember"
      decimals="INF"
      unitRef="Days">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <MYMD:MilestonePayment contextRef="From2022-01-012022-12-31_custom_MilestonePeriodTwoMember">10,000,000
    per each incremental increase (it being understood, however, that, if such incremental increase results in market capitalization
    equal to $1,000,000,000, such $10,000,000 payment in respect of such incremental increase shall be payable without duplication of
    any amount payable in respect of a Second Milestone Event, as defined below)</MYMD:MilestonePayment>
    <MYMD:MilestoneEvent contextRef="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember">Market
    capitalization of the combined company for at least 10 trading days during any 20 consecutive trading day period during the Milestone
    Period is equal to or greater than $1,000,000,000 (the &#x201c;Second Milestone Event&#x201d;)</MYMD:MilestoneEvent>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember"
      decimals="INF"
      unitRef="Days">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <MYMD:MilestonePayment contextRef="From2022-01-012022-12-31_custom_MilestonePeriodThreeMember">25,000,000</MYMD:MilestonePayment>
    <MYMD:MilestoneEvent contextRef="From2022-01-012022-12-31_custom_MilestonePeriodFourMember">For
    every $1,000,000,000 incremental increase in market capitalization of the combined company after the Second Milestone Event to the
    extent such incremental increase occurs for at least 10 trading days during any 20 consecutive trading day period during the Milestone
    Period</MYMD:MilestoneEvent>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="From2022-01-012022-12-31_custom_MilestonePeriodFourMember"
      decimals="INF"
      unitRef="Days">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <MYMD:MilestonePayment contextRef="From2022-01-012022-12-31_custom_MilestonePeriodFourMember">25,000,000</MYMD:MilestonePayment>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">749090</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4086902</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <MYMD:WorkingCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2632796</MYMD:WorkingCapital>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14695056</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-93758904</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12270068</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15197336</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">695191</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1686595</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <MYMD:DecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">540560</MYMD:DecreaseInPrepaidExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zF3Gkqu4OxWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_827_zzofitw2FMx4"&gt;Trade and Other Payables&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLkHF2WSGX6f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
and other payables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zmu5VpD0hIN3"&gt;Schedule
of Trade and Other Payables&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zWFKnewnHzU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zBPCCn91pAcb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableTradeCurrent_iI_pp0p0_maAPAOAzNsj_zaPxxI4z5X0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts Payable &#x2013; Trade&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,356,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;867,518&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzNsj_zWsHh3J32ut6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316,666&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119,108&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzNsj_ziwHp0LUz5nb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other payables, Total&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,673,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;986,626&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zHX8XofOYbzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLkHF2WSGX6f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
and other payables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zmu5VpD0hIN3"&gt;Schedule
of Trade and Other Payables&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zWFKnewnHzU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zBPCCn91pAcb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableTradeCurrent_iI_pp0p0_maAPAOAzNsj_zaPxxI4z5X0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts Payable &#x2013; Trade&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,356,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;867,518&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzNsj_zWsHh3J32ut6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316,666&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119,108&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzNsj_ziwHp0LUz5nb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other payables, Total&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,673,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;986,626&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2356555</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">867518</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">316666</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">119108</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2673221</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">986626</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zrA97pS6VZy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_82A_zjs9c7Jwh4Uh"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Secured
Promissory Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 11, 2020, concurrently with the execution of the Merger Agreement, the Company agreed to provide a bridge loan up to an aggregate
principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember_zJJ6Yt3FtJN7" title="Maximum principal amount"&gt;3,000,000&lt;/span&gt; to pre-Merger MyMD Florida pursuant to the Bridge Loan Note. Advances under the Bridge Loan Note (&#x201c;Bridge
Loan Advances&#x201d;) were made in the amounts and at the times as needed to fund MyMD Florida&#x2019;s operating expenses. Bridge Loan
Advances accrue interest at &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember_zVJlOmZFd6mg" title="Interest rate"&gt;5&lt;/span&gt;% per annum, which may be increased to &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201111__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--StatementScenarioAxis__custom--EventOfDefaultMember_zziOZUn1ClEf" title="Interest rate"&gt;8&lt;/span&gt;% per annum upon occurrence of any event of default, from the date
of such default. The principal and the accrued interest thereon are to be repaid on the earliest of (a) April 15, 2022; (b); if the Merger
was consummated, then upon demand of the Company following the consummation of the Merger; or (c) the date on which the obligations under
the Bridge Loan Note are accelerated upon event of default as set forth in the Bridge Loan Note. The payment and performance of all obligations
under the Bridge Loan Note are secured by a first priority security interest in all of MyMD Florida&#x2019;s right, title and interest
in and to its assets as collateral. The outstanding principal amount and the accrued interest of the Bridge Loan Note were convertible
into shares of MyMD Florida Common Stock in accordance with the terms of the Merger Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and December 31, 2021 MyMD had advanced MyMD Florida $&lt;span id="xdx_90E_eus-gaap--AdvancesToAffiliate_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zfGlQKpqb7Ii" title="Advances to affiliate"&gt;&lt;span id="xdx_908_eus-gaap--AdvancesToAffiliate_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zAXb6ORFthh5" title="Advances to affiliate"&gt;3,000,000&lt;/span&gt;&lt;/span&gt; under the Bridge Loan Note plus accrued interest
totaling $&lt;span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_z4QyR6kPyiqj" title="Accrued interest"&gt;&lt;span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zgB0v11mDtZf" title="Accrued interest"&gt;26,137&lt;/span&gt;&lt;/span&gt;. The balance of $&lt;span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zjAwYpS9kbn9" title="Notes payable"&gt;&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanNoteMember__srt--ConsolidatedEntitiesAxis__custom--MyMDPharmaceuticalsFloridaIncMember_zn8mjVxf4YS1" title="Notes payable"&gt;3,026,137&lt;/span&gt;&lt;/span&gt; as of December 31, 2022 and December 31, 2021, respectively, were eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-11-11_custom_MergerAgreementMember_custom_BridgeLoanNoteMember_custom_EventOfDefaultMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AdvancesToAffiliate
      contextRef="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:AdvancesToAffiliate>
    <us-gaap:AdvancesToAffiliate
      contextRef="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:AdvancesToAffiliate>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="0"
      unitRef="USD">26137</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="0"
      unitRef="USD">26137</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="0"
      unitRef="USD">3026137</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember"
      decimals="0"
      unitRef="USD">3026137</us-gaap:NotesPayable>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuQw2yYrSRTa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_825_zIymIP6YDXRg"&gt;Stock-based Payments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Equity
incentive Plans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2013
Stock Incentive Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (&#x201c;2013 Plan&#x201d;). The 2013 Plan was amended by the Board
on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides
for the issuance of up to &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20140123__us-gaap--PlanNameAxis__custom--TwoThousandThirteenStockIncentivePlanMember_zujpekTuZSb5" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;2,162&lt;/span&gt; shares of the Company&#x2019;s Common Stock. As of December 31, 2022, grants of restricted stock and options
to purchase &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedPlanMember_zWe5KItoIMxk" title="Share-based compensation arrangement by share-based payment award, shares purchased for award"&gt;1,406&lt;/span&gt; shares of Common Stock have been issued pursuant to the 2013 Plan, and &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--AmendedPlanMember_zMo031D5W25a" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;755&lt;/span&gt; shares of Common Stock remain available
for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2016
Stock Incentive Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2016, the shareholders approved, and the Company adopted the 2016 Stock Incentive Plan (&#x201c;2016 Plan&#x201d;). The 2016
Plan provides for the issuance of up to &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20161221__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_zky8YGjAAVJg" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;50,000,000&lt;/span&gt; shares of the Company&#x2019;s Common Stock. As of December 31, 2022, grants of options
to purchase &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_ze4jzwGnmjb4" title="Share-based compensation arrangement by share-based payment award, shares purchased for award"&gt;4,188,315&lt;/span&gt; shares of Common Stock have been issued pursuant to the 2016 Plan, and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenStockIncentivePlanMember_zQvnBXNVOmr4" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;0&lt;/span&gt; shares of Common Stock remain available
for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2017
Stock Incentive Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 7, 2017, the shareholders approved, and the Company adopted the 2017 Stock Incentive Plan (&#x201c;2017 Plan&#x201d;). The 2017
Plan provides for the issuance of up to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20170807__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zDwUPIQYPqVe" title="Number of shares authorized"&gt;3,516&lt;/span&gt; shares of the Company&#x2019;s Common Stock. As of December 31, 2022, grants of restricted
stock and options to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zqW9Qk2yTAg5" title="Share based compensation arrangement by share based payment award shares purchased for award"&gt;2,538&lt;/span&gt; shares of Common Stock have been issued pursuant to the 2017 Plan, and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenStockIncentivePlanMember_zWuQY7XR92rk" title="Remaining shares available for issuance"&gt;978&lt;/span&gt; shares of Common Stock
remain available for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2018
Stock Incentive Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 7, 2018, the shareholders approved, and the Company adopted the 2018 Stock Incentive Plan (&#x201c;2018 Plan&#x201d;). On August
27, 2020, the 2019 Plan was modified to increase the total authorized shares. The 2018 Plan, as amended, provides for the issuance of
up to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20181207__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zXwAcLzX7hZ5" title="Share based compensation arrangement by share based payment award number of shares authorized"&gt;560,063&lt;/span&gt; shares of the Company&#x2019;s Common Stock. As of December 31, 2022, grants of RSUs and restricted stock to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zcw8E6ociSI1" title="Share based compensation arrangement by share based payment award shares purchased for award"&gt;263,026&lt;/span&gt;
shares of Common Stock have been issued pursuant to the 2018 Plan, and &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zGTGjOIsRTKi" title="Share based compensation arrangement by share based payment award number of shares available for grant"&gt;297,037&lt;/span&gt; shares of Common Stock remain available for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2021
Stock Incentive Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 15, 2021, the shareholders approved, and the Company adopted the 2021 Stock Incentive Plan (&#x201c;2021 Plan&#x201d;). The 2021
Plan provides for the issuance of up to &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210415__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zPBhOV286lW9" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;7,228,184&lt;/span&gt; shares of the Company&#x2019;s Common Stock. As of December 31, 2022, grants of RSUs
and stock options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zuSkjtTViWlg" title="Share-based compensation arrangement by share-based payment award, shares purchased for award"&gt;3,149,207&lt;/span&gt; shares of Common Stock have been issued pursuant to the 2021 Plan, and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zZNwZIVmqg" title="Remaining shares available for issuance"&gt;4,078,977&lt;/span&gt; shares of Common
Stock remain available for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKU7dP8dbSzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activities for MyMD stock options for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zhogll6lP7H8"&gt;Summary
of Stock Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zXMCfTt0c42h" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of Shares, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,176,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkraZcEptGI5" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zdXh6kDV7ztk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUesiIMkAwR5" title="Weighted Average Remaining Contractual Term (Years), Beginning"&gt;1.29&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zrU9x5VANKu" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,493,284&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zgw5BWoHTN81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zIuVXPcxzkXh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zAmc9CVvaB5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--WeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231_zGUCNxEruRXb" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;5.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zz9wlBdJF9Fg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zDQNPuVB1EM4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zU3f8FWpT9j8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_znHg0YZgsh63" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJbHi3RYI4ae" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1010"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zlOrdKKXojV2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_z1ukftiBAJm" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Canceled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEuhLHZi1wfh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Canceled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1016"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zA8NUICsMAn9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Canceled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zNiHI3IoqRke" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Ending Balance"&gt;&#x202f;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,476,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zeilo4IWirH3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zIQMsZ9v8hMf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOAkMHVCEzE7" title="Weighted Average Remaining Contractual Term (Years), Ending"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z6DuQ00yoaR5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,376,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zkE7UZjWJfO" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_c20220101__20221231_zNltyrsJ5DJ9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z6Ga8wHrZmGe" title="Weighted Average Remaining Contractual Term (Years), Exercisable"&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z57thjqMWK5h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5XgdiqaIo7" title="Share-based payment award, options, grants in period, grant date intrinsic value"&gt;1.15&lt;/span&gt; for the Company&#x2019;s common shares on December 31, 2022 and the closing stock price of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqOLaxsJZqQ5" title="Share-based payment award, options, grants in period, grant date intrinsic value"&gt;6.06&lt;/span&gt; for the Company&#x2019;s common
shares on December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 279pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 28, 2022, the Company&#x2019;s Compensation Committee approved the issuance of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaZFC9QM7tr" title="Number of shares issued"&gt;200,000&lt;/span&gt; stock options under the 2021 Stock Incentive
Plan. These shares had a grant date fair value of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zODikesMNY35" title="Weighted Average Grant Date Fair Value, Granted"&gt;3.59&lt;/span&gt; per share or a cumulative fair market value of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220127__20220128__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zy4lACyTZfib" title="Cumulative fair market value"&gt;717,660&lt;/span&gt; as calculated using Black-Scholes
(exercise price $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9cCu8I5Qv9h" title="Exercise price"&gt;3.96&lt;/span&gt; per share, stock price $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOgTUnzIjL67" title="Stock price"&gt;3.96&lt;/span&gt; per share, volatility of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDUBtKd2wC38" title="Volatility rate"&gt;124.43&lt;/span&gt;%, discount rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4FVhkS9NWN6" title="Discount rate"&gt;1.74&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zP6O40mI5097" title="Expected term::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;seven&lt;/span&gt;&lt;/span&gt;-year term). The
grant was segmented into four vesting tranches triggered by performance achievements and expire on &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTy4TPnm22u3" title="Share based payment award vesting expiration date"&gt;January 28, 2029&lt;/span&gt;. The Company is amortizing
the expenses over the vesting cycles of the individual tranches.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2022, the Company granted &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPVhU1mUxvae" title="Number of shares issued"&gt;100,000&lt;/span&gt; stock options under the 2021 Stock Incentive Plan to a third-party consultant in consideration
of services rendered. These shares had a grant date fair value of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPhNXqFw41c5" title="Weighted average grant date fair value, granted"&gt;2.30&lt;/span&gt; per share or a cumulative fair market value of $&lt;span id="xdx_908_ecustom--CumulativeFairMarketValue_c20220619__20220621__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6qtipIBTOZf" title="Cumulative fair market value"&gt;199,360&lt;/span&gt; as calculated
using Black-Scholes (exercise price $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfKcF5ZNusk7" title="Exercise price"&gt;2.30&lt;/span&gt; per share, stock price $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWjsBjBkCR12" title="Stock price"&gt;2.30&lt;/span&gt; per share, volatility of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMxMHrYkuaGj" title="Volatility rate"&gt;130.51&lt;/span&gt;%, discount rate of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_pid_dp_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNcpLktSkc2k" title="Discount rate"&gt;3.24&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220619__20220621__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zde9VwxFUttf" title="Expected term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;five&lt;/span&gt;&lt;/span&gt;-year
term). The grant vested immediately and expire on June 21, 2027. The Company is amortizing the expense over twelve months, the term of
the consulting agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2022 and 2021, the Company incurred stock option expenses totaling $&lt;span id="xdx_90C_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3HuxmX5kY44" title="Stock option expenses"&gt;444,342&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--StockOptionPlanExpense_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOFPPfSN5vfh" title="Stock option expenses"&gt;0&lt;/span&gt;, respectively. The unamortized
stock option expenses as of December 31, 2022 and 2021 totaled $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231_zqZOJAXWrIcg" title="Unamortized stock option expenses"&gt;113,847&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zVs8HqjlGux3" title="Unamortized stock option expenses"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Assumption
of MyMD Florida Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2016, pre-Merger MyMD Florida adopted the MyMD Pharmaceuticals, Inc. Amended and Restated 2016 Equity Incentive Plan (the
&#x201c;2016 Plan&#x201d;). The 2016 Plan provided for the issuance of up to &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20161231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zF9YGcEDF3La" title="Premerger common stock, shares"&gt;50,000,000&lt;/span&gt;
shares of pre-Merger MyMD Florida Common Stock. As of December 31, 2022, options to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221229__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z9uSWkESH62b" title="Options to purchase of common stock"&gt;4,188,315&lt;/span&gt;
shares of Company Common Stock have been issued pursuant to the plan and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zXDR8J6JeEB4" title="Remaining shares available for issuance"&gt;0&lt;/span&gt;
shares of Company Common Stock remain available for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Merger Agreement, effective as of the effective time of the Merger, the Company assumed pre-Merger MyMD Florida&#x2019;s Second
Amendment to Amended and Restated 2016 Stock Incentive Plan (the &#x201c;2016 Plan&#x201d;), assuming all of pre-Merger MyMD Florida&#x2019;s
rights and obligations with respect to the options issued thereunder. As of the effective date of the Merger, no additional awards could
be issued under the 2016 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, under the terms of the Merger Agreement, the Company assumed all of pre-Merger MyMD Florida&#x2019;s rights and obligations
under pre-Merger MyMD Florida&#x2019;s stock options that were outstanding immediately prior to the effective time of the Merger, and
each such stock option, whether or not vested, was converted into a stock option representing the right to purchase shares of Company
Common Stock, on terms substantially the same as those in effect immediately prior to the effective time, except that the number of shares
of Company Common Stock issuable and the exercise price per share of such stock options was adjusted by the Exchange Ratio. Additionally,
the number of shares and exercise price per share of Company Common Stock under the assumed pre-Merger MyMD Florida stock options was
further adjusted by the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assumed &lt;span id="xdx_906_ecustom--NumberOfStockOptionsAssumed_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zTYyh4KAh2U"&gt;4,188,315&lt;/span&gt; MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited
to, the amendment of such stock option to change the term of such stock option for a period expiring on April 16, 2023, the second-year
anniversary of the Merger). The Company recorded expenses of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zQe8kepESZRi"&gt;15,036,051&lt;/span&gt; for the assumption of the options and the modification of the
terms which is included on the Consolidated Statement of Comprehensive Loss for the year December 31, 2021. The Company utilized Black-Scholes
using an exercise price of $2.59, an issue date fair value of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zfdyZ2m0EG4k" title="Fair value"&gt;4.94&lt;/span&gt;, a volatility index of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_z27P0wXGAE3f" title="Volatility index"&gt;122.31&lt;/span&gt;% and a discount rate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zIdSDqNS5RPa" title="discount rate"&gt;0.16&lt;/span&gt;% to determine
the fair value of the modification. The pre-Merger MyMD options were valued at $&lt;span id="xdx_909_ecustom--OptionsMarketValue_iI_c20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--AwardTypeAxis__custom--MyMDFloridaStockOptionsMember_zUVeZRaeIhW4" title="Options market value"&gt;0&lt;/span&gt; on April 16, 2021, as there was no reliable method
of determining the fair value given the material events that had occurred since the last arms-length trade of common shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 11, 2020, the Compensation Committee of the Board of Directors approved grants totaling &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3DYtwKM4pLh" title="Restricted stock units"&gt;394,680&lt;/span&gt; Restricted Stock Units to the
Company&#x2019;s four directors. Each RSU had a grant date fair value of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCkJwKg45tr6" title="Grant date fair value"&gt;4.48&lt;/span&gt; which shall be amortized on a straight-line basis over
the vesting period into administrative expenses within the Consolidated Statement of Comprehensive Loss. &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200910__20200911__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK23X6shFLeh" title="Restricted stock units, description"&gt;Such RSUs were granted under
the 2018 Plan, as amended. Fifty percent (50%) of each RSU will vest on the first anniversary date of the Grant and the remaining fifty
percent (50%) will vest on the second anniversary date; provided that the RSUs shall vest immediately upon the occurrence of (i) a change
in control, provided that the director is employed by or providing services to the Company and its affiliates on the closing date of
such change of control, or (ii) the director&#x2019;s termination of employment of service by the Company was without cause&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 16, 2021, concurrently with the closing of the Merger, pursuant to the terms of the RSU Agreements between the Company and four
board of directors, the &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7wQDrx0zKz7" title="Number of stock option to purchase shares of common stock"&gt;394,680&lt;/span&gt; RSUs granted on September 11, 2020 under the 2018 Plan, as amended, accelerated and vested in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Per
the terms of the RSU agreements, the Company, at the Company&#x2019;s sole discretion, may settle the RSUs in cash, or part cash and part
Common Stock. As there is no intention to settle the RSUs in cash, the Company accounted for these RSUs as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre-merger
Akers Biosciences, Inc. recorded expenses totaling $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIprk2eP8nkh" title="Premerger expenses totaling"&gt;979,758&lt;/span&gt; for the acceleration of the vesting of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6UiWYRg3mxa" title="Number of vesting shares"&gt;394,680&lt;/span&gt; RSUs, the holders immediately
surrendered &lt;span id="xdx_909_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYRcjPBx5Vd" title="Number of restricted stock, net of tax withholdings"&gt;139,457&lt;/span&gt; RSUs with a fair market value of $&lt;span id="xdx_909_eus-gaap--RestrictedStockValueSharesIssuedNetOfTaxWithholdings_c20210415__20210416__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbXVtDuCoza" title="Restricted stock value, net of tax withholdings"&gt;688,913&lt;/span&gt; for the withholding of federal and state income taxes, as directed by the
holders, which was recorded as Payroll Taxes Payable on the date of the Merger. The withholding obligations were paid by the Company
on June 30, 2021. As of March 29, 2023, the vested RSUs have not been converted to common shares of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 14, 2021, the Compensation Committee of the Board of Directors approved grants totaling &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zSHHg4pMbPcd" title="Restricted stock units"&gt;2,795,000&lt;/span&gt; Restricted Stock Units to the
Company&#x2019;s six directors and seven key employees. Each RSU had a grant date fair value of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zvvplYS3Vvwi" title="Grant date fair value"&gt;8.09&lt;/span&gt; which will be amortized upon vesting
into administrative expenses within the Consolidated Statement of Comprehensive Loss. Such RSUs were granted under the 2021
Plan. Vesting of each RSU is:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_znzp6sMHQxzk" title="Restricted stock units vested, description"&gt;One-third
    (33%) of each RSU will vest when the Company&#x2019;s market capitalization is equal to or greater than $500,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z8Xe7i4mozN5" title="Restricted stock units vested, description"&gt;One-third
    (33%) of each RSU will vest when the Company&#x2019;s market capitalization is equal to or greater than $750,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20211013__20211014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zKNpU0DcyTH8" title="Restricted stock units vested, description"&gt;The
    remaining awarded units will vest when the Company&#x2019;s market capitalization is equal to or greater than $1,000,000,000 for at
    least ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market
    value of the Common Stock equals or exceeds $5.00 during such trading day period&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    the event that (i) a change in control occurs or (ii) the participant incurs a termination of service by the Company without cause
    or due to the participant&#x2019;s death or total and permanent disability, then all unvested units shall become vested units immediately
    upon the occurrence of such event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, none of the vesting milestones have been met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 28, 2022, the Compensation Committee of the Board of Directors approved a grant of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_zxGgFHjXetni" title="Share based compensation arrangement by share based payment award equity instruments other than options grants in period"&gt;4,040&lt;/span&gt; RSUs to a sub-contractor with a grant
date fair value of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220127__20220128__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_z3BviRjGGRR2" title="Grant date fair value price per share"&gt;15,998&lt;/span&gt; and vested immediately. Such RSUs were granted under the 2021 Plan. The Company recorded expenses of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyEightTwoThousandTwentyTwoMember_zB72KGScdNUk" title="Share based compensation"&gt;15,998&lt;/span&gt;
which is included Stock Based Compensation on the Consolidated Statement of Comprehensive Loss during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 7, 2022, the Compensation Committee of the Board of Directors approved a grant of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220706__20220707__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_zsAn9sxkLgq9" title="Restricted stock units, granted"&gt;50,167&lt;/span&gt; RSUs to a sub-contractor with a grant date
fair value of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220706__20220707__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_z4zR9Gl9pdSa" title="Grant date fair value price per share"&gt;150,000&lt;/span&gt; and vested immediately. Such RSUs were granted under the 2021 Plan. The Company recorded expenses of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--JulySevenTwoThousandTwentyTwoMember_zKGVXwKA857e" title="Share based compensation"&gt;138,587&lt;/span&gt;
which is included Stock Based Compensation on the Consolidated Statement of Comprehensive Loss during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zP6y0EIgRuv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the status of outstanding unvested restricted stock units outstanding as of December 31, 2022 and the changes for the
year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z2h1ggkmMNRa"&gt;Summary
of Restricted Stock Units Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Grant
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;RSUs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VanMWyalIj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRJZ6TxhYHSg" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za4oOKNcjzU" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhnwmuWgJ0hg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD88faltMzu6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1146"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6roEJbUYSr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJx5G7mIb8w6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(54,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo9jdXvPZEre" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5AL2xCNq7d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbgsmnENAzKa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1156"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzdPEWqALCl9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1158"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUyqnmMouUs7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1160"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUMpOav64Jpa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUIeSvX75u73" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zj4rzrtxNay6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the unamortized value of the RSUs was $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrv0TPHS1Df9" title="Unamortized value"&gt;&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPhOxFUackgc" title="Unamortized value"&gt;22,611,550&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2014-01-23_custom_TwoThousandThirteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-01-012022-12-31_custom_AmendedPlanMember"
      decimals="INF"
      unitRef="Shares">1406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_AmendedPlanMember"
      decimals="INF"
      unitRef="Shares">755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-12-21_custom_TwoThousandAndSixteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">4188315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_TwoThousandAndSixteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2017-08-07_custom_TwoThousandAndSeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_TwoThousandAndSeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2018-12-07_custom_TwoThousandAndEighteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">560063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">263026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_TwoThousandAndEighteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">297037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-04-15_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">7228184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3149207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">4078977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKU7dP8dbSzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activities for MyMD stock options for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zhogll6lP7H8"&gt;Summary
of Stock Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zXMCfTt0c42h" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of Shares, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,176,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkraZcEptGI5" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zdXh6kDV7ztk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.59&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUesiIMkAwR5" title="Weighted Average Remaining Contractual Term (Years), Beginning"&gt;1.29&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zrU9x5VANKu" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,493,284&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zgw5BWoHTN81" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zIuVXPcxzkXh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zAmc9CVvaB5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--WeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231_zGUCNxEruRXb" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;5.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zz9wlBdJF9Fg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zDQNPuVB1EM4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zU3f8FWpT9j8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_znHg0YZgsh63" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJbHi3RYI4ae" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1010"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zlOrdKKXojV2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_z1ukftiBAJm" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Canceled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEuhLHZi1wfh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Canceled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1016"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zA8NUICsMAn9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Canceled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zNiHI3IoqRke" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Ending Balance"&gt;&#x202f;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,476,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zeilo4IWirH3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zIQMsZ9v8hMf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zOAkMHVCEzE7" title="Weighted Average Remaining Contractual Term (Years), Ending"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z6DuQ00yoaR5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,376,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zkE7UZjWJfO" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_c20220101__20221231_zNltyrsJ5DJ9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z6Ga8wHrZmGe" title="Weighted Average Remaining Contractual Term (Years), Exercisable"&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">4176737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">2.59</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31">P1Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">14493284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">3.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <MYMD:WeightedAverageRemainingContractualTermGranted contextRef="From2022-01-01to2022-12-31">P5Y9M18D</MYMD:WeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">4476737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.64</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P0Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">4376737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.61</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P0Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember98108171"
      decimals="INF"
      unitRef="USDPShares">6.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-272022-01-28_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">717660</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-01-28_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">1.2443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2022-01-272022-01-28_us-gaap_StockOptionMember">2029-01-28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <MYMD:CumulativeFairMarketValue
      contextRef="From2022-06-192022-06-21_custom_TwoThousandAndTwentyOneStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">199360</MYMD:CumulativeFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-21_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">1.3051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="From2022-06-192022-06-21_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember98108296"
      decimals="0"
      unitRef="USD">444342</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember98108171"
      decimals="0"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">113847</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-12-292022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">4188315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_TwoThousandAndSixteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <MYMD:NumberOfStockOptionsAssumed
      contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember"
      decimals="INF"
      unitRef="Shares">4188315</MYMD:NumberOfStockOptionsAssumed>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember"
      decimals="0"
      unitRef="USD">15036051</us-gaap:ShareBasedCompensation>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember"
      decimals="INF"
      unitRef="USDPShares">4.94</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember"
      decimals="INF"
      unitRef="Pure">1.2231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="From2022-01-012022-12-31_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <MYMD:OptionsMarketValue
      contextRef="AsOf2021-04-16_custom_MergerAgreementMember_custom_MyMDFloridaStockOptionsMember"
      decimals="0"
      unitRef="USD">0</MYMD:OptionsMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">394680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2020-09-102020-09-11_us-gaap_RestrictedStockUnitsRSUMember">Such RSUs were granted under
the 2018 Plan, as amended. Fifty percent (50%) of each RSU will vest on the first anniversary date of the Grant and the remaining fifty
percent (50%) will vest on the second anniversary date; provided that the RSUs shall vest immediately upon the occurrence of (i) a change
in control, provided that the director is employed by or providing services to the Company and its affiliates on the closing date of
such change of control, or (ii) the director&#x2019;s termination of employment of service by the Company was without cause</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">394680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">979758</us-gaap:ShareBasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">394680</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">139457</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="From2021-04-152021-04-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">688913</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">2795000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">One-third
    (33%) of each RSU will vest when the Company&#x2019;s market capitalization is equal to or greater than $500,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">One-third
    (33%) of each RSU will vest when the Company&#x2019;s market capitalization is equal to or greater than $750,000,000 for at least
    ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market value
    of the Common Stock equals or exceeds $5.00 during such trading day period</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2021-10-132021-10-14_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">The
    remaining awarded units will vest when the Company&#x2019;s market capitalization is equal to or greater than $1,000,000,000 for at
    least ten trading days during any twenty (20) consecutive trading day period ending on or after December 15, 2021 and the fair market
    value of the Common Stock equals or exceeds $5.00 during such trading day period</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-272022-01-28_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="Shares">4040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-272022-01-28_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="USDPShares">15998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JanuaryTwentyEightTwoThousandTwentyTwoMember"
      decimals="0"
      unitRef="USD">15998</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-07-062022-07-07_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="Shares">50167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-062022-07-07_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="USDPShares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_JulySevenTwoThousandTwentyTwoMember"
      decimals="0"
      unitRef="USD">138587</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zP6y0EIgRuv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is the status of outstanding unvested restricted stock units outstanding as of December 31, 2022 and the changes for the
year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z2h1ggkmMNRa"&gt;Summary
of Restricted Stock Units Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Grant
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;RSUs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1VanMWyalIj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of RSUs, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRJZ6TxhYHSg" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za4oOKNcjzU" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhnwmuWgJ0hg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD88faltMzu6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1146"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6roEJbUYSr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJx5G7mIb8w6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(54,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo9jdXvPZEre" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ze5AL2xCNq7d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbgsmnENAzKa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1156"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzdPEWqALCl9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1158"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUyqnmMouUs7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1160"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUMpOav64Jpa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of RSUs, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,795,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUIeSvX75u73" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2795000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">54207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">54207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2795000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">22611550</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">22611550</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRINVxicGu4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_825_z4rl4q9GFFDc"&gt;Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of preferred shares or preferred warrants are entitled to vote per share, as limited by the certificate of designation for
each class of preferred shares or warrants, at meetings of the Company. As of December 31, 2022, &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_z7ncAdrf2z9c" title="Preferred stock, shares authorized"&gt;50,000,000&lt;/span&gt;
shares of Preferred Stock were authorized and four classes of Preferred Stock or Warrants are designated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
D Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 24, 2020, the Company designated &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zL3NL94lXDZg" title="Preferred stock, shares authorized"&gt;211,353&lt;/span&gt;
Series D Convertible Preferred Shares, &lt;span id="xdx_90E_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zuqjEpgTGVK2" title="Preferred stock, no par value"&gt;no&lt;/span&gt;
par value with a stated value of $&lt;span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyLifY4w5sT8" title="Preferred stock value, per share"&gt;0.01&lt;/span&gt;
per share and filed the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock
(the &#x201c;Series D Certificate of Designation&#x201d;) with the Secretary of State of the State of New Jersey. Pursuant to the
Series D Certificate of Designation, in the event of the Company&#x2019;s liquidation or winding up of its affairs, the holders of
its Series D Convertible Preferred Stock (the &#x201c;Preferred Stock&#x201d;) will be entitled to receive the same amount that a
holder of the Company&#x2019;s Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes
any conversion limitations set forth in the Series D Certificate of Designation) to Common Stock which amounts shall be paid pari
passu with all holders of the Company&#x2019;s Common Stock. Each share of Preferred Stock has a stated value equal to $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zoOK7jaAytye" title="Preferred stock value, per share"&gt;0.01&lt;/span&gt;
(the &#x201c;Stated Value&#x201d;), subject to increase as set forth in Section 7 of the Series D Certificate of
Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
holder of Preferred Stock is entitled at any time to convert any whole or partial number of shares of Preferred Stock into shares of
the Company&#x2019;s Common Stock determined by dividing the Stated Value of the Preferred Stock being converted by the conversion price
of $&lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zjeDksW4AeG3" title="Preferred stock, conversion price"&gt;0.01&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20200322__20200324__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ztkVIdHSqtx2" title="Preferred stock, terms of conversion"&gt;A
holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company&#x2019;s Common Stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company&#x2019;s
Common Stock then issued and outstanding (with such ownership restriction referred to as the &#x201c;Beneficial Ownership Limitation&#x201d;).
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days after such notice to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subject
to the Beneficial Ownership Limitation, on any matter presented to the Company&#x2019;s stockholders for their action or consideration
at any meeting of the Company&#x2019;s stockholders (or by written consent of stockholders in lieu of a meeting), each holder of Preferred
Stock will be entitled to cast the number of votes equal to the number of whole shares of the Company&#x2019;s Common Stock into which
the shares of Preferred Stock beneficially owned by such holder are convertible as of the record date for determining stockholders entitled
to vote on or consent to such matter (taking into account all Preferred Stock beneficially owned by such holder). Except as otherwise
required by law or by the other provisions of the Company&#x2019;s certificate of incorporation, the holders of Preferred Stock will vote
together with the holders of the Company&#x2019;s Common Stock and any other class or series of stock entitled to vote thereon as a single
class.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
holder of Preferred Stock shall be entitled to receive dividends as and when paid to the holders of the Company&#x2019;s Common Stock
on an as-converted basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had &lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zwYANJCRt7i9" title="Preferred stock, shares outstanding"&gt;72,992&lt;/span&gt; shares of Series D Convertible Preferred Stock outstanding which represent &lt;span id="xdx_900_ecustom--NumberOfCommonStockSharesRepresentByPreferredStockOutstanding_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqrFqPYMGxA9" title="Underlying shares of common stock"&gt;36,496&lt;/span&gt; underlying
shares of the Company Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Merger Agreement, on April 16, 2021, the Company filed an amended and restated certificate of incorporation (the &#x201c;A&amp;amp;R
Charter&#x201d;) with the Secretary of State of the State of New Jersey, which was approved by the Company&#x2019;s stockholders on April
15, 2021. Among other things, the A&amp;amp;R Charter (i) changed the Company&#x2019;s name to MyMD Pharmaceuticals, Inc., (ii) increased
the number of shares of Company Common Stock available from &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210415__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zO5Ntc4lkiH8" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares to a total of &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z6ZiiAHLaxV2" title="Common stock, shares authorized"&gt;500,000,000&lt;/span&gt; shares of the Company&#x2019;s
Common Stock, (iii) changed the structure of the board of directors from a classified board of three classes to a non-classified board
of a single class, and (iv) simplified and consolidated various provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of common shares are entitled to one vote per share at meetings of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 11, 2021, &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210210__20210211__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2pkCf3yGxa5" title="Number of shares issued"&gt;466,216&lt;/span&gt; shares of Common Stock issued pursuant to that certain Securities Purchase Agreement, dated November 11, 2020,
by and between the Company and certain institutional and accredited investors were cancelled and &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210211__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zVON2Wc1Xtud" title="Warrants, issued"&gt;466,216&lt;/span&gt; prefunded warrants (as defined
therein) were issued at the request of a shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 18, 2021, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210517__20210518__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zpZhpTUJuN4j" title="Number of shares, exercised"&gt;466,216&lt;/span&gt; prefunded warrants were exercised in exchange for &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210517__20210518__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSMh62Tcias1" title="Number of shares, exchange"&gt;466,716&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 5, 2021, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210804__20210805__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqHyDjK6snW5" title="Shares issued for services"&gt;16,826&lt;/span&gt; shares of Common Stock with a fair market value of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210804__20210805__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjBJTUDN0aki" title="Fair market value of shares issued for services"&gt;90,002&lt;/span&gt; for services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 9, 2021, holders of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211208__20211209_zIJcRz0Vwft7" title="Common stock options"&gt;11,576&lt;/span&gt; Common Stock options were exercised for &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211208__20211209_zb6LcgDzfgkk" title="Common stock options, exercised"&gt;11,576&lt;/span&gt; shares of Common Stock at an exercise
price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20211209_z5N636Vl2Gb2" title="Common stock options, exercise price"&gt;2.59&lt;/span&gt; per common share. The net proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20221231_zJM5rIRuICzj" title="Common stock options, proceeds"&gt;29,982&lt;/span&gt; is recorded as a current liability on the Consolidated Balance
Sheet as of December 31, 2022. The accumulated proceeds from the exercise of these stock options will be distributed to the former shareholders
of MyMD Florida per the terms of the Merger Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2022, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220215__20220216__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zqZlm6bGPqB8" title="Number of shares, exercised"&gt;385,135&lt;/span&gt; prefunded warrants were exercised in exchange for &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220215__20220216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFvnn8dNU04" title="Number of shares, exchange"&gt;385,135&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 17, 2022, pursuant to a securities purchase agreement with certain institutional and accredited investors, dated August 15, 2022,
the Company issued and sold in a registered direct offering (the &#x201c;August Offering&#x201d;) an aggregate of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817_zIoV9F8vOmsc" title="Stock issued during period share new issues"&gt;1,411,764&lt;/span&gt; shares of its
Common Stock at an offering price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20220817_zW7pfVSQyK19" title="Share price"&gt;4.25&lt;/span&gt; per share and &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817_z0wroB98M1Ph" title="Stock issued during period share new issues"&gt;1,411,764&lt;/span&gt; unregistered investor warrants to purchase up to &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220816__20220817_ziWAPPdqBsff" title="Stock issued during period share new issues"&gt;1,411,764&lt;/span&gt; shares
of its Common Stock at an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220817_zleGxkNuJbCf" title="Exercise price"&gt;5.25&lt;/span&gt;, for gross and net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220816__20220817_zlxb5qpjevtg" title="Proceeds from issuance of common stock"&gt;5,999,997&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_c20220816__20220817_zQxS11gU6kee" title="Net proceeds from issuance of common stock"&gt;5,550,028&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFkPcvMDqjg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zUHlIhuGm3Fb" style="display: none"&gt;Summary
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCIUzgfiGM98" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,074,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zio4pID9j5P9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgZMHVNocLqk" title="Weighted Average Remaining Contractual Term (years), Beginning"&gt;4.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeg1CBIpIr8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,554,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTLF2wpCzQbj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,450,029&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKIQSLNimS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.27&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVHdIWWxZGA9" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;4.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVR1fnyZgg8b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkL8JJxHRuK8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbmMkCqfeAW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z82sk2wBeyhg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhFq1YzDwA7j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9,691&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgxDyxsMcYk7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;222.55&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XINGBMFcWi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwK4Ys4Rs7K3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNsxEbOoXQE9" title="Weighted Average Remaining Contractual Term (years), Ending Balance"&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOoihMVONPek" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1266"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLhYk0yV4iXf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWwnM3AQmSE4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSgelimLgNig" title="Weighted Average Remaining Contractual Term (years), Exercisable"&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLblHPE20cM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z4ObSUF6dT4l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP1hRM1LsrJ2" title="Class of warrant or right, exercise price of warrants or rights"&gt;1.15&lt;/span&gt;&lt;/span&gt; for the Company&#x2019;s common shares on December 31, 2022 and the closing stock price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1nzKe022WFc" title="Class of warrant or right, exercise price of warrants or rights"&gt;6.06&lt;/span&gt; for the Company&#x2019;s common
shares on December 31, 2021. All warrants were vested on date of grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 7, 2022, the Company issued warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220706__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQU4EuaCiGK5" title="Issuance of common stock for warrants, shares"&gt;38,265&lt;/span&gt;
shares of its Common Stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxbhXdYLFmB4" title="Warrant exercise price per share"&gt;5.98&lt;/span&gt;
to a vendor for services. The cumulative fair market value of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220706__20220707_zZo0ssnvcwl5" title="Fair value of warrants"&gt;93,233&lt;/span&gt;
as calculated using Black-Scholes (exercise price $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220707_zZEftDmBLzYf" title="Warrant exercise price per share"&gt;5.98&lt;/span&gt;
per share, stock price $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20220707_zxNbr8MLHmwk" title="Stock price per share"&gt;2.99&lt;/span&gt;
per share, volatility of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_c20220707__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zSfbBke4HGfi" title="Stock price per share"&gt;131.06%&lt;/span&gt;,
discount rate of &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_c20220707__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zr27joCNfuH2" title="Stock price per share"&gt;3.07%&lt;/span&gt;
and a &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaSbziPt8nS8" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;five&lt;/span&gt;&lt;/span&gt;-
year term). The warrants will be exercisable at any time and from time to time, in whole or in part, following the date of issuance
and for a term of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsZjIKIhyoj2" title="Warrants term"&gt;five
years&lt;/span&gt; from the effective date. The fair-market value of the warrants was amortized over the life of the service contract.
During the year ended December 31, 2022, the Company recognized $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoY4i4YTJ5Ya" title="Stock-based compensation"&gt;84,851&lt;/span&gt;
in expense which is included in Stock-Based Compensation on the Consolidated Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 17, 2022, in connection with the August Offering, the Company issued unregistered investor warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220817__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zU2rx2PcFFb9" title="Issuance of warrant"&gt;1,411,764&lt;/span&gt;
shares of its Common Stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmzNJKpmXTB8" title="Class of warrant or right, exercise price of warrants or rights"&gt;5.25&lt;/span&gt; (the &#x201c;August Investor Warrants&#x201d;) in a private placement. The August
Investor Warrants will be exercisable at any time and from time to time, in whole or in part, beginning six-months following the date
of issuance and for a term of five years from the initial exercise date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Pre-funded
Common Stock Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zuKyqluIE4Mf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the pre-funded warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zOnA9QjAv8f1" style="display: none"&gt;Summary
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zc3R2h01hbg9" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;520,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zxS5jU9uZnCd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zkh9XShkctni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,151,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5hesPOZ4O36" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1312"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zyX1PqfGIuSg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zoobEKmUY3bd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(385,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCF1LkSgZjYb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zmGL1uFNUSye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zhtkgmIBblO9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJ5ZBbB6XP2i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1324"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zV1cpsQwPWZ9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCIo0kSUXXjc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5NgHI1oApo6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z1z95icvQrb3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    as of December 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zIh74WklD2L5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zUOX35pfcVu" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJlRxnOtpnzi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zUNuvOZ3Hywa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
pre-funded warrants were vested on date of grant and are exercisable at any time. The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying award and the closing stock price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zTNgxEfajyFj" title="Share price"&gt;1.15&lt;/span&gt; for the Company&#x2019;s common shares
on December 31, 2022 and the closing stock price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zTR5X61Asx47" title="Share price"&gt;6.06&lt;/span&gt; for  Common Stock on December 31, 2021.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
C Convertible Preferred Stock Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zVkcq8Siov2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zdD6CFV0UyG7" style="display: none"&gt;Summary
of Warrant Activity&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Term
    (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Balance
    at December 31, 2021&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zXkWw4XeT4F" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zH1xQdMrXnx" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zie5Y6BR6nB" title="Weighted Average Remaining Contractual Term (years), Beginning"&gt;2.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z2aslaOoKOL6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zERsFR22gIZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zeFpboMFUfAl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z8G5iHj4p9d5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1358"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zcS46sSV1Mr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziEddDLpqo79" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zpUx2CcZBGhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zBNZcL8trjOh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zECF6ZiIkEEl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Balance
    at December 31, 2022&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zmE1ebquwRm" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zl7MGpBgKCCj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zKdJFCSU5F49" title="Weighted Average Remaining Contractual Term (years), Ending Balance"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziJdhv0QoMl2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Exercisable
    as of December 31, 2022&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zyMSKudRgTW" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zx7nCp5KYcv6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zotenN2Co6c9" title="Weighted Average Remaining Contractual Term (years), Exercisable"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zDJfQPkARKA8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zna53PEszS7b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zMeqrFdCFUS6" title="Share price"&gt;1.15&lt;/span&gt; for the Company&#x2019;s common shares on December 31, 2022 and the closing stock price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z5g7fqKqwgEc" title="Share price"&gt;6.06&lt;/span&gt; for the Company&#x2019;s common
shares on December 31, 2021. All Series C Convertible Preferred Stock Warrants were vested on date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">211353</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2020-03-24_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="From2020-03-222020-03-24_custom_SeriesDConvertiblePreferredStockMember">A
holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company&#x2019;s Common Stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company&#x2019;s
Common Stock then issued and outstanding (with such ownership restriction referred to as the &#x201c;Beneficial Ownership Limitation&#x201d;).
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days after such notice to the Company.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">72992</us-gaap:PreferredStockSharesOutstanding>
    <MYMD:NumberOfCommonStockSharesRepresentByPreferredStockOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">36496</MYMD:NumberOfCommonStockSharesRepresentByPreferredStockOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-04-15_custom_MergerAgreementMember"
      decimals="INF"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-04-16_custom_MergerAgreementMember"
      decimals="INF"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-102021-02-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">466216</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-02-11_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">466216</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-05-172021-05-18_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">466216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-05-172021-05-18_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">466716</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-08-042021-08-05_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16826</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-08-042021-08-05_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">90002</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-12-082021-12-09"
      decimals="INF"
      unitRef="Shares">11576</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-12-082021-12-09"
      decimals="INF"
      unitRef="Shares">11576</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-09"
      decimals="INF"
      unitRef="USDPShares">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">29982</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-02-152022-02-16_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">385135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-02-152022-02-16_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">385135</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-08-17" decimals="INF" unitRef="Shares">1411764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SharePrice
      contextRef="AsOf2022-08-17"
      decimals="INF"
      unitRef="USDPShares">4.25</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-08-17" decimals="INF" unitRef="Shares">1411764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-08-162022-08-17"
      decimals="INF"
      unitRef="Shares">1411764</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-17"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-08-162022-08-17"
      decimals="0"
      unitRef="USD">5999997</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <MYMD:NetProceedsFromIssuanceOfCommonStock
      contextRef="From2022-08-162022-08-17"
      decimals="0"
      unitRef="USD">5550028</MYMD:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFkPcvMDqjg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zUHlIhuGm3Fb" style="display: none"&gt;Summary
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCIUzgfiGM98" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Warrants, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,074,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zio4pID9j5P9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgZMHVNocLqk" title="Weighted Average Remaining Contractual Term (years), Beginning"&gt;4.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeg1CBIpIr8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,554,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTLF2wpCzQbj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,450,029&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKIQSLNimS6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.27&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVHdIWWxZGA9" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;4.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVR1fnyZgg8b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkL8JJxHRuK8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbmMkCqfeAW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z82sk2wBeyhg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhFq1YzDwA7j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9,691&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgxDyxsMcYk7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;222.55&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XINGBMFcWi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwK4Ys4Rs7K3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNsxEbOoXQE9" title="Weighted Average Remaining Contractual Term (years), Ending Balance"&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOoihMVONPek" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1266"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLhYk0yV4iXf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,514,827&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWwnM3AQmSE4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSgelimLgNig" title="Weighted Average Remaining Contractual Term (years), Exercisable"&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLblHPE20cM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">5074489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.25</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">P4Y4M2D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember"
      decimals="0"
      unitRef="USD">9554827</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1450029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.27</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">P4Y10M17D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">9691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">222.55</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">6514827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.93</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">P3Y7M17D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">6514827</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.93</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">P3Y7M17D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">6.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-062022-07-07_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">38265</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-07_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-07-062022-07-07"
      decimals="0"
      unitRef="USD">93233</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-07"
      decimals="INF"
      unitRef="USDPShares">5.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-07"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-07_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      unitRef="Days">131.06</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-07_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      unitRef="Days">3.07</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-07-07_us-gaap_WarrantMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">84851</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-08-17_srt_MaximumMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">1411764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-17_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember">&lt;p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zuKyqluIE4Mf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the pre-funded warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zOnA9QjAv8f1" style="display: none"&gt;Summary
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Term
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zc3R2h01hbg9" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;520,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zxS5jU9uZnCd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zkh9XShkctni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,151,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5hesPOZ4O36" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1312"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zyX1PqfGIuSg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zoobEKmUY3bd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(385,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCF1LkSgZjYb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zmGL1uFNUSye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zhtkgmIBblO9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJ5ZBbB6XP2i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1324"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zV1cpsQwPWZ9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zCIo0kSUXXjc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z5NgHI1oApo6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_z1z95icvQrb3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    as of December 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zIh74WklD2L5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zUOX35pfcVu" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.002&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedCommonStockWarrantsMember_zJlRxnOtpnzi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">520270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.002</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="0"
      unitRef="USD">3151796</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">385135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.002</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">135135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.002</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="0"
      unitRef="USD">155135</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">135135</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.002</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="0"
      unitRef="USD">155135</MYMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.15</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_PreFundedCommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">6.06</us-gaap:SharePrice>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zVkcq8Siov2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zdD6CFV0UyG7" style="display: none"&gt;Summary
of Warrant Activity&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Term
    (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Balance
    at December 31, 2021&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zXkWw4XeT4F" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Warrants, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zH1xQdMrXnx" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zie5Y6BR6nB" title="Weighted Average Remaining Contractual Term (years), Beginning"&gt;2.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z2aslaOoKOL6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;-&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zERsFR22gIZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zeFpboMFUfAl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_z8G5iHj4p9d5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1358"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zcS46sSV1Mr1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziEddDLpqo79" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zpUx2CcZBGhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zBNZcL8trjOh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zECF6ZiIkEEl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Balance
    at December 31, 2022&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zmE1ebquwRm" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zl7MGpBgKCCj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zKdJFCSU5F49" title="Weighted Average Remaining Contractual Term (years), Ending Balance"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_ziJdhv0QoMl2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Exercisable
    as of December 31, 2022&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zyMSKudRgTW" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zx7nCp5KYcv6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zotenN2Co6c9" title="Weighted Average Remaining Contractual Term (years), Exercisable"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCConvertiblePreferredStockWarrantsMember_zDJfQPkARKA8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">27500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">8.00</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">P2Y11M8D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">27500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">8.00</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">P1Y11M8D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">27500</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">8.00</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember">P1Y11M8D</MYMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.15</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">6.06</us-gaap:SharePrice>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zArKxzeQ08C" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_82E_zio8C6qM5kVg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zoK1Q7XEWVH1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s income tax (benefit)/provision is as follows for the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zsV0g3b1tHg3" style="display: none"&gt;Schedule
of Income Tax (Benefit)/Provision&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z0prSLIoi1sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zC7VPToJc4J5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBziYA_zKJi3HzmnZik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1394"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1395"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBziYA_z8nfiAwm8a6k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(5,914,000&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,219,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBziYA_zJsR53boBvA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in Valuation
    Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,914,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,219,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBziYA_zG4moYR3Z8L7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income Tax Benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1403"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zDd5Dk5LOvte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfOV2YvTSGj2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December
31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zASRnJr28zp7" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Rate and Benefit from Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zwQqHj4CXgk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zdqzOJo8RcFc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zdMn1hw0DIsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Statutory U.S. Federal Income Tax
    Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zWbi3Sd1Hgt1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;New Jersey State income taxes, net of U.S.
    Federal tax effect&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(14.5&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_ziYTR5nYljZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Adjustment to deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_zip9QRej0Chg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zIOZtTK0kCj2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in Valuation
    Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;38.9&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zGeYYSEJhCW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zwE8UBpNacK5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, and 2021, the Company had U.S. federal net operating loss carry forwards of approximately $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZSg2HVDhAl4"&gt;107.1&lt;/span&gt;&#160;million and
$&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOyTyWjiEUO7" title="Net operating loss carry forwards"&gt;101.9&lt;/span&gt;&#160;million, respectively. Approximately $&lt;span id="xdx_90D_ecustom--OperatingLossCarryforwarddSubjectToExpiration_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_za6FQW8laGX5" title="Net operating loss carry forwards subject to expiration"&gt;57.7&lt;/span&gt;&#160;million of the U.S. federal net operating loss generated in tax years beginning
before January 1, 2018 expire beginning with the year ending&#160;&lt;span id="xdx_901_ecustom--OperatingLossCarryforwardsExpirationDateDescription_dd_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zVMzX1U9362k" title="Expiration date description"&gt;December 31, 2023 through 2037&lt;/span&gt;. The remaining U.S. federal net operating
loss of approximately $&lt;span id="xdx_902_ecustom--OperatingLossCarryforwardsNotSubjectToExpiration_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zhhSkjQTwk5b" title="Net operating loss carry forwards not to expiration"&gt;49.4&lt;/span&gt;&#160;million does not expire, however it is limited to&#160;&lt;span id="xdx_905_ecustom--PercentageOfNetIncomeForEachSubsequentPeriod_dp_c20171229__20180102_zI3W4bYjVAE3" title="Percentage of net income"&gt;80&lt;/span&gt;%&#160;of each subsequent year&#x2019;s net
income. As of December 31, 2022, and 2021, the Company had U.S. state net operating loss carry forwards of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zMAt34nYTMJ8"&gt;41.0&lt;/span&gt;&#160;million
and $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zFi18RXRvQBd"&gt;38.2&lt;/span&gt;&#160;million, respectively, some of which expire beginning with the year ending&#160;&lt;span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationDateDescription_dd_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ztYwTGwH4eEb"&gt;December 31, 2023 through 2042&lt;/span&gt;. U.S. federal
net operating losses of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231_zvr0dPnJFE7e" title="Net operating loss"&gt;3.8&lt;/span&gt; million expired during 2022. The timing and manner in which the Company can utilize operating
loss carryforwards in any year may be limited by provisions of the Internal Revenue Code regarding changes in ownership of corporations.
Such limitation may have an impact on the ultimate realization of its carryforwards and future tax deductions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Section 382 of the Code, use of the Company&#x2019;s net operating loss carryforwards is limited if the Company experiences a cumulative
change in ownership of greater than&#160;&lt;span id="xdx_90B_ecustom--CumulativeChangeInOwnershipPercentage_iI_dp_c20221231_zmZzZHunlGU7"&gt;50&lt;/span&gt;%&#160;in a moving three-year period. The Company experienced an ownership change as a result
of the Merger and therefore the Company&#x2019;s ability to utilize its net operating loss and certain credit carryforwards are limited.
The limitation is determined by the fair market value of the Company&#x2019;s common stock outstanding immediately prior to the ownership
change, multiplied by the applicable federal rate. It is expected that the Merger caused the Company&#x2019;s net operating loss carryforwards
to be limited. However, the limitation had no impact on the Company&#x2019;s financial statements since the Company recorded a full valuation
allowance for the deferred tax assets as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxtH4Vfy0KYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of the deferred tax assets and related valuation allowances as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zopZG5pvkGKe" style="display: none"&gt;Schedule
of Deferred Tax Assets and Related Valuation Allowances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zgGUYS0jpUXj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_z5ettnnAHKyd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pp0p0_maDTALNzOrT_zU3gfbiIzQ71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reserves
    and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;745,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;179,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzOrT_zu0aQFEYrbag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    operating loss carry-forwards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;26,176,000&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,526,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_maDTALNzOrT_zzDvfhPEYTgj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,177,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1452"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTALNzOrT_zrptaCcKFBF4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;610,000&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzOrT_zI6OYdLPDECf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,542,000&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzOrT_zpkpTZXujqx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(34,250,000&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28,336,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzOrT_zatvi99tVnZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1463"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1464"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zFzZC2LH8FC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation allowance for deferred tax assets increased by approximately $&lt;span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20220101__20221231_z9U4ZHTKzpbi" title="Change in valuation allowance"&gt;5.9&lt;/span&gt;&#160;million and $&lt;span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20210101__20211231_zeogcwDYqs4"&gt;6.2&lt;/span&gt;&#160;million, for the years ended December
31, 2022 and 2021, respectively, due mainly to increases in the Company&#x2019;s deferred tax asset related to its net operating loss
carryforward. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some
portion or all of the deferred tax assets may be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which the net operating losses and temporary differences become deductible. Management
considers projected future taxable income and tax planning strategies in making this assessment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were no amounts accrued for penalties and interest for the years ended December 31, 2022 and 2021.
The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any
issues under review that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company files
U.S. federal income tax returns and state income tax returns. Since the Company had losses in the past, all prior years that generated
net operating loss carryforwards are open and subject to audit examination in relation to the net operating loss generated from those
years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zoK1Q7XEWVH1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s income tax (benefit)/provision is as follows for the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zsV0g3b1tHg3" style="display: none"&gt;Schedule
of Income Tax (Benefit)/Provision&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z0prSLIoi1sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zC7VPToJc4J5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBziYA_zKJi3HzmnZik" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1394"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 80pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1395"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBziYA_z8nfiAwm8a6k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(5,914,000&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,219,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBziYA_zJsR53boBvA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in Valuation
    Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,914,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,219,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBziYA_zG4moYR3Z8L7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income Tax Benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1403"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5914000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-6219000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5914000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-6219000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfOV2YvTSGj2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December
31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zASRnJr28zp7" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Rate and Benefit from Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zwQqHj4CXgk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zdqzOJo8RcFc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zdMn1hw0DIsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Statutory U.S. Federal Income Tax
    Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zWbi3Sd1Hgt1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;New Jersey State income taxes, net of U.S.
    Federal tax effect&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(14.5&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_ziYTR5nYljZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Adjustment to deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_zip9QRej0Chg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zIOZtTK0kCj2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in Valuation
    Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;38.9&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zGeYYSEJhCW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.145</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.090</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.041</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.093</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.389</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.208</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      unitRef="USD">107100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      unitRef="USD">101900000</us-gaap:OperatingLossCarryforwards>
    <MYMD:OperatingLossCarryforwarddSubjectToExpiration
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      unitRef="USD">57700000</MYMD:OperatingLossCarryforwarddSubjectToExpiration>
    <MYMD:OperatingLossCarryforwardsExpirationDateDescription contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">December 31, 2023 through 2037</MYMD:OperatingLossCarryforwardsExpirationDateDescription>
    <MYMD:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      unitRef="USD">49400000</MYMD:OperatingLossCarryforwardsNotSubjectToExpiration>
    <MYMD:PercentageOfNetIncomeForEachSubsequentPeriod
      contextRef="From2017-12-292018-01-02"
      decimals="INF"
      unitRef="Pure">0.80</MYMD:PercentageOfNetIncomeForEachSubsequentPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      unitRef="USD">41000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      unitRef="USD">38200000</us-gaap:OperatingLossCarryforwards>
    <MYMD:OperatingLossCarryforwardsExpirationDateDescription contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">December 31, 2023 through 2042</MYMD:OperatingLossCarryforwardsExpirationDateDescription>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">3800000</us-gaap:OperatingLossCarryforwards>
    <MYMD:CumulativeChangeInOwnershipPercentage contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.50</MYMD:CumulativeChangeInOwnershipPercentage>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxtH4Vfy0KYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of the deferred tax assets and related valuation allowances as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zopZG5pvkGKe" style="display: none"&gt;Schedule
of Deferred Tax Assets and Related Valuation Allowances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zgGUYS0jpUXj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_z5ettnnAHKyd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pp0p0_maDTALNzOrT_zU3gfbiIzQ71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reserves
    and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;745,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;179,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzOrT_zu0aQFEYrbag" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    operating loss carry-forwards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;26,176,000&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,526,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_maDTALNzOrT_zzDvfhPEYTgj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,177,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1452"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTALNzOrT_zrptaCcKFBF4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;610,000&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTALNzOrT_zI6OYdLPDECf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,542,000&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzOrT_zpkpTZXujqx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(34,250,000&lt;/p&gt;
&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28,336,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzOrT_zatvi99tVnZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1463"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1464"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">745000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">179000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">26176000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">23526000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2177000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">610000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">610000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4542000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4021000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">34250000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">28336000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-5900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="-5"
      unitRef="USD">-6200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6ATT4wXUqZ3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_824_zj0qYknxvO17"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Scientific
Advisory Board&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 1, 2021, the Company formed the Scientific Advisory Board to (i) provide strategic advice and make recommendations to management
regarding current and planned research and development programs, (ii) advise management regarding the scientific merit of technology
or products involved in licensing and acquisition opportunities and (iii) provide strategic advice to management regarding emerging science
and technology issues and trends. During the years ended December 31, 2022 and 2021, the Company incurred costs of $&lt;span id="xdx_90E_eus-gaap--CostsAndExpenses_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxUcjzvT6mIb" title="Cost and expenses incurred"&gt;148,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--CostsAndExpenses_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zCiNHjwf9Th9" title="Cost and expenses incurred"&gt;174,000&lt;/span&gt;, respectively.
These expenses are included in Research and Development Expenses on the Consolidated Statement of Comprehensive Loss. The Scientific
Advisory Board was disbanded effective September 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;COVID-19&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China and has reached multiple other
countries, resulting in government-imposed quarantines, travel restrictions and other public health safety measures, including in the
United States and India. On March 12, 2020, the WHO declared COVID-19 to be a global pandemic. The various precautionary measures taken
by many governmental authorities around the world in order to limit the spread of COVID-19 have had and may continue to have an adverse
effect on the global markets and global economy. Such government-imposed precautionary measures may have been relaxed in certain countries
or states, but there is no assurance that more strict measures will not be put in place again due to a resurgence in COVID-19 cases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ultimate impact of the global COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet
know the full extent of potential delays or impacts on the Company&#x2019;s business, vaccine development efforts, healthcare systems
or the global economy as a whole. However, the effects have had and will likely continue to have a material impact on the Company&#x2019;s
operations, liquidity and capital resources, and the Company will continue to monitor the COVID-19 situation closely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severe
and/or long-term disruptions in the Company&#x2019;s operations may negatively impact the Company&#x2019;s business, operating results
and financial condition in other ways as well. Specifically, the Company anticipates that the stress of COVID-19 on healthcare systems
generally around the globe may negatively impact regulatory authorities and the third parties that the Company may engage in connection
with the development and testing of its product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
anticipated economic consequences of the COVID-19 pandemic have adversely impacted financial markets, resulting in high share price volatility,
reduced market liquidity, and substantial declines in the market prices of the shares of most publicly traded companies, including MyMD.
Volatile or declining markets for equities could adversely affect the Company&#x2019;s ability to raise capital when needed through the
sale of shares of Common Stock or other equity securities. Should these market conditions persist when the Company needs to raise capital,
and if the Company is able to sell shares of its Common Stock under then prevailing market conditions, it might have to accept lower
prices for its shares and issue a larger number of shares than might have been the case under better market conditions, resulting in
significant dilution of the interests of the Company&#x2019;s shareholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Litigation
and Settlements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Raymond
Akers Actions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 14, 2021, Raymond F. Akers, Jr., Ph.D. filed a lawsuit against MyMD Pharmaceuticals, Inc. (p/k/a Akers Biosciences, Inc.) in the
Superior Court of New Jersey, Law Division, Gloucester County (the &#x201c;First Raymond Akers Action&#x201d;). Mr. Akers asserts one common
law whistleblower retaliation claim against the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2021, the Court granted MyMD Pharmaceutical, Inc.&#x2019;s (&#x201c;MyMD&#x2019;s&#x201d;) Motion to Dismiss Plaintiff&#x2019;s
Amended Complaint and dismissed Plaintiff&#x2019;s Amended Complaint. The Court indicated that Mr. Akers is &#x201c;free to file another
complaint, however, tort-based &#x2018;Pierce&#x2019; allegations, and/or CEPA claims are barred by the statute of limitations.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 1, 2022, Mr. Akers filed a second action against MyMD in the Superior Court of New Jersey, Law Division, Gloucester County (the
&#x201c;Second Raymond Akers Action&#x201d;) again asserting one common law whistleblower retaliation claim against the Company. The Company
believes that the Second Raymond Akers Action is without merit and, moreover, was filed against the Court&#x2019;s specific admonition
that Plaintiff does not attempt to circumvent the statute of limitations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 27, 2022, the Court granted-in-part and denied-in-part MyMD&#x2019;s Motion to Dismiss Plaintiff&#x2019;s Complaint. The Court reaffirmed
the ruling in the First Raymond Akers Action that any tort-based Pierce claims are time-barred. However, the Court denied the Motion
as it pertained to Plaintiff&#x2019;s contract-based Pierce claim and &#x201c;Repayment of Monies Owed&#x201d; claim. On July 29, 2022,
MyMD filed its Answer, which included affirmative defenses. As of December 31, 2022, the Second Raymond Akers Action is in the discovery
phase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
legal fees incurred were expensed as and when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">148000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">174000</us-gaap:CostsAndExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zlUBvMRuBGS" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_82A_zwbBvqt7BbK9"&gt;Related Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Taglich
Brothers, Inc.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 23, 2020, the Company&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;retained Taglich Brothers,
Inc. (&#x201c;Taglich Brothers&#x201d;) on a non-exclusive basis as a consultant to render consulting services, assist with review, and
analysis of, financial planning and budgeting matters of the Company for a term of 12 months. Pursuant to the Consulting Agreement with
Taglich Brothers, the Company agreed to pay Taglich Brothers $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20201122__20201123__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TaglichBrothersIncMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z0h2UJLPq08f" title="Amounts paid by related party"&gt;10,000&lt;/span&gt; per month. During the year ended December 31, 2021, the Company
paid $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TaglichBrothersIncMember_zIkmIpLWketa"&gt;80,000&lt;/span&gt; for consulting services to Taglich Brothers, Inc. which is included in administrative expenses on the Consolidated Statement
of Comprehensive Loss. This agreement was cancelled on August 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr.
Schreiber, a Director, is the Managing Director of Capital Markets at Taglich Brothers. Mr. Schroeder, a former Director was the Vice
President of Investment Banking at Taglich Brothers until his death on September 1, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;SRQ
Patent Holdings and SRQ Patent Holdings II&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MyMD
is a party to two Amended and Restated Confirmatory Patent Assignment and Royalty Agreements, both dated November 11, 2020, with SRQ
Patent Holdings and SRQ Patent Holdings II, under which MyMD (or its successor) will be obligated to pay to SRQ Patent Holdings or SRQ
Patent Holdings II (or its designees) certain royalties on product sales or other revenue received on products that incorporate or are
covered by the intellectual property that was assigned to MyMD. The royalty is equal to 8% of the net sales price on product sales and,
without duplication, 8% of milestone revenue or sublicense compensation. SRQ Patent Holdings and SRQ Patent Holdings II are affiliates
of Mr. Jonnie Williams, Sr. No revenue has been received subject to these agreements as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Mr.
Jonnie Williams, Sr.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an obligation to Mr. Williams, a shareholder, for various expenses incurred on behalf of the Company between 2016 and
2019. The balance due of $&lt;span id="xdx_906_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--MrWilliamsMember_z72ITYnqcn42" title="Due to officer"&gt;14,577&lt;/span&gt; was paid on April 28, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Supera
Aviation I, LLC&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2018, the Company entered a three-year leasing agreement with Supera Aviation I, LLC, a company owned by a shareholder, for a
Gulfstream IV-SP aircraft with an annual leasing fee of $&lt;span id="xdx_901_ecustom--AnnualLeasingFee_pp0p0_c20181001__20181031__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember_zJAF8JiXjkng" title="Annual leasing fee"&gt;600,000&lt;/span&gt;. The Company incurred expenses totaling $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember_zqAVZ0tIv394" title="Operating lease expense"&gt;150,000&lt;/span&gt; for the year ended
December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 28, 2021, the Company reached a negotiated settlement with Supera Aviation I, LLC to retire the $&lt;span id="xdx_905_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--TypeOfArrangementAxis__custom--NegotiatedSettlementMember_zgDpKLpbu15e" title="Due to related party retired"&gt;627,042&lt;/span&gt; debt due under the leasing
agreement for $&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210428__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--TypeOfArrangementAxis__custom--NegotiatedSettlementMember_z3soMpqhEdUa" title="Total future minimum lease payments, undiscounted"&gt;517,384&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lines
of credit payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2018, Supera entered into a revolving credit facility which allows for borrowings of up to $&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkVbdHT89455" title="Maximum borrowing facility"&gt;1,000,000&lt;/span&gt; with a shareholder. The
facility had an initial term of &lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationPeriod_c20181101__20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zKKXO1SaWGX7" title="Line of credit facility expiration period"&gt;38 months&lt;/span&gt;, which was extended to &lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationDate1_pp0p0_dd_c20181101__20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0jTa4d6m65a" title="Expiration date"&gt;December 31, 2022&lt;/span&gt; at which time all outstanding borrowings and accrued
interest, if any, are due in full. Borrowings accrue interest at a rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181130__us-gaap--RelatedPartyTransactionAxis__custom--SuperaAviationILLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z2RZPKkT0NL7" title="Borrowings accrue interest rate percentage"&gt;5%&lt;/span&gt; per annum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2019, the pre-Merger MyMD entered into a revolving credit facility which allows for borrowings of up to $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zLworK7LEbcd" title="Borrowing capacity revolving credit facility"&gt;5,000,000&lt;/span&gt; with a shareholder.
&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_pp0p0_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z5fbcYgMbTWh" title="Line of credit facility, description"&gt;The facility had an initial term of &lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_pp0p0_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zd3OybZpaEa6" title="Initial term"&gt;18 months&lt;/span&gt;&lt;/span&gt;, which was extended to July 31, 2021 and further extended to December 31, 2022, at which
time all outstanding borrowings and accrued interest, if any, are due in full. Borrowings accrue interest at a rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zTs3baJuMuAe" title="Borrowings accrued interest rate"&gt;5%&lt;/span&gt; per annum.
Pursuant to the terms of the agreement, the Company must issue a number of Common Stock options to the lender based on the total borrowings
under the facility, with each dollar borrowed requiring the issuance of one Common Stock option. Upon issuance, each Common Stock option
will immediately vest at an exercise price of $&lt;span id="xdx_906_eus-gaap--StockOptionExercisePriceIncrease_pid_c20190501__20190531__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zKa6jJFPxPQj" title="Stock options exercise price"&gt;2.59&lt;/span&gt;. The Company recorded accretion of the debt discount totaling $&lt;span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zCUmSQSyI5C6" title="Amortization of debt discount"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zv9MDJyXYa8e" title="Amortization of debt discount"&gt;608,460&lt;/span&gt;, respectively,
during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 28, 2021, in accordance with the Merger, the Company paid $&lt;span id="xdx_903_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210427__20210428__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyPJPG97Msd5" title="Amounts paid by related party"&gt;3,208,426&lt;/span&gt;, inclusive of interest and net of the debt discount, to retire
the amounts due to the shareholder under the two lines of credit as of April 28, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2020-11-222020-11-23_custom_TaglichBrothersIncMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-01-012021-12-31_custom_TaglichBrothersIncMember"
      decimals="0"
      unitRef="USD">80000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent
      contextRef="AsOf2021-04-28_custom_MrWilliamsMember"
      decimals="0"
      unitRef="USD">14577</us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent>
    <MYMD:AnnualLeasingFee
      contextRef="From2018-10-012018-10-31_custom_SuperaAviationILLCMember"
      decimals="0"
      unitRef="USD">600000</MYMD:AnnualLeasingFee>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31_custom_SuperaAviationILLCMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2021-04-28_custom_SuperaAviationILLCMember_custom_NegotiatedSettlementMember"
      decimals="0"
      unitRef="USD">627042</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-04-28_custom_SuperaAviationILLCMember_custom_NegotiatedSettlementMember"
      decimals="0"
      unitRef="USD">517384</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="From2018-11-012018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember">P38M</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="From2018-11-012018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember">2022-12-31</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2018-11-30_custom_SuperaAviationILLCMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-05-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityDescription contextRef="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember">The facility had an initial term of 18 months</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:DebtInstrumentTerm contextRef="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember">P18M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-05-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2019-05-012019-05-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="USDPShares">2.59</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">608460</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-04-272021-04-28_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">3208426</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjkUkq543CT5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; &lt;span id="xdx_824_zpE55G3U0wlj"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified
employees of the Company (the &#x201c;401(k) Plan&#x201d;). Under the 401(k) Plan, the Company matches &lt;span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20220101__20221231_zvDSC4GBp3mk" title="Employer matching contribution, percent of match"&gt;100%&lt;/span&gt; up to a &lt;span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20220101__20221231_zPQVDxRE627k" title="Employer matching contribution, percent of employees' gross pay"&gt;3%&lt;/span&gt; contribution, and
&lt;span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMatchesFiftyPercentMember_zSJ7oC6zJqb4" title="Employer matching contribution, percent of match"&gt;50%&lt;/span&gt; over a &lt;span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMatchesFiftyPercentMember_zPLeJ7dKvQvc" title="Employer Matching Contribution, Percent of Employees' Gross Pay"&gt;3%&lt;/span&gt; contribution, up to a maximum of &lt;span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOneKPlanMaximumFivePercentMember_zaZ806lwcc1f" title="Employer matching contribution, percent of employees' gross pay"&gt;5%&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company made matching contributions to the 401(k) Plan during the years ended December 31, 2022 and 2021 of $&lt;span id="xdx_900_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zmL40eN5GMS" title="Contributions to employee"&gt;41,443&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zIORIKftZ8gg" title="Contributions to employee"&gt;16,514&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="From2022-01-012022-12-31_custom_FourZeroOneKPlanMatchesFiftyPercentMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="From2022-01-012022-12-31_custom_FourZeroOneKPlanMatchesFiftyPercentMember"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="From2022-01-012022-12-31_custom_FourZeroOneKPlanMaximumFivePercentMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">41443</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">16514</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_802_ecustom--PaycheckProtectionProgramLoanDisclosureTextBlock_zkAUboJurTXa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12&#x2014;&lt;span id="xdx_82E_zFZSPUXbwJIj"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 16, 2020, the Company received loan proceeds in the amount of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromLoans_c20200415__20200416__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_zULpMKTuNrX9" title="Proceeds from loans"&gt;70,600&lt;/span&gt; under the Paycheck Protection Program (&#x201c;PPP&#x201d;).
The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;), provides for loans to
qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued
interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities,
and maintains its payroll levels.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The
unforgiven portion of the PPP loan is payable over two years at an annual interest rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200415__20200416__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_znwExR090ZQ3" title="Debt interest rate"&gt;1%&lt;/span&gt;, with a deferral of payments through the
date that the Small Business Administration remits the borrower&#x2019;s loan forgiveness amount to the lender. The Company was notified
on June 1, 2021 that the loan totaling $&lt;span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210601__20210601__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoansMember_zpbE5QsBole6" title="Gain on debt forgiveness"&gt;70,600&lt;/span&gt; was forgiven which was recorded as a gain on debt forgiveness on the Consolidated Statement
of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember"
      decimals="0"
      unitRef="USD">70600</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-06-012021-06-01_custom_PaycheckProtectionProgramLoansMember"
      decimals="0"
      unitRef="USD">70600</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <MYMD:PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_ecustom--PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock_zgiUuIUWrefa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13&#x2014;&lt;span&gt;&lt;span id="xdx_821_zbmt1Y44aPG9"&gt;Patent Assignment and Royalty Agreement&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2016, the Company entered into an agreement with the holders of certain intellectual property relating to the Company&#x2019;s
current product candidate. Under the terms of the agreement, the counterparty assigned its rights and interest in certain patents to
the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as defined. The agreement is effective
until the later of (1) the date of expiration of the assigned patents or (2) the date of expiration of the last strategic partnership
or licensing agreement including the assigned patents. &lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20210101__20211231_zb74UuDN8Pn5" title="Revenue::XDX::-"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20220101__20221231_zf01aOEfKrXg" title="Revenue::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1540"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1542"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; revenue has been received subject to these agreements as of December 31, 2022
and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</MYMD:PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zIjPUKwOlzf8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14 &#x2013; &lt;span id="xdx_828_zPmZqcfL9Qti"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;On February 23, 2023,
pursuant to a securities purchase agreement with certain institutional and accredited investors, dated February 21, 2023, the
Company issued and sold in a registered direct offering i) an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNaC7wvNgPui" title="Number of shares issued"&gt;15,000&lt;/span&gt;
shares of the Company&#x2019;s newly-designated Series F Convertible Preferred Stock with a stated value of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zoMYnRpoinxj" title="Number of shares issued, value"&gt;1,000&lt;/span&gt;
per share, convertible into shares of Common Stock pursuant to the terms of the securities purchase agreement, and (ii) warrants to
acquire up to an aggregate of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvEzXU1vShPc" title="Warrants to acquire common stock"&gt;6,651,885&lt;/span&gt;
shares of Common Stock, subject to adjustment, for gross and net proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zespgBy8OXNj" title="Gross proceeds"&gt;15,000,000&lt;/span&gt;
and $&lt;span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InstitutionalAndAccreditedInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcHiMIW3vxFh" title="Net proceeds"&gt;14,041,500&lt;/span&gt;,
respectively.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_SeriesFConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">6651885</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <MYMD:NetProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-212023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">14041500</MYMD:NetProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MTL;M,8U;IK&3Z1W(IB)=(5IEZ!KF5<'7>J5V<HY[7!(OF@2$''#NQT%4B+W
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MT^Z4>^24>Z3D& .<CT$<I"%#@4 N"]\A'=\@HA&M+XN4I&*\?I_O@Y#=S>2
MG#/^PF;WJ"\K@#CND4-+3C'<O]P;FF;<+E[.X]Q32#<P-FRK6=#K%IP;MFD1
M2O1F2;^G)"74TG1R*MB(A7Z*A3XF%C<HWP7RSD?%1$F<$),K.#]\ATWMY[[
M'&'F60,1FU)=UUIMOH+TZD'"?"!8(P^,4QX8RCSX1:Y^XBS/^^*MM)P0;R".
M"\19 7$\HY-Z<^+8MJ,9M-6+QY1LA(^>PD>5X5M]93R,<E9,X+*V>SE_(':<
MK^6R]37@:Q1FJ>!R!9@7WZ#S.:LOYDIW$V(.Q'&!."L@C@?$\?\^IY$OYBE?
M3-A\"<_636^315_>*-U.'!"7D##7[/0]PS0M;+:F!TB?'B3,!X(U\L4ZY8NE
MS)?/3*[%9;HDC&\9EWL5L4,?OLBOT,<HR\.(R35$CCZE(6*;#2NWF>C#GD<Q
MPF:YD,!]R6)U%C78,"AI+:>65C=R1->)K;<*NLI[F#!( '$\(([?UP"&9>G4
M[I\U[%-4[7\XJJJAP.[4VB*.0UK!5=9P:A_ONK1UG9JDO0:$=.I!PGP@6",=
MG%,Z.,IT^)3GAW)C5DP*62[F55X\?'MPT:.,<R(]'T04RAUID11O<\)IYQ"D
MB'T-2_T \4#N90N2]LZRL(WV$B3KW&"> _HR2%G="8L0I]M_Y'Z,&@YN#2!.
MSWZLN[WKXN8#^SN@&_#_/J>1$%BK52)-F1(/V3K:R("7\J$,IM@Q)!A/\N+"
MN,&V?:-CV@GL45[)]H597H:^85A<5,6#+6>E]-0K(2DK-R$!*M!YR##5=%.C
M[0R <KF" GE0('],(S33Y$Q,Q..7DXP/YT)OE)7L*5$& KE0H!44R(,"^0"@
M9H[4HA]6JWZC<T2UIE#[F+J_ *6Y%:W1OS"UVAL,4*<>*,V'HC53I-8BL5J,
M/"KHQ1.F8ON9[%F:'V>>8@=:N(O"@;2 DB1Q5T9T-$TC[5D"R-\*"N1!@?R+
M+=",;:TO8K7 ."JVRJY_A5RGZ/J0-!=WA3ULVJ33]2&=>J T'XK63(]:O\3C
M!<S7@/,@'2E4JKE3NC[M&;YMQS:T=N>'TB*A0!X4R!_1!LWXUGHC'B\X-N([
M5EA4\R=W?U!I$7>U16([VID\4P4<5%P$I?E0M&9^U/HB5@N, \^$>V5#/%(W
MQ%W=#&M$,PV"[7:?AI(.H4!>3^7GEDU-3,U6Y?V>HD0W#0M;QD"WK05"K%8(
M+SP>[@_/..%/[7ER%^PZU2W3TC'6VIT05/P#I?E0M&:T:_T/JP5 U4-@M>F4
M>18(Y$*!5E @#_<H@YABQ])UL]UGQQ1MGJZI13NB%NV*,.YY%C*VEG,LSQ)Y
M%;T$@J%]+&_C[: 7OC$POK%,HRGDWJ"4E;]GFPWC4;J5/^>BU.V^-PSGAFK]
M!W6@M#K2E:DHE4Y)>\R^QN-@UUM!U=^# ODC&J*9(+5<1]1RW;^3(%<H3\,+
M.%":6]$:*P5Y[_+6VR>[(-UZH#0?BM9,JK-#?1/T/8@C*&I_4T84L,-_D&+;
M"JI:'A3(!P UDZ=6_HA:^?O'SJ.H_4X>=4"/+)*NU*;;%.NT/>B 'ED$I?E0
MM&;>U*HB&:$JSGM4Q1^^LPG&/U]^^J1V,&64Z6J AF'H1EL[OL:A8A"!.L0(
M!?(OMT,SUK5$2-02X<58RWH)'H7%&PW'L!_22/0''4HT)#V"F4D=QVH'_0J'
MBJ!#"8=0(/]R.S2#7NN&1*T;7@SZFYC8&^8K-*W^,'<%/MNP.X<'KO&GB#)0
M[3THD%^!Z& S-(-<BW]$+?Z!/!I6^Y@\TT/27%#:"I3F@=+\:VC*)60M59)1
M4F5;HB2]N6*/4Y#[RFFVKCE&6]!QU;6;H$9!@;R>RL\=W:+%ZP;MMXOZVL-T
MJ$:'Q*A:4R1J3?&"@MP?GJXXUJ<@JSU/[J-=I[IC6)JF.>WU.*1?#Y3F0]&.
MT5Z<O6!:O*'\$/!ME.8H9AN)U]Y9,F/X\:7?XX7(]N4[I\^9$%E2?MRQ8,UX
M44#^OLDR\791O,9Z>O7Z_O]02P,$%     @ '8A_5O-R')O+ @  HP<  !@
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MQN<3^[P^\CRP[[J 369I@\+G+@54. F2"DOCC;3GG@1$W(G)\,%9-9:V>M.
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MJ3*"<T7N6/G)(FA.&.A_"' G!W3U2FM%I6=5<"(^GIMHT\]9GOFB^-2'9K!
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M=)5BKT.&-!2>K,TO?@I>!Y7TC+D@8\ZYW?@5A<';6[Q9Q\-QE[07B<[%C=J
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M]T&U.Z5UC&S<'"^DH:W@S(+6,"J;0/&EI(9N'7M!M]@G?P!02P,$%     @
M'8A_5G'=O.&V @  Z04  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
MA51-<]HP$+WS*W:<3DY,_ %)F 28@=!.>R!EDFE[Z/0@VXNMB2RYDH#P[[N2
MC4NFA![ J]6^MV\E[8YW2K^8$M'":R6DF02EM?5=&)JLQ(J9*U6CI)VUTA6S
MM-1%:&J-+/>@2H1)%-V$%>,RF(Z];Z6G8[6Q@DM<:3";JF)Z/T>A=I,@#@Z.
M)UZ4UCG"Z;AF!3ZC_5:O-*W"CB7G%4K#E02-ZTDPB^_F0Q?O [YSW)DC&UPE
MJ5(O;O$EGP21$X0",^L8&'VV^(!"."*2\;OE#+J4#GAL']@_^=JIEI09?%#B
M!\]M.0E& >2X9AMAG]3N,[;U7#N^3 GC_V'7Q":W 60;8U75@DE!Q67S9:_M
M.1P!1M$[@*0%)%YWD\BK7##+IF.M=J!=-+$YPY?JT22.2W<ISU;3+B><G3XJ
MBP96;,]2@>/0$J7;"+,6/F_@R3OP.(&EDK8T\%'FF+\E"$E+)R@Y")HG9QD7
MF%W!(.Y#$B7)&;Y!5^# \PW>Y4LM++C)A#(;C?!SEAJKZ3'\.E5MPS4\S>4:
MY,[4+,-)0!U@4&\QF%Y>Q#?1_1FEPT[I\!S[_Z_B+/RT.,?9NX;+BU$2Q_?P
M)@4\8T8GDO=66E7<&*7W/@"^RMZCVF*5HH:XN8FH#YF2%*Y16K&G1VI+L"4"
MOA*)[R^U]HXEZH)PLT(C4O/:OO<^J*IF<@_,N7.P"FJMMCQ'8)!JGA<(0C$)
MF]KMD<$*BBP8J:\UEQFOF0!6J8VT+M$'&/2C*'(_N(81S$R/O/1T&M&'YT-$
M^3_>&);[Y0)*E@/+MTQFI,=[/@E%2M@;\N2F'P]NG:.U3MUS>-1^E2O?#1E#
M!T9JFT[LO-T<FS7M^S>\&8)+I@LN#0A<$S2ZNKT.0#>#I5E85?MF3I6ET>#-
MDF8Q:A= ^VM%-]@N7()NND__ %!+ P04    "  =B']6Q P[J<$+  #L(@
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M7O'7I9(8YF@!GB_JVG47M$'_ Y?7_P%02P,$%     @ '8A_5D8T<P2M"0
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M5-^HJAN;K_B[T"RW-D_Y<JDD'*()>#[/<<)P-[1 \Z'P^E]02P,$%     @
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M,!4=&47#DX\5X\ED.LQGT2F:?;X83B:G7;?GR)_G]Z!_'TEOZ+3'9 $105Q
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MQPTK#->XTI+E"?B^-#@T=P^\0'])OOP;4$L#!!0    ( !V(?U9JJ[I&@0H
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M-7_%:0*]GQ;@_<KB()M^D(+^'R;G_P502P,$%     @ '8A_5OD^(/EE!@
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M3@_.)J+L.ZA1\C8P'4!:A5G>:!H]-'QZ0;@+'$((_:;%4<@%F]G>D+^B2\1
MR*I2C<(WEV Y+K"_&70?$K\BM4JVT-8=!C^9D4"-6*R(]$.LP>??"-O0:,!*
MCLKD5@E<;)]1D[LM--"*Q<0-8^^:"&_RT,N1O5@L.['Q^8E3@9D/=E*X&F[5
M\)([!#?'>VF5Z9&>;QPIQ!Q*Z*V-&EE1+9OJ>4]=D=^PAWF:'85.C8>?8KY7
M$MT9F2PY%15WOX/IX?&QN.LA%YF<WZO(# 7T\>,EVD[R"SI3V*32;/FTLR)
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M:#@OX"SA(-L*INGL^' B;+SUQ!=ONG#3P Z)>TMXK'%1),L3\+TR.'\.+[S
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M+,TBO\UI^*-V!G2^4%1.C> "[/Y.AG\!4$L#!!0    ( !V(?U;2UD].P@(
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MS8)F/&KG0.=K11]!OW )AG^-Q6]02P,$%     @ '8A_5D^G^G(H P  :@<
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M<VI\_'$2@.DZ1;<AW7AUKC2QUOVRY.:*Q@6P?ZWY-?N-.V!HU\N_4$L#!!0
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M$%^HO_WE:G%Q]9.L3@6KJ[-=!AK84]?VT\!0?J-/&1<XQ9&1^:05TR# HN@
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M,>IMTUH!<RJC;09)Q#)6IT.,K9CU&K)+?"*G ]?%NR2/#E$\HE;HMFM35"7
MQQX^L<K*W0XM#P(163Y<&AD&68%^'TQ^[RKVL820?'GHTRV-I%9([7_J'+!
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MG]^[[V<:>WZ>>C,?QZ_QW^GL 9 '@>?[D>=GP9:?CD WZ:&;G S=&VT$)%-
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MX2.MUFF&'T7>(.B.XNH#](:8Z^PK"^ZY+Y" E,AE@CA/7-Y(PBYO^'Z"ZS$
MQ@O\")$6Q3G-(+4D :XD%" 7Q( J^R4ND2U:>QT9]J5'VV:+.(MG$!I;^ 8^
M"$ESFZDR+\RPY&FXH-_:.TR)737X5,.UQTMF4-*\69(#J9?$,[AOVR#OG@[
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M9V:?BE#F"'?B 36T[\0J0WTV<0U!LX ;[F&N*IC@!1@_@,^R,(F&GXH(HZ<
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M8@%Z'TMI#AN^H)[19_\"4$L#!!0    ( !V(?U:/1>N*!P,  '8)   9
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M=ZXHFWQI*)Z;QKKD"MNT&<9X,0*A)^#_%>=J:^A>75^U_-]02P,$%     @
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M@PVM<_6!'_Z%MJ#(Y%OS7#9_T:%]-_#0NI:*%VVP=E"P\OA+O[<=,0@@9"2
MM &D\7T4:EQ>4D73N> '),S;.INY:$IMHK4Y5II1N55"/V4Z3J6W>IBS.@?$
M-^A]!8(J5F[1->A"T0TK65$7;6M)?^C14!*]N@1%62Y?SWVE'9@\_KI5NSBJ
MD1&U2UB?H0E^@TA "/IT>XE>O?PEC:\+Z*H@716DR3L9R:O')*<K;MSO ;T5
M@I9;,&X1+;-[[?=J!P*I'2W1_:"OUSHGNE)0R/]LA1T-A'8#9NV<RXJN8>'I
MQ2%![,%+_WJ!I\'?CO(F77D35_94]];$YND8%3519OGMTS@.@FCN[RUB82<6
M/B06VL2.4=.A6!A&V"X6=6+10V*132PZ$8L2'-JUIIW6U*GUD2N:HTVM:@%F
M*35S.V_F=M7.[3>H+C,FU[PN%60V8],38SB*21S8K<6=M=AI[1JD/$=7155K
M6<2TN)Y$RJ8?6_2C<&:73SKYQ"F_-%-6+XX]S>N&!,Y.LME*3FV%."8CLV/6
M^9JY?>54*:3OF.WIZPT4*Q#6Q>E,\\3%B8,>H<&?ID_KX)DK'&P2^$D :L.&
MXTY(F(P0"/<XQTZ<CC*H#;NG-\'!9$2OYRM^$+!6#+5AC^,0[@F+W8A]%A+A
M4R!'. S(B+F>R-B-Y,>S"%LH'<U&UCSN,8W=G/Y]&N%32H=ZW,:<]93&;DSK
M:8+1!<T5*[@VY"*2.]-3%VP/=)S\<20Y]Y2G5MAO#=B]-XPB:78Z*<.(C&S0
MI(<\<2)V%$EMV/UE. F3$;T>N>1!Y%J1Y ZS=SMR?6(/OK'=4'X6:I%3@N,@
M2J9C_=4CG+@1_GALD5.HSV;1F($>ZL0-]=_'5BLP_)Z?:9[^.G7]P6G/G)QO
MJ-BR4FJ!C8X+SF*=0!P/H\>&XE5S %QQI8^3S>5.'^!!F!?T\PWGZJYASI3=
MOP32GU!+ P04    "  =B']6? X$W$L$  #1%P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6S-6%UOXC@4_2M65AKM2MLF=CZ +B"UM*L9::M!9;OS
M,-H'$PQ836+&=J#]]VLG:4)H<(>N'Y"JDH1[C^\]]\0]]7#'^)-8$R+!<YID
M8N2LI=Q<N:Z(UR3%XI)M2*:^63*>8JEN^<H5&T[PHDA*$Q=Y7N2FF&;.>%@\
MF_+QD.4RH1F9<B#R-,7\Y88D;#=RH//ZX(&NUE(_<,?##5Z1&9&/FRE7=VZ-
MLJ IR01E&>!D.7*NX=4$(9U01/Q#R4[L70/=RIRQ)WWS93%R/%T124@L-016
M'ULR(4FBD50=/RI0IUY3)^Y?OZ+_632OFIEC028L^487<CUR^@Y8D"7.$_G
M=I])U5"H\6*6B.(WV%6QG@/B7$B65LFJ@I1FY2=^KHC82X#1D014):##A.!(
M@E\E^$6C965%6[=8XO&0LQW@.EJAZ8N"FR);=4,S/<:9Y.I;JO+D>*9TL<@3
M M@27&>27BQHDFMFP8S$.:>2$@'NGN,D7Y %6'*6@@E+-[G$Q114UAWF&<U6
M DP)![,UY@3\>DLDIHGX#5P H9^(H2M5L7I)-ZX*NRD+0T<*@PC<LTRNU>J9
M6KH-X*HNZU;1:ZLWR(AX2^)+X,/? ?(0ZBAH\O/IT%".7S/O%WC^$3S-M@VR
MO_^E@,$725+Q;Q?-915!=Q5ZE[@2&QR3D:.V 4'XECCC3[_ R/NCBR)+8"W"
M@IJPP(0^_IM)G( -DT0QAY/D!=3T'1=9"1D5D'I+VXZAW^^'T2 <NMO]SCH"
M4>1[P2"H UM5AW75H;'JNQ\YE2_@ZZ88X?=[DLX)[QR4$>?405D":[4<U2U'
M9Z'LR"9AEL!:A/5JPGKVE=U[(]C [T4]OW<@[(XXJ.,&W;KNUS7WC34_9ELB
MI!KF@_K@--:7,\GB)_"842F,2C<BGSHX2V M$@8U"8.S4/K )F&6P%J$0:_Q
M&YY]K5>8^R)&O4'H>=Z!V'\BL%WWGD^"QKJ_8<YQIH0M&9CF/%XK[Z@GFZJA
MEKHW*=X,?NH$;:&UJ4 -%>@L5%^588LT2VAMTAJW!XW>Z(.Z]]_(.0IAT$>'
MFWQ'8.CU@J!_9)>'C>F"9M<UY>1BF6L+#O[G*V!<Y^1I6D)KL]*8.AB>QRM@
MU13:0FN3UMA":#11'WP%H@X''ZJ?PS?@;5RH_E/K'=OX&V\&S>9L1KB>[ 2H
M-V%).%?#G3!E?KBD<_5_<_U2&+5O7.+D,5I":Q/2&#_8/P_M6[6)MM#:I#5&
M$1IMU0>U/^AP,^%;T_->6/NXI+%JR&S5*N7?'E'^^UN^&?_4"=I":[/1&$ $
MST+VR*I5M(76)JVQBLCHJCXF^PIS7\]^% RB ]F_&U;6[.X=CJ:$KXHS8P%B
MEF>R/#RLG];GTM?%:>S!\QMX-2E/EQN8\K#['O,5S01(R%)!>I<]]7>6E^?'
MY8UDF^((=LZD9&EQN29X0;@.4-\OF6*HNM$+U*?XX_\ 4$L#!!0    ( !V(
M?U;0=ER%B@L  $Z>   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+7=
M6V_B2!X%\*]28E>K;JD[X!N7W@2I.Z[;J#,;=6_O/HSVP8$*L6)LQC9)9S0?
M?FU"J!0XA;U[F(?IA+A^-G!$_N$8.'_,\OOB3JF2_%PF:7'1NRO+U:=^OYC=
MJ654G&4KE58_N<WR9516W^:+?K'*533?+%HF?7<P&/:749SVIN>;RZ[SZ7FV
M+I,X5=<Y*=;+990_?5%)]GC1<WHO%WR+%W=E?4%_>KZ*%NJ[*G^LKO/JN_Y.
MF<=+E19QEI)<W5[T/CN?9#"J%VRV^%>L'HM77Y/ZJMQDV7W]C9Q?] ;U$:E$
MS<J:B*I_'M2E2I):JH[C]RW:V^VS7OCZZQ>=;:Y\=65NHD)=9LF_XWEY=]$;
M]\A<W4;KI/R6/0JUO4)![<VRI-C\GSP^;SMT>V2V+LILN5U<'<$R3I__C7YN
M;XA7"RJG>8&[7>"V7>!M%WAM%_C;!7[;!<%V0;"_P']CP7"[8+BWP!V_L6"T
M73!JNX?Q=L&X[8+)=L%D$X?G^V]SYX=1&4W/\^R1Y/76E59_L4G09G5UG\=I
M'?;O95[]-*[6E=/O\2*-;^-9E);D\VR6K=,R3A?D.DOB6:P*\BY4910G!?DU
MRO.H#N9[\I'\^!Z2=W]]?]XOJT.HH?YLNSO^O#OWC=TY+KG*TO*N(#2=J[D)
M]*MCWUT!]^4*?'&MXN=5?D8&[@?B#ERWX8 N[<M_S1[.B#/:+'<:EH<ME@\F
MF^6#AN74OOR7=?)R\,ZD83FS+__'K#PC[G"S?-QT9]B7AVIV1CSGS9M.M%_>
M=-/)%LL'C7LW@N#MDNQM/.\-[SJO?@/DY=,'<IW4:8[2.:&_K^-5]=!<DM^^
M5IL36:IE\9^&8_WR;/O-=OT;YU.QBF;JHE?]2BE4_J!ZT[_]Q1D._MX4.206
M(C&*Q!@2XTA,(#$)PHQ0^[M0^S9]^DT]J+Q0I/H],+LGQ2J)RZ;T6I&NZ45B
M(1*C2(PA,6Z_%YV/U53ZT:V&PS;WID >F01A1GJ#77H#Z_7^D5;S=Q+_H>;D
MW:(:O-_WDZPH2#7C5H/U?358W"35C:%FZSPNJV&C*=G6'71--A(+D1A%8@R)
M\6<LV&#U7TX/4W<25,/&P^O$'F[TT7='$\_<3((.S,CB<)?%H36+[[@1P"*J
MHI?=M@^B5>\:1"06(C&*Q!@2X\_8\%7&@LG0WPOBX48?O4DP&>T%$71@1A!'
MNR".K$&L<_B_Q]!J=XTA$@N1&$5B#(GQT6'"&G)XN%53#$$'9L1PO(OAV!K#
MZL^EF5+S@MSFV9*4=VJ3Q:)3&*U[Z!I&)!8B,8K$&!+CXX.8.<XH&%3_[>6Q
M8<.Q/_:<T7 ODJ##,R(YV45R8H_D.I_=146W!T0KV36#2"Q$8A2),23&)P?1
MJH(U''M[#W;B<#O'\P?[(R+HT(S\.0/]9.C FL"OJBA4E;^5JI_K3!<D474>
M<Y6JQR@AI<J731FTJUU#"-5"J$:A&H-J'*H)J":/Y,YQR7+SM+@MQ:^>TG>L
MFGB:*W)=/8 2%LWB)"Z?R&]7:GFC\L:G/NU:Y_0BM1"J4:C&H!J':@*J291F
MYMG5>79/^,S^%D?%&ZF%4(U"-0;5.%034$VB-#/>NK=RK W"])_55%&/O+/J
M-T >S1J?X+<3G4,,+:B@&CUR8WG#QM^4V\A"&RFH)J":1&EF9'4KY=@+C:^;
ML5C]7,7UG)RE9!Z5JC&WT&8*JH50C1ZYQ7Y9IV?$&WP@;Y7M#'HX'*H)J"91
MFAE>74HY]E;J^[K^\XY\?HB?LVN=C:']$U0+H1J%:@RJ<:@FH)I$:6:8=:OE
M#$\Y&T-;+:@60C4*U1A4XU!-0#6)TLQXZZ[,L9=EU]%3'>2"W&9Y_31<\W ,
M+<6@6@C5*%1C6^UU;3\<')8''+I7 =4D2C/SJ4LTQ]ZBM?K;#5J30;40JE&H
MQH[<]+:_!#GT2 14DRC-C*PNV1Q[RU:?J4R^1$D9+[-<V:=?:+D&U4*H1J$:
M@VH<J@FH)E&:>>J_[NO<P0FG7Q=:VT&U$*I1J,:@&H=J JI)E&;&6Q=YKKW(
M:S-=V(G.(8:V=T>NWANMYS:RT*X.JG&H)J":1&EF9'57YUK+DO;/#-N=SKF%
MUG)'KN/F15\OS^4VO?*)0@^'034.U014DRC-#*]NXEQ[N53?G2U'8[O4.;[0
M0@ZJ4:C&H!J':@*J291F9EE7=*Y_RM$8VMM!M1"J4:C&H!J':@*J291FQEN7
M>*Z]Q&LU&D/+NR,'9!MF0^B14*C&H!J':@*J291F1E97=:[]%6CM1V-H*W?D
MJ(QAMNG$A!!Z.!2J,:C&H9J :A*EF>'519Q[I(A+HK(DU27U&_!8!V-H&0?5
M0JA&H1J#:ARJ":@F49J99%W9N>-3#L;0,@^JA5"-0C4&U3A4$U!-HC0SWKK>
M<^WU7JO!V$[8FM5+^]K.D86V>%"-034.U014DRC-?-\FW>)YQUYUUW(P/N)<
M1?GS&U+5HVS0%%X[T#6\4(U"-0;5.%034$VB-#.\NJ/S["7659S&R_5R-Q.3
M/TG'U]_9=]!UI(!J(52C4(U!-0[5!%23*,V,N.[TO%.^_LZ#%GU0+81J%*HQ
MJ,:AFH!J$J69\7[UOI'VUJ_5.<9VHW.*L>\0B7V+R&?->,<O=^#OO>47@^Z4
M0S4!U21*,^.IBSS/VJ0T#1@=3N&TXYUS"RWRH!J%:@RJ<:@FH)I$:6:\=9'G
M!:<<+J 5'U0+H1J%:@RJ<:@FH)I$:6:\=>GGV>NU=L,%M/"#:N%6,\8!_^ U
M0A2Z4P;5.%034$VB-#.>NM;S[+5>\W#1]B0X.]XYM]"N#ZI1J,:@&H=J JI)
ME&;&6W=]WBF[/@_:]4&U$*I1J,:@&H=J JI)E&;&6W=]WI$WS&PU7$!?Q+?5
M7H\#@3O>'P="Z$XI5&-0C4,U =4D2C,_ND+W>OZ1/NYPN&A]&I&=[II:J!9"
M-0K5&%3C4$U -8G2S'#KWL]W3CA:^-#.#ZJ%4(U"-0;5.%034$VB-#/>NO/S
M[:]Q:S5:;(V]JL#;&P8N[;OJ'$]H9P?5&%3C4$U -8G2S'CJSLZW=W97T<__
M\ZP+^PXZ/P)#"SVH1J$:@VH<J@FH)E&:&?%7G_SFGW+ @/9^4"V$:A2J,:C&
MH9J :A*EF?'6O9]O?[U<NP$#6N]!M1"J4;_A<]8\S]T;I1ATIQRJ":@F49H9
M3]W;^?;>KF' Z'#6A1WOG%MHH0?5*%1C4(U#-0'5)$HSXZU[/W]TRN$"VOM!
MM1"J4:C&H!J':@*J291FQEOW?OZ1#[=K-5Q ZSVH%FXU8QP(_*&[=]8%=*<,
MJG&H)J":1&EF/'5OY]M[N^;AHNU9%W:\<VZAK^>#:A2J,:C&H9J :A*EF1_Z
MK7N_X)3ORAE FS^H%D(U"M485.-034 UB=+,>.OF+["_XJ_5<&$W.J?8.3SK
M8CAP]CZ\-83NE$(U!M4X5!-03:(T,YZZN0OLS5W#<-'ZK L[W3FUT-X/JE&H
MQJ :AVH"JDF49H9;]WZ!=\K1 MKY0;40JE&HQJ :AVH"JDF49L9;=WZ!M71I
M.5KX#56!&TSVSKJP[ZIS/*&='51C4(U#-0'5)$HSXZD[N\#>V5VMRW64$+:N
M'G6M8P2TMH-J(52C4(U!-0[5!%23*,T,LF[W@E-^:EX ;?>@6@C5*%1C4(U#
M-0'5)$HSXZW;O<#^JKX?::ZB)/Y#S<F[112G[_M)5A0D2\DRRN]5&=TDBA1J
MML[C,E9-;_/VQ;Z'SAF'5GQ0C4(U!M5X</@)?>XDV'LK#M&PE>^.)IZYF40=
MVG,H^\6=4F48E='T?*GRA;I425*06;9.*[Y^MF)W:37)WM:?2_;IL]OK'US.
MG4_"J2_O:V9ZOHH6ZBK*%W%:D$3=5N3@;%1=PSQ>W.V^*;/51<_ID9NL++/E
MYLL[%<U57F]0_?PVR\J7;^H=/&;Y_>:PI_\%4$L#!!0    ( !V(?U9<)Q>D
M% 0  %83   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+68;8_:.!#'
MOXJ55J=6:LDC(>Q!)!;V[E9JNVC9WKVH^L(D UB;Q-0V#_WV9R?9+(&LNY%2
M7H"=>/YC_YAQ)AX=*'OD&P"!CFF2\;&Q$6)[99H\VD"*>8]N(9-W5I2E6,@N
M6YM\RP#'N5&:F(YE^6:*26:$H_S:G(4CNA,)R6#.$-^E*68_KR&AA[%A&T\7
M[LEZ(]0%,QQM\1H6(+YNYTSVS$HE)BEDG- ,,5B-C8E]-;,]99"/^)? @9^T
MD5K*DM)'U;F-QX:E9@0)1$))8/FSARDDB5*2\_A1BAJ53V5XVGY2_RM?O%S,
M$G.8TN0_$HO-V @,%,,*[Q)Q3P__0+F@OM*+:,+S;W0HQUH&BG9<T+0TEC-(
M25;\XF,)XL1 +K39P"D-G-<:N*6!^UH#KS3(49O%4G(.,RQP.&+T@)@:+=54
M(X>96\OEDTS][PO!Y%TB[42XD($4[Q) =(6^R#";< Z"HTGT8T<8Q$A0M 0T
M21(:85'T_Z8T/I D0>]F(#!)^'OT$7U=S-"[M^]'II"34M)F5$[@NIB \\($
M)EO60[;_ 3F68S>83_7F,XAZR+5S<Z?!?/9Z\S/OIB19X70JG$ZNY[Z@=P]<
ML%TD=HQD:S2E7""<Q4A>!K8'].V3'(]N!:3\>Q.J0MQK%E=;P!7?X@C&ALSQ
M7-$(_WAC^]:?3>"Z%)MU)%:#ZE9079UZ>'.,@',5H?,=BS8RR]&<D0C0W1Y8
MVZAMPJYUWQ9[(=;/Q=2NNP]MRQL&?7<X,O>G2%\QL(;+JW!Y6ER31V <71/*
M(P*91/<!W681^O89TB6PQKC3"K8%T*78K".Q&LA^!;+_.Y.YWR74+L5F'8G5
MH/H55%\;G0]4X$3"E)5## RKAW\3//\B.3S'&PQ<SZ]GT53KK2V8CL1J8 85
MF($6S!3S31Y?>>-&[F1[G$ F>!.>0LH_W3O<P KZSAD=K<NV=#H2J]$)*CJ!
MELYGS!YEM;&4E<H"(IF1@D CF>""C#/T JOO>&=HM/[:HNE(K(9F6*$9:M'<
MB8U\#-Y#!#)B)*!&+,,++*[E^+8[.*.B==662D=B-2JV]5S96EHN<P9;3&)T
M<Y0O2;P92RE12Z2AX]KGP:)WU99+5VIU,"<EOZT%<YOMY9--OKP)1#)TQ_ >
M'_,:H=>(R+Y$U+?4YYR1UFMK1AVIU1D]U_&VMJ(-'QB.(=^.B_2:XY\OYE8I
M=4KHH^M;MN5<(.JT)N]*K8[HN2JW]66Y*KP?<+8F:E,^J\ ;,;F7>Y ]' 2!
M=;X)Z1VWQM216AW3<S5NZ\OQW_[V4OK_]1O'5#_3UEP[K<W-DS,,=>(D'_AK
MDG&4P$K*6[V!7!\K#G&*CJ#;_%AC286@:=[<@$Q:I@;(^RM*Q5-'G9141VGA
M_U!+ P04    "  =B']6'[9A2;T$  #8%0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6S%6&U/VT@0_GZ_8N2B"J0(>Q?":X@$;5$K'2HJO;L/U7W8
MV)/8PO:ZN^L$[M??[#JQ$YHXH02!!%G'.\^\SSYL;R+5O8X1#3QD::XOO-B8
MXLSW=1AC)O2^+#"G-T.I,F'H48U\72@4D1/*4I\'P9&?B23W^CWWW:WJ]V1I
MTB3'6P6ZS#*A'J\PE9,+CWFS+[XEH]C8+_Q^KQ CO$/S5W&KZ,FO4:(DPUPG
M,@>%PPOODIU=<6X%W(Z_$YSHN3585P92WMN'+]&%%UB+,,706 A!'V/\@&EJ
MD<B.GU-0K]9I!>?7,_1KYSPY,Q :/\CTGR0R\85WXD&$0U&FYIN<?,:I0UV+
M%\I4N[\PF>X-/ A+;60V%28+LB2O/L7#-!";"/"I@ N$7RER5GX41O1[2DY
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M-2YX;6RUFEMSXC88AO^*QNUTDIELC&1C( 5F."3M7FR;2;J[T^GT0A@!GOA
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M6OY"-175M!=^4GWI,4VRIBO3Z"\L.7QV20-]!2:J6:AFHYJ#:BZJ>:CFHUJ
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MFYW\>?166J;;798\^;+=-[E;S<O=JN;\1;N,J*:BFH9J.JH9J&;NM>/\E8L
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MPU>>?.JA 4YJ*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!936CW
MJYKMX&MJMA=//J&-6U1344U#-1W5C!<V\3_N=O,L6;I(9LOM'$_YR5ML\=VV
M_G,FG^3#U-/1]--V-;934*\]_;1=DUW/\4^>?D)KSJAFHYJ#:BZJ>:CFHUJ
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M*+Y_LUKEAW^4 SRLLD_;U?[P?U!+ P04    "  =B']6X &,?M$&  #8+P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R]FFMOVS84AO\*X15# K26
M2(FRW3D&<NFV NT6-&N+H=@'1:9MH;IX%)T+L!\_4I)-I9:.+/KR);[$/.?E
MT1$?O1+'CRG_GBT8$^@ICI+LHK<08OG6LK)@P6(_ZZ=+ELC_S%(>^T)^Y',K
M6W+F3_-!<601V_:LV ^3WF2<?W?+)^-T):(P8;<<9:LX]OGS%8O2QXL>[JV_
M^!3.%T)]84W&2W_.[ICXO+SE\I.UB3(-8Y9D89H@SF87O4O\]LKSU(#\%U]"
M]IA5WB,UE?LT_:X^O)]>]&REB$4L$"J$+U\>V#6+(A5)ZOBW#-K;Y%0#J^_7
MT7_-)R\G<^]G[#J-OH93L;CH#7MHRF;^*A*?TL??63DAJN(%:93E?]%C\5M/
M_CA892*-R\%201PFQ:O_5!:B,L"U&P:0<@#)=1>)<I4WOO G8YX^(JY^+:.I
M-_E4\]%27)BHHW(GN/QO*,>)R5UQ-% Z0U]]SOU$H$M5J% \H[,;)OPPRL['
MEI"IU  K*,->%6%)0UA,T,<T$8L,O4NF;/HR@"4U;H22M= K D:\84$?.?@U
M(C8AZ//=#3I[=8Y>(0ME"Y^SK'P!,CF;DCAY)K<ATW4:Q[)?[D0:?%\7)4/?
M/K+XGO%_ZFH!QE/GU=MLZ0?LHB=/G(SQ!]:;_/P3]NQ? +7N1JV;1W<:U%X&
MP2I>1;Y@4_2G6#".I'Z99Z'.G >&WB=!&C-T]B'-LG/T[8,<CMX+%F>U,W&/
M,!.ZF0D%Z_['2A6XTHG9:W3%YF&2A,D<7?F1GP0,_5=[H OU17POCZ^6HX<)
MM0>N.QR-K8<:8=Y&F <*^YJ?VK*^EP^,RZ4*O7MB/ @SAFYY&+!ZE;HSZY06
M"0=5I7U"ZV4.-C('W61^8FI95K*NY;G(Y0*X\B/T%^,Q.GMF/L_.*]+K5,+Y
M7)0'02Z*BU.=H*G_#)V!P\U,AF#DR_F<L[EL:=F]@H>RD0/TQ8]6+THM2URG
MN8A,*Y4=4>H.R:"^N*.-I%'GYOQ-O<IZ0RTYVFI)[%+;)@TMB6V];MO[-:56
M![=BF>>'7FPH%ZYP!1^N&_\NN['47"L33K=N1FRONQ$/VMH1$ST9TOGHK^L-
M'W\X</V*BB#-FF(8QEAK@U0GT-(B!H #)Z'AAD'BU!9>7HW-6-AVXL&!#31K
MC&&88ZV%KTZ@I?!@)H-):.1AF'EUA;]6:(LB-K7>/2U#WG8 O*VE[\W(&^&&
MA453#G?$W(_EK9/94N;!UA)(".G3!B!CS3$,@ZQVW4BFNU[/E-&K)?0H;H89
MUC3#,,[:%X<?5;94<+150;<_<NIE$@TYTA%RNUS2O)1>I[8EJU.R9+ [2HCF
M(H%!!5S;E,(;+FS@N-W7 J+I1XSIY]]'< N7H7=N8:+Y1@[#MU(BW+]EKAW[
M5^.+P/@RZU^MNU8JG-*D>37:"(PVJ'E?5KM6^8%I1C3-"$RS6\[>S%;J3@3J
M[N[AV(:FF&C>D<$)#3X!X6HZ&0U$TAV(W3P^V68B)389V WGJD8BV1.)W5U^
MF7%4T6KWI?FKE^IH+#HPH/;QQV7HJD%V,,6#D=>@2I/-@<EF:I'AL-V7!4>#
MS8'!=C /#><QF$+E7B5,07-G6@9^<7WN#"EV&JYZ'4T]IR/US)UGF6G7,TB#
MS.E^KW$W7PD'-CC4&F+.GK<A=_>5<":#26B:.;![V]]7P@D,M&MX.3"\CN \
MX8P&D]&X<[K?T.Q@39V:&YM.\^+A:K:Y>][7[.A,RW0[KB"NIIU[)!]7QJT"
M&%.@<IIF[O%LFKMMT\##J?GDGM"EE;EV/9:51V@PL/:S-67PG0^HAI0+0^J.
M\9!EZ%IY15D]$2H1TLK,&%=K2P<+ R<R?4*IR>5ZIWQ&>0P_YFJ"N=T)ULW"
ME FJ)QL94+O!P;B:3^Z>?.KN8-SMQVG#!IF:/&Y'H[7W<\J6A&3]; BO[XD,
MVVZ)4,TK>CPO!H?N3G^JZ46/X]7@L :*-=WHB;P:G,=@"IJ%]%A>#0YLH%FC
MD9[,R\&9#"91V5AR++<'!S;0K)E)3^;VX$P&D]"LI,=V>W " ^V:IO3D;@_.
M:# 9S5QZ5+='M]T><,7B:7AZIS5[WO;-S8;+%4^CTCO@1I;=GT&V9,7Y-4N7
M2Q9/H]2#46IL7>&XW?O7T^CTC-'9ZFV][1N=4/-J-'J'0>-.UM;;-I%-G:NQ
MYW7<B'* IX\M*0W:MK(+$R;B?BX=#MZA=ZW*9NN8\7F^I3Q#0;I*1+'O>O/M
M9MOZ9;%96_^\V//^T>?2(60H8C,YU.X/9'%YL8V\^"#29;YU^SX5(HWSMPOF
M3QE7/Y#_GZ6I6']0"3:;^2?_ U!+ P04    "  =B']6P_.Z9RL4  #S,0$
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M<U'-0S4?U0)4"U$MHC1Y*&BB=V/TQG=C-'N':B:J6:AFHYJ#:BZJ>:CFHUJ
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M^W.+:B:J6:AFHYJ#:BZJ>;4FQ5$&EP.]79RC@S-:ATL%9RT5HB\@HC2Y1)M
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MOT_3XN67JH'G-/N\Z?;-_P-02P,$%     @ '8A_5B,0L-:T @  &0@  !D
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MT;1>;*J:M;N8=N'"24 UF-E.TN[7[]BD*!%.6FF[23"<\_*\Q_8QXPT7C[(
M4.2I8K6<.(52S87KRJR BLHSWD"-3Q9<5%3A4"Q=V0B@N4FJF!MX7NQ6M*R=
M=&SNW8ATS%>*E37<"")7547%\Q4POIDXOO-RX[9<%DK?<--Q0Y<P!W77W @<
MN9U*7E90RY+71,!BXESZ%]-S'6\"[DO8R)UKHIT\</ZH!]?YQ/$T$##(E%:@
M^+>&*3"FA1#C]U;3Z5ZI$W>O7]0_&^_HY8%*F'+VH\Q5,7%&#LEA05=,W?+-
M%]CZB;1>QIDTOV2SC?4<DJVDXM4V&0FJLF[_Z=.V#CL)_O! 0K!-"-Z:$&X3
M0F.T)3.V9E31="SXA@@=C6KZPM3&9*.;LM:S.%<"GY:8I](Y+HM\Q8#P!9G!
M H2 G'RG3^122E"2T#HGM\"HPMOWE*VH*?XEP]FG=0:2G,Q T9+)4S(@=_,9
M.7E_.G85DFE]-]M27+44P0&*&61G)/0_DL + DOZ].WI_GZZB_7HBA)T10F,
M7GA [[K.> 6F#+-29HS+E0#R\_)!*H'K[I?-8*LXM"OJO7@A&YK!Q,'-)D&L
MP4D_O/-C[Y/-[G\2VS,?=N;#8^KI;:O83CU7!0B;W58C,AJZ4ZS39!AYGC=V
MU[M&^F%^<KX;MH<X[!"'1Q&_87?#/B9P,=9+@M,C24:%>!Y@5]M0D4L;<2L9
M[Z $L9_$?69+8!@%\4'JJ*..CE)/:5,JRLH_N)7TM%&1%:;(.:RQFS;8&Y4-
M/.KS^$G2YS[Z=ONB(4?62]S9BE]=+S8K1.'VR;"=E%97<<]5['M]4Z^&[3$G
M'7-RE'E>4 $#W?YS@EL=CT1I&IL--.D1#*-AT">UQ&$W.H@ZZE!'1U$M3==&
M.>J]?1 .@\A244MD, K#P^O[O",]?W57YB]'B)Y\JH\0&^Q1G3>MU-;*O^NT
M1MV=\U-_NWRE8EG6DC!8H+)WEN#6$NWW0#M0O#%'Z@-7>$";RP(_H4#H 'R^
MX%R]#/0IW7V4I7\!4$L#!!0    ( !V(?U8!@RP16 0  ' 6   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;+6876_;-A2&_PJA#4,+;)8H^3.S#:16
MAZ5HNJ!9MXMB%XQ$6UPE4B6I./GW(RE%MF*9BP F%[$^>%[R/")Y#L]RS_@W
MD6$LP4.14['R,BG+"]\7288+)$:LQ%2]V3)>(*EN^<X7)<<H-49%[H=!,/4+
M1*BW7IIG-WR]9)7,"<4W'(BJ*!!_?(=SME]YT'MZ\)GL,JD?^.MEB7;X%LLO
MY0U7=WZKDI("4T$8!1QO5]XEO(CA3!N8%G\1O!='UT"[<L?8-WUSE:Z\0(\(
MYSB16@*IGWN\P7FNE=0XOC>B7MNG-CR^?E+_S3BOG+E# F]8_C=)9;;RYAY(
M\195N?S,]K_CQJ&)UDM8+LQ_L*_;3J8>2"HA6=$8JQ$4A-:_Z*$!<60 QV<,
MPL8@?&80P3,&46,0O;2'<6,P-F1J5PR'&$FT7G*V!URW5FKZPL TULI]0O5W
MOY5<O27*3JZO:,(*#/Y$#UB -S&6B.0"?$*<(_U!WH)?P)?;&+SY\>W2EZH_
M;>4GC?:FU@[/:,,07#,J,P'>TQ2G70%?#;0=;?@TVG>A5?$#HB,0A#^#,(#S
MO@'9S6.<C$ $M7D8]IC'+S>'%F^BEGUD]*(S>G^46%.F._"1"0$V"OJC6LE[
MQ%,!OGY4K<&5Q(7XIV>H[VKI<;^TWBTN1(D2O/+4=B PO\?>^J<?X#3XM0^;
M2['8D5@'Z;A%.K:IKS^IG9*U6'.%M8^=56,HNUIL8L3T+GN_CN:!_EOZ]\=8
M''7:P3)IL4RL6&XP3S"5:B,'; NH@D3,NN^#4RO!X,BA8#3O.K.Q=C=TPC@2
MZY"9MF2F5C*;JJARL]6!)$-4 2(4L#W%7&2D!&4+;M3'RJH]=")-^\!/GLTB
M1SUV6,U:5C,[JQ;0/<HK5,?M7&4.B":]4\DJ-Q3/[&2=319P?+K.3MM-0[@X
M;M=Q?MXZ/[<Z'ZOE(B1)=*@$EY7,&"?R$7R]QL4=YKU;M%5PJ/LNQ6)'8AV0
MBQ;DXO6BWL(E4I=BL2.Q#E(8'+*XP$'<LXL,Q=>H38]6&@QFL"_V]38UB_+<
MLH1'"2P<Z#I(])P"[:02U=V_ZI@!) /XH23<[%R]?*P]#>8#3W>LV:P7CZ-^
MNP3# \'02O!]"P6D2&)U;!())^592E:UP93L8U,YM]E@G_+N",B,LVJ7J9MH
MUK<070VO"_.0TT-K?ON"Z4C92Z:BT_R^43N>BN/%N'<JOD;V#@_I.[3G[[=2
M3T!$4Q4<$I2##Q4G(B5UC< 6:^VZ@WFY5(M=J769'G)_.'F]@ M=9OH;IVJQ
M*[4NU\/) =J/#B^,N4[/"(U:9R'7$?=D(9^VC.:A+>(>C@'0?@X8&B^<'@/^
M9VRV>#'NK?FX&EX-TS\JQ168[TQ)4X4 5E%9U[G:IVW9]-(4"Y\]W^ARJBGQ
M'63J6NPUXCM"!<CQ5DD&HYGZQKPN;]8WDI6FX'?'I&2%N<PP2C'7#=3[+6/R
MZ49WT!:9U_\!4$L#!!0    ( !V(?U9\9P#YB (  +H&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;*U574_;,!3]*U8V34S:R$?3@E@:B:9,0X()
M@=@>T![<Y+:QB.W,UVW9OY\_TJQ4;;4'7A)_W'-\SK5]G:VE>L8:0),7W@@<
M![76[4488ED#IW@J6Q!F9BX5I]ITU2+$5@&M'(@W81)%HY!3)H(\<V-W*L_D
M4C=,P)TBN.2<JC\3:.1Z',3!9N">+6IM!\(\:^D"'D _MG?*],*>I6(<!#(I
MB(+Y.+B,+XJAC7<!/QBL<:M-K).9E,^V<UV-@\@*@@9*;1FH^:V@@*:Q1$;&
M[XXSZ)>TP.WVAOVK\VZ\S"A"(9N?K-+U.#@/2 5SNFSTO5Q_@\Z/$UC*!MV7
MK'WL* I(N40M>0<V"C@3_D]?NCQL >+1 4#2 9)=0'H ,.@  V?4*W.VIE33
M/%-R392--FRVX7+CT,8-$W87'[0RL\S@=%Y(SIDVVZ*14%&10@K-Q )$R0#)
MR10T90V2[U0I:A/^D7PFCP]3<O+^8Q9J(\#2A&6WV,0OEAQ8+$[(K>&OD5R)
M"JK7!*%1WLM/-O(GR5'&*92G9!!_(DF4)'L$%?\/CX_(&?39'#B^] #?/2!0
M5=8NE5-8F4O2VMR2JQ=S[1#(TRWP&:A?^W)WE-K>Y@ML:0GCP%Q7!+6"(/_P
M+AY%7_;Y?B.R5UE(^RRDCGUP( LW$G'G(#W=F!ARK8'C7N_I6WI_([)7WH>]
M]^'1$U!(U&[WP>\X$B;*I5*[I]W;]EQ#QV7K[2J/T_,HBK)PM6UH3]A9NAWF
MI89;98"#6KCJB*242Z']E>I'^P)\Z>K.SOC$%&9?1__1^*I^2]6""20-S UE
M='IF1"E?*7U'R]85FYG4IG2Y9FT>%U VP,S/I=2;CEV@?Z[ROU!+ P04
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M=T*I1)1/EN[?Z_Z EV%OLK/^H%X&E!9 :11*8U!:B**9,FV\#/>]O P7ZF5
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MD"@7DJ55L"I!&F?E;_BMJHBC #I^)<"N NQS T95P.C<@'$5,#X-<%\)<*H
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MJJE1J@5$.8]EK#JYQYQ'6S5+(#<;#I 6PY$'T#UAYU#$R.TK(B;,PX3YF+
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MW'FY6*[<D6Q7+.Y:,BE96FQN(5P!UQ>H\VO&Y/..3E O69S_"U!+ P04
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MZAU_J?=8/O=YO/1\K_$[]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#!!0
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M?\KZ9.WZKW^RZ.]Y:^KN/9\-?[)<O0)02P$"% ,4    "  =B']6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( !V(?U;K*+S#[0   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !V(?U:97)PC$ 8  )PG   3
M          "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M'8A_5F/8]<*2!P  .3(  !@              ("!# @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !V(?U:;857P$P8  /P:   8
M          " @=0/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    "  =B']6GWQ6QAL#  #W"P  &               @($=%@  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ '8A_5C.2,"19!0  :A4
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M965T."YX;6Q02P$"% ,4    "  =B']6%K]1SHX(  "6%   &
M    @('N-0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M'8A_5C=F15'Z*   WWH  !D              ("!LCX  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    "  =B']6N\@=X=H*  "-&P  &0
M            @('C9P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( !V(?U;/\LN&D0(  .0%   9              " @?1R  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ '8A_5G'=O.&V @
MZ04  !D              ("!O'4  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    "  =B']6Q P[J<$+  #L(@  &0              @(&I
M>   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !V(?U9&
M-',$K0D  #0<   9              " @:&$  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ '8A_5F-I-^AL!@  , \  !D
M     ("!A8X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V(?U9/I_IR* ,  &H'   9              "
M@86L  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ '8A_
M5D\B*N>D @  N@4  !D              ("!Y*\  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    "  =B']6V]_\AJ0J  "/AP  &0
M        @(&_L@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( !V(?U9WU5E2KP@  # 9   9              " @9K=  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ '8A_5E,_-1QI!   / L
M !D              ("!@.8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    "  =B']6B3C$=),"  #1!0  &0              @($@ZP
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !V(?U:)\VD6
MW ,  *()   9              " @>KM  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ '8A_5I]L >DM!   O \  !D
M ("!_?$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  =
MB']6-F@^I7L$  "O"P  &0              @(%A]@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !V(?U:/1>N*!P,  '8)   9
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M970S-"YX;6Q02P$"% ,4    "  =B']6-*F?=<(#   (%   &0
M    @('Y"P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M !V(?U;?C\W0A ,  , /   9              " @?(/ 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ '8A_5G!IDN[+ P  'A   !D
M             ("!K1,! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    "  =B']6? X$W$L$  #1%P  &0              @(&O%P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !V(?U;0=ER%B@L
M $Z>   9              " @3$< 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ '8A_5EPG%Z04!   5A,  !D              ("!
M\B<! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  =B']6
M'[9A2;T$  #8%0  &0              @($]+ $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !V(?U9!%I;$D@P  !MN   9
M      " @3$Q 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ '8A_5MY]G,V% @  ?P8  !D              ("!^CT! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  =B']6[<V7?8P#  #.$0
M&0              @(&V0 $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( !V(?U;Z*"/0= 4  (8D   9              " @7E$ 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ '8A_5G!F;";<
M P  (A(  !D              ("!)$H! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    "  =B']6[!F'%:T@  "U8@( &0
M@($W3@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !V(
M?U;@ 8Q^T08  -@O   9              " @1MO 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ '8A_5L/SNF<K%   \S$! !D
M         ("!(W8! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    "  =B']6(Q"PUK0"   9"   &0              @(&%B@$ >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !V(?U;I@%3=+@,  )H)
M   9              " @7"- 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ '8A_5@?P%K8? P  H D  !D              ("!U9 !
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  =B']6 8,L
M$5@$  !P%@  &0              @($KE $ >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( !V(?U9\9P#YB (  +H&   9
M  " @;J8 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M'8A_5D=YE0FF"   ;UP  !D              ("!>9L! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    "  =B']6/@SH34L#  !W#@  &0
M            @(%6I $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( !V(?U:_QG*+@ (  / &   9              " @=BG 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ '8A_5O6:Y1<] @
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M96QS+RYR96QS4$L! A0#%     @ '8A_5N>*'=$C!0  22<   \
M     ( !G[8! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !V(?U99=@'X
M]0$  #@C   :              "  >^[ 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( !V(?U87R,P;VP$  -$B   3
M  "  1R^ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(  "C
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>225</ContextCount>
  <ElementCount>366</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/StatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statement of Changes in Stockholders' Equity /(Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity /(Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statement of Changes in Stockholders' Equity /(Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity /(Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Recent Developments, Liquidity and Management???s Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans</Role>
      <ShortName>Recent Developments, Liquidity and Management???s Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://mymd.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stock-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/Stock-basedPayments</Role>
      <ShortName>Stock-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Paycheck Protection Program Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/PaycheckProtectionProgramLoan</Role>
      <ShortName>Paycheck Protection Program Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Patent Assignment and Royalty Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement</Role>
      <ShortName>Patent Assignment and Royalty Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://mymd.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mymd.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Recent Developments, Liquidity and Management???s Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables</Role>
      <ShortName>Recent Developments, Liquidity and Management???s Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mymd.com/role/TradeAndOtherPayables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Stock-based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/Stock-basedPaymentsTables</Role>
      <ShortName>Stock-based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mymd.com/role/Stock-basedPayments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mymd.com/role/Equity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mymd.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Organization and Description of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>Organization and Description of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Estimated Useful Lives of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails</Role>
      <ShortName>Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfLeaseExpenseDetails</Role>
      <ShortName>Schedule of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Operating Lease Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails</Role>
      <ShortName>Schedule of Operating Lease Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails</Role>
      <ShortName>Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Summary of Milestone Events Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails</Role>
      <ShortName>Summary of Milestone Events Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Recent Developments, Liquidity and Management???s Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative</Role>
      <ShortName>Recent Developments, Liquidity and Management???s Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails</Role>
      <ShortName>Schedule of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://mymd.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/NotesPayable</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SummaryOfStockOptionsActivityDetails</Role>
      <ShortName>Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Summary of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Summary of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Stock-based Payments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/Stock-basedPaymentsDetailsNarrative</Role>
      <ShortName>Stock-based Payments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/Stock-basedPaymentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SummaryOfWarrantActivityDetails</Role>
      <ShortName>Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/EquityDetailsNarrative</Role>
      <ShortName>Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/EquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Income Tax (Benefit)/Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails</Role>
      <ShortName>Schedule of Income Tax (Benefit)/Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Related Parties (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>Related Parties (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/RelatedParties</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Employee Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>Employee Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Paycheck Protection Program Loan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative</Role>
      <ShortName>Paycheck Protection Program Loan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/PaycheckProtectionProgramLoan</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Patent Assignment and Royalty Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative</Role>
      <ShortName>Patent Assignment and Royalty Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mymd.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mymd.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToOfficersOrStockholdersCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 26, 16611</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToOfficersOrStockholdersNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 27, 16639</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 17998</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToOfficersOrStockholdersCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 20596</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 20613</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:WarrantsAndRightsOutstandingTerm -  form10-k.htm 147, 148, 161</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-1.htm</File>
    <File>mymd-20221231.xsd</File>
    <File>mymd-20221231_cal.xml</File>
    <File>mymd-20221231_def.xml</File>
    <File>mymd-20221231_lab.xml</File>
    <File>mymd-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="704">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 704,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 225,
   "dts": {
    "calculationLink": {
     "local": [
      "mymd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mymd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mymd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mymd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mymd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 596,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 110,
    "http://mymd.com/20221231": 52,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 165
   },
   "keyCustom": 66,
   "keyStandard": 300,
   "memberCustom": 54,
   "memberStandard": 30,
   "nsprefix": "MYMD",
   "nsuri": "http://mymd.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://mymd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://mymd.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Recent Developments, Liquidity and Management\u2019s Plans",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans",
     "shortName": "Recent Developments, Liquidity and Management\u2019s Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Trade and Other Payables",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://mymd.com/role/TradeAndOtherPayables",
     "shortName": "Trade and Other Payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Notes Payable",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://mymd.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Stock-based Payments",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://mymd.com/role/Stock-basedPayments",
     "shortName": "Stock-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://mymd.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://mymd.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://mymd.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://mymd.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://mymd.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://mymd.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Paycheck Protection Program Loan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://mymd.com/role/PaycheckProtectionProgramLoan",
     "shortName": "Paycheck Protection Program Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Patent Assignment and Royalty Agreement",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement",
     "shortName": "Patent Assignment and Royalty Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://mymd.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://mymd.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://mymd.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Recent Developments, Liquidity and Management\u2019s Plans (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables",
     "shortName": "Recent Developments, Liquidity and Management\u2019s Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Trade and Other Payables (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://mymd.com/role/TradeAndOtherPayablesTables",
     "shortName": "Trade and Other Payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Stock-based Payments (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://mymd.com/role/Stock-basedPaymentsTables",
     "shortName": "Stock-based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_CommonStockWarrantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://mymd.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_CommonStockWarrantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://mymd.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://mymd.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-04-16",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "MYMD:ExchangeRatioPricePerShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Organization and Description of Business (Details Narrative)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
     "shortName": "Organization and Description of Business (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-04-16",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "MYMD:ExchangeRatioPricePerShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails",
     "shortName": "Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MYMD:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
     "shortName": "Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MYMD:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MYMD:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Schedule of Estimated Useful Lives of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
     "shortName": "Schedule of Estimated Useful Lives of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MYMD:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
     "shortName": "Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "MYMD:ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_PlattStreetMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
     "shortName": "Schedule of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "MYMD:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Other Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
     "shortName": "Schedule of Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "MYMD:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Operating Lease Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
     "shortName": "Schedule of Operating Lease Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://mymd.com/role/StatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails",
     "shortName": "Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-04-162021-04-16_custom_AkersBiosciencesIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MYMD:SummaryOfMilestoneEventsPaymentTableTextBlock",
       "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_MilestonePeriodOneMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:MilestoneEvent",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Summary of Milestone Events Payment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails",
     "shortName": "Summary of Milestone Events Payment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MYMD:SummaryOfMilestoneEventsPaymentTableTextBlock",
       "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_MilestonePeriodOneMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "MYMD:MilestoneEvent",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Recent Developments, Liquidity and Management\u2019s Plans (Details Narrative)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
     "shortName": "Recent Developments, Liquidity and Management\u2019s Plans (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "MYMD:RecentDevelopmentsAndManagementsPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "MYMD:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Trade and Other Payables (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails",
     "shortName": "Schedule of Trade and Other Payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdvancesToAffiliate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Notes Payable (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://mymd.com/role/NotesPayableDetailsNarrative",
     "shortName": "Notes Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_BridgeLoanNoteMember_custom_MyMDPharmaceuticalsFloridaIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdvancesToAffiliate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Summary of Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://mymd.com/role/SummaryOfStockOptionsActivityDetails",
     "shortName": "Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Summary of Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails",
     "shortName": "Summary of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-08-162022-08-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Stock-based Payments (Details Narrative)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
     "shortName": "Stock-based Payments (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_CommonStockWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Summary of Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://mymd.com/role/SummaryOfWarrantActivityDetails",
     "shortName": "Summary of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_CommonStockWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://mymd.com/role/EquityDetailsNarrative",
     "shortName": "Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://mymd.com/role/StatementsOfComprehensiveLossParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Schedule of Income Tax (Benefit)/Provision (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails",
     "shortName": "Schedule of Income Tax (Benefit)/Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails",
     "shortName": "Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails",
     "shortName": "Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://mymd.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "MYMD:RightOfUseAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Related Parties (Details Narrative)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://mymd.com/role/RelatedPartiesDetailsNarrative",
     "shortName": "Related Parties (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-04-272021-04-28_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RepaymentsOfRelatedPartyDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - Employee Benefit Plan (Details Narrative)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative",
     "shortName": "Employee Benefit Plan (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - Paycheck Protection Program Loan (Details Narrative)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative",
     "shortName": "Paycheck Protection Program Loan (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "MYMD:PaycheckProtectionProgramLoanDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-04-152020-04-16_custom_PaycheckProtectionProgramLoansMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - Patent Assignment and Royalty Agreement (Details Narrative)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative",
     "shortName": "Patent Assignment and Royalty Agreement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-08-162022-08-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - Subsequent Events (Details Narrative)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://mymd.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-02-23_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statement of Changes in Stockholders' Equity /(Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
     "shortName": "Consolidated Statement of Changes in Stockholders' Equity /(Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "MYMD:ModificationOfPreMergerStockOptionShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Consolidated Statement of Changes in Stockholders' Equity /(Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statement of Changes in Stockholders' Equity /(Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "MYMD:ModificationOfPreMergerStockOptionShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://mymd.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "MYMD:AccruedInterestdividends",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://mymd.com/role/OrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "MYMD_AccretionOfDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of debt discount.",
        "label": "Accretion of Debt Discount"
       }
      }
     },
     "localname": "AccretionOfDebtDiscount",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_AccruedInterestdividends": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest dividends.",
        "label": "Accrued interest/dividends"
       }
      }
     },
     "localname": "AccruedInterestdividends",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_AkersBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Akers Biosciences, Inc [Member]",
        "label": "Akers Biosciences, Inc [Member]"
       }
      }
     },
     "localname": "AkersBiosciencesIncMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_AmendedPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Plan [Member]",
        "label": "Amended Plan [Member]"
       }
      }
     },
     "localname": "AmendedPlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_AnnualLeasingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual leasing fee.",
        "label": "Annual leasing fee"
       }
      }
     },
     "localname": "AnnualLeasingFee",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_BridgeLoanNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge Loan Note [Member]",
        "label": "Bridge Loan Note [Member]"
       }
      }
     },
     "localname": "BridgeLoanNoteMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_CashPaidForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for abstract.",
        "label": "Cash paid for:"
       }
      }
     },
     "localname": "CashPaidForAbstract",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "MYMD_CommonStockNoParValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock No Par Value [Member]",
        "label": "Common stock No Par Value [Member]"
       }
      }
     },
     "localname": "CommonStockNoParValueMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_ContributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution Agreement [Member]",
        "label": "Contribution Agreement [Member]"
       }
      }
     },
     "localname": "ContributionAgreementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_CumulativeChangeInOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative change in ownership percentage.",
        "label": "Cumulative change in ownership percentage."
       }
      }
     },
     "localname": "CumulativeChangeInOwnershipPercentage",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "MYMD_CumulativeFairMarketValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative fair market value",
        "label": "Cumulative fair market value"
       }
      }
     },
     "localname": "CumulativeFairMarketValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_CystronBiotechLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cystron Biotech LLC [Member]",
        "label": "Cystron Biotech LLC [Member]"
       }
      }
     },
     "localname": "CystronBiotechLLCMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_DecreaseInPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in prepaid expense.",
        "label": "Decrease in prepaid expense"
       }
      }
     },
     "localname": "DecreaseInPrepaidExpense",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_DisclosurePatentAssignmentAndRoyaltyAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Assignment And Royalty Agreement"
       }
      }
     },
     "localname": "DisclosurePatentAssignmentAndRoyaltyAgreementAbstract",
     "nsuri": "http://mymd.com/20221231",
     "xbrltype": "stringItemType"
    },
    "MYMD_DisclosurePaycheckProtectionProgramLoanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "DisclosurePaycheckProtectionProgramLoanAbstract",
     "nsuri": "http://mymd.com/20221231",
     "xbrltype": "stringItemType"
    },
    "MYMD_DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Developments Liquidity And Managements Plans"
       }
      }
     },
     "localname": "DisclosureRecentDevelopmentsLiquidityAndManagementsPlansAbstract",
     "nsuri": "http://mymd.com/20221231",
     "xbrltype": "stringItemType"
    },
    "MYMD_EventOfDefaultMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event of Default [Member]",
        "label": "Event of Default [Member]"
       }
      }
     },
     "localname": "EventOfDefaultMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_ExchangeRatioPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange ratio percentage.",
        "label": "Exchange ratio percentage"
       }
      }
     },
     "localname": "ExchangeRatioPercentage",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "MYMD_ExchangeRatioPricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange ratio price per shares.",
        "label": "Exchange ratio price per shares"
       }
      }
     },
     "localname": "ExchangeRatioPricePerShares",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of prepaid equity forward contracts for common stock.",
        "label": "Exercise of prepaid equity forward contracts for Common Stock"
       }
      }
     },
     "localname": "ExerciseOfPrepaidEquityForwardContractsForCommonStock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_ExerciseOfPrepaidEquityForwardContractsForCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of prepaid equity forward contracts for common stock shares.",
        "label": "Exercise of prepaid equity forward contracts for common stock, shares"
       }
      }
     },
     "localname": "ExerciseOfPrepaidEquityForwardContractsForCommonStockShares",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_ExerciseOfWarrantsForCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants for common stock.",
        "label": "Exercise of warrants for Common Stock"
       }
      }
     },
     "localname": "ExerciseOfWarrantsForCommonStock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_ExerciseOfWarrantsForCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants for common stock shares.",
        "label": "Exercise of warrants for common stock, shares"
       }
      }
     },
     "localname": "ExerciseOfWarrantsForCommonStockShares",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_FourZeroOneKPlanMatchesFiftyPercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401 K Plan Matches 50% [Member]",
        "label": "401 K Plan Matches 50% [Member]"
       }
      }
     },
     "localname": "FourZeroOneKPlanMatchesFiftyPercentMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_FourZeroOneKPlanMaximumFivePercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401 K Plan Maximum 5% [Member]",
        "label": "401 K Plan Maximum 5% [Member]"
       }
      }
     },
     "localname": "FourZeroOneKPlanMaximumFivePercentMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_GainOnDebtForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on debt forgiveness.",
        "label": "GainOnDebtForgiveness",
        "negatedLabel": "Gain on Debt Forgiveness"
       }
      }
     },
     "localname": "GainOnDebtForgiveness",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_GainOnForgivenessOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on forgiveness of debt.",
        "label": "GainOnForgivenessOfDebt",
        "negatedLabel": "Gain on forgiveness of debt"
       }
      }
     },
     "localname": "GainOnForgivenessOfDebt",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_HydeParkFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hyde Park Facility [Member]",
        "label": "Hyde Park Facility [Member]"
       }
      }
     },
     "localname": "HydeParkFacilityMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_InstitutionalAndAccreditedInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institutional And Accredited Investors [Member]",
        "label": "Institutional and Accredited Investors [Member]"
       }
      }
     },
     "localname": "InstitutionalAndAccreditedInvestorsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of post-merger common share.",
        "label": "Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share"
       }
      }
     },
     "localname": "IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_JanuaryTwentyEightTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 28, 2022 [Member]",
        "label": "January 28, 2022 [Member]"
       }
      }
     },
     "localname": "JanuaryTwentyEightTwoThousandTwentyTwoMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_JulySevenTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 7, 2022 [Member]",
        "label": "July 7, 2022 [Member]"
       }
      }
     },
     "localname": "JulySevenTwoThousandTwentyTwoMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MarketableSecuritiesUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities Unrealized Loss.",
        "label": "Unrealized (gain)/loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedLoss",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_MembershipInterestPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Membership Interest Purchase Agreement [Member]",
        "label": "Membership Interest Purchase Agreement [Member]"
       }
      }
     },
     "localname": "MembershipInterestPurchaseAgreementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement [Member]",
        "label": "Merger Agreement [Member]"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MilestoneEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Event.",
        "label": "Milestone Event"
       }
      }
     },
     "localname": "MilestoneEvent",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "MYMD_MilestonePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "MYMD_MilestonePeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Period Four [Member]",
        "label": "Milestone Period Four [Member]"
       }
      }
     },
     "localname": "MilestonePeriodFourMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MilestonePeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Period One [Member]",
        "label": "Milestone Period One [Member]"
       }
      }
     },
     "localname": "MilestonePeriodOneMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MilestonePeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Period Three [Member]",
        "label": "Milestone Period Three [Member]"
       }
      }
     },
     "localname": "MilestonePeriodThreeMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MilestonePeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Period Two [Member]",
        "label": "Milestone Period Two [Member]"
       }
      }
     },
     "localname": "MilestonePeriodTwoMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_ModificationOfPreMergerStockOptionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of pre merger stock options.",
        "label": "Modification of pre merger stock options"
       }
      }
     },
     "localname": "ModificationOfPreMergerStockOptionShares",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_ModificationTermsOfPreMergerStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification Terms Of Pre Merger Stock Options.",
        "label": "Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement"
       }
      }
     },
     "localname": "ModificationTermsOfPreMergerStockOptions",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_MrWilliamsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr Williams [Member]",
        "label": "Mr Williams [Member]"
       }
      }
     },
     "localname": "MrWilliamsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MyMDFloridaStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MyMD Florida Stock Options [Member]",
        "label": "MyMD Florida Stock Options [Member]"
       }
      }
     },
     "localname": "MyMDFloridaStockOptionsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_MyMDPharmaceuticalsFloridaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MyMD Pharmaceuticals (Florida), Inc [Member]",
        "label": "MyMD Pharmaceuticals (Florida), Inc [Member]"
       }
      }
     },
     "localname": "MyMDPharmaceuticalsFloridaIncMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_NegotiatedSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Negotiated Settlement [Member]",
        "label": "Negotiated Settlement [Member]"
       }
      }
     },
     "localname": "NegotiatedSettlementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_NetProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of common stock.",
        "label": "Net proceeds from issuance of common stock",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_NumberOfCommonStockSharesRepresentByPreferredStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock shares represent by preferred stock outstanding.",
        "label": "Underlying shares of common stock"
       }
      }
     },
     "localname": "NumberOfCommonStockSharesRepresentByPreferredStockOutstanding",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_NumberOfStockOptionsAssumed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock options assumed.",
        "label": "Number of stock options assumed"
       }
      }
     },
     "localname": "NumberOfStockOptionsAssumed",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_OperatingLossCarryforwarddSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforward subject to expiration.",
        "label": "Net operating loss carry forwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwarddSubjectToExpiration",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_OperatingLossCarryforwardsExpirationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Expiration Date Description.",
        "label": "Expiration date description"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDateDescription",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "MYMD_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Not Subject to Expiration.",
        "label": "Net operating loss carry forwards not to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_OptionsMarketValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options market value.",
        "label": "Options market value"
       }
      }
     },
     "localname": "OptionsMarketValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_OtherAssetInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other asset investment.",
        "label": "Investment in Oravax Medical, Inc."
       }
      }
     },
     "localname": "OtherAssetInvestment",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Assignment and Royalty Agreement Disclosure [Text Block]",
        "label": "Patent Assignment and Royalty Agreement"
       }
      }
     },
     "localname": "PatentAssignmentAndRoyaltyAgreementDisclosureTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/PatentAssignmentAndRoyaltyAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Trademarks [Member]",
        "label": "Patents and Trademarks [Member]"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PaycheckProtectionProgramLoanDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program Loan Disclosure [Text Block]",
        "label": "PaycheckProtectionProgramLoanDisclosureTextBlock",
        "verboseLabel": "Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanDisclosureTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/PaycheckProtectionProgramLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_PaycheckProtectionProgramLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program Loans [Member]",
        "label": "Paycheck Protection Program Loans [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoansMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PercentageOfNetIncomeForEachSubsequentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net income for each subsequent period.",
        "label": "Percentage of net income"
       }
      }
     },
     "localname": "PercentageOfNetIncomeForEachSubsequentPeriod",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "MYMD_PlattStreetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platt Street [Member]",
        "label": "Platt Street [Member]"
       }
      }
     },
     "localname": "PlattStreetMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PreFundedCommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Common Stock Warrants [Member]",
        "label": "Pre-funded Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedCommonStockWarrantsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PreFundedWarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded Warrants to Purchase Common Stock [Member]",
        "label": "Pre-funded Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsToPurchaseCommonStockMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PreMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Merger [Member]",
        "label": "Pre Merger [Member]"
       }
      }
     },
     "localname": "PreMergerMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded Warrants [Member]",
        "label": "Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PremasBiotechPVTLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premas Biotech PVT Ltd [Member]",
        "label": "Premas Biotech PVT Ltd [Member]"
       }
      }
     },
     "localname": "PremasBiotechPVTLtdMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_PrepaidExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses [Policy Text Block]",
        "label": "PrepaidExpensesPolicyTextBlock",
        "verboseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "PrepaidExpensesPolicyTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Estimated Useful Lives of Property Plant and Equipment [Table Text Block]",
        "label": "Schedule of Estimated Useful Lives of Property Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_RecentDevelopmentsAndManagementsPlansTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent developments and managements plans text block.",
        "label": "Recent Developments, Liquidity and Management\u2019s Plans"
       }
      }
     },
     "localname": "RecentDevelopmentsAndManagementsPlansTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_RightOfUseAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets [Policy Text Block]",
        "label": "Right-of-Use Assets"
       }
      }
     },
     "localname": "RightOfUseAssetsPolicyTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_RiskManagementOfCashInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Management of Cash Investments [Policy Text Block]",
        "label": "Risk Management of Cash and Investments"
       }
      }
     },
     "localname": "RiskManagementOfCashInvestmentsPolicyTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of condensed consolidated balance sheet information related to operating lease [Table Text Block]",
        "label": "Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease"
       }
      }
     },
     "localname": "ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Estimated Useful Lives of Intangible Assets [Table Text Block]",
        "label": "Schedule of Estimated Useful Lives of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Information Related to Leases [Table Text Block]",
        "label": "Schedule of Other Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SeriesCConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Convertible Preferred Stock Warrants [Member]",
        "label": "Series C Convertible Preferred Stock Warrants [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SeriesCPreferredConvertibleWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Preferred Convertible Warrants [Member]",
        "label": "Series C Preferred Convertible Warrants [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredConvertibleWarrantsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock [Member]",
        "label": "Series D Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SeriesDPreferredConvertibleStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Preferred Convertible Stock [Member]",
        "label": "Series D Preferred Convertible Stock [Member]"
       }
      }
     },
     "localname": "SeriesDPreferredConvertibleStockMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SeriesFConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series F Convertible Preferred Stock [Member]",
        "label": "Series F Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesFConvertiblePreferredStockMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.",
        "label": "Number of RSUs, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.",
        "label": "Weighted Average Grant Date Fair Value, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercises in period.",
        "label": "Number of RSUs, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercises in period weighted average grant date fair value.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
        "periodEndLabel": "Number of Warrants, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of non-option equity outstanding and currently exercisable under the non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments forfeited in period weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term (years), Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term (years), Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term (years), Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term (Years), Granted.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value, Cancelled/Expired.",
        "label": "Weighted Average Grant Date Fair Value, Canceled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value, Exercisable.",
        "label": "Weighted Average Grant Date Fair Value, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value, Exercised.",
        "label": "Weighted Average Grant Date Fair Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "MYMD_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1",
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_StockIssuedDuringPeriodSharesPostReverseStockSplits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of post reverse stock split.",
        "label": "Issuance of post reverse stock split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPostReverseStockSplits",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "MYMD_StockIssuedDuringPeriodValueCompensationOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value compensation of warrants.",
        "label": "Stock-based compensation \u2013 warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCompensationOfWarrants",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_StockOptionModificationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option modification expenses.",
        "label": "Stock Option Modification Expenses",
        "verboseLabel": "Option modification expense"
       }
      }
     },
     "localname": "StockOptionModificationExpenses",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows",
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_SummaryOfMilestoneEventsPaymentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of milestone events payment table text block.",
        "label": "Summary of Milestone Events Payment"
       }
      }
     },
     "localname": "SummaryOfMilestoneEventsPaymentTableTextBlock",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "MYMD_SuperaAviationILLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supera Aviation I, LLC [Member]",
        "label": "Supera Aviation I, LLC [Member]"
       }
      }
     },
     "localname": "SuperaAviationILLCMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SuperaAviationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supera Aviation [Member]",
        "label": "Supera Aviation [Member]"
       }
      }
     },
     "localname": "SuperaAviationMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_SuperaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supera Pharmaceuticals Inc [Member]",
        "label": "Supera Pharmaceuticals Inc [Member]"
       }
      }
     },
     "localname": "SuperaPharmaceuticalsIncMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TaglichBrothersIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taglich Brothers Inc [Member]",
        "label": "Taglich Brothers Inc [Member]"
       }
      }
     },
     "localname": "TaglichBrothersIncMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandAndEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Stock Incentive Plan [Member]",
        "label": "2018 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndEighteenStockIncentivePlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandAndSeventeenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Stock Incentive Plan [Member]",
        "label": "2017 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenStockIncentivePlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandAndSixteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Equity Incentive Plan [Member]",
        "label": "2016 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndSixteenEquityIncentivePlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandAndSixteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Incentive Plan [Member]",
        "label": "2016 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndSixteenStockIncentivePlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Stock Incentive Plan [Member]",
        "label": "2021 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2013 Stock Incentive Plan [Member]",
        "label": "2013 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandThirteenStockIncentivePlanMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandTwentyBaltimoreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Baltimore [Member]",
        "label": "2020 Baltimore [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyBaltimoreMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_TwoThousandTwentyOneBaltimoreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Baltimore [Member]",
        "label": "2021 Baltimore [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneBaltimoreMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_UninsuredCasualtyLosses": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uninsured Casualty Losses.",
        "label": "UninsuredCasualtyLosses",
        "negatedLabel": "Uninsured Casualty Losses"
       }
      }
     },
     "localname": "UninsuredCasualtyLosses",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "MYMD_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Units [Member]",
        "label": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock [Member]",
        "label": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "MYMD_WeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term granted.",
        "label": "Weighted Average Remaining Contractual Term (Years), Granted"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "MYMD_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://mymd.com/20221231",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r563",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r563",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r563",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r563",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r563",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://mymd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r200",
      "r427",
      "r428",
      "r429",
      "r430",
      "r464",
      "r521",
      "r597",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r200",
      "r427",
      "r428",
      "r429",
      "r430",
      "r464",
      "r521",
      "r597",
      "r600",
      "r601"
     ],
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r351",
      "r472",
      "r497",
      "r522",
      "r523",
      "r539",
      "r546",
      "r551",
      "r602",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r351",
      "r472",
      "r497",
      "r522",
      "r523",
      "r539",
      "r546",
      "r551",
      "r602",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r330",
      "r351",
      "r386",
      "r387",
      "r388",
      "r471",
      "r472",
      "r497",
      "r522",
      "r523",
      "r539",
      "r546",
      "r551",
      "r593",
      "r602",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r330",
      "r351",
      "r386",
      "r387",
      "r388",
      "r471",
      "r472",
      "r497",
      "r522",
      "r523",
      "r539",
      "r546",
      "r551",
      "r593",
      "r602",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r214",
      "r356",
      "r573",
      "r587"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r214",
      "r356",
      "r573",
      "r574",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r589",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "verboseLabel": "Trade and Other Payables"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/TradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "totalLabel": "Trade and other payables, Total"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r550"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Trade and Other Payables"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r17"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable \u2013 Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r186",
      "r187",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r584",
      "r585",
      "r586",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesToAffiliate": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.",
        "label": "Advances to affiliate"
       }
      }
     },
     "localname": "AdvancesToAffiliate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Options issued to key employees"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r38",
      "r49",
      "r135",
      "r305"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Accretion of debt discount",
        "verboseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total potentially dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/RelatedPartiesDetailsNarrative",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative",
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r142",
      "r155",
      "r177",
      "r197",
      "r235",
      "r238",
      "r242",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r427",
      "r429",
      "r438",
      "r550",
      "r598",
      "r599",
      "r709"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r172",
      "r182",
      "r197",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r427",
      "r429",
      "r438",
      "r550",
      "r598",
      "r599",
      "r709"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r197",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r427",
      "r429",
      "r438",
      "r598",
      "r599",
      "r709"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total Non-Current Assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Current Assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r426",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r426",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business acquisition description"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r128",
      "r129",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Total Consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "verboseLabel": "Investment in Oravax, Inc."
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "verboseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Other Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Trade and Other Payables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Net Tangible Assets Acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Acquired membership interests, percentage"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_CapitalizationLongtermDebtAndEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the total consolidated (as applicable) capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.",
        "label": "Pre market capitalization"
       }
      }
     },
     "localname": "CapitalizationLongtermDebtAndEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r174",
      "r525"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents",
        "verboseLabel": "Cash on hand"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r44",
      "r51",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r44",
      "r134"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r197",
      "r216",
      "r217",
      "r219",
      "r221",
      "r225",
      "r226",
      "r248",
      "r272",
      "r275",
      "r276",
      "r277",
      "r281",
      "r282",
      "r309",
      "r310",
      "r314",
      "r318",
      "r325",
      "r438",
      "r524",
      "r572",
      "r579",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of warrant or right, exercise price of warrants or rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Issuance of warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants to purchase",
        "terseLabel": "Warrants to acquire common stock",
        "verboseLabel": "Warrants, issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r148",
      "r160"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r265",
      "r266",
      "r518",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r584",
      "r585",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common stock, no par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r550"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, no par value, 500,000,000 shares authorized 39,470,009 and 37,673,110 issued and outstanding as of December 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r152",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r10",
      "r11",
      "r82",
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Preferred stock, terms of conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r34",
      "r476"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Product Cost of Sales",
        "verboseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss",
      "http://mymd.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Cost and expenses incurred"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r121",
      "r411",
      "r419",
      "r582"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r195",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r299",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r143",
      "r144",
      "r153",
      "r200",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r447",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r136",
      "r137",
      "r283",
      "r447",
      "r535",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Maximum principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r24",
      "r136",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate",
        "verboseLabel": "Borrowings accrued interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r25",
      "r200",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r447",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Initial term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r49",
      "r121",
      "r412",
      "r418",
      "r419",
      "r582"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r119",
      "r695"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r117",
      "r119",
      "r695"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r117",
      "r119",
      "r695"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r119",
      "r695"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r119",
      "r695"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Reserves and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative",
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Contributions to employee"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r360",
      "r391",
      "r392",
      "r394",
      "r399",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersCurrent": {
     "auth_ref": [
      "r5",
      "r138",
      "r154",
      "r165"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to MyMD Florida Shareholders"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent": {
     "auth_ref": [
      "r138",
      "r146",
      "r162",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.",
        "label": "Due to officer"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersNoncurrent": {
     "auth_ref": [
      "r9",
      "r138",
      "r154",
      "r165"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are due after one year (or one business cycle).",
        "label": "Due to MyMD Florida Shareholders, net of current portion"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r17",
      "r274",
      "r275",
      "r276",
      "r280",
      "r281",
      "r282",
      "r461",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to related party retired"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r189",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r223",
      "r433",
      "r434",
      "r492",
      "r495",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and Dilutive net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Earnings per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r198",
      "r403",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Statutory U.S. Federal Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r693",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r693",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r693",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Adjustment to deferred tax assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r693",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "New Jersey State income taxes, net of U.S. Federal tax effect"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfReconciliationOfIncomeTaxRateAndBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unamortized value"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r170",
      "r186",
      "r187",
      "r188",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r213",
      "r224",
      "r249",
      "r327",
      "r395",
      "r396",
      "r397",
      "r414",
      "r415",
      "r432",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r457",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r49",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r435",
      "r468",
      "r469",
      "r470",
      "r535",
      "r536",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r297",
      "r332",
      "r337",
      "r435",
      "r468",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r297",
      "r332",
      "r337",
      "r435",
      "r469",
      "r535",
      "r536",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r435",
      "r470",
      "r535",
      "r536",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r468",
      "r469",
      "r470",
      "r535",
      "r536",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Intangible assets estimated, useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Functional and Presentation Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r49",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on debt forgiveness"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r176",
      "r252",
      "r491",
      "r533",
      "r550",
      "r591",
      "r592"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r33",
      "r197",
      "r235",
      "r237",
      "r241",
      "r243",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r438",
      "r532",
      "r598"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross Income"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r29",
      "r141",
      "r150",
      "r164",
      "r235",
      "r237",
      "r241",
      "r243",
      "r493",
      "r532"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Loss from operations",
        "totalLabel": "Loss Before Income Tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r404",
      "r405",
      "r410",
      "r416",
      "r421",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r199",
      "r212",
      "r213",
      "r234",
      "r402",
      "r417",
      "r422",
      "r496"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income Tax Benefit",
        "totalLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails",
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r400",
      "r401",
      "r405",
      "r406",
      "r409",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Trade and other payables",
        "verboseLabel": "Increase in trade and other payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r578",
      "r704"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r66",
      "r473",
      "r474",
      "r475",
      "r477",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r190",
      "r192",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r147",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "negatedLabel": "Interest and Dividend Income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r247",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Warrants issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Schedule of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Operating Lease Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total future minimum lease payments, undiscounted",
        "totalLabel": "Total future minimum lease payments, undiscounted"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r197",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r428",
      "r429",
      "r430",
      "r438",
      "r531",
      "r598",
      "r709",
      "r710"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r145",
      "r158",
      "r550",
      "r581",
      "r590",
      "r701"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r173",
      "r197",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r428",
      "r429",
      "r430",
      "r438",
      "r550",
      "r598",
      "r709",
      "r710"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r8",
      "r9",
      "r197",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r428",
      "r429",
      "r430",
      "r438",
      "r598",
      "r709",
      "r710"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Non-Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityDescription": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.",
        "label": "Line of credit facility, description"
       }
      }
     },
     "localname": "LineOfCreditFacilityDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Expiration date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of credit facility expiration period"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Borrowing capacity revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Investment in Oravax, Inc."
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r72",
      "r73",
      "r267",
      "r268",
      "r269",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Gain/loss on sale of marketable securities",
        "negatedLabel": "(Gain)/Loss on Sales of Marketable Securities",
        "negatedTerseLabel": "(Gain)/loss on sale of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows",
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized (Gain)/Loss on Marketable Securities",
        "verboseLabel": "Unrealized (gain)/loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r44",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash provided by operating activities",
        "totalLabel": "Net cash used by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r50",
      "r151",
      "r163",
      "r171",
      "r183",
      "r184",
      "r188",
      "r197",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r218",
      "r235",
      "r237",
      "r241",
      "r243",
      "r248",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r434",
      "r438",
      "r532",
      "r598"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss from ongoing operations"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementsOfCashFlows",
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Schedule of Non-Cash Financing and Investing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total Other (Income) Expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (Income) Expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r8",
      "r144",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r235",
      "r237",
      "r241",
      "r243",
      "r532"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r451",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Lease Costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability",
        "verboseLabel": "Lease Payable, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability, net of current portion",
        "verboseLabel": "Lease Payable - net of current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r450",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash used"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right-of-Use Assets",
        "verboseLabel": "Lease Right of Use"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r455",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r454",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.",
        "label": "Amount owed on investments"
       }
      }
     },
     "localname": "PaymentsForProceedsFromInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Purchase of marketable securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r330",
      "r331",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r357",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred stock, conversion price"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r11",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, no par value"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, stated value",
        "verboseLabel": "Preferred stock value, per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r550"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r181",
      "r250",
      "r251",
      "r526"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds from issuance of Common Stock",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Net proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoans": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from principal payments made on loans related to operating activities.",
        "label": "Proceeds from loans"
       }
      }
     },
     "localname": "ProceedsFromLoans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Net proceeds from note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from sale of marketable securities",
        "verboseLabel": "Proceeds from the sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Net cash received in business combination"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Common stock options, proceeds"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Net proceeds from the exercise of warrants for Common Stock"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "verboseLabel": "Property, plant and equipment, useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r70",
      "r159",
      "r494",
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Tangible asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for planned major maintenance activities.",
        "label": "Recoverability of Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPlannedMajorMaintenanceActivitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, plant and equipment, useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r339",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r169",
      "r460",
      "r461",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r339",
      "r460",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r42",
      "r580"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of the line of credit \u2013 related party"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Amounts paid by related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r113",
      "r168",
      "r717"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted stock units to non-employees"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Number of restricted stock, net of tax withholdings"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted stock value, net of tax withholdings"
       }
      }
     },
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r88",
      "r157",
      "r501",
      "r502",
      "r550"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r170",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r213",
      "r249",
      "r395",
      "r396",
      "r397",
      "r414",
      "r415",
      "r432",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r546",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r546",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r232",
      "r233",
      "r236",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246",
      "r328",
      "r329",
      "r476"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Product Revenue",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/PatentAssignmentAndRoyaltyAgreementDetailsNarrative",
      "http://mymd.com/role/StatementsOfComprehensiveLoss",
      "http://mymd.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "(p) Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r453",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Operating lease right-of-use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Trade and Other Payables"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Income Tax (Benefit)/Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Related Valuation Allowances"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EmployeeBenefitPlanDetailsNarrative",
      "http://mymd.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Reconciliation of Income Tax Rate and Benefit from Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Summary of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsDetails",
      "http://mymd.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Net Assets Acquired to be Allocated to Goodwill"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfNetAssetsAcquiredToBeAllocatedToGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r99",
      "r107",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r178",
      "r179",
      "r180",
      "r225",
      "r309",
      "r310",
      "r312",
      "r314",
      "r318",
      "r323",
      "r325",
      "r539",
      "r572",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r90",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Summary of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock Based Compensation",
        "terseLabel": "Share based compensation",
        "verboseLabel": "Non cash share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementsOfComprehensiveLoss",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation:"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Restricted stock units vested, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of RSUs, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of RSUs, Granted",
        "verboseLabel": "Restricted stock units, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of RSUs, Ending Balance",
        "periodStartLabel": "Number of RSUs, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Vested restricted stock unit",
        "negatedLabel": "Number of RSUs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted Average Grant Date Fair Value, Vested",
        "verboseLabel": "Grant date fair value price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.",
        "label": "Share based payment award vesting expiration date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Volatility index"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of shares, exercised",
        "negatedLabel": "Number of Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "negatedLabel": "Number of Warrants, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Number of Warrants, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Warrants, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Warrants, Ending Balance",
        "periodStartLabel": "Number of Warrants, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Premerger common stock, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Remaining shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of Shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Number of Shares, Canceled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Weighted average grant date fair value, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Ending Balance",
        "periodStartLabel": "Number of Shares, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Exercise price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "verboseLabel": "Common stock options, exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Percentage of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Number of stock option to purchase shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted Average Exercise Price, Canceled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r364",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Fair market value price per share",
        "terseLabel": "Share price",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Number of vesting shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term (Years), Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/PaycheckProtectionProgramLoanDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r197",
      "r216",
      "r217",
      "r219",
      "r221",
      "r225",
      "r226",
      "r248",
      "r272",
      "r275",
      "r276",
      "r277",
      "r281",
      "r282",
      "r309",
      "r310",
      "r314",
      "r318",
      "r325",
      "r438",
      "r524",
      "r572",
      "r579",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r28",
      "r81",
      "r170",
      "r186",
      "r187",
      "r188",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r213",
      "r224",
      "r249",
      "r327",
      "r395",
      "r396",
      "r397",
      "r414",
      "r415",
      "r432",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r457",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/EquityTables",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r224",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/BalanceSheetsParenthetical",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r11",
      "r12",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares",
        "terseLabel": "Common shares outstanding",
        "verboseLabel": "Stock issued during period, shares, acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r81",
      "r82",
      "r88",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Number of shares, exchange"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock based compensation for services, shares",
        "verboseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued",
        "terseLabel": "Issuance of common stock for warrants, shares",
        "verboseLabel": "Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficitParenthetical",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r81",
      "r88",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of per-merger MyMD stock options, shares",
        "terseLabel": "Common stock options, exercised",
        "verboseLabel": "Number of Shares, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/SummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r28",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Reverse merger with Akers Biosciences Inc effective April 16, 2021"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock based compensation for services",
        "verboseLabel": "Fair market value of shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500",
        "terseLabel": "Number of shares issued, value",
        "verboseLabel": "Cumulative fair market value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock-based compensation \u2013 restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r88",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation \u2013 stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of per-merger MyMD stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock options exercise price"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://mymd.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Options issued to non-employees",
        "verboseLabel": "Stock option expenses"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r14",
      "r15",
      "r61",
      "r550",
      "r581",
      "r590",
      "r701"
     ],
     "calculation": {
      "http://mymd.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/StatementOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r196",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r445",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r445",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r445",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r445",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative",
      "http://mymd.com/role/NotesPayableDetailsNarrative",
      "http://mymd.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mymd.com/role/RecentDevelopmentsLiquidityAndManagementsPlansDetailsNarrative",
      "http://mymd.com/role/RelatedPartiesDetailsNarrative",
      "http://mymd.com/role/ScheduleOfCondensedConsolidatedBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://mymd.com/role/ScheduleOfLeaseExpenseDetails",
      "http://mymd.com/role/ScheduleOfOperatingLeaseMinimumLeasePaymentsDetails",
      "http://mymd.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails",
      "http://mymd.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative",
      "http://mymd.com/role/SubsequentEventsDetailsNarrative",
      "http://mymd.com/role/SummaryOfMilestoneEventsPaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Cost, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r227",
      "r228",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates and Judgments"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in Valuation Allowance",
        "negatedTerseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/IncomeTaxesDetailsNarrative",
      "http://mymd.com/role/ScheduleOfIncomeTaxBenefitprovisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/Stock-basedPaymentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Stock price per share"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r215",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average basic and diluted common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://mymd.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(17))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r557": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r558": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r561": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r563": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r564": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r565": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r566": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r567": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r568": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r569": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=16397424&loc=d3e949-110221",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001493152-23-010384-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-010384-xbrl.zip
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M0%Q..0H/78DL7@2DSP,2XP/1G<N8U=\P[WQ^N;U\B6G<4"Y2[QKN[10%:C9
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M6%YL@ST"%^3LT0 RX<);D"F8,E(14I3G95RC<21F+E?Z!TZS.;9N8(G8@P)
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M3?P%0TO19,F%M81NAH_&-H]"(;-07MV =GV?1Q%CWQ&QXY *)1)M#B!5(Z=
M(R 7)6I2^,34,O2?$Z;?8@X#48P7!Y8ZB#\KSJP*(BC.K/YA#FMZ"6M@&I$#
M1>&I,AY26YP!IR0!:79L-&?T 8-+G;Q3X:5*0*I7 ]-W;%[!5#G]I ]WJ,BX
M=(,4H3;4EBQ3(L^R6I*VA"I 36 ZA@YS)<R C'U@!QBZ&E&B!3>^EU2$L!\"
M:Q'"[N.J%(=*FI>#Y!UJ1X R,X EF5*4P+/JG>>$D T=X_%@%GHSAH%>0"?)
M^]LB$:',GWKA@L'3N1MJY4F?T#W0\W="X32&?B6?G^]6U15?;'J[-;UAUR>
MKRN_;#5? [NYJE'=40%JX.K"()>5RZLMV6J"^FJKH&\6U>_"2Y9S'$91Z%?)
MV*/6 [DXOP:XZAT:W>0/#>#3?[8Z@GJG499E#?RY+S+>G;?!HCN-;?FQ;6_)
M/?5C'P!6;L<D6VAMVQ1;IH"5AY5]*SH+L#9_-9J<]O6+'G#+?&16C&>:Z<.S
MGRDP?L[O8 #H?Y5*Y)8SSZZ2/BBX&C3P+88('"O62&^J4F95TJ4R(J52NISM
MSA\I*CV$S-W\&T>RXH)N5ET0#&PI;/)"9E7H/'5IZPIE1<FL>YJEU6],P^2G
MW&..JI'MU%S3R_E+USY=]WH9YB*=EMQDEG$V]8QM(:.XU9^,.5G*RS+^M(W^
MK1O\29S_ U!+ P04    "  =B']6L-'A87H(  "510  "@   &5X,S$M,BYH
M=&WM7&USVK@6_IZ9_ =M9G8GF3&!),WN#%!F() M<VG(@'NG_2AL&71C6U22
MH=Q?O^=(-C@D:=);N(7$_= $6R^/CG6>\YPCD_H']V.O<7A0_]!IMN$GP7]U
MM^OV.HUZV?Z$N^7T=KW5;W\A0_=+K_/^*!"QKI*SRE03ET=,D1LV)P,1T=BQ
M%QPR9)('1] 1NMYF_2(JQSRNDLI1XX]XI*:U>OEVK<E+AZZ1Y6!372.:?=,E
M&O(Q7)!\/-%'C?IU_\;-#UL*:,3#1?6Y@4U;Q?_++ X8J=7H?)OP$=>'!Q=G
MI^?U<@M,A,,W]F,!F;&W!]ECL69RPT:_Z@S<[G7WJNEV^S>'![>?!L-/31C>
M[==; UC#L'/U:=!UNYTAZ7R^^M"\^;M#FE<N&7SJP:6S"UHZ>W=,3TCSIDW.
M+GW[:=L/;RN6: X/#YKM_JW;:9.<&0A8 &U#+BKGI']MK>)^Z)!A<]!JWG2&
MI?[G7N>+,4K_FIQ7*EO?NYM?_O8W[W\2I7FPV"3HKG-XT*4Q&4R$C^VZ:!4>
MD:L)9P&YYC&-/4Y#T@\"[C'I@-TD8B!Z0G5USQ;[^!-RFZU>AUQU>KWA;?.J
M>_/W^Z/*D?E\VVRWL\\_O+ Y]_4$FU9^KY&1D#Z3)4^$(9TJ )3]=F0B6MT=
M_"\ART;"]H]CF^%#]&B8V5J+Z1)PY?3\DL>;-/O9Z=+D;OMG8&_;%RRT"9TQ
M(MF,LSGS89]S19IQG( 3#-A42$U$3*Z%C*!7Z5]$!.3CXB.PW83*B'HL,88U
MGN2=UO(+A_\&N_*TM^A5._V('V)]K4_E?$^<KD45\RT\\*MH0>YB,0^9/V:.
M]3UIG<X7,&PL-#!GK"F/"8T7)(FU3!A1FFH604!';Z004C"&@;\&U(-+DHB(
M:["O;?>@0<P\IA25"XL"VD7TCL'DN8$57/,!$<P;HNC%B;"!QZ671- LAC$
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M<?]_H6,%=Q_8K<T4#)T))9.V/$]"#J95'DU 8+VT"R96(P9<8J=+DR612!@
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M;<(DC1"%,INW94F5' &>G?9IU3_:4&%[)#;'(>=#^\/)NXQ647K&NN;0O()
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MFDT3^#7)HJ0J(UBJI- 5#&6TC H]U87.QCJJ\@@ZC=1<FH*W"UU6JH(/8UW
M<L.D*HV333)O$C'U*F_M> ,]\5KZ8%IZ$;;TRF_)3&DX,%/N',QHN9>JJ[*W
MW^?\NUT@>&Q<%S#)*EWB&NCI5(^K.!KGBP1. XSB:I:,9Y$J=#1-4EY&S0P
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MSB7( 64M?!3.#C#2;(*3QL]9[IVVC4X'K-V&:SD<K.I^@ZD]/H*3?=0>8.M
M]'0!A_-*%87*X(H#(U_4T),J==1WJ)$@V'F#6)5'1X_C8TL0FO>]M9AR8IKC
MM4=CLU'O,Y7<DOG[PUZ_L(C#AU"NUU:L^4;K_NK9/W(D<,/!![39E#_]\&J[
M\#=$:,[4>#8<D$PTR].)+H [ \7-='29@VXY!::DX1$FQ2VZ/=/I!)4XE:8P
MDZH"W1STYM$\J9"E ]E7W R\YW51 L?R/\.K2WIN. !5;P$/H(6@0*5O4>2?
ME_O160JJ)JBVQ LFH':/JQRZPB%--/0Z3S+2:*&_15H7L(35TM@8L&%07559
ML88)0\V1-=H!<ROC9")-# =S]1N(N9U-P ,@-P+K\^=#MH JY2G3A+$G$#E+
M^"'JGM.W/SN'7_;DW)LK\%R/55W"X4/[1+"MDQS$NHKEU7$]KU.0RR[I.*"@
M0@9G:#=X!?^2%!-U'"+\89&#1(;?46^=XA (6PF<TA$<(Y2?X$QI//]\=/E%
M>P?V(U3,KFTCHB?%PH,'\A)./XQ25?YL0$636X<7%(=#)A_L!P833>IT"9<B
MQ7,_UYIFU[CH>.)!6"QKD!QQ'E<%4H:,]$6\&K(T_E*UZ,0"KJ9*X5+V="%C
MDX'0_=1T]Q(\+W$TGB5Z&NG/>ES3[N536!/<@H*>'.6JF(1DQ1^Q0H-9GM:\
M: M<*I3'I9OF'K<;VQJKOHU$<9K@$<XF6YGBVP[Z? :$T][V::#)]2A[R&]]
MA@DW1>/%G,@6EM@(OC6M\4.J+^!J U^^5$E*!!&H#UZVBH9*YOD,OP!R-<]K
M4E&1D"&9[+C<2"ZLS! ;VC?A=PK]>YV@6FG'$D?)%/I8QBCF-(Q(GB%CH9()
M$3MI;C@ R6D_^AF(/>C!,4YS@G3X2O-+R%;,.R![I*H@FUHY@Y[+JDA&M8@[
MA;\L&4TJ7$R8OK IWSJ/C@SH%*U;2]/NJF9X!5'< YE%TRI/ZZHN]'[T3^W:
M@P6J5,+RGE9%!KML5F@27<U@(2YTILER3W.>)IG*QL):\X5FY@-T'8Z-S%L9
M?U!CE&9$-(K(,,10VNNAWR-5PN_U0B9J!PJ;0N,!=H(<:)*PW\68,F7S@956
M?*Q83"R ^5XB-YBJ+47_AA3];4YV'CU?,-LNHH\)-*:*:$OAO^6@?V;B3L;0
M%MWP)>2%VRPC&N,M:AA0F51YYL$<K]@$7D6J\X4OUU??/!CA?^WM12\34(1_
MC-ZK"_T4&OB]1C\EO!CM[4F,T$^GK_X1QO/LC?*JRN<_1H]P$T=Y :MLOWN>
M*EBMP_UCF"Z(G\D$9G)^\OSU6?3B[/7K]R>GIZ_>_OU_OCOXCCY_?'_RPGR6
M/J2]<9ZF:E'"6,R_G@(MG50SG-7!7[INWOD'TP9M$<C5YG!5^2(\;:F>TANG
MY@VO:;=@YZ<8&?4!_X,S@+^P%AW+,BJT^K0WTLB$?@3NB&LI2P4]TSI!9^VH
M*']SWH>M>WOS VX.[\>M.E9 Z<S@[QP]@[$3+2;O_@<1XUXGP$8GS-9/?6'F
M#D[PWM@X?EV@F9LM!Z719^,H]?8*Z/!50H+[7KV(.6ZD+'75)8%/22YU>VNB
M7@+%G*--YB ODD%D"I(;W.HERE=T8#RMH2E8BSHM\KR3P=&$0"Y$^'49*!(Q
MF_',F&B4(%O"WR4V P/ !@-%I4 7H\>;RGKT&YI94.O/EE&IR24',FI)+Y0:
M!&P0&?56 OQ&M(5TR[>JG*C?(Q. \D85GW0%1*9$8]"6I-P<27G7ND @W*6P
M+YI< JCA=>\=:/6:;6_E<C[*4^/'?_.O-Z?BKM_>L&]TPPJ5E5.T])Y<H#V6
M[<<72$55L;U<-QDQ"Z2ODMV)E-V<PFP.L>"V&0>#: R;BLSNPC->F.GA@^/'
MCZ.76I%UXR-PV$ET6H#D!J.IDTKS&F*@5O0BU:JX4A5:L%ZF>0&B0O3@P>-'
M1S?@O?KB2WPW[^SS9^\H@AJM6?\T(3ET;3_^6FXC&&[N.)VPA:09A$4&WTGT
M,#Y\_"A^_.!)GU$<(YA(:"6SI?ZLBW%2ZJ9%/9>]CX[C@\='\<,'1RM#U5R#
MR&W]1DTT%YMH@"3$\/_-QM9L"F3W/;34H]';-;LZWFNSP6T6:D9._0QHY 40
M1X5!!-#$T:,'\<'1H\WZ!R4'5(BY."0O-8DP&"=?).3M9)VDSC#JWZ0:X'5S
MH?&9F)OQ70ILP6_"9OUMK#/I!%LA8SCH+JB_',6/GTBPI/<X/F5B#-DF[?]J
M5PL9 I^/2*&&-0-N@#Z2K3#U;0AS,UQS2XUOCAK_4V,4SY(#0TF=MWI\T]:
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MYKJXD  W^ W-B,I7#0PV (N_'%L&[S&5Y=I:.+I-A^?UC!')*?#"5%,**3!
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M)M("!8^0J_)8,"LTT#H\$07L"32J,5"N#!3=L87 PJPO(K(*B^$8O"[@8W&
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M%+'1P!%^08JGI0KB>S"R)HM>H)J;0(9#"A2L:%)A4(.7!&-1D9%145B(A3T
M&2*MN0CAYDT-!SO&C07,\Q.L_:YI/<NSO;"'[HI+DKC+*$E&"PS> 2T1/P?Y
MNFT#42NVQSC)FO$'/3LFV^6'[7"&ZY0WL#>'FU<+B0ZTPKG.)7EZ7%T-)?G1
M[>ST_>B5<(-+:[ Q=#)N5EDQRQ>22J/5]Y0O].M.3"2?_8\=8A/5TCH>?*HL
MVC0>DEZP[+:/JVV<X3 =[[X4)/H!MS4)2L9,9^'#$W\53<%-O#88 N5.4Y(U
M=3?BGW+")KIUMIIU/9B6<Z&#%4]RCGM4SM&:5;1B6K9T_19-A&2[1I59(6JQ
M55U7@.FU+T]'.98 G=UD]$AM/Q/N9U/W/*&J&VZ+/>0)@P":OXN"3[^%W<+C
MGS2I2P-^*);:1H[$8B4?KR8+U[P)ZN(T(B!;\Y=+%12C*]>]Q'#W6-@1OA$V
M,!P4(G)S_!FMXA75<N&"?.BHIKQ%&Q'H54=<M3V^?=<OO) )36HU@]% K1%7
M48J2.7$NDG8I]JTR8:P6Z'##@<6.P%@!NI']:@ 2UYR_J6?^@@]X=4:PKJA'
M2+& '6 )$@8(K+U&L#?@9YB\@?%H =O>C5TU1,NIAP-'5#T)H&](NZ;8%NP6
MAQ**Q<#?4*]Y^$].0!Y.8$XR.58^#"'R@MW]X> \N*(^639WJ76/VT$EI1=5
MLGJ!PY2\X/X2?V6[!8E):'[JOL1]5Y-P^#K!^>(6=A@9)YG4"&2?7Y]IRV9N
MT43^F52H/N14L-.Y*;.N,]'@1E1[2U*/)%[+"F@V#I]M#^-Z7J?D^0G@XD1$
MP_<K*J*'BFJF#7(E*!!_V364:D7GECGM1V]SX$)\SE1'ZGPW??>+GX^T&,1!
MA_ NOFFT],PLZ)L#UI":D&GN:6U46#\Q4LCX/'L@F3)\X-+6U&).D5J:.K*-
M32.*&12@Z>(!_00[,W9IMF>3,[JWBI1QRQNZ<V^O^>HPI\?;,*=MF-.?A7M@
MI'-#P57-V)+H/PPM"<#NO-A@YC65+40@A?!LE$\  1-(1'&C$&+.&'K&RC-.
M"N!7**J-<>[])2S%6LQ2:!B2NDNCX1"M!@ YIC136HVU5-C$JH L6XY6H=O/
M2HX2%X%/X*6YR*DNI0L)(U.!+>C'@3V;&(QC,A2)7,H[B=%1*/MS!$?G\K2S
MNUOQ%,"B"HSKZ8;-P^FT;=>,C&=Z-$4^"4(>7>-&RLAJ=*6"L'F9)Q.+&.=.
MBO/6E5Z&$>,541&YPM8.1:N.-NJ %'(TB62FNSHSD?%VQ_+"N6UM*3KC\[.(
MX)[FW/#-8 9K]\Y%FV[<*O?.O>7!=W$B;6(9BU_>IYGJ&E23'4@F.K-]HWTW
M5>+"(BF6K.6JZBR8ZBMN1 PZJB(W4QP,0<0\E(+P.1=P$1C;$^2:22PF)TPD
M%,#+ #@:$R4Y6&8CNA^M(_L!B?7:H3Z\O+G5I4=-05X,P;B:-5)!9I1I>:$N
M'!VTQ#FPB^](<C"0,J*-3&@KZ\=T-1[\MVB&R@CO-N_C>ISD'MR@>T,*3BIF
M0F0D%4"VCK#<_UQTZO$FH\K(SG<F2<*@R&N3HP482RM([0GDNAR*'=9(D2(I
M?)=V5J<0[8;A1-#SG.UM[[%%ZU=FBUGA?@XMS^)=(1KABEB8I&=<2P)RID^$
M\"XQ="9H:IQGG%E>4F!1]](D5/:S1$I%=LYQH6DHV+D&J6>4)N5L/WKEJ<&6
MRKB ;(X!;#5.J>IBM>#U;]:SCTPX!RG_EJ+9B]T,9W092<:62%&!_&+>LG4W
M(B$]]QDUW-B8+<VX11-YAQ#)W7>9KB<>6G9(]"5.4)!>2\1\F28+&'5T1F+)
MSOHP=2Q^;H^LHKQ_(A+FN%6(_> ;N_%D^O%(TN T[X6JHO&[>\&EFO-5Q8XM
M*8I7E'(N]!0O($OJ_09L4@/:AFM9.9J175-+A]@\Y@G]/23 E>(1P"D&!O5F
MV]X\QQJ:-9ZP+2_T7F%ME159-997M"IMXZ,=LMWZC)=N4HAQ3VN24XBJ=1.^
M+T?A*-7')W%K*\WWH#Y(LS.=MC#K0\0,%L/\@[NEHK=H(A(@;G2 I+2L-8Q"
M]'&'3<1-['#MZ7B16)[EQFG(B/,NBJ:5I6PM$!90=SA(/<3;0(?AT)RBLR3.
M]D3=HHFLX,L15G-G=E(O%JD)_6RS5 NP+#YYT(N1,$\]>Y9/W'P. <IRBOGT
MJ@Q$>1=>BRQW/SKQ2S2&CV7< B'FF!?( \B9!F[DJ'_@A.8<3;"D4 XU(8<P
M5=^;<O&5F79Y:_T4VG>O=9FU* ?,,;= ^Y$4PE86HL1XC%6-?N_.E28?'YM,
M<"Y<3LF-!/66,:8ED,^->.Q'S:SLZ'%_UJF+P<*NO8> U%R@,N2Z]7;EFP"T
M.#?)5P2!,:VO<(S];>L8NY>.L?N#"_1% 9N^X'#[!FLPH:*7JRH ,1+4UQM&
M'WUI<UU>IB^U5^=D9+5("(66 %V0LI*%2AV6D(MQX*&^' X:2_3C3:S/%SP(
MKK*F()O>Y=F<]T5GRNZUD86[HL*]4'V$<M@'U79!FC2H=#%!V^7HUIR MIM5
MLW1I\J=,6U[TH''W]MLJ2.%MND&,+:9#HB KB7\\QR$2]B2L\[5V"<BZ.AP$
MV$_FT7Z0;0=8\*LQ8'JV(52V)W5A').8C)MD-A))1>>@J8#,B+];R]%PT# =
M;3J4W;@=J]6>)6?.CL=%[9<'%>^)5"4>#A#4RMMLF5T(9>I,S*WZ,LUQ]"VY
M#:/LR$5 _=(:DS T:X]KZ F^]/[=OJ"VY&7DUU^ZRS,Z7WO!T,&7D5+.V*9D
MJB(SJ)3Y:Q3W\P%-C6[75/5QN+^@[K2,GAO7ZPN35)^C=E,%;I/G+T[,E65T
M  )0Q2S=,EV*,W5R_;NW'YWG8K6J;!2/*\8!O=)?DRJTV75IL=C8K)U)SDZ7
M;#!I5/;CXKDV*CWV\9HI4+2&Q2Q T$)'.5RUK.%TL<86TJ2G"+VLV#QK#"I>
MI4UTJ?X&K54VI*;;WKGR;-B96<NL;(#+3\/-8F^:EYS.\X65IFA]+V#66_G8
MI6%CCA'ZX"8UK!R9(4UU49OZJB(X'$4]QS5S;W76&75^9KL".[JC9J6XW+I'
MMRO&[ :.@6^_8.,V[Q", C0ZYGYFUR5?L&OK-SB7?Y!L=U0(18HM!4&)0W>V
M'*9H-7<=URV3F74GM/6-B5=11L4KTD[UDZJM-F3!I?P%U<22WC*N/>*+5[PU
M(7LHN6^\])/AH,NYV_0?$(2)AY*S&]6ED1U6E6ZE[6]@C/J1%1I(=<)15^8*
M9^;@4DZC25DV2%GYU,LU]Q"0R:&)\P,=?EQ30-G=Y\->-<2[SX5)3KM6*4&^
M*]>L)>A'%84UV#>YI=W)IXBTVZ@7Z(8S5HL$0>7)#%Q@.G/</.6NWHN[S&O)
M1E=:-B?Z V4^/#K^B^FEB1?K$&36=[)#Z=<T1I<JYHFT!F"_S@C@!>]5-(:F
ML7J<"Y%UK_+SNT$='>NE9/'8PKS38C:7)0"X%[PW=H\D 0R\JS0C]9XWG/#J
MXHF=&0_^X/>CD]1//#&;7[*JVMAW>Z9^8S!@#'95&=5_Z"K]V#?FKG(U)E,9
M@W15*>6'*!A'*CS@0]Y-L\3P[A(0J@YC"/[=IX?KM9*DG2<J4!!M/N]K$KU%
MO$#F(N=-0OGMGLY,D5]Q3\H@>D5UA:P=ZP2(_W]3]8,D_.^/]H^.C_O&& :)
MT1!;C'VLLB#SGL=$!8+LH#96B3@TI2.IT0L:*4W5EV8\S11D5'0MX:WWHD=
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M=0L"!'["_2,2CJ9H+@INI,#,$F!LL;.IMLG#>)QM%$[6_[8IGN/ %NQC@:^
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M,7_# 5UGL01088#5*]1L@%9 &:LT]#'%K5EJ5=@D8AQDEPAJRLN2?:511BT
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MYUJ7/T:O$5)Z&TFY)I+RSL8Z_O#\W>F_D&;_\//YF]?/_C]02P,$%     @
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M8S+^Z2MKZ]8%K3<F++UBTTN\*G/%@LA^ '/4A_'A(<#.X"G@A%!13U&9K;O
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MG8!T='G@3 6BY Y1UH W%5B5.ZS*;Z.[\)?UJWR>G?GZANYAT\P:1A9>_!,
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M$'XU*'PJVF($FF\2SB[=6[S(+BG%>2__O!?0;V32>1<NW74]__<)- 4F;+R
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MD0Q3H,DRT20ICATMH*%ZDD"LN#B6ZUNU8K!=%"J.(#W73/<"E^[KE=T+?%$
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M;>Y@?8_;= XW8=@E=CQ49<0] YBW'7>0+=K4_@P.KYXO^Y<]MM1PMB$7"&V
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ML908S*^+7EDJ$T?3/0]D OQ*G3YKM1A9"FU*>(-O\56.%D0;< LYANM8GN8
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M86G_^' 8V;:W)+810DBNJFCW?JEV?%S:JQU,1-*(ND\F'IFL U63!#%0;F?
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MWZ-H;%=60$!N'?/9VQ3B[5-X)&Q.#SRL<^ #+F]OJ7KQ\+3)6RV&S_@,^Z\
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M6&C,D2Q&.*%(:1/U)CRE0)U]J0.QQGA[Q\7F11RYC/I"Q'EU'=L!Z !/<UY
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M=ZP ;@IU(L4P.F%Y)_L-*#HR(P3(LZOJW*G]B-L((YV#5M$-CZ%V(B87@6Z
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M<&+% BK"2#M/*"?URL%_E)V'2F[C]9:UF3%>@4P\*78N,B<"UP4P62)%(1'
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M$+(:N@.2LUT.["?;>;95"DHI8QDPG^NKG&51=\#GL"G./'2FXJ&+=0R%TN+
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M9/F&&9#"?#$01@@A7:J$R- FY;3P[O4%RR3;&5:\^("M.>)%5C3##41]/QR
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MD#@W KYO0;[@H]KVWQE+)Z*;:-Z3GD=AF1P '(@,.:;ZI5]7U392DM!=[ZR
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M/SW;;>JNO*L16_992M]HB1Z@%WW3$9 Q0BM,+@_4?GX_S06>K]MYL.4U-_A
M\WF?:SZO.%NO+8W:PXTP'7+CR5"_K"/FZ:?*LKM7R"_(L7HG2=F\(ANNC%'D
M;GE9UFN (94M.;'=@V(*06X+Y4*MR"ZK"8_XG-8UB>X8,AO=-]/VG$S.K0>+
M$>@3D4%F8N0(7!,=Y/('/,$?FW7]1D[D1.)X0D[,DF.ZK' :]'RF4G5/E":]
M=[TG#7GWRJVFG2#)V=3O3HH0#8I!_G27/$=XSQ;RD2&.=EV%ML"AO*_&Q6U@
M0?A7BSN6V5V7U[UQNLI])Q%V38/)JCY 77>A&JI=P1J]5 '6=N=BV?2;7H3,
MHVH!)HD G1"?.SR!URB=-5]8TPB3VT+)ZIVV%1^@[3WC:+T5%<TV,=#5U$;+
MH=6N.<?_U7;NU.G7!YGP1^H<O+2D0:IT#TH-]*3;>#TIG%1S\O+K_(P+4>.@
MR'Z)I!A&;PW$1^F:@H=)60[+!>LQ%>(1U@Q[M2ZU+1=%HH7-R.(T2HK5J]
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MWHI>8Z#!MQ*[)Z=:WQ\;ZV@R]1^INUQQVJ5M(UM8M-KFYXK*DGTJ@3DJK1G
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MNF/<&N1&[RNGEDO1>K)3EY5H;:W?&/*"/[PO,6?&$6/+$08:DO%P>O<RW<V
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MB$:^?/GZ;!:ZT95*PQAR*$@PJB)515 VS8YM41Q(O$=^XYW"\MR4/,^ZLJ&
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M+TMY?=6H&7"MC-DB&[?($<J'OQ,W7WM#IH(T>1'=,>.P==""Z"+X%(U1^B6
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MM4Q+_1N?>=P43'+R/>\.H#V_?4"[\NC\J_7BSZN??_ DO]C#LX?^ P^_>O"
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MA)ND%L&QEV^ILC=UOP CTAGYPR34=H"S$XKA29Z3/"=YOE%Y?BR9**V2PCN
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MAFL6)L;BQ%;N.F(E\ZEB(OK?-=NY8 P6<EO@(D '>4.VU$0P/9;?=4D)NLL
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M1^X5M 8^[:1EFQ4W]5,$TVFB=65^(T_&N_?XBY2*X"1)MVCH!J(3P^U $X7
M&K_Q>?8L8##DM$\=7\C%P(/L&8[?&<^K#M(6$:R$EJ=,Q^X%@DZ&#;ONG,M,
MWNAKC"5'S_OV>=YZA?M?'QV7:]]?]@&O[YIMO#\\Z[XU/]H]MP6P>?X!0H$D
M?BK ,[%GR4<A:FQZSQ'8TC;;)R+S!X*3?-<+S^]3$UH'%SVQ_YCOTQJ[Z:[M
MONF1M_H'M LW)G.XXLV( H?,BI;^U? ICOP05=TK!6K(O"'B3&M<FV,')O1R
M06U(#E*.&\-#9D\Y*FB0]>$]W3)3'M[KP^Q4_F&V:&4-RG0Z1XL0 X<D\IZX
M90W+X;Y!$AGN)!P>M'5])9_![^+H:^P@.C?2H9%)%L]#(31A\'KL&\@<2L^%
M@C+R^_8VT"7Q 848*1P]Y/((V?N>@/Y?#1YCW_KO=%SSGNZZ1ZF[[N-VUSU,
MW76IN^YN=M<A>G.S53%D6&6E^B-ERQ'0+SG)#.%EJF@\2]V%, 3E0'4VI,FY
MPX4OXM/:KCPQ-IREO=KQW3V%8#1PI9GTDA/CP+M<RXW1D\2)0)B;$F8\3&+I
MC#'#ZH8)8*W4G)Y<P<Y@#]"?;S8"3H88+\"3R00*/!J%O=V/3J;08R$G&8&5
MW+%3]5FD.UA"W#Q$W &AY]H5_$!'W:@;[2;A/3P>3_?J5'<\$<F^J?LA/D5(
M+\@$YO94I52!G725F\'HNM7,])Y1?I7<T'?7(H9B#!S!JMT#Z..6B.:#ZP?Z
MMT+6@F$%]\[XOQ\>C"/8K7E0"DC&0'TB-J4(*J T?35=YO[2K(;R#-5^?@'S
MN2F:-D;<R<-"=U!VN(LO$(2?GYX\[1M(.7S9L;7&^FP/GI'''8&O[,H$OH=Q
M4';85MBZL=&II%!Z5WWO>ZM2^9?RC.]45%W/M>RPC0X.#OJ1^VC2N.81/^ %
M>A?BDZDZC!V F6]8XMA=.PE=\Y*KL9U-*(Z !@EE,IR-&1E=-8YQHM]!Z8?!
M*QW#,PNK[0/:EH52: 1@0$I16X^+01U\T+*ZPR*<#N<1/R!WMJH[)V7>Z(QI
M4]AD _^,CL26$1[DO;0$Q6F&N;FL&U>@K6@MOL\]5[B8C58FV$+/;6.YJXAL
M3<^YC,:E*(2$SZ<&?0T7S"/:.A-\/SK[ *=$6B1FD0@E,AW:GXL5$?%AU#0_
MM(^;A-G& :I;M"_;N9(D 4?\@& Z"3Z4IO 5SG"'Y /C)NBC8]+UH33X "JN
MNLG!9R=S8BI.F<XM5L-MMOKOP'MU>B*_B<X:RLX!E5"_@>ZO;LQ'VD)=Y&/.
M*V>/%$_&.I_[,]G)EE"4(DOR\?X'S6[5V=2T2PE=*X7GW/9GE*HA7N:5MI#F
M?A"%OL0I$*@!"B?ML.$M%LO0'8P&7YVG\#,4#'P@K^=.IQ[ODDQ=>&\G8*7)
M\/=.8H'S 5=6O.RB<X@RCJ<&AW'0B1.&TQV@  _X1[ M#E_=C]6/+ 9Y"TF2
M\_TC,:5C7;"@SVBK&O;!!LZ0M'30KQP*9]&Z)EG1'H/'5!LHN1Z-$)@H)#*1
M,+[2&ZG)%%D^*O\,4*_7T/ CY&GB3 IL8*5IF8'U[=M0EK0Q"#Q:_'=1X)UD
MOQ]4=B3C(CV^/.;&N:'0!!TFQ[AIW-4[=7J?01XV=V5 _UB54LA:KNCB&)H#
M!Z/25/&A<*CM;RDJIJ.$28AZ8VWK\9=(]E+2[;@T]9L:3C>_.U$4/8^G3!L*
M\G)]\;F.1(KO3HXY(\#_F]1S,2]LR*F1_$\+"/,<=%*=G2Y#WBT,56I7065+
MS\4Q-\!;'F*5"&$O7 ZDK>"-- 6BA%GXOM.4LYH5I3X&1[)R>)V')(^!G\*B
MHU4$.CH>K7/327[!G*[+89RNF?^,!I*D9]\.<;V0G 0^3+-RJ-U[J*%<OE!
MN\A@R96+2,X4YVPK&>DPY+:RESR<RIIZO Q@=S9[9).X>85[-XJ:7VQ=UHL-
M&2.TZQ>M@'$K3I")8'.<[9G$LP$Q-LZ(FAFY?2@D!&*5V"IMPP%+-X0>8]HS
MK9=H0^;P%":G\DA4U7,> G(-%WRBAZ<Q3-N[@IN<;.NI'/><;DD,.'\R3&^'
M&,H3->;<]XN$14<>5-&^E7J< \+%0%J%GG\':ZUBX]U)=E999['L:3P&$>$.
MG)EF4(1&DAYSO:Z;KJ]$_G&'B05R%+?23&64!5YM8]%[(Y@'/+F>O:[]G)/
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MIR #,-0\V63+@K/V2DN4?:&LV\R*-;7%VD\W%<"NP31",$D4%LH<E R5">!
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MOI7/5GD^MICRUZ3$SV82O%SY T 31$4J-!)S-O&X,& 1N&I8ENQAOF4G47L
MV_N!10J?=LZAZ-SS[!].\_)E1/\I-X*L!5<U FS*'7'T.5M) [@T3DD:6$N/
MG#GVU]3"(P81N+\)G4+JF9LN="A-:Q[RG+C>HM!B<VFK6=UHVOD>@-TDGT+/
M?A]=R.3[+XOUVA6DT88D>+\1%U&DYZ>EY9XOU__ETN9T;Q1#>T E:%?/3%SJ
MM]9OZ;FL@LD8PCM!IMU1- Y>RZ0O2H%WY68B; "WLG%;J'M5N("B^22S<B>6
ME<S*(;Z5S]:L_!1-W&"-3YPJ<N8%ZHQ1'4@C>3T%U$V/*R/Z7=/5K-:ZN*?4
M><[<D#J2-^8^$725JN71//.'99/?Z%P2LMLMACS1@>)OHNV*G4'O,O]"&_#1
MU>I(<TK[3N=+< .M-FK21-(_HKW98K2#7AFV1MKO1-\'@#H:KV?U2AN/*5)H
MT+49D(D6M#'K>$AI0D\D_?ZMGX.1Y=6- (9@);3AS1EZ7=>=YRC2&]_[]>+-
M_8SS_6K&N<E7T#[/M$7XTB;S<2>6E<S'(;Z5S]9\/"9G]=6[8=K]3330YY&!
MO)K;HQ&%8(+<75NV/!'KXPT>[N-0Q1<_C0S2L;[E/E,0@DUJ60:ZR$ID\7^N
M%TJ4I-QU/<"->PX G,^/B07Z[\(*FX?7RE.S;I$.DJ5@\*ZN2E"E,6EB-&J
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M<67M3$C''0B@BR$J\K<;#A2"^][V+0].![41(\EA.;=E4C[U -AW:0#LXPZ
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MAA<8?9L[0>A.'"F#1!&R-WP:Q@ZKYS+&/Q+\IDC@./0.J"&"F^\Q!%$ %OQ
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M7%U7Y4VI=/F\I\"@=.G-AN\+?!CAZB3#H*/ON5O8^(X@<7'K=Q., QL^'*O
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MJ1>V17+$>:[TE]8E*OE+VS-PR\/"N(&*&D-T37*\+443_$926$[%CB5HAC6
MZNR\_-/RO3L*[M1 83947&EN[W6CH<Q.$ARJD)B&ETNHIKH'2M3R7:LQ)TWG
M6WAXPTFTT:I-H$<\P.3%)-EVZY)G)>\8YB/-S6(\->]AC^ DFC8G0MU;]>-9
MKK"L$V-*NMSL>8]:G.E5GY\Y!?D[Q_1^KXM9-?C*-$[BI^M,E*Q>[0SD$R(R
MQF;0H(NJF@+<2 O4<FAIC;8E9QQ7*'?[;7,LW5*0&= *UV@2-"N&Q#%3JB)J
M&ZZTLCH6(_)U*=XW0QM=>[HF9+CY,HCB>NXTF.I9EI@0^#N!=C'5&L8BQY3F
MQJ0V)?0#C(7Y*79/&%=;W$Z-/$IC9^,<C/(VC4^&LPO196_8KG58M5>:%L8=
M*))J[\V:.S]T-T^=H7+,2#;@0Y?;^'K($>):=@"BXEBGB' I42S .4UKJDP/
M.J1Z2*>78KPU&L\7K[:728%@X/:=2@VCW"\0S()&F?]9F>14?ADUZZNBA72E
M*G@3%)2V^/J@^UA]//'J!@+>F9-GH)SHA6[>=Z$S+[@KR_ZD@QA_,.$I=F-7
M,=K_6Y[G(R"ZX!_"R85\>B]YD8*YCFZ/VE284,ETE(#Q"=XM3"L5Q^.)_9Y'
M1M6Y$T*4QT)(R&Q?S$Z::EBFOXR\VQ:5/W53^V;5;-,T\_),N=X"A%%T4Q?_
MVS]>+Q=_>_[:Y^V2!NUB6]QV2U^#E;2?X45$OC@8^TI;'8<^@J6.;$'ID13A
M4ZT6<@]6S^S<',.52 "#M)#$OI^2M@O3X4J*91VF(SPL'[&_;@G?17:X"8<<
M\GU[203+_5G$X]T5RE.%0&&?S7O4<I/O5E*YY3FOFL3V(,.0#$&19>( &I.=
MG.8:0U3MO;B8B[Z(11\N#BC%#A>0GIV*=3G4?!^XH@)FSL^4>$\J3OS(2FXG
M) %Q29URQ3C'L"]EFX?CD+2(9AUYQK' H#5:2N!NC=Z>&7NU;1[@1VG,]%I0
M"@DS@-+IU%"/FBR?^LCP]0)S*@VC=XSUU^'PU8D)[Z:R8!*O9 "%FOKE+IP(
M F:U;2PL+>JSR_\/-[=*.*[^]NJU[J-,-SDM$=L5:0^.WTX;7&&4GH?^ACA7
M8OYH^Z3P3:OFJ^F<E GX3R>ZB9QD^9%7Q*X7[Q+"_K!8F[6?&&S/;LJ7]C"2
M;$)8'7S53%DR<89Q^V)IE/5-U3:UX=B!8EA;#TFS;:1N)$4JU<!F<T;3\715
MN&\>#G#AFQCFE+BVF:"#*K]'0+-@*-0&H!)$0P7YJI7XS4DQE!%<N''</1+@
MM+MW+VTYB0=]FLD?WQX-U)0I7J(<\POZA^9TU#USZ-F:?%DU?;FZKK$#) VA
M6X(8,9& .70*P&E9Q87#'2[Y/](IQ7T45A)W#AU/NQR]<;\/61P.0P^[,,/&
MH5+8!Y>P%$=^#P!9"P':?RI4AEA=J#.JZFK" &V:%7L-FMIV%\]Y2-B&<#Y$
M) "%^BIHL 7HFV@.L:HGQEZ<4F1?)NX23EN4J1EX#RK) O"J^^IQ<<50N:A_
MKDK-Z*Q+EK?#'?@LM!9H#Z"U\C/#E,&60" >.SASPDY$B3=_&[AJ_LKB*,.M
M5\6ZW(7G#3<MBS:8"M2/J_Z@Q7D/% ].7 3+"H=4!AZW*^#5I$L8GJS69FWY
M3O!YRO(MZJL:X_3B*TD6*/6B)8POA9#;%J8V36*ZG N9!ID(,6BKH9[]?#C?
M$Y/S1K86Q>QM;[7EB5T\V&3#3;T^=@YT![!"+.<#-G/H&_X"R;2.)<W9A[LO
MR^25#XL28U*6B"VVVF%@,4F%ZC/BTN#),<:M*8\>T\$YZ/0*BR58\N@U+>7@
MBE;6PGC-ZBH^E:F#A(BBR4ZF2XV^LUX6 "U3W*F 2F?5<A#5Q>)5B:N*;2Y6
M(:SJ*C&_52V0]P\YM"4V0X"#/8*829S-E*^6G"V9 VN5-RYV.*+#6;T+DQ4>
ML#[L+H&&V_AW<'%^]L,ADTIOR)U-]?B4XC)X*9Q:E )J21UDEXJN\="\.R:1
MZ"N##JM=RE-$-QF=>GC+F_*6L#VIN_ H+S-)CF7RM\,CA^FH-,^./_-'2.E)
M8P!?N:*$A[ @RR2Q$B"COX"XG3U2.*IPU.-C!7R?5!OP6'%9R/&AY56IBV4K
MT%TS^ZVKRZ5*140CZPH8AC#Q?*[DC8MWIG%!B'[$0=$X9H!=)A2&8;M\GW06
MF'(/IR8Q *!PF&.+<+R3:-,G_N14B 5@8RG/MSJTK;ZP5"$<OIM@]<.[;7;<
M"YB8RZ[9ECT6B1:F7!]]BH<2M/H._LSBJH!+E&V$AWRNO ,5]OL9%?9Q46&_
MFU%A,RKL8:+"F'!(G@]#>L%NL^2$OLR?ES'/Y('.[D=Z)(1- ?! B3(X.E)0
MQ;:.'-,.8!U$*R"#*V;CP"D8+T?7SE]S.4R@63\ I$*VQQ-L.WH<GR3;V;BB
M8G#J-#T^N),>\N.VLJ5=_\YAG>+0<D#PG-[-O 57F 1915@Z>V*?']2:?/!1
M%/+B"8N5\C!Y[#&!C"DB9"?Y_5Q5E4+1_!X&"&:'4$I6<"2YT'!KI1FM$&>%
M>[L. FUM&3<=IL;P<8U;>_M<(;N9+K5?++Y%Z=M&[2M4H#I9H==C]"C<^K!#
M(;)DKG C?V(S2=>5#NUT6R>5ZW@3 ;6P%5(R:NMF1X;&9ZEG%<^<ER!U0Q>9
MD=,*1#>XMV_Z#)N4Z+%-E0MN[]L*<40S%6+0(JJ!4"J]1 !R?B9$"=+Q$-YH
M>]CW2DO%:$E-0Y$56M95A^]I#L8%@W(;U.L\CX&2,2@>K2['SX(05\KB81_\
M9W@@7DBZN7SY,(4T&Z%1$9N5BO&3L9;E/:UU4KN6V;(6\[-QI;CBLB$FR.*,
M<":^]JH3V,!:BL6;K)B2'4=OPO9:,= R2@K<LJIOFFV>H-#^)RZ"#@OV+< @
M?*?VT(763S6D SH4"R-NACR2%A09*D4/.EAY2.9;F6.Y_:6YW)OML=^$]K1M
MA+8KILAUUN_@SNS1DUMU;Y%EFKZ>7J8[=(!T";!(O MI_&JZV'1(-@-C5%HN
ML&D$YZ3 @26X-EC,D4:VK>9JL3&MSHXGBS]<FG6(WT#2J&U!I5+5;,+OPGFV
M.K*W[ @W/TP@ZCGF!R7_SU6J.K(=B-1;[BMV8:<8.5C:J&9TM;DM/*$4;XTT
M@)8S_&T'URU_+<E<#XV4I<'<;>P!(HE3R0R52S^JJ4XV5K ]NVK5-I=,6MY4
MS*>GUG3_3N30,%@GEH2 +,)X#<ND;F+F#6M^TWV+Z9)DJU=A%2C-"PKK(-)8
MPW +CBD">L.7$T[)4+*[<FW,$=GJ&2-#AJ@6Z2TU9-RH AY6M&MB3@*?$7'3
MI1J^0)GU,)=C:R^8,?& \#M S3Q\4&IHB<-..%VEIL8$*H SRWA;MLP'TW#D
M&1;S=,*J3R^IE$;Z52RM-JUTDC*KC<-^OT6A4/)KSC=0DX_KJK^6?<RGK+K\
MN2[.SS+8T)A46L%9_K47?2+P%&(W=Z/UR".)3)--?=5(3CF?UDBY(@BP#(QI
MMQ_JM.I&$%K/>'[[%Y%#'@U1;]"^<;8]]0:3,XHH,EBS\/X&L+YGPI&RS->,
MLZE*PD* ^4T53#MS\5-H/C!TPBYTHTD1P%68$?%BD/%%=2,L+_A ":O(]/:Z
M.(:3ZO&Z2 \8X?0.NZ2[6EI*3KC1<=H& XJX.,-;WK4)9/"S2W$_7 K/'&=N
M/9<&/ *L3Q*^&5Q0\ @X(LO!#O+)BX2(SIQ__BJNDZ56E*2;B7F&KN?*;0]8
M4)DJ2EAWNRXB%NG^\'*/#_ME_$LPCC1<@LH%[K*//D#7'0QZXC?:5=,,3 '\
M*S0CK?#UK>"!S<40@R2]%TI_4YD*7A;SIA;X,9%9I/J9+O;<S>U@;Z@"-%E
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MG7+._0B$!0)%^>?T.+YY"IK@ALC>$/5MB58-CN#VB,;O3?#^Q"XJ!7%V4VZ
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MGN9_!L ZK&&%#CJ)*C$9ITXOC"6B(0>'SHF2R5 O<%!LGP)7TQBP75*WH#W
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MJ31WS"S%HB,MUC*9K#RI:1GS@_7 3 "3IEX",PTCD(V]?R$":-BP=JCUO!"
M_*B&%H(4P4@5@F@B$BHV2&)VF&9(KY,;+<+@C0%LU3P6GNS41#65V/6OU=+
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MZTLOCB-+)['128E@J'@]?N@PH7QB<F2ICI/Q+JDBIEQ<]6V$?LMY?LHR-5X
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MOCXJA@>! 17U*N;P9/VOJVY_@ MX6?:W$+YV>TDN'#[VBRX,I)=<9AC(9>D
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M-#>=DGJORNGS) L8KRNV[+;%_\_>F_<V;F7[HO\+T'?@S4M?N #:+7EV)S>
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MUACRE\;MLN+JX.'U>S?=>6DLX153+=V32S$I[P)K:Z-:BXPW0];Z6\S)YL8
M&Z%K3T ?W4G;.'7PPNS;]2>NOEPCEP9A>F5^T^)M+E6.&(S"&(V(#[&4^\1
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MF9?U*#P^V0\'@Z%(CPTA%3Z ^ :)S95 YAN8+JSP*:B'-UQ#99QCV"W5W-X
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M.$HDV]:FQN"'+Z[J^ZT +TW=MP'5TU\MD"C*8 QX-*BXV32+HA ]O ;LUY!
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M%6N7F8\NY=L80Q35JK(O0%9FC#1@E8&WA+WWXCJK]3Q+8KY7<KF)(@M10HG
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M2.V._68<>^3%E'/-2K-85FV,EY*"("QVAP_I;QQQ"4V0O:GE\4-7GQ@+LL*
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M;DL8KSP*=>;]G%OF=N)VMTT9^SW*,9"Y00EU_G-;-SV_19]I+U=;!4_)I=Y
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M/*L?X %_5EB._;?@</>'X%\JJ>#'W6![VQR$*+XP(Y)VD68>/R=J_#48[AS
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MX\-P__AP=4:^L"K$P5OVP^'Q<;@W/)"O$>*Q/9/O$#!W!5@T\!+6'2IM4IN
M2^@=P9I$*"F<?+8EKVWXEI1T=7'N/><'IRAE<U= S((:D(#P7OX>]WN[NSLG
MM]CD#L^[(>KQ%Z,#4?AP$_?_-C@(YK/@%W"?=9[2]U?4<T_ *8X8Y&3@DB )
M6"-Q*E!*AH-B[U;XQUNT.[%HKB1="\?.PQO:[A(,YFC1A#O!*=:-</C6'+>6
MSX578$:NUO@<Z<""<T\'(!%,37C/P:HEJ*<O,ZOQ[BTC9#2]M4.8B&:<@%:
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MQ_@-N#T5F?7$GQ$46*S-LD!]I31_SK[8C&B,+BS*@"WP9HH3RR%+Q1<%1B9
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M!W@U#/\%+_2S.TEK-B8_(&4B7-J6MX?.R^EXG&NCS=[I41F\@V.!>C38,BV
MR31X\\06YZO;_K7#D^S^:V__E;__$>Y_9/8?<9VD&KB9/!62KJ)QP$M\.YML
MP\/@<@PL#;%&>[6\U*!Q$+I$KR07]JQ4^666P;]RF'ZPA0_!]MB[@Q]^)8-@
M$KRE9]$OAS^\ 0UV'H_/P1 &PP'L Q@4CJ "/<A93U!EQ",[\2[X8/7]WN_-
M54Q 6>0M#U22P9?M?!"A-:OX^,>R<$%4Z<Z(W5P%>(;^2;_WLRI@4Y$F$X2
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M#1S*KWB[G@9=?S\JYCMMUU,C[%\\A/>A)VAR\HSIO<2D/+8KS[5"^L3O=X]
M;^\.FKCN56#/G0 ;U9GO!W$1J++,XU%58I,Z[E4^J9*$'S+.I".K@JFHR228
MT=-@*%'$?<X_JH5@1V%P8!*D%>).YRJ6I^5:!WHV3[*%?MHVY]TYO.<$/7NK
MWYMSLE0."!RGI(HT;'<&9TH513:.%1XHZG8_S_7V.(E3M!U]F'(8V-_""50)
MHTXR\NIG\'7\W1*T65Y<[/1[;^G=D;:BP$B-P?[)384!@<Y*VC+B*<?/CS,X
MK99)N3;V,OL68\1CNH %K2)L&=SO+7_G\SE*UK!U=OAI-?ZSBHO8?!Q[3](3
M,*+"D.UQE><X6?S&I"JK')8V5W'2"= F3]#/ZF'?:4[K.1$RQ_CX(!P,;WR&
M2:'3"<+'8$/4>1YCE4"R@).=*-'KB9Z*-,WA5W"VY&_]WD0CWJLALP3_S[-2
MC\TQQ8(#[,N=)/"["IX%?YZ#1[CHSN0&3]!E??H]6S7BG<4]\ GWP^'^X<V/
MHY=(\I](%X15B;9T)<NG*HW_H[@X;>OM[Y_>L*&3N\=@:WC0T/CZUL/*"G?7
M/1VU\P)NA@*6$B:/!SD#Q8W:?*Y,(9Q1QS.%QSI5Z5B;.X#;OL=3?'V_-\JS
M\3GHX$[[;O($*5O0[UU?,P4&14+MG[\?'H?'P^/;*N*E0Y\H<"OY)!?5?)Z(
MW0 7>FHZ5<,_8"1T]T=X1$NV=71>9&D*?[@\CQ,=7&;Y5_R&:.@XC[;QLPLV
M, (P*9[VC#[X>83I_(_M[>!]K)/H;\%G<(5^@ ?\66F0W;\%AT<_!/]2204_
M[@;;VR:D$,47-P_F-F9Z2'65MZKXNED=5UOYIHO)-B.ML!-M;KX71%A&P#?*
MQOR%,TOV0_!E,8?WG^9J%(]_"'Y3,\W+^EN&"WAXZ'_KK^9K^"<76S!QA1__
M"@O=MN9PE7S='FDXV_#P.>V9?\ V9HEKR]F,L+2N@K]XN*I\*!],)M=<2VRF
M^&+JA6%.]>Y=_=[C5T5W=_8M)GA= ;2J;>?ZRYX#6_7<[SU)V7-7S?QHR<A7
M5<U<>.7,735S5\W<53/?<>>[:N8[K5E7S7S+->NJF:\J15Q1S?S9QD\H5;0I
MQ9\/6<H\/#P)A\?W*!%Y046V#[G.>R>'X=[18Q39/O]U?N!BYJWAX<X]\,E7
M#GU#8)/M%8/WTWH;540Q# \')^'!<*U=+EY1$<HP/-H]"'<'7>W@76'<ZZWA
M>5'5S-Q0\Z/*O^I2NI5_H 1KAM4[B>)T[.M15B>'P_!@OQ.UNZW>\<E!>'2?
M"I=7O7IWCU/_+1A\]],16EKSGS:H7/$Q2Q'KV:7[.IU=@918)D<GX<E]B%:Z
MDK;'K4 ,]P>[L&MK;,[1[=C#%B'N'FQX]Y[G4Y3.A8J-FT!@!B_HG-ZLVFU]
M1_0@/-@=A,.#QVAK^N*4RF-OUF&X#YLU.'F,PN87MUE/U,!M_TDZ!C]\36*'
MM[I-A8I)F/5[XV9QU>[N43@\.;@Y&OK=C3X(_[55@Y<ZUP8U'?5[<1I,=:IS
MJ5M9 ?8*L5) Y5&BB\+@]TW!X?_\OXYWAT<_%%(2@P4QQ3Q+BW@4)W$9Z^(F
MH^SW<#XA?J30];&J),G&RJN<5'.LBLFQ-L$'<H]H"2MX=?OPEH;U0A"7+U]@
MKBKI\BL3D2ST^.AN-5U&(KP:+C4>@ZE;FO*!8J[',<S\/R@V7K6,'9!7"(;O
M_JCS*;S.PSURU67K"[R'8$5.GBQP1%BA2 7 7/]8Y06A)4=5$:>P(CO]'M89
MFR7 .N/6LK0T2[=SC4_#5[6^WZ(ZX7-X"T8W7,4A?$"5_1Y):NL"=/4\&SQ!
MRBKT>S-.*^"9B4U2(;=)A:7:RL.#\.CDCK65KLH9%'V:8@WD;ZJ(U)_]7@+W
MDBE/"^'PP@U%BMP_=U^UGIN7%N<JU^=9 C8=U__&Z23+9_C!<W!BIU0T7=#7
M<>!4PP8#24OE:M=89,?9;%9AU1O^H=_3$WA.Z8K;7 $_#]A_\4QK''17UO8$
M$WPV(Y&RN%5(>N\..P0CZ/C@GK+S<P:FFF>[F?L"/E!4.=9@AGB#Y7.LF-.F
M+LZ<YD*79:+)I((C[9]EM)NF) ,K5#T?A#^TN[NP.#2>@.3 T\PT<1P\8EB2
MEI+H4N>P3O0[%>?C7$W*@"0T#%H'S1>:&W:!E7SC\^ 2K]S)!/X0C!96/\%R
MQW#)@0HSEJ&ISH9'+:\4#W2'S]+3GZ3.6'U&D_EQ]-,'1(["A6BKG.@8G8[A
MK)F:_G=Z5 ;OXH)LK1=4Z?7D6_DHA5&_@C[ 77P+VBPNG9N C"9_5J!)2%&"
M&HR+HH)/IF)WD.XD3 ;626D%^BC"ZIP<JW;R[%)'3!(T 147B'UU@76U(7H*
MD68EB XM:*1IOT?!J.VS,:AB'#/J-C4#*P3=D0 KIDAUPG"DX#F))[;2OCX'
M?F]C7BHILF"LP$/ N:5BR=###_Y"E!1XR@-4O9TEL\$3;#O3>):\.Q>TUBFX
MD4DP/!07CZ[K-!6:$GM/&P>7"+.$C@H^2L16]B&[Q_R0G2=?VA=U3M9\C9&?
MM_TSVJ!(^33#JTQQ35%W7VV*;'.4E<FRKG(:0KZ8MCE@.O9V&^ZQ4B7DAYP<
MA,.3X4JZ#;[:LCE[RG3WD3/ !':@$FR@#HEA+F)P'RB(#,Y//$8MPP\ IUK\
M:#AT,Q@ PQ@OX2)2:,C+@_$*-1&R6\2\+T'713$V:B_9(X$W+59/WDRR"PP_
MP\D8)=7O?:)#%WS,(G(LZ1]=X_67K*XN=;!"C$4#!3/_,%@YOIVFL)'O[X<'
MX6#O,!P<D.ES_8N:T9#]<'A\'.X-#XC94,RDCXN/[X+W29;'D;**$X/GDN4"
M33?#VW>TX(_:1!:E&F8S9?S)YQ%:?U%'?<V*2L)]'U*X7C@@8+%)G7K:%/5T
M'2T*9P9BM\<OCQCEB0Y1QY9R"^!41Z+241S<8FD[$I6VVJ*.1*63EHY$I2-1
M>3(2%9-&Y)Y+,<;+X =V(#:%@>+AF#ZVCO?"DY-[2.)-Z"=>]P*')X-[%/^]
MC/5]8 J5X_V]^\#_;SSTYU[?^]U/?U=QBAE"0D: L3^-+S2B;EY%<?AV5U1_
MQ^J9XP%<PP_! /+B5VXPN(_F>=$UIK \J([>_/77#$M;TN#]QW]AX.V7/ZNX
M7 B'"J$*7\=9V0U/#M;:I?UUR-C^;GATTA%CW5E!'=ZG-GZ#*>4:RN>UJ9N#
M\.3P'KTZ7[?4[)V$!R>=/70'=3,\V%DKM]4+LH=6!N#^F5)-A(Z"MZJH5 +&
MD:>\.FZ >W(#[(?[^X_8H[[;J;ONU##</3P(]P8=\]*F[!CYOVOL"/X$U$N/
M2:O$-'M;G'QX\]>.5NG>Y^_X(-S??0QNO9>DW!][EX;AX.@DW-N[1_"CT^N/
MK=>/GH12[^$)E9X&>7=-Y\_CKO.G SJLH_/G4=?YTRWQJ^K\^>+1TP*!9WAT
M&*2:R"0<)84M-&/;J(:97ET(XAA9W)/DT>9-]L'V/N_W;O#P85=+\: GZV:5
M.+NNTIPZAQL@E-U<Q.0S))Y(1*AXGJKF\0@@*C]V ?2 &]Q+%?M4Q6D13/)L
MQB0G<$CXV'B?S[7'G\7E]$CRA9_+8RS#KQ?"/P4KR(LZ*FLMNWEN)W[-E2A3
MP<Q$B)F9.,P,*SP\F]\+0$).+9;-XFG?BM_ GP8GX2'\R9[_5$^SDGEWZGP_
MQ+LU0ZJ2(HA KJHTLMP25.36[R'CXJ)!(!$VJ'I(^.;$=*F2(,F4\&EMQ3B<
MHT%X.!BXT?CSD3%\5HL<S([@<YZ50CP /TYS->.G4;V>AB\1YP#HCD''2['!
M$WR?Y==6@E*=9H W HQ(>$HJFY48FZQ$DO$I^MY&:OWZS,L8M/PD5U5$QQM^
MHZ@*'(YBC!7A.H'3EF=I/$;:NS@Q)(E8"1]3_3L-(!CI*;P>CAX^.3BMIK!.
M4L\E?!@14OZ '<R4&I_&989SV152#69A0:H%E2XL1RG=+R@QN;Z(8?&R"5:P
M%R-D?N1+:J8B[;.#@8S%662DQ@[/ULOR:BVH9!9-_S(6B2R>N-*]$YE[3O 4
M!2;.HVW6Q^@ ID4\AK>.S],LR:8+.MCUXX76CN%P&V?I)!8^1"I#EDKDX"(&
MA3O#,W5W:7D/RCN[-*?4G$N2X'-U 8]27W4:S."N .G%6PR$_IP(U]",<\\-
MZ+$%LI<B'@N%B[[/A=@H6V3UB=C P,8ZPB?"XN C\>E\IU7P7Q"%,3X%9C97
M"[KR0'V4>447#!:,ZV(>EUIHB)%F^'R1(-/DV XUY,LP+KX2Q5,U/@_&"Y#L
M;566:OP5KCDR-<N@ BT$2@W'Y^^3I<.H$\[A'U/\+5,XP3H7*-F5<&#L!&_Q
M)78=S(**U:KS"U7 91A:%C\<(*E!&MP8S%HP(O"SN'V)_D8?A!-0QBEOK+[(
MD@MXSVE2GA,Y)NP4?GZFOA)!K4?D9_@OX5LXUE()0VUMEW!/IKFL-F\2LF\J
MIM L%D6I9[P&^!;PY[ T'EYTH7C:_M$ <4#_WE]XY=Z&(1#8!7#R0%7F%95Q
MT2[A;$'81F#N9%1@SXQ^=-IA1$A1(H_P&3WMBR]CL#_@R_!'M$#@T)$?"5^&
MK=:S.1M/M4'HHCX,>$A6):R*X4EP6L:PV9,JH8^IF0)%,GU^6MCHSN<RGB<B
MG4!&"+[ OZ?TO#-8V?8D,MHXA4,5@^Y!H8_+"K?]^>WH"[I7U\[@B+&%?N^+
M^O;D_#$O?N\>W":">Y\H-UM#A]:'.%=1\,^=LYU@HB-J?4!!1+A%%1%,DP>!
M9(AD55VJ/&)V9^P[\"V&*TPG"_2ICW:& 8PS06,*GP^_&NZ<F%^%Z*(B:3Q>
M'<D";M;Z]P^.=H[LU\5^OVY0W*JA%%)X]4TX)L 9B5.B?>1$0/ /E5;8BH&F
M/SSN]^!^15/.?="R^!DMB+]LKMN>9<K>'>P=L<OB*":O&VQSR?J][_=/=O;M
MG*,,]A9O1AY<&)QGEQJ9+)%GLPB2>!:+TW8\^ N%C_&:+ZI109F2DH9N;5L<
M ,<)8:6+8.4IH$X3C6-0E.C$W>40[ ]W!O4SL'>\LVN/0."?@# HD"L$S6KD
M)U['INSO/K^KYN4:#__$6%B_=R;QJ+WC72.W;[,(SF]5V#CTJK-DCY)WP.,)
M'D;,:.0Q)0#!QZIF%=+K@\W)X6Z4]^P2'83S>$YA@2D8G"6%YF!V!P,D:84O
MSK(+]KERK8DJ1@($.\$?_BLH=N*>)^] 3EDOYMW@^"2#FK0+3E!1&Y4%N5E@
M\V"0_683)[]#Y^0TC)F M/$!>(,L#6L<^@>[K'&-&G?$47K, M@>!;5LP)A)
M!87!JRI!SEFFXAFXO3'+\!S6)S?47<TU"8,9MOF8)[%['ZB !!PAS*@:[4>\
MN,&'LM^#$>(R$\<A^0K>*HY558C'>NTRP7A&WCK\;U:-['QZ"X(J#)R;&/S\
M<8EQ)GRXM4G!PT'-QI$C<#3'VIBU.7,8$U<K+AD_3:'/3CX2ILSP49&>:")R
MQ\L&7"B-3E*[=K57[$ZP=:9U\%L&.O48)L+6]EOPAA $0+?7>VLUG]D!ONDT
MV4/9N+_&?U9Q1.)*7)MJ'B/2[W==P!Z/G]SL[4S<M9BX94M >:R*<U:Y^ ,R
MEH.TDSH@Y2&AZN^/]D_"P<F XQ^D2$F]270#>ZQ0:!#<X,'Q87@RX,833!6,
MD>5S5;B>#ZC;.+[,87ADDCT*]_8.V4#:/0F/C^%U^P>W9$JSUA1JK473RNOW
M6E>"-.1EEE,0:RP''X>U&Q[N8=$>CTKQ)<&-+@I9/EHO#F!]/]P/D1-W<' H
M'+C<%@H#GGQ78\LD/<'X(NW/]R=[X=$!\BKLWY2'$@9.NS0!)5P$=%7@K6]O
M":_C#>_&<#?</1J$@\/CD%@BI3^.S6'30)3=#PY?R/,P-M78'=<K@S(;IJE4
MBKTV(NV!+^9J@<?#9%D.X4@<P-K JUPKJA2Y+XD2W$ U>%D.]@?AP2&?-.Q+
M13/F"[J5C)?>8=F(S^@.P_^X*%_@'\(9>@$EVE:B\7R:?FJ/!=?.'.XYM%S$
MC*[A >!#-2IBG$@U@ON>,YHYR ]<:_-$C?F1,":MF3X?3\WNX(??-2+$8'?!
MYL_F]"'ZR_ ')A+LD"8;HFD_4M09-[#?P[.EV5#24;NF1>67EBS"M4-'MI23
M.F;3_W>5>G3Z,_LJ^SQJ$P2>X1@/6\J>*YR?&(Y5X2S+5:-P8<G<7/)BM^&W
MT BS*<.BJ#CO,I&TQ]BWU%IMR9",]**:H+Z3_A>3"H/^I1N"4URC*II*^S#,
M..2@R+!-5@9B-95%66E3$BDFN. @LIB"ZO=PO23?D,+V!^6E3B[T-D@LK*-D
M0T.T9/5%+'H3V8*K$1K_):Y(E%4C1/!0!DML^N8ZGL?8Y P1C-X\V#4JA-X<
M?E=,%N1-P.\PKS:C%7.J)]4Z$CI0&F1 @_102#==^\ M_?/S]U^01EFKV1W_
M],F<G'[OU-[=/_XU[FSM#3F0GS!)B.83*?5*]$6K1>9PI]8HNWD3M]]JKQ!3
M3D=U<T7T]4VM.4PHQ_C-==IUU"^X:=@%][;K.GEXP?)P$AX,#\/]HYMVM1[>
M31YTNT1XWB;[>;Z+<J4 [(>[X%B=' Y;1<F<<1C'59T!1"BEG< C'?2G+A0Z
MZ0J%UELH=-P5"KW20B&P(LT47XS9"'-BGJ/.,GXAEH!@&B/NLRM;VVH-'(8G
MP[UP>+AWHXHO=/\)PYHS#F#UR_J]YMNX) )N_X-!>+A["^/CIJ5*ESJ85_GX
M7!4.!Q@S\-2\?C\\AHO_>.^(; RXVOP/^L,<AD<PS,%@<..>1:M>;Y_:[WT/
M*[T_V NO>O%QN'\,^W%T*-524E(!UO_>\0#6SL.\S;J>0\]U,J!1):/::=1-
MU:C@\_1[2PIN8K;5UZ8WC"MP:N\@/$#5LGLL7=&=-^4Y4(2;UQ&V0F]62/K9
M$,\S6],@AY)_W L/]O8,+FIIB."7@>=E4!V-]K5.F^V%@\/=<']_W_/3S,S8
M$]LE)>MT6K,+,@9V0?<=[QZ&PSTIEU.P96,J,?I,90]%EB\8W$"U.(A_*?A-
M[;W>7#-ZBIK@1"1X7\8S&X;W@#8IGH3ZN,,A^+#'^][(]3>=CV,&'-EVF7BG
MUO;K287_:O@$)F+C\2V& *^ZL9:YU$@1\C?PTO.92K[[B>NS>$ H&OW>I\E$
MXP%=VPJM&MYS@Y:TC^=3"O<&%[$-#SP(/+FPE(BFVA_/B##&1Z"FN>;RT2T\
MF)(%;:XX_W3V^51RH6\X\25(,#3?& Q&T+3(!],3M![-O"RGMV+*A#).(E@R
M@L@U81^&^VA1'>YS*_:BJ<9HH/W>BI$&9_0E.T["U>5ZBAH)ER**P4Q"@!P?
M(!INE7H?L.(( [*K5,VI>@J>-8713CD!U^]=.U1Z.RA$DU5;RD!?N>K!'S(6
M,QO!;:S\'!=7J=3I%W@A)ZB^/]@!,WH.2HJ&&@8C/58SJXD8,!)_LTFN6@&8
MR3B:C!<#D?AE 0+ZF!Y"WJG_Q/P@)A41 <GH$)<T2V-*X]E/1P2^^T,[\]6_
MTI9K_LO6%>!=M_53*U<H#-0$<9=PFV'9&): :/F>4%/83* ](C8<* %&R3I:
M_$S8@BP^V#DP,&(#=?FHX# %NR<, PXQ!FGOCVMV=*2UV].(+SIW]JY]AA2E
M>1#*COO@^4SFQ]%/;U$KCS%+?\H5F'CL/F<)YN>?&M[WXM/&CT( 05DWSFR@
MO+9A P1:@F66"#^@"U:YXR#9$\QO<!T)9C3@[WIN"DJP B6E.YA@N:1T3L'O
MAY,5;,D5\\^S?N_OIZ>?[?TH6)?" [%PS>97;76A%'IBCV.IBU0C4";!I"JQ
M0%=?T/"YMI*J+6L\%##S+/?&V(YOIC>,I>09YYMFR-$2O*^]0_1[G$M9)T(D
M4RG/]*#EO':C(DNJ4ALKI5S0]<DH>,:>F:\H+FO%2\Q.V2Y,TU[_=Q5-<<R@
MUQD)8X E\&KPGN"&6'#Q:13C#6)NL*SP%I0KFJC\F#^%&0'<@P7"A +\3![S
M)5I;,A]*0NCZ608VGU_=ZYT8-Y<XQ7E3O31[9/736$.=>Z\@!JBDBFHG 3RH
M,5./T"KGN#,5P]*G:<RX/@2T8VTZC@<LP 7X@TS7 ]?/-*8<'<T?;:3MD>(T
MH4LS=RB9#9X@Q9;=:9IGA1P*(R9XX%R6UZ*;&3>+R#0NA_ J-CPE*'>B)2)0
M43:G$HL/<))S(KO) H*K475$OT<,.+9RY(K##E8<V&,S]*'$L!TG&/E8>L"J
M(>G9/,D6.)93Z39MBN?[O;%<\*U?C!'9J@MTUEBH#$ .-2#.AXMAKH&6H04*
MXR7!3PI]207T]"1X_FF:5JAP?R==3(URX)J!'=O^KT[8-GB")&PM\%-DKZF*
MPI0U^DK8G1TX4LPH(]F#-O&$[[!^;A8GU21'(G_.5^$+AN]\//)Y1$!)NC&H
M9A-M$+[!;G@7R1@%J@_32S+F>;#W=%48PZ7?6VVY-*T4:YT8<P5].:F42A$.
MRJ5R,>["&"[;HM8MWC%VN"$1;0=1<TP)?-S^-"H.6#%76AC$N##)1D[0T[C,
M<@FOT';^AQ5DQ7'#&JW>6%XWCO-Q-4/=!<9%R$Z[-2V\;S!XU:W9F%@OLO&8
M>#_8 B$SC/QT/ ],\V*_@-4H#G+K"A7#X&N:72)21Z=2/,B&G P&OF<(0]C[
MQK%CH,A0V@ADFM8 <3]92@ZXHS6K3]&C_2MLI2ZN#X<08.0Q+Y?0HAA3#BP=
MMFCID5C)QUPF2:6O.!!REG+2U#B\")D'00TK!G$3GHFF)1AN+N,4''IC"1OG
M%(S1E*H\TVE&(&P<^D[P"6LWZU8GV(QV4^'U=:.SOJ^\;,;@+&MRD>5.'W0P
MY4V>X!_G<:*9N6B%8V M#SR[$75/'[&NGF7TFQ)9F^YFA8C'$#DCA%"GGA42
MM!@AH2_LMCS"!2%7#9[=JB4G2-PF*]X<,?,$H7#N:,O]T\'X7U!LC?!*-9(8
MS*IW%;.;<AYKE:K"55!0*@8OY=J=O. HO.([WY-<3WVP&8D*B(+_62ZT(U@B
MKPMCDF87,1G/S;\30P ;Q-4\2\W?X%,$ZN?<@HIP:2CZP3 IU%%@$L%L*09#
M5EW-=J"4>22INN7(%'F=ZAN9/D*2TN^],[7]_OAP:NQ*<HI:?;.!,GB&'VH:
MZ?(2+?5Z>,FM#-FU\'6VF2Q11KW.BNTBMN5\PTCTMT[9C\?GY!*(DO$TBH?A
M]VRKL2GMABGL<L+(D%&X*2]TIX W>((UB3;F<&&8V9"SS8@SGMDV"@OT(PJ,
MM,8%DO:I5A(,,#Y2(2,BLR:)OVIB!H=IH-"A!/9[1.I#AQ[E+,?OBP NOY>B
MNA)M-M3D.X$K-"7GL_#-CL*8(L1Q":)9.H$6^4S4):(.41W,$/: #P??+$DT
MN&>B9E#;50)Q81X2Z[YAEAKI9M&'\ARR"3_;*$:*C[7$";)YG%)P3D68M2TI
M4R'*KUC2?EXR$L$S\-")\4;JZHDB=_#^?U=Y7$0QE\JBIV?*//Q N*.UM7N'
M[D\NLJX2F@YJM?R"8^3$":F1BU'EBU>G"JXNWS@:=.4;ZRW?..G*-UYI^<;+
MOXG5-\PWIGH2"Q>QI/'^0Q'?9,%F&FARD\;Q#-?V2S5CIMP",Z[F^M+?E#5E
MY69 0N>,L6@":N+XJS^ V-((1\(D )=E/J7^(OQAN!=D]#PL^$:#6 WM;B+T
M, /-_,N;A^=:*(!9?>IY$SAYR9LC1,P.C.QB635##A(7CID+OX>VC?^Y8)RH
M>.8,_*8I33:R+JM<EKC?BS):T9G6I43RO!RKSW5,I@=EJ)![#,F[;\?+DV:-
M.?N3!=/$GP4"827B'MG%Y CZJ[N(7]($OW"D#K<7">FLT6?EJW:X212E:O=6
MATUH[#RLB8?:,'$_9%Y%^:R9R@@*;+/)8R8AO4(966%GS*(GIU<PZ"$<Y(K7
M=F=]@R?H^Y]6_U)8F=4?GX]:PRCNAP,^"H<W&A@8OM"BF(\C12GP"8SOD21>
M(;T7LE1:]0B(BX,G*@(1B(DT"#&SDEX4O!+SA2$)OJ0H$6U=B2AZHQ+:?AKP
M[<02[KTO'A673^V+L1J<6)4:VD_?'*"R/J8?]2I&/&8?P1/7O.38L@R!L%:I
MNE2<-(578WRMJ&RJ2OJHD&+@I*3PF\(P_'B_M(- ;Q*7AES&W*4Z(R83RDP+
M,9R/F<'SD^3G5ERP9G/3PX/O#H8G'ATR'$A!*A?5Z-^4H,^:MJ.A;&7X&*91
M_1C#,]3++X:%E!#V#-;#&B^'UNN2*9LC@7]HJM4AYPFOB,)MJE6B*&;&_B?:
MS18"(#\'0I%^6S51;^I(A1LM[R!X@U]9,L5*!<)'6(/P3@_F!^'0"G,;T1>;
M_-+T?82?2G8:81\,[\7K,X\IW\ $2$K8XW,.E6V?C<\S8IEAYABLL,%7S;)(
MVZ2Y>9AP5\\=UM%Z5K5U18E";!'<_X0?QB"X!,3!URJPJ1&&/[&61TCR.%WB
M59VP@VRJ]^53;A6F2):#+B/XW<C,C>7XR9BH3ST:[MKZR+!#2_A=0X#G4D&)
MY5!L+5GSQN:+:$U"CW+5[D?M1739)X2Y\:NG0FH7M#W)M:ZW[@R#BPSYU=%A
M#5UZR#8<76"XR>*TZ&^R64D\P69,+G9.8$YO6FQE4(B]WZO!)VQ2SW[/^@UT
M;MUR(H3 #;#V>+<?$C>OH["6CBGW.>+B77#K)SHN"?36"-48GD6";#%*J$:!
M**++&/8BD,B"% %3?9R%5G&^#R]>D3PN)^-E!)\(B[VDF1@'9,;22<NR28)(
MJQK2_M*)L8#I33X/'T88-K,J13R;)]P9S)[4ME]CK;4L=]'R3(D6*4PE3>TQ
M,[)!'YDG%7_(Y[3$X]$X_=(VH_T@>NE@T6<$;OR24V!F(0?1)3U;*H=)7[&Y
M;K[EE6GBRL:@ZA59L]2KB@=4/U2X,W%J56>[I/GJ4G2:RQ;CF1WAM+S,S$@
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M_?L,,DP0)1N!U7UJG9V"+LJ)_-ACD%H4.I#'GW!2/6PFQW*H.*0"5]."W6G
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MQ(#:/5^ ' !E*+A(YA$. F"ZO9JD))>Y'^[>$8I"-5/43IJE[P>2!BRI:)
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M]50=VEL-PVK>2FH-&[PFZX]?=B:*"3(/U\:%Y70,SS*;LS0NIX,2:+*R9?]
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M)"+J7:9CA5Q,W'_!O=&T(5P];5N-BVFJ35KL5QJ;; ?=NF&8)HGN_5H5>I+
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MP\?<IZMIY/6#THA=IE(>!!;(J&3A&6(8&:[#5E>PZYFGT6H!F],N"#H,C27
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M-K>=H^W8$BV3A6 EFW+L2.5F#9_HRJ7O89KD95Q@D*Y(><,#&91YY8I?XG\
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M*&:J 'AK=-9X,4RGL//Y8]ZZ_E EV(<0'NL=J<1CP@_8V[B&":_E4.+8GN
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M(Y-[8<W;6TDT<PETCU,6QI7E3+J,8$E9X%4 7RE/<:"$>992:"$F[4JG HH
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MCS?4).\Z.Y/=>]+)"OLEXW]P#/.B((NJNBEXS@IE1K@M)KN9WX%##DA\7/Q
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M4C&BG(.\$(BZIWG"V(N3>N^)$CBV40+U1@D<V2B!^J,$"B=! OJEN.;ND7P
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M\QD#8B)2F*B<I:*UJI"6*6\\L8&A"D(AW961BJU&=/.YX%=!(>,Y<NTX+,]
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M+(:3<Z+-V9Y87*'<C=ZC1?:&+")!-@J1F>YNSG;L],N+664@)1-YS:(XZ "
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M,ON27NIR&PA,J>-6FE7#RRX>:OR!GZAB05-OX;_Y9GUX]:J&\X$[:'J8)C3
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MTXS?48<HYR-&67H\QLS5;&_=LYS]8[?5NGLUTHY5_>XB%WAZ[6=6:,VZAM7
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M-%6J@R9K:+*8.53'K\W[CYX]T.>=!E1C5O/:31>;26WZO58YOAFT_:!=F6&
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M!7Y%86A[BUJN%RH(>->Q8-[F&AWZ"CQ/BH+4:R_IQWX/^;D 5D(/,.-4[0I
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M5FYIOZL,(1ER8AB;&+Z!5: EBR-B0$G(6 9EE"^KQ_C8)^S$B_X&\IH[*%
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M /&4='[XZNVI&3OSS@O(PWDY%")-D(R71[%K1Z3+ILO.,NER;:'XJ$2BAJ#
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MES*SZM0U6\U&ZT_+T[B+N5DO0?]N[>^WF_NM3O/@H+7?>7W3.6@==H[_*7Z
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M'B#Z\.*?>)HS3D#.>!/^B-(37-DNM] DETZSF2CZ3.-VTI0#DL,!46J%8^&
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MR1"NH&A .2M]9>I0^A)ZUG5$PK3W2_\XWT)_F0D41YC\^P^DM!_1#2 ^GW<
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MVCP:P%U-\$>@ G(1=\YXL<@$@J(XU$T?)&X1& NF2<ZVSZ+(BCE417@@T'T
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M=$(X!F#*(=<3D0Z[L)AV9,7PUPPA(8-I2"5" B0"#3)3W$2I20JIQ&@2"K4
M0>;<CHIU;D97!,%FJ2"^6G^>U#\=_UCS&DV&E9@S.@L]-];Q9WLFV=;'<- H
M=#J;97,\#4,?CY1(AD*B64\*M3U!C68\*-3V!#6:\:!0VQ/4:,:#0FU/4$M.
MQL,_#!W@*C-<Q$Q^#5TT^(*Q(D$'>?K:*#5NRC\NWJ;1QI]C5<",:007:0+D
MDP^&0#-%[.\BM]RT:4-9/ $L3N/*%#<1JH8T)R1&-5"H!8@K![AWG@0.WZO*
MR&+)?-JX?M#2AC+(N,'D0!HJUD'C0$7+[ZA\V(+E+)L7:*3X>/@^>6SA;Z8?
M?%)(@6,YCEXB3SECO\87S:%0J.T):C2'0J&V)ZC1' J%6L),RX]E-_H'V3-^
M)6F_1,,0M?=EW?RMF#9__JY_O^\GMZS[*S,491D"Z)PL #[E<V885K7WJTVZ
M2*JZPU]Z /'4T0T9&.X;2RH\+O)>QM151?[*Q 7AT:_Y\(%]7P#$43-0I"8:
MJ4'M/C[,^R8HN(\$W+/41"&X?1%U=;M:YD87OR7MYS3G6][NJ.[U9>RQ9=H@
MA>ZKB'_01(60+[!<9NE%W52L?'BQ<KSL=_!<",_RD/WR:8ZR'V6_A+)?4),U
MS*Y*"FX*[EB!.\SL(@4W!7>LP!UF/I."FX+[*+P":O*_3W!%F)S:M>?CT *%
M)K/WP?41+"D.1*+@H>"AX*'@H>")"UTH>"AX*'@H> Y]4A0\%#P4/!0\%#S[
MJ]Y.Y7RKI1::P?NZ*@/#) 53;:7:GG[O9#I]@;M^LWKQJ./NP"5N%5@4=HR%
MET15U"3 B!93 1*NH"!+3/$L@P@:>BATUQ5O&[W'[V5D?=110:S"]TO&&."B
ML,;(,BU10P1$P!TJ8=VTUC1 %Q@&D+T5@CZ/*:NB:3:Z^%/D$4XU(]H3,"ME
M7</\ *GJ^\QIJF(\\<WKN]IS=U9UB'<$&0:#+UAY81CG%W&'SN*1S:<OBI".
M/C6$OE2SZYR"T7BGHL.<P!8*$?3R^+)]'#4IE4_NTO^S268Q ?SX3OG'BR'?
M)R33:38CI"DS4F9<;RQDUQD+D?416#FA]=3D,S^O9:K1(^\*2.78;"[%\OP>
MRA2H7(B_7/C82CK"!@!.8+DL]-7Y/73@4$:CC':P*E(AS.F7%-D4V?%!=I2=
M+139%-FA(_M3)"&,.V")B@;DJFAH$!GFII:1"?<&&6W11,KEV4R6A_]-I(7T
M-V6T#\QH8?+9MBZ&D&*SZ1S+YXXEQ!=J4K;S7>VFQOT?CT)GBZ2LK)A#582[
M@%0%1YFCI>*+9F)WR\1^?U0?K\7[&B^Y<=L2#=C2%"QU8&(CF#ZT7453L)09
MX\2, :XS/U *5N7N^_7OF>^U)ZK):>J5R@.JG&GJE3(:9;2X)ZA2-$%%D7V<
MR(YR[AI%-D4V3;W2U"MEM"0R&DV]1I9ZA?\CPI.%/\&?AYLO?2 :/44[M_3A
M%X9#B[9_X6R%6]R(!.#)&%MOA4#PW%2F@"SPW=Z&2=[+?1^<GH@2NMI9U":H
M(4+3+?@$T0 ,?(4"W]<S1!4BQK#0C0M6'Y@ H1T/:!0M(#-=11,U28$?,IWP
MH'D<Q/$]:+B;_W=^SEPH0)6_,$VQ!Z54"[R,@":A+_(<<W[NB&99&:^4=7.S
M+A?VE\7: C,+W)JJVCR+)07Z-UR4Y/Q[_AV2KJKBT(2K<7[ZRKPJLM5'^^+^
M\MFH9_[B8AD"I+^O8)B)G?=G,/>ZLV\7YUZ*.;3ZRMQ/AG %14/L*-)7I@YE
M+*%G74<DS'J_](_S+?27F3AQA,F__T!*^Q'= .+S>0= "0R?/<1GY<558F@\
M1T\'EBNIX"4>(BI!962L&";;_=MQM]CY=AR2!&X)C8\]/6E>%>]NB^7JPWVM
M7+QIL4RM7O[,%.L5IO50:M4JM>)=K=HZJHV3AZ$<U'6;Y\Z<C94].N3TQ,TL
MF4C+E$6SSURH^JMY/)3PMQJ"R1XG@9?BA#;/"^VI_O@];]7Y[_>J#"73: "W
M,\$?@?+5H21SSGAIS"PC\1:E:\&$X-GVLWT#U<;%=J+OUG5W4<X)AT>$?OV_
M,V&&IW3A J5Y!3?A*^"$[S3[.%%+E[E"]BF[\0U:@3<?(KM!;PFN/2EG$N>U
MK<-+INU3(#!MW8K7+V;_5K_EDX.7U8."8G0FCN<<WI!T*CFWXH2D",,+W1Z)
M!;UUYC<0#9.I:C(T 9R!66A65E+.(8I+ BC^M]4$B< _-08H!)*GWQ>:DCCO
MN)PZL)##UC3TL0(%>6GR8 *YIC6&P! MN+JB9"ECQ5* 6>R8%LH3M)52>]I0
M:I/KRDOF*9=-V-3($%,1V-/M(D^7Z1KZ@-$=HI$UBB[IOM#9KQ$5'7RXV:\4
M/!0\T:J#FB;I W"CFV9;@<[X<,@-N?9 K)>;I8>IT?K3GO8KYE-Z7!XKC4AE
M_ZZ7:[DAPRQ*FX1(64@D1H7TL:6^UM-1>M.6_KIF[HP">]W"7W'A72?V&BX=
MEU5O;+ZN[%][K8>:XQ+?B_D$<C&?I>.?-RS7,"%[@%454'R&Y0LY-I7*AE_!
M$<U1[U[U1'DBZ3RQPV65:SE"*+#Y?('ETIED<H2_9LY[-'-1?AJ9%LZRW>MW
M -)74E0P1_5[?6-7CN.A,Z<8TH-V^6)V'_EX.'-[MI0\I&4LG3$<XC*:H^CA
M;]'/$B0O6?((DI91M)G+1[T]:K#'@4@4/!0\*W4*WP;.L)2B)!DCI"(L8 #3
MDA6D-S09^7V"G]]WU5&$X;U@7 ^5F#M^82H'0B1<L(JH](]+)LJI">#4H#U;
M&3[$GJVXD91";1]06^(@H?+,+\M$[=X=I13+13'29<^.4='K& UTJ%BF./36
MZ%9 QZHHI@3UB=4TP$ 9#9:IL\*+5:C>?O]5G!8^IML#,0DP4/4N1%''0L61
MF'!4W"1 W 36;&%V(\>-I!1J>X':RLC?6@$<G9*;UVU9+L^FLQ$,* KQ=#>,
M^MV*QC/ I?PMZ+89.+YT!^!2ID"^%!7-3M,)=5O!R4I[8'ITG#)\NY*G-X^_
M*Q_'8_N$"//W/SAP!\%J0K @#3=P2<F8+BVI^$F\^ G"(@?(T6780C;>AC95
MP(GA@#6YMZU9( (EG"JPF4(NUL /XF$69F%2/^H^:(9-7T<#^WF8CTJ]T)#3
M^9^YCYE8FU&)^=2;4\I4&1^9*,)1KO6<<@!%++"%3 23@F)4'$.!?S@K=!?<
M1Z!]TP*;*Z1BC?; F4INIH*1$=/0+G2CIXR!!M#E#RC.L,KS[=_51$MHBC]_
M"Q_']45T0NJU.Z.4$]RE,B8),B9@3#<;YNS4N)&40NW0=MP2<;LO)<;G.>C&
M),EF\U=@PN*=""71!#*ZVP!H)@Z7>PHQA5)[*CY?7'!#\]=4BTE7W9Z)BN<?
MPO6BXDK)0R9:49D$B9*(HC@*'@J>D/V4S,Q/P0*L,40RZU:7E2X4Q^CGZAL2
M90#%"5-^<4)E4%:KUGU'Z,@Q]U6<GG5$6_*-4&E.2,<,/+1C "$>Y>($<'%@
M_Z5 _1<*M:C"<6ND\-[<F S+I;(LE^%C[<D$UG,%;]&EJNH2&O[H[]?8I%ZF
M[W[]NFUE>L_YR^^9Y/@Y>U%])J.8)FHWL'3F&4P8,!BJ^@30W%B"99);)Q>(
M9Z+,D"UDZB%7%(0(+MN-VR%3\,?)]LLE)W:]M(/.<V^I:VHT57&=WOLA9:^O
MS.:ED@+4SYM7=E  G5-EERA^7W^5S3O&V)]RX[D,FQ;B70M.E=O' WL$?F:!
M8SDN<6;<^MZ'&E0.Z!KO1A?3MZC)OT3#$#7+O- -^."Q(@&S891541DL#:T.
M?MVUK)?NXRN7H)1:Q-K7(:.C?B$ &=.F)Y5&B9=&&_'-_C1R/LWFDQ<*HRP0
M4Q8(ZFTF)].P/NIZ!TS+4"040D*<O<;;;(ZJU?O6].WF(MHH:^R]S1G9X+=1
MA0D23*9]D0%U/1/(_"OUGS^7[-'US&;80LQ;H*BF2P[8 VJZO)!P3><MEZQI
MD@%$$U0 ^5_/&,NR.%0L45THG>QHC[_^7*LOUP_/R?'SPKR+H"]J/8!&4HJF
M":!O)VHRHRIB1U%I;UU26#T117 4/!0\>Y7\30,,147V>#O+>KXD\5')_WD;
M#SCI8WL\-LF<VDDJ_9/ P&NB>FOXXA C3M(<FXGYO"6JP!*#_S5#3K9B@"C2
M;;S YOD([AG8_X23%4JW*.$);F93G*"^]GM#E)<&&N\XS4B_35Y21K2MUDG*
ML6&"82=,M_K @*_#=*2:. F2:%-!Y,<L>XPWLME\ELT4XBV2J").#/PW5L2!
M\1_E9&NH%[)YMI"-=XHYB&:^"!8(O4'_OK%#?).EO876FZAUM7KACW@$/G'X
MM^8VYB]M51%1=[_!;Y]7*-N/"WIM<ISD6U1KWK<!L(0G]VD#%/@(,HZ^,(ZC
M^J/\EFA^V]CBV(3AHC0Z\A%8&]$S71 CA-_JDGATH^"]8X98,S-D();+U;OR
MM"H;[6GM]6=OTGG^77[MQ2->L/7E\>$+'DAJLDATUR"Y9K S\;UFD,I,*C-7
MW\<:D&</<8&QP HYCN6R$0SYVK?XI*Q'62]4UHO27N$+;(;/LNE<!,'"0]HM
M,0YL'-HYHC%36GU#P4/!$TWI5FZ]FUC3QL!<=@%]J3U]^?-K=*]<Y0?IF$P#
MVMH=W*5^%[E[755_-9DN- ,8Q2$:62.]79YR= R(1,%#P1,X==D4)P.@6>:]
M7I1>1HH!_*[)0 %#GW+>U['9GN8FZF-O^N.Z6^O&/'499NGNR)#Z* =)[RQ,
M,@^O"1$$XHW]I0_3;#Z5A?^-=],BO2?I0R,_BA&M*3;-Q?NZI""YNK)7ZQJZ
M!(!L(J*UX*Z+FGPK6HBNDT9WF09>*!S"VO?EJB37)K5R<9J*AUNV;T5L$Y+X
M8_06X:3+I35B:5.VV6-M#\_F,FC&%^VTH:R0&%:(Y%XH-IU/L7PNFS1&". L
M+Q#=;'1+(U-!EV\5NUU%540+'03\F#Q"L4!0Q&W^RY3W6[&9OQ:Z_-7D*6&N
M<R0E-:2:Q@ 2@)23&44C"^[8%$:737443410HKG]CYW;#SAN)</E0QRW0NML
M*;CCI_@#ZJ"]J7\VE>?8?":"4;<'X3]_HZ"X54+5K^X6&0)S=;>W0O_U3[?[
MZ[6>CH='']NZVZ%-<51[ZV9B:>TME:.!Y&APMMU?$"'+%GCH.F4C"'92XX4R
M7>*9+@I[I0"-%8[-"HFLM5UCL,0XIG!H04-CF+1(AH*'@B<:_["PWC^\4#11
MDY87W+Z.9/5QW,D\YY/N!X98<-MUB+98<$L9FC(TU0;QHLL'!$^0VT&&=FU5
MHWN#HK:-;MD LF(MJ;&5Y4I[JJMCT*U<EW[<Q_V2D% O!+$IA2IZK#Y@5$@N
M]+.$Z<7\]__R L]_90R@HOMZR:*'HF%-*#\G@)^#IO#X7&)N3*!0BR?4UA2[
M+A7)^XI!I5@N*[#I=/HX*F:$)14SLROO*J!C^13%8%U7SBK=:U5/ 2L?#[]G
MSV1&A3##N:K6CFX8^BMT>JB7DP1I$U2Q"1Q5;!1J>ZH4F9>]>TNN"(FLB%[?
M1.\E;5VW@#-4=YE2>ZI,AR^ZF=.DSL=QX-YK,@V2RAFR3@5,$@1,4%V6HKJ,
M0FU/NLPK</=7UI@7LBP?\][;P+HLN]9%*^N#@:[ANUF7*;6FVI.FI=QX/(GV
M(J_D>&J*33X4I20$9# %J0 Z*@'DRR7[JQ+,L!G4:2A$,)8S;B=,D1\K*R\Y
MH7A_M9=9HO9^B88A:E;U#1B28OIVVV.-)[]9PVY9'$H#D# W+IJ&O7GM9_4!
M63&PZ8C4X"LAK8FD7I@ZD18*)[U0.*C0*= 6/@KNI($[L"VYJ'KVY]#R^0*;
M3T<0G#UXV;N_P@]>A^G7IX?T_UR?'M^\N_ZA/'9O?A?BX?V&V*<G1-:GYQ9P
M1MFGM^ORMQ66^+V,K(\Z*DB,M QCT0=I&O)AW*/PP7W1G 0;A;(=9;M(;99<
MBLVD]M ;NQ>.HWUZ- (8FPA@(HKK*7@H>$+V#TL>_Q I._3?ZLM(&4,%I%GF
M'3 M0Y$L(*,_%#5Y_A>>3S;ABW7Y_168DCI"JJ7Z)O5%K0?N1 M4NUV >OQF
M'J;'JU1S@[2@#G-J^>-6ORHV%>$/Q($4-9G\ &8$IY(A 9)AM8&Y7X;;XRC8
M0HKEA7@/K*;JE3)16$P4@:>7YG)L-I\X%EH_+&ZGXW(/IJ*80]T4U4NHTX?P
M&_#?Z%P4;01D^P)+73/;2LLV,::5%)?C>WSS^8K_\(GK\C*3PIXI8#$=T%,T
M#06I]2XS :)!TWDTG1>1"-Z0I^<%<-%L=,,4NYE,ABUD(ZAQI7EWRJB4404N
M-!<C#=WV? 3]PC'*W?,',YNJCMDTN/_^W7CK%>%GDAN-"3]1M]Z" O"/4=E.
M'SC-^)_CRC >7!Z'%O+)I0LL5]A#+14M!J!<^M&X-'GN#2T@B"A(?.CWTR!U
MDG/ %#P4/!$.!6F-AD,5H$%BHHK4X(6JO]8THK2@FIF;[ILKUM/WY7%],(B'
M8WF(X;Y>>A%7$DWZ9909R2CW4NZEHC]>=/F X%EZG[<T,J'@)>')IJC(%[HQ
MD_(<#^7\'[VJIK_?MZI_HKV?.U:#GW!\< CI@3RV+Y0/*1]2(1XONGQ \*P?
MS5[3+&  TT*2O Z0!!><1-"-I3UJO[02]RS$PUX_1$C6H0^-%=-8\9)8\0(+
M[;'F-L6FA#W<.4OS+Y2G8LA3$93@"CF>S4<QN_?@R9*9]N?FM+^D#\"]^(9F
M2[XS *:7RM53[=)Z&?02YL=%80<@2C&85%1N?62YY?WBBA%.F3"G U.-3)$=
M'V2GDX[L/541A.C8'IJS:4R)QI0H>"AXH@](UG4-I<5KVABZ?VCBCB:[TW=J
M%AC,7QC\D+OY5;^XNE N^P=T40Y>2-"2^D >J6CX+%DBI").T#$7L]ESFLRX
M5&6*84VBH\Q-F9N"AX(G&LW@O5;Q#I&AT7TP0=$T@=7H6**BH>EL3LO^A6[8
M5=5:[P8U]=\H8D=1%6OBF6T^Y80J?W>E:E<7V>2DM:(/<+F4@\^'I".@.]>[
MYR/3GG N(JHSNDUV-*@&V(3'<\[)U_0.7*080AT;C24D.I:P^O+9[3EYC]-.
M4RQ?R!Y)*H#R'^6_Z/@OBE'M:9Y-Y8^Q;6G.N'&**1M6'QCX,(B+AOPZK]%R
MVQ*&^O>7^T9&IJDXET+(!FD8XEA\(PN^!3+:)@O]7.DSE7\?6?X%S&5DA:3G
M,BBR/QBR?37[[>_;RA<_);*_JU4R7$3W7A]68_]CH2M7X<^G)_\.-U_\0#1Z
MBG9NZ<,O#(>6;?_"V0RWN!4)H-*GK3=#8'EN*E- %OAN=\,D[^4>7;<F2I(^
M@$^<H&@%NE[;9$0#,/ 5"GQ?SQ!5B!G#8BP=7<]F L0">$*3: '9N8T%?LBT
MX"\0DYB?CX,ZOB<-=_/_SL^9"P6H\A>F*?:@Z&J!EQ'0)/1%GF?.SQUY+2OC
ME0)P;MK5POZR6(5@;H%;4U6;;;&L0/^&BY*<?\^_ ]J>JC@TX6J<G[XRKXIL
M]=&^N+]\-NI)W"_:MI#^OK)A)GG>G\'<Z\Z^79Q[*>;0ZBMS/QG"%10-Z I)
M7YDZ%+R$GG4=D3#G_=(_SK?07V82Q9$F__X#*>U'= .(S^<= *4Q?/80GY47
M5XFA\1P]'5BNI(*7>(BH!)61L2(5L/Y[08;$Z4GSJGAW6RQ7'^YKY>)-"SI4
M]?)GIEBO,*V'4JM6J17O:M76X7>,?.GK-L^?N59&:(3 %ZZ?GD =4O9JCPM7
M>[1<[7%X.D2'8F+,U4<#^"TI<.P50#-QB$2M,0)G"\&GAM$3-66*<P0STJ)9
M 9K<-*"ZUBS\ST;7I?6,U&B"CJJ;(P/<PW645'0']3=(<">HDN<N/!FCL%_5
MGK[=WT@_2]\YJ[3-<+R-3_EI9%I*=Q+F,?_;P= ^/>&9__Y?7N#YK\R,ES )
MA6Q[>C_]>=5_K56O7@MGW[QDQ&4$%7B^AC+$_]:[3&ED*AHP9WS0^78(EHB
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M_ M\M:5+SW Q,OH.$.&Q*:8Y L1Y@-]'JDK&9GL?I2#AUY"8MZGG:PA"+V:
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M0;XY4B0C4G^)FC59)#M%9 RCT\->A@*A"9&*'&L"2+$'M5(/^0]XZC'\K 2
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M!YI:DG'<#-;[Q"@4G;;=)?V7N$ <RD$<.$<ZR3;HH*3""2 3%;N+)$>"!-A
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M%35DDW96!VJ,ATN92ZB-3%29?*.;6%X3?8Z$.];BN*"X(ZHHG(4:&#7=GGF
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M2VZ;*(Y]#NXA8H<BBM6MC-NL]VVVB^P0;V*W[?SP%,TT70%2) +DUB- :JX
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M9Y*:-J5@D :-88I4(G<*GL<:+MIW[ =#0_] U4 =L;'PN 1!][X5PIINAOK
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MRHI<J7H7%M$]@Z5RV\S>F%S%R^H9HH7QH'RHYEJ3KG<N=T#>$8W)4BF'<.J
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MNQ3MT*63P<E^("N"*>^CKVYN'+/Q;+9]+^GM-M;E DZ_^N9 HK)GI<;J*OD
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M%#,QF >)#^K4I\D+;$S^6-QN?-<:>5TW0P)@Y K$E2-&<6@9XC1<9IJ;+!R
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MW=<4&J[",6"T\?=XM+%<;@S/3[U?CKE;^O:Y V8BX4 ").AN%F9<Z<VDM@T
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MP$]V5[32FZ$CW=S0H^?88L?GTG$&%R(VBZ\\ZA@A12L/@\2@_"R?%"L<.[T
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MKS[\.Y\#4F#H0!J2:"Z()M4OKZ53>X=^O9VKR#&"(,I1E'\2:$7Z<&7W09T
M@7V4I:,>TK+.AF/"KDYM2QPLZQRYO1L58)L;$0+^@"!Q$D4HI.L^G@,GQH]B
MX*!N:6QY/I(O\BBBBT;/(A):=I].)  /X:%&JAKWJ?G1]P4L@#;85,L+1F.J
M+21\A*UC(XII3 9#.Q^Z887[<W>D<S@)1PP$C< E1X!0^WW3$',:X=$H)%$
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M.+K>1VG4S]UK#//75Z=-Z^BN?MK9^B0@99.@0EC! G)'/-X%#I:+=[);W(?
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M='621/Q@X"4Z,@)=<L-2=OPN3P7/TFA/D:ELT*,[4;)S_2 \IC@SR6SA_X1
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M*7ZLY'8&EY OE(I]JY7NGE\?SII7<P^S23$F,/FCSH-$,+LT!9[- YZ#T*<
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MA*5@PFL\&,\C4O6!.*E&OQU:)\8@=V)^=AX+;T_Y_)B;-[;>0%F^B84NV[M
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MX*]@/,\P#=,@]D"6.A(I/3=4:AQY)V#S C_R6@ITKL(BC\\U20L$'0U(RYK
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M/17KA^^7]<+-]?"T7EQGAX&;>LD2S>P>ZSONZAMXH2(""X_]71I<CYK+<:^
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M6M%6-EMAL\1S@9^"-&\,190(*)'/F_J=TTAS^&3TSB_RW3]M5YV,_14K.0,
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MR4U.T&@E\E!M/-X;A^:!.N#],V'65/%P9"'09N-@3XKE<J;"^MZEY-@3%RV
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M##,>BZJ"J&SW)*--F&U][@K.<[#2>Z;-3$5#+4G'"$H$"/*AKD13@&3:P:P
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M7R!ZU^'[6"<=3Z?19S +/R0=LKUVI'4*PYL4[##?8-](,>&5(CC5+?PT6)E
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M#Y_R3PBC)4O\/R8_QR]I'_1Z@_I#2 120FQ%!5GX 1TDD*9NHS,2S\HU++K
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M-<C? D>F,.K^,D7OJ"_1PI^FA.C#2U*Q;29#FCAM-%+S;W>/+"DYLL3:!,T
M6=(J6HH'CJ3AI9G8W W9]!_WD7_</Z+$,@@^;]J%6A>!&(G/ML*U1VX)@]8=
M^[J3OLI_OPVYLH,"_ 'C'CAE(MC5C?L:M 7_!"^=.]*=^N_K3K!*/;@,:\,#
M *X;>41+)(X:]9<ZB)5'3'^PTG3$BF'ZKP8$H(W:D3D*D$:3OYGS6WN3"YV(
MW0?PESB"PVSXC$GP#MU/A6]Q<= XB,8#X;#U./1#7  &(A6!$]M<ATAO B]A
MB0XTP!;4F448^@96$@]</>2' AW* HSP"?[UN4.2[4(L^1'M$RIJ!R(_[>_Y
M87_ S_[!/PR._*>"_4?Q/[LX]M.D;3SP[]NT=8P&O"^_CQR'#<4>^58-RC*Z
M$QT8RH4_&3W"#_^%^"*$^-X/Q+D_U.]!VIG_J=T=TF[R4_LI0N2NX;\EG_"7
MO,=O\K0TH$4M9(W0BMZ/L,P$)_C6UR!&4$>,'(5:;BUJ&]:%!WXX^,5\ZL&%
MGP3U_B#H(8ZZD **>U#E+X:JKQPQ)/0'0S$A\.();,<ZY8KUCRXRH%'X[_7Q
MDB?S,(%R%GP,VOX("7&($MT@$*($2B\_H\CX"-+N'Y!\6J!!SO<SBGXV$?O5
M1.9?-FE50>QJ_> I_P=/'?^4^,73T"^>Q 1A@[=QEFB276BPQ?DN8RQ_ ??^
M)_"5/X$GQB-_Z\-;]L4OI"R_D$+!C:0$_])08PF%:]:/6"K\LT%F[=B_W^#%
MC_@V!EMJ=GW%Z()=&&:5S/JV!SFC_=DXNZC;/ #R354;W;8:*":C"Z'A]>XI
M"A>FC[&IQMYGN#N=\F;52T) LTZA.?<._Y=J^?6 NL3,8#'5:V0/B,5UG=O\
MTDW=2J@O;>Y\+G1->9>IH_5]TD'GN0U'FL\&'CBA4@_?&KZ%!U!?\4 =9.27
MF TU[$XW:FT+W!#;%J.MZ%OT9/"]A7RYU8'E%:+! QU&5W!X /+H&<0_+YC(
MJR/Z^3Q/+KI4=R2A)I31F3BOA;&]?10Z$?ZW,\S9$-E*S2;9=)6V_24<#3($
MG"MX@P? 5W@@&/+W4]Y)Y/Y2)C@V"TUDMO,W># S)JR8.*%+<RBT1A*4?).J
MW ]Q#CBN2+1&S6^G-4]2(@NT-RFS-;9DO2$U_+^IL08G;OQN 44(:)@[#=-(
MG_79AV@P@&CH5_N-AGB(ANUN//"3!UH:7[?"J)I4R-X]'$T%9&\&\I>]J?\X
M+WR;E;I4YA.P*%K=@00G5(XZA4;-CUY-T!HX'LC>1/"GO7Z0O;V;E%E=6P<=
M2-3$38_4OV3A?S_%' ^1_:#;))N*Z%B3!2%PPI.1^PN9>. '.F@$/KWTQX7=
M'ZR=X,&L0*R%P^#5$$ <34<(_*>1P[](_KO\V'SFSF*-B:/OM4CDJ <)EK>0
M!NQ0A4.>K?CI:N@</")H!2*H']6)Z,_U]/V">0JI7Z=$:QKSX'"_*Q>;C%Q;
M@$P_A$S?6^3![#@(O9=-AFR7)L'1C(7 47]T?&2Y^+\4/HFCF?N'L.3OPD,\
MF$-(&%XROW\XYP=^>;V!V(/R]P%N#*L*6\_T43\\_ ."\8$"S"1_9H]DU_?(
M9CA:L^8WFR$OKOW6D>T83^8.9M3$$?5#LS_X)0G27/J7YFKUPY4_->_]J9D2
MTJR&UASEP>W^IGDO!/[Q3\VC\ZE+.]4UX[CVY+F])*C&/0'6PT:/(NT W("*
M".1O'7E_IP&M=#8/ @ZD@B"O"&&A8*<!O?]P0^??&XNM::D?)ANTKE(N+[*
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MT*E  ^@\2L]MS!"UY<P?&37E\$UB0S<6IENI:Y^-K8[K/*/A]".+4J)5!/'
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M]2SH6.\1N*U$A*.Q'5GISDTH,A5"H>)(5>$;E:GFW: BUE_V%=,:$N4KV6[
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M(='*_5B':)GB;4/78T;3P([0[RX2(0,S3XFSK0[IR[?8XL&I5V$0_K 3QS9
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M6E"),7O<KT7Z,(Z-2"[Q!X:6]M9ST%OS+_0"@?+?@%6XT8!1 !B=U0>)\PM
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M&[S)PP5]1)2P]4"JOIL3&JT9/#2\%8\O#49XTWI?5S##.1]+;U5S@HM>.IU
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M[:!/,XH=>>!3:W9$ND)NP<H4R.E6>9L<^Y[%\WK,!>@5Y\0M82P4O?2^C((
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MFR]?DZR;8?EAZ&OA8<:NAY*.%".[Y* ^ZB#.S*:[ I6\Z![('"XQ)0B%U"^
M'':&L;G,.<.H=K_T,4_BPS:P+!M.(5F\BI1;S-ZBE''@'2+$M_H*W93>1MZ#
MRIB.%P];/IN-R"W5F $7/23YD,0/9=H,,45W"RBE>\+76);F;\X5!-)<,ST2
M?X?&,<8_/@&4:7XW"$L(N\%M2?4P\HL,.DQA7',X24W8'F1]=MYXXX\_TR=^
M&%$.^8WE>GGZ])DAM)5F+1OG7C?.)RYITBDD"E^HB(P;!<\(MO[&* KN.>\3
M&!.H\&*QU3=K1H=J$X@\ :+$<L/M/=HY;,&9BS][WA BEB4?*F8%_EJDJ34D
MZJXRR$/B/F2Y@F+.;H(]I(G6;*<73:*\-^P5,;;P-(&ZMS059N$QKMP,&@#Q
M!FGB\>9-=EC^@O:B&+Z*$H.YX>R?2RCO,0RI9>55$?%JUITN4VZQMV%?*JT]
M[,='S#[4A&!"E*/(_K.4.5CQ%Y?K"M#17YSM05<H8N:12GBY3<RD>\LPX'0'
MV<ML^AHZMVU(]./DX!AVV0QA"H8;O_J;05+)34_U$/D$R+I#/Y"F2,0C-Q3W
MCS+]D=CMUL-1T2(] 7$PUPOY"B0?"!#*J/!E)(T7$&O(V!"7$D9"+,B*_E50
M@(3/' &)E_*<TOM:W;4"PS:T@2#,BX?$6P9;CT6R;<-58#-OB4IA<\LTMX70
MUM9?:SI?OEO=7G![59E]PVT;9B;"(.F8]]JQ/^6JAB]*0;==%$+\T[9#I*'^
MS'@B=#=1)=PAGF]MD\X:H702!SPN<'E=48&FQ4?F+K!DD]W(5) D4%^%)$>D
M_>]-14"10'UHT*NK8B4*Y58#XH%"3(]/AYH@*U:U3 FZA/,*7#M+=OGK9KZD
MR)V%+?L!(N=2_:F/>!N:D5"?$H,U(F&-HF_\-9D(-X,,(K&#'OS9G2CGC61<
M]4T=/W5"H;(2B1\K*E8D,B/X>[\V(S7\AJ]_Y L+CHXU3 LL)!A7YG.0VOSU
MU62**5'B3K]V3J,*;JR>;ZKQVL0R=*H;(*P_X'UETT5C(.T3&W!:MJQQ9MEV
M@A^KI",]*Q(=<'F#L\<V+/X69-_0H9! FQ"<S! W7!PJ H\PCY#M+\0L%T%N
M6F[R\.W$7(9=7G!.Y?I%4;@#3ILNJPJ5;==5&H5YPJU^"<M+ATSR71'A)FL\
M?Q0-)$6PUJ0-,G3#J?:#SCM:S@YY"1KQA<Q[L0BGJZC6Q?H*]D#F\*75#@O1
M+7\<SP[6.5+%TZN^Q6^6@XNP91O1S:1](Z_N7QQ;J=>WTY+AZW0X0M?H'>@W
MMG2,K:=6U5(PSM&,4;NO>TJ.'9^PFT4E_$7ZP%R Z#+139P'4.^5H0MM1+4@
M.6X!'>DAP2NR[4:WRVNIE",[XD(UB/)F+H1'0LQ0DO"((GG26)GKVV+<B+X7
MU]H]^$M2QKZ?DGE!G]?&<I3X3NH?XY^H#E*N351_)JAT+8]2T\QNPS,5FG 7
MTG4C]]Q6FP>H/*'J!*M[M6O>_AQ''[RLCM%P/P^,#)SYL\B 57L_VT"B$MH5
MQYP[2$XEUX)+32=P%D,^])XVCWD--$N6??7^_H-15L&A.[_G^ZJ[$,0$(J*,
MO_@=!W+@ESJ;L/!0JMO6V:NG-_\H&3N[*"<\&CR&'X_K+U-MPY7G.NQ?9_2P
M'NY^Z(1ON$^PV+HZ+BP/YY&7=-.6$*X7S#=,Z?!>J5JR@A*BA<K'H8M&(.YC
M1*]4@0LVEM@5-]%#7P.YV$M,] 2*>:-Y4+W(#M47&2LMC]*6(B:6#VM68FK3
M-R6#JT?^7I:WI(7);?JW=!$L:)AHP1=_T"Z&N1@*9W"FP+<+?JU&8IN?[NM/
M[R^E1G]HJ!.(CU43W7Q8(FTY9B93-T\[XUQ]K(!DJFH&3%P;(/GPC@=D\QJ"
MY;]?F^+(46E702QOBN3NINY*G/TK\. T'34(?5-(D.^<<^1Z5_#A(W'91GIQ
MRVE?:N'G6N *T>CDC>XM^.,=9OUZ@]K9O5)B&;&MWYMOB0),AT=1J#7TB>R;
MW<.%Y<J2<C;>X@- ]6BH%>AEY[3#^"+\4JIP5E?H1^IM:D39R]?ZQ^\Y9I9W
M7W(W7=IM=.#8GBF1%#=XFIK-F;U^GRKK]OK:*-"S(2I&\8*)J97F$IJH )&J
M$\A6\L!R'0T5#Q]?+)#N7M\ TM?*BT\W,Y061)K].Z156(=AN\P&L2[;M6\7
M"?\@LT+-_X/+8GB 49QQ_)TI;U[)A[Q9^T*A-:-58*H/17G;#Z+5>XNY6WA*
M$T92<!/EZ+=@1-CTZ -MC2).4\D8?HT/Y(M4%QDSEL/[8:PF=\I'*>FEWHD]
MJ7ZCYW.!9,1M/J%YHB?7*S[\M^9X.3L_3!VX%1?"S:RBD'- *S1-3Z1(%.+^
M! #EV"&=/IIR#A^\_S#]M\-L0OW8XPY&K2@NU_2MIL%FW(?,$?8BM<*Z=(P-
M.+8CP SZ[8( SY,D;)#,7!E<847%[R@.<]A@Z%\,#//KMDEN+$QQO3'G2Q]D
M*RVL4O,2;@>X?_P'?AB44X$=57:WX*LJP,>SH?@.SK:H5*3?]FEVB+UQ_'!Y
M/W+MS#&LPHZTH<S<C<H3F3.Q0JG^RSJMYI>,K3_'1WYOSUXPGYM'.M\-WBF,
MU%-A1[L^SL'.,)>63@QK8XZY==^'M(:_JJTTR_U>LSP?SU!U.@99#?WBY.#/
MD_J1;-SKDR_V394I_$5L@E>ES4BYR4-*Q@?6]V\R:8\\H1,H0P[<(4<TTW##
M\.:E\RT2T=W@Z5H_'PADIZQ@XDU;THODKP0:)=3J9+N1-'!#\C6::7>L* ==
M5I@7[TMD1RV'X5)F6F'*NJ0Q)S_)6)8V04;/49,7+<GRVXT$S5<G1C=AS*?W
M/'907]03@+.&ZMW$ZM81 ,]O0>'T*B\09W"^G&!E==B<K)]4*N6#8F"DGT^A
MM^S!-([J%H%1%E/?^-0!2$?B+421*.J7_&\RRYJNRCAB;[<[NPOUY%_+*U$^
M*([)%I%[<M\JY,OGX]V[:/0+,S)UZYI+V!2[S^2AQ<*A3EFKRVT@&F=%:<AG
M;[41Q3D)7@<?!Y=KGUB%3/PE_LNJ,."I8PQT7UM?U;Y&@:4?T60I!=-[>\H9
M%R90^L?]KB*]FRJ-D6!@'C()8;EH/'E$;KO>N?'%-1PS_7 W\R[0L?TBK,_F
MEW>8^BQ&7& *[Q,@U?74MGA"!]85:^@+F5#2MF4X_,C5GRWN,.<^4)>6EXY=
M_7#)1BT*S>YS ^XJPYJ=>-%3V .I%&C33XSFKG-]BGBS^JXK^ *]2YL!X*,G
M .9W>Q@.+\JBHH>Q](G/IR< N//=&DS@L-5?F8"3RR)FX';0DLQ2*N1CLU#E
M5*6U Y?W^C>/([' \!@0"#6I7""$CI8]]K=5^^?A*X'Z.[GZ&)?"P2WBKG6[
MU2[:U4>=KF5O\8_3;0XNY88&W8?XMLC=/T70FXB7#-5:HB3GOS.Z') ]W./<
M<*$[*YAKRFHJ_=KOFU)6UDA,;'Q7'?OV=04#FCR@@G50"IZ;JWS628P8^'@Z
M=IT&*BR$%AI5&'4QK\=)?C9UA+<'L+8M>V__^E@;R@:.OA9<$!%($@'_RG(O
MB*>*!,;_U_[^.Y6W^4$S'T^XH?5[%+[-TR)I)[P55C57ZMC[&1/ICAM<XZWJ
MHRY_==ZE7J?VR<D_7O>-4,LO:(2KV$JX,CACV,]ZW;:G9IQ!9B$F,I[E^8Q?
M9N=4F;M;3&*H5&Q?:K_Z*2HQ?4BAL[I6:.MKR\C.R#(402JZ(J[)97B7+V7B
MY&6N3'EH.V7"NFEIN2;:Q3"?PP4=GR?LUT&@.^_^TB/F#GIC(S6>D?KK>V,:
MW<FXJU[UJE0* X(DL'[XS)2-L0VU2TK]+FLVWD,/",W.KC-2=?Y*Y[GEMW*+
M[5'!HTX]BC^&/^K(5T(V6/7IGBKL;?U,;_[:FCG7[C@CXY7@Y'YJG'EQCP-C
M!TB^5643BL*%R4+]GT%[_"6D2)(%&?)'4]62;XQ G69:660X2X_]]YC5@DY'
M2^RZ[.,(/MV0Y9+%#<W<).@V!&@2X>'%IG96;E:)U?SWDKC+CYO$]2 C9BPU
MW\4]5)#&N/]=_@1#3G(\_AJ.]9T5W)3I]QK6MJ+5Q:P,H23F[HGY6;76$ 86
M0)]+D0:V SYJ+XXJSQ:ZT<-?7#7F_!4B S1>;A7^8!T+FI[=>27#F)"R"^51
MB#;Q#C7<<^+8G8;+&<)_J[RDE\9?;0D0G/;.U6K)0@2@%*DXO&P-B8@5PLWE
M$KO3Q5GR3N$2I-OG7Q[R;1LL)TY^_MN#P-$WT"< ,;77Q"FB@R1TXBA^UTS*
M\5'T\E 6#<P82:V<$V*VP%Z X,+A.K[UL4@,K%=J1A$5?^&1O5>N98NC5!!V
M+?G]V0PMW&8%WS*'V3,VJZ0J7!12:JGNTNG^@!053?[]_OTA&8E)O#5$]/'1
M1LCK<-1KN3V;785J*E+TFZ?EKD[X_52/V!.@UMGF<1[_OI%'!<7];ZC"/C"]
M^(<N&8.TIH*PRX670K;?^RE"_4EA6PB%-LM*_D^<X[>E$@*"U.AJ#<TXNY7L
M#=<K64UJHQU-576]4L2U"P+[G(H\_*ZU\B[!.K$I4M^M494[S+X)%0U*??K3
MTU01_;KE9/+HMCN'6C/-9:DJUQK.R;&ZK\V=,W373%CHBV_D&%9T<&JGSB-M
M/7LD&DE"1ECM <TD7QH_EYL9=?FP'-FMAI]YUW24TY]_VC??#O<^23*N)Q&^
MKDT"T8F8\<^L^"Z\ >+R:ZN;#'"4JHF56#1>"#_.-R8PM4/*" ?.30R?8UR4
M4H99SZK0Z0/V02TX"0YE4 _MAA%CFIY80.UM=IN\>$JWG9!I#]]UBO\ >.?W
MI,1;IS/9]5[=VR9UG)6)%)VT;ZB!%>S+.5<M=7KRML9&UUE3JN,^1VI%= 61
MK$'_'%"DO.@=<J*Y0:?I$92DW]>Z_N'1_(4VDG-9PU>;Z"?;\7K]!3!-^"NG
M$*A>JXN!,WBMY%4_[2B&<,[+ 48M56RW'D8^5HL$Y=I+> %^XDJS,K=Y>G ?
M%&N9"8)<N-K]IE'?Q_QQ3.4)\'(\9N<'GR*^V@S3FO 3P.U0=Z%[26LY/>3#
M*G*-JP'O+YK9PAXQ[I2MAPA/I[6/23</ ; R%'L_3?/2@V#U;V_N]+6F64VO
M H$!,>7&ZP=ZIRI$LFMSUQPU#5Z-+HB/UQ0TN<7CU@UA]L="K34CPK-SK>(L
M' G3&-WH;@R;K31*>5C_6O?GM\P7(CWD=YTDG?GC@( -+H\H+%HRIA2\, WE
M\[C+U4P- O%<H 3(Q3UCK,AB[4WMSY,=@_(TSA6J)P N>Z98:&;EO7QC*N4(
M@DNN?Z&Q6;9<YG%/@A;J*<7[I7Y_<Z%P-G&R*- J4(C_=8K3M0*8C.%=U_2$
M="@G8Y-<K"PN<A!?\^]X\7GNF*O]>G]?.7P#G\C1T1DBSL:&24E5>V_!2O5O
M#@%=$DF&,3^5#SXFY7A+OK#TWCG4;YQU_U+,:D%PG,C-(9P.1DJZ":C/>5[\
M PCFMAN#]3*6WY'B6N*:-QCQ,.8F'U\.'!JC]_P%!N*-L<N>UJT.CQ'F?$QZ
M=B+$ ^%1X1[\Q&U.?"/9C;SA/\VSJA36?@X(5O]&$9UD$J8G^;TZ;*$__I'J
MNMPLMH(HS_=S[.S'14=>E^>P$0E/V59F'S;+PQ O)S&M@?9^Z35'*.@ES;AC
M)_U?RH/V0[&->*."@_DG@%6SA((_^BKSK9ZFQA#%A\I$MEJ:\AX!D[L\B4S9
MA6/[#GH[E;)WGF::C4=LN5SB_.8P3W!J)E4(2$Q4+QEGO";+B::0^C!KQH\=
MGDW;O["4J98&%/@2!.-,U)O$7/^Z:K[J6\ ?/G"[++%1*/5S=K:[.ZF>>GZ;
M*?]>T'Q"PFGC4)W2U,#8R*[S<^L7SZ1HCF#1H4O)BLDVP0I*RS"E5B^-<A*2
MY/L5W)";"7,3_\T[7H^RM[[8$21G=Y,EE(-7)KUZ(&RAENLH^PYO0D;0ME')
MZ2OQV[AMHR;P^8[S]P63[)?:6D57!U[YH2R#5:8]'?2V.0[L>LM.Y4 N0Y>?
M*>**'6NPZ7>O50B&""L*7<G5WE;UA*?^#U<9T#)&9STR_27U!ZN4HS<^9LP(
M#.%;:%7F1;LS1$84S\5O%K;RUQ^YKFO&\D6\KHO>2#[3 %% 5XL+K<VM49TX
MNUL=W8*$HN>'7\OG$\M^F4&!:,S6@U2U%(N:]/!>T1OK1Z/,AS,UHLW\Z@L>
M .O7WLG]3)3PJS6SU+F(*5R9'=ET8 U&NTB)M[)D'V6H$;12Q[(YE[*HIY0!
M5"D:Q<$'JMO%U+'V"5<$QD"A3E=AC$[74K#/<C[WRF].MY;ZDLU'9#TCFBYX
M?P[,-]3_M<I5^VJ8WJLMAN9.VZUN%[1/HFJ6B@9P2 CF\ _%53C4.P4 ///0
M<9/_?9@6!N$D0DJIUE<HVUL@<5U3L:J]+[99QD:OJ3+\N20?G'>P]"TVS9=S
M;#B(F0\[4<%_];!\H=+1@_.UKXK!ZU@#-.(BHR\('6E<;P=WLK<$QZGOD3_%
M8H$C ;_]WOI3GT3XW<0>',PO;9MEMT'+T;S)C_E-JJ3G2J._:71R-U+II9N,
M55*#K6VXI>:N3^/[D1^RDR0'JM;<3 J4SD,?<44'G( O9L_$#\63O,I7)JH7
MUV07(BMK2=1S2]2O0:5G4KE>V!TTV5?634'&W078SMZT/-)0,SM>6VZ?0,'^
M$C"7[N_72#8\YK?F.>+S Q%0=_T3/ZEKKW[#+A\,_277 4?TTVMXB!#XVW\_
M,R$KB 3LW"ML'/HK]X/"DP=\*0BQ$TY=Q?1R$;AWQJU-+?5GDK.3JZ%CR;78
MPC0/?;ZX[/S J8TY:%M#]X<P=ZTOP\((W4FHS7DGPEQQMB-ZL 7M7"[T6#!.
M4ZY;^GV3]EX@Q/L/OH+#&=!0MG&!0LD50NNLDT;=D7(@U)@(Z9JZ4CQS+F&G
M%)*8N(8[[1O!QEOY$%4@40+K\,>CA9&>%[1]CS?M%LFE#=,M9IN:()R6G*B-
M!\71T'X?X;%7HX[@X>RX6??7+?@FGZAGST;(8^5 I;77Y[$O?EY*Q<46M+:3
M&@0;SDP?H/7X+S(X4@A3OZ4N8\IHH2]J^#7W[&]&3T_2_;,A57XC%9@:,*H]
M^@1P@N@7TW0@(#OH2;;OX%[W'",)[H</,1/K.YSM#7<+D /DS3N*74>IJ6TA
M3)>QEQ7[YZN9(L=PT)?XSSACAJERH<RI\IB1?*.^F,I*[<ACCCY7L/$26^*V
M#+M5:*MLI[V/GHO"XRGUP=M*1"N.R[5FS!VJK(1?TQ- /["[Y4[2KD<#VZ%*
M)T4>KN_P\VH79G)!Z(D=U4K>[S, U?FY+:#ZSK1MSD(EQ?)'Y&MSSS@<_L /
MFAMX1_1EIO[UHYJA)VLTQ'4SAY$''Z:.4)7(40FD[+<^"@&SL^_$ED9KB40<
M>6R03_]!7+H>[S- _$;^=]:7V.P]E/&D;C'<.'BFJO*N<09H$<()R&YT#0S!
MG]0YH;5SJ4XJ3K1(E;L@P9CALPA\)5EV:QI\_ 2HWYKU(*<WT/(_+>?:6KZ4
MQ%'8Q&J&+SA\%.RK1UN=6'* ]E:./?3LL>##?@]QOCGMJUCL_AQ1J\SO*-ZZ
MNU8CX9?1N]#R'NSP &NS,C-A-04U3YBOX"FOGOHE*6U$R6>LR&S1(#LP6I?1
M%/_P"X@?\H ,N$@G$2H+_PCV99;V%K;[@+E&- .S)=17\5?EW+IHJ N]J-T4
MM?><(&X\?6",DTEA2AI--AZFOMYTF6 F'O,V59\J"=:-]=?9C!;1&.Q?.4+=
MB'+)2@05('RHG!&>BOEN'" /%H755N<)HYOGA:@C4AGX#I.E4. _KE3\<QE,
M$L1UITPX<MVJ<"=XX![O[F1%W6='4Y].9/+3>[=7_ A)D%-(^I7!BJ$=Y*<!
M';D2FN]MY!)(=_IXWI?L<;SR>^(,+2O91ORMKYY3^1[0JCY<$(NE"MN:9;R9
MS3_&<A6H;NU(UQ)37?\$^)T0.-_S*/#QFUA"O4X12 U:;XV^>=-X1OJ5JV."
MJ'/)<Q3U,W>JXL7"02CL$>L8=NH\X[B;;M+'(-XEK-^UIS=GEQO^9VOFC^I5
MT8\)F[$?:KB,T;0;3II7Y;=R]RTQ1;Q_#T'EAD+V50,KSM)?)CRD(:[RC76Y
M-: ='46%U&>W>:"Z&NCAMD9Y1@%2>M-V]I#VL?&O(V?ZI?2:J8YDC#OY[H+@
MO!DGD6;&OR[#X+BL23:?J7:&<:WW>$ZU#P?I-%J>K:/,MZ)HJ$OHGGUG]HA!
MNAMU9A5*K21>'/ 3:SOS6 ^#KO=>[R6EBEB+Q%?;1[;"#=/"=&IB53(S?5]7
M&76K&=3\E  O*+WHU6/=><>F^+U_RSXR]/QQ?,2L-4/D)C=9&DR<TP5R=$'I
MHZ&O@[%=6QFD;>LO\3<OW&W=?BY)ZA.[YU="G5<>(Y77'U^\^ 7^W!J^)FI.
M(#^XUT/_95P!QL*>D&7=X#N#$M,Y"VN68,:9"8T\4 JPC'&I<>OWQW%OH:H;
M*P!*3KF)RV.E'>:":]P\7A1)6?84N>Q6T%R)B2E&[@T/RK^EQ@%(N/][;_N?
MJ[*\)ZJ 8,3,?E,>'L\"G2J#EC_?#; A<OQXW[%':M,E>X7MXG!@NIW3,UGC
MY5T;X7R3$P'"5V].L#Y+_RT?"T"1B;T))9[,<P#F.7_(9MA?^PT7@,K]81(]
M_@#D0'A@*^%5:\R5'V29SHKU50U7A&R"N 0N?D1@_$ZFL:[6HNW."&>G7N0O
MCW0L3(J>44A(HTW(V6IG VAK$15@ $8Y!NM:1U]EZ^B]5T<H9/5S;5@X_W1T
ME-+<EZ$IR> W^G(F'=ZYI]7R!.BL>!0([%:'2]\2.7:>'$RBFSZSP^X9'QF>
M /GRAX^/T(]I_;>C8M%">!N&^6Y\SQ.$7KQ83CW2JE7T OVSZRT=7I.+>/]/
MVR= #.UI$B+N\1ME]=UMYZ8,M:?-F.MSD7=<]?UK89$G0%7%HZ 6+=4A*45,
M7[0)<8LPR0'T]=^*GY+BD^A>_TUO-6+J7]*? 'N:_^JG#+47T3SZ?#,OW G?
M(@[QONJ'Y!O3L_)4&I%Y099M7W4LH\$:Y<G.$[U0$XQ#&6JFZH)%D%"'W-:G
M<&G&2.>S7 W0X/&;,Z:4,RH%%^JQ_N^8?^6WZ4?('AY4P:3WC&NO_TOOM'"$
MQ+OH)T WO;/;PDV%H6:OF)[NRC2_"^].#:RSP9:C2+9Y_+,(^5'"G.%:W>7R
MW1@WD/]HV;.'H-@Y+5)\MRYNOMZ#<GDLR63%FPW.S:K25J-,'$25U%4I'@X;
M<U.-W1EXUY*X]A&/+"4YRU<(Q&T%8>];VKRQ ,N51-8;0J*Y\C&5MU"P&J@-
M)^. BZC'7<07&38=W/5GQK4-WQC@<BGA@,NCEO; 1P(G?!:1TY0)VLNYP/XJ
M"#.6,=274 12L[ 3?:='[+8I:=+%\&SD/:0\AJ0??3Y$>F[=ZEGA.H-W$PSB
MQ2I,#*$K.(3B=)*3O^=RYG#Z>CVG_B8VS.UG6:7>(D_".:6H."CN[)BU$N*;
MS?(^A?H?5K?47K@WV\^_2PW/L]H]$QQ?]GL_Z2BA[9:/E;#;0^;ZD'ZC(2GG
MWB@<@9;)"4<^2$A#R1=(H9&%,'..*[4QE$Y05]:I."89]+Z.%1P?TILZX$;(
M5$N481Z$J$T[K6'YK_^S&UN"'B71^$60W>FU2KC?LD=$K05Z@Z2=YJ8#T;#V
MA%FY)W_*[\:; -C[^+T.HHP>W=3''0^/1+X(P/@OMT6?LGH\7*4B.R]2U]%*
MZ@\N!9<ZXW9C<1%_N*]>U(:H7&=#LC&? ,]6+7_3YVHXX6:?X4M>F"X?>12T
MZ?AG$OTC#J?F#'<HI*3+.U+'DGP@?U^O%%#$(%"O@:).AGI5I=#':ZJ_/E!A
MJ&(_Z<.T"F])&Y%1/[.>;[DPJHZQ/Q&DYK7?F(E9^; QWD^N2\U7\I4%>3U$
M2Z2-WR[!%&O.Z!%!%;T;+_G-TGN*,[2DH+VWL3Q&JFO+_-,3(%!2S@8AU;VI
M.ED(2YU<1F4LKQDBO]YC5]><.:I^K= <-7;'[U-#M[F#'"2"\Z*-JV'I1SLL
MR] G+ZX^^T";V7'%<]R[*FQCL=$)I[D>8$A9YE?I++0;^?,TM(**]^"<*68W
M2>B\H= -.^D\>Y7WP<X4PSO#UY_)W13/SG7G6/N<[;?;3+4=66Q2;P[[$R#$
M$SXM5).ZX4AK9B'M/A\-7BWD,EA40Z*+38GBCLAQ+5;'LHNKW_:2SZ(=3WLD
MB% WQ3HHD72->!3TFX1!RPJ3.2U@@H*T^ ;[MWZ-T<;3O*F8;?#\:0F=$KOY
MEUZ$]2Z=JP1<+V\J6SN)D*QYFTX[BND_,GWH3U^.];W]" R,V' 00ZL];2B8
MA_"3XU<)/;J?X!J'>;O^\5 I-Q!6"2D)M#5X DQT!WB,/QNI_.ZCI:3ZXT,)
M8IKVU6YUR)7TW77NIF8^J8)RXWSUC?6S(?\LUQ2PL!!+N*IB>@+T"8']"U=-
MO$TU(U_T[_)6D__V*JF"4@)&-E0_H@S^-#TK&-XXOA)3A*V*;6J R*HV09!#
M,HGYV V$7E87<1%%VU*6"=D\@6WH2XU"IT,@ND&33B^8JR/]Z!O#W[EQWCVC
M6:D1<:UE< Z+1*PTVWD<X0$X9 %L_I!KU, M->J@0=LA(CB-1P#BY1JLIY8[
MY4W3&7JP<;]L,=LHW@I\U<8M5;$1!9NFZ[LS^_.N7FFB!.HJAA=R]2#<@]]^
ME/F05V,=++JY_VM!O=2[I/?$FFW1V^Z:/?C&TJP(Y9A?RV:-]0S;TRZC.O1D
MJXFJ/N';DD*C8'E4"J6!M/$8Z[#[IL6E*'N[G$%!<PRD?M;!.V;[A;'"#=Y-
M:CM*#PUOX[Q#HGB#(C?R_;!AZ WQ]XI#H&XAGVU+7*B394LV5I&5X(K,P=N)
M=F>3UZ?1<2!VFUM'F,//7JV-9']<-Z.SKRVJOW+DA(O#6A1<J!;/BQ0&T$'6
MQ-R"FX'8C'/WW"7&7;Z%!U[J["<OB%Y)-@NNQ9&LF#_*00WCKO7N[<K[>5,*
MCJ.W:?3,2\=9QC[M=3#$&;0VU0OI"7F1_.8?$ '\OI2@6#[14&RNLNZC(7,
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MFR:JNL-N1]Y\_OXBE/%-?ZM93C)OHKQ>1W6--'-9NK0TBU.^KI_1)=<LF(S
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M(85\N^:)=DAP&X-CGE5CXQW;-U7K(/3 I%4'5Z)M-0,9I!,U.5G5J15)]JF
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MLY35["2-+A=E>#>:/-#T07CZSFL7RTJY,RXN6<JTAZ\7&@O 8J,['P:.807
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M_(SL(B5-^X+60,//<6=XR6G6S%PIC:CSZ?,A>E>EZ19J-.99"S1DNL)'2^O
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M3;?WIS6HS2@R=I ,4+V4(J*^P(LM[*$M]N0!!5'BK4U1S?SA[90U;C8*T,V
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M7X,:/!V2V<"B5@R4.VO=YX0 ]"].;CQ6UY\!S+9B)S3/@.[ D_..-HN^^F=
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MRCI0FJNFK]VT//1IB&.6/B23]?B.Q$35$U]W"5AXKV$>+:JP+NQ6J428G+_
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MSY$%^W)_L+ T*,$P,_6&N[LL&^2\QMUM8C9O_7QD0=\D(RIU<Z1_ .+)I$A
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M=%8)7:<O+K3N41DJ_.7WDALU;O"V&,D6=N_$(F%]H$.YXGTQ,45MIV,PQ*J
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ME-HIT\6[#0@"PN^2+Y%1;O*UM97/G(II7AM\R3E#(["UXWVS;K'EAWXU%M*
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M2F,L'@6^.U$%MF?R:&)/$X.&[T+&QSII18CN-]V(Y4_+?D3KY;?8'.UW)\^
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M_,9)VC(LN#37TWKRJ]F-B991^":TF"68-A.=.\:YE&WM:YUY=DX,9PH?7^M
MQ'<5-/MJ\]$9BO![5<]G#.3\"P;2)8:V;\J#V_>[?!]Q9SQEG[]'X_)'>[E'
M&'G8Y/]"+0KRDVG)W$UB*")$&([L@$Q$.:E<WP(-\[H(>V]'HA;ZF:4*MMTC
MG_C )P 1]JH$HAIT"'.R#:_0.-0!7Q1919)/?"D0%;@>NJ.[%S=<M%(N:0,_
ME+J]&945]>-^'#[=2V/:F=&S"R.-3Z(-E_P4:1%'G_(+:D1E5(IIX]5ZXW'
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MP+'^OKO,#%0G0)=V0;X^9!8*;U!:P3PV$LE=_%4>/C4OK'17PR>.JBZ9:8N
M9VHK6 *[GVPA:+MHD_"1KL4'%WR@E_$N<L:DKC46+-:""9"]"%Q&NN0O)]&X
MV*,%C98X63O,[W7]K!DWF-AN;(PTY(;>S7#I@<?7;1\4C"_-&O86"J\UMSW
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MQ#VV&+=LX4=P(J8CYPG+J\"_YN*L^G-LY$[NL*:^7Y:U%6MK='I;,M;^D&3
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M@*KLJ+(/@-GNG7-=2KZ(L5FZ%D:FJ$Z+KZY&7;99+RG?1X#7OI?)#,HL9^G
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M$O2#/%QDNDBS"AE.^R57Y+#5*+3[]D6[9\P8FFX([Z;RIU9)!) 4 [D LR*
MAZ*DHZHX-T])(#<GU0B@B1]Z$0=98AM" !L9 W"DNRYM&T0[)?"^ [V^H0A
MF 5ZB*T+?QIZ\1L7]'++%@%XV-SU!Q=2$>3K:O?:8C=L;X-L)<0L?*@.?'^R
MA;M:?+9!?N2!Z&=2=I:;T/H?%%G#Y9 EYJ&2OLJ75[<A=T]*$-)-0PKEV$
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M+-V>YM88:?2ON"RVG1D?R4.(.DO,U1IJ0#%]IMA."W;RB77K\Y]25/C(GRO
M7#!6%,QM7'BPUA VJ8G+V.8ONL!+) K6U[;0-]4A'#IU;79T?T];=?^!]+I
M8DH$N$?")?F[![TIG+!JS%Y6L&/\X)V96GCJ2U^.0/5#9YT4*QR->#AN[SE5
M8X ]$W8/+C2LT%7C<,//KMY,QOD33X7\</JR6><KZBA2 +5Z0UA ]>8CVN$,
M%;7"=^?E92WHIC(2W0TU'J=OI/98+'8@'>--3L$2D7:E2%DAI6A-4"#DA>0_
MQ@7D;SVJB$R)/IGVB->E+1_:F"VS,)[0@#74L=QMLU9S&8.]T#?^OFQ1FW&W
M!&JD'I6\]R &8AH.M:/19;-9F)UK-V;UK..;B=V:C9Q>UFV]R$;:6DS&>4(
M'U %%Z[3(  !L45=# _P&4&D?JUXY&4<Y'\=3#]KYF5;NPG;AY@J0I>.)9XY
MG9!3Y=[9D=PIT4W,%X$#EJ +Z_O%(PW559%W<-Q=U<%S48[=SNF12@FK&Z]S
M_H=T\YM.R\<EY]:BY-+#L#.J>%+SD.1JW<,<\8SB+90W>]<EZLF'7A>V<,].
M!(!,^P>)SU]5BBAITDL9CI*4*ZI"@>LF"_?EJ+'7*DGS(_UXO6^+OP7,.>SQ
M42?YT?SHZF"4N\%8:JHF<:0.C_\IU99A(<&E^ )7M=*8[KB756CS*'4.QBNX
M*1] UC_V5^8]!,>"E5>1!LHAH.'J@__3\/<##<>IHX%,-J:+(4MHAXNK)AO4
MR1<7/T_FURX@;07GFUA8ZHE'P#*WQ$>]'5ZOKCA"N &'*HHO;UW4A/]/&F=P
MT>7UFXK0&H5!5? _QD;?N!M&1N];M&0]5:@(GE1-N'SSDP-BYMO^5HH3I*E%
M:+@,^++=-JVI@;3SQCOT%@'\_*2,?PJ1'!M\24#J=8_:<4GKVHFZ]07DB(6.
M'#I,<_<-%+DD?CY"''IUL'(O[@99U?"'>S9HOWD1A/8W=6T;(\LV@MI=EPW&
M5T?I*.NE-29VCRXM*HGFCE>31,Y?38[[^37^3%S4K<R"^P<6"_$O':!OU_SV
M!!=KK8\M59O+T4:$9N:[U <;L?6:6VJ)D1--Y\<C!:IS-.[[($*F21!-A/0B
M3H\'U[^S[S.C@?,TIXUI#W)Q8/7]'^GX=&T-SH?[*='?@ELUJX)8E:Q<7,?+
MN8(JC$$#;MCF!A/3VA3TP]U<54^JCB.-?S23\5Z+&@GO#'[9&(\+?X;Y[-GJ
MZAY@,-+4M.Y!&-=4W"X0".AECM.%N#.<*+&W1(K>JU)4QVV^,6/4&&LLV=LK
M)$$^ZK8EPWZAWSMO7;L0P8BL2ZG)N)-=44HXHHW'U'CC%G$MHJN03'V8@MT$
M$/'PD3?EV)[FNUKBF? ^VLO"N$ ],?TMS/<Z';-XX$7(J<1*1XU4V8^3:_\#
MF=E64"Z[4H.^S]S JP%38&LSGZ'.<&F3@$1.]4%A7^!LF$P"K]@@!>=PD2G)
M>'R&!D;>3M62I[^*GFU5DH=^T9(HF5H;_51Y/4%6C==TLWZ"T#G;90G3)ZP4
M[XZ5+O#.? WDGM3QA:RL"7-#[^,*K28D).%B9XJZ,84+6::B&TG]M*T=@L.J
M3[/=O+$\XA16;.BKD3.3X]Y.D0J5,:\U<U#N99;>2W?;N_25@ @IHBUN2==.
MCK\481AZ6F]&?TI/LO;:^;<5#PYG(2O^3M-OD& 89Y;6_+2.I%W%-4:^,]B,
M3WLV1%)8,@.P,Z_M),?B?V2*NHO&E^_:2+@IX#X%JQU="EFD^[J6L$$T\&Z"
M;*7@H5.MJ*<%B;;JG.J>8Y.-U4Z"T:3!>0I61+/+T8$H/T&4=9&)M6E 9K?[
M?1TICG"RM:JNL^_\[8*MTVT:9P%H:7A"9BP'X9>&5.'>EXIHD0R6\'KT6K%S
MKNW?/9FXH_VOA#E+I*OQ_4_H^SRI]7C#^,#DDN762;3Q+V+?F-ATHKA$K2??
M[W>WC]:4$B5+@1P/)JP0G0HSCB4Z FPX)=G3<V0W1QWN/=ZB]\QQ]8-??:87
M@Y5T4X]G9>;>S9P"^3N7[UY3/Z_5S]0D!B2TZ+\Y1W<PH$-$I=(_O:H.%K<\
MO2(=/8P5QI72IYY8!2R&24(*[.<I*N-&6ET,Z[^_/-+HB$"V>8$*!#9T27=Q
M+0V^_Y4%@B;DNM6D7Z2A08^$@22EA<R! \G Y&BINM7MV$E_8SK,'10Q:W(N
MB]Q4T-?\A6?IX@/DD 38Q>GC6X3#_#W!'_B6JX=6F 48>\NK[7V_3]-KS7$:
M<'9Q/$#JYFN^,>V?^&R'829K]K5<"H\TX5*N>RXD"S#0G_?@:093G)0/M"[7
M"YG&J#IR=()CN*Q?KI5M/%)L!=T$UF8Z^4F/&\8QBYP)^GU"WDX)0K9.DJ2F
MSD[!NB?&5O7:E\I#LL#9TNM;(VR":^;]]<O2-A;QD]?3GS2U*GN4Y!K9]2<B
MD\IG9^^ZWVMY>UI.'D=DC'@MU)&*OGOC&Y5#+B&<1>U0[R)NNZ_U0[.,1.F^
M7M"2&!WY1U-@VQLD(X]F1K+2=L7\I4S<-KN=+.R)]).$M1>W\\"VN\ (BY#^
MTHZ9INM=DU1)/7[[C<,1:<*#@WU!F!YD7-R)O\"Z#@YA)&3%-REPSGYYG&^M
M+DE6^IM"ETJ'&/XUA,C)53'Q7?F8Q6IX&H=GA,BK;J&0^41CT(?X.B."2)/E
M NRKZ?7EF5>!4@5J=GT</#@ZDO+/TC^R#G\XX.IUE0VWBOLL$R[UM07V%B]=
MG^K' CD]*"U[FJ,UP?Y "?N+(O K3,<>MAIF91:8+#-RTDBP\\AFJE9CUD1S
MO\?7EM,Y.'QV@QPH7([MD34" H'%NGO"#6DY<]L?7T_/<M>(8?E71+!;(M\.
M]C6!H5GR40O93>V\[S:RN-90L%T&D?]5:]+CU-O>VOI@NMG2^'PZX\174/8E
M'XMKA#N:Y(:Z6A+34:COHMR+MCB"K\.?D80J;/<C9BE6H0_2C[C"-=ST#\O[
MEZ8^',KARR_828=\W947+:QM)QE/7-I#WG@U)N:JWJ0:K"PHG;QTWXEF$*V^
M+H"[SJ;#)N3;EROOKIQG&/Q*KD2T 9C6=:8]06S*N&'H>Z_QP*_O7&M>EZ1/
M2OM$W^_<[<P#K16N11N./SVCE*$[K^C"3\;"3*RN6%(Y6GW@R]Z0 5D:91I@
M%AW:] A]GM36$=<55*M(1[='=V#=>=XM-.$J#CA'W' U\.+-2-M^,*_K#5!R
MWS?L2SG1 82.;6R>45ZH"D2MQ]!FK/6G,^GYS@JQ[,I0>_7= YE06:5].]#)
MDA:E,(1X<!_LSI JUQ1'F_$E39/FURDQN99F%*-_$,@AHDN84"@PU@A:D:@M
M<7UC:=?)7+J)2U8=E.8^U+Q!';B58PSR.USPW(?I/B@LXF[#H8D>IMEZ\-BM
M\TOWL?<--=_IHLK$(3S[ZK9M75:A6-81=1"E @&$6_5(L ^ ^0L+ X$?ZB)D
MVVRZ,CFVQA;CRV:Q=#;]5"9(35/!:2BGW5U[KYH7R=T)]XV26O=PS/#9?>,D
M9X]Z2I$[C5L2JYK(WM??6;)529^#C8:RVEK7YX/;>/-LB@H]O3Z*UJ,N$[R\
MK7**+%W[3&MO]J;GWS%6X7HS5CT#+GTIB?A6U7)>B9(%P?%KDW<OXQ;83=FU
M'U%%Z$OU(,'/%4Q'#Y-BG%,O'!;DZMF(F7N?P9BD#&>EA$)PA!E-_U$METZ#
M%"FQ*(^T[@$:&:]2>.!4J5MQE/^1=! 6+U@=-[ GOD_'OF@$KJPJ/*[;NKRX
M?G3K28D 7N CZ2L<9>89+6,(D[:[/#,IU4G0F&V&Q..'0#XEM9T1S!NH);@I
MVU5%M@K8H?"D\60&(^/4 =?]N^SS]:0-KHJ@[-0X;='NGVJ7%T>#%W-%Z&[X
M2U>Y#%MJW?T+RDXA"QKZDV?@X]="I?,6+.<5X].L:$[#53U9/7YG44/5D^O"
MUN/"TKMN,(:3;ZO"*2L\=&8&LF<6W-,Y"97#\2W$F="4?3KY=E06EBH*,'F.
M-0<,1CCDR-N8J7/IP[T--5$JV+OX!LI=@O&1UL<7L,NU!=NLS0@%HK(9\#2)
M:(*^&-<5YUM/KB*CN5C)F5P(MM04>F?/RMJ=Y9B^PZ6MKPOJ46<7[%CZ0@2Q
MPV.LN+,8VRM- E%KM2:<W>]NHRL?:N7WD [8+-[DLWMVKVZ$MUO,79B>*0 O
MOK4S8;EBU=<P-KPT7*9WM4&:N9I0$0>L:AH_<5LH=4F]+W]4L@VQ$)]M?L/N
MX=/416640-(3L[1>>89?Z;O?1>-E*4"U'UCTF))GD9</L.-#^:&3+"U*QNSW
MB3M> E=HG!DSP&R#C7G\L2^@'V:%WB_N> A?W^?]I#733A;C6(G9E67UD.71
M$?EM7F-&"H[0L!!.GH:>='J)] /-E\BUW0U\JYBK$0)A?$1- QI#"O=-"1MH
MY53G99\W?HA['Q2M.]<5F+Z*K<F88+=>^^P? <BP8G)C3"(#Q7\KLX!E".86
MG&$$WI[3,D!D<53*,R%Q^GI43=CHL%$^\'A^16G4GEG;(E;HP;QL#=>[P3UR
MZP/M-7P@D"TMR/6UMJQ1H2N).SY2J^RR^_L)A2/F]GZO=F;?5C,4YZBNMVR:
MY K\35O*>VYJN?.T]9]X>2),*WEUQ'Y8Q$%*/7RZ#>C6O_/M::OL>[#$*S,Z
M6X-T_>%.V./^V0 !Q"._;-%KIG!U[ .I*B^&%:L7H)P;!=#)U4H3W4$82BQ3
M6],KOK@]7);4:$WGF[(HEB#EJ ']H/'WX=D7E>K#!:?H$GYD:O?J<<?UFARZ
M!S3J<7Q49^0J2BO'R@4MZ5R[F; #1VK)^P:BA%8CV$,RBZDLY!<6ZVPVYYU'
M(^41@.3Q:SN?'Z/8-M#[P,+,"NO!)N5YV\**="B1OLC[.V?,30[.O3'_0)=\
M1T-\E>2PX4?T/H1Q;PCV.-*,< W@^PZ1F91=(-IZ,*/I3'\H:3XL<\[^J!5K
M]>86T*(G%@IR20#L^8Y";TX&(0<!C1U!3IUP%^-?;] ZBU]V-WH]PJ(?,FY6
M0A_-QZ+OD3*+C;TOS[=1))P3)_%M^4! D('Y?>"<Q?+GOHC9_> 2(B;II9(8
M85?;0&"+?87R<BL%NO 0&@R&/T1" ,Q<.-?+ED>Y28\%$,!,-/-3-..V>_Q?
MR!B[BKPI*]8@&?H+IA^9Y22.AQEE?6$O/ME7"E8U=WT(PI'G7TE)P0Y" "UO
M(6N9O[>9J^HH "X,AE_$WYAQOAAU>^WNH#?Z) 2];84ENH\M5J\[,E2\%3-$
MSM#TS&6_!&I7$;2NGE&-G;^;1X%\J=Y,R:XCX32@ 6P=K9"M?/1,/G^* $C8
M5\AN;T$_'VF:F<GM5U):5L+[T;SD-FYY;<),T@?30&2#5(S,8+C;\6.%B^PL
M./1U]/I3]J!=04_,9"]?&I>@0=3Z) XX_(\O-#^*.3_YU>3"4.KQ2.IQ#_ZY
M_WPZ)!#8X''JO;X"WQ[Q7@R5=>@N_-X=-0+TH(2I?W>ZQ  Q%/J3>>'GUVYN
MIF#;&@4U-OXN8U(APS\^WBPMU8.____C-RDHU1SY)F9JZT+., I@K.R*D<C/
M<_AV]K0)/G_=L]B_O]B-UR#,P1F8LPR]Q#]-OCKZE56K,8P 5A\:(@"MAPA
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MY-9N.S >O3[2,;BMV$I6R4L8\$ 5RL-F@&+_003NU'63#4J'=TP@@$WS& 0
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MY;=UR"WK\QCM#J75;OA5&.?^G8Q[2>5IJ+<!M8W17(PTKYGK6_>V18GH)C_
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M\!"H^3LA]Y_#\@]"K;_@_'_4PM#_+1P%AG;A65XA@-_16DHAM'GA&"4>WG@
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MST+VWL58$;MH-]\*%[!M8E5OC(T^8+IQX/;F;>73$7EI;MGOOJ3<\_@( (8
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MC9:)\@Y8'#FO@IA(@2T\ESJQI,B9DAS_8STJ1'=<HX6^(/_;M6J6;7M],=]
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M!\N5<].95!1_$R$W1#"[$=GN3Z'R/KE5>\#6,T=#WIJ<1JT\RLP^YSWA=O0
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MO5>$-Q76)O4+$ZK)RR@F*)+:A&+X<:6\M#H""+P)<VB)DY\^]8Q0L2>Z2:,
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MF+!FR6VU;QGDR&R8???;2 (F=J%GH9[]Y^X7\_,GBW_IU%@^5/0VR+>&)*C
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MHXJXAEY^,@D[L1CY^QB@:$THQ4OKY?#%#=F[K*5H/!P,0)N!@\=W\6A#+$]
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M3>R(8D[?9]6S][]G7+,6#5^^]*[-Z_+WF_IMV"-/?<MS[NSL_ZH1 A%3]\$
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M/*V(W0[W$!I)2B85__@KRIS,KJ!M=0,KZE,=Z]V^D_"$0*K1*^1M:1!NT;-
M=5A/BI! A[=VQ29]')P4M.A@+<-<N9MD,*-O:& ='@UC?[W7R;X7&*(J2(/#
MN"<K+E*\<]2A7O9Y*[NF\@/YK*6Z9:VV E_-3K<2_NPF']G*E#P-+!?+RZV
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M_ MP]P=6 'U<I?HE./#?I.#_TO+#3/P/4$L#!!0    ( !V(?U:;R)\["E@
M 'Y<   0    9F]R;3$P+6M?,# U+FIP9YR[!5@;_=<F' A6G.(4+10H6JQH
MD%*\N#O%(<7=I5@I3H'B% A2".Y2W(H6">[N#L&7]I%W__OMOM=^.UR3'&9^
MDUPG<^2^SSGS,/6P!,"5E921!" @( ",'O\ #[, <0 Z*BH:*@HZ&AH:!CHZ
M!C8)+C86%C8%(1$>"2W5"[KG5,]IZ)EYV>E?<K^D>?Y*C(.;7U!86/@%VUL9
M<2%I7I"PX.\/04#'P,#&PB;'Q2479'S.*/C_>WMH!>"A(60AQ ,1G@,0\1"
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MF<U\:*647:7@""]=8;]"9;]S,=Q4$,SB'CM@']%@';[UECF'YMY\/B/\Y/0
MH.+TL4*@(% 6?;Q;$JVHRN?Y\ _&/E*30WGLRM$Z0V,']%$W*EJYK:=B?#RY
MOJ34@BQC%!,$B31J+O3U?2X>K)J\Q+&=@.%#$LSPU5O55>9TI8YO[IY;>OIS
MIC(LWF%)]?25B)E13;K?W4,.5A6.^ASL\CZ^&.AU:*00Y1EU]U*1-Q2M:H[L
M3Q2KJU7J"'S9@!H*K6*EW6,"-OE?G<0.!)T/&L%!N;^\Q0K=#32PR*@$YC*P
MQX88@15('V/L?:0(S4&R.]0$PLNSM!"-.\L=$<HO"/W>JC [J@Z\*<D;@P/]
M'+MG_CM,P^WI^ME'>AHKU-[)I%H9FSQ)T+<-EYURH)?#UZ T+&:$J5@8!.Z(
MI.,*L180<VU3.P>"MH"_5F"KYAAT9J ;=1OT'6*O47(G>X>4;+YK3[(-%U9W
M=R?)YG'OCUP8<0592Z9G@U:$!QP4L,H5+*ZW-4\-YW)]36PDAED4R=$+TY9;
MFCB1[5.H0MA<P&'>8BO:D0.#H8%3F8G4'J2$\_':D1Z?'PT-X7%'[+DO]UL@
M',%.&/Y'^@*H-CAPL+'BWB3YA.'HOF2>#V*.A"?YL% 2O]:HL&EH23"* /;U
MM=TQ(CP <&X-'59NGO4=&$71(FWP3+F_GYI\;Z!_5-%U*[)" >[8IW% S%F[
MCAWT=.^1!;@0)$.R$)NB%O;TO;V23!#+WRBMCJ.?6VUHL:XG-T@&1R\Q=WDS
MOG&?Z>CD]%Z<2>*2%,'^@K!_GL![&Q'S )C$UVEF9C*\(J5Y#'OT:9X!!<QD
M-_<BE#6ALET_'CVFIU!43() %<!3:?( H'2X8R:#Z&O(.>.%M:FO<B/4^%QK
M/CF6O10 E81BK/BH+)O,X AR]5UKRC; [#&%,IHF,ZJ@*X;A*HN,\Q:0KG*9
M-=1#^ A*9M2^B1V23^*@:SJ'BG0:MIBA[-@OGOY(Q3<5/TY)/,H"6RE#O^4;
MZ+*>)W05V3.\:;J9Y#FZ7@^)=( ,^'GD#YF(O#L6I9C_44[GKIWD?DYAO35A
MHR@8O:ZEIH3R"\;:;X,0I<")["$25I)]3%2YHB_QGE/"Q&I-(C9-Q)&YOBZ=
MU2:O+K:F6+DR_HRP&RX[_0!8QH"QSROLGM*%<\1)\65A7[;-1%:Z2[T;:(N>
MGJ1+.XVR/FAF<;0*5^[P/?>D\EQI0OQYCU'1UB??UASEJ9%7-M#@,-.)P_.*
MZU 3V8-:T/2W<W[^[9Q/?:P;%N:?^U<<1SE-J>;X\8@?S#>F;4+EYH0:HA[3
M!T!9@L ?%4GSA=M2*M1/=;ST[,X8_"Q]^75TG21_[WE)E0N5CEM(MRT/^_4>
MLUHSK'5]S_>IMFSXS 7$I6 P2LR1P(?92>&(Z%.VX@M8O*U1\IB=7H2F@H3C
M]:/V+E1$BU;%!:S0GI]B:RE=??1)3EHJ7\; IB4] MPV-1),"Z&PNDS*MM>9
M#OGPN$%M\QK[RH;+-Q[#U9[0^2]NUKS>Q0*OBGWD.D).%>JK735EC-\'"JZ&
MYSQ/:-IVL<$:>$?Z0O2GE'BLBNV31)-@)>T?@?4BH;Q[P4U<17;5C=4,?:>2
M0EW#'\Y+)CLKI^!^'<23%3TQL;A<?701"%<CJ!A+,2XBN-8+M#$10C_>@;=0
M/85>IAJ2P4.&WGTR>\^$,%+:["*"[8Q<<>22HT]O7D=OWMM&RH]8R3U%-+8J
M<68IK+W7@>NEA"I.474@.25#);LDY(-4[FXN\3Z:\P% 0KCGWKH*T(SV%FT\
M=;$1?*?!LFC+V>2^P]56)'_")2M[3EPX!I=T@SF;LK39VOA+B4\&M'797*\Y
M+92QQ\#!G34S*2]U!3OQ!FNS/M@[Z&[&9V2=@7J+C>:K>;O$G)QZ+."/$5?#
M\?%%%(/JNNL!X*XI*J IE,O,C->>EO)+7V?27RL"1Q8P4BHP[E#BK57S>0!E
M3/+C0(R%_V;^JG["1;V5Q7O0K_@P$S9'$++'H;\&.%+X4JM.Y<7X >F)YSYJ
MP%D6AJ,A%M?*9BH9D"@'7$7I'ZMO#V/ B?,/F&FZZ1Z"I3P 0DO58C]=X.^!
M*]^?ICGOBSZ#74?@9[&T/:OCX:_W]^M7O]W]VGIKV>US5X"X&.'"9]-$6]A/
MOD,NVFIT^;SI4+8VJAL'X>T D+N4>;.<)W_URA5NPS*R?&BA%3HF-&%(VLK*
M*B1(8&(5LL/]S#,@(,,2"'L;UA."N@7F_"=J5&)4E#,-Y%-6H\X>T$YF"=9&
MTYT7!3;?(?OP"!Q)F!CZ]<S>$W04#4FA%T7=)Q@P=[4H5M$6!WQZEI1/(?%F
MRO2+L@0 6"H2[#AI0..#T8D_XQYTE]+N\&/HD%0UZKO/;H$0#E2[<:1JWNM=
M");"!!NM>+VX*S="V^#JRVH"L!^695)MG+"Z1>SK_$GA!)-6 ;;"?'??Y?-G
MJH2=M2Q#.*J'9Z6B,;-6.DXDJ])+@5S!ROX "J;0D/.M6PFC21D\B055U)F$
MB3V=H#0]:#;7"0J.$HZB["IWH+/=)[+$=.H[6':@Y; Q^-=!59*57*LHUM0D
M<-5+,)*V4X>RJM<[-ZG/]6SXW8TJ]<XVLR362TAGU!(-*<FAIF2R->#9DTMZ
M?Z$'0,^DH=E1\&@(S0':IU<>=!F!5=PWKZN.BC7>OZZ8WN^I)U3MOB@S<!_N
M2&%:[;=Z-UH $MU.V8?\VI]Y22B'^%-T,Y^"$3@L3-Y0&_S:^:5@D8\8=/X]
MF3Q?PANIK^FHS1IP3:0GD!T=YS R7;E-S(5Z(4W-TN["O ()C)N)+=!.UCY=
MZZD=V4Y*L>==:2C4@BAV0?(;A#8&1T\3G#<5R?6NM@+;]$3II2L_BP\XL:GL
M<Z<?[GF!J1W'/DM\+Y/OJE^D\[5RG8!Z[4SE9M#,VCF=ALV.LRR'\WCB5KT$
M@3KY\F^,)1 -%>PPW#VGNMY[^5$P:5?Q: .Y.XL7,UFL!Z)C)5&R6CG9^VNB
M)#@C56C=?RIH[6*E:7>Y0_K^16.*BIQLZHG7VJ34,>)-_QC-V/C]R8FH/\Z[
M4^T+6%$>?%.QQO\#E5D'PB)A'\B:G1;6H4.BW3W3YXMVALZ8W8!#O=&DO_S,
M#U^7+FQC5JE&<+^$.!"ZY2/AT1+N+54()M(0QIW(LN11=OW,3/E4'34$=:&Y
M..).<))W11&X_8-^?._P($5ZHXI?E;3[P!-?]-G%"+2Y^!6[]*HZ<(LY9#QT
M6IC#ZK3OINZ %9W9SSMJ8B&X/9@<P '71#C&^M&U(H*Y\_E4AF+R"^X9]3DW
MPA8#Q-TB;-/JGJF#&)/F"P#50-XKPRG\F$<]:96G _,U/4GK( .S1,FF J%!
M?EY^L76*&EE-&NLF%6,'<$M"F1P 0D&VJ[N;OM9XLN-;Q:S7-22OFU6E+,'Y
M&XJCR.J_CXUUXU-1]Y$F1U_!7V&-D!U9M*JU7\S!NU"/B//IJ7:SNB]7M.\@
MS+I6R'QQO<-N@:_/M/\T@1317^BS)DQ(>26=?X][$6NN ZD8V#LONPEQ<W5M
M,2JOJ>+P$%83DZ72T[B %D]O)>[RK&7SS0=&"8['S785Z+)\CBA#UB5?B:IY
MIB(C:#DL  ]]8H<CY?Z=R\(^ZLE20(:$,^P4X[,6&X&1#%D9Z;"RNK<Z9)@]
MQ(5Q+:SL1(;<(E]<S1O'V47QR9204>5SCP^H0E&,>/42^A^E,Q3/(W M\CW+
M[\);3J<VIY10T]Q[JWO"O4%&".\W2+5<5R#PJ'WDJ%3GIBO><(?=(:8S'?>)
M'TS]9#(-(+9Q@**Y;355%X@'>@NRW+L)G<4E=^W+PO[L>J;9S<O(QR-I/EW4
M#9^O0;'):7:&S:BW3']C311$];/.*>BBJ-ZMLD30E4%;'=&(<568#R4JJ4_X
MM2D0^MG.I?SN(T3WRBV)S21..8Y687-7_T<H1"K;,O':V784+40[M9$RK^ER
M^:IA%&*()U<.M;,E(Z8S+1@VM#X'!T9R6+:BB])28+TG_G5@%Q8H+\LL*25!
MH)'XJO8K)?B1@H#PM[7JM@]UKKW#+XH^7BK@P&*BO%8HEFN.!F*_"6X(BJ+&
M*]URDQS]#'SEEC9.^=QPWY!4:WOM()PD15/O.&.ZR _G ;!&Z@IH_YPT ^(O
MYKD(+666 O9-5 U51IA.<AP#Q7S\VI-P)0<J.FZVVB^9>PG'2FE35#C1A#[J
M9H@-N]/JRKNUP]R GTP,F=3O=]F1-*Z,OFNE,:[%CZ"?'F)DPB6%? K@EN4W
M/%N\KFO'@9X!NB*XU;^RW77\6#8V]CQPJ842;;G@2JB@93#-2BG53@9]>O+^
M7NX-Z!MJE$#*69,MX<<E*/$-L!VFP8*:@N^=ZV;2Q],B2NFWA#GM7M1YK7U5
M,_=)W'.SVL676N28377[>?S5),/RQ[5;U6-RVMCG1?%;X,)CKB^_<NWMU0)Q
M("KS"-VWO.Z'M^HKX*6OYG7HPH$-LYEP>(P)^23-D;NMOJWY^EHC/VVSRZ7(
M\2-5TTE'&9N*>G0:L=^H'!M-^ [,U5$;X&U1.)VT\[W5X@>SLF? 6*R>S7[/
MA<AG8C7E,NX0?FQW(94O-I2^/;9/A7_]S-2H.G]]3G<_<WP.+>B0,,HPN5P[
MR]_-V5L0',U7;&;DR(10HGTJ9:]FM:G\G/PZSP>9X?.<KGN21)VOYL!L3V&Q
M;[^%BN*L%UM?:7K49#5%X??9&+PN@5JAJ.Q1$Q%9%P+ UU)A>!6Z58IZ+WF'
M=ZC[#@IX1%%VQ9=I-MF;F.6F_$);1<_3WU,)5<=BUF3SO%/WOLF\R7!Y+=)G
M]=-A&J(M@VO;6I0"?ZE*(EQFR;5Y1HTG:@\[A]G \"A2W#KFQXB;'?\!_Z'V
MT(5!OBT6F&&::V8Q;'9;2ZKP&K;WD:,&Q(QVS@.)8@OXA[OD+QI>!MOYH14C
M+8]?XX*=*1$H.%)>C^,(P./=*ZT%?/RO:GI))TG),YA'6$9>Y#(),&&+H)^R
M:G#Y>4!WV)X0[64S[,=X:N9LJU3-Z!=']EEV^]85T_A:;'A^K<IYDT8L?Z?-
M>E[76%97R]]97G%O7!<=)',ACWBI^,&VJLE9R)'_T" @"AQX%)[.M8(:5M5$
M*",[ES5,?@X=9CD,YAD:9\WXR)T5!6;HO.[480@M95_G0PMB!$T=(0,<'@"8
M TDS#X!//%;$=S:P+MM.[/:26P/2(VTZY[IHU)$-"-SDFX'E/:55J1G6BYNK
M>ZVMY(W,8]EIVR8LUZZR]RXQ7C&//[1\7MJV:S[=!N':';*Q>[9KM5S]%U-(
M1)#%MBX9=X9MJ!D-"2LBN2]B?6:8IKQ%KJ&L/_Z%),D%C_*.FOI\N##Z+Z/Q
M>R+=60+  &F%2',&EI6E@WY;;A?R-KU[GTI/'073IO^^REB;CJERVD?<#S<9
MUH-+76,X/90)F6RUW!=QZ\[7>,HR$EQ)TS]6HK+&*4E;+,9=!%_BO)*I=]JR
MME.47:].G1827'E2TH.W,!N3?_=-F;>_=,&33T>VED>X&4L1L^<N?P5DJ!)C
M ;YB] 'LAL>W'I@T34"EYJ+68N&PT, ]Y*30;*>!)."@HU>\]@)!5TNX2Y%X
M/_%3BZEQ*3F]A>+Q!.D+&9\>\Y>6!!J;B?943_?,:N\'CUFS8X53[85@%-X5
M'K=,P;?E[J<KV)DV'W;I,R&2M9R]V.(<:^AG6 :]U@*@B8R1!>=W651Z#GJA
M[8MH^NZZ\HWW(T%2+MS-8L,_!91075ORK1V65%X.6S^# #SNDV\R(ZYSK2Y-
M*S7MH';PE64;H1=>]DL);_L0R^Q:J^']1D='DQH1+RZ!$&MON0_N&*I]W29=
MQ)5U,"A)"XJQ\G+R.H596BW/^%S:O,QYL6(P+ITP9JT9R6*_#]AV\UZ8[GH<
M&LFL+1_[2X)0\G<X>$4A!:OWP[,:++ 4R.F$Y ;:=P 9CDJR'NF6D-"WO/$O
M_F*I+;)%3JIQ)]PYZK\*\FK?V06LG#0Q6PI5!)5H\>K!I*)_Z$M)FK1#6_OV
M];.4/E>+ LD!KY@CX)'M5LF[%\'%#,_>]!B0%64P)Y_7S[QU(LM48I(-7[P'
MK3X [/V8$JNED*I,"K+#D6BVM2AYJJ-.V\ERV2 ],8,!.R@2=BDY1=^2I)LE
MEJHP47R_(&Q"B[EN<652UI[,X"'&SE?ZXRRK_R#7]@GM'/[PZ\J&L"$N(R@*
MC A36L1@9?%?/S>* /G:3BS"#5X8DNSD,@KB 6SO!,PA_6I1 X)5]+=1$S]6
M?;#>9^35DM_O_T@(\LR$@H:H'^EH!&-V."#<]:4=\\?>-Q+R])7D!G@VTK48
M3[9W1U-^7<56^2VHY!\3=KX8KX [;V%E<I0*I;D!^8OSF:WF#CJ4U$U\APW%
MS?L5%X\V-J3H0*U<'" 9!IYQ=V.-U(X:E=><)H"5G/$/L-EVU1EV!-:+Z%8U
M8;2Z&ZE@&UV2]OV>T2 H75.HAL'H%\C=ZC<A]-,6O$]-(L=<"I,;-BD^*SXI
M&A2$C>;-N#"JS[?"&2^.UF%I/>"R^6>>K];(QI=>!ZCP F,\2C!6F/UL#+<-
M"#Y%)[N]2OE B63MZ*3CA\,SO*^(S0H=(VP>^Q2XK'7",9)94)R)GG]+]YC6
M_' S4Q9&?!+G+OAV) !N-<<LN%+HF'36A+[^QO4MG]"'E_3?,L6] ?IS+31\
M[SR.OOUT77KG57N2]>16J)\AU/E" ^F9<QMJ5$+/K6;]ZVN6V((Y6]J3^V00
M^-L1%27JJ-3=*\*^6Y.OD(1<ON&T-J<MQY?9V[-?#[PYK#_<\N;K5MJ^M,VA
MW59>].M9G9A_B>FIGF8S8:3DQP3Q>0!01<-5:&*4)0@ H5G%.)16FKPSKID\
MU95#)G[)FB5<NIO5X!G,F?S1/.6-R.1F]*%@"67;$*M/Z]NPW;("O("JBQ)#
M"3_V%>RB9VE<64P@"5?W/>90?QMX$9LD%RKE^5,-&8_4]W</ *N-5,&$;85<
M"%2!QJJ.=(@_7UD4F:=!M3 _-AQP>DC637/\  @^,/DI?<+)]3$B6ESCGF6
MYHBUUUCRBE!2\%3=E_:V83@D5\CX#&LA :=;-T01>WH&@#ZG5Z+H$"Z_-?BR
M:)"=*_N(L,IU :=,:_)9#M*=O%;]QO)]M4F'/6MMZ%ZVPF?<>W6#1X^EVI7Y
MP-0P[IOKK"RAC/ OOT@;+G@ 3+Z_+<PIN!YKXKUO5'YDH!U7&K%PDH;4'LAC
M$L";\"NG\<;J%UBZ))]\/U,?325:Z6ZN_8P_^&.$&S6,2U-*@7"F2KO9U,G,
M5I%?[/;[H,76:/(9F/^K495HYL_2:Z7J2LX"Z.O07](OK<-PQU4E*\59;'Z-
M%_9\(V2S/!2E!.82^6B,=?CCD5D?,M(Y9GE&RYX- V\G/?LS=/??VAX&S-3-
M8CR!WG/O?%A60S.0H,R*:M'9]7WV]-IF+3+.8/F3R?BI=M_-UGYNR_2.B'B5
MW[G-63'^..S4I_N:K!TD;RC^Z<GODEMV."."ZF%IGH1CG-7*XHJS[&Q3?>A7
MP!:6BZ6PR_D<L\E>&7>_H&2>!#D'>71WMG*CE 3FVX)ZW>_ENMIOKGE&L?/H
MJ2#&MZ $TZ,FZ?RO<X6WNUGC2GWY0]\Y97%1E_5:.IQJ)3->+R>Z(OERIU3]
MRN7ID)N@2& 0];&2)T&IXAMF/!ZHA!/KU$TX;_75PK(YWB'<5)@ ;C1-CF[>
M"A '[=O,=_0SGIKR#[,.@JVO*3-+M9^!9.<M0NUM\LLING1K:\-A"WPT2N7=
MW]2P6Y60YNN*]UT7!)M1KI\XE2\9V7MLZZ@KJJHX-U8KQ[TW$J$5)5_L$/S$
MYHUELN&'8#DYA2@ZZ$1%.I7T:]6@E ]X6O)Y62WL_DDPT"PG1>+]EJ-[,4X$
MFL$#0&P&@W=&#9GBBL"@2\+:4S\NH2) ]Q!MG.IGI5W+ZJ/!HL,^W^F8&NT3
MQO]Q)3$Z F4)  VTB!U^&KVMU9/UN[=TJ@@!O/,RK[."PW/0R,VQP?4@"8>4
MAK![ZNVH+!1GFNB"XIT/S0H#M)5Q!\G3T;(^7,W"57R!C]CRO3SHI9.\21<B
M'WNX=?N85!TM7H=O\.)-#@B,OW);))S_K9/*D6-!LYS<:%+F6(64_DBMY/.7
M<#4WX7 <^KH6RCD)CU*XO=2II$ULP#DA_B\*/C//@O-F&E>KU]\%T'I.OO.*
M')\RP*KV1.5(")S1F#D??</T>H(UPOSP]6WO5G:X:3"!LBA@1[CJ 8#U "C]
MTW92:QOWL;I_]@ P_,M;BJ1O,;$&'+1\7]5Z96(L=*>[6IQ !V"V/[BR%DWX
M.:C6M?J7S:LHODN-?VRO9!T.V9MVBF8!9BKK\FWK'0:$"1-6]?"1K%8[2X9Y
M,[I,?/\YWX/]I>J+>4%GN+8*R8P,FKIR(MU9GJZ^N!MQJMWSWM!OJK':PISU
M-^PA[.28<4$FN]J&F/.*(8$E[C&;##RIZ7G9+BR"[FZZE>7TA<M\JIW$!@RZ
M24]354D_URI4+89D^;4+=&)7\IY"]SW"M]R"R(UIAY?U+CL0%8-;]HO\!$IT
M?ZYWW(T:%.Q1!=E]*^8:A^UE[CRB6H;"ZPERFM_9_;?OF#P M%H.T1<1RVC_
MDK9090%1[[_JN<V 8XX SUDEM-XG;I_@V(++WR>(R*[=DHN.5R=L^8XX@ICY
MO672G3,/S)NQR\C35(.YL9T4H-@2955?JD+\,<=Y+>ZP_:XW%G]""C80EF(5
MW^12_?3G,PRRN']9U/0 &%[+'"KP%J^;7S7$GB4D(4:H5/6F=CWAJ>/U/6#>
M0 <Q4>'UUHH05^EZT"(;JW2 !N7F1E.:%V.WO]Z!*?\4WU$90+O/?TL% Z7_
MW_95SV_N*(H?'[[:I'X3C;\U^;(C&1U_#USJN>;M*)0:R719$+6$"')25ET6
ML$\9K_5*=]]7+(BM"/=$1"AD&G)E?<'*/2(=FM)[3-1(&9!W5R$](];$1ES*
M4^).V'&K$)-.C^',,.#!"Q!<34GN3V1-U]*1A5JV[?5G\)@4W/*/TT7*)MM<
MV@BG@P=TG"=NU7,8;8[$;9XZW#+4E<JFV.V+A#C5F<1;.BH6$*[^0,\P*= M
M,Z+U"D;R"D\ZE/!(7=XN6"'WTKM^@_SD*>,6 7IW_:-JR<+5U51S5&):DR+'
MQX_F+@6<"_^;N?V&:IG++>?7T7>N5#^_/J8!D0Z_WV6F_3OF1[N6/%>"M:SA
MN#P ]*)/BLY5E95F?-IC8TSXBS.ZQEQ3SE_Y4E'!(2O\][2WN_DEJLO+PZ':
M7BS#T4,-;;)4Z#R=#P R@^P1R]SO_$-2*P2A-T0D0/)!@1)4AY32)4R=_H+M
MJ9YX:K[K<+?H5)>A>!1[RC55[N4+D; DW)"9RME"VDG"H4?.X3094B=BL7!X
M\-K;=%V(PUV])BY!LS6\?(OI>QU"Y=6X'RYI4D<K"JWS3VS!B+.B>R)UN9?J
MD@0BP+'PK>@9"^8Q]"17FY;KFFNRMD/=X7OHCY RQ041':(>8J6_&LW_VO.C
M%6^N_I=!*^JL>8."CZ,JBEI_WOZ [^J[@J,JA34[O:H,$PR0S2GS8=FZ.7DA
MY2DG@GBPQ+@ M=B!X*PT9;'M=RB4YTGTM19WA7=QIO3;JRQ%41.%X:<V;XZS
MX!",P-?'I,+)^\HJ&E(:Q#C[]4FF4P^ H-X1??>0&75F3L.G'5/CC@E-\,6G
MTO6XND]_],"@WD+ ^Z>+A$[#,SLAJ:G14;P?W/%T<9$%226F1>K.$1Z3'O'B
M,?R\1$2G]T]GZ3LG\Z]'2$,96//!;_67<$+$OU:NA+113Q4&O$/\J=#G&)0I
MEK(;Z>B'V\U-8-MN-CS&0RA,Y+PL$HV?[Q\:^)H"/3RQ:"KFP[>VWBF.*_7P
M7*<^G7<NW&.%><FTTB547?T7A_A36AEJDH?PE<;X+@?5!T#NK>S;GNLBI[2;
M:S6U":W]-F'M>E?Y3\MFNHM @VDN0K07$0'C+J5,1V8-T%L.YY/#5SA.'PW*
MERT[!8:J(?'!;BP<XXC\)8KW>()VV.XUS.X6'F^AFT\7ZK=EG]$UIMO7PBS8
M=C9+\^<?S;GVCSG7Q!]$9Q7K9L+A\;LZE.)_SPXPDF#G["H>+5[?2=TW^LD:
M_<\QO/8,2GO$\6R"L/T)ZUK$F=ES2%[+G(CL8*3M(\3!F8-4WV6M&]49X93R
M3*&O>C_U3I?3JK2E(T8^ F&YBD,E0%$1Q@;3U6N"U2_8K:U 3$.JGX]1V&Y=
M(#K(;+3(TUXXGCR+\"3XYKLF"GI5O&&Q-R+IQR!X3[S=U4;FZI$*J_ :MDF]
MX:;>W;-3D/LVGWB3'\<B[I#S+L\.U#Z9L@E6&RKYO!Z8%7^MP1Z9)IW";_RZ
M^N=3$-A-;'7_XZB);H?5;91U46*09N'W!\"?R'Q(!;43^6/>!U9I8O]=IS2D
MKN_)YQ5CFVW6ED&XIKFG)GY!/$YG$3W5R>ASK+?77*4817$G%C:R JI.M]L=
M$.U>5IIM.7G;+X"YR2^[J9EJS1.J@#;W<*Z15?+)@KF^=9V?F]F%(A"/]82R
MEB.%?.&YVHPAKKXE&"';7K0< @-&?W/2@NZ1[?CQ9EB0B36G% WPFS$_3\*R
M!6\F*<\G_YGG824@Z\7 DG;XL,K"JTD-Y=Z/XP@?M1=QS&\4.P<=/Y@X9H#X
MH?C-459CZT[ZR;O4OM71?X"&+BW$Y#><OR>TX#!XC&6 ,\(_3=38.V:21]'L
M3S^5$=%)KZ63Y@% 4-QR6'I:DL,3O$JH>51]L82FU4>Z)_'NPGS*S;K<U^R.
M;E.VYC"LYZ1H(G)9TTJ(UWC \9WXE<8@WYZ\F76D1U0N)"_%W)ALE5OB1C.:
M1RXG\>3+\XR.<4W33?2>$4V:):=-O9U+DNZ;^,ERPJ<3.24A7S;9:1(7MS*?
MVA+^4'8 ,!](Z7S[3E7MON+Z:&*4Y7G#;V2*%A@-*]PK)9L4$U+$GU$I>:F_
MH/0+<_D<<K--9_GCZR"C%5W3$.1((',>A"R\] !P_H_IA+\;H&#QG__W!G_6
MO:9:B%;<NM+$YK!*\8$2$E R 0X?@1]?%$4A*,?J?]W5'IO=<%GE3O$9);="
M@^3)SIJ8GZ% ]QQ?%'9;6MO>>GS79^?H#A3*Z*ZZM;.>-""KFQ)V+UNZ-DF;
MP$$(X$Z![#K0)='A"A@YET1K?1X:?61=_&'1HY6RQQ8^,HXKM.NF]I.UXJK-
M1VWFB\]\EJ=B!";-LAU>'-ZY\6P:8&?N&U"7U7XYN.&L0_<$9F0WXXO?7#[F
MKXR-[Q\W@I)+S!2G95_MM7"I/P F:D=@6'_;?)%0V7\?Q:U*>/5#^X\W$NP5
M,2&BER4#9R5275*]QRB1SHOVLJJ40>-J4SOM@FK@!@O=Z$T%@A%W@IW*+SKB
MHXDIB@0(22NDWNDHQY<VG5*9[66W5!]Z6G\6?^7,H?3:;+:$CRI3!1^T41/K
MYX!.-80$;2[LL*?; D4<$89MF7F+?TA]>-$?<NX7N_$#M=[L."]WB+^FPG3M
MQ-X2KM:]VGW=W&L8V]9&P962_R$:<BL]KF:*'"A>>]-!L:NX=,SJY7TCBCQU
M?)XOIW]#MO)45D7_@^<(Z.\1 N1_S#]%[/\T@X/4Z5(\[TN8^:8Q\IHDRH]I
M[+MGA=WH01*,]K90SGB[4=XS61@Y-O<(6G(:5Z]\AAJ^590$]Z-_ &!VM\RY
M&L(:PE/\T+D[BS22"JK(&'G,D<%]1,_X<TW\"V1NBU+@/OA8SU?,M[GW6J\C
M8*7A)3J3'6Z5]+QH0UR'RNX"TS9-');^+O(]PODI@[>6.Y&KH7:-7$V>J2Q0
M=L]G'A.5^RE=O]:(%8OT41X V@(FE!,3\!^3^P:D30JY-"()#@:8>G#K#;L5
M<)"JC!\A156: :**5[[)N.I_CNG<[QO//0!Z!C)UQD_0"K+# 8S9X2C 1_IZ
MRWO?\IN^+H[^;T -*H0@I!(87C;@]_10S9X,H%A?,EI7*#4M_"('VW<"&Z>&
MN1HEF\)'H4FC!*?A34J1[X)^T)Y[.Z4?>K6V,'W:K+OGB3KUJXA5'D63C+BF
MT5-.7\H\;M[XJG@.U,F4G1?*= JA,:WA'4?R=;5'@_D_Q1SJ/NZ O2C/.>#*
M)<\UBQ>3UQ?P*XDR\=BRJ(U!7:+[*8?<BBV/<4U_T%3\VT+;ZC0/XZJ8%9V6
MR2)/^3><C,O[QA1GDWX%Z44J;8TT,]]/9)%_0(P7[/0!4/0(TO$O(Y5;?S.O
MWSN+WR[QW;+N*L1(ZM^X']KL*,R'(K+7__&2MEZE9U??UJ-$<P7M$5L1*+AC
MV =E?A@?-LG!N+7,*8@(B=1RIB:+*])Y!>;3(@_\B'I4!(0H!R7DCE0IBV5)
M,:SVS.?IZAPW> 4;^%:/ZC(DV1!8?"^@@CA2<M(;XFW91U_MQS%7&;QB(H*F
MJZL7M+DU"H7V2#@;AJ'L&IG]J#1KW4TSX8$<Q>#LC;<"DF+BYTZU%TFI>B>K
M"M4EO?-)><J/BMDO>#X!D8.";M(FQ@Q.SYX,G:F<@LA=BL&'\%O/:<*_4L";
MJ?5_,4[+ZI (Q.1?":!@77U-7)8NA?0->%+$0[!4W>3O,N.70*_F2^=$A6//
M3:2PRP4\'W0)K*<"O)[%*(C&3L*J]^$$EQ"^@BO7,, '=+ (DHOXAYQZ5#X<
M-;?>'P//H:"G[,P251&G8:$GQ3A4T@8SW8,X@Z#VR)8%THV&KV\Z;#^W?R\@
MORB&55KHS9<=Z\^:"D1068W9TKQ//X[M&:VC0I^9TX9[GI NN=?, R#=O)CG
MI5)S$?8D5$I89KL[17GO74L/U4['2CVK"3:2<4L91Q.8+><'31^-?.MO>*.+
MU_!%#U<2]7EYB8*MZ?48_V^.^G]G\BCA6.:HA,4!-L? =QD*3[5^OKPLZ=5\
MMC**WZ5#6P[P"#(]*^GS4%:FF!$H1S_;;J$!)\!#11*6\Z*1DDW52:XGU?4,
M.S4L MOGG#;T&)EW!U\V2H1@&31Y1R7)8=CEZ@*#U<-,+\C5:#M3Z&4? -:S
MMD,B,.SJ/G##CV]Y[BG="W+##/+.:GB2""R*).^WE8:SMK97T]_PE 5)IEA]
M830 >J["H*S8'C^L:C>&[G@P> ,8= M2& 35.S#QMS-UNG]5^_"PV[%BG0E[
MZ;VF7>R[1C^MHY3G;6\ Y<' <K-MSV4R&V:C))Q]<<9H3WDH9'7!QN7ZL@M6
M>KVY;L,0G5_<,EN*G3:9XEJ@(<^->D-4>,F-\K%-=^:+57T=.0SIX&[T&$_T
MG8:TU91T?\:_?E2 U@, QG[3WH P6@__5_1_6F\8EOR(UW44+R>O)M47ZDNI
M  OX#72. !$%:R9OENWV1LWHPM+<3/@7G8R6!L-US5#9WJ-&XJ/YSQQT5^+Q
M.E?Y5,&DZAJI!L:C^.$Z;Y@BA@0UP@P>OT$A[(0ZHA%AZJ*DA8K'T=/I\V(8
M<04BAQV:@>!&PR]M<;7%Y(FPAO5H4P_4'D<3,KUP82,MC<L.D@EN5KJH4HSR
MZXT*7P&Q2"[%YN&YV'BKPXSS$3CVN+85&9U8K6T5:YHG;&OS1Z)@>/<?B@!-
M^>O]EDGYA2=CMC]P1&,PZ=:CYZS8Y!\IZ\D@=Q3.:*8\7Q? X?[) R FL4SP
M+FOR?<JJT.LN(3#T>1K#3]<+5%@CK;;JU$[78SC]_D;H,QF12;!RG'54.G3[
MNN0!4#[' GFB 3C!DEIY%@#^IC^@Q38U3%\W2-O..6=)U)"1ZGCA-L!+9! 9
MGR'!7Y,>L_4KGTE!U176.W&L=7HKGSU;UON4^+;0AN=9NH5J_:B+F;0Q_TFV
M:@BU6V^QKN[^F]WN!I\?4 29_2^12]X5%LUN2I87KR\C/<@!"HN='MT^C'D'
ML^RDV-+M.+7BPY QNM .FQ?!ZYV:=@4>,B]CTHR.A!,L],<S5<KK:MA,ZX.Z
M*#IIPF^7KF\FO>[BS=;1?@S]T(H?!-ZUZ Q,<O?S[>?61TT364'>[*&RB*WR
M?.=[]XGMP)LWBSNVN\:-;1JOGR;>'<A Z"0[KE *T=UA"<#LJRO8 SM>RE5.
MT$2R4S\-)M6[6$T9O.$F,MR"'8>M1 <KCZ"+LEL_W@)TQNP __\$;GG_@>I&
M18!XS6+;$BB5P"!XZ&,4;. _O @(WT\Z8!C1)#Y^S"8"RATOVI?N>:9FA7<M
M4R=018(M<#ZE3R3=@'AW9,'!Q\T[T;A;1RQFTV:8;9+25+('E>.3Q&:XX\+/
M]0=\S6HB&(>IR9BLBR5QYFWMLBWD7G_.6]#O\'&P((_O%)9ZWULXE&YYJ>@\
M0I.^>C)]W&<H6_%R(E\\]L""@E@>; F5SS4GH?*VBB)LEE ;8?T688W70X(V
MB57O17X._=D[<G]W>>=-5G#+@EQU=!"?-W2IX8HGSH&ZJ3P,LL[W7/A=K.7Y
M.#?N_[L:_WM_A#3%AI?!SD"(T_&_(H"FV)!(L@)N?:YGZF%ZJBM9 .8H;@"-
MONKE((]NSY,]MAR-KWY[^Y,2PWB!N))N+0BQUBEB$K1DDHFINUDC>KN;Q9"B
M[$DS.5IT3MW07%L1.E2?;!S-UT^.F9% G: CPJ&@%A$H.$FQ.C(YMCWS&% U
MG5ZC4=@+CN.+E<(E7UOF^D@ITB)R7:[>>H4G\;I&A;U7^T8\6+0EOY1(+'!1
MZTQL:SY[I6D3L5+G%S+6XV3F]6I%AN'%Z;BF@[KB,A$_CWX)3.KKK>.;>[+*
M]CCA7X'SP<X+Y+6O[;?*N%!>FO11!9O=&NO?HS%QQ#M0<IU#YWED]:TLI^98
M_/FNT4<92$=@/)>WOB++NL#F/Q!P5%3S-_P%(7^8]NM)\Y/M_E<"E%EEK:E&
M\H22*Z&2Y@90=<K+B'7#VZ@?$?"2)MYWW4CF%>2,;)DGKC]TR8\S)F9=BK>W
M739<C?>NZ&JLR$L[2:>=N6LTVNH35(_H&[ $YFV<=]V)_6,#KC4Y5BK8FV1R
MMSLV9N[!"%O,%4J( 0HB^(2&KD&T"WO^,^UCQ1MTG 6MCOR(>01[Z!R:-3WT
MS5W%I7A^O=Q^D^KW+D7:!L\?HXGU ^#Q/^?5!J"\\,H=\C]0;D:QKN4?=A^#
M][<Q8/Z9OK:[\\UYQ$DMD%<N5#I^(8_7[XB<SU[_;E%$[F 1D U@J_9<FU@+
M(,0))=6\IP;^$(!EAI3&*X_8V.)_$\7VD3!L#+"U,0L(>1LN=EN4>$2P,<_.
M;<7G)2-MZ )B%M3QS3>V=;>@6G>[&?J^H4@_H^W%%'^M^7()B6MVT=JN?VYH
M+E,4K-N5] "8OJ>L_V(_T*BYX_Z=#'DC=7G_:7OWP0%??KHXLDD_ON2I&)4;
M]J*;21%!]9"UP4M]0:JM]0? :!PVCO[\KL_7[T1MU)AICF#QZ,(7IEM^OC?W
M/[ TJR=+(.,YM75C"PND?;B-E H":VK75(N/8;IDHT0$ ZC\G\RG /#?$Q\<
M6:C'TT$+;OE?,1^C(=H@IB<YBQAY*[R(G(+F>;J$%$-.K9RV(RFTHZ3IJ)OZ
M_&OD+EO,GX[8;^7.L52E75^L?*UCJ /MUI  Z;]0K$0>.\A6U@RLL;6LF!RC
M3..\-,$S!@VZE'R;2/!GDD3CZ8&K56]^YDGM7E?OM/9-F ZGA4X="^_E4/81
MLE3MRE&TPY#"^/MM2/J*M%L? &1ZQO7,4-L'P/W3!\ >.%?Z X-\>1K%D-?2
M!8^KG$ER/:_KP0?P#&7FBC[?]G7 /)[]E$9;[YKJ6QD;Z,R;-#J-&TE%43["
M#OD\.HM.8^;&NID9->EG@PS]PPZJBX;S;+///B>"=W6?4[2UV3M\S-2QFIZ2
MRD718  #SWAB_\!'K>?@:&QW[4,3,>2!\$;,45)@G*#71"2^:AV,^ZM=R0C+
M8<P2)L+'<17$.P)E481_6-7_S*_61BDE^")&3<(!ZT(>9G0-;PS:'5Y\"50^
MHY"PW2;^J#0*+9G,+?^H8JC#NAX$&W6L>(E2'XUDP*WCLY'\\FJ/SHS\8E^[
MQ=4@W]A@#,>VW.\CJ:7PXC'EBOI5'(PB]QI_IJ'^D-7F-6M7IP,QG_X>BF)6
MB6'KYXM/+B")*X\2M%MD37A _K"3PWN>YHA:E9"I;Y+*CIZ9LO8S*UW;JDD5
MT@N&!-K-Z^O9.5>)<2QV/4BU[S3Z^218>OPYW4N%B5(B@X<J/6>\1X/CB+16
M23F-G*+U-.:K[ZN+9+!S;"/-3)-/;6QI[U971XO7V*T,7H2JCK^HO'G1B9D\
M,UJ"Y.]&R/OO<Q7&<">U^HGSW4^E58W]O!&$GP?UJ/4NA/-JFB0> -03?S_T
M,T(&OB3>8B;Z,S( &_7IND;O^EV>_B1<Y?^['OU[!,_H?T:N+S_^!ZJMBF[M
MM%/!BY43V];VGUDQI16'A]!]"*LF.<(Q:F\T&718Q&7)!3_3?\-R6/F5G[:$
M:_#M1<.6RWLR%W[*0:WH%3RO@+PI24?S-%O*+#7*%T<'WX2A9BYYVK0RY-:!
MQHX$V%GAU'5DEY$V)*\L;: =4;>9.@<]LDIN-CGOY+?;"19V#9M6FL2RK>.G
M#VMJM?.B3OAK@)&M+EW@'A1H(4FI@=5CWF:'%K3A1*L>ZBZI7&Q4\2G(2=F8
M[QIZ077EW&O6WQM=O374\TR9'+D"'UX?@#4I\RJJ1)K_$#\]7R*4G+_8'-G?
MB?!/&>__6,JKFG%Y==X#!3@TY-!_6@4+MIU X">9.P*:B@5SK'F9H YRI#>+
MD/?N.\-#HT^O5#FU9>D,LX0F_ BM ^V 'D=E@S^9 OEW9RJ:2Z+%Q&>9[(8&
MRI>8-:+?>A6BT#4DY(I\6FGP/4]=OG&RRM)NE40+LS@I;J&0!_T(JQ 7["02
M-33B?[^%MJU.@=<?EL2C<3MX=;B_?_DI]TFY&_D%9;7A#5.[U]IX!-.I">/:
M)N62)E>!#,LUEU[54^K7U#%SL1\S?.2MM-R#JRD$YJNT)$:[$8=;&-5,:CPG
MOL;E_B"O;VDHBURQ.B A3;K9 ]U)$ OH1]S3AO79!J4Z!C?&"*"WUXP[4^AV
MX8JA5U=JO^LR.0GCE/9,NR0<EWL T-)1G7<5YB)_;F8;NA[1T7M#2=@] 2H?
M(TR!Q6AQU-1$2)'=C8"N80\ G;\0<"[2;]Z,F@5-_:^VY1])E,CJ$961@8>J
M;Z+ADD)R3HXM+)I'E()VI1+T=8MA.F^O\U*!.K.D&U'*K7N",!?\]8:Y_=8A
M] K5Z0/#(XD<';@C/@/.2TZJSHUJ.MB'Y[U>P7JRS_GW-K-*&#J/Y[7UM@;B
M]8R8:*K?!3-,THYF39+,Z/:Y<'->.5C']JZKQ?L+K'QG^C6^"17VC$MR]=2Z
M%?#E>2-OIRCGL7G: 6G\$&\T-+8=H'W1T TI7)P=S-.58HNGOMIP5!^_7"G<
M.KH+-,3E5B*DM%U[T\318^AK'1&)OW)'H.-36-(;/7#2K;96FT4P+WN_J/+K
MZ<KT9YH$T1?2AUO@1%A5:NG>/N(\!MVI >F+!!/4]T)KX3O5NA;5OVA#9(1@
MV@157[L5?)#5W$1M&>8,_RF^Z\K\EWN/!Q#^]=24:.M_)&K5/UD<_%<6#SWY
M4Y8<)V,$,;]ZIE;MI=XTQL8Z92I M:[I-::%B":T&:%BO=,1E&::LC7,#S?!
M9J]&=66EDU\_$4 PB&&"0H*K4P5UV\N3^#]@FDY\D\5;UQ#@4+]KEN(85T%W
M41[X-[."-11"+TM;=NN+HMM;Q_YRK[\[0=: _Y[N 4=3,ZRZ4WPL\9EV7A=Y
MF( :G6-)%5>8!UC-/;AW17"DNW*C+L' OAD<G?-X/0S+.+%C5K;5&B=@W@I\
MB>QG]@37:.MX8,271GW/]'%K6M&/)$H @N EA^ID*@82/J%K3=Z2G4DBLOTJ
M>>?GU=Z POY**CO9;V 7K.I^>8=7X>S[P$0G?[YSJ*;)D(5-N2()DO/V[&@6
MU[1.^R@I3<@K>RU<%!^FEMG[27N;G!#)P+>]=>(G]RCU/AP?]H18O[..\.)V
M.-]XKZ;%CYUG81<L6"E_GR/=5\,_^2$E7,>C)T=^?=Y4UM# S1JB&N-'ME(-
M>JKK=8?8(2=-)"65D.C]A2XB@[FLLM9+7^$G*1&/<ZU@(D<PZI2ZU!G07>,W
M$ 5]<./YJQX#5\OZ7^HQ9%,5@A]6^_87_%FH8$5S!C,SA,3$>%U-RVYEI,(3
M_!2[L<>N7R9K$Y-<:RKTAJEZZ_C%AOD)$(IX/[%2QSF;.:U)ER?NR3EW?3 E
MI S2Q"FT:OABO_BNQH;68Z3A;=#35I>>T=K]W/'2M=HF;-CKW9-^&\Y W45N
MP#EL_R"[T4O.HB%N\(( (U"QQAI2^NE;PUAI28GSM,WHR.TV-5)]C]B.M?O^
M 517(Q'-UP/AU:I_#[D&^35;K=.W[88/G!XJ?0SI;H).59M\/9Z '6?]-Q2:
M[\)/9K@('#&#S-I4MR3TT5'<=V'UAY@ZUC,V7?L96?W<NAUMG!&FE#F$O[B0
M]<K14:$ &N5N-7+GXD7<!\#?V#=?VY>&?PP!R0]JN"EOBY+];QY,%JXNBWA5
MU(@5L?J#F7+W]RC"*"+37[0P-"\'8=S':N'9X[K(1RJ(L_ZNEX0A"U3($G>C
M&'5MR=JTRK%(@DJ^VFR9H@RNBXIPAA2GRDM>@]7<JE1I@.Z:2"\/7GXNM*::
MX7QS(?H6E^ J1.NRN'4JN_P<2UPYY%=N8#\;"2970(^3!M')_OBK2CI<;'%3
M*@C 4HF9C?D&YD&X#S 38JICH#PK]?&N? Z-4KI;K3/WY]X&"\W/+V66Q[SR
M8%7?J\:2U#4#?\:JB',D; -F, (-*KA%_JILTC5$Y5#FD-N8%]GV.NXM><_[
M%]@(SQO7LEZ !EF"QVW)@;MJ*<I&MB)SCRD0_4>M6R3NHKD8;>97!^V[:Y-9
M'@I1'<;LK__K T$?V>IZ'O,ANRQ 8\NCRW3'<S\CU7C2K+.-_*76D(),*Q0C
MZ-0&$DTZ%VR/S=7E4:S#5N8\VT_B//T4.?8U:91^V(<TRE4"A'DKSSD!R/QZ
ME4-%JB1ZYV7O(-E!(SA+!S(QPD(I$:GF0I>&OE%5.WZ6B;M#- B9XS3HA;#%
M('[NYO1-\.LBT_CFLMQ2:7MCTUHGJ4* "+"5!]#7?^^R*9I)S<1I'K55)IRD
MHJ7LV%:9U[>\;+@ZFA]*VB@J3=-/6IO?/B]RTW&N%:B..,GA)G(@!@H1]Y![
MPH!6&30<Z49E-Z(-I\*# >G)W5QG6=BPF85GTD1HM'B=']&+1M _G=WPT[CK
MS&,ZOM[4LU>$:DDNA*\9Q3Q!K>9;PAQ!0H'-YT69?WH7BTF+]S/:.I_]-L+U
M 7#>5:2(6/GB 1 ;A7.]8M6));90?MBR>KQKY/M7837R+-?_SV"$U>1Q!W;\
M1:'95V3JY6?DUZJ*8C)0P[;W6<SRS^I\ <H9/EO -S/3%H'\02<EQS&\YI7.
MO;2!!V""N$WD_D]RID\]HZUA8[+]>:(_T8L8 .>$\5G3<[/622&BWGG&F@Q\
MUTH(3MP<N\RVT?;#),^&;@$X68>JNQHQ)<ET<?VN6W4VY90*_+??6\*J&C_O
M[LJP3/9GT ^G3_MAG^=\IZ7@5]&&:"QQO:UG\3K>%L6;_3Z8!]WI>_W:%NT9
M \GV><%9P4I3C96*7,$EQPO3I4#KM=?KSJ4TI &,HGQMF]<3(CBYWZ,JNAQ(
M%9,NB[$//0%1JIAD!4'5TWR ,A$V>4&]FIK/\N^=G/BBJ1,UMJ.LP5?55/N,
M-+55D5ES&+*#O13P(K*F^"[C[H5I-I(' # -I]N?>;N/\"Y"$Z_?/JS_)$0H
M=E>M^'W@O1<4M-*@5FOT-HZ2CG^'656&UR;O6Q-:/'EZ^9GRE(;KIT*AE/3Y
M-/@"](L1#NWBPN<IY+I $IZ"\HM))\JY?*:<\;$-138+^:XRSXR\="\?/[L2
M,;*WI<:2=!\"JC*^)/T>82JQ1!3X*U!$4^,8>HXHIS\72Z2B6?>\)\S4_"0R
M%;<4XUT9H83,_J0W&I*@QES>R]*3)'Q_+JZ:>.!'-#/;9]V/_@@^DW6I],*K
MEZ8.DQ22[:BU*FDX]K<Z)G<56FH\A.3-UPH4(#)KJW593V[E,$,5\2577V6H
M5X:@1ED>K1T_ (RB6=.#M+$:"VA+0-\5<2%%5EVE2!LOWL<^V8#\^O'S6A9#
M=(5-:GARD1LA?7G7TF3<UHZ6EVX>JV>(G W$M  UC9.M-7 .WZE#AT98%.9M
MN[[:OASMKN62'8QK7*1%+2,D#EMMH'_".A#Y,3","YX"F)BJF/;P?3^E^NSF
M#LPN7A/2K]STR8ZN+KFLDU>"HEQG5F[ZP[IV/&F/ C-.A[QCK::#O@2UF<@N
MA3V))SJ@:,6MLF[R;%<[+]8,U;'$ON6^87HR,F7[';N9>S8=9HY1_)1YV:VF
M/2WL0X[E$\X8(+9KQ#DT$_>*&5*D+T5>L],QN#CE&>U)5D?D/$7S41[QJ2SG
M9N*<G\#0@6^UB:BEH4("] V&8\_/&:?80_6M?Z@Z@&0NZX@+EBAM'*T?Q9/B
M02E]7":,&*U#+#@>?8AN]@"8GNV\$)M1Y-=D0@7@[(H2'WXP#A^5LLIK+U&@
M0ODVEK)P/SR,8Q\@UNOHR+$ W;DXGK<:[6%_9U'"?STN0#0&83RY0(B-V'05
M'$%F?>[./O#K[:4N7A1%'\+5OD1[&U$S)C-/6VP\,A WRW,C^]=Z<Z9!IJFY
M(%TOTZ\E_%E"ZQ7+G&-$R7UF082@DXJ<15 !8&)F6#Z$R\E!",P<C)F;1E9+
M4=T4P_)K3OHX-J8M^OEW]Y0Y>0L,;B>^*%'73@2&.5APX/[8*F:PKV&#)".0
M72Z*.,X2<_*-_,8;.@8^T"L?)L$^EGT7Z=N^ R<2M)]/VEA';B;F^==3E3.D
M:K6Z7P<^HUN=K9;Z+M0R@\OR.K;Q $FZAX0"?BCZU/KUR*R6G/V88@U'W;ZM
M8MGW:V/MG1J'G9\,$7NTF![ 9@.8\J)<@BHIJ-E'0B);AN174E]0-RT2@6VG
MGRQ^&6&5EDT)-/7G_RCE.H.B:)?U$&1!D"0Y1T&"P )*6L)'!LE(V,4/<<FP
M(%&"2Q0%"8L@B.0,*ZQ(6"6#Y)SCDH0E*P)+^!00KNF><^K\NE7W1U?U3/5,
MS5O=T]U/S_-.^DZ8S\N7/-E!9E_@=#9@,C&0M[>K ?7Z]MH;MNU)S-S#/HKE
MIZ4,+Y?VOQX2_:PW1%M:M5/XMBKV(C@UV8_F$J(I!#\J/?HF@-*(CD[74 (3
M)2*E=U39%3Q3OF=XKM+;$;H6%KP2CE(*TBZ =V_Z:AYG9A7N*:=@[L\=]L08
MB;%\,YF!8[W/:=UL=V(/L2FK[?3GCM[4053'N90X@C93=4EOLT-@C@NNFX5K
M$EV^9%"R50%I:L%Q!A .XM:KL/T4UZ9KME;N*7LNDCVBHD[CPC8$.[^?PKA_
M[BF7%WG@3/SNN?@\3L-[7@33?EU1FX>K+7?,UB1UW?-=/\5<5\_)QF*%RSN*
MXEG!<F_%UTY4W0+CB)H&F#[:(]^"?LA[0WX0$%Q,?_F>]C9!IYALGM&0A#O4
M->FD4Y925]Q!K!2?5$**O (EX=;S TRKJ@V4!V %U:^I*3-S.J8<8YWW76]-
M<[M8YZ8\364FO;X[B!BL[DD>.,TPW"WR:6:HUE?SG\(C:JH<99=JOSL30_YV
M!CW[_-'[;J:3$P_)S.GDW//85Z F[0JRA( ;#!V<@G=L4&D1@<2%]2QUR9D'
MJG2C?R;#=]:?\XP*IMH>N;&*'W::E%T *L>BWX(?NLO-@U78@-X]F23]@IYU
M@U&9P@ZP+LF23'I<Y:U8#-S%WIKA2AGJ10)>UJ=MQQ?G$ULZ2N[YHJM!C='2
M_"J*#F9P;)]-%U?E_>GH*)?R7"@%/O*&4F<4#3";) GO376-W",4@]&D('ZR
MG(K'2"8OOC==)K62)9M:\YM[R!1B#68B3<!X+&H NC @3>8\_:7'$MAX*]L2
MF: P>AYD%@4PM,FS<'45YH=)5KSYC)_,?;)F-@ B'YR(Q.6LW'SEZ_(()=SP
MD4CB-E?M/^59MD8P%./<0H]D#W"[EN13PE$=ACPJ\8#7.F&_DA(N-#-"RL6A
M[UP3R=@,?G7 S,G.\2QRJFCD3B=V3I?*N$%/5\,=G[ QE:_$]F^(<W[R7<NU
MN>Q[S@5 X9@M014K93N/4+JZZ=H66F[[SU,N+,R$6@GN4&\5YZ!L->MM?A*I
MRHY[;-(+ETQFP7D;6(Q<YN23C8\46256'/N46'@":=/EC=<[ I&&R-(\@<_F
MP;HN)Q*M&8;VYI(?9LP*3;[9^3M44C4(Z5)?C/$C0WO"$<X#=\-=]EMM""(T
M-#.];IAM4P:R6^[E456ZAWPUNX?%S?7O:V%H.\FW@I8%1#,C)$<N-^"5<+?+
M?=VECJTDTS([$CO<L_O(TC+]!/],E(>K6YE]X[ND19O'B?=VY.0*JZKU*>W?
MQ7K%DY'ADU49RWT?5S77-E@7PN5[+90DQN+5M5'&Z13INOP![*(U>!7H>'X8
M^*A'>;1(G_QEW_T648\/PUCUO#D;: "2MR'9-UQW/E#NLX'FRF1XC<6I!D)H
MZ*:PN_WQ.L9%,"&&:3YU%I6VD0X,[:7F>96ROZ]-L9=J[G @I;K\_L_.@LW>
MM?G;=6%[%(0&[B#]W:]GH6UA/#_+0.'D$8O881IOYG+)/71V5G"Z&:ZX.16W
MI/LLN"9FQ2S)P28J]XHPH"]+N_PVYP:U]H85SB"SQ#Q]VTV=CL-3R4-%;<*B
MT3#)2E0SK#SGQH?N=Z+\ZA.K$[**T:O6]V]^JNE:8,^N 99HYPN#LE_1K?9+
M>"RFC!Z7S]; 7(Z(@KZ![ST().'*3LDGDU0X'2%!._]J'L+XGS/IS'(X6-%J
ME\IF%%DO6!O(F(KINZM,D&Z#'DUA94KYR<*DCEC]%Z*6Z,_Z(_ "/C-F-Y[<
ML(V<;@D:RS#$UM;IO[*[(H(<"[9 _.)HY/XO*0,0^10#4T^Y9TQ(&YJ$#!>9
MEBT7&G N"B[PY8G08 #-Y27LC12VOZ'LUI81&54T3>J"+T#FNHO?4Z4D>FD_
M,A\.'Q9_A9G438@YN)4^>I?P5^[!0?"!N;]-+_YFU!M^-^>]%?':#Y"#3ZIL
MRL(Y'HE[GE(U%\ /5]' 3;_:T^6U4OO$W8N[7[/Z1-[2/9K#28Y?9DWS#NXU
M0Q"U,-'A3^9$%MHYEVINAVW8)/WZFZM@S7]8..AN3T52 FUS.T0L](IABJB@
MB=;"N4' P7D#^:+BV,RCO",NCHEEV[6DX@"SP1*/JBSGVOCT:^CQ4R[G((,>
MM(Y[%)JM]#M? /Y6G<EU8?>47ZQ> %;-#4_U4@E(94@(3KZ\_:["BGSE2)#Q
MI29KP6 C<3YZ_JPJZN7@YR;.3*'WWQ(>._+6?KR:B8)Z1GLX58ZS;2]8XZY1
MF81&!['Y1Q_,NUP7_Z"XU@^OCQPQO@3A6BZ<QK+HV*T]3U"8_DO!PB.KH+-$
M7P MVJ#CW3FDBU$ ]*"_1ZU4"XX]ME8I=&)C6@^UR@.&FZ0-8*6'F/=>W51Y
M1GTYOI<G6HNK1*^;@FEL1L@,GR4D]3=/B7IKLU/KH\P,?G\Y%C6DM$+,U+A%
M+!CZ6/\LF!= %/"'CX0-=GQY0@+MY4ZKHF(< DO?,3#P<3B><T.\S%:+3FI]
M. Q79488S[F@60R*9=K>!%MXA*^SOTJ7XX<][#U@1KL3KKAJ\,%,J))!>-+U
MLJUZ9'8:H?$6M<9306L":,28K/BZJT2-^@4 83XHV/F!KH<USS:)H2+_CW-M
M];]!>.5Q=.A&_KE?O+>ZC;PI^;#)O\N.19P[NBAI>.W-^,OSW2;'DZD7DNU^
MQ;(U'0P/U*GPD:J,CQ0Y]!W/[VPOY"5FM;_'.GY/L#XS%=*?C#<A&$O<@$AO
MP10,427.J3N7(J)'Y[PN52=;^L.>+I(&MS1U.1/;Z9O$7#W%'Q0=7#UM/\@%
MC=[^I10,&.W2#(5Q:TK_4E!2*HTJ"@"28?B7HM1QOG>V"836+JE;@= G4_B>
M*/9U3IJ@-I[5G"  ^AL6A)&>;@UK,;CZDVUT^#,;D%2U@=]@6I574I1/G$[;
MM\QLML#S;@]<Z;;%.:3B9$@*V "G9W-L4A8QA=H/./COX7$E>U_]QNY;\SA'
MR]WQ&5*\:E%1CO%C>6P)6K.@DISA>98JF" \)9O,&] K+T.D+*W_?W]RHD.S
MW\J?1;-U_@DNFWKN%>XL^&+F0AU'@GPNN?//+-):8X;8:/QPE55^$]1D63;-
M5'R@GC1K:Y="?F5+U8\O8D@QNB-QOC ZX%(@0\0B* LS1> 7W@Y_HKULU;(7
M"X;MC%?$X  '^@=&H47&=7M,A9[97X;.U 0B-Q =F:=!QC<Q>=.A#K?.#AE:
M9@U^1 AHS?J$.OZURW0QK&&]-KJ# >2>&)R^N4GWZON+I8.1$/-?QHQ%P]AK
M6CHL/=O")(JGUULV<L]*S_M"OVVJB(P-<NL!@^=]GC\/5*HRSH-H^FJ:2KD.
MB3*^O[@ #D;NR/,3%A(3]?:?PXZB?O]SZE]H+HQD9&)_MC$QYE%KJ5:@7*>:
M96-QCDZ ):LO_P_?/E-D>D72"=8I*1"U-Z6\!F;IV'_):?F0?Z_<:WE0V_"9
M6LE='3-G.Y9DH/*3N>/>5 -'U=_0 <V!=K'/WWCP18"?RFQRZ*,0WY;9Y L@
M(,1/7;UZ&K$[LC3D&-9&P@1AJU<;"P.W5 O]=,[Y0,X/[V!L1M.!OM]ZP2DX
M](=/L3Y:SB2BOW74Y]X+X(=C)P<9B!)]MR;LW[9R88VI@IR*?.E_;L!J50GX
M[OPO)&222C*QDA. ^,S*M'W0?P-,+<<P<?KIB.$[3*^JL2GBRXG&[&7:UX/A
MR2/I-RANY5.8+K+$#2/I<UG%&[#@&=S?<7-+_#0^<5-^&X_93HSOU\??>Z[\
MR*=G"^7ZNIG([A@YW2%@NLO+[J%=[$QIM974'B H9 %\3/1Y]O#8)N< ES_B
MV^L;J\N3&BK'2LDK)$ "70F3#JWZD9ZS:T(=?BP$XJ8O$_XBDXPTH7&$[-<U
M4ZC/=2H;&!?[H''OYH)I#.!T ?RR+#WO3SX/FHIVZ%GU&0=A%,*D57[=:-(T
MH!%-9;^:<%1+#E&T@/P<F/Y*D,1W?H##V!R:7L:RSUD%O.2O2^+,ZQM?C@:8
M;AM(^?B_3:;M"BP\LA !N^H>RU50!?AT/!#?-AQ7;PKY"[9[,VAJ_7E!0-3'
M) .MG>6LC551>Y;]<5SM,+%;B*Q_"S/Z(3BE(^1^XIWAXF!+2^3*W9 9'$VE
M[CK/]T,'BAM(GRT]J379#DN_C8'))HK#V"M![;!;;"\&9#:M&RL;!,.WTI%K
M"=6!F'XO-YF(H;OEY>Q$7CLFG6^^1KC,:#NE^%UY1;MC:[>K=WY]ZGSTR@NH
MXS7'=BGU&AIH 76^C>8*Q(*QWGA?$LZBX6[OA$:K5&&?QN1KI;,2<XYY#NVJ
MBEP_,Z@0[)A"V&%3P(+F DA-#YPK>-'92+!=1EK,OEHD$_5 F-CR5/M8(LDN
MR1H?1V;S,?FS6^9+G?W+@[0)UM8,ZV8MJ:!<;KUP/V3@!ZKIRV6M?-*I1KO?
M75W\(%;P_NS5B#2?M<S7QY[HW"N0:^.6V C\H(7TCJ"^LCK'_K,\'_B*?F]2
M:+8T[^5-;@ (>C92.XD-AER;6E6MHN/:(E CXXW?[5-C2P.E9P6\-70M%*FE
M53G3[?DB)XC2.^M6UKKS7I\S3F#O:B%5MXW3'M7Y:^7ID 9%6GC4UB4&CY":
M_^%A"EHU,:OLH6Z+70#3:4/#&$LTEKTA@YMJ?F&V?<-&_:J,R[9J7ED9(ZMW
MK]YTM9P$S8>5XEACZFE1PJ/BVQL/(&7!>JB.ZK9I9I28=+^DEF&;\FKP-._'
M):Z ,C.$IJ>R;X)XFSJ74O&@?V5 _C=$7Z#;K1=E]<NU5 ::<H0R]OMNIX%U
MA*)-#6Z;JGW&1K"NU#@\)5LW<T]MD^*PQ/6JVZT0_A3?;_8(9=^[57G+Y)^^
MC6_LIW2D![YP$1MM2 OS^,KIM07U?SG-O1<C/EFOE8P7RWL 4HI#B@SY4)JV
M[$-.RD_<-4G%1JHDM#[;[J'%\J?(\GMV?3U(Y1Q5MOOPI?\,WCSH@!9A3W!M
MIN3V7>N$KY$MR@VE=?LW,9R$UBKBI'L-T1? )-V92CS@";7145(>N8O,G>\F
ML\<IA[8OUO5[[D0V-BS6W,X1[B)'C7_?GFO:OSWU$$/Q5BR65ISW(QE_&/)U
M5DELA:>YD>>]"@I\!6E"+6232$9E)Z7%,=.&MI);8F#3\JO/KK$K<PA/R]N$
M=1:G"&/,5:T"CI.II2B_#(S'4'!&:6-^-8-Y%SEQ/=5EH*!8K+= ]3T5U(Z6
M&H:6VY!-"]D_^1?+=N+?R>OGYM'3MKH+(+I>N1(M7CTCVD__8#_OPS#\+C%R
M[4<V#57 -]\(>-G!QE.%TG.* )'V@JDRCQG!*+#S8I2+27JZ[@R6[.F*5<T<
MHV6RLG6"PU(/J&1%%+JA/L$EGQM31&@>HH(/*.DOI??N70#/&C6%GOJ>QF;8
M*JR;U.R:@A6E"B,[%_G>3ZV>(EHRB$"TA4[AGX/']49UGF$Y=>6;F^)#J:\5
ME-R=MW%3Q-/S=;,XSH,ARECM4^D.RE*;V^-ZJ?L#XW_-$:0VM8N,?F)!C/A<
M6_K]7OKE2#DEITPX+C>4S76:V:20R?GYDV^1Z'::VR?CTJR0G!BL:,^7F.>(
M+_S$JO'QA5R2HEIS>A,"M;[795A  \DA&LUA019=9<$BF_U>".$G9A%DTLE;
M5BB,ZYCT?77:1TSL*I/P]WA53E+"K6.;D=A AX#$*[D?*[OA-IGIRK5J4A0?
MW"4%ARD6E+&^V[@"DO-4.)CJ_9<?<?)\)$0V9/?NA+C]>_,:>GX--BUY%N46
M/2!2O[(YUH)&P+0\V(?528 /G_?/H-GDSID1TB/'T2)A9=&4:"&<+_L"2*']
M6F9=/Y!Z7"D7,RMP1Z",;IYM<N\8&_IZ8;YHK261#Q )>X \4&5N5''Q<BA4
M]_3M++[]1<S;"&_\DV<U-;QF-5URR_-3Y^\.-[#LP5+:?;IO@:WX;*QI=:.:
MG^S3IYZ[XO,";S6L8:P?\K;)_CE._#LQ3'I(^'Q\6-EHQ6U@IQ&!U@QVGTY%
M49%-LC[O^=;/90N)LJG=/RP3&\6Y;,E%5XJOPT4445#@D'M'#'4DUPU5P2I^
MXYJMN%FWO[J?M@A3I^P\D-&9I2<&@Y&NG<,H#['"&ACFINPM14KA1VGM'%0C
MH-P+P 7U;16RR9;X:97J$#]6>M1=^Z,B!Y\:G:>ASK'<./7S %1;Z:@JLV$^
MJUX-#YJ%OY)A+K@'D4^GYEZ9NRJR=\D\/TSBBAE(V7(*W7-N'S?3A<\T<_X%
M&WX)1BUXK8V/T$[%L=%TI]R6V?4E]-93A^9JD6O6C&IVSR."::# )F_2T *G
MW=MG,HEGVPQ7EFRA ?7AQEWOO#[C11C@A#=,2UVW4F^^O0"<8?VA7G(WP@&#
M:(5TAPI43/:Z6X:%&^WR_5<Z[& %NOD14.CQ3%_4S5)5)>)+PLWQ#*_GHD@)
M('4;H3,QF /AT<*-9:4OEHF& W@_MZ].%AG0\9*ZM,AW_AJMW7T*CF$*_(%7
MG?S*$0T5))F^N0MM/AE60X9&)$D*;&69HZI,3G5/UH42W!P<$NW"OUP7+WE?
M'<43,0J/ ?45L'#K56@"=PW4:&G?BD0$4G:Y7 "XEL/^H_(38>(#U^ 7*(G2
M;FB^X1_T_%,N*>I /O24T0_=@,]!RLUXMIK46,]<:[<5N28WE(6:)Y,[TI.A
M!OYO9[\YW$8\1@EE)AQ>0AG!5EX#3R29HVR02WL%.QV)CZ(/IN7.[VR 5I@*
M-H;0=NR%NF'=O#'=II K] 'CL#B%!1@L,'!FD,DG"4Q^8@PJ^-X4KE*KJM/3
MNIZ\<V_C.Q<?T:<:OS<D1OM16^;QJ>3+SY1ZJJ^N]QGY'3-"::*AC\?T:69W
MWGL0RV?P,G#M[*IR)1^/,;N$ R"Y[D]ZGC/)IVGG[DX)+5!" S?G]KL(48LH
MCU5PTMA[;=8N9ER3 $?^.TDK,OYQ?ADBYR4G^2?2V2T24*ZO/7$H>O#SR&Y7
MC":@ZR9P4S(-@8#'4/0"#XPPAO61$@OQEILB10Q$/J>&ME]0&(MT=9DG?TD:
M%8$C?Z-F;26I^=;C ZTJ39YV46KR?]#"N9=]7!3\^J)2Q^1!J7PVJ&7.IUA-
MILA"U0R^MS%$IN3=:O,6\0Q$FH<0$=.',QH=<=YRG3<1E'IUKZZE=UT7B /B
MM%45:-IJA'-)R5+_])W_+:]Q3W+<7L]B4U9#[,74^.56?=?+1U59F<Z91G>\
MUMIY>?4BOL" (];2\0^XR_KKXJ] IT4)RH5!4PL,1"FWGO@&ILY *LZ"XC2?
MK-*H;XNL944U9UWM=&%^R=Y, *$_6?S'>_-?0KKI\Y7CQ!R!( G,R/]K.&R#
M.X#ZU1':.??R!6!7O3B&3*+]+#G 8(_2\ZK&NG_!1J^NGD44YX>)9BEW%EJS
MC1%O%HHRD(9O0M %^N./$2R58?RH5W]1<6.@/VPN *>9<%HF8QJQ=4G:*R6X
M$J%F0]T-?HSX;RC['T)T,?L_4$L#!!0    ( !V(?U;\F&F]3E(  (5:   0
M    9F]R;3$P+6M?,# V+FIP9[2[!50<7;8V7(T[(;@3(#@$#:X)'CQH!TB0
M!$E#"*Z-! CND. $"*[!);@&[<;="2[!I?LC[WMG[LQ\<^_,=^__5Z]GK:IU
MNKIJU]G[V?O9=1HYA5P"[JDH*"L (! (>'GW 9"SP!, "P,#$P,="Q,3$QL;
M"P>/!!\/%Q>/\CXQ(0DM%3T=+14-#0,S#RL#(Q<3#0V;,#L7+Y^@H" ]JZBD
M"+\$CX @_^\? 6%C8^/AXE'@XU/P/Z!YP/__O"%; 2(L4#3*.U00(X!"!$(E
M B$[ 7H  *&#_MB _]A **AHZ!B86-@XN'=?J+X'H(!045'04-'1T=#N1KWO
MQ@$T(O3[#_AD,8BU7F$R.I#P^\5D83')5;21:H\>,@N8O??'QB$CIZ"D>LC"
MRL;.(2CT6%A$5.S)4WD%125E%9WGNGKZ!H9&YA:6K]]86=LX.CF[N+JY>P1\
M" P*_A@2&AL7GY"8].ES\I?LG-RO>?D%A97?JJIK:NOJ&]H[.KNZ>WK[^F'P
ML?&)R:GIF>65U;7UC<V?6]M'Q[].3L_.+RZO?ML% E!!?]G^J5U$=W:AH*&A
MHF'^M@N$XOK["T1HZ _X,.[+:F&^<B!FY/?#(I&+R:IHPV82T#XD-7L_BD/&
M++C\\.BW:7]8]N\9YO\_LNROAOVG73, 'BKH;O)0B0!IX/R*[8LOSM_@WDFA
MJ_#9! 2K_O,K >7UGL9&#Q\AIY-2Q^Y$;6,WLVU59WQ'V[!/(GUSJ4L^ST%E
MDGO-Q2/R$OVQZM>,.N,I(\^'V@5YU$=(,HZ$-H@N*JIG0YID[0E3[+.W9F\J
M^7U@MXIC9D47MEI' 3OW) ]F[ 1W+FCWR9;A1&GU&))-*[Z2PJKCW$)A6 =O
M+7]!,L0M$$>8&(D_=+ZUU#7X3ZP_C!V_J8\F/(6$+UU/QEPH[8@]"JZBU9.$
MY'RK&U.KG7+QHXA(:SP=)O71(%HTJ U-Q-83-=4+&J), (X#" RN5L=&,/,6
M;,C.4%CJDW[<5V)\%EGL@5/5<ONJR_TLZZO)U@PDE=QC=CNK&NRB& _T33*%
M;E9S0[MFRCZ>*L(M&I6JKMO0>#LUF0#W1S'IWOFHTZ!!;OFW0Q.C@J%D<KYU
MM)&B!5; EU"V/R#)*:PSX73+VDL5N.:RX4K427-[)MW.J=+4L_(UO>%[V;(G
MBES3N7I%!8)\1B6CU4^&+M SWV@KD=_$5#T:W,E_+-JJI5Y3%W0\(9[_\'X'
M1Y"BB2SMQ[)'*?I2'+"7AQNYE+'[_=C,XR3><SWMF[<K A?CU_;WI(,%;W&4
M+3A?.>8)6F7O%__H)^S)!5R%DZN#4IPA$%=W&H&YFBESQX'@$9U3;O5AY2K/
MQNOXVEIM5*5-7PU9$_EB:['2>H=E6V_U]S.=AR^,GVX&$*^^!YVL5%5+RM%3
M;L48S==^ODVR/0N[Z)G_U8-#N*8&N":7A571DNY-:H]#]M*=?C'BCT^.Z06F
MYUE#+6HG7(D&K7;J7^OU9QR68E"#.<M"J.1,P+,#+5,<+@-9_C?S,H)( ']F
M6CK<2RMW)NHB>C=J( 1,Q-5S@-ZC/L^&V@"O%J<UF9N;,GXXP+&.V_V>GY"Q
M;!+[L%^$^Z1$FX+TON#8Z^?R/8"0JQ.@)4_R7T)/XR-7J3,WQAD,MKRW;QGR
M03NK31\U:J*Z *M'!?CE&:&O.R%!FV5H-'2T3>Y83!ZGX&,U(7#=D='JXZPM
M'>9RL"*R6[)G!N&=\TX:LB9,'B#@)X<+P;9\"+R%NY(CB^V]?HA'>Z7PUAFH
MFKO?.!@^SB"P%QR$6%:,E20I$U\BGB86P@)2$PC#5WP%<HX(RC)MTUGJX"<Z
M^48]+LSUG_JJ&%^^RZXG'>TK!2N61<@II(*A%M253VX:!>:AS7I1@;FVT'N=
M/"-0FUYCWI;M"]1DS ^D"T+I2Y)U,"3P+4>SJ5;:PU<T#6QZA%&VS TINY$^
MHQ6S)8M=6%*A[%T%]9C)R^??R""!#V#9D;?<KVK2]W;-$V#N.('/G#$GJO::
MB%<$<N>W/()# @=39JJKB"Y%I@AX#<X9<%R*EJCKL^&YL(,]R %W2>*$(0_W
MAR+&R$^868. 4SK%$7IMR FUM][DAR3_NNMBL2B/V>)FW&<05H7:2G<]0R9Z
MB5 _5+HU$*R:[:_1<0<0H=&QI[?K<[@/FTWLH"-7@^K\PY3.N6+TX/Y6EZVH
M[N;7==,2Y$Q(H%TMI0N_N,YMT9[WGLBM%2K_\8Y6RT7 &U?\W6S5FK02-**,
M6,791.Z=@"X3*.V7K9JAQ,9JW(@GNRACM0_:-@][A.S5#J%G=BG91O).AL4/
M^0>94#^G1FIL&HJ]]J_T,A@7>@#A,)*]+Q9"O&8]6U3VG0U5N".YNPRRNG-6
M7Y^XJ=S<Y&FI+P'NSV:B-TEX/W'^O.4BD/:7B8I@[:^2O1)X("0@2>H2H9OK
MO.2>-^H<1G%*C'<^";4.=:;I]#2K>GOSZ$QZUR)T=0UNYC;+=/OJU>2O#5^1
M* (KUYGT &B98ID->T&;HVB85]>7]KA B_UJ>^-Q(6/'Y<#21M+K:=4*.OG:
M2]4Z+SIOD0*(%)U;Z S[R?"%\K@3.&3!\%4DC9)NI,K^>8DT\<4CS7$G<0CY
MD[%EN&#O*M8HA>M^6^^&KSCGDX89,M$^&75O!YW0P9$2(5QN%@HA\<ZF1G4J
M"[7,R#F]!(!$2_Z_@'*=)@I<98THG?"M]IKV",;KSYG6#9+%-0W>Q>]D!2.8
M8_*7/S>,XPNT7F'$N O-)Z3WY:(K\RAI>BS1)8QJ6VAB//4AAYG!(4XG-2@S
M$Z\DE#,:EN(R!I*EE\EA.-ML$X5]^34["79/HGD)JVTW$GUY!0\PK!J,_0W!
MX+I 5N*(?8,#6@(U :U#J8!"&X=M8;V7<UE]%F99P]<RSJ6AH8 -@SQ.$\"+
MF9GW^W:U40B?J,J@DV@E YQ2U_(58_9<I?M?%H7BTRWP,^JFNFV?,,8Q^@HP
MC0C.>H9=?]J+5X,B 7HN3!Z^T(XCX0\M-8+- DK?CLTJJ^N5F0E$L9I\.<M>
MQ:AU =H9"M_JQ[F=V9D&QPLKVY' '!ZO37-+X$G*\['[N+JR^:*>J<[1$\T\
M\H"C1ZV?$ZV=IW59B>%:35A?2$)_='JJ;L5R!+>3\&AVP(\*YYD^RAF-L=/A
MYK=K6C$R-&<!2VF$'?KW-7*-/C''N+0,*4G=G)?ZXFG#B$,!HW_(TG^/G-Y,
MM!F!#*_1<A^Z^-W19,!N[CR3H4='?9!%P4$&8U2Y2GLSU B0X5/]S8,*5KV"
M?S*BDA(J2W1#9!Z]$>#,,B/+2+]"GT8-O^[XE0ED,F'$_6AM-0\UWKI=OAS=
M8#T/WI3!0:?(60@H EV,-DLW28L!FG44@^COV24Z$1<W/W\1_SX14TMM(6/!
M="B $12[$U4"B(6JM<)&0/(DFO\(%.+0(N[;)M>1Z:J4-_%D\CV:'*JYKK4Q
M9F]%*71^VI*KC)::U=N6:)M*+5-\^BB!W@4H/QS*<RA5?4,$MF(*%U/ZT3@X
M;-I?<IORO.<&V@W=BRY]TV'R_N+ .*2,A^?!<[DP_M4?0^\QJUV00(<,981]
M81!%2Q3]::]VBK$.*X*%Z*3UMK<$C4MV@6]0O)F!#Z)0].X<QWZ5[GF@]#BA
MRK<SB []\;THQ,UH'K2G.PL)& \?D^8N?*)L>3TNO8F0OOZE.%VM<8D$HA"W
M.+ OO@(^@X70X1OH^4]=S[5QR.Z;3Z8*@U3DJ/VH>4+5SX6B+E%-D, D&>(Y
M2#(^0BB>6'@A5LC\(GP\M" /VLLS3/^K2SJZ>-[LET%-G3Q\[VDY29_/\C<9
MJN.!BO9C.CD4MP-#/:/(7&]KVH''[[#6J.,%@V\X(M9K2G+<+"=58BGMDIPJ
MO8MC>=T9S*J\!)A4ETND]#5+#X->2EJ!-C;U]+3.5+V(8KTZ$"1%CH4B_6 P
MT1Y["9#QV+%M3ZN-(D+I.1;_.W3 4K5@V\%T=H::0GB@>/J7.@8FK,3]JN7F
M<A8)+,(1I/B+-^%7KK?OXR[U6C/Q#L3UD4"&*O3Z"MH>-SR.!#:'9A&(C,,2
M,394@;\YSOU5[84$>G);;F^EEXV>!_GR'0CA:_?#P)^Y&:8IN!P>#*';/&%-
MPWO_,F*;FE[KN?,1$KB/NWBU9K.><>-^=^E)(82<+^O?)(Y_!"AG7/4Z*73"
M' /.7S;/FM<,=DA@$NG=V7HQD9N'RTVU_Z8A9M,5#Y:.#1RRH9J(>W:'@/?R
MF%'/V1<M&^]LV$ "W]$- SXQL9:VW10^"P5RS\!-T)Y?T$640ANH726<A^?^
M26($+F&T7M<;V\5C4#,2*%7PO3]#W5?R):&,%\98T>X1FK2;!/UULWC>6E#<
MLD9OCP1>)%WB5,B0^/2Y(@'I023@A2/UG[O-\H#6]</%&R0@?'O(5F'=-/OI
M:]S 5"N*@K@N?*9@^NZ)C6]>KUYJHL_@DVBB$<\]L4O9B&%ZL<KUCI-J&X$[
M#N_YI#DHTJG][@4>(J',_0WZ+@;GIP\QIVW%@T;HUW:Q[>CBK"#3AG J 'Y-
M6BM=;\+NTP5! A)Z>;DYZ- *,'28-.>:M.SFR.B;DJ>WM5]@,5B>IH::"1!<
MHO,('?]]3IV).D=D+:)6'0F4Q1B=@,"[CUM^=5G=#?T^2Q[0^W.O)-\0C 3>
MO#![B/EJ4RA7MYKP$G,..BD@@P>'KE':N+/VFZ[K<WS]C 08?IA>K;7TE_PS
M2OA\EHG&["I$$ML=&5,56HH$')3;I%5XO!:_]:V!-I;VADL<S\0DN_9VC8*J
M<DR,^*Y%%9=01)><,['?QD=1FL;28/CQQ0/TW0WTRZ4:\I[+J\9ZN(T5#B1:
M#SY^0+5SC'8P!F_^$/=8#05"E5WR.?V%7XZP:&9];D,[BCR-L'3TL-\/[%1=
M0_W8_][@.K21N*3J[6N0&;U8>HX'O!SW:[F *3TXX";0V-V%%*3<UT-;)*">
MY'7^RG.P/FJ)$YQ>GX,2:J1B!'!$5MR9:;MXM;+87Z9+^P8A,]ERVM62 "A_
M10*]''!$7=XQJ44XBKPN7%VP2.-J):-7SZ5Z!0/VVF PM;*(Q35/QC$4:"QH
MC]M*(FI ^<KOD'YJVJ%"WI'(N47'*09.L[]C1M:Z#S:. DE//WY@IZ2[[;*Z
ML)-]%%QL@:/O]7)/4E^J"I3?I;C &']/3=:!@Y'/G4Q:SJ8Z8KK^0UV"15LW
MT(:ZX,O0N-E%]6<DUTD6D5W6N,5IO!973&!EW3)2$]RD>R%3P(0'SL_$98#!
MB5PV8QTU,E%"V01!*65W5F"<(^JI:M\@ ;H[<CT=A$87>IS?^-I#=V**$J%'
MZ[\]?_(2!T@/9?M]TC^!G'N7D*E#)J:PRM"$2VF"E((,;3=49<1K3V0GDC.Y
MJ78L$_Z()Z]>OMZ,!'+MY[BU(T.+QTJV-7Q(N*X6:]4F_BG<J>NI!=\,)M,7
MU*CV<A[GC)-@"^I1*4A D#VB^@7#9GE*!2SGPX?A)W.ZDMYC5L*?#XAZUI]5
MUBL>9Q#2?^);CVD5(FO8O,8Y=R0\?88A%5\L(->[T3V;<6F1ZD,JM7LL:2NN
M$2?FA-.)0?0(:E.!VPNL5=+#$CZ1=6@2R"N84C(!!#GP<;]6FO-!!MJMY[M(
M8'7[U^W13>%RH=Z;6Y[SN]U\E%,2+1D\E]9!BWGCV?D4=NZOD4^O%?@)'5)7
M2K?%G(PB:F,$>HNBIQ7:>HN]-=1K K1@S$&TQ7$0:C=:0GLCX&<82*MJ.X [
M(U?1@5,A,$$8(A':WS!.:<\8\HH%0\0=NTWGI%#+_J7P$U18_$FABV-5H2L*
M%N*PK4N#N1&+5KF@G#*Y;>[*&@GDQ8!I=Z@-D8!A'B#VHL0V\>W-%U\: FOK
M; ;M !G<O\:KGN<X1!$A.TE_.C""ZC1\B6%TQ[T/$;IVA=89Q[C5=YRG>E,X
M_W?%(65.;[<U?7FIV4&/!WY! MW>#TX2&2:1A&!JS7/1%5^QB [2M,?5YO;%
M8&OMN<*%N2()+>(^K;%Q;L+.&H_UDL[R+@>\FB8-"#\1(\T;BG/2I72&VB.%
MYB.<19- EJH6IUAOJ=$V_$JF<"+$A+01<&5*27.2R2..,SA:3?Y]A%L(M\YH
M0OD!H: V#X[P.QO"/4>'0K"\F9[GF_F-NN%>!QG2W=V]72]3J-1AB82* 24F
M?:!=TV$\!VN4I-1%J='4SSL+0^T&Y.U8@DB511D*!FU>N$&5B.Z/O&WK?1 !
M,+Z8SIVNQ11@':Y_\7)L6) ?(WRNA^FIZRNE'GB)HU' SS.N(T6[0B2P@\KW
M0 4)-.\8VA;\G*0:<YFQ2WY]K2[[V4<W,/B\R%4!XD@I%JU=/;2JG@@2NN:J
M**KJB5T=T?-7NX?J=!0'%^]Z:=U EB!N3&Q7=KW81!W0NF5$?QAE+7)77^CV
M7'>7O_Z:-/,2":2/WB5BLZBJ-B0@F7V7M )?TQ-:HY947GFOJB(!K(T$)" 5
M@+@2!.6>?9+>;(*>3Q6*=76R*C:A6/7QUAX1JMC?,"7KWUP17O\<Y]:7A9O!
M[&FYG_,&EK_W9D,U54>S=@E ?"H[)GV5K4=AB4G++Z!IW63M\FEK[8ZT++_O
M 9KCD/4,U;I([ \\O3[>]7M;NEZBC(K+UP^ML^<J?'O>;90\7!,+3.L JS9:
M6;#2.UWIJ8=D;1UOD<&4[503+E,<*#=AOH('$Q,KY!$+T@M>C6%1\?"2[)KJ
M^Z1\6:P9GQP-&JK3P_+\-HWX1-%%1;@10JG^[9Z])4O^["%/F'-SF>PS.8T4
M[MO*U']S.1(.$3QU)PD@^?P##V<F>/>P,_^ANO0,:1>68)^$;&Z;!"#>\X M
M\"/FSDEIA(1TCCKJ1U6(Y-.@K*_IF;;NATA@V  )'&2I;G;=/4P=Q!5IRMT3
MW+]+4E*;B&M!:+OX5^AP_=TS'F00;+IHV2R$+LI%23VZW,XX'RE>O%"\BX]S
MZ?/I; 31O #">_CVS KDW&<.P3G!ULQ@0P+WBB92#67_8$(]LF]9UB,_)[69
MT?B[E<2'C1:J[J:537HG&0EP ,G_C"&CTZT=U=Z^23\!K6=0WCBZ+C=SX LK
MO4:,UHM/KZYU43#%;<5U.9L 1S)';P+W#M;"NUP"^NM"&HH([7VJAVXT1[EV
MFP2*=Z*[Y6\78TABB3/B15KI$B9_&I$FIG$E1U1)O3@_ZH8OW>0$HOK-^ HW
MZKVN"6&)>U=22^T^]TZDA)SY 0.Q'ZR^<>>ZWJFH+P>>T;LB%%).'^?O$P]Z
M7) /ELVI&A2TB^F*+6 85CF>KCYXK&NKK#JP+8/7$8D$ EV3S\)RP3\7G%P*
M*%[<EQG"$)_\S)*!OC< #].-%K#D.UXEW5DB%8$YYKO7!_$+WM]PD916&$>9
MXDK2'ZV?KF)W:)3<-E:YFOI9VVKRM'?T?K;;?",MGXDI2WK-0,@9'QM^O:XZ
MA<<O(XBWI02QT:T_F^5QI!=\(-5YN/KI8;]R?TH#&35?MLFHA@Z,RX[,UN!I
M[3V%IZHWYI+H1JH?[M$F:>8#X9\Q!Z!B&V^Y!">KOQGL9IF-!KKSJYR<%A5]
MM3I.[$K%'"=05%^:)/XZK+*QYI&6$Q-QKL7+A"<<B?]"]8?,XY).!L(K*\[4
M6O@)^ZM./3[Z9>G=# ^8,:K"LDD_UX2V'F6^/;?&35,'$H"BZY?'BO+84XD2
MC=6M&]"-8]XP>8BL&71IP(I+BG,;0V=((X0#_'9"HX78OD2/ #VHZ0D1I7WX
M+5-Y*>L1K)10=8[;X_GJ^FMJA<K-8M]5TF ':Z&XK?+;O,&/P]=3Z]1A]PFA
MLC+$-E0;B7V#Q\L:\\"O*WU6A[+IE*CD2^$LO%Q9$=&#+A>JO+BW06HQ_GDN
MCPD2UL^_LX;8OS9X4+N6RL_R+&/9)!*74"SD^+-N 1;GMU%(DV*N?%/SL06!
MFZC4+<><%./HO/!MPV/,]. ;SOZ5H\ IOYCBD7+I'9=(PJPB([JR MNK*L5>
M$&3HQ9>([!M;E7K(\]2<@0*S@F&EM(6*TBV81IZ?2R!^[R8F? N,:@*K"'#+
MB$$".$,MM3(-KYQ"%:^5?J"AU#XEZ\R84[PKCT./Y^,JQ4IUD,"' .6ML[&;
MJ M-H5M6!%3G6'I9'X^L@[4W"G%!$H9>X^[_  D )+Y%2  ;(R'CXE:C]\X#
M=<>\9'/QQ99NJPE[/5 1I&5G8.CE,OGM(4=-MJW];9H#(HI^3KJ=#72E@P$K
MH51_WIE#WUZJ*RF D$VLH[B%'5WH]@-L7T+_"@M?UWT^DT<K2B?<Y+JVE%Y/
M7-2*@SRI;3V?,%3&I^Z_IG67Y)S.8V;GG+1N.^]R;PF6D+\-SFLNF0PZ-7R$
M=TQI"?9>>&T0[3AG3@*J75(5G1G:,6@:6QKC.64E. :',W*$<_C-+E16_T("
MY"WMJXA45D2U:^NK1=TC]#$C[\&(A(&?1_)B>S]>[C.XD&K<:<G8Y>6HJ\.,
MJQ',3.5[3D[.<^&\BI,ESRO@$*>N&(@Y&S-D0$!_-E:J.NXK2\[7$]/*:$L6
M/*A+'.HCE8\]JQ&&H6\)T2SU 3S'WJX71PIYMVG9:HR,_;N\]VH6Q)/7?.@6
M;<^_\QV1GYVPL$39="1TZ[#2?^7,.4IU^!ZI>K 3\8-N-;*YP=MF]8A2]_V:
MBPB1O41% 9?A[ :?^#Y YU\C06U_UBSG6>1 9S; A;,DNF,HL-_\M-9?@^$9
M29^(1" M4/84[M0G."CRM*)[>^JA?CB>!SQ+KS%\_:-+8Z6)XN</'=W.X[:U
MEA>GE*2['BJ+*B-*4TF,(D$NX3BLDS274:2-&$\74BYZAZ2I0L7=Z?<L K@>
MO5>. %,K8)(&NF9M"WS<YWX=D\;"8^9#ZC T=T67D,O6M<,T[C4AEB+Y;- !
M3T !;X#?Q7NQQ Z#5IIC_42-QRUFYD3048/UTT>"I^8C5%OFX6RHS#$[AF/5
M)^RF!=Q:$XHWRF72.W%0CN;GU7]5]+JHM%^/<F>@DZ0(W<_%5N?)$>VJ$)]7
MNFJ!XG0>$XEW684A17VS3V.-/3DQUS[7Z+9P+89NJ8G0Y$XE&\#?+AWN'@DT
M$7U)6HBHY3[0N8!\;N++H]F',KSW3,Y;?42\]9WJ<,?4QC.BJ85AIK%>4J1(
MBB[-XC#WPX]?3.!@5 IFYRS[ES.[*U[.993.SC"N =A\=\IGLRW*;0+;H>[:
M(K I]FNN)%#+>$%[ FU(Z0^U6'#1[(^=L'=OTI>3;&AV9=Z)%A<-\AL[=IV=
M)8YT,7:BJI2Z=7E^MA/&WWL3Z##!L9?.7+1B&:+";CC_*,FQ\%#;1-7UZPN;
M^\5API]&07TF GUE:IKY6+HXH&'2OBZJ+;'(./0F<*;!(HH0:FVNM8F&JQV5
M_,OG!?:\J81?)6W[RUBULVV?3$>U1WQ-N&?'!9RR?(@6LT<CVN9, H<5Z(D[
MKO?1?+:(I].@V:A>3E0P96'CPP&>!(Q-J$OD9^N%VFRBNAHY*U$V(($;WT>_
M-8?+G>:P@V[=9=,'ND)(X!)8N)L7)KW?17G_(J*^[)@$)'E7BJ/_+3!S28)S
M <>9GA!3A48E8OFQ1ZX\QV>C_N2S):^WZ(FXG*.(6((:7++09Q4L6)2ZN^C6
MZ#C%>US2.<9.V?8$"Y:IGCD<-(38H6D33V[89=EL!II/<F\$L0OB\\#5K/JN
MU8H1YAGJT#!!8#$L6)I " \ZK-1RPF><F/:G!KY3??K41_8(Y>KSZR/H3[-&
M;O$[XKD3BM+1F;A"2:4/XA337!,D:"9R+7?>=]'%"2A=DY8+FPNB3JUZ.;IS
MEJ0E%)=1U\S?6!!%KE1*.WP5U/-_Z)[#4&XT>E1^SW3KW":<8*3QL@//M;#;
M+439JYH_G\)\\5>IQ+9(B%:N2N3@B838Z>%(5]_*.,SH$?_7(F=["*_>!W],
M#E'&[$"&RF_-]>DB&\+WB'!YD8!^E[CB-V]3_5A%0Y"RSYOM1MOJ<2=.@4R3
M_*BU>ZD.X4<F-63AO 9NHREVQO))2^:N(2J#>VOO(2N,3ODQD-#N"O9VO&-V
M\PF2&/Z9*K9,7KEIT=)V>/L$_?0[A<P/? ^8;]D/ECTUF7 IT,$N,DNWMD4[
M@MJC="W,99[Q;TN9K'K==/4T/JMF-!]T0:QK->?;PRO=0RD"7XW F4:6%:*[
M 7T$C3=\+K3ZC47-)E'AQV 9<@JA'FVMQ/Q1]V0 I,OUG^+L3JFUK.[_5F=%
MGTF,OX2R^T; *DX_F0L8#/6K*HHP!,!#)\U#UV]4"]30]S.L:GIW'!YTYAY5
M^$HVPE7V6X<X>Y)3YG=4<SL$2 @3+21^P?-L"NQS9SO(5C&YI,P4N;SSX=PK
M2?K-Z:_Q!9045G]*8KY*'J\%9_#K./4SL:ZSPBH'O]G4J50=QL?I5=_L>PT]
MPM7A/?MVEEI(^ZB^S_B!M\R7#J99A2=*(3?FL.9';5=F8#"&%GT<PX"/P4])
MPN9W,[3-=]5J>*GVG/(ZXVM1AX2[!#E99E)9"P9;/N.R<F? <S39%[]_&V^6
M_O.$/YE#\!5+-<?VM!Z\6WI]7:;'9KP;O+Y5-_&Z$N='WOE@_T9UTD%YEUM/
ML8+J9YS*=2L*%XIA4G:T@K8\MG8_&:S/?<SF0AA9=RY['76.;UC8$'434"J]
M\SD3#2Z]1FG[1X-+MZ$@]W=C8Q)1_^BXZ._?O_4,+6$(!(1/TBYKW -_M"\^
ME501'%NJ<Y1PE(*%Q=7:>9J33O/O%_\X(+"F2EUP/OML[<"VQ1SCOY@&."Y@
MCH&?CTG(.J#!U7)OR\C*6!PR5F<SEH<XI?\F^4UZH^?HE>=H,LK30)V)W@$G
MI9BF?XQ"_TR-617=[CW-VO5CF?Z(F2&UKGW0U(_>E0CUKH.2&9(Z-V$4_N_5
M.O*C"FDV10X,#6G8G)S.E+MLJ*R*L>X2WB4EK<]R^':G''LDO7>RQ[A@QQ-/
M+;EH($PBO:4>DO?M"7;B%JWU8,8IN]@#L+AOE$QE-C^."#OQS3N."Z'MG,YN
M:(R&1AB]X<3A]!X2K5N[$D)YTZI<7TA>QU&BO:O[B?X6;?A8J-.*3FA"Z&*_
M[W#L+&ZV$I5DV+^M'HUJPMO<^.G<#,/0;2:VQ_6XJ*@=<^S4"#R;WNJ[9&<G
M8:]N/61"CB^0\H?G)'N>;4/KD5!W',]',VNF:^VAX7C)FEM;39ODC16,R)S+
MK]*GJ1#$.2RAVYXC\*?(>=[KNA]19#N)\&["H'4KNE>$R<Q+Q(MT";6.WL4=
M=?)YBCS$[S@NAJL9'LMK31 X>0[_;F75-^MW&6TD?!WV0-"Z/^6@G!#E=Y<L
M4G _];R59%)E\Y_O=.5SO&Z*7/$5JEJ\1#?",S_GO F46IGA_!BJ0:7T(:#Z
MDD;;**NVRO^^XWHW2<PVNN6/TF>U6@J)]^-=< PB%9L!@:YDGSCH\A9<OU:Y
M1,NUL*X7S6DEBA"<DTY4'N)C,%BG.]L].DMJA* %:XS8O:JM%:LZ[IW27G9A
MWYJ$Y1Z>WJ9*T9?[>^:;I8NTBPGXZC:SE]!VGBHFM16IYMI0128S)MM^6G/M
MST.7M"V]@&896Y?/V5#Y1U69*EFJ%36:G:%-*IU+45,%SU!=:Y"S42I;/W],
MJ"EO'*P%BY60]X:LIY;/LO4L[QGK\A%9'RL,[E^G/N?ER]8::Y[EG&.POV_=
M=KC8X)B>5B2WTL_.V-TZ-41RLE&Q7RT.6@%C"I>C&>3T\1.(E%A,"&Z15)K.
M5B(!=PLT'^?>TL@5$:?Q4.W%!^$\1,!U\'>.*X4L&5J.3Q."0\ 8=[D[?1,-
MC*<^EP^G(:' 7I:-)<PO*UQ[_-$>&)2ZT,HWR2/R]7%];JFPC9XOW>?/[ID8
M=W%Y#/S1H"XU@O;$TY_V01,L;#URPY.Y!Y3=L=T9'P .B5*^KB6>S\)$,*37
M_U"A_U>O+OHD-_,DDX"ZLV;F:CL)"4SK)>K,+LZX/\RK(XH78<KSJ7+C=0M3
MKRZ'.5/C2W)#EJ?>!.UX6A"T5WGI9\_,&3W.OHWCR77%FJ4A4EM/I)LO(N[0
M_TY6F_KL4#G;AF_=: %AEN/-_VXQ$#"XJ,VXT#N_1 +I,7^?"DLY5SJR;X2^
M6[SL'R;"(W#\%6E;#6_YDWET+G& ;R^20O:%B)=3VM\F05,+ 2\SR46HM/KX
MQ(1PR%M3S9%2[@D%N7>=^7TBDFS@P%WWR4B>-;&$)CEY3^?G_<01>70ML,J\
M!N\C UE$C>604G_9JC%7LEZ&>[[2)#E?_@QNJSN'PWFDA][&G?U8-RX_C^9F
M^YK0]*.BW7=]JG<DY+%TPHT:%:,^_B!CJ2R0"FBBSH*^L:Z@U/7J1JO 4W?<
M 1MMYX\\XI5>C[D1*9@XGN ED59OI<HJL7E<DK60]\D]Y-MQND@9?XF^MMVS
MTRQ2>A>6W-@@>$FS1 Y"KGA)SS(HV\;IAZ+A^Y+[2W[IX^(V+H7O+-MV>6UP
M>""9>+I8U6&4'9]*42_?V.Y1SGBS;VK74-QNZOAU <9,0BK#"*D#Z47Z_A2Z
M,DNN,BJ-I*A$BBWE/*6'R=ORF+:\W0ILJ')W\XS%L^H.21=9YQ/ PZ0MBCQZ
MJM.SHD$X9/<YRQ"GNJ;5JR.ROG0^6-V67A^&F#ZSUA:T_43/MIE/>Z1FA_G9
M]DIWOB9S,MFK>)+\49 BM9[@>?[KJB/2%7D[[IKLB.++;<EFSMJ&L6JKETUU
M]MC5[4^Q4 >T87X_.0Q.TVQ$BM?HR)PBWV<%I^9T96CM&<.Z9:?[<;2-#=MT
M>/*TO7:3VM-I$%V5<I?$1+]2UY*W:C@)%'RJ9?>%2+AKNF@5@<LTZRCW(O9V
MZX]S;VZM4.JVGR<H.RKM?2!AS*:-GG_K<ZW6HU&%-]%6:EA:+:F-:_T5#H,9
MV*D_2)1-ZG&(,AJS'=21/B:0$T,");3>'%Q:^9AVUK;HU=Z6CR!+$*)P1^+/
M>C)Z$A[C'\;LU]$SOX4^G:_B[^?UUEB6H9HNG(D2<V[=6T\>O#,OS-,U0="/
MIU59-]YB%9;H^6,V7VJ@9I0+UHW[P$>37DN&BNH-E7'9[7O3=;UM7!&CA2&*
M%_Z]?NIB%L]/_J]%*OJI.YN(1\&!2&"G';IC$C'3M-GM(C9?&^ED3VQMI#7V
MY5MM+#:#(LZT77 R<&(BOA(IKI^!!-KM5X:O[AU('UQI_^V!)J:78N8:[*W.
M#=/(9O,[Q>X%;B201? +@01R66]8OO\^PKG3G"CW?<5*6*[ 6_9DMH[T<7Q/
MS9$ -WE%R8L32LHRZ3L5/MOUP<(-Y]?69NY[Q.-)"67WKU!KU>4]1:6Z<O3E
M!O*/Q%+A]9>!@$=B?;[:UYFP,,]7 D[#Y][#U?++/SB+;&U#]E_S4Q=(K,M-
M3Q&^>O&F/8K6%L$+[QT_J<&E6+GA&4N:I:O>ZN5+!A0HETIE<WOH>W7R,[%R
MAR961=!6:;V+8LN;QH3V3$B3QW<GNC5XPY>D*=H0SE/IV9=PE*7T]!LS7Q+4
M2 _8DGDN6VXF1DQR-DN<.?-W6\/V(0.^_G/2+'G ?2/OL+;-U-I;1[.:\Y?
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M@V2-,?XBPYZPNOU$-:4)M.YU =QW[HWE,9GJ)M"=//E1PG8%GU4+EKP &ZS
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MVR BQ]3UGMJ\9L!#T/UXTJ&OAS57&B6YB>:-X#; 'M@K =^*HGCW_!BKC02
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M@1AFI%:<DMC);7,VPJ[X_>A>"ZO+;:,.[*_4Y#*5T/+<@X\3EP*OBK : >2
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ML+<+93]UY$6TIEP;0+;0H>-8K8W%H2O=N?&<L^*D.-PF<G KBFV(3TBV@\O
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M!>XAMJ&O>CX\D^J?]CDA[/7R"DNB]:(!0_^(4N"5P/[GFU8W]9$Y^3.R#4J
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MPIJE&F-"!:&?75_HA+CPF4XD&@$3*;$W=A;4*K9:9\#LQ%3,E<G&,P=).BZ
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M/V%;1\DW3F%%@5*%*QN=Q@!X"0DKP2JU'87P"Y)7Y""/Z,L=E6"/<\:>=0Y
MM] IB/.O(2,?<(!OW:(]?(*VGK)_$BN. _2>'JT7"(([[V)1& :ON;)-N5VS
M</DXI&6/BA(=)6&?W]''OS/:U3FZLM!._>A3G_49SQ6N2&G:NKE09)4G7#K+
MJ-M6G_<YE?K*O%HCN8%5C_:BD.E>5W2XP$03&= /"Y!;U.1.3R*I1J+%&/60
MR#B5I+13[F3 EOVK98K^\MZ*MW<_P%_A@ VT[7;^Z=HZ/AS@_'H]INZ@W0N=
M\F( L1W,_4<.E.:MQ=C)^>YR87P>G0:;J[KQMU +CD-=JT829Z=V7$6++9,'
M$0KT+)AQ#AUXUSYVCY7ZAA8[3.W6*7$G,V><X\I.[=32TQJ1)F1620*YZ_.B
MY588LF\G6%ZY9YX;DO"/#P 6;Q,R@B]):\J" &W+]MSK?W9 =4-"P0IY][?(
MKNK:SEV2^D'?8/VDB97X>DF-_JP9D[HF.&:_;-^0:N*/B5)R5PG_(S#@_9.B
MX 5[S<4S\Y>J0$6&5:07A*J,^BO!]!C^#N3K,ADIRK'9_G651^  L,RO3A[.
MRH$ ]Q>[26R]=L2$ [)K<("K(7#9$+X^>*BY=M!0G3MY.+Z?T*)YA*;IOHPP
MNH:*K%5CM^.'Z5R]\^]? OR%U+&RH@#<RG]F\+>JXZSQ\#0\6J&9$H7OQD!2
M$+R]4DE_;&76G#J,S5'&[N'4+6#%! <TFJ$EZM;(-HOANRZ+3QDE#I!:<JL\
M5N Z]\[\]^U%"&.ZVHW7\R.75DE0"4PP".$&WR'\-_0H*&B3'4]Y=L[^:.O4
M7^\X_N_QS(O]"]@</_9_9G9R=7E'Q'XW*^'%F&ZO2WI!B,P8>':/;D#\D(W_
MB9$-1O%866]]CL\2<1@HML6J6#BX$.9ZFFN<]_WZB+C&#&E+=]1I;'C7NT6"
MLM__SM1%L8-/ G<KWY38^'9M=!.K<Y_SE@?0242K9FMD"HT'#5%M5^=L.:YL
MPR!SLE2?#O1!, A"CSY3UA8X#G?W]^&*:5L6J&X^_\." $./]2%OBE75@X8*
MJI$/D[[U# 6/95\91L7!/Q0/?:Z;2'$G0A^MI[J#I:4SDYF4VJ8E?PP%#BX%
MNS[,@P<-P?S2A&Q&(!90+!U.*1]/!6>H1"8\]_K_<2-Q' :\<^SNRP;PO1%&
M/QN$A"@,[Q?=QT/!SY$$O?!/JN,+R%^_YDOGWY?';R5M:F!_M'JH97X.![B_
MGF=MYN=RT# [$_SWB>]? A?O;\#5HT2[P*;]1SSY'5;E \[Y.&"JX#M=N]VL
M._B E@Z(.USD2G*!E<0W\S\+_>_+^*>]Z>U3^^>]]KML_B?-]O\PFV)]?Y01
MT]\S:T@I"0H\."CP:"2.!9[./\OFLU^S2?";]G&[6?Y;,G=A)2_R_E8R22PB
M3@6FAY2E!$1*O\LUJGE9E*9CHMRK]L7+O2=G]):IE>/H*(SZ4P5S*RV(")]7
M!',S3@,<5R]SS\D@(<B@<!9M[E/@(80Y!&P$E5T?-G5WO:MJ"W)LCALLP:5@
M[;S.'T4)L5N#I4/S'W$>N"F3%'7(B2VLP@](^$)N6,G>Q-O64?>KMB/FE%9B
M]LM*VT0FA+NI_= &&OACNG0,QX#@T/NFI3;\H4S2_2OU#_!EMGU=<<!<RM&3
M+ZZEXVRL088ROI5UDF9[BSA@M]\M.J!UJ"LBU;=,7#>*5R73;0/>=1V[\ Q3
M-Y?B^63FZ-GDUC .D)3:JYLK/GK2=?B^+KSQ0 W.L\ANZ7_DSC6G,L*) Q)>
M[PU&[6W!NRRP\UNSX-]=>WU'0V9?V$<T]K2TMZ;!._Y[/7.M.$":?JM <"L=
MO%&  SQTYC3!6V9;J0=WX-PXH"1J,R'YEUFI*U0XH.L*=JD-NU WEW/DY/;#
M_;%;P15Q;&:6VP8X00D[+T$5O&=9%^\&CY? HN$'B\$_0HMG'SVQIWB@">=9
MF+0,EKJ(79AP>CA$F;;#^.L"]OKC)=68]<N)5$Z50<6U.V#I;5^NBYYHBPK?
M?@]"^_-Z%UCS:U46YTPPPZ9?I(7KYRK2T\CHD])_5@[!Z3 [>)?Z$QCPXON[
MBS?';R) 5?B3E)UQ !C&].+HPBT5]WUL\>$(5\,#'+ F@J\$,TQSD_\#P8/2
MP0.4#OIK/\C@I_3Y'?5Y3WS7.B#U49SE24N9O@1E\,#P1N6GMK![DLTLS8JR
M3Q?7M]1-O <U0%=EJS-;Z:GRMQD;)Y;1S4(L0@\M6%!E8@<Y,:O5 [9E6747
M99W+T@FE.ZP4XQ?OY6IQ\%*+OE\$TD-)4_ [ J.D17@UKD6>34!'ZM#A@(K9
MI&J-K &NV*^WE-X\OCR0_]+V:>P[HUL9=R+,*7LN&LRKI@U-W ACY_G*;C0A
MTNQ<=%ZK^FJR>0"<.#MW:?O-U!V?VK:3(] MZ[-^NVYAI-J]\\E*+.X]MP)%
MP[1SC*QPP.N\\@.T0>Y"W2:L# =XEB6[&/#U!AZ^<Y&^)#.?J6>X&IPN6=MR
MF5T;Y-",OZN-0)GROVLC)G4]-94[;_T"9+"T;0D1?9CZHTVR6:CZWK-6S/(>
MUG[C!HAC]0Y!<NGU]A\F%XRVM#([[-Z3CG /OLM:NH&TF)=>LC28$?>YIHL4
M'E;M5>)]WSKF'KEHR5FL8>S,!QE;?MI/.;2RH!9$DI$C8'RCP";=WV K/2^U
M2L BS'NY9DEND>[CU02;>ZWEGUL9<^WV4M^S>G>(OWI6QI2_<GL6P9W+_$&(
MK#0#_DEW]' _QZ!D<H]L%%YG= ?,,8VZ;).TN.?\OEYVSJY*;[R9.6MP)AEW
M2M9?4,L?BMF%_7LMCU0X#/R> <'=^"M=\SO2>_0/-//E^(PZF;U\[QC(\,&6
M6N6Q^1:R\]5=ETE/36%>-'C#;_\3;[0T;^:O%S-;[-.B<QMUS:!H-H2T_!$O
M:6U %'E3^FOQT'TOGD8<<'(@> -ZS:Q*)GS1^K!G.]-P2,5\ 22&=W_!3NI6
MW/@=1R"4M?;_D' _WO#8ISO<>O =LUU>K[N5'[3[]F@TLQBF.K93(TRY4?Y>
MX;H;*K!;!"E1B(LI7\_"JG6:Z2'@:: 6/ V\^WX:P#MNZ='O+5U=/7HXGE#V
M_3"@,I&>$52R"!93/=.U[8S0H$85]FDH^KVAD+NA#GCQ9E#03# &SII =!F3
M"\JFK9XF,%2A?WC!6IR! SX9@3N<9^#TRPY/'>^P$;C#E_[%#@/]-P5M4ZLT
M+&(,+ ZRM,[E)D1TCEF60U$5I6+<W<L0?S9YMG!(#_\%->JSXYP^9KJ/>!JR
MK/?URXKO[K@85V<LO?_:38 #;$ME-[>@ASO<![8%6"R8;P_$-[]&=B@+(- R
M<2FZ%P<TO%_' 8?2\,EI.4;VD^E!QG'FL%?3AV%O#6E#PCZA:N1E6"T?O2BU
M> BJ# 5K^:\4]"PM(' _=97JC&>RIIY_-BO!'>^^JK/H9JJ2Q^(^^ YT"4D!
M45\".X\#7N(K@2ANOS>HM=,AT\JU0V@Z%W'/O2=DR30/!Y!0^N, J<FMM-_F
M]1R6:KV'YZ"?)NB'+"FKY+D78$\Q"6*WX)W!&#DQL[W9[YQQ_8!XO\ZP<N:F
MF9&(M$U_W130(SL7=^0$__F?CT8RAV3?G]^5RN0<" @V0MO_?)KKI\.56(\7
M!W@%CE\>$_'68!SY'!1=9E5?5U:,.1B;K7M93H[!.Y.CIEI\1.]'/N&L4E5Z
M;"[*8)CY*:B=4D]*_+Y.35"2Z8B%K)7?T0&LSK8$!R1&P]<*;[W!W)E:VW<_
M@P/ZS%6PO%"HNPF86U,)O?DJ5OM16_C<+/O!LI[F2H'L@A .F+Q;J84Q8&/'
M 9D%!UA+'.!C/K4<C-GO.G26ZH7*;=PK;%^/3C-D_?(655G-KKZXXLDV7_:T
M.EC*(G^!-$=VW=>JM@CTHC^-*MH;R/H6?*&64M^B/4@PG3O_DZN@YG(O?/)Z
MW;KO0FMVV-%^/GPY)AIN<76:XAPON-Z7HIIH\&[JT<D:T0$SD).78_QVG#I%
M$2*\Q>"HX-5?1CN$X%U:Q\/9P0<75!B;:4&MT<"8L?])]NMU.'@!%L;WX1C_
M@PLFG8)$ 88@3Y \B%D2/$2K8#EB+7(3=_O9AT6AR\,LIA=SF)X2(%?\3[YC
M/ALL;V(&CML?BN& VFSVCY*W"L4>WA\:?V$07E39HK9S/@%/)Z*COZ:43+87
MA,7:YLLK975;Q^7,&PIF"LRSQL^D?77T3P[>?V@SIOX)W5G+'&W1%2;VV#Q_
M@)B6_XZE#%U?M>1F:7#<06?R4.PXK/[GM\E6M_JR?E,*::?#R751D0>^J5#U
M32VJVF+[=]8253XSWZC.Q!1'CD:GFNTL#5X8Y,K"\.>G5YZT#FNT<G*4KMR+
MJ$T(/Y*[T8=58XEU%)4=89I :IXIW/:\;&#BUR3>+S.P$WLO@_<*E#.L6S^G
M #(2;5Y>5!W;.Z8X(\)QT%#9P5PO(63#E%<UH65[V[F%1'9)I89^$]_(_O6^
M>E%>48G?9QJA54BV4\$KWKR\L3))ISS"<B@G"WG?6BW+ CW-1_Z*"[/B5+4]
MNTC]-GN"&R-6DD'Q!$6YAAV5KRZ>]\BJ>V.IDN%:LN0X/GRS)<<-]K3/X<N
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MI5S&LD[HGRO4_WJ1$7YZN&%Y>2\-Z_%;BO<C9S4Y</^6$TH0TT-CR^48%#J
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M<+(-.(&QT;"&&+9%W=J>/P(MV4!/]JCAP7[@HM$;YN08:;VEYHI9FIHE&T_
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M$@P[ 'C0*UC#7[/>BJ^.;_'7 W[GW4JY?@5'&-U8[KA--SG5-8!<N$>C"0D
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MF4RY])BQ-Y%V[W4EWK_;^UK"2"EYJ'Y V0GCVE.-.)0V._2CD=;_^IF.>(N
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MA>WE$&C;*.?&8V_$%[OXY&8UGR!C>^?\9;"@RQ/QC= CMJH:CF-0"."BMK>
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MFJT$;\Z?<!2>)"T<WW*5HPG\DOSI[.%PX.=$E5/V#-G3T^R3.=2S\1PTD"6
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MEIH3#%_V)T0##!/%9X&]<O2:_QD]5+8O2HPM]I43-+ZIF^HD<(SR7>WUNG5
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M^X:M8FVAKDINM^^'+T@+K02L3Q^V) 3JY7,(UF.)IF7WTZ,ZBA9L4R[18:A
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M)VZ.[/03/KWS"AQ1,G'VXK6#^:3_Z&2V^D+!MDRN5_T!SULZ9C,U*G$^%9?
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M+\ 2!C#19L $V<0\[*>1O3$/;%\^77^/\(N9[=>!#J=I058^@O\4T_@9"B\
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MA?+! LKF_+Q"?$'.(Q_&BD#2$(WFHON=NQK>2VXN*;[V^(=.27!K>TU5.IQ
M44O")9W-44"RY^ZR_^>H>MFJ<H^D!U)3CR[F8;1Y'#YF'4&EM?O5Q)M-)HIM
MA]=4K\/I&3-)N3UL.Z[E,5%S)PI-33N<KC&6ETO*[N ^J[4];*^E%8>EVVGR
M]ZVQ?*^P+7'3S: FN*-[,PI=UF^V,1&34WZ)\1P $(J2DWL_ N+=PX13O&U_
M5EJA;'-4CNX)&2A^7_&Y-)75F:#%"^AGRZ5XK8PSQIJ%*1<(Z+OR>6^$CNXM
M[6\/AJ)TR2HZ9/$=(K8>/LS!M>*PM3S>R+E[L;SB>EHLSPD(U5=+=8(XZL@4
M.FNLD7O$X:SS*A(U'9LW+2.T#N.H.])77[] 7)IARM26'P364UX5PE'/L9_J
MVH3AJN(*,RM=*6@Z_"J@CI8A'#H*6\3CJDYEBOOR%9  MN^]MK#:A'*T1F$_
M378)Q24E<FYK#]L566_Y\%WU!Z66MX! '#:3,O*6I\O70)3R\J>*+Y=+$"B<
M[-1TV(Z[[,B]62!JFH]S\@"4R\)4K02=O!#296&JYF%'KIU<D)6/9*VHN%N(
M!@1NLLK1?&&_H[ER;. S?TL7TB#"_+ K^U)&Y?DH]$K(^.&! MTX)Q[@"HGZ
M(93(_10F^%L<P<JEIF463M[562CA\ HD7H%E%,KO0"#>=MY=ZT2O(+-1MBC=
MBG0;\E?9$0Q>@M'!RDF=E0RI5\;ZW]X.K]!/@?G/?_IT>O+S+]23/8S"IMC6
M8@PMDC4@,OCOX.:TSHV %40+:*\ 'X74UO5)A<+W=0H%B-=8K@U\J(?%UK,G
M7DB5)^3;J?O0,.P"TBM 1R&R=KUNA:Z/=;KJUUT/2DGI'&D[.3_5R<D@/ DR
M"E$Z-R]7B/RY3F0)@Q@1'3=2#SQ%B<O8;WV2=!+ZJ3D%"2!O!S6.O<6;"&]!
M?N"4SV#M]#4<5@[I25 O@QV%2C;H@C4(?K 0(6%Q!*^G(WA%_/@*=]![VO!.
M.0ZO0.))+%Z&9B326=/DC%+F'+G5\8 *;_G%%F<K H3_:&>@X9,R3%Z!2MBO
M1.:5L(TS>Z9/%/R1\FL3GSNGSM.&ZRG O!QN^OA%&<><-IQ13QSCO<D_C7;\
M5,7,0[?G/VUZKCY6,FQC,6(6FZDX:_B^ R*TL;EN#=54S#4\:5? -C;E+2&2
MBNZ&<VT+E,:F.0N"5&0V7*L\5CXR8:4 2D5=P[&6PZBQ:=19P%[PYV4B>L,3
MG'Q/NI6-]PU_J[N@]=[(#KQ=#Z.9-PL PC0"[;47DHQV]AK>.,?%62FP>06Z
M'5_C<W-)$QCS8/&1@F4:73$1TL62!3<;0)(MG_-XV,&M7DR42D:;'KS$Z*XC
M+^O)$UWQW^2=B1DVBTQV_5F7Q!PE/EI!II^LGD(I@&8XH"6 H@\OZV1"KMD:
M)N2ES6'Y\HGRDRASM,0DRP?*9<4#KA93*D72#"M*(MEUKGA$Q2L1L%O8)-C;
MT> )(B84F>A/5H0K>6\$'F7>,ZHEF@FI%U%!FU(%06K[;@0;98:R<*-#6QGR
M*=FLF.@U1#!.8_$Y#RZ4G#;#DS*G-=.3V.6W(GC9,6MEQ^Z*OYP".NJ>=T)0
M/4*HC\'2,W":]-TP"WIX =$SN,8H62LVG??':'N?T%3;]>?C#A2E2UO5NKS\
M'?CDX04?;@T[1+;W-R<R@IK@_FUUS_H<8/8KH;*])3NE_LO"<V5/M7#_9RB!
MLQ!&*5\3%@NK[&$Q$&;78,:;-/&S!6O^_NDM(.+,O#(X:"0%RL%!I>?RFB[O
MV^-J\TJ]B\6![-]C!'B"@O%C)56F4&_AWL@_].8,+:S7;T"2K:KD 1H6ZGX#
MNQL2'C!_S.P%1I%*Y1^:&]8EE;,>\H5;W@>/>9_8<B[OAG_/.QI?LWRV(/R8
M"(P 33 "6?Y<#F$EH\UD189,Y"IR=#(?GX>ZHS-DE@O6LMT/C63%05EA"W;=
MFBI6ZE:9GNC.&]M=QM2.Z.8,RUOS2J_2GJ>$@-8'L?);48PQ6;KFIN50LBES
M52#;BY-]=5B_UJ9?,"[%HON9J*XM3KVV&$Z'/>T=B27+E4AZ'J61ZJQ4)DWI
M(W+_7[I$B,I*R*W20S0SEH7W%\@\B<W+T4T7S-0N67E$,-%CJIFU+)@JD$K^
M!-H)N6ONFNH9F^;^Z?0V)P\S:&FFN9 J-"/Q3*>*_*)R'>DW*YKDMK"%.'"W
M5RR+J3:\%IHR]"K1?U0N:(IM9.^-Q/J7X]L<K^V(<+SG'28Z2I,Y/&,V^N!L
M1WE]#U%@(V[<B^<NP!(PFD-CQ?4"VH[MS#2G*0>75/>['Z69.*,(O_#-Y9P)
M1KY(W62/2<S16=SQJK)$98[)=E+83+G[2LJ=9V9VCO$.!!@%XF8,D>/=">(N
MNRI#"D*<I2WJK91>4UG*4^VOYD=YGR*[DI<\BRQPM5YKLLWQNDJI.*HE-NN;
M^E=+1%GSD_<C)" SI*+P6!8&[#KSBMYL1Q<-V926JC= 8Y;O!+3KM79DL0_Y
MS^2,P)^X)\^ 6X%8GOL1%6M[ UY-D-J.4S0UW.'U#I"C2QZQP4ZQ[8<I/6?+
ME^T2DQ>?M+['TB43%1+;0<Y :N^7D]-J9A^R:W<JI.\QW+NQV YXAAO??9+Z
M-]0TGZ,8P>N#E5T@LGVKRJCZKLO+=9777%+YVO\BY*7M[P*<8]7KP>/T9OLB
ME]&"@;TE[[2%-9<'!@;3!FS[;9N!]-\M%V<6QLTUKCK)_;%1+M"Z6AT_U:TX
MN*W'2&-C3GF0>T+.JH>[]9AI.<U8.>P](?DM!\#U>&CLR+4>")^0$^4A<3V>
M&AMR?8?&)V6O]R"Y'I.-#3O-@^63;D16#YOK,=:L9*P?/N]F04[A_!^^_<I^
M\B]02P,$%     @ '8A_5B1@E4SY00  ;*8$ !4   !M>6UD+3(P,C(Q,C,Q
M7V1E9BYX;6SM?>MSXSB2Y_>+N/^!5QNQ,1.QU56N=_5,WX:?L]ZS+8?MZKZ]
M+PJ:A"1N480')%U6__4'@*1$B4P\*)( 59P//7892&;F+_%*)#+__N\OR]!Y
M1B0.</3;JZ-?WKYR4.1A/XCFO[WZ=O_Z^/[T\O*5$R=NY+LACM!OKR+\ZM__
M]__\'P[]W]__U^O7SD6 0O]7YPQ[KR^C&?Z;<^,NT:_./U"$B)M@\C?G=S=,
MV;_@BR!$Q#G%RZ<0)8C^(?OPK\['7XZ^N,[KUPIT?T>1C\FWN\LUW462/,6_
MOGGSX\>/7R+\[/[ Y'O\BX>7:@3O$S=)XS6UMR]O\_]EW?\>!M'W7]E_'MT8
M.51?4?SK2QS\]HI]-__LC_>_8#)_\^[MVZ,W__?ZZMY;H*7[.HB8WCSTJNC%
MJ-3U._KZ]>L;_M>B::7ERR,)BV^\?U.PLZ9,_^HGZP[EQA_?9'\L-PT$I$M,
MQ\&O,9?D"GMNPBU$RI$#MF"_O2Z:O6;_]/KHW>OW1[^\Q/ZK B>N;()#=(=F
M#OM_"O3ZJ\O5TF>XOF%_>'.*J=U2+GF7!4&SWUZQ!I3RNW='[S*Z_[+5*%D]
M4?N- V9^KYPW#;YYXH9,-_<+A))8]NW:QBWS<.L2%"4+E 2>&VHQ5-MS?^[8
M:$)+2CF>S-A )VB!HCAX1E<XEFI,J7/'/&II5)]2B]S33R[<:([BR^@^P=[W
M!0Y].J&>_S,-DM49F@5>D"@+H$.L9QF:(=*8<LOVY<:+BQ#_T+/]W4[[\S0A
M<S<*_N33^''DGZ'8(\$3^VTR.TGC($+RX:E#HP4M!O,HH#"Y47+L>3B-$KHI
MN<4A!0[)M:G2>7\>[Y!'$3M#SRC$3QR\JX :F$]-C"KHVHW<>8;I+9UYI4PW
MH[:_% _$]1']PH0.!7+KKMS'4*YA8:?]>;K!"8ISLC)6ZMJV,8KIK/&:;59\
M2IOK73Z&P2[[\Y/-7#(6MEOM_]5+>AI8H@?W16X1-4WW_SY=59=!PE5)C>T4
M\X%,CR@*<X!"US9F@)#.VQ1NDBBP5-^Z!=N@7?$*H1-ZZ)K1=8W.#U)#@;OL
MSP^U?GIP\+[?$CHT/;9"T)_FQ%U>83EG2IW;X#&AIG$<QW2I8$9";>0.K]R0
M3K9S@OA$*^=4F40+\U'Z&*-_II3F^;/29 2T[WAE;F6%;G^E%G[N06G%TR#1
M]\Y"38!]:':TRU!C7*%K)^N]HEW(.K:U]JNQ4]>VU7V &AM@AW[.,F<H<8,P
MOG$)H>V>I7O(?6BV8'MTP?/3$$UFUR[Y3C]#%7:/O)0$;)^0?U=JASI$VN3Y
M/$Z")=O7?(O1+ VOJ&KH(98NVD^()"LVF;"5D=DEGW6TQ=F/?O>27D:)&\T#
MJFZZ%4")/EZ-R+8I%]T<^RBB$QC](:8KFL^8*;L+F<.<+/GHR/>P#WCRQ!S\
M= V\0G3NTQ:Z_6^VJ1%.__SEB7&H+9J@<YL\\N6P3DO\^_IFJ$>O54FV8+T.
MHF"9+OG/Q8JJ+XPNR3;E.:9[P]=^$*9LF=C,P><O7ICZR+\@>,G<Q6GB9BO,
MN4LBRFI\B\C]PB7Z%M?R!SO>;^LNSHV(M8GG#4JR.?C8HZL,86/B!!V'(;L7
M8[_\ V/_1Q"&VK@U)-S&:7*Y=,F*[A4"NC=+<(2R4V(^.%0%T:+2]ZE(U\S:
MH=ZFW=4>?+2-3(5*NQY;7<VK]&W1YOF);<)W]W3@T8_P*R$]BU>@T2+'=W1T
MD<"C<P+_[K<H2!ISKD&KDU.U]NRO3J)%C?_!:+/UIIF2Q=W;\@CHJE+<J\V9
M:WW\S_W+3P0_!RS81WOV4J74)O=T)<"1%X1!OEU:\W!'EV4ZD^:LL&U5R<^A
M+5HKGVE3[C,T0X3M0MR7?%L2^?DI@(5'9=X1NCOYP0YI^O+N1;Y5'Y;NP%'H
MVNE=ERZ_#4BU?1>FO_M2Z=W)79GV-*I.HN.[-%W.&Q'KY:Y-7Y+&)-N_B]/>
MTBCV%W'J$J]@MJYQF0$@)K,(#67!F!\Y7PM*@GCI(WKM!TL6R8:C5T[^H;(V
MUE2"*'E#F[[)V[RI)= ]W^N/O?;QT@TTF:[V[H%C_J772[1\9 &J6NQN=^V>
M5S<,]3CD';KG*\+)L2YK19]>;1+-W#1,&AMET7V;9_K/ 3VZT197]-<MOM$+
MG1M]Y!><,X(J4=1)D+"&>?S[D?.:!<NG;"JE/^8MNV"B/E)ZBYEWE(-UB"3G
M9G-IX.3]G9Q SF'!8XB]+<:X<PV3*JQQ@<?,C1\Y*&G\>NZZ3V_8Y/T&A4E<
M_ N?SCG,^3],U\Q11:!+^N-:D-!]1"'_[#1O7-?VC5FN'\K!<P*.\W:[W&[L
MX)@4?.>6K#A=9,/G5WH@2JCEG(?\:W0(HGDYC&9&CT)25>9JPT()RKJEC+QR
M,/$1^>W5T=L-+R&.D?_;JX2D-2+W#-!IZ,9Q[G8Z?@E4K*O:I578:M=Z&4S;
MV@<@@F2M0<L4+F46S_)= P1(7=M6D:AN8&0P@!K&4LXA*-Z]'286TZ,:QMN"
MHUBZ]YW=&N/%I8,@>]\4LNJ)YOJ_KL^F]XBPHSM=F^E6(6&1"[<D=_EPEJ[S
M+6L%'-9;K?.TSLSV0VM[.PT@(1@)N)$,X# R-J7E+KG'."&NE\!#:+O=]*,9
M0)07_AIV(=T;F\$R'D]3PMXCJ2*PT]P4$+!^ZW"H8]J^Q=V-%\QM2O^/W9@\
MNR%WI":G+B&K()KSI\*"-4:ENUFX!##@AK* $YHI%.NB('.Y8>P$G0:"F$P"
M<#-@"B>Z1#ZY@9_'RTD1JFT^$&Q@WB%4/EBQ)"DN10-!H<HSI/V/9K5_@R-/
M;T]0[3&,;0' -X3+)U.X;$>5W@7S13*9?8NS"&T8'&$WLPB)-8\UQ8  ^VP*
ML"* $L:F:#$<&+8XAC3^Q93&KW T?T!D>4G/P'&R]0BZJOR:QL/! 6(>@N2K
M+:N)^BHR'#!J.1<Y^4U"(0-@&(NV6,7&3N]7@?L8A/S<(]\VU32VWJ,%\0Q"
M8>P(7N)4V;D%]S$%C$3?(#A:OBYCQ^_\14T1?B\_\=6VMP ;]?,?+ $(C[%S
M^%F*'O!D-@L\1.()*>>RDD(E[SLDV!2E 2$T=IC?/C85HJ^D\(G[#0DZ!4E
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M]C-E\O_)$_G;Z&GJ+AO6#>9)M)&?I1;MX""@RX*Y<WU7&]]>-6>=X[L'\?]
M+.<M\H^?$7'GZ!\L$^Z9FZ +-R"2=$HV<#=:?%=*_8DF<JZ!V&2*R6T.1J/>
M1W'6W:[T);V54[DFBZ/I=ZK9MN^NH$(@G0E]_H*(%\1(-%OS<AO]<7 X)FM"
M<0J7>@.SR";3<,^:_XFF82LU"QF]O95X#R=]^\%8M@G%089KK"A.7]);N;?6
M9'$T_4XU"XT-<REA.U//!28S%!B>URM,C/:]I^X@"S:62K=S!:0$Q59.[3K\
MC7;?G5JA(=$T1W'OQ]-3%H'.ZAP:<YA4.#@<>S6A.%$ WT!-TCZ/B3Z+HU%W
MJEG0ZDO7D;T%_[/(E]>/)=%CM6RJGRMQ\AM*3D'*IJ2J8VS\&!L_QL;;%AM?
M!.J)0^.W6QUL9'R=,BP*6E$-1K8C&+U6F?7ZMC>*O)G*;8[<UH:EUYP7#S_P
MPP*GL1OY#XN ) A%63GCB+U I]L7QILP]X4&!4,1UN+8Z 8RM#U1 =@<+_FF
M5HI I5WO::N4%5W/JLKYH&5C/X[\^^!E/W.7TY@:*N:A9?&*8H S4K<@(9;A
M;&^89%2FGP8"E)(@X$5OIU"=<U? GDC)B$R_#@,H)3E _W2G.#W\H,RL)A':
M"R@IE>E1WQFO&D*E* FX2#6NTJ:S2A6NN;V6*9#(]-U0YC\E0<!C3>,)<'P2
M;^1)O+U1_]8_9AZ?Q)MW9@S?BFQVK(Q/XJLUQ+-[.MDS^$K3Z9&M%Z#M/7X'
MA :W=1];WM:Q]*IY/M5RWC%I7EFPS_2=H;-0'Z I2@_.^5^-;1TZ24WQWM!9
MJL?QJ:  <-(U5RA[AVM-E'/A/OQTZ)8%AU#]8+#\>5'D(CMH,NW@B.E#?'J3
M=#O8TYR2NBS*N;K#IFQC#30W<[Y2TS56$<"^ U,;P-A\9&D-/$O/()3+)8Z4
M5L)*4V-G$/'HP"I<PX<(8]M0MC@?2!WK+I8LH7K:>] ^V*K(8]'K@X;7YD6R
M0Q,86-%K4PZ>SLI>2WPV[9[W)!6X'EAT_V1V&?G!<^"G;@@7I@.:'M[B",L*
M@=9NT@M=R/X(DL4="KG0\2)X>L#GK,S52E1)39M(_Y7NQ!@(L%+31^<+H(4P
M6KG@=0=UG^=#"=IG 4$>)06N?[31=IOI^P_]U\IK.I:P4 @0@@_&#H8L.T80
MS<7'P:U&A[?.U4D)064L.T[.G<P)MM/,S+&M3I.UNK;7]]A$W5:N*LT@L=2C
M" Q\/K+IX*<3Q"1"TG@'=2+3]X:\D/7C0RF:!98#Q-.<7U(NP\,/O#^@:R+3
M]X9"6]L!=$<.$-!/-@-*O]3"&"V1F;[_/&A0=R4!8?UL#%;.+TOEH!"PO&EV
ML%O%6G58E"YNS9]L_U)I:#!,N*)/0.?V;AJ;JMWFC6,#:'KUJ_^G&Z4N667/
M=O@[J_+S7?ZOHBT$HZ%#8OK^BR$O/&#^>!\Y0)"^-%UI()32<,5?*^J#(^\Y
M_?#67DQ4V0?OFM_:MI>3YWG)ZC#EBV]\G"8+3((_41>I1:%/33_8&L/>>R9%
ML8H@N[/MC"^7,Y/O-B7>@OWI A/^SQT8'?"ET>;4- 29W/#*4>T,K6<W"-FI
M@8K+<]]U/]_M?G$T03U-@6>(P9EB;26A=0;&RR@A 3T0>%UE0=;Y_&BD>Z@-
MW+(;?6EX&<<I\L]2RNX\$R(;=C?H!_^3\)F$2O\#M!D-N<'#P6%,4R;2MC>L
MO'9X9FA"@9 ]FRN:5#\8.<O-Y[#M[@=H.^IB6Q=/L:_=3](D3MS(IU+O&'U1
M2.R6!%Z',Y<B P=H=7TJSKJKG<;2KZ?@8SHLET7-NR?$7N'^CEED6Q@DJSLZ
M67=@L^H?'^VUL=(@6QU>S1^661^G47)!0;IVR7>4\"%9^)/.NC%2A:^.UJFO
M+<@LF];=:<<L'^4B/^H,R =$ED<2H^SDFP=JDAWJ"O0_#^_.@TH7$-ZXHSEQ
M^P,':FMM*08TK):31YVFRS3DY628Q6>3KZBX$MC^@/!4D!.$QYRW?Y/(BN7-
M87-5%(N&<6W[ T)104X017,)9)9/(5XA=(_(,]T!U6OE!D?/O!(M5T#\@!,W
M+/_]%,?)#4[^"R5WR,/S2!POT=DG#\^6.E85:(Y-??/ G+^^SBSEON/;G%HS
M85T$/0X(925)09#,.9QK%:&[@3L@'!7D!%$TZT16\?,>LBM6P5MZ=!CNTAUW
ML1&OJ9"' [6P'G4'6O#!.%$GLQEB=W7].E'+7QVM5%];H%VV7+V\R*HL]2E4
M&QX0K"(!P9#!X7D/^7_R1XQW;&KLHLIO]2,'9"A=*0<T,K,QTDV<\L>>AT*Z
MWK)+RTS0[+C6P5T)]*D#-;CV502:G2WY\[/HR"SDZ 8E173W!28/[@O+T;/
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MZA#):(E9&CDV&7S\DO%J<W5ZGN8DB:->IB'-X66#@K]]6QO@V[U;G30,(ME
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M%."7GZZ&#6EJJPV(K8Z01=)R,<3E9LY0&#VFR>+I \G+)TST[T*I9?UE=3#
MW>9O4 @&)XD-.N'&="V.6OF]O@BE?HRXJ%)^E=/J*6*5L,^'B/6 ^\\0RR5A
MD,,$3Y;=MI:?X:#>7,.:^S@&9N!R'*D.86BR'HMZ.O..2U?DYR1-DVBER_\B
MR/A+^:* M\WR,A((S@ =*N%L 4&MW.P[-M4:D^CX.>&SPXO+RQ/-WHQ2UM\N
MC 'N=K]%(0B#!P9TPIH1%T>M/+HX0E1E;FI\Q(]YF3#G<X?+,C6$(#II;_0P
M0^X(HA:%01$COC%)M@IHJP$G#CDA.$[*\VC!C^IIP@^9H,^H0PVT'VR(4L%I
M8X0F!*Y<$+62<)8&G_/TF8;30T,,BX):';]1JP7\8=RJ40##*AN48NS:Z""!
M:E#<TBTND_H4I\4[("IAO_32 1[R2B8)B% :>"*36F'DZ>D0]@3>?V.27V?X
MSSQI9U0NGG!QGBS+S0TF"VTPY*#L+39R-J@+E:PU@W-K$MPQUW[S_5OTYYIF
MC2KZ[??_8^YH6T3]DJRJU3G+&>M.-Y5N0+;IS=&03:X(E6M:M%JJ<4WTV]F9
M=A-M**D7GV](7F*^E$3_]$BB%7O/3W?ZUTK/W_E?!S.V)X ME& PRP&I< JX
M445;7=0H\S<;9U]48@^#)F7%/AREQUE\O%CP^ _'%]DS>VF6:&CFH.R-:\X&
M=82SUH3!.E>XXKF3GC[?\]^6@+HB_!Q#/U<>7#8=/S=K>CYV;FO*Z+BY20T&
MYYRP*HZ7GVN/EX.9;;)+8/CO%3L[PY[Q,5R%5TK[OH:G@3R^A"<1#<XR.WSB
MHGLKC>KG;B'=@A^9HC\/+)<-2"+-V5^9(%0"&?9L1O29Q0D5>/'M8_[\78R3
MFC;T#UNVT+_\<I)3MWC\4)0D6I0CNR2_^V"%$A9C@O!C\-97(1+/@5 9ZB :
M*=\-?9HOJE7CUB06#'_VU<PR4&TK]W\#T<@20.*-D5J$#P:>&YB_9LH^?IY&
MCQ+XH]]]-;$45MO&@Q]!-+(,D?3=6-[,3"A4,Y_B8D$2GN1$9\= S'NC2T *
M;=^3@44!$9B:"3W90([]%C\F;&AA$+J+'1HWII#W[?JUL,=C@508!&EL$"I'
MB[[2]E).(!X=9UD5I;=XG1,=?89BOEDC SDF2U\&%$<DP)34J&51+1R($?^[
MBDB)2;HQDD*0],T+!=0Q-49BH-@AQZ8D2"<>EB/\Y''"')B1)**H]^F& JPP
M]1C)@>*) IQZ2M+)AV7*W1-.4_;22)29'8I,V#=;U(#'?!$E03%&"4_)&:Z!
M&A4XM.$K9NSI$$MC>_(AR2/ UO&G$P9+H3%"2Q;5RYU,+Q"3;C!)\IB&V<3$
M(4'2-WL44,>\&8F!8HP<FY(KM3CB\N%)<I;%5A3IY,(09 133H]&"" YALA,
MU#C+XI#$.$^*19366,[IOXUW9PVRO@FBA#LFB2 (BB@J=$JRU HM9[A*4,+\
M!4?$CBX]R3!D$:#*J=*) 23*&)N))DP^"$E.*D(&J-4CCEK4VZ:L 6RW/ZN0
M T$4 SAAU[86'Q ET ATEI5)N3E/4ORQDISGD(OXXH8*7,N)\>\@N*  ->9
M+8:8'*H%@[1\NTN0E>QZB]*<L9A?!LA!#EDPE '$!"DP!1NVLORV41!&G%#/
M1*+T(HOQRY_Q1FF7(.>7$PJ80U*,A "Q0HY,08M&&'%I1,6#$..&)"OVE$"R
M, P5HJ!?:JB #KDQE@)$#@4T!3L::71W<1)R)+F/7BYB2M1DF=1I'PTL4<K[
M)8L!]I S"F% U-$C5#"(I2(>:H4D$LLC2M9Y[[A#DU?Y)(_5$8I!RR^IK$P8
M4DNK HA@-C@5-!NH'M5G4E!.4%, 8B4$8=QQ'-.**IK_7"89?JNT7RKKEUT:
MN$-.200!,4F-3L&?1O*H_0-B.N@Z@T*:=PZFO@M/FG>VI'D'FC3OII#F_DL.
MA#3O'4Q]'YXT[VU)\QXT:=Y/(@UM^*"^YH3^\9K<YU]DA[.5DD$H(T*5$F8K
M!H\N C8369@"BV>82DB:\,#JFMR0_#G)%NJ0624>A# *T%+6C&3A44<.T,2?
M+B!N]8+ZFCHH-W:25BR,EQF"E+N86@8>28; C,ZEE@Y)B9N\**/TOY.U=B(N
M%PY"#RE@*4D&DO"H(H-G(DRM@ZA2B(EU0U>VH2&]2C;ZW=\58 FL[17@WH\@
M2"!#)%X!KE=/:B'?S<PX2G"D\ C#G[TUL@14U\:]WV TL0A(:&'>KZE,B([,
M7PR[><HS]0$!4<172ZO M:T]_AU$BRM C5N]?JJ-RP5:C7\I<5;(W7?O-V\C
M^QA.-Y"W/X!HW3$:89AN?_?<FC^3I*1?9D\T5UFSRR,[-ZB0\]7*6IAMBTN%
M0+2^#MF8"8TL&@I[IL5=GB:+A#TD<T4GGR2)9%;)A'P10@VP98,H 8(*2EA"
MUIY.$+62GDEP0S C(:8-P2\!XBS&Y'JYE([V.F%?I# #;LFAE@1!$B,\(<\F
MP6\6/0U4JR"N$Y8V%T518>)$'HE*( HIP2N(),A#I),*I)%4M6)(;MWA1<4>
MQG[[[N$^*5/9Y%(4\38F*<!U(]+H=Q#<4( 2WAUDOZ%\B=Z^^_KA&]1J>6[^
MC_D]B6(Z)-YM5@]YJL@^)97R10(-Q)8'$A$05%#C$A[XR5$CBFK9$-FI!F E
MYHQ^]T4 *:RVZ0<_@FAT&2*A\P_:.I#+/WM9/%%06'$A02[FV_7+0([=?U\&
M! 4TP,0<Q[4H:F5#7$C8#EF/YB#@,5@0\&@( AXA!@&/MD' 8[ @H/ULG2*$
M^J7KAS1YC!3)";72ODFA@3SFAT04%%74^)0^HU-!6QW?&2UYBK.+;)F3%?_^
M.?V#Q$J%G+><ECJ875)+F1 (CNB0"6DMZZ1S/6'$I'WSHN+O0M1@SI,LRA9)
ME';I$64KXF85;VRQ!-\1QR /@T-V( 4ZU6IM+L-.<9OJTO=2>GT XV><IG_.
M\B_9'8Z*/,-QO98BVRG2R_L],6. /3PTHQ &02<;A(JC,TSIS6>FA5JU9B4L
M")-^RM,J*R/"[Y(3F6=2R/EEC@+FD#$C(4!,D2-3,*031K5TF O:=?:(+LAB
M#D^: D8O[OFZMA;TZ-:V5!809[0 57>XFYP?V]BXU@ITQ;+$[+V(Y!F?1F74
M8%/:JQ+W?:E2!WI\FU(F"XA"6H#*^Y.=#DL5$[6<"I8RAIS04.LQUYP2'TGY
M3QPC0!1SQW0B@.@APZ7)($-0*QN$"W>K*$T_5$62X4(]$(VD_')!"G'(A8$(
M("[(<"FXP$51*QN$"V<K3![I\/8CR;^43TU^5J5M"FF_W-!"'G)$*@J(*SI\
M"LZT*JC6:5/JAB'/RS:A>)UE46VI1-0S;91@1YP1Y" 11@5.8$N*%VR]Y6->
MHOL<?2HP*I\PXL=98_KOO4SP=3FA7AI9+-B%B#HJS^*(R"BD$_;^ZH@2L/#V
MB" )@DA&>.IW2#H-U*IX9LTUY3#IS^,XB(L2KY2W'<PJOAAD"[[ED4D>!)LL
M08XYQ=6&DVNNB)AFR&Q&_>3VZA!O(.0Y,I8 ' 7&/0D0'%'"4H7%_;<"PN3.
MJQ[29'&>YI%ZE64@XSECG@AOE"QO*P"( 2(J58H\+HBX9)#V_Q!EGTFU+A>;
M&Y(O,&:GK(K.6YG6WRRU_7+&R:0AFZQ4 ?',!:^"@=LB4*^,H]Z(%7(QCQT:
M9]G<\L7GNZ>(5N!U519L!*7 U*O@6B7/VPL6!HPV&30:@*AG 5.UX< U$5<]
M0K4RZFD'FI\5VRR ./ZPN<5+3-B]@WO\4GZ@'_JLF6%8Z/J>O5F;,Y[,&15!
MD- 5K6JJ5Z!^ >B!G1%KBD!_984@7HKO]\LO%DO"#Y+DY+@L,>T:_!"3_+:!
M3M@7[<R 6YZI)4$0RPAOS*2+D_-;U&B@GDJ0Y[)K&.<)65W(EI=&OWL]'C:&
M-3@+UOX(@@(R1-)37K3!F1"Z. W3SHJ+"(-?/;>Q[-I![R=([:NY9-"V;H"K
M!<VG69(-U6/W8PG/33R&-FKF]F=(33W"I&KN5FRO3;Z,B@>.MBK>/$;1NFYW
MG)9%^R]; C3_\$MW5/0^>A!NEZB$?-! #Y Q02X1G Q:6,)]@5:(AH!,;+_1
MWTZ$N$PRS%:.QZ<9=()!B"$ E9*CDX)'D#$T#4F8*%_/+\(SY;@H<%D</[#7
M>A;CE3N5D$^&R 'VV3&4 ,,,*2QA*+F[.[N_ \*"9N7.B@R"K'].*."*U!@)
M F.(')WJJ;U:)SAA3J+BZ3B+V7_._EXESU'*%D>.RY.(D$V2/?X4I94J$+'4
M]4DH)W/Z!+-2!$,X%[0" :D2BK(8\3_TU(-S\2HBGW') J_FXF:""_E.E)6&
M3]Y90.^S32,.AF-FC&-F;3705B4XJVX(7D=)?/:RQEF!]7Q2R/IDDA9NGT-2
M03#LT:&39'MBLJ@1#D^9P7AN,^8'C)J,T9)72I1Y&:67MJ&2*MD#*P0!"Y1J
M&!]IZS@$US)Q_TQ1@Q9)(\J"<2D&@&*FJ.P-, Y=KS%[:RY[O,11@6^3QZ?R
M>OFIP!R>PFJ#CD\V6<'O4TJK (97-BB%TYVM#N)*B&N]R9=OV#%T(&S[,<_C
M+TFJ,GO[LT\.C4'UZ=+^!H89(T!C$K0_!V_IRSQ[O,=D=9$]XZ*4I0W12OIL
M?PW4/A4D8F!8H<8F'!'H)%"2H6L2/4<O1^S@R;?!*3,>3"W'W+#ABTW8 C'<
M%=#)(UZ $4L-0VM<"$JHB0"Q^;6-#J2A+Y/H(4GYBHUA9B.5]#J$J*$.AA!1
M#,X0HL0F/+IR<?SAXO+B_N(L_.92#[7=#I-.(1!C+/::U-(0^>.VZ]13#$ZG
MYK)E<1-MV)JQ8;E-(>QU[-$"'HQ%4DDP]-'"DZ5@QGS#J+[2V"B%Y\]IA>_S
MZ^4R66!27!-^K^ I3V/Z-SV7;!1]\LK>D#['S%I@^&8-53BM7V%4YNAJ<W7*
M[LJ1)([JBR.-=G .#M>.6N^ZT?//I!1N34]E@'I1;ZP!AG-6,$W+>IU:<**)
M([YU:! ZUK*+L6!-W)3X]'M5D,*K'A;K72N#3B >V>U?:17 N"4;E+J=+$@,
MTPSKQH5%2UT@89A^"=)*$0P#7="ZQF-'*,,E>Z:A*0;QN^0 +E8HH@$C32WT
M $1K>GH:E<!0TQ:I==@&EH_28<!ER  P&%L/PF!#NPG[,I#&WQX6LZW!"&.@
M"5AR:"D!B08LKT92[T.S,^$YSU^'LX6:%EH-K\?US= 'A_35XF#&,#-&86U^
MJU&?R^_K!&=7/SYDEP7*C6$.J5/P>R/1!'QX,U$E#8991HC"3<7_/+X]^\_K
MR].SV[M__9<_O'O[^S^AL__]Z>+^+\%9=4-8MA6"8VZ4[I*15-+S@7P5U-%Q
M_+$8&.:HL4F.XM>2J&"BZ)G)!F=++^>4]CZ:(.9[+).!' ]@?1DP#%$ DPU5
M>59S@\ZM<K2.2,V1(_3;[[\_^K[^_ZBHDWM%5?F4D^0?E$[O?SCZS>_9CS_P
M,>[][X]^]_OW1V_??H\2]J!1S/\UWR8#0U'!YFVG>(%9IE3T_NT18KS@<N-_
M?1N<H;>XC)(,QV<1R5@>O>/%HEI5*<LM=8J7R2)1C98VBCY9;&](G]=F+3!,
MMX8JW/#>"J)&,CCMQ)# .G8('8S9!6&P9H=*?/))8G]EM(N_N%IPXO0/H&6Q
M-8W,:J$. NJ,4)T*E.G (IPE6N,:!1\U =-Q&*!^S&\B8C\GZ(N'FQB(H-6S
M@ZTLF&'1 - P3QC&@L#H5&>:/>YB4:L:$)7"44ME@)I@8PV@-%/ -))-F%X
M8QSM/&QCE86*O!/=8,)-M:H4M7(X!IH,4C-1I0F4D0:X9F9R5<!ND#\?[.("
M6X70[F\(W.3Z:FF@))- M'5Y]6()2&:I,_1;:X7FF")'OZ4*:+:9L_2K*)?/
ME*%_QX5@XR1!(1MH25@_/9 *@N&3#IW]"C$D\EA.";0:@8AD,QG0B$,DE>4T
M8$@M>', P2)MK*64#LHK=92E$(7+)VU\)>42D.#*X>TC.Y6@C#+$5*!?/7(
M:44P2*'4+7[&687/:>NQ T?L&,G/2?ET4E'(*TP,AWRLM?WN73J9--S M%(%
MPT@WO&-R-MJ(51]J]=&7A#VVW92 _MJ6$3ZUN<'8LY=%6K$^Q5)IT/^+[Z.7
M:=4F+PD0A76F.M!95LRA4%N#79S1YG%%B=V4&)S')WE17B]9UC"^FX?)<[+
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MQ7MUHF!6+1\IQ10_]Y_8T:T'S?&A4&'7?BM*%8WMYRL .]Z>31,3K/?T4:\
MWAO[?Z^G^>53E*&A$I3%JSW4E&EA:[^?\/N:P/XK9_C\P/[*!],+9S!JCOX'
M:76M3D_$UU1N(G)-[DHVG/-G9=H#E\K*MM#T_*B:K2FC]]1,:H (;HM5\HI:
MEX;J"*TC@IZ9EHY_<\8;#$:=_^*T(BR=!B9)'G,#ZI.&!4__)W5=ULJ_O .7
MBLD9NC0%$TKJU"$Q+X/E&Z.%'*&"%W.$HEY!P1W,8$I"'5_<S)UYMJGM4_>6
MX;55&<$FG[;F*:><I@+ .*(IJ W32U9*M[#"RT&]@L!$K:*]6Y2F<-12UR=_
MG<SI\]9*$0Q?7=".>2KC9H^:L.(Y678@19W(14-G:))Q328'AEH:<&,F]5(O
M%7M+O;3'$5J9K,=N<#:IAQF7[8R2#\EZ73 4= 3L]*(0F(%7:9IIU+51!/$D
MAG:\-6N!H:,U5$<B0AIGE3:V29Z6*G]II0F"CZ(I5H3<JL%GI(!53<EU1TG<
M:A^AJDZ]E;+46W Y*<M YEI3\C) \%1GGA5C905 6SJ: OZ0R=Q[DFZ4*L_H
M8>U4O3YG[V#,X#5["STP3M8!K.9=P:@^6X!;5MO3<L;V&V:'&;VI)&LXK0*\
M=6D[N.-6JW/9<&FVAO=)GX#,6_-TR7M.*D*H8S.WSU@#>@,I\<I;J+FS>X06
MM3BL5F(;L\X-M54ZF+:20-8V%WJ#,LP[ED6S>1F2AX:Q=(56-5 +^AQNU4#5
MU&)28(92)30Y8V"\@#$$W:8XL[)P*QR.)F/ :JJTDD#I,H(WILPV,]TB*IY8
M=!4#H\[/F(44.#YFCY@^XEN\BI*LR]*+R>JM53W8%!..;O9&JHEH+@,H1:V!
MC\G;*KZ):DU$6E64<E=84F78=&8[ARQ/"[M,<(/)HA?XN-29M!@P=-88:4UG
M21F'06<U<".=XT85T=+#9QW4ID9MAYG3"G_$+^7]%YP^XZL\*Y]48_[TXL"D
MQ+4PVCHOKJ8L,#S?T8 QWRG#WA\,J_^"(W+_)=^Q9KI2(')X9.(4ZC9%'!QC
MA[@E1/W-81&5?E.U'CZA'+!D[9LYF:ZLD,,D; ^YA+*_/1C*[E@7, FZ"R^]
MTK',RRC5+6$ZHAY3\9Z5CY95R8Y'KIK,]_7\;-TH'Z$J:X-=  L06H,_]9">
MO2RHZ/&*_6U*Y:G+ L-HD[G6]%85=!BNUX!>7(DMBC^B"Y9('L<HH5H4+;0U
M^\XXMZV+D L+ F2+W2$P!-/C$X]GX((==.,WL]C&C]:#!J?6_EYTL#I=O)^/
M'.:;(>:3ROOX IAN,XM9IG="]O!,")BSTCM6VZ4I7^3>BO>:1W+/E3+(+[FG
MLL%TP3T;).2CW%>'NP1T)GS'.M-.*O94]@'U-_6D8R\%OY:>IIV4U!/Q=5ZR
MMWRB--V@KM/5E\6#]QDQF^<M?J9_QOR'NS4-EU5!@HVFUW#/WA0AG8%>#0Q7
M[;&.F=C(H8+G+RB89*!CB++[FI\R@J.4/7OU8Y1D+ FRK*7L-.$=2'3$/6ZZ
MK2CZ^I$*?_-=2L41'9-7KO=9/3?K[<1&'>O]\AY,#W2".VY))M U7A'5<Q](
MC7A#\@7&<<%&O;N(OV'4OL!ZO;2]+>Y<"+P>.]T$R94?7E(=4)=/F+=[ :[A
MFT6M^[QY#M"ZL6T4/3>PKO^ZX15:DT)Y8HN 4YK/SQW$QK[SG-RJ3[8)4E[O
M$<HAREC5B(!CSQ"7P))&"BUS@D#<')!MM+!CGBQ=9E:2:.&RES96#+UQ)C?$
MM$LVU +#,&NHPE23"O'+*HT8 ,Y1Z&<OZX3PF?-I5&+5N7&YJ%]>J<$.F23*
M >*.$IS\W@KN9%$,];PK];/X2Y0R>CMTF8%6: <E,<'DG7HJ@.AE@U.V+X]I
MP-3=>JEW44FM"..^0/_][:(DU:+DB1UIU-^D5^<7O.RV22U*"/4JNZ5IJA?7
M#>I@>.J.6?\@1:^,0<I]7@R8+<<!3@:-VUM@\FS<3K13]<E:%V/Z=+71 \-3
M![#B:FZ?E$RW82;7AK4K]Z$J*)JB.,E7#TG&HPT:RA9)C.O0@V?_KA^W4,6'
M;D7X).H4X_J$==$'0]P)H.4;8P,MB$1EKQ$]9FQM]R)F6WC+)&ISJA3-^E$\
M?-B%_E:MZ! 3%4]-DJ#G*-7<PY[[HX$[PPP5:.@^>_PBM%5I+]8*B>O9)74V
MN/ _].1?5W^M4WS4D@XY?#UC.-C>;%N]LW5N$X!7W=<MC=>D2[Z#L\,Q6\W0
M4C!U;E33>V\??/I5='))97KIV[WO0HZ7YS)62#;#'T'JR;W>[GM#\#I*XN8]
M7BK/;:]_\]TP>BROHH/;5+>7'J\#\JL9U2TJ07+;B:F@1N<5>P9>%[Y;I/GH
MJ^CK@PKTTJGY%W\UO;=OK9B:]QD7)4_ GV3HFD3/T<L1>_/ZV]?88?L_+/CE
MWZ))Q^FO3708#KP[FZMWYMZM!N"GL_]0=_8,/[(M/,^=W6B\L$I.HKA^\+Z.
MXQOIUS54?\2JPV=[_\JA]MZ/\B3G>_[$JYPO;^T:=R[Z"[IOL][7):&VJ$"G
ML'_,\_A+DJ:RQFY_@W=87D VKNDZ>P<[3-&=G[XAR0*C:UHZ8NTPJGY4YNB!
M-DK*O5?]]_8KN_J^U685<X?V]MW[M]RI7?WEZO27JX3ZU3+/\-FS>&Q:*N'#
MF6B@,6Y(?@[>B=68A.7E5@AQJ>"#VBE^*"\R=K""1=LG.0V\2<F\ \OZ5;!;
M=VP\3K+'TVBC?F'4J0R_+XU.,&_XXJA# <%YN MJ(0YK15%9RZ*8"L_MB9IK
M!-K^U<GX]T8C>*(_:@2",T&'2NV3&KG@7DD2#-V5>-U[K+R^"'S19+RZR)I1
MM$U]'#TZS)TG%!TXJ)Y<&89(VKG<X#R?P1@A;4@;H*WPZ@&3XBE9=ZG6BB.T
M[O2#=YO>3:W^9<[M:IKR 3X+Q4"WY0R&*"[0*;3 T-4:JD!&GGD#Y5\H'_.,
M\K!3 ,.^[I:I/>_D*B$8IP.OO0(,F64:D,IKG'3V"8E<K7_O.?137"Q(LJXS
MU+1.^BPKU9DF70L),<J[&2@;S^U* $/22;#'M&T+0=&V%!1OBYEIVL(ST%P4
M187C4WXM@08321[S'$G%35Z40J::L2><7HRWR<\.1G;SHPEE!"?HCL"%/4U:
M2$1KFBT)KMGE%>*6G6@'FIZ]+)XH%'S+XF+E#$DOZHUN!K =I11R,&BC!R=9
M*^;2B%\*@32C.$FCHKA>_AP1$F7E->'OKGZLV#SH>KD]'WL2I2F./VP:N:(1
M5(5].Y?J<V#>4Q7T1^H=BPQ.\?W:(;Q/U8BQ$'3=[)V$[PC1.BE9QBN^M'"9
M9X_L$C=;9VTNE"B#3BM-KX2V-V5 6K,:'&):8Y4<$&R2'*'%H)#@#+PA+)U
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ML2PC0'-C0=9,&G%XC6,#5I/V('A>[HN,]FC,DLK7#Y%D99)5E%1-%D8:TWW
MRYSM9C.Y^^B%O5Q2DB@GU'U$9,-S@'VDWV%98?.4?N&Q/?8C:]L9/^>+&_8W
M?'P8*V3#9,G_>2KXO/O*3#M=/^?D,TLL5R_=R79FQA+>]K7DT+KMK.'/P0=W
M-29AN;X6:I=+0ZYI#1Z)42Y>#:1^^4WPJK8 )^3J[(G^&\)<.%#%W])1(\EP
MW#X1=;Q85*N*)PL]Q<MD(7]_R*P%SW4Z8!:/D':B**YE S771URRZ.N&Y,])
MS#;E/A5L<:1+<'R\*)-G978J>VUXS3<!N^SVW(+%KNNF$/2PZ25YCKH2PC7N
M=GQ7M-]6P)?K<VHB"3Q9*[#WA$*---+IKOWL']Y\P8!3J'\Z<^.]@"^(H0>F
MR.;@G6:X:0-A:=9/<?U?=L1_<.&<WRQ7S  L-.$UG"-N,<M&K<9R;)3=K?N<
MW[I?[^G6O2).WR(>)O&11:%J66^QNPEN%\6K!(,'F3;HQOQHQ1D_UDWB)%QK
M!%\&EQ%]M'XSZBQ:#:]/U)JA#QZ>58L'9Y4]1DE$S#7:]![H7__E#^_>OOT3
MXKH0Z$4JW$^M8"272MXSM?2P1\22"T.BE1:AA%1,'DYVMU&_Z%+4N;/+L9B
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M7+]2]^(M??NOP",-LW9Y;]/QYU^'9Y%7JA_O,?SVX4\WIAEL"CH./J6D8[7
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M>[7U.\1L'PONW'Q9..Z+G[)HE9.229B=X@XC9G=H8>LJ"AXF"_W#+.YMU+0
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M[&ITOV],+0M,%]C1 #73R6BP.4(9#=SH#V7T@K[T2H+6"7@8*M3#I Y@651
M\CL9JR&^53E02>\"WAA3-3>4)I =8CA^2$])PMPN\&FY7< ?_/J<IVH!ED +
M]B71B7N.(2OF55YJ_G6]*?(K<ME3J\:*Y?7=1K2FH3>?60:/J2?7X\>\J3"Q
M0K?W0,U+.K-_^B 64R=4YG[RZ=A_-T"JR+LR(N4L3L#=;O7\^>>(\''Q"'W
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M7"AZ<DVF+A0Q>*PGH'%/Z""R\*O&R%YBJ3//H"_COCF\/OM:>@]/? *G[SC
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M28I-6"+I:I]+A:WC>G64AG>J12F%(-!ZEZ-4MT MCZA"V!.8'?ZZ(VJ:H1:
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M79$ ,:0+_$IJ<K^7"GLU()W*66(400_"H3*62%X?B\NHLR IXZ<LMR5O'&+
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M?HB#>P@YA>]HN^;J5(BFMP=<=ZH54M\+A@*E?]4P$N*<?H?U8T\"WA<1!<W
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MU*[K%(EUYUQ750^8[%_Z7VM-EAC6H+/B7:>@-#UPF%V%AP"L5:.=Q[V4@@M
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M^2DY:3Y2XP8PP()9;A:D3C)C# 89J3]]8/]B/]<_L?_! 9#]\G]02P,$%
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M.J@."?A.^:"L8C+B?%"% '&3,8FY 0G,"=7>;8RPM%."GANJ-BU=>BA)<\<
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M=AYY>O!D[?$?_'8!2TT].CC[YX]%3H XJ$0R;P/Z9_0\\D)5-)3A,/A/?KM
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M>G<W)B(O7?%>E\U3& UE6)ADA7ZLKU#15RQ$T7NRZX[UYDM\G1$C\IUZ$>!
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M8,&^ MT(;BBE/=P$.@+Q/032&0+< Y"^;D!H*K30NJU.^02DLSS;\*M=M4,
MU/EM@UFE%-T+(">-?51G^X,ZNP&F@=!"<:P2B6WD2R>I,SJT';&-?0,!A0+G
MF,EQE=,XS/B;NCBX"E_Y3]K0'U4?;%.Q.V)Z3J"#563N)Q2\P*0=L*N?=(=)
MPP-TC$2=#IX+XGK]3).7PE>APTG9";L817>L +RP@U=*LPI6[+<]3NR77^]Y
MC(-$561_K_S9#?VAJS)X2(N=('P(JZ7BOYV@(S&BA_QJY^5 L9Z=F'D;QN$Z
M7ZO866N"ID#5V=5@9BLM*+O!K?>JY>IA$[2;##U7VVA!/Q.EN];6A[I0>-)
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M2$UJ9S<:CDLN5'OIJ"?<0"K#]!_;#3D:?.T-977<N%2>IB"3?4!=JZ'6[.M
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MAU];NDZ5".N'0\\(VWN90EF&OC2K)PO7D;V8S[=RTP,[9"5=T3-V=#UDE:S
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MJ"<CI:M= >G/V!&+B W9P(^:PI&*L8@#YP4E_%\]NJDVTJ6^[#LN]AEN42R
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M4$L! A0#%     @ '8A_5ESFOQ#6 @  Y18   H              ( !
M &5X,C$M,2YH=&U02P$"% ,4    "  =B']6Y!MA1_@"  !'#   "@
M        @ '^ @  97@R,RTQ+FAT;5!+ 0(4 Q0    ( !V(?U9ADQ4ZA0@
M !E'   *              "  1X&  !E>#,Q+3$N:'1M4$L! A0#%     @
M'8A_5K#1X6%Z"   E44   H              ( !RPX  &5X,S$M,BYH=&U0
M2P$"% ,4    "  =B']6 !=S114%  !W&@  "@              @ %M%P
M97@S,BTQ+FAT;5!+ 0(4 Q0    ( !V(?U:/]+S:#04  %0:   *
M      "  :H<  !E>#,R+3(N:'1M4$L! A0#%     @ '8A_5CY+XDUF.@
M?'H!  D              ( !WR$  &5X-"TQ+FAT;5!+ 0(4 Q0    ( !V(
M?U8J J2DK84$ +Q0+@ ,              "  6Q<  !F;W)M,3 M:RYH=&U0
M2P$"% ,4    "  =B']6CXQ\B=9;  #.>   $               @ %#X@0
M9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0    ( !V(?U9%V_;+V\4  #3/   0
M              "  4<^!0!F;W)M,3 M:U\P,#(N:G!G4$L! A0#%     @
M'8A_5M2RNNM$3P  /U,  !               ( !4 0& &9O<FTQ,"UK7S P
M,RYJ<&=02P$"% ,4    "  =B']6:VS(3 *>  !2L0  $
M@ '"4P8 9F]R;3$P+6M?,# T+FIP9U!+ 0(4 Q0    ( !V(?U:;R)\["E@
M 'Y<   0              "  ?+Q!@!F;W)M,3 M:U\P,#4N:G!G4$L! A0#
M%     @ '8A_5OR8:;U.4@  A5H  !               ( !*DH' &9O<FTQ
M,"UK7S P-BYJ<&=02P$"% ,4    "  =B']6<"5HNGMR  !B>   $
M        @ &FG < 9F]R;3$P+6M?,# W+FIP9U!+ 0(4 Q0    ( !V(?U;.
M"T7]=R,  !0M   0              "  4\/" !F;W)M,3 M:U\P,#@N:G!G
M4$L! A0#%     @ '8A_5G(RIZ!51   @4T  !               ( !]#((
M &9O<FTQ,"UK7S P.2YJ<&=02P$"% ,4    "  =B']6\NMHA*0F  "2,0
M$               @ %W=P@ 9F]R;3$P+6M?,#$P+FIP9U!+ 0(4 Q0    (
M !V(?U9,=-'&Z!,  "#C   1              "  4F>" !M>6UD+3(P,C(Q
M,C,Q+GAS9%!+ 0(4 Q0    ( !V(?U8$D!4C&!0  .'J   5
M  "  6"R" !M>6UD+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  =B']6
M)&"53/E!  !LI@0 %0              @ &KQ@@ ;7EM9"TR,#(R,3(S,5]D
M968N>&UL4$L! A0#%     @ '8A_5FD[H-F4A   4>0' !4
M ( !UP@) &UY;60M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( !V(?U:[
MG]?ZM5H  .M$!@ 5              "  9Z-"0!M>6UD+3(P,C(Q,C,Q7W!R
;92YX;6Q02P4&     !< %P!X!0  AN@)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
